<SEC-DOCUMENT>0000320017-23-000028.txt : 20230509
<SEC-HEADER>0000320017-23-000028.hdr.sgml : 20230509
<ACCEPTANCE-DATETIME>20230509160948
ACCESSION NUMBER:		0000320017-23-000028
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230509
DATE AS OF CHANGE:		20230509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LISATA THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0000320017
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				222343568
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33650
		FILM NUMBER:		23902050

	BUSINESS ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920
		BUSINESS PHONE:		908-229-2590

	MAIL ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CALADRIUS BIOSCIENCES, INC.
		DATE OF NAME CHANGE:	20170808

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Caladrius Biosciences, Inc.
		DATE OF NAME CHANGE:	20150608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NeoStem, Inc.
		DATE OF NAME CHANGE:	20060906
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>clbs-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:8a27d5e7-fe33-4755-a32c-690f224065c0,g:57aefdc3-f3d7-461d-8b12-8991faaa8b7c,d:5bfad0e6eb2d444eb181b61964f9b0c2--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:clbs="http://www.caladrius.com/20230331" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>clbs-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80L2ZyYWc6ZmRjMWY3YTk2OWIyNDk1ZjlhZDMxOTdlMmUyZjdiYWEvdGFibGU6NWY5ZTNkNTQ2MDEzNDViNzk0MmY0N2EzYzMwMWRkM2YvdGFibGVyYW5nZTo1ZjllM2Q1NDYwMTM0NWI3OTQyZjQ3YTNjMzAxZGQzZl8zLTEtMS0xLTI5ODAz_036ae607-7bd7-4e8d-8019-0932d2d567b6">0000320017</ix:nonNumeric><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80L2ZyYWc6ZmRjMWY3YTk2OWIyNDk1ZjlhZDMxOTdlMmUyZjdiYWEvdGFibGU6NWY5ZTNkNTQ2MDEzNDViNzk0MmY0N2EzYzMwMWRkM2YvdGFibGVyYW5nZTo1ZjllM2Q1NDYwMTM0NWI3OTQyZjQ3YTNjMzAxZGQzZl80LTEtMS0xLTI5ODAz_18bf34f5-7e2f-46d1-9b67-ea7b218f677b">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80L2ZyYWc6ZmRjMWY3YTk2OWIyNDk1ZjlhZDMxOTdlMmUyZjdiYWEvdGFibGU6NWY5ZTNkNTQ2MDEzNDViNzk0MmY0N2EzYzMwMWRkM2YvdGFibGVyYW5nZTo1ZjllM2Q1NDYwMTM0NWI3OTQyZjQ3YTNjMzAxZGQzZl81LTEtMS0xLTI5ODAz_0810a67a-36f8-4790-ac7b-6f7df54aab79">2023</ix:nonNumeric><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80L2ZyYWc6ZmRjMWY3YTk2OWIyNDk1ZjlhZDMxOTdlMmUyZjdiYWEvdGFibGU6NWY5ZTNkNTQ2MDEzNDViNzk0MmY0N2EzYzMwMWRkM2YvdGFibGVyYW5nZTo1ZjllM2Q1NDYwMTM0NWI3OTQyZjQ3YTNjMzAxZGQzZl82LTEtMS0xLTI5ODAz_35ea7e08-0d04-4630-9bb4-58752f916127">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80L2ZyYWc6ZmRjMWY3YTk2OWIyNDk1ZjlhZDMxOTdlMmUyZjdiYWEvdGFibGU6NWY5ZTNkNTQ2MDEzNDViNzk0MmY0N2EzYzMwMWRkM2YvdGFibGVyYW5nZTo1ZjllM2Q1NDYwMTM0NWI3OTQyZjQ3YTNjMzAxZGQzZl83LTEtMS0xLTI5ODAz_04bb1053-b145-4153-b607-dedc460a0195">false</ix:nonNumeric><ix:nonNumeric contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfMi0wLTEtMS0yOTgwMw_684390b7-3bb3-42c7-8a83-13f2f83e10e2">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfMi0wLTEtMS0yOTgwMw_7e944932-8384-4e08-8716-1c2ac79100ed">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNi0wLTEtMS0yOTgwMw_37de52d8-2557-479d-bbaf-f29481bcc474">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNi0wLTEtMS0yOTgwMw_69afedb4-8e13-45d2-80d7-456feaf20302">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNy0wLTEtMS0yOTgwMw_16c9c39d-ad71-40ba-bf95-bdb2e5413413">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNy0wLTEtMS0yOTgwMw_bcfccd01-1243-450c-981b-7940b87eb256">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ie5c1886b35e84c7695a04666f5e1137b_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNTcyMQ_03645692-ddcc-455a-9649-721f44f866fe">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="clbs-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81865228b8a54f5ea02f2339cdf0bacf_I20230509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i724c150ab27c43fb92268e63a43d2567_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idccd6d8b24e84252b1bfbf4c82909880_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83c32766e7f045148be714d2464b2a0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i172b6566e2954903a795810c0f7faea8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i659cc88ca4174728b2be88034cec77d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i167ad6f9efc349e8aeb1f3afc4eb06f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3016a907934548cf89814e3cc5065bb5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61be37acd3b24fdd8277d7ebcc1a2524_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4046547dd294ad49c799697f6ddb110_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c1e7ed7cdb0485db6a09b8f120ae70a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30dbc205504449d38986e42bcedd9a11_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5530dc46c414ce092189cff88a3f7dd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e1630a3383b43cb9dd10a9949f9a4e4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5e281aca39d4be8a4acaf10e78a17c4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57742d73f1a641e6869962f1ae17f160_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38bd3b8625604395bc59611e78cb1d4c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b6d5d55db744ce2adef5755fc8dcf38_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia56329ac6bf74270be8df5d045aa6494_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12937a3ada6d4dd2b874669455d35962_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bb37f6848ed455f8b7792e91866123b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9619f9b64ebe471ca599503ec1560977_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ce139ad8e764eb2804ef24019b88cdc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fd2bb5d543d427ca3beb6d8dae402ca_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d1ce795a4ca4649ac9b72bf8edca70d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i800befd23f3841569b227ba2e2d706d1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d5c507b54c44f3382ccc7e3b5440bb2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79e1062c1f414381a135b2e72a0a68df_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac1d983470804b2cac2936f1132412ae_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0482b3971ec42ce8127564740a1f058_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7ee28bcb50447fd965f5db978a79599_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13d0c68aceb945648fc95a868eb9e3ef_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9347bcc62e74b129f2045c4859eb549_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if20c8a9a03b14863bb4789b2d34ee496_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8cc3ac77efa48088686b917cb62e54f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1083fcdc93504069ab0c6b8124da6c36_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bf4f3fb7021489abb1e920d657cfc55_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffe6cb540c934ae58b0986186454ad7d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6da0050ca7b24feeba54e912cec8a0d6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1306a47c84604f74bccf2442a61ec582_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50382c5190684ed1bbbe023c4f418b3e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee22d1576f8f42cfbcb560d4e1373257_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac5cf83f8935401bb2f5aca604012ece_D20220915-20220915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">clbs:CENDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-15</xbrli:startDate><xbrli:endDate>2022-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="icbaa2961421947beb045865325d7915f_I20220915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">clbs:CENDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic072dd5659984964b08dc7870ffd5237_I20220915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie18f40d4e2884dbfaf339b40535a723f_D20220915-20220915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-15</xbrli:startDate><xbrli:endDate>2022-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fba73856db44b87a21cac709470eda2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ee0cb91c75d458c950b56f03890e10c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied9953ef26fe438b9a0b57d97f79bdea_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7bcd8f5631a452dbabbd9fc97bbc4d8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied1922d4661541beb53e95573627a550_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab073f0d92e84ba6a575d902b1c5e90b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5bdf116a27d45e4852970a908a1c9d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fe5dff51cd045c6a67c3d6af3c855d4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66c395e4236040e08deda6719527e329_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3379968f199147d999b83005f594ec07_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8ffd44b3aa94c9a96419561b18f7289_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb513457df6349bbb925697c05f89164_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if531ec7b0d1a4289a1d93db89b2325ff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3aa127bddd44877959f1946f1b707a1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea3f0934334b47bfbb1b2334acb69624_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19bc8aae9d6b47a3a7633a871fba31ca_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae124bfea4fe4e4d85a6e62fb5a67fa4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3f5e8fd57334737879297c5b890af27_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94a5f2f4d8634a6482193404d866f108_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aa2ff8c93a14a628ddf610567129143_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f52a94bfea84193af9a8db010f1aa88_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3d4362e69d54f54aaad194fd8645f31_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i239efe19fad74784b328fdf62d219847_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c17a022357047ff92faad6cb21667dd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i504afb254cc84fff8865bdb6c94dc145_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i014d15d0d777404b8e448a8905b727ad_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i039c3f49b8da4f2d9b6cefb4c7bdaac6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6f24ed5b4964736968a44cdbb684fbc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3c9472dfe66456db347e101f7b9c855_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71685748225c4034a7cebd3a48175ca9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51755cafee74432a96fde0a4fb4c5bfb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="office"><xbrli:measure>clbs:office</xbrli:measure></xbrli:unit><xbrli:context id="i2d6b8752305947b19367c1e2776a4b9b_I20210604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8175b9d271b74085bb0ba378fb359200_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35acb9e033324b219fe3495ddd939d9c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e7ec6bf429543dd8edca7c206e09fd8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i997e64fe38cd4696b408c8f14ff89821_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcccbb1ec967438ca65784bea06bd71c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9391ecdb3584403a88b94bdd91f8a15_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5c1886b35e84c7695a04666f5e1137b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bf2527917654f82a4c8b3249bbddab5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i123fae5df7b2491e87422b22888cdec1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cd4f16a626841558cb57f42b71c9c60_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i787b9e2301e54c9785a066d7cd81323f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id03152d7237c4f9b90a0fc7dd766e90b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c93ce6862cc404f9f8ce8668c15838a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83f0c391f25941a899f1eb4e31178bdd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d650d9bcb5a4a57b8d4315548c62afd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c3f59edeb884c01895f1ea44c1ef3d9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93afe9d3f6ed4cb09390722746228408_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f68282f0c334dd5b5c7b36cb0d6ba8e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id704a5defa6d483f841dd1efcd484f49_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a48869ba93a417bb2d014c285a349c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dc12ffc2bcf4c17a7efd9e7f1736478_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ba87c90863144d990c890ebce4a437a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">clbs:CENDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a535f623a624914a6711e4e82eebafc_I20220915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">clbs:CENDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice2ae4d365344c85a05b88a31a78ac50_I20220915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">clbs:CENDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3afe3e21f9e14d83ac8486daad4e1b82_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">clbs:CENDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia25852cf0b524a4a811255369807adc6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">clbs:CENDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35714006bb8c4a12bfdea57e263522a5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4403bf2ab03749ec86046716a8f3d4ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafb81e753f5344fd8594c25ddabaf02c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9ffa93082d045a0bbf2f1f37390955e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i128ebe4deb504c3994e29fd10cb3bd21_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28c8467f29d64fef93f97e7c8af17104_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcc2b98561db4f2c9078a1c50bd84b01_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:SanfordBurnhamPrebysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55d91e2a703a41a4b67672acbce81809_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:SanfordBurnhamPrebysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b47136928e3471f891783820d0f46a1_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:SanfordBurnhamPrebysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5743124ce7d40908442e8bd62e47009_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:SanfordBurnhamPrebysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ac540323fe04816bb43b23a4a4cd560_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:SanfordBurnhamPrebysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i402d926e5cb44e54a8d375857d19b288_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:UniversityOfCaliforniaAtSanDiegoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73ca6b3e79144046b283ad153b819bb1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:UniversityOfCaliforniaAtSanDiegoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if616b4f4bf5141008e520b036ed05453_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:UniversityOfCaliforniaAtSanDiegoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie64acccae8a54473b4916dda6d9766df_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e38bf3272614bd784e0e3713d21241f_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbe067b5df1b486281624627370f5bc7_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i628328038b2b4904ac047c8f5980356a_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a3db4b42dc146229cb4171314c0ce3d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8788a48508344937b3068aa082fec1c3_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:QiluMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic152646f8baa44789d4da65765ea5a4b_D20220914-20220914"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:QiluMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-14</xbrli:startDate><xbrli:endDate>2022-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie65ed995e0f7462e8f1737be572b0839_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:QiluMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b06f28b1d2f42819f88a1b59197ea04_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:QiluMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c7a64d6081c499fbfec9b5f2a137f04_D20230401-20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FORM <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGV4dHJlZ2lvbjo4N2I2ZGU1MWM2NGU0MmM4OTA1NmJjYzZmODQxYWNlMV8yMDYx_98ce9706-e546-40f0-8502-9b242444c05d">10-Q</ix:nonNumeric></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6YTBhM2MyM2RjYjg3NDBiMjlkN2QzZmI4YTUxNGIyODEvdGFibGVyYW5nZTphMGEzYzIzZGNiODc0MGIyOWQ3ZDNmYjhhNTE0YjI4MV8wLTAtMS0xLTI5ODAz_f175b077-6fad-4407-9301-c3b7e6bf3528">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Quarterly Period Ended <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGV4dHJlZ2lvbjo4N2I2ZGU1MWM2NGU0MmM4OTA1NmJjYzZmODQxYWNlMV80Mzk4MDQ2NTEzMzMy_7f4c5602-60a4-4224-bab4-42be3bebb027">March 31, 2023</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6Mzk4OGZlZDUxNDI5NDcyYWFkMTQ2ZTBkMDgyMzU2YWIvdGFibGVyYW5nZTozOTg4ZmVkNTE0Mjk0NzJhYWQxNDZlMGQwODIzNTZhYl8wLTAtMS0xLTI5ODAz_dfc0531e-98dd-4df2-b094-a9a30e99ea9f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Transition Period from __________________&#160;&#160;&#160;to _________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGV4dHJlZ2lvbjo4N2I2ZGU1MWM2NGU0MmM4OTA1NmJjYzZmODQxYWNlMV8yMDUz_3a4932e9-576c-4128-9bce-9fe1c3e24d2a">001-33650</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGV4dHJlZ2lvbjo4N2I2ZGU1MWM2NGU0MmM4OTA1NmJjYzZmODQxYWNlMV8yMDU3_1bba046f-5340-4916-9181-127575b93486">LISATA THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6NzgzYmFiMzIxOWExNDVmZThhZmQ4ZjEwNDE0ZGM0NWYvdGFibGVyYW5nZTo3ODNiYWIzMjE5YTE0NWZlOGFmZDhmMTA0MTRkYzQ1Zl8wLTAtMS0xLTI5ODAz_3344ba09-b0cf-42ee-b86e-b02f264ff74b">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6NzgzYmFiMzIxOWExNDVmZThhZmQ4ZjEwNDE0ZGM0NWYvdGFibGVyYW5nZTo3ODNiYWIzMjE5YTE0NWZlOGFmZDhmMTA0MTRkYzQ1Zl8wLTEtMS0xLTI5ODAz_b6c0cb41-857f-4fc9-ad8b-e172558dca02">22-2343568</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6NzgzYmFiMzIxOWExNDVmZThhZmQ4ZjEwNDE0ZGM0NWYvdGFibGVyYW5nZTo3ODNiYWIzMjE5YTE0NWZlOGFmZDhmMTA0MTRkYzQ1Zl8zLTAtMS0xLTI5ODAzL3RleHRyZWdpb246NDIwZDhlNzVjNTQ3NGU4MWFlZmUzMGNlOTk3YjdlZWFfNA_30128fe0-dcca-435a-9e61-f693b8169a5c">110 Allen Road, 2nd Floor</ix:nonNumeric>, <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6NzgzYmFiMzIxOWExNDVmZThhZmQ4ZjEwNDE0ZGM0NWYvdGFibGVyYW5nZTo3ODNiYWIzMjE5YTE0NWZlOGFmZDhmMTA0MTRkYzQ1Zl8zLTAtMS0xLTI5ODAzL3RleHRyZWdpb246NDIwZDhlNzVjNTQ3NGU4MWFlZmUzMGNlOTk3YjdlZWFfOA_642db119-96a5-4bf2-b849-fa9be90c9a45">Basking Ridge</ix:nonNumeric>, <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6NzgzYmFiMzIxOWExNDVmZThhZmQ4ZjEwNDE0ZGM0NWYvdGFibGVyYW5nZTo3ODNiYWIzMjE5YTE0NWZlOGFmZDhmMTA0MTRkYzQ1Zl8zLTAtMS0xLTI5ODAzL3RleHRyZWdpb246NDIwZDhlNzVjNTQ3NGU4MWFlZmUzMGNlOTk3YjdlZWFfMTI_23308f61-e1f1-4117-ad13-9476aeb72096">New Jersey</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6NzgzYmFiMzIxOWExNDVmZThhZmQ4ZjEwNDE0ZGM0NWYvdGFibGVyYW5nZTo3ODNiYWIzMjE5YTE0NWZlOGFmZDhmMTA0MTRkYzQ1Zl8zLTEtMS0xLTI5ODAz_c5087235-9dd3-4aa3-8813-113a25f924b1">07920</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(zip code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGV4dHJlZ2lvbjo4N2I2ZGU1MWM2NGU0MmM4OTA1NmJjYzZmODQxYWNlMV8yMDU4_4c89f554-9c98-4428-a166-4fe3a38669c2">908</ix:nonNumeric>-<ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGV4dHJlZ2lvbjo4N2I2ZGU1MWM2NGU0MmM4OTA1NmJjYzZmODQxYWNlMV8yMDU0_a79f5668-5cb5-4b3a-ab2d-8b9d4250bdc7">842-0100</ix:nonNumeric></span></div><div style="text-align:center"><span style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:34.255%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6MjAwMTNkYTJhN2FlNGZmOTk3ZGYzZGRjN2U3MTA3M2MvdGFibGVyYW5nZToyMDAxM2RhMmE3YWU0ZmY5OTdkZjNkZGM3ZTcxMDczY18yLTAtMS0xLTI5ODAz_89430b85-3ea4-421b-88fb-47cca76971c9">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6MjAwMTNkYTJhN2FlNGZmOTk3ZGYzZGRjN2U3MTA3M2MvdGFibGVyYW5nZToyMDAxM2RhMmE3YWU0ZmY5OTdkZjNkZGM3ZTcxMDczY18yLTEtMS0xLTI5ODAz_3a0e8105-ff18-4815-8210-138ae41cab95">LSTA</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6MjAwMTNkYTJhN2FlNGZmOTk3ZGYzZGRjN2U3MTA3M2MvdGFibGVyYW5nZToyMDAxM2RhMmE3YWU0ZmY5OTdkZjNkZGM3ZTcxMDczY18yLTItMS0xLTI5ODAzL3RleHRyZWdpb246YTYyNTQwODBjNjY1NDkxMGIyOWFlNDBlZDY0NjFhZTFfOA_de42c332-f079-40eb-bc39-5b1b10cc860f">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGV4dHJlZ2lvbjo4N2I2ZGU1MWM2NGU0MmM4OTA1NmJjYzZmODQxYWNlMV8yMDUy_244acbd3-9138-4eba-8609-4fe6f5b22007">Yes</ix:nonNumeric> &#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No &#9744;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGV4dHJlZ2lvbjo4N2I2ZGU1MWM2NGU0MmM4OTA1NmJjYzZmODQxYWNlMV8yMDU5_b0adb9c8-66ef-4f00-9986-7259afda1f92">Yes</ix:nonNumeric> &#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No &#9744;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6YTA0OWUwZWJhYTc1NGE0ODkxMzNmOTVlODYzYjc0YTMvdGFibGVyYW5nZTphMDQ5ZTBlYmFhNzU0YTQ4OTEzM2Y5NWU4NjNiNzRhM18xLTAtMS0xLTI5ODAz_f7cebbce-a6e4-464d-837e-8249b1f5f75f">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6YTA0OWUwZWJhYTc1NGE0ODkxMzNmOTVlODYzYjc0YTMvdGFibGVyYW5nZTphMDQ5ZTBlYmFhNzU0YTQ4OTEzM2Y5NWU4NjNiNzRhM18xLTQtMS0xLTI5ODAz_c82a404b-9922-4034-8b23-8f3365334e61">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6YTA0OWUwZWJhYTc1NGE0ODkxMzNmOTVlODYzYjc0YTMvdGFibGVyYW5nZTphMDQ5ZTBlYmFhNzU0YTQ4OTEzM2Y5NWU4NjNiNzRhM18yLTQtMS0xLTI5ODAz_d6ae17a9-db25-462f-af86-7f20043eb94e">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#9744;</span></div><div style="text-indent:20.16pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#9744;&#160;&#160;&#160;&#160;&#160;No&#160;<ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGV4dHJlZ2lvbjo4N2I2ZGU1MWM2NGU0MmM4OTA1NmJjYzZmODQxYWNlMV8yMDYw_80326170-8eb5-4b99-9afe-c53f6dc573d1">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:3.3pt;padding-right:2.25pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:331.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of May 9, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $0.001 par value per share</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i81865228b8a54f5ea02f2339cdf0bacf_I20230509" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6NTk5Y2M4NjhlM2NkNGY2MmIzNWQxYTNjNjY1ZDQ1NzUvdGFibGVyYW5nZTo1OTljYzg2OGUzY2Q0ZjYyYjM1ZDFhM2M2NjVkNDU3NV8xLTEtMS0xLTI5ODAz_5aef65cc-b9b1-455e-9128-81af4f7d9286">7,974,464</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">shares</span></td></tr></table></div><div style="padding-right:2.25pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:3.3pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="margin-bottom:3.3pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report (this &#8220;Quarterly Report&#8221;) contains &#8220;forward-looking&#8221; statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical information. When used in this Quarterly Report, statements that are not statements of current or historical fact may be deemed to be forward-looking statements, including, without limitation, all statements related to any expectations of revenues, expenses, cash flows, earnings or losses from operations, cash required to maintain current and planned operations, capital or other financial items; any statements of the plans, strategies and objectives of management for future operations; any plans or expectations with respect to product research, development and commercialization, including regulatory approvals; any other statements of expectations, plans, intentions or beliefs; and any statements of assumptions underlying any of the foregoing. Without limiting the foregoing, the words &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;forecast,&#8221; &#8220;outlook,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;likely,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;target&#8221; or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements, although some forward-looking statements are expressed differently. We remind readers that forward-looking statements are merely predictions and therefore inherently subject to uncertainties and other factors and involve known and unknown risks that could cause the actual results, performance, levels of activity or our achievements or industry results, to be materially different from any future results, performance, levels of activity or our achievements or industry results expressed or implied by such forward-looking statements. Factors that could cause our actual results to differ materially from anticipated results expressed or implied by forward-looking statements include, among others:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain sufficient capital or strategic business arrangements to fund our operations and expansion plans, including collecting amounts owed to us under various licensing and other strategic arrangements, meeting our financial obligations under various licensing and other strategic arrangements, the funding of our clinical trials for product candidates, and the commercialization of the relevant technology;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to build and maintain the management and human resources infrastructure necessary to support the operation and/or growth of our business;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether a market is established for our products and our ability to capture a meaningful share of this market;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scientific, regulatory and medical developments beyond our control;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain, as applicable, appropriate governmental licenses, accreditations or certifications or to comply with healthcare laws and regulations or any other adverse effect or limitations caused by government regulation of our business;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether any of our current or future patent applications result in issued patents, the scope of those patents and our ability to obtain and maintain other rights to technology required or desirable for the conduct of our business,&#160;and our ability to commercialize products without infringing upon the claims of third-party patents;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether any potential strategic or financial benefits of various licensing agreements will be realized;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to diversify our pipeline of development product candidates, which could include an acquisition, merger, business combination, in-license or other strategic transaction, and whether any of such efforts will result in us entering into or completing any transaction or that any such transaction, if completed, will add to shareholder value;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the long-term success of our recently completed merger with Cend Therapeutics, Inc. (&#8220;Cend&#8221;), including the ongoing integration of Cend&#8217;s operations and the advancement of their development programs;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our development activities; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to complete our other planned clinical trials (or initiate other trials) in accordance with our estimated timelines due to delays associated with enrolling patients due to the novelty of the treatment, the size of the patient population, competition with other clinical trials for similar subjects, patient and/or investigator site availability and accessibility due to external macroenvironmental factors such as the COVID-19 pandemic and the need of patients to meet the inclusion criteria of the trial or otherwise; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which the COVID-19 pandemic and/or its long-term effects may impact, directly or indirectly, our business, including our clinical trials and financial condition; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors discussed in &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 30, 2023 (our &#8220;2022 Form 10-K&#8221;).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The factors discussed herein, including those risks described in &#8220;Item 1A. Risk Factors&#8221; and elsewhere in our 2022 Form 10-K and in our other periodic filings with the SEC, which are available for review at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could cause actual results and developments to be materially different from those expressed or implied by such statements. All forward-looking statements attributable to us are expressly qualified in their entirety by these and other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they were made. Except as required by law, we undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></div><div style="margin-bottom:3.3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="margin-bottom:3.3pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:3.3pt;margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART I- FINANCIAL INFORMATION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Page No.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_10">Financial Statements:</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_13">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_16">Consolidated Balance Sheets at March 31, 2023 (unaudited) and December 31, 2022</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_16">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_19">Consolidated Statements of Operations for the three months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_16">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_19"> 31,</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_19"> 2023 and 2022 (unaudited)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_19">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_22">Consolidated Statements of Comprehensive Loss for the three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_22"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_22">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_16">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_22"> 31, 2023 and 2022 (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_22">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_25">Consolidated Statements of Equity for the three months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_16">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_25"> 31, 2023 and 2022 (unaudited) </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_25">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_28">Consolidated Statements of Cash Flows for the three months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_16">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_28"> 31, 2023 and 2022 (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_28">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Unaudited Consolidated Financial Statements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_31">10</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_85">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 3.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_97">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 4.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Controls and Procedures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_100">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART II- OTHER INFORMATION</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Legal Proceedings</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_106">34</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1A.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risk Factors</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_109">34</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_112">34</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 3.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Defaults Upon Senior Securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_115">34</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 4.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Mine Safety Disclosures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_118">34</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 5.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Information</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_121">34</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 6.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_124">34</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Signatures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_127">35</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></div></div></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_13"></div><div><span><br/></span></div><div><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands, except share data)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.951%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMi0xLTEtMS0yOTgwMw_7db614e5-e345-4fa2-9086-180d7446db68">28,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMi0zLTEtMS0yOTgwMw_bf11aa2f-8cdc-45d5-95a0-a42fae646952">32,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMy0xLTEtMS0yOTgwMw_3f1257bb-744b-4299-b69c-7fa41c18383c">32,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMy0zLTEtMS0yOTgwMw_cafb9e0b-1502-44db-abb6-ebd90dd2711d">37,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfNC0xLTEtMS0yOTgwMw_764ac289-efa7-44f0-b9b0-7c985b54acba">4,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfNC0zLTEtMS0yOTgwMw_9a62a0c2-b7b1-4f83-ae75-f787ec686a69">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfNS0xLTEtMS0yOTgwMw_8f7109b5-afae-4d7f-9f7f-fc8c839f5e8a">65,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfNS0zLTEtMS0yOTgwMw_c8cd0b51-7407-4cf8-9f2f-f1c68fce112a">71,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfNi0xLTEtMS0yOTgwMw_3470e8c7-2283-4444-8f1a-2d372829ba7e">262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfNi0zLTEtMS0yOTgwMw_567c4e11-4418-4055-943c-4e2416606fa1">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired license - intangible</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfNy0xLTEtMS0yOTgwMw_a18c3884-10af-4601-8f5b-9aaac877f4b1">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfNy0zLTEtMS0yOTgwMw_183862b6-fdcb-4b7c-8925-08a38d56dfc4">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfOC0xLTEtMS0yOTgwMw_cf2acf4f-5cb5-4ba4-bf68-edf898627072">449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfOC0zLTEtMS0yOTgwMw_c77b7bc2-e866-44d9-a554-32f63ba7e2ad">528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfOS0xLTEtMS0yOTgwMw_5621b9fc-7084-472a-b5d5-2aea550ea918">66,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfOS0zLTEtMS0yOTgwMw_2987fe9b-bef7-46d1-92f3-dc1d1d38064f">73,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTMtMS0xLTEtMjk4MDM_e0b3446c-eb6a-4223-9209-7d243c2bfce8">1,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTMtMy0xLTEtMjk4MDM_36a52505-a95b-4f62-87a0-38f56d4540e2">2,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTQtMS0xLTEtMjk4MDM_1e219fc3-ca4a-4e9f-b1a7-d67587d6f165">3,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTQtMy0xLTEtMjk4MDM_d6095233-375c-4091-a86d-29fbffd62634">3,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTUtMS0xLTEtMjk4MDM_bfbe367e-576a-44fa-a53c-e026819a6a1c">5,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTUtMy0xLTEtMjk4MDM_7e910ac3-9a48-4949-86f0-2961ad08765e">6,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTYtMS0xLTEtMjk4MDM_cc2cd460-43b4-43d6-9822-724e3c319145">337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTYtMy0xLTEtMjk4MDM_6716a7eb-9467-41a9-bcf1-9e9d8e12bef4">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTctMS0xLTEtMjk4MDM_7dd7a968-8cab-4cb7-9b4d-ae61ce59e499">5,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTctMy0xLTEtMjk4MDM_10318444-e07f-4dd4-80ff-4105a2317c6f">6,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commitments and Contingencies (Note 13)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTgtMS0xLTEtMjk4MDM_dcb3b903-7b8a-4b0f-a0a6-02479080e7d9"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTgtMy0xLTEtMjk4MDM_d8e4cedb-8dd0-4851-9b1e-1dacf33c54f4"></ix:nonFraction></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjItMC0xLTEtMjk4MDMvdGV4dHJlZ2lvbjpiZWVkNTJhM2M5ZTE0MWY2YjAyN2Y5Yzg4NDcxZDMzOV8xOA_0c2376ac-224e-4e4e-a334-e404335045cb"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjItMC0xLTEtMjk4MDMvdGV4dHJlZ2lvbjpiZWVkNTJhM2M5ZTE0MWY2YjAyN2Y5Yzg4NDcxZDMzOV8xOA_5ade6d5a-fb4a-4d68-9cea-faaba2ebb9cc">0.001</ix:nonFraction></ix:nonFraction> par value, authorized <ix:nonFraction unitRef="shares" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjItMC0xLTEtMjk4MDMvdGV4dHJlZ2lvbjpiZWVkNTJhM2M5ZTE0MWY2YjAyN2Y5Yzg4NDcxZDMzOV80Mw_59572931-458a-436d-b30a-a4dda3f9919b"><ix:nonFraction unitRef="shares" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjItMC0xLTEtMjk4MDMvdGV4dHJlZ2lvbjpiZWVkNTJhM2M5ZTE0MWY2YjAyN2Y5Yzg4NDcxZDMzOV80Mw_852bbd37-01fd-48be-a8fb-f49178f4334b">33,333,333</ix:nonFraction></ix:nonFraction> shares; issued <ix:nonFraction unitRef="shares" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjItMC0xLTEtMjk4MDMvdGV4dHJlZ2lvbjpiZWVkNTJhM2M5ZTE0MWY2YjAyN2Y5Yzg4NDcxZDMzOV82MQ_9b71aab0-d304-4110-961c-7337294c8181">7,999,080</ix:nonFraction></span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">and <ix:nonFraction unitRef="shares" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjItMC0xLTEtMjk4MDMvdGV4dHJlZ2lvbjpiZWVkNTJhM2M5ZTE0MWY2YjAyN2Y5Yzg4NDcxZDMzOV82OA_81607cee-25c6-4272-a231-7310b1bd365c">7,866,799</ix:nonFraction> shares at March 31, 2023 and December 31, 2022, respectively; and </span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">outstanding, <ix:nonFraction unitRef="shares" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjItMC0xLTEtMjk4MDMvdGV4dHJlZ2lvbjpiZWVkNTJhM2M5ZTE0MWY2YjAyN2Y5Yzg4NDcxZDMzOV8xNTU_2a8d912a-89ec-4702-b2f3-ade8db99320e">7,998,342</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjItMC0xLTEtMjk4MDMvdGV4dHJlZ2lvbjpiZWVkNTJhM2M5ZTE0MWY2YjAyN2Y5Yzg4NDcxZDMzOV8xNjI_01649941-73fa-4caa-a462-843fc229d0c5">7,866,061</ix:nonFraction> shares at March 31, 2023 and December 31, 2022, </span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjItMS0xLTEtMjk4MDM_d923915c-4c30-4b6b-9890-8077bfb8bf44">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjItMy0xLTEtMjk4MDM_8930496f-69a4-4a51-99b5-3ad8c3d923d0">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjMtMS0xLTEtMjk4MDM_27be3862-633a-4a1d-89bb-c989f1747c2c">575,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjMtMy0xLTEtMjk4MDM_d98f222e-d6a8-4e95-a61a-6b580c9dccad">574,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, at cost; <ix:nonFraction unitRef="shares" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjQtMC0xLTEtMjk4MDMvdGV4dHJlZ2lvbjozMmE0ODEzZTM0MDE0YzVlOWU3Njc3NGZmZjczODgwY18yOQ_6502dc8b-1ffe-4ea7-bab5-62489344ffde"><ix:nonFraction unitRef="shares" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjQtMC0xLTEtMjk4MDMvdGV4dHJlZ2lvbjozMmE0ODEzZTM0MDE0YzVlOWU3Njc3NGZmZjczODgwY18yOQ_7852bb53-3a93-4956-85a2-7ade82e5d79d">738</ix:nonFraction></ix:nonFraction> shares at March 31, 2023 and December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:TreasuryStockCommonValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjQtMS0xLTEtMjk4MDM_bcee2ad6-d391-43ea-96a8-c28d8f31d598">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:TreasuryStockCommonValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjQtMy0xLTEtMjk4MDM_a50375e7-7152-4afc-8993-e8676f4ba7fb">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjUtMS0xLTEtMjk4MDM_0ac481e3-a56f-4c51-9b95-82377a916fed">513,428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjUtMy0xLTEtMjk4MDM_085e2168-add7-4bed-9e06-1ad92f8cda67">507,241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjYtMS0xLTEtMjk4MDM_e9e590ec-3b54-417d-9445-968844c693be">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjYtMy0xLTEtMjk4MDM_7e1da76f-6990-4892-90aa-c1f1b8256285">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Lisata Therapeutics, Inc. stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjctMS0xLTEtMjk4MDM_548c15ac-5e15-4e50-8c24-226f56563b55">60,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjctMy0xLTEtMjk4MDM_e7768e33-d819-4896-b5e6-5050b9a84b74">66,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjgtMS0xLTEtMjk4MDM_0f79c4d6-6bc1-4507-94f8-d9077da9365c">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjgtMy0xLTEtMjk4MDM_6336b2b6-b3be-4e61-a9c6-cf214b51d206">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjktMS0xLTEtMjk4MDM_4ed68879-35a8-49a3-8e9d-00271d55acea">60,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjktMy0xLTEtMjk4MDM_f6b6616e-2141-4715-85b1-1696b829efc9">66,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities, non-controlling interests and stockholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMzAtMS0xLTEtMjk4MDM_3ebdc6d1-8a34-48a4-a15b-49107218497e">66,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMzAtMy0xLTEtMjk4MDM_d79570cf-a34d-4836-9010-b4efae50274a">73,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="text-align:center"><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands, except per share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.596%"><tr><td style="width:1.0%"></td><td style="width:68.041%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.258%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMy01LTEtMS0yOTgwMw_a78d663f-4412-44c8-acab-eb00e28f9a4e">3,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMy03LTEtMS0yOTgwMw_22c78d16-4cc2-4a9a-bfb1-59b64f86b46a">3,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfNS01LTEtMS0yOTgwMw_e0cce1ff-5e00-401a-ae4b-9d0234d9d211">3,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfNS03LTEtMS0yOTgwMw_9c3ac61f-a381-4a72-8f34-e02a2db2f1ff">3,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfNi01LTEtMS0yOTgwMw_477e6199-9e71-4cec-a1a7-1fcce623670b">6,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfNi03LTEtMS0yOTgwMw_739786ed-d83c-4932-9a6c-79f3fc0d3f47">6,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfOC01LTEtMS0yOTgwMw_b1e4255e-8718-4870-9f40-cf42c59aaa55">6,844</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfOC03LTEtMS0yOTgwMw_7886ab4c-1eb5-4d50-8b0b-9ddc8b2630b8">6,620</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTEtNS0xLTEtMjk4MDM_ffd17a0c-8071-4f62-9674-6af1e35701dd">670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTEtNy0xLTEtMjk4MDM_45f376e8-1662-4e6b-9bc3-faa046da55d3">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTItNS0xLTEtMjk4MDM_e511c4c0-8fb0-400c-8ed9-36a68d1c0dd0">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTItNy0xLTEtMjk4MDM_b468a745-d9e5-4a46-8833-f60081c5ebf1">148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTMtNS0xLTEtMjk4MDM_648cfd63-8676-403e-9caf-3db8a542214b">657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTMtNy0xLTEtMjk4MDM_123320cb-e8cf-4d55-814a-6617bafd54ac">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net loss before benefit from income taxes and noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTUtNS0xLTEtMjk4MDM_57b88eec-ffbd-4d78-8dfe-e8125925b85b">6,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTUtNy0xLTEtMjk4MDM_e7c50d56-b2ad-44cc-991c-7b53f15b21e5">6,705</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTYtNS0xLTEtMjk4MDM_7354c5a0-2ec3-4a70-815d-2d21927588c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTYtNy0xLTEtMjk4MDM_65057c12-e65e-4f73-b7c3-cc67af42e2f2">2,479</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTctNS0xLTEtMjk4MDM_18917001-e73d-42d4-b039-e58c390afdbf">6,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTctNy0xLTEtMjk4MDM_ae3c5eeb-35f7-41dc-acfc-21b318114545">4,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:25.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less - net income attributable to noncontrolling interests</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTgtNS0xLTEtMjk4MDM_7c4cb063-1787-4d7d-b903-da87089d7efe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTgtNy0xLTEtMjk4MDM_18fb4ed3-697b-4722-9573-976de35fe794">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Lisata Therapeutics, Inc. common stockholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTktNS0xLTEtMjk4MDM_31b0405e-6a7c-4774-849f-49d816196adc">6,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTktNy0xLTEtMjk4MDM_1360eec6-caa7-4dcf-8880-bc31f8100324">4,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic and diluted loss per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lisata Therapeutics, Inc. common stockholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMjMtNS0xLTEtMjk4MDM_1e35bca2-7fba-45c6-b5d9-2ff6391c8b1c"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMjMtNS0xLTEtMjk4MDM_4b81915e-280a-4a78-ac26-191ccca7dff5">0.77</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMjMtNy0xLTEtMjk4MDM_1a1e6490-5038-4120-90fe-f7615976e913"><ix:nonFraction unitRef="usdPerShare" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMjMtNy0xLTEtMjk4MDM_58fc1a97-ad5c-4a17-947e-4fd3de0999ab">1.05</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average common shares outstanding</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted shares</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMjYtNS0xLTEtMjk4MDM_831a0cef-cd2c-477b-b2b0-9ca7dc364c02"><ix:nonFraction unitRef="shares" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMjYtNS0xLTEtMjk4MDM_e9176691-7381-420b-af75-ed31d4156e16">7,987</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMjYtNy0xLTEtMjk4MDM_1681825c-d6bd-4651-8794-95ede7e8b4d9"><ix:nonFraction unitRef="shares" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMjYtNy0xLTEtMjk4MDM_ca30b010-861b-4984-9bc5-8a38d1e10fac">4,037</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 </span></div></div></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"></td><td style="width:66.732%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.111%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yMi9mcmFnOmU3ZGEwOTZiYTQ2YjRmMDViOWFlNTAwMjMyNTE5MmM2L3RhYmxlOjQ2MjdlN2YzM2FlYzQwN2I5ZDQ4MDBmNzIxNjE3MzBmL3RhYmxlcmFuZ2U6NDYyN2U3ZjMzYWVjNDA3YjlkNDgwMGY3MjE2MTczMGZfMi01LTEtMS0yOTgwMw_02047a2f-beab-4e5a-897b-4016b2321205">6,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yMi9mcmFnOmU3ZGEwOTZiYTQ2YjRmMDViOWFlNTAwMjMyNTE5MmM2L3RhYmxlOjQ2MjdlN2YzM2FlYzQwN2I5ZDQ4MDBmNzIxNjE3MzBmL3RhYmxlcmFuZ2U6NDYyN2U3ZjMzYWVjNDA3YjlkNDgwMGY3MjE2MTczMGZfMi03LTEtMS0yOTgwMw_578dcf90-4e1b-4e01-8fd5-630b7d18e79a">4,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale securities - net unrealized loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yMi9mcmFnOmU3ZGEwOTZiYTQ2YjRmMDViOWFlNTAwMjMyNTE5MmM2L3RhYmxlOjQ2MjdlN2YzM2FlYzQwN2I5ZDQ4MDBmNzIxNjE3MzBmL3RhYmxlcmFuZ2U6NDYyN2U3ZjMzYWVjNDA3YjlkNDgwMGY3MjE2MTczMGZfNS01LTEtMS0yOTgwMw_514e1ae6-2b33-4a98-adbd-9a4ef2c12c78">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yMi9mcmFnOmU3ZGEwOTZiYTQ2YjRmMDViOWFlNTAwMjMyNTE5MmM2L3RhYmxlOjQ2MjdlN2YzM2FlYzQwN2I5ZDQ4MDBmNzIxNjE3MzBmL3RhYmxlcmFuZ2U6NDYyN2U3ZjMzYWVjNDA3YjlkNDgwMGY3MjE2MTczMGZfNS03LTEtMS0yOTgwMw_ea36ee45-c1bb-4e49-a66b-fde279ff2e5b">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative translation adjustment arising during the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yMi9mcmFnOmU3ZGEwOTZiYTQ2YjRmMDViOWFlNTAwMjMyNTE5MmM2L3RhYmxlOjQ2MjdlN2YzM2FlYzQwN2I5ZDQ4MDBmNzIxNjE3MzBmL3RhYmxlcmFuZ2U6NDYyN2U3ZjMzYWVjNDA3YjlkNDgwMGY3MjE2MTczMGZfNi01LTEtMS0yOTgwMw_dd06a293-f19a-455c-a8ce-713891583223">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yMi9mcmFnOmU3ZGEwOTZiYTQ2YjRmMDViOWFlNTAwMjMyNTE5MmM2L3RhYmxlOjQ2MjdlN2YzM2FlYzQwN2I5ZDQ4MDBmNzIxNjE3MzBmL3RhYmxlcmFuZ2U6NDYyN2U3ZjMzYWVjNDA3YjlkNDgwMGY3MjE2MTczMGZfNi03LTEtMS0yOTgwMw_983d03f1-31d3-406a-ad3c-0277c755bfa6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yMi9mcmFnOmU3ZGEwOTZiYTQ2YjRmMDViOWFlNTAwMjMyNTE5MmM2L3RhYmxlOjQ2MjdlN2YzM2FlYzQwN2I5ZDQ4MDBmNzIxNjE3MzBmL3RhYmxlcmFuZ2U6NDYyN2U3ZjMzYWVjNDA3YjlkNDgwMGY3MjE2MTczMGZfNy01LTEtMS0yOTgwMw_e91f84bc-3646-4ee8-94b7-4bc68d67b18d">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yMi9mcmFnOmU3ZGEwOTZiYTQ2YjRmMDViOWFlNTAwMjMyNTE5MmM2L3RhYmxlOjQ2MjdlN2YzM2FlYzQwN2I5ZDQ4MDBmNzIxNjE3MzBmL3RhYmxlcmFuZ2U6NDYyN2U3ZjMzYWVjNDA3YjlkNDgwMGY3MjE2MTczMGZfNy03LTEtMS0yOTgwMw_8dbe7973-ccbc-4a3c-8139-9dc8dfaa90fd">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss attributable to Lisata Therapeutics, Inc. common</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">stockholders</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yMi9mcmFnOmU3ZGEwOTZiYTQ2YjRmMDViOWFlNTAwMjMyNTE5MmM2L3RhYmxlOjQ2MjdlN2YzM2FlYzQwN2I5ZDQ4MDBmNzIxNjE3MzBmL3RhYmxlcmFuZ2U6NDYyN2U3ZjMzYWVjNDA3YjlkNDgwMGY3MjE2MTczMGZfMTMtNS0xLTEtMjk4MDM_5e88cd90-b6cb-48ce-9ff2-93b939a862da">6,210</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yMi9mcmFnOmU3ZGEwOTZiYTQ2YjRmMDViOWFlNTAwMjMyNTE5MmM2L3RhYmxlOjQ2MjdlN2YzM2FlYzQwN2I5ZDQ4MDBmNzIxNjE3MzBmL3RhYmxlcmFuZ2U6NDYyN2U3ZjMzYWVjNDA3YjlkNDgwMGY3MjE2MTczMGZfMTMtNy0xLTEtMjk4MDM_da1c9924-92a1-48a7-a331-0fca931931e6">4,352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 </span></div></div></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.610%"><tr><td style="width:1.0%"></td><td style="width:24.986%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.146%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.542%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.643%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Lisata Therapeutics,<br/>Inc.<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest in<br/>Subsidiary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idccd6d8b24e84252b1bfbf4c82909880_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMi01LTEtMS0yOTgwMw_da5e5980-530c-44c7-ac2f-89774c5d55ff">3,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idccd6d8b24e84252b1bfbf4c82909880_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMi03LTEtMS0yOTgwMw_ab423787-dedc-405a-bda9-c0a4d3e16ac9">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83c32766e7f045148be714d2464b2a0f_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMi05LTEtMS0yOTgwMw_0f82ba03-a9e3-4bc0-a303-df8fadba4f10">546,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i172b6566e2954903a795810c0f7faea8_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMi0xMS0xLTEtMjk4MDM_8c926559-9f52-4b64-9b11-8b14cbaeb23c">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i659cc88ca4174728b2be88034cec77d9_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMi0xMy0xLTEtMjk4MDM_64d3b8d8-ea55-48a6-9d31-5697ddb5592c">453,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167ad6f9efc349e8aeb1f3afc4eb06f1_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMi0xNS0xLTEtMjk4MDM_f948bfed-dcee-498d-85cb-91151981abff">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3016a907934548cf89814e3cc5065bb5_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMi0xNy0xLTEtMjk4MDM_68cc6149-776f-44df-aa34-a4337ef61e55">92,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61be37acd3b24fdd8277d7ebcc1a2524_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMi0xOS0xLTEtMjk4MDM_02172db1-22b7-4b16-8eaa-a7e97261804c">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4046547dd294ad49c799697f6ddb110_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMi0yMS0xLTEtMjk4MDM_ecf7cc78-fa84-4c6e-8eb9-4afc1ae6f811">92,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c1e7ed7cdb0485db6a09b8f120ae70a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMy0xMy0xLTEtMjk4MDM_f0b51f40-e88c-48a2-abfa-471352048541">4,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30dbc205504449d38986e42bcedd9a11_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMy0xNy0xLTEtMjk4MDM_76ff2bc1-7635-4e73-8211-04c96be81ce4">4,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMy0yMS0xLTEtMjk4MDM_f207fc61-0204-458e-9455-769a21bf1606">4,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5530dc46c414ce092189cff88a3f7dd_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfNC01LTEtMS0yOTgwMw_24585502-f9e9-4df9-ac9e-3a6a6f545c3a">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e1630a3383b43cb9dd10a9949f9a4e4_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfNC05LTEtMS0yOTgwMw_881b7d57-ebad-468f-a8e0-c30eb161de7e">593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30dbc205504449d38986e42bcedd9a11_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfNC0xNy0xLTEtMjk4MDM_8ac503a4-fea2-4868-a9cf-f3239e0a5dac">593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfNC0yMS0xLTEtMjk4MDM_761d4117-743c-454b-a33a-add5f393b58f">593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5e281aca39d4be8a4acaf10e78a17c4_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOC0xMS0xLTEtMjk4MDM_4490453b-2237-454c-a4d0-ebf8f348671a">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30dbc205504449d38986e42bcedd9a11_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOC0xNy0xLTEtMjk4MDM_ae42fd83-2c84-4987-930e-4714c25481a0">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOC0yMS0xLTEtMjk4MDM_863af76a-4abe-4458-99b8-c9c0f7f13203">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57742d73f1a641e6869962f1ae17f160_I20220331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOS01LTEtMS0yOTgwMw_de47eea6-1b2a-4079-91b3-1a4d7839dca1">4,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57742d73f1a641e6869962f1ae17f160_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOS03LTEtMS0yOTgwMw_b6d9b220-6606-4ee2-ac0c-7c489b33ed2f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38bd3b8625604395bc59611e78cb1d4c_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOS05LTEtMS0yOTgwMw_5a46514a-4887-4a51-897e-d6f3c35e0871">546,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b6d5d55db744ce2adef5755fc8dcf38_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOS0xMS0xLTEtMjk4MDM_71e3e1be-c93f-4e03-a474-f564f101beef">196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia56329ac6bf74270be8df5d045aa6494_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOS0xMy0xLTEtMjk4MDM_d416f003-63a2-42ea-b9bd-c6b480a3000f">457,242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12937a3ada6d4dd2b874669455d35962_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOS0xNS0xLTEtMjk4MDM_308106fc-0c3c-4b88-93c2-f4eb2fafe6e3"><ix:nonFraction unitRef="usd" contextRef="i12937a3ada6d4dd2b874669455d35962_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOS0xNS0xLTEtMjk4MDM_6aed78d0-6771-4f0d-95bb-0016a18daf74">708</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bb37f6848ed455f8b7792e91866123b_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOS0xNy0xLTEtMjk4MDM_6b31f0c3-e674-40e4-8c9d-1d5de08a4ddf">88,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9619f9b64ebe471ca599503ec1560977_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOS0xOS0xLTEtMjk4MDM_7f33ffec-97ac-406e-b590-738ec3379be7">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce139ad8e764eb2804ef24019b88cdc_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOS0yMS0xLTEtMjk4MDM_5f9fe031-6ee7-4b4b-a94d-21fbb8f7da85">88,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Lisata Therapeutics,<br/>Inc.<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest in<br/>Subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3fd2bb5d543d427ca3beb6d8dae402ca_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTMtNS0xLTEtMjk4MDM_d98f8dbe-238d-429c-9cde-e69309c4609e">7,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fd2bb5d543d427ca3beb6d8dae402ca_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTMtNy0xLTEtMjk4MDM_2628ce51-8d03-4eef-bdf3-5d48a1c976e8">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d1ce795a4ca4649ac9b72bf8edca70d_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTMtOS0xLTEtMjk4MDM_247bbb40-a6a6-4022-bffa-e0e7b9d4bef7">574,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i800befd23f3841569b227ba2e2d706d1_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTMtMTEtMS0xLTI5ODAz_2a2be77b-d408-4f05-a92a-68b387ccfe31">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d5c507b54c44f3382ccc7e3b5440bb2_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTMtMTMtMS0xLTI5ODAz_cb4bf56f-177d-4728-b363-dff9e45c15a5">507,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79e1062c1f414381a135b2e72a0a68df_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTMtMTUtMS0xLTI5ODAz_e642026a-803e-4596-97f5-34f8782870e0">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac1d983470804b2cac2936f1132412ae_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTMtMTctMS0xLTI5ODAz_b5872176-20de-423a-89e8-91434d6584d4">66,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0482b3971ec42ce8127564740a1f058_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTMtMTktMS0xLTI5ODAz_d1f90a97-d8f0-42be-86ee-953e987a268b">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTMtMjEtMS0xLTI5ODAz_529ebd1b-4c7a-4df9-bff1-81ad4308f6cc">66,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7ee28bcb50447fd965f5db978a79599_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTUtMTMtMS0xLTI5ODAz_f3519a00-c389-4a94-88b5-271e22a643a5">6,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13d0c68aceb945648fc95a868eb9e3ef_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTUtMTctMS0xLTI5ODAz_c68862c8-9a5f-492d-8738-1e0f287113ed">6,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTUtMjEtMS0xLTI5ODAz_33e2a5be-c2e9-4b85-8d23-a252dd309b1d">6,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9347bcc62e74b129f2045c4859eb549_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTYtNS0xLTEtMjk4MDM_8e34bef9-0f5d-401d-a3ed-c929bc6ebf65">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if20c8a9a03b14863bb4789b2d34ee496_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTYtOS0xLTEtMjk4MDM_ffaded0f-dcc3-427b-83e6-433ff826d74c">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13d0c68aceb945648fc95a868eb9e3ef_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTYtMTctMS0xLTI5ODAz_6004e2b6-b3bc-4f0c-8845-676992761e55">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTYtMjEtMS0xLTI5ODAz_b809ac91-c166-4cf2-8485-1a5955c6b41f">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8cc3ac77efa48088686b917cb62e54f_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTktMTEtMS0xLTQyOTQ4_c5ac4a75-b956-4963-b2a6-96e18916ba7b">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13d0c68aceb945648fc95a868eb9e3ef_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTktMTctMS0xLTQyOTQ4_68b11189-b58e-4f0d-9c25-48b601fdbf0e">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTktMjEtMS0xLTQyOTQ4_161af1ac-1e36-4643-8b6a-6792b761707c">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8cc3ac77efa48088686b917cb62e54f_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjAtMTEtMS0xLTI5ODAz_cc4bba6e-a0ba-46e8-903c-4c2e9ec111cc">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13d0c68aceb945648fc95a868eb9e3ef_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjAtMTctMS0xLTI5ODAz_7b254b99-3a41-418d-99b2-f58808b336a9">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjAtMjEtMS0xLTI5ODAz_726ecbfc-2437-41d2-81e1-f113c88039c6">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1083fcdc93504069ab0c6b8124da6c36_I20230331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjEtNS0xLTEtMjk4MDM_1b3f86af-46d7-457c-a511-138810b94668">7,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1083fcdc93504069ab0c6b8124da6c36_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjEtNy0xLTEtMjk4MDM_fef12001-9596-4190-9e4a-67d8c53f4e08">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bf4f3fb7021489abb1e920d657cfc55_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjEtOS0xLTEtMjk4MDM_cf359a52-86dc-44c1-9b53-cd549c1674c3">575,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffe6cb540c934ae58b0986186454ad7d_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjEtMTEtMS0xLTI5ODAz_6d4dbc4a-5544-4e27-a458-88a9e863a6de">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da0050ca7b24feeba54e912cec8a0d6_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjEtMTMtMS0xLTI5ODAz_ae9a7862-8cde-4f55-a902-d70600d7cf40">513,428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1306a47c84604f74bccf2442a61ec582_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjEtMTUtMS0xLTI5ODAz_48dbe205-0f10-427a-afd6-bb112e78b701">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50382c5190684ed1bbbe023c4f418b3e_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjEtMTctMS0xLTI5ODAz_a845a989-d246-4911-ab55-970331df7e7c">60,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee22d1576f8f42cfbcb560d4e1373257_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjEtMTktMS0xLTI5ODAz_10885861-bb33-4a4f-a1f8-2d6f56f251bd">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjEtMjEtMS0xLTI5ODAz_c3ea4ba9-7b92-4751-9b29-6e8da030f848">60,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></div></div></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMy0xLTEtMS0yOTgwMw_a0fc73e5-4705-4788-a175-dab0c5c92f29">6,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMy0zLTEtMS0yOTgwMw_883474be-2e67-4f29-bd77-3f443eddad62">4,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfNS0xLTEtMS0yOTgwMw_685f1a6d-7e1f-454a-ba9e-16c80db706fa">675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfNS0zLTEtMS0yOTgwMw_ae64d0d2-8c7d-4534-9f1d-76f2a4106af4">760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfNi0xLTEtMS0yOTgwMw_71226f95-5653-461e-bfc9-7f318e4ce8f6">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfNi0zLTEtMS0yOTgwMw_ad167424-536b-4d1c-b54a-41abe5ac2c94">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on disposal of fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfNy0xLTEtMS0yOTgwMw_8357cb18-234d-4091-b004-e59b58f9f87c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfNy0zLTEtMS0yOTgwMw_9ae57018-516b-4b3a-8591-83194f5d2a7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTAtMS0xLTEtMjk4MDM_533e8733-a28e-4930-962a-cd3e34f38a13">167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTAtMy0xLTEtMjk4MDM_6b415275-c116-4d54-84fb-c529f9bdb070">515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTItMS0xLTEtMjk4MDM_542a6189-abda-4873-a294-df5edc4268b6">1,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTItMy0xLTEtMjk4MDM_1942af8e-00ff-4261-80c4-d6faf97566c2">969</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTMtMS0xLTEtMjk4MDM_1f687cc9-8615-4916-ac99-89c207674a5f">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTMtMy0xLTEtMjk4MDM_07f84d19-3539-4325-ba78-b39959cef443">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" sign="-" name="clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTQtMS0xLTEtMjk4MDM_a7d42f92-6c07-4354-8478-f70780941ab4">1,083</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" sign="-" name="clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTQtMy0xLTEtMjk4MDM_76616228-f5fa-4ae5-b6f6-82d43ed61138">1,786</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTUtMS0xLTEtMjk4MDM_3dbb574e-dc67-429f-ad13-ed57133d7f42">8,196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTUtMy0xLTEtMjk4MDM_192fb3c9-eae4-42f7-aaec-d12ca757fe71">5,642</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTctMS0xLTEtMjk4MDM_bb9f41c8-1c40-43d9-9cd3-156c66999f92">30,121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTctMy0xLTEtMjk4MDM_5c4312c4-9daa-441a-8c14-2bbd3692304d">26,546</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sale of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTgtMS0xLTEtMjk4MDM_a8c024ab-ea25-4523-bd87-5af1e05981e7">34,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTgtMy0xLTEtMjk4MDM_22884777-9de6-46b0-8277-edcf3a1c0bc6">20,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMjQtMS0xLTEtMjk4MDM_0dedb1c1-23a1-4726-a7cf-76b742a7bf01">4,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMjQtMy0xLTEtMjk4MDM_7d890bad-d0ee-4e75-ac45-788ccbffb7bf">6,090</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax withholding payments on net share settlement equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMjctMS0xLTEtMjk4MDM_4453ddd9-298f-4be5-972e-1262456a6b69">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMjctMy0xLTEtMjk4MDM_a3f6c9fd-c251-433b-9107-548b02f04268">168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMzAtMS0xLTEtMjk4MDM_1620d447-dbce-4a53-b2bc-fe4e24bc7dae">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMzAtMy0xLTEtMjk4MDM_357a5c66-0636-45cc-97e8-759050fbaac2">168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Effect of exchange rate changes on cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMzEtMS0xLTEtMjk4MDM_59300e83-f33d-4d94-b907-c0ca13fcafce">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMzEtMy0xLTEtMjk4MDM_5b789eec-fd66-4192-bdfe-e074cbe72a66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMzItMS0xLTEtMjk4MDM_9538c7bd-e6f2-4375-a333-1484b575403c">3,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMzItMy0xLTEtMjk4MDM_5440fb07-cb7a-465c-96e9-c7177f132e99">11,900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMzMtMS0xLTEtMjk4MDM_cabd7464-cc90-4f1d-be26-7d5570366cd0">32,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4046547dd294ad49c799697f6ddb110_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMzMtMy0xLTEtMjk4MDM_06c4e295-7025-4614-84da-2abc7c925fcb">24,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMzQtMS0xLTEtMjk4MDM_baa05d08-76e9-4d5b-90c4-cce0811b6f14">28,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce139ad8e764eb2804ef24019b88cdc_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMzQtMy0xLTEtMjk4MDM_136156dd-9c4c-4742-9722-0322e277a2ac">12,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 </span></div></div></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_34"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 1&#160;&#8211; <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="clbs:BusinessTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNC9mcmFnOjU5NDM4OWM1ZWY1MDRjMWRhYjc2YjlkYTcwMTZkYmZmL3RleHRyZWdpb246NTk0Mzg5YzVlZjUwNGMxZGFiNzZiOWRhNzAxNmRiZmZfMTQ3MDE_b83c6259-d7c1-451e-88e0-fb0a2dbc649e" continuedAt="i1dc5a03c65824b1c8f7b392cf440bd83" escape="true">The Business</ix:nonNumeric></span></div><ix:continuation id="i1dc5a03c65824b1c8f7b392cf440bd83" continuedAt="i1e0873b8392b48b2953cb869e7c3272a"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lisata Therapeutics, Inc. (together with its subsidiaries, the &#8220;Company&#8221;) is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The Company's lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are not expected to be affected. LSTA1 also has the potential to modify the tumor microenvironment (&#8220;TME&#8221;), with the objective of making tumors more susceptible to immunotherapies. The Company and its collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. To date, LSTA1 has also demonstrated favorable safety, tolerability, and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. The Company is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. In addition, the Company has development programs based on its autologous CD34+ cell therapy technology platform that it will look to partner while incurring no additional capital outlay.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. Its goal is to develop and commercialize products that address important unmet medical needs. The Company&#8217;s current development pipeline includes: </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LSTA1, the subject of Phase 1b/2a and 2b clinical studies being conducted globally in a variety of solid tumor types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a variety of anti-cancer regimens.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merger with Cend Therapeutics, Inc. and Name Change</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, the Company, then operating as Caladrius Biosciences, Inc. (&#8220;Caladrius&#8221;), completed its acquisition of Cend Therapeutics, Inc. (&#8220;Cend&#8221;), a Delaware corporation (the &#8220;Merger&#8221;), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), dated as of April 26, 2022, by and among Caladrius, Cend and CS Cedar Merger Sub, Inc. (&#8220;Merger Sub&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms set forth in the Merger Agreement and effective September 15, 2022 (the &#8220;Effective Time&#8221;): (i) Merger Sub merged with and into Cend, with Cend surviving as a wholly owned subsidiary of Caladrius, (ii) Caladrius changed its name to Lisata Therapeutics, Inc., and (iii) Caladrius effected a 1:15 reverse stock split of its common stock (&#8220;Reverse Stock Split&#8221;) prior to the Effective Time. At the Effective Time, each share of Cend's common stock outstanding immediately prior to the Effective Time was converted into the right to receive shares of Lisata&#8217;s common stock based on an exchange ratio of <ix:nonFraction unitRef="number" contextRef="iac5cf83f8935401bb2f5aca604012ece_D20220915-20220915" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNC9mcmFnOjU5NDM4OWM1ZWY1MDRjMWRhYjc2YjlkYTcwMTZkYmZmL3RleHRyZWdpb246NTk0Mzg5YzVlZjUwNGMxZGFiNzZiOWRhNzAxNmRiZmZfNTQ5NzU1ODQ3MzY3_96e9c084-a54e-460c-8371-99917853503a">0.5338</ix:nonFraction>, after taking into account the Reverse Stock Split (the &#8220;Exchange Ratio&#8221;). In connection with the Merger close, the Company issued an aggregate of <ix:nonFraction unitRef="shares" contextRef="icbaa2961421947beb045865325d7915f_I20220915" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNC9mcmFnOjU5NDM4OWM1ZWY1MDRjMWRhYjc2YjlkYTcwMTZkYmZmL3RleHRyZWdpb246NTk0Mzg5YzVlZjUwNGMxZGFiNzZiOWRhNzAxNmRiZmZfNTQ5NzU1ODQ3NTE4_7ec92184-c9cd-492b-a449-efe8313e8bd7">3,772,768</ix:nonFraction> shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Merger Agreement, Lisata assumed all of the outstanding and unexercised options to purchase shares of Cend capital stock under the 2016 Equity Incentive Plan (the &#8220;Cend Plan&#8221;), and, in connection with the Merger, such options were converted into options to purchase shares of Lisata&#8217;s common stock based on the Exchange Ratio. At the closing of the Merger at the Effective Time, the Company assumed Cend's stock options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ic072dd5659984964b08dc7870ffd5237_I20220915" decimals="INF" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNC9mcmFnOjU5NDM4OWM1ZWY1MDRjMWRhYjc2YjlkYTcwMTZkYmZmL3RleHRyZWdpb246NTk0Mzg5YzVlZjUwNGMxZGFiNzZiOWRhNzAxNmRiZmZfNTQ5NzU1ODQ4MTY1_409da001-fff1-4575-ab55-1cf355aedd17">1,227,776</ix:nonFraction> shares of the Company's common stock. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caladrius was considered to be the accounting acquirer based on the terms of the Merger Agreement and certain factors including: (i) Caladrius owned approximately <ix:nonFraction unitRef="number" contextRef="ie18f40d4e2884dbfaf339b40535a723f_D20220915-20220915" decimals="2" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNC9mcmFnOjU5NDM4OWM1ZWY1MDRjMWRhYjc2YjlkYTcwMTZkYmZmL3RleHRyZWdpb246NTk0Mzg5YzVlZjUwNGMxZGFiNzZiOWRhNzAxNmRiZmZfNTQ5NzU1ODQ4Mzcx_782090f5-1a7c-4d58-a270-2e58c865ddf5">52</ix:nonFraction>% of the Company's outstanding shares of common stock immediately following the close of the Merger; (ii) although both entities contributed to the new management team of Lisata, the Caladrius team had more individuals on the management team and holds the chief executive officer (&#8220;CEO&#8221;), chief medical officer (&#8220;CMO&#8221;) and other senior management roles; (iii) Caladrius paid a premium to acquire Cend&#8217;s assets; and (iv) Caladrius was significantly larger than Cend regarding total assets, operations, and research and development activities. The Merger was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;). Cend&#8217;s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;D with no </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><ix:continuation id="i1e0873b8392b48b2953cb869e7c3272a" continuedAt="i1af7bfa32260453e98b0f00f1854a13b"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alternative future use being expensed as reported in the consolidated statement of operations. Operating results presented in the consolidated statements of operations and comprehensive loss prior to the Merger are solely related to Caladrius Biosciences, Inc. and subsidiaries.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coronavirus Considerations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lisata's Phase 2b FREEDOM Trial of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. experienced delays in enrolling patients as a result of COVID-19. While early enrollment proceeded to plan with the first patient treated in January 2021, the impact of the COVID-19 pandemic contributed to a general slowing of enrollment, including supply chain disruptions affecting the availability of qualified catheters used in the diagnosis of CMD and/or administration of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as with a contrast agent typically used in many catheter laboratories. In May 2022, the Company announced that enrollment in the FREEDOM Trial was suspended and that it intended to conduct an interim analysis of the data from not less than the first 20 patients enrolled using the 6-month follow-up data to evaluate the efficacy and safety of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in subjects with CMD. Following this analysis along with Key Opinion Leaders&#8217; input, the Company determined that execution of a redesigned FREEDOM-like trial would be the appropriate next step, but the cost of such a trial would be prohibitively expensive to undergo without a strategic partner. Accordingly, the Company&#8217;s board of directors concluded that XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> development will only be continued if a strategic partner that can contribute the necessary capital for a redesigned trial is identified and secured. There can be no assurance that we will be able to identify such a partner and enter into an agreement with such partner on acceptable terms or at all.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2022, in connection with the Merger, the Company implemented the Reverse Stock Split, as authorized at the annual meeting of stockholders on September 13, 2022. The Reverse Stock Split became effective on September 14, 2022 at 5:00 pm and the Company's common stock began trading on The Nasdaq Capital Market on a post-split basis at the open of business on September 15, 2022. As of September 14, 2022, every fifteen shares of the Company&#8217;s issued and outstanding common stock (and such shares held in treasury) were automatically converted into one share of common stock, without any change in the par value per share. In addition, proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options, stock appreciation rights, convertible notes and warrants to purchase shares of common stock, the number of shares issuable upon the vesting of all restricted stock awards, and the number of shares of common stock reserved for issuance pursuant to the Company&#8217;s equity incentive compensation plans. Any stockholder who would otherwise be entitled to a fractional share of common stock created as a result of the Reverse Stock Split received a cash payment equal to the product of such resulting fractional interest in one share of common stock multiplied by the closing trading price of the common stock on September 15, 2022. The Reverse Stock Split was effectuated in order to increase the per share trading price of our common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from &#8220;common stock&#8221; to &#8220;additional paid-in capital&#8221; in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.</span></div><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNC9mcmFnOjU5NDM4OWM1ZWY1MDRjMWRhYjc2YjlkYTcwMTZkYmZmL3RleHRyZWdpb246NTk0Mzg5YzVlZjUwNGMxZGFiNzZiOWRhNzAxNmRiZmZfMTQ2ODk_aa8f323f-e1c4-474e-94fb-83acc580c1d3" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2023, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2022 and 2021 included in our 2022 Form 10-K. Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNC9mcmFnOjU5NDM4OWM1ZWY1MDRjMWRhYjc2YjlkYTcwMTZkYmZmL3RleHRyZWdpb246NTk0Mzg5YzVlZjUwNGMxZGFiNzZiOWRhNzAxNmRiZmZfMTQ2OTc_b65ecc0e-8d62-4b0f-aaad-8aa51e366577" continuedAt="iecf3f257f833469d8725739e23fa1b2f" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><ix:continuation id="i1af7bfa32260453e98b0f00f1854a13b"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iecf3f257f833469d8725739e23fa1b2f">circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and the valuation of the Merger which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;). Accordingly, actual results could differ from those estimates and assumptions.</ix:continuation></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNC9mcmFnOjU5NDM4OWM1ZWY1MDRjMWRhYjc2YjlkYTcwMTZkYmZmL3RleHRyZWdpb246NTk0Mzg5YzVlZjUwNGMxZGFiNzZiOWRhNzAxNmRiZmZfMTQ2OTg_5ac7a4af-f18f-4c33-a671-33be381656e9" continuedAt="ica571a0104764e9d9b22a945991d5c18" escape="true">Principles of Consolidation</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ica571a0104764e9d9b22a945991d5c18">The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation</ix:continuation>.</span></div><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNC9mcmFnOjU5NDM4OWM1ZWY1MDRjMWRhYjc2YjlkYTcwMTZkYmZmL3RleHRyZWdpb246NTk0Mzg5YzVlZjUwNGMxZGFiNzZiOWRhNzAxNmRiZmZfMTQ2OTU_629db4bd-e96d-4c0e-8527-92378ea898f8" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd. which is a foreign subsidiary of the Company is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_37"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 2 &#8211; <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNy9mcmFnOjlmNWU1MzEzYzkzMDQyZmJiZTExODUyZDE2OWU4YWEyL3RleHRyZWdpb246OWY1ZTUzMTNjOTMwNDJmYmJlMTE4NTJkMTY5ZThhYTJfMTI2MjA_47f79cc2-25d4-445c-8887-4b1b0a464b75" continuedAt="i079f9be9ac8a4ca686286ae399341e0b" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i079f9be9ac8a4ca686286ae399341e0b" continuedAt="i8808063fcbe0426b865c4ca76481cc69"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased. </span></div><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNy9mcmFnOjlmNWU1MzEzYzkzMDQyZmJiZTExODUyZDE2OWU4YWEyL3RleHRyZWdpb246OWY1ZTUzMTNjOTMwNDJmYmJlMTE4NTJkMTY5ZThhYTJfMTI2MTg_7aeda70f-7f4f-4fcd-90f6-558a345f22ec" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><ix:continuation id="i8808063fcbe0426b865c4ca76481cc69" continuedAt="i8ca1608c908b459bb286beb17d70d52a"><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9fba73856db44b87a21cac709470eda2_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNy9mcmFnOjlmNWU1MzEzYzkzMDQyZmJiZTExODUyZDE2OWU4YWEyL3RhYmxlOjQwYTE3YTZkZmUzYTQ0MjFhYzk5YjkwZGU0Yjg5MDQyL3RhYmxlcmFuZ2U6NDBhMTdhNmRmZTNhNDQyMWFjOTliOTBkZTRiODkwNDJfMC0xLTEtMS00NTg0MA_9294499d-00d8-45f9-ba8a-ca2a06cb4fbc">10</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5ee0cb91c75d458c950b56f03890e10c_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNy9mcmFnOjlmNWU1MzEzYzkzMDQyZmJiZTExODUyZDE2OWU4YWEyL3RhYmxlOjQwYTE3YTZkZmUzYTQ0MjFhYzk5YjkwZGU0Yjg5MDQyL3RhYmxlcmFuZ2U6NDBhMTdhNmRmZTNhNDQyMWFjOTliOTBkZTRiODkwNDJfMS0xLTEtMS00NTg0MA_b7b48265-614b-43b7-9a2f-ccf9f1b00d89">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ied9953ef26fe438b9a0b57d97f79bdea_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNy9mcmFnOjlmNWU1MzEzYzkzMDQyZmJiZTExODUyZDE2OWU4YWEyL3RhYmxlOjQwYTE3YTZkZmUzYTQ0MjFhYzk5YjkwZGU0Yjg5MDQyL3RhYmxlcmFuZ2U6NDBhMTdhNmRmZTNhNDQyMWFjOTliOTBkZTRiODkwNDJfMi0xLTEtMS00NTg0MA_5b745664-49a6-4110-a5cd-bfc1a9918d49">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of lease</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (&#8220;R&amp;D&#8221;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further drive the Company&#8217;s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company&#8217;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.</span></div><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNy9mcmFnOjlmNWU1MzEzYzkzMDQyZmJiZTExODUyZDE2OWU4YWEyL3RleHRyZWdpb246OWY1ZTUzMTNjOTMwNDJmYmJlMTE4NTJkMTY5ZThhYTJfMTI2MTM_8c7ec0ff-0c00-44a1-81fd-f5fb32820a2c" continuedAt="i774c38767fd5481a9881acc22b929868" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#8220;business&#8221; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><ix:continuation id="i8ca1608c908b459bb286beb17d70d52a"><ix:continuation id="i774c38767fd5481a9881acc22b929868"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Asset</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible asset consists of a single asset, Cend&#8217;s license agreement with Qilu Pharmaceutical, Co., Ltd. (&#8220;Qilu&#8221;) acquired in the Merger, with a value of $<ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNy9mcmFnOjlmNWU1MzEzYzkzMDQyZmJiZTExODUyZDE2OWU4YWEyL3RleHRyZWdpb246OWY1ZTUzMTNjOTMwNDJmYmJlMTE4NTJkMTY5ZThhYTJfNzk5NQ_ed1af4ba-74e5-45c7-b7c4-510c35b87dfe">0.4</ix:nonFraction>&#160;million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of 5 years. Amortization expense was $18 thousand for the three months ended March&#160;31, 2023. The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.  The projected amortization expense is $<ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNy9mcmFnOjlmNWU1MzEzYzkzMDQyZmJiZTExODUyZDE2OWU4YWEyL3RleHRyZWdpb246OWY1ZTUzMTNjOTMwNDJmYmJlMTE4NTJkMTY5ZThhYTJfNTQ5NzU1ODM3MDky_db2137de-7c2f-4859-bbd4-c661536de9a0">71</ix:nonFraction>&#160;thousand per year for the next five years. </span></div><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNy9mcmFnOjlmNWU1MzEzYzkzMDQyZmJiZTExODUyZDE2OWU4YWEyL3RleHRyZWdpb246OWY1ZTUzMTNjOTMwNDJmYmJlMTE4NTJkMTY5ZThhYTJfMTI2MTU_04e567e3-4fb9-4166-9162-b0179cd15fdc" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three months ended March&#160;31, 2023 and 2022.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestones</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#8217;s collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#8217;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three months ended March&#160;31, 2023 and March&#160;31, 2022, the Company has not recognized revenue related to milestones.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.</span></div></ix:continuation></ix:continuation><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_40"></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 3 &#8211; <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:AssetAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RleHRyZWdpb246NjhlMjk0ZTI4ZTEyNDY3MmEzODdjNmIxYTZhYWRkNTlfNjE2_2bc8cc7f-7a99-4283-aae5-f894dac73d14" continuedAt="id0e58bf9d1af43389ddcf88aaf2d7135" escape="true">Merger</ix:nonNumeric></span></div><ix:continuation id="id0e58bf9d1af43389ddcf88aaf2d7135"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger was accounted for as an asset acquisition as substantially all of the fair value was concentrated in IPR&amp;D. Cend&#8217;s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;D being expensed. The fair value of total consideration was $<ix:nonFraction unitRef="usd" contextRef="iac5cf83f8935401bb2f5aca604012ece_D20220915-20220915" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RleHRyZWdpb246NjhlMjk0ZTI4ZTEyNDY3MmEzODdjNmIxYTZhYWRkNTlfNDIy_6741fe89-7d72-45f8-992d-1d8a328a052f">36.1</ix:nonFraction>&#160;million. <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:AssetAcquisitionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RleHRyZWdpb246NjhlMjk0ZTI4ZTEyNDY3MmEzODdjNmIxYTZhYWRkNTlfNDM5ODA0NjUxMTg0MA_0a660f7f-b111-493b-89d9-6cda9e05037e" continuedAt="id6151dbe126f416a8f7ac0a290aa5962" escape="true">The following table is a summary of the purchase price calculation (in thousands except per share data).</ix:nonNumeric></span></div><ix:continuation id="id6151dbe126f416a8f7ac0a290aa5962"><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of common shares of the combined company owned by Cend stockholders</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbaa2961421947beb045865325d7915f_I20220915" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmNhZTQ3Yjg3ODcwNDQ5NzI5NjIzOWUyMjk3MGMwYTI3L3RhYmxlcmFuZ2U6Y2FlNDdiODc4NzA0NDk3Mjk2MjM5ZTIyOTcwYzBhMjdfNC0xLTEtMS0yOTgwMw_821b22bb-68a8-463e-9ffd-a417c8b69c4d">3,772,768</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multiplied by the fair value per share of Lisata common stock on September 15, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="icbaa2961421947beb045865325d7915f_I20220915" decimals="2" name="clbs:AssetAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmNhZTQ3Yjg3ODcwNDQ5NzI5NjIzOWUyMjk3MGMwYTI3L3RhYmxlcmFuZ2U6Y2FlNDdiODc4NzA0NDk3Mjk2MjM5ZTIyOTcwYzBhMjdfNS0xLTEtMS0yOTgwMw_c314fec9-017d-447e-929c-9ddd48d05515">6.25</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="icbaa2961421947beb045865325d7915f_I20220915" decimals="-3" name="clbs:AssetAcquisitionConsiderationTransferredEquityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmNhZTQ3Yjg3ODcwNDQ5NzI5NjIzOWUyMjk3MGMwYTI3L3RhYmxlcmFuZ2U6Y2FlNDdiODc4NzA0NDk3Mjk2MjM5ZTIyOTcwYzBhMjdfNi0xLTEtMS0yOTgwMw_1b9530cd-d5cf-49f0-9bff-ee7d8cee561d">23,580</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of Lisata's cost method investment in Cend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac5cf83f8935401bb2f5aca604012ece_D20220915-20220915" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmNhZTQ3Yjg3ODcwNDQ5NzI5NjIzOWUyMjk3MGMwYTI3L3RhYmxlcmFuZ2U6Y2FlNDdiODc4NzA0NDk3Mjk2MjM5ZTIyOTcwYzBhMjdfNy0xLTEtMS0yOTgwMw_3dfdc463-35e1-4134-bfc1-7b21c4538fb8">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental fair value of Cend's fully vested stock options</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac5cf83f8935401bb2f5aca604012ece_D20220915-20220915" decimals="-3" name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmNhZTQ3Yjg3ODcwNDQ5NzI5NjIzOWUyMjk3MGMwYTI3L3RhYmxlcmFuZ2U6Y2FlNDdiODc4NzA0NDk3Mjk2MjM5ZTIyOTcwYzBhMjdfOC0xLTEtMS0yOTgwMw_61adb8c1-2efc-4add-a6cd-e913ecf93507">2,136</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisata transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac5cf83f8935401bb2f5aca604012ece_D20220915-20220915" decimals="-3" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmNhZTQ3Yjg3ODcwNDQ5NzI5NjIzOWUyMjk3MGMwYTI3L3RhYmxlcmFuZ2U6Y2FlNDdiODc4NzA0NDk3Mjk2MjM5ZTIyOTcwYzBhMjdfOS0xLTEtMS0yOTgwMw_13091b82-67cf-428b-b8ca-889cb04dfddd">382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="iac5cf83f8935401bb2f5aca604012ece_D20220915-20220915" decimals="-3" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmNhZTQ3Yjg3ODcwNDQ5NzI5NjIzOWUyMjk3MGMwYTI3L3RhYmxlcmFuZ2U6Y2FlNDdiODc4NzA0NDk3Mjk2MjM5ZTIyOTcwYzBhMjdfMTAtMS0xLTEtMjk4MDM_4dc5ad98-4edd-41c6-a0c6-d16496720b8c">36,098</ix:nonFraction></span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The allocation of the purchase price was as follows (amounts in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="icbaa2961421947beb045865325d7915f_I20220915" decimals="-3" name="clbs:AssetAcquisitionCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmU2MTliNGY1MGJlODRhYWZhMzFhNjZhYTJlZDlmZDllL3RhYmxlcmFuZ2U6ZTYxOWI0ZjUwYmU4NGFhZmEzMWE2NmFhMmVkOWZkOWVfNC0xLTEtMS0yOTgwMw_3d7f05db-5327-45ee-a115-18a4fae90b50">7,062</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net working capital (excluding cash)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbaa2961421947beb045865325d7915f_I20220915" decimals="-3" name="clbs:AssetAcquisitionNetWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmU2MTliNGY1MGJlODRhYWZhMzFhNjZhYTJlZDlmZDllL3RhYmxlcmFuZ2U6ZTYxOWI0ZjUwYmU4NGFhZmEzMWE2NmFhMmVkOWZkOWVfNS0xLTEtMS0yOTgwMw_384f19d3-5402-4919-97d4-154038f95449">1,690</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbaa2961421947beb045865325d7915f_I20220915" decimals="-3" name="clbs:AssetAcquisitionOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmU2MTliNGY1MGJlODRhYWZhMzFhNjZhYTJlZDlmZDllL3RhYmxlcmFuZ2U6ZTYxOWI0ZjUwYmU4NGFhZmEzMWE2NmFhMmVkOWZkOWVfNi0xLTEtMS0yOTgwMw_ca645968-5a39-44ba-af29-cb30ecd52560">22</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbaa2961421947beb045865325d7915f_I20220915" decimals="-3" name="clbs:AssetAcquisitionAcquiredInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmU2MTliNGY1MGJlODRhYWZhMzFhNjZhYTJlZDlmZDllL3RhYmxlcmFuZ2U6ZTYxOWI0ZjUwYmU4NGFhZmEzMWE2NmFhMmVkOWZkOWVfNy0xLTEtMS0yOTgwMw_35ae0649-ebdd-44ff-ae2b-77a42ba82bb0">30,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbaa2961421947beb045865325d7915f_I20220915" decimals="-3" name="clbs:AssetAcquisitionIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmU2MTliNGY1MGJlODRhYWZhMzFhNjZhYTJlZDlmZDllL3RhYmxlcmFuZ2U6ZTYxOWI0ZjUwYmU4NGFhZmEzMWE2NmFhMmVkOWZkOWVfOC0xLTEtMS0yOTgwMw_5bff1f5c-8103-4ebd-96cf-c0fea66ef47c">355</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="iac5cf83f8935401bb2f5aca604012ece_D20220915-20220915" decimals="-3" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmU2MTliNGY1MGJlODRhYWZhMzFhNjZhYTJlZDlmZDllL3RhYmxlcmFuZ2U6ZTYxOWI0ZjUwYmU4NGFhZmEzMWE2NmFhMmVkOWZkOWVfMTAtMS0xLTEtMjk4MDM_ae5babd8-ed89-4cbd-8ac4-bc4bcf475290">36,098</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_43"></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 4 &#8211; <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RleHRyZWdpb246ZDQ0NTRhMTQ3NjU5NDkxM2IyMTlmNTA3MDc5M2JmMGFfNjM3_8bc0ea79-acbe-420c-98d9-c386eed8a33c" continuedAt="ib7139ca73a804d4d8b0ecb926bbbe874" escape="true">Available-for-Sale-Securities</ix:nonNumeric></span></div><ix:continuation id="ib7139ca73a804d4d8b0ecb926bbbe874" continuedAt="ic2bd30a13462484db5cc679290e413bd"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RleHRyZWdpb246ZDQ0NTRhMTQ3NjU5NDkxM2IyMTlmNTA3MDc5M2JmMGFfNjMx_8535841a-4219-4b82-a52a-7e5e5c1e83fc" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7bcd8f5631a452dbabbd9fc97bbc4d8_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfMy0xLTEtMS0yOTgwMw_3e378253-eb68-45de-b46d-c01fbd1080ad">37,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7bcd8f5631a452dbabbd9fc97bbc4d8_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfMy0zLTEtMS0yOTgwMw_77a32c04-161e-4a3f-8fba-975a3cfdb91f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7bcd8f5631a452dbabbd9fc97bbc4d8_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfMy01LTEtMS0yOTgwMw_b24cf3dc-6aad-4d09-8351-c7ff03f918d5">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7bcd8f5631a452dbabbd9fc97bbc4d8_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfMy03LTEtMS0yOTgwMw_db975066-debb-4a0c-a543-15f617ec1326">37,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied1922d4661541beb53e95573627a550_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfMy05LTEtMS0yOTgwMw_1163ebad-a610-4d9b-9341-a7352fcab800">44,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied1922d4661541beb53e95573627a550_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfMy0xMS0xLTEtMjk4MDM_2eb1a808-d1ce-4466-b282-615fe20464b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied1922d4661541beb53e95573627a550_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfMy0xMy0xLTEtMjk4MDM_776d0e9d-55b4-414b-8bae-fa7672efc7a1">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied1922d4661541beb53e95573627a550_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfMy0xNS0xLTEtMjk4MDM_e51691e7-8c69-425b-95ae-17c30b8edcc6">44,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab073f0d92e84ba6a575d902b1c5e90b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNC0xLTEtMS0yOTgwMw_8e092d23-3e54-48db-b0fd-5b8e70843681">5,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab073f0d92e84ba6a575d902b1c5e90b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNC0zLTEtMS0yOTgwMw_298f8035-dc8a-437b-8ea1-e50b1bb117bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab073f0d92e84ba6a575d902b1c5e90b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNC01LTEtMS0yOTgwMw_5b6270a9-26e6-47ea-9e94-304090bd3486">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab073f0d92e84ba6a575d902b1c5e90b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNC03LTEtMS0yOTgwMw_2278e9dd-4d40-4a9a-b372-9d8a7433f00b">5,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bdf116a27d45e4852970a908a1c9d5_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNC05LTEtMS0yOTgwMw_70a044e7-96dd-4d23-ba94-f4d96dce96dc">7,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bdf116a27d45e4852970a908a1c9d5_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNC0xMS0xLTEtMjk4MDM_dff32b6d-78e9-4a3d-8c7c-3b07fbcf6ba1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bdf116a27d45e4852970a908a1c9d5_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNC0xMy0xLTEtMjk4MDM_33771511-3257-4ef0-be1d-fe6b08f8fa1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bdf116a27d45e4852970a908a1c9d5_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNC0xNS0xLTEtMjk4MDM_5c9dee7a-8fc8-48a4-aefa-6f9a8457988c">7,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fe5dff51cd045c6a67c3d6af3c855d4_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNS0xLTEtMS0yOTgwMw_4cb75444-c61b-491c-bebc-b22b38ddbb00">12,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fe5dff51cd045c6a67c3d6af3c855d4_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNS0zLTEtMS0yOTgwMw_1e4bc7e1-68be-4692-a416-0ac917fa8d61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fe5dff51cd045c6a67c3d6af3c855d4_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNS01LTEtMS0yOTgwMw_7cba934b-efc6-4b52-840e-5efbfddfb4b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fe5dff51cd045c6a67c3d6af3c855d4_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNS03LTEtMS0yOTgwMw_f5499d4f-8938-4c10-8e6d-37f939b1d2fb">12,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66c395e4236040e08deda6719527e329_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNS05LTEtMS0yOTgwMw_09b1c6e0-e367-430f-a425-e23de0f0d36e">4,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66c395e4236040e08deda6719527e329_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNS0xMS0xLTEtMjk4MDM_c3f1214a-38dd-423b-8fe0-2c6112439b69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66c395e4236040e08deda6719527e329_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNS0xMy0xLTEtMjk4MDM_1422072c-fd78-47a7-95e0-997bb3777ea0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66c395e4236040e08deda6719527e329_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNS0xNS0xLTEtMjk4MDM_e6fa9e32-0f97-47fd-a2e6-4aa27a0cd4ae">4,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3379968f199147d999b83005f594ec07_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNi0xLTEtMS0yOTgwMw_5d40633a-f7af-4d18-a12a-afa9760be6dd">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3379968f199147d999b83005f594ec07_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNi0zLTEtMS0yOTgwMw_68f98f40-7f06-40fc-b1a6-1699c9b0adc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3379968f199147d999b83005f594ec07_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNi01LTEtMS0yOTgwMw_e3a46c05-6d91-453e-93ab-a244809bd40e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3379968f199147d999b83005f594ec07_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNi03LTEtMS0yOTgwMw_1a12ff00-acd6-4a3d-943f-2646ec7c882b">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8ffd44b3aa94c9a96419561b18f7289_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNi05LTEtMS0yOTgwMw_8c1bf105-d6d0-4440-80d5-a23377976d3a">7,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8ffd44b3aa94c9a96419561b18f7289_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNi0xMS0xLTEtMjk4MDM_e6bbf29f-9dea-41fa-b9e7-bdb36bf2fb29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8ffd44b3aa94c9a96419561b18f7289_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNi0xMy0xLTEtMjk4MDM_59787819-5c12-4d2b-acc1-9fdfa23c721d">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8ffd44b3aa94c9a96419561b18f7289_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNi0xNS0xLTEtMjk4MDM_707e6235-1e0d-4265-bed1-b3d98746a243">7,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfOC0xLTEtMS0yOTgwMw_eb2b7500-eded-4f09-835a-47eeb197ad64">55,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfOC0zLTEtMS0yOTgwMw_60ab006b-4c5a-4e8a-b2e0-03b2789b5cb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfOC01LTEtMS0yOTgwMw_69005b4c-9943-41c1-80ee-fc94893b8ae6">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfOC03LTEtMS0yOTgwMw_9f42ad13-0ba6-4fd6-bd85-864b5596c03f">55,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfOC05LTEtMS0yOTgwMw_1cf19b8e-452d-45a2-890d-31421677ae63">64,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfOC0xMS0xLTEtMjk4MDM_6a4881b2-20c7-4d7f-ac2b-0a2f8d4f4edc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfOC0xMy0xLTEtMjk4MDM_392f82c5-491c-46ac-8c78-00fdeb16a33e">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfOC0xNS0xLTEtMjk4MDM_fdf87a98-efb8-4dd8-8aaf-78e8ccf95f95">64,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RleHRyZWdpb246ZDQ0NTRhMTQ3NjU5NDkxM2IyMTlmNTA3MDc5M2JmMGFfNjMy_64009e95-d378-4241-9cb0-9b12bb406b30" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:360.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjk5NWE5OGQ5YmU2YzRjMmE4ODkyMDY5ZmM1MGQzNWU0L3RhYmxlcmFuZ2U6OTk1YTk4ZDliZTZjNGMyYTg4OTIwNjlmYzUwZDM1ZTRfMS0xLTEtMS0yOTgwMw_48015862-ffd2-4825-9c28-dc9271356e7b">22,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjk5NWE5OGQ5YmU2YzRjMmE4ODkyMDY5ZmM1MGQzNWU0L3RhYmxlcmFuZ2U6OTk1YTk4ZDliZTZjNGMyYTg4OTIwNjlmYzUwZDM1ZTRfMS0zLTEtMS0yOTgwMw_37740375-ac82-4f4f-837a-300623beff8c">27,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjk5NWE5OGQ5YmU2YzRjMmE4ODkyMDY5ZmM1MGQzNWU0L3RhYmxlcmFuZ2U6OTk1YTk4ZDliZTZjNGMyYTg4OTIwNjlmYzUwZDM1ZTRfMi0xLTEtMS0yOTgwMw_78fe2543-e610-4125-b5dd-a5c672688387">32,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjk5NWE5OGQ5YmU2YzRjMmE4ODkyMDY5ZmM1MGQzNWU0L3RhYmxlcmFuZ2U6OTk1YTk4ZDliZTZjNGMyYTg4OTIwNjlmYzUwZDM1ZTRfMi0zLTEtMS0yOTgwMw_072d11ce-840b-415f-91b4-ffe0bfee1bb5">37,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjk5NWE5OGQ5YmU2YzRjMmE4ODkyMDY5ZmM1MGQzNWU0L3RhYmxlcmFuZ2U6OTk1YTk4ZDliZTZjNGMyYTg4OTIwNjlmYzUwZDM1ZTRfMy0xLTEtMS0yOTgwMw_3cfc1401-e836-497f-8705-96cea39d3575">55,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjk5NWE5OGQ5YmU2YzRjMmE4ODkyMDY5ZmM1MGQzNWU0L3RhYmxlcmFuZ2U6OTk1YTk4ZDliZTZjNGMyYTg4OTIwNjlmYzUwZDM1ZTRfMy0zLTEtMS0yOTgwMw_987d85cc-400b-4d1d-aa1b-9899b3d88fd7">64,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><ix:continuation id="ic2bd30a13462484db5cc679290e413bd"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RleHRyZWdpb246ZDQ0NTRhMTQ3NjU5NDkxM2IyMTlmNTA3MDc5M2JmMGFfNjI2_bfd66f61-cc9c-45ea-9669-6152424a8bee" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:361.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjE1ZjcxYjZhNzRhZTRjNGRhOTMxNWUxNmE5MTUwMzFlL3RhYmxlcmFuZ2U6MTVmNzFiNmE3NGFlNGM0ZGE5MzE1ZTE2YTkxNTAzMWVfMi0xLTEtMS0yOTgwMw_d881a086-98a4-4d69-9077-77601f1389f9">55,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjE1ZjcxYjZhNzRhZTRjNGRhOTMxNWUxNmE5MTUwMzFlL3RhYmxlcmFuZ2U6MTVmNzFiNmE3NGFlNGM0ZGE5MzE1ZTE2YTkxNTAzMWVfMi0zLTEtMS0yOTgwMw_b37efac4-f6d7-4d72-b545-d1b9e37fedde">55,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjE1ZjcxYjZhNzRhZTRjNGRhOTMxNWUxNmE5MTUwMzFlL3RhYmxlcmFuZ2U6MTVmNzFiNmE3NGFlNGM0ZGE5MzE1ZTE2YTkxNTAzMWVfMy0xLTEtMS0yOTgwMw_c9a4cf4b-a2a2-4b28-9bf8-6d0f71a61ff9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjE1ZjcxYjZhNzRhZTRjNGRhOTMxNWUxNmE5MTUwMzFlL3RhYmxlcmFuZ2U6MTVmNzFiNmE3NGFlNGM0ZGE5MzE1ZTE2YTkxNTAzMWVfMy0zLTEtMS0yOTgwMw_41edf229-93f4-480b-abc8-9589dc7d15d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjE1ZjcxYjZhNzRhZTRjNGRhOTMxNWUxNmE5MTUwMzFlL3RhYmxlcmFuZ2U6MTVmNzFiNmE3NGFlNGM0ZGE5MzE1ZTE2YTkxNTAzMWVfNC0xLTEtMS0yOTgwMw_91d222cc-9bfc-46bf-887e-09ec6a583149">55,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjE1ZjcxYjZhNzRhZTRjNGRhOTMxNWUxNmE5MTUwMzFlL3RhYmxlcmFuZ2U6MTVmNzFiNmE3NGFlNGM0ZGE5MzE1ZTE2YTkxNTAzMWVfNC0zLTEtMS0yOTgwMw_198d64ac-0850-4456-9712-4fa208152c27">55,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_46"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 5 &#8211; <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RleHRyZWdpb246MDBkYTA3NTMxZWI5NDkxYzk1YzczODc3OGFiZjFiZmZfNDM5ODA0NjUxMTU3Mg_2a526786-3764-44ad-b6e0-15e8d0fd2fc2" continuedAt="i96afdb6079a344d8a68b055eb5fd87af" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i96afdb6079a344d8a68b055eb5fd87af"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RleHRyZWdpb246MDBkYTA3NTMxZWI5NDkxYzk1YzczODc3OGFiZjFiZmZfNDM5ODA0NjUxMTU3Mw_7d60e38a-48e5-4690-a1ed-0b6310089b28" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:505.50pt"><tr><td style="width:1.0pt"></td><td style="width:363.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb513457df6349bbb925697c05f89164_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfMi0xLTEtMS00MjU5Nw_7ca6dacd-678a-43f1-883b-e1e88d868e49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if531ec7b0d1a4289a1d93db89b2325ff_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfMi0zLTEtMS00MjU4OA_5d41bd85-d9f3-4b20-8a38-b09387680bdd">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3aa127bddd44877959f1946f1b707a1_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfMy0xLTEtMS00MjU5Nw_17da85c8-f7de-4c52-9fd6-3d5fbc2d890a">589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea3f0934334b47bfbb1b2334acb69624_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfMy0zLTEtMS00MjU4OA_7d5b7e91-81f7-4b5a-986c-57d467cf6bef">589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19bc8aae9d6b47a3a7633a871fba31ca_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfNC0xLTEtMS00MjU5Nw_ce074fa1-816c-4499-8a5c-821235313e22">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae124bfea4fe4e4d85a6e62fb5a67fa4_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfNC0zLTEtMS00MjU4OA_7f94f88f-ecf0-45e0-8d52-77dba189589e">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfNS0xLTEtMS00MjU5Nw_79809b63-dd23-4eca-8925-5b34a0c5c10f">661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfNS0zLTEtMS00MjU4OA_ff0b85c9-cdb1-4727-8df0-9b986020a700">713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfNi0xLTEtMS00MjU5Nw_08f36585-464a-4316-a263-7c119d015713">399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfNi0zLTEtMS00MjU4OA_4625e40a-db95-4894-a63f-f5082e54244b">417</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfNy0xLTEtMS00MjU5Nw_681fc4a9-5883-4a99-9d9a-4e72b8792deb">262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfNy0zLTEtMS00MjU4OA_db5fba9b-ed58-48d9-bcd2-345364904349">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results included depreciation expense of approximately $<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RleHRyZWdpb246MDBkYTA3NTMxZWI5NDkxYzk1YzczODc3OGFiZjFiZmZfMTY0OTI2NzQ0MjY5OQ_55dcf44b-c2ce-4a0e-85ca-b43a918d8fb4">30</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RleHRyZWdpb246MDBkYTA3NTMxZWI5NDkxYzk1YzczODc3OGFiZjFiZmZfMTY0OTI2NzQ0MjcwNw_be3926df-8885-434e-b56e-01350fbff007">7</ix:nonFraction>&#160;thousand for the three months ended March&#160;31, 2023 and 2022, respectively.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_49"></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 6 &#8211; <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80OS9mcmFnOmI2NzY1ODIyMTkyYTQxNWJhZjE3NTNjOTk4ODFiYmE5L3RleHRyZWdpb246YjY3NjU4MjIxOTJhNDE1YmFmMTc1M2M5OTg4MWJiYTlfMzIz_258a0b9b-7349-4e5e-a56a-e0d5e608cbc3" continuedAt="i98bbb67e867c430a8683dbdb6c03938a" escape="true">Income (Loss) Per Share</ix:nonNumeric></span></div><ix:continuation id="i98bbb67e867c430a8683dbdb6c03938a"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023 and 2022, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive. <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80OS9mcmFnOmI2NzY1ODIyMTkyYTQxNWJhZjE3NTNjOTk4ODFiYmE5L3RleHRyZWdpb246YjY3NjU4MjIxOTJhNDE1YmFmMTc1M2M5OTg4MWJiYTlfMzMy_3102e226-12a5-4661-b2ab-c2e0782f058c" continuedAt="i85b2b2764d36410db99ff5cd76b3fd72" escape="true">At March&#160;31, 2023 and 2022, the Company excluded the following potentially dilutive securities (in thousands):</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i85b2b2764d36410db99ff5cd76b3fd72"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3f5e8fd57334737879297c5b890af27_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80OS9mcmFnOmI2NzY1ODIyMTkyYTQxNWJhZjE3NTNjOTk4ODFiYmE5L3RhYmxlOjU2NjNkOWJiZDgzNTRhMDFhZmVkNmU4YzEyNGE1MmU5L3RhYmxlcmFuZ2U6NTY2M2Q5YmJkODM1NGEwMWFmZWQ2ZThjMTI0YTUyZTlfMi0xLTEtMS0yOTgwMw_a4766968-7aee-4fb0-b4b0-2be6e132606e">1,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94a5f2f4d8634a6482193404d866f108_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80OS9mcmFnOmI2NzY1ODIyMTkyYTQxNWJhZjE3NTNjOTk4ODFiYmE5L3RhYmxlOjU2NjNkOWJiZDgzNTRhMDFhZmVkNmU4YzEyNGE1MmU5L3RhYmxlcmFuZ2U6NTY2M2Q5YmJkODM1NGEwMWFmZWQ2ZThjMTI0YTUyZTlfMi0zLTEtMS0yOTgwMw_d53f6f90-edd6-41d7-9327-18d93e21caac">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1aa2ff8c93a14a628ddf610567129143_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80OS9mcmFnOmI2NzY1ODIyMTkyYTQxNWJhZjE3NTNjOTk4ODFiYmE5L3RhYmxlOjU2NjNkOWJiZDgzNTRhMDFhZmVkNmU4YzEyNGE1MmU5L3RhYmxlcmFuZ2U6NTY2M2Q5YmJkODM1NGEwMWFmZWQ2ZThjMTI0YTUyZTlfMy0xLTEtMS0yOTgwMw_1d48f9d1-7e8b-40e2-a733-cd25589be9d4">1,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f52a94bfea84193af9a8db010f1aa88_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80OS9mcmFnOmI2NzY1ODIyMTkyYTQxNWJhZjE3NTNjOTk4ODFiYmE5L3RhYmxlOjU2NjNkOWJiZDgzNTRhMDFhZmVkNmU4YzEyNGE1MmU5L3RhYmxlcmFuZ2U6NTY2M2Q5YmJkODM1NGEwMWFmZWQ2ZThjMTI0YTUyZTlfMy0zLTEtMS0yOTgwMw_741101ec-ccdb-40bd-b02e-7a8922a5ecf5">1,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3d4362e69d54f54aaad194fd8645f31_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80OS9mcmFnOmI2NzY1ODIyMTkyYTQxNWJhZjE3NTNjOTk4ODFiYmE5L3RhYmxlOjU2NjNkOWJiZDgzNTRhMDFhZmVkNmU4YzEyNGE1MmU5L3RhYmxlcmFuZ2U6NTY2M2Q5YmJkODM1NGEwMWFmZWQ2ZThjMTI0YTUyZTlfNS0xLTEtMS0yOTgwMw_182acfb7-fad1-42e9-befc-5fe38cbf7d3f">237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i239efe19fad74784b328fdf62d219847_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80OS9mcmFnOmI2NzY1ODIyMTkyYTQxNWJhZjE3NTNjOTk4ODFiYmE5L3RhYmxlOjU2NjNkOWJiZDgzNTRhMDFhZmVkNmU4YzEyNGE1MmU5L3RhYmxlcmFuZ2U6NTY2M2Q5YmJkODM1NGEwMWFmZWQ2ZThjMTI0YTUyZTlfNS0zLTEtMS0yOTgwMw_000121e1-1ce0-4a03-99c8-3d9c24589a6c">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_52"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 7 &#8211; <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RleHRyZWdpb246OTQzZTJmNWZhZGVmNGRiMThkYTczMjY5YjZlNWUzNTBfMTQ3MA_48376114-12fc-41ab-b608-63e6a00a19e1" continuedAt="i3330cec8a04148be841e84541a4240f1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i3330cec8a04148be841e84541a4240f1" continuedAt="i70978449d0d94c4b943b6902633c7bf5"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 inputs are defined as unobservable inputs for the assets or liabilities. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><ix:continuation id="i70978449d0d94c4b943b6902633c7bf5"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RleHRyZWdpb246OTQzZTJmNWZhZGVmNGRiMThkYTczMjY5YjZlNWUzNTBfMTQ3Mw_6af68cdf-d327-4c99-815d-fb4a6cbc85a5" continuedAt="i6557cbf979d643b3ae297b362cd9930f" escape="true">as of March&#160;31, 2023 and December&#160;31, 2022 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i6557cbf979d643b3ae297b362cd9930f"><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:116.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c17a022357047ff92faad6cb21667dd_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfMy0yLTEtMS0yOTgwMw_25053d46-224d-4fb8-9cba-bc948ee24315">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504afb254cc84fff8865bdb6c94dc145_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfMy00LTEtMS0yOTgwMw_2ee141c8-3921-4786-bdbf-1f81438e9f8f">32,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i014d15d0d777404b8e448a8905b727ad_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfMy02LTEtMS0yOTgwMw_8109806c-8c93-42ae-9d67-c4418ae5c7af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i039c3f49b8da4f2d9b6cefb4c7bdaac6_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfMy04LTEtMS0yOTgwMw_5274424a-971b-40c3-ad19-9e5c129dd46d">32,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f24ed5b4964736968a44cdbb684fbc_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfMy0xMC0xLTEtMjk4MDM_56b5a014-bffc-4517-a2ce-e644ac544144">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c9472dfe66456db347e101f7b9c855_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfMy0xMi0xLTEtMjk4MDM_db56ced5-3688-4777-965b-e2f29e77d4a2">37,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71685748225c4034a7cebd3a48175ca9_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfMy0xNC0xLTEtMjk4MDM_723f0736-eaca-4821-b135-df13a0fa7592">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51755cafee74432a96fde0a4fb4c5bfb_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfMy0xNi0xLTEtMjk4MDM_c2298950-2cb8-4618-bd19-35626f57307c">37,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c17a022357047ff92faad6cb21667dd_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfNS0yLTEtMS0yOTgwMw_daf23c95-ce4f-42d4-8955-9e27bb877901">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504afb254cc84fff8865bdb6c94dc145_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfNS00LTEtMS0yOTgwMw_4cb7c312-fdff-4ec9-b0a7-29b21cf54f6d">32,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i014d15d0d777404b8e448a8905b727ad_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfNS02LTEtMS0yOTgwMw_05443ef6-6c53-4db0-a3a3-58a917124ed1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i039c3f49b8da4f2d9b6cefb4c7bdaac6_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfNS04LTEtMS0yOTgwMw_3bf85a21-017f-4b04-91a9-2402181ce3fe">32,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f24ed5b4964736968a44cdbb684fbc_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfNS0xMC0xLTEtMjk4MDM_68fe1ec8-bbdf-4bdc-90df-8da955e6484e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c9472dfe66456db347e101f7b9c855_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfNS0xMi0xLTEtMjk4MDM_ad837ebd-a316-4b7a-97fd-4fd7733b825e">37,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71685748225c4034a7cebd3a48175ca9_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfNS0xNC0xLTEtMjk4MDM_f4c0a359-f882-40bf-8f32-8fc2f1710a5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51755cafee74432a96fde0a4fb4c5bfb_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfNS0xNi0xLTEtMjk4MDM_71b61321-d5d6-44ef-b516-9c5181a49bac">37,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash, cash equivalents, accounts payable and accrued expenses approximate fair value as of March&#160;31, 2023 and December&#160;31, 2022, due to the short maturity nature of these items.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_55"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 8&#160;&#8211;&#160;<ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RleHRyZWdpb246ZGIxODU3MjllOTdiNDc4ODkwOGZkNzYwM2IyYmUyZjlfMTE1_2c665b88-9e9c-4793-9668-ac2aad0fb431" continuedAt="i1254192def584f6bba46ea719c546f14" escape="true">Accrued Liabilities</ix:nonNumeric></span></div><ix:continuation id="i1254192def584f6bba46ea719c546f14"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RleHRyZWdpb246ZGIxODU3MjllOTdiNDc4ODkwOGZkNzYwM2IyYmUyZjlfMTA5_09cba4b5-213f-456c-ae69-376387b26fbb" escape="true"><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of March&#160;31, 2023 and December&#160;31, 2022 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:313.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfMS0xLTEtMS0yOTgwMw_1f77495e-2b36-451c-bc63-64dab7352c42">1,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfMS0zLTEtMS0yOTgwMw_958ad543-6171-4e54-a876-8fa2088f2c2b">2,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities &#8212; current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfMi0xLTEtMS0yOTgwMw_3c63dc53-5449-4691-8592-149db33102a8">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfMi0zLTEtMS0yOTgwMw_e2517739-f94d-45e3-9a96-afd738f943e7">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D&amp;O insurance liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="clbs:AccruedGrantFunding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfMy0xLTEtMS0yOTgwMw_7f013256-89c3-4803-a631-58d541cd4d44">956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="clbs:AccruedGrantFunding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfMy0zLTEtMS0yOTgwMw_256c0cca-c5b7-401b-8932-14a177b020d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and R&amp;D related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="clbs:ClinicalAndRDRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfNC0xLTEtMS0yOTgwMw_86e107af-61b5-402b-a5a4-a94443f9f4f2">1,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="clbs:ClinicalAndRDRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfNC0zLTEtMS0yOTgwMw_b3e39fb7-3429-47aa-91aa-7feafea57b3b">785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfNS0xLTEtMS0yOTgwMw_cbd90762-0aee-4b2a-8972-26475ed3b5ea">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfNS0zLTEtMS0yOTgwMw_4d277cf2-a54d-4552-8d92-e23cf3d92c68">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfNi0xLTEtMS0yOTgwMw_69afb331-dcfe-4be9-bee0-b30352e99648">3,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfNi0zLTEtMS0yOTgwMw_2746322f-7818-4a9f-906c-572aff5f132c">3,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_58"></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 9&#160;&#8211;&#160;<ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RleHRyZWdpb246YmJmMThlNGYyZGRlNGIxODg3YzQxODQyZDQwMTQzNWFfMTE3MQ_8cbacbf3-5e04-4e69-82b0-63a1c094a6a4" continuedAt="i151536d23e2b45a1a4a01f5b7ddf669f" escape="true">Operating Leases</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i151536d23e2b45a1a4a01f5b7ddf669f" continuedAt="ia8486ca6902944ac8b1fb5fcefe2d6c7">The Company adopted ASU No. 2016-02, Leases (Topic 842) on January 1, 2019 and recognized leases with duration greater than 12 months on the balance sheet using the modified retrospective approach. The Company has operating leases for <ix:nonFraction unitRef="office" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="INF" name="clbs:NumberOfOfficesUnderOperatingLeases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RleHRyZWdpb246YmJmMThlNGYyZGRlNGIxODg3YzQxODQyZDQwMTQzNWFfNjg_f9f34e50-1003-4de7-992e-4696dfdb7a6c">two</ix:nonFraction> offices, one of which expired on March 31, 2023 and the other expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. Each of the Company's leases includes options for the Company to extend the lease term and/or sub-lease space in whole or in part.</ix:continuation></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><ix:continuation id="ia8486ca6902944ac8b1fb5fcefe2d6c7"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RleHRyZWdpb246YmJmMThlNGYyZGRlNGIxODg3YzQxODQyZDQwMTQzNWFfMTE3Mg_985b9f39-e417-461a-997d-da34fcf923de" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:325.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfMi0wLTEtMS0yOTgwMw_684390b7-3bb3-42c7-8a83-13f2f83e10e2"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfMi0wLTEtMS0yOTgwMw_7e944932-8384-4e08-8716-1c2ac79100ed">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfMi0xLTEtMS0yOTgwMw_2b33a763-3004-47f6-a434-30af7830d071">425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfMi0zLTEtMS0yOTgwMw_5fa8bcf6-17ff-41a9-9178-eee19a93c71b">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfMy0xLTEtMS0yOTgwMw_d32d6a32-255f-4563-b080-2b39ca5ea087">425</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfMy0zLTEtMS0yOTgwMw_4e7895cb-462c-4355-bd25-385519727d05">487</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNi0wLTEtMS0yOTgwMw_37de52d8-2557-479d-bbaf-f29481bcc474"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNi0wLTEtMS0yOTgwMw_69afedb4-8e13-45d2-80d7-456feaf20302">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNi0xLTEtMS0yOTgwMw_15946c5d-cfef-41c6-a20c-c374c5090fa5">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNi0zLTEtMS0yOTgwMw_5af0ee4e-f682-4f73-84a6-7502268faf1b">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNy0wLTEtMS0yOTgwMw_16c9c39d-ad71-40ba-bf95-bdb2e5413413"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNy0wLTEtMS0yOTgwMw_bcfccd01-1243-450c-981b-7940b87eb256">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNy0xLTEtMS0yOTgwMw_407b5fe9-3aed-45a7-9f79-90442310c76a">265</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNy0zLTEtMS0yOTgwMw_0706f4fc-c303-43bf-a533-92f9ad03aa45">305</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfOC0xLTEtMS0yOTgwMw_31c1b0f0-f986-41df-9d5b-d80f46acf070">421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfOC0zLTEtMS0yOTgwMw_a9560b05-ee44-4843-9c26-b95e990fcc17">485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the weighted average remaining lease term for our operating lease was <ix:nonNumeric contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RleHRyZWdpb246YmJmMThlNGYyZGRlNGIxODg3YzQxODQyZDQwMTQzNWFfOTky_8e6d15d0-2143-41dc-997d-b694e4ee4696">2.5</ix:nonNumeric> years, and the weighted average discount rate for our operating lease was <ix:nonFraction unitRef="number" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="5" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RleHRyZWdpb246YmJmMThlNGYyZGRlNGIxODg3YzQxODQyZDQwMTQzNWFfMTA2NA_cf9c1116-1f3e-440d-826b-c8830f04cb6c">9.625</ix:nonFraction>%. As of December&#160;31, 2022, the weighted average remaining lease term for our operating leases was 1.50 years, and the weighted average discount rate for our operating leases was 9.625%.</span></div><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RleHRyZWdpb246YmJmMThlNGYyZGRlNGIxODg3YzQxODQyZDQwMTQzNWFfMTE2OA_18736b3b-1736-4db4-a49c-e3bc43160940" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under the lease agreement as of March&#160;31, 2023 were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOjg2NTBlYzY2NWJkNDQ2Yjk5MGU0ZDJhMjA1NDUyMjc5L3RhYmxlcmFuZ2U6ODY1MGVjNjY1YmQ0NDZiOTkwZTRkMmEyMDU0NTIyNzlfNC0xLTEtMS0yOTgwMw_4027e585-ce44-406e-9ee3-34129a9af345">143</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOjg2NTBlYzY2NWJkNDQ2Yjk5MGU0ZDJhMjA1NDUyMjc5L3RhYmxlcmFuZ2U6ODY1MGVjNjY1YmQ0NDZiOTkwZTRkMmEyMDU0NTIyNzlfNS0xLTEtMS0yOTgwMw_c520725f-3bbf-4f68-b65e-aac1016aa650">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOjg2NTBlYzY2NWJkNDQ2Yjk5MGU0ZDJhMjA1NDUyMjc5L3RhYmxlcmFuZ2U6ODY1MGVjNjY1YmQ0NDZiOTkwZTRkMmEyMDU0NTIyNzlfNi0xLTEtMS0yOTgwMw_5ccd12de-f405-4ad3-9b7b-e4e727295fe1">143</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOjg2NTBlYzY2NWJkNDQ2Yjk5MGU0ZDJhMjA1NDUyMjc5L3RhYmxlcmFuZ2U6ODY1MGVjNjY1YmQ0NDZiOTkwZTRkMmEyMDU0NTIyNzlfNy0xLTEtMS0yOTgwMw_14dc4701-8eef-4922-b317-334559799f1f">476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOjg2NTBlYzY2NWJkNDQ2Yjk5MGU0ZDJhMjA1NDUyMjc5L3RhYmxlcmFuZ2U6ODY1MGVjNjY1YmQ0NDZiOTkwZTRkMmEyMDU0NTIyNzlfOC0xLTEtMS0yOTgwMw_17a2d68f-7ef0-4d32-b57d-3e8e5386d17a">55</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOjg2NTBlYzY2NWJkNDQ2Yjk5MGU0ZDJhMjA1NDUyMjc5L3RhYmxlcmFuZ2U6ODY1MGVjNjY1YmQ0NDZiOTkwZTRkMmEyMDU0NTIyNzlfOS0xLTEtMS0yOTgwMw_67b041da-bc13-4297-ae79-e39e2bf4c242">421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_61"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 10 &#8211; <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNjI4Mg_6d1ea461-815f-4fc0-a60a-3e107bf4c5c6" continuedAt="i586c88d8bf994589bead928c454b42a0" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="i586c88d8bf994589bead928c454b42a0" continuedAt="i5ff27cd53c314ebfa8d4803bb5cd23f1"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2022, in connection with the merger, we implemented the Reverse Stock Split, as described in Note 1. All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from &#8220;common stock&#8221; to &#8220;additional paid-in capital&#8221; in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Issuances</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">At The Market Offering Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC, as sales agent, in connection with an &#8220;at the market offering&#8221; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i2d6b8752305947b19367c1e2776a4b9b_I20210604" decimals="-5" name="clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNDY0NQ_c387e7a6-336d-497f-b85a-25a0caf7d8f4">50.0</ix:nonFraction>&#160;million. Subsequent to the filing of our Form 10-K on March 22, 2022, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="i8175b9d271b74085bb0ba378fb359200_I20220331" decimals="-5" name="us-gaap:CommonStockValueOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNTQ5NzU1ODIwMzU4_66614f23-6d57-494e-939c-cc883d7ee6cd">43.6</ix:nonFraction>&#160;million. Pursuant to General Instruction I.B.6 of Form S-3, since the aggregate market value of our outstanding common stock held by non-affiliates was below $75.0&#160;million at the time of such Form 10-K filing, the aggregate amount of securities that we are permitted to offer and sell was reduced to $<ix:nonFraction unitRef="usd" contextRef="i35acb9e033324b219fe3495ddd939d9c_I20220930" decimals="0" name="clbs:SaleOfStockAvailableForSale" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNTQ5NzU1ODIwNjU0_72e0aebf-3115-4236-8153-bc4ebea88b23">17,698,943</ix:nonFraction>, which was equal to one-third of the aggregate market value of our common stock held by non-affiliates as of September 21, 2022. During the three months ended March&#160;31, 2023 and since inception, the Company has <ix:nonFraction unitRef="shares" contextRef="i6e7ec6bf429543dd8edca7c206e09fd8_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNDcwNA_c0bf2f4b-b4ef-4f65-aed3-92aed2777a77">no</ix:nonFraction>t issued any shares under the ATM Agreement. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger closing, the Company issued an aggregate of <ix:nonFraction unitRef="shares" contextRef="icbaa2961421947beb045865325d7915f_I20220915" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNDM5ODA0NjUyNDA5MA_7fcbf966-d337-4547-b035-1e29a2c491f8">3,772,768</ix:nonFraction> shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><ix:continuation id="i5ff27cd53c314ebfa8d4803bb5cd23f1" continuedAt="i419a47088cdd46ab89d233b24fa650c3"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Warrants</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger and after giving effect to the Reverse Stock Split, the Company assumed <ix:nonFraction unitRef="shares" contextRef="i997e64fe38cd4696b408c8f14ff89821_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNDM5ODA0NjUyNDEwMQ_fc8e8b6a-f62d-408a-8e89-93b838a43fd8">1,227,776</ix:nonFraction> options outstanding of Cend. The options granted under the Cend Plan are exercisable at various dates as determined upon grant and will expire no more than ten years from their original date of grant. The Cend Plan stock options generally vest over a four-year term. <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNjI4NA_061aaa7e-97d3-463d-8f92-dfe30e2e3bd5" continuedAt="i1a2b05c0c4384435b2ce87d0530ebdf6" escape="true">The following table summarizes the activity for stock options and warrants for the three months ended March&#160;31, 2023:</ix:nonNumeric></span></div><div style="text-align:center"><ix:continuation id="i1a2b05c0c4384435b2ce87d0530ebdf6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMi0yLTEtMS0yOTgwMw_53874520-5cb8-4cd1-b10d-717a3940a9ac">1,391,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMi00LTEtMS0yOTgwMw_661c3d87-42ed-4d47-ba7a-b66f75a9914e">10.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i997e64fe38cd4696b408c8f14ff89821_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMi02LTEtMS0yOTgwMw_e1e0d258-589e-49b8-aafd-820be32ae753">7.03</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMi04LTEtMS0yOTgwMw_cd4a372b-f6ed-4184-bea8-bbade034c831">187.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="INF" name="clbs:CommonStockWarrantsShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMi0xMC0xLTEtMjk4MDM_633e68eb-ce38-497e-8860-5d3440f09c5b">1,423,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMi0xMi0xLTEtMjk4MDM_9b7ddd00-09bf-447d-8f9c-58b3b9fe4f17">42.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i997e64fe38cd4696b408c8f14ff89821_D20220101-20221231" name="clbs:WeightedAverageRemainingContractualTermwarrantoutstanding" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMi0xNC0xLTEtMjk4MDM_67ea26a2-129a-48c0-92e1-af51473ad5c1">3.37</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="clbs:AggregateIntrinsicValueWarrantsOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMi0xNi0xLTEtMjk4MDM_1b6a071c-2093-4a82-afc4-638391e7e5ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfNS0yLTEtMS0yOTgwMw_e0b725c2-4417-4da6-b24f-0fbb79f8388f">103,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfNS00LTEtMS0yOTgwMw_668f4a60-7269-4520-9b53-4daf2b752fc9">3.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="INF" name="clbs:WarrantsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfNS0xMC0xLTEtMjk4MDM_2b273b0e-5e3a-4305-8d8f-b9434f3cd5be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfNS0xMi0xLTEtMjk4MDM_bbedad18-6b22-4c16-b8bd-a4a656d5a840">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfNy0yLTEtMS0yOTgwMw_92bba47c-728e-4a18-860d-47c179f4b009">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfNy00LTEtMS0yOTgwMw_51fcceef-dfb5-4049-aa58-f6cf5b0b10e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="INF" name="clbs:WarrantsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfNy0xMC0xLTEtMjk4MDM_8a28983c-5179-4d66-a6c8-c4228084149f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfNy0xMi0xLTEtMjk4MDM_8ec0b18e-6499-4e7e-a8cd-0477594c373e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfOC0yLTEtMS0yOTgwMw_3619e71b-11ad-40be-a9c7-7674cd325d5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfOC00LTEtMS0yOTgwMw_a3f016f8-fda2-46dd-ab07-3954ed4c3a76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="INF" name="clbs:WarrantsCanceled" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfOC0xMC0xLTEtMjk4MDM_28c5efcf-9aca-40ae-8d13-3ca714f1eb20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsCanceled" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfOC0xMi0xLTEtMjk4MDM_e5123428-51cd-4d3b-a95e-86caf538fe7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfOS0yLTEtMS0yOTgwMw_a549a26a-4776-4f39-8bcf-4ffad36fb545">2,520</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfOS00LTEtMS0yOTgwMw_d297351f-d70c-4b92-ac31-27afefbd54a4">224.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="INF" name="clbs:WarrantsExpired" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfOS0xMC0xLTEtMjk4MDM_6edaa803-13cf-4bac-b3af-25c7d7910f60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsExpired" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfOS0xMi0xLTEtMjk4MDM_96adb97e-7c42-4513-ae34-8a57815b95ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTAtMi0xLTEtMjk4MDM_20717567-25b1-4f6f-8bbb-859a5986fea0">1,492,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTAtNC0xLTEtMjk4MDM_ca0333df-82f5-4022-aad3-ba5408106032">9.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTAtNi0xLTEtMjk4MDM_744844b7-8cc7-496c-8e7e-ac599b0b578a">7.01</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTAtOC0xLTEtMjk4MDM_711ca45b-1edf-4381-bec5-e3f7bd9f5dda">359.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="INF" name="clbs:CommonStockWarrantsShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTAtMTAtMS0xLTI5ODAz_8f079c96-6a2b-4487-b7be-2daa0d1cf1ba">1,423,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTAtMTItMS0xLTI5ODAz_a63f5387-2c8a-40a2-9dcc-ef5813e2cc76">42.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="clbs:WeightedAverageRemainingContractualTermwarrantoutstanding" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTAtMTQtMS0xLTI5ODAz_465cedfd-ceef-4c3c-a6b7-9e8113d46a7e">3.13</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="clbs:AggregateIntrinsicValueWarrantsOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTAtMTYtMS0xLTI5ODAz_39617fd2-783a-4cd4-ab89-dfa7da6734b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2023<br/>or expected to vest in the future</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTEtMi0xLTEtMjk4MDM_54f36e11-e554-4deb-b552-9dea3dc09f83">1,486,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTEtNC0xLTEtMjk4MDM_ef92ba85-a368-4b72-8ee4-8bb810983a1f">9.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTEtNi0xLTEtMjk4MDM_f536beea-5847-4496-b4df-0ecd3631e36e">7.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTEtOC0xLTEtMjk4MDM_f7861414-edac-4b85-ac7d-f4a6da3c5924">358.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="INF" name="clbs:Sharesvestedandexpectedtovest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTEtMTAtMS0xLTI5ODAz_9f6a1190-8423-4111-8b7b-a60c1c25576b">1,423,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTEtMTItMS0xLTI5ODAz_11e6f390-0fbb-4441-80b1-686db81ebe39">42.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="clbs:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTEtMTQtMS0xLTI5ODAz_c689ae4e-0066-407d-b7f2-4a7a7867cf3b">3.13</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="clbs:AggregateIntrinsicValueWarrantsvestedandexpectedtovest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTEtMTYtMS0xLTI5ODAz_7b178f4a-2560-4bb9-ac54-4bc8b82357d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTItMi0xLTEtMjk4MDM_745ad601-33d0-48d2-8cbb-ff02c2653832">1,207,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTItNC0xLTEtMjk4MDM_adc94ea1-adf0-4ced-9917-2950e7e750d9">10.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="clbs:OptionsVestedweightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTItNi0xLTEtMjk4MDM_51770c4b-6de0-40e1-b29b-2a71d01fd05d">6.64</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTItOC0xLTEtMjk4MDM_06e241f5-8227-420d-b6e9-b567c99e4111">344.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="INF" name="clbs:WarrantsVested" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTItMTAtMS0xLTI5ODAz_41389543-1697-4418-aca4-04a157fcba74">1,423,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsExercisable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTItMTItMS0xLTI5ODAz_cdacd9c7-b858-44f0-8612-b1ef3b49b596">42.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="clbs:WeightedAverageRemainingContractualTermwarrantsvested" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTItMTQtMS0xLTI5ODAz_f2c14f2c-58da-462b-9fd6-9e16aa4f95e1">3.13</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331" decimals="-3" name="clbs:AggregateIntrinsicValueWarrantsvested" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTItMTYtMS0xLTI5ODAz_4c863d55-b789-4836-ae6e-5899ceab3f04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNjI4MQ_ac25a340-6d1f-47f7-9582-a34cf01a86a6" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, the Company issued restricted stock for services as follows ($ in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"><tr><td style="width:1.0pt"></td><td style="width:322.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifcccbb1ec967438ca65784bea06bd71c_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOmYwNWFkM2FiZjM1YTRhZTc4MTBiNjg3MmMzOWRlZDAzL3RhYmxlcmFuZ2U6ZjA1YWQzYWJmMzVhNGFlNzgxMGI2ODcyYzM5ZGVkMDNfMi0yLTEtMS0yOTgwMw_4cc81a3a-3490-4dbd-8fc8-8974f244f61b">159,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9391ecdb3584403a88b94bdd91f8a15_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOmYwNWFkM2FiZjM1YTRhZTc4MTBiNjg3MmMzOWRlZDAzL3RhYmxlcmFuZ2U6ZjA1YWQzYWJmMzVhNGFlNzgxMGI2ODcyYzM5ZGVkMDNfMi00LTEtMS0yOTgwMw_80061ab6-ad9a-4992-881a-9f141c089151">70,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcccbb1ec967438ca65784bea06bd71c_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOmYwNWFkM2FiZjM1YTRhZTc4MTBiNjg3MmMzOWRlZDAzL3RhYmxlcmFuZ2U6ZjA1YWQzYWJmMzVhNGFlNzgxMGI2ODcyYzM5ZGVkMDNfMy0yLTEtMS0yOTgwMw_b91f1169-0bba-40f8-ac49-a64ee6d4ae94">480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9391ecdb3584403a88b94bdd91f8a15_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOmYwNWFkM2FiZjM1YTRhZTc4MTBiNjg3MmMzOWRlZDAzL3RhYmxlcmFuZ2U6ZjA1YWQzYWJmMzVhNGFlNzgxMGI2ODcyYzM5ZGVkMDNfMy00LTEtMS0yOTgwMw_fe1a31e2-3409-4bc4-a8d8-b1fbe23eaea8">973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vesting terms of restricted stock issuances are generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNTcyMQ_03645692-ddcc-455a-9649-721f44f866fe">one</span> and <ix:nonNumeric contextRef="i0bf2527917654f82a4c8b3249bbddab5_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNTcyOA_a3e74e5a-bf64-459d-842e-50764e290486">four years</ix:nonNumeric>.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNjI4OA_a6860201-1ced-4a8e-8a2d-7418415f3124" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, the Company issued restricted stock units for services as follows ($ in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"><tr><td style="width:1.0pt"></td><td style="width:343.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i123fae5df7b2491e87422b22888cdec1_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOmI5MTcyZmUwZTFjOTQ2ZTlhYmU0MWVkY2VhYTcwMjFmL3RhYmxlcmFuZ2U6YjkxNzJmZTBlMWM5NDZlOWFiZTQxZWRjZWFhNzAyMWZfMi0xLTEtMS0yOTgwMw_37168da3-c014-4c2b-98ea-7e18cd2eaec3">188,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cd4f16a626841558cb57f42b71c9c60_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOmI5MTcyZmUwZTFjOTQ2ZTlhYmU0MWVkY2VhYTcwMjFmL3RhYmxlcmFuZ2U6YjkxNzJmZTBlMWM5NDZlOWFiZTQxZWRjZWFhNzAyMWZfMi0zLTEtMS0yOTgwMw_375a3cd4-3adc-42fe-b532-1155edec1c6e">91,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i123fae5df7b2491e87422b22888cdec1_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOmI5MTcyZmUwZTFjOTQ2ZTlhYmU0MWVkY2VhYTcwMjFmL3RhYmxlcmFuZ2U6YjkxNzJmZTBlMWM5NDZlOWFiZTQxZWRjZWFhNzAyMWZfMy0xLTEtMS0yOTgwMw_20fb614e-885f-4a77-b5af-92bdd0a922cc">567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cd4f16a626841558cb57f42b71c9c60_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOmI5MTcyZmUwZTFjOTQ2ZTlhYmU0MWVkY2VhYTcwMjFmL3RhYmxlcmFuZ2U6YjkxNzJmZTBlMWM5NDZlOWFiZTQxZWRjZWFhNzAyMWZfMy0zLTEtMS0yOTgwMw_f2a6fa68-005b-43f9-b372-9bbae5dd36fb">1,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i419a47088cdd46ab89d233b24fa650c3">The weighted average estimated fair value of restricted stock issued for services in the three months ended March&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ifcccbb1ec967438ca65784bea06bd71c_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNTk5Mg_4e2429b9-7ab9-4e45-930a-f9996a404462">3.00</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="if9391ecdb3584403a88b94bdd91f8a15_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNTk5OQ_14e0edf7-24f0-4772-a7ec-77c495219f9f">13.76</ix:nonFraction> per share, respectively. The fair value of the restricted stock units was determined using the Company&#8217;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally <ix:nonNumeric contextRef="i123fae5df7b2491e87422b22888cdec1_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNjIxOQ_6cc55a34-4dbf-46d3-8fdb-1701b3a7cc4f">one year</ix:nonNumeric>, or upon the achievement of performance-based milestones.</ix:continuation> </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_67"></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 11 &#8211; <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RleHRyZWdpb246NTM4YzI4Y2RkN2ZjNDQ3YjhmODM5YWU4YzY5MTg0NTFfMTE0Mw_2f0f7aef-f111-46a9-9a4a-04d1afaba990" continuedAt="ie156e05ca9104870855f85979feef43b" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="ie156e05ca9104870855f85979feef43b"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize share-based compensation in the form of stock options, restricted stock, and restricted stock units.&#160;<ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RleHRyZWdpb246NTM4YzI4Y2RkN2ZjNDQ3YjhmODM5YWU4YzY5MTg0NTFfMTE0NA_5e0edfe5-1d0b-43ca-8f3b-4a8561492949" continuedAt="id492f06e5e1649828a7063902cc5272f" escape="true">The following table summarizes the components of share-based compensation expense for the three months ended March&#160;31, 2023 and 2022 (in thousands):</ix:nonNumeric></span></div><div style="text-align:center;text-indent:18pt"><ix:continuation id="id492f06e5e1649828a7063902cc5272f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:70.349%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:2.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i787b9e2301e54c9785a066d7cd81323f_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOjg2M2U5ZmY1MmVmZTQ2MTJhM2RjMTEwZmM5MGFmNjY0L3RhYmxlcmFuZ2U6ODYzZTlmZjUyZWZlNDYxMmEzZGMxMTBmYzkwYWY2NjRfMi01LTEtMS0yOTgwMw_27634cc5-bfec-4d66-b6b7-d87883e1434d">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03152d7237c4f9b90a0fc7dd766e90b_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOjg2M2U5ZmY1MmVmZTQ2MTJhM2RjMTEwZmM5MGFmNjY0L3RhYmxlcmFuZ2U6ODYzZTlmZjUyZWZlNDYxMmEzZGMxMTBmYzkwYWY2NjRfMi03LTEtMS0yOTgwMw_482d577e-258e-453d-bc44-f1bd5e2c200d">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c93ce6862cc404f9f8ce8668c15838a_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOjg2M2U5ZmY1MmVmZTQ2MTJhM2RjMTEwZmM5MGFmNjY0L3RhYmxlcmFuZ2U6ODYzZTlmZjUyZWZlNDYxMmEzZGMxMTBmYzkwYWY2NjRfMy01LTEtMS0yOTgwMw_ee0d53c7-8987-4685-b663-8df64c6438bb">488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83f0c391f25941a899f1eb4e31178bdd_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOjg2M2U5ZmY1MmVmZTQ2MTJhM2RjMTEwZmM5MGFmNjY0L3RhYmxlcmFuZ2U6ODYzZTlmZjUyZWZlNDYxMmEzZGMxMTBmYzkwYWY2NjRfMy03LTEtMS0yOTgwMw_6ac22f3a-ea0d-4b19-ba55-083f8a888715">542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOjg2M2U5ZmY1MmVmZTQ2MTJhM2RjMTEwZmM5MGFmNjY0L3RhYmxlcmFuZ2U6ODYzZTlmZjUyZWZlNDYxMmEzZGMxMTBmYzkwYWY2NjRfNC01LTEtMS0yOTgwMw_3deb9475-9e0f-41a5-8fff-fd97661f58f2">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOjg2M2U5ZmY1MmVmZTQ2MTJhM2RjMTEwZmM5MGFmNjY0L3RhYmxlcmFuZ2U6ODYzZTlmZjUyZWZlNDYxMmEzZGMxMTBmYzkwYWY2NjRfNC03LTEtMS0yOTgwMw_4e06b8a4-298a-4c9c-8dcb-44377e7225e0">760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RleHRyZWdpb246NTM4YzI4Y2RkN2ZjNDQ3YjhmODM5YWU4YzY5MTg0NTFfMTE1NA_1a0dc195-0df5-4e5a-bfd5-52120ed91d51" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March&#160;31, 2023 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d650d9bcb5a4a57b8d4315548c62afd_I20230331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOmZiZjk4N2U2NDA3OTQwMDRiYjcxZmQ1NmM2N2I2MzQxL3RhYmxlcmFuZ2U6ZmJmOTg3ZTY0MDc5NDAwNGJiNzFmZDU2YzY3YjYzNDFfMS0xLTEtMS0yOTgwMw_f1bd3d5f-4bc5-42de-ac68-1bbf33ab54dd">1,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c3f59edeb884c01895f1ea44c1ef3d9_I20230331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOmZiZjk4N2U2NDA3OTQwMDRiYjcxZmQ1NmM2N2I2MzQxL3RhYmxlcmFuZ2U6ZmJmOTg3ZTY0MDc5NDAwNGJiNzFmZDU2YzY3YjYzNDFfMS0zLTEtMS0yOTgwMw_b281ac99-91e7-4fd7-931b-bacfca98fa8f">378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93afe9d3f6ed4cb09390722746228408_I20230331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOmZiZjk4N2U2NDA3OTQwMDRiYjcxZmQ1NmM2N2I2MzQxL3RhYmxlcmFuZ2U6ZmJmOTg3ZTY0MDc5NDAwNGJiNzFmZDU2YzY3YjYzNDFfMS01LTEtMS0yOTgwMw_060a428d-c33d-4b29-a697-bc29e51ab916">459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1f68282f0c334dd5b5c7b36cb0d6ba8e_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOmZiZjk4N2U2NDA3OTQwMDRiYjcxZmQ1NmM2N2I2MzQxL3RhYmxlcmFuZ2U6ZmJmOTg3ZTY0MDc5NDAwNGJiNzFmZDU2YzY3YjYzNDFfMi0xLTEtMS0yOTgwMw_3d245b8b-811a-4a6f-8314-c8c61cbafc83">1.42</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i123fae5df7b2491e87422b22888cdec1_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOmZiZjk4N2U2NDA3OTQwMDRiYjcxZmQ1NmM2N2I2MzQxL3RhYmxlcmFuZ2U6ZmJmOTg3ZTY0MDc5NDAwNGJiNzFmZDU2YzY3YjYzNDFfMi0zLTEtMS0yOTgwMw_b73a1dc8-e871-43fd-9fc7-dd3eeff72e48">1.22</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifcccbb1ec967438ca65784bea06bd71c_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOmZiZjk4N2U2NDA3OTQwMDRiYjcxZmQ1NmM2N2I2MzQxL3RhYmxlcmFuZ2U6ZmJmOTg3ZTY0MDc5NDAwNGJiNzFmZDU2YzY3YjYzNDFfMi01LTEtMS0yOTgwMw_aa357cd9-e3ee-48cd-942c-c0a3f8b4f4bf">1.47</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RleHRyZWdpb246NTM4YzI4Y2RkN2ZjNDQ3YjhmODM5YWU4YzY5MTg0NTFfMTE0Nw_e6aa29c4-a05a-439a-b162-8394b3ef99ee" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March&#160;31, 2023 and 2022 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:378.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f68282f0c334dd5b5c7b36cb0d6ba8e_D20230101-20230331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOjg0Mjg4NWI2MWIwNTRlZTViYTUzZWVmN2Y1MDk1MjdlL3RhYmxlcmFuZ2U6ODQyODg1YjYxYjA1NGVlNWJhNTNlZWY3ZjUwOTUyN2VfMy0xLTEtMS0yOTgwMw_9f2d0dce-de3c-42a6-b2c9-2fccfec538ef">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id704a5defa6d483f841dd1efcd484f49_D20220101-20220331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOjg0Mjg4NWI2MWIwNTRlZTViYTUzZWVmN2Y1MDk1MjdlL3RhYmxlcmFuZ2U6ODQyODg1YjYxYjA1NGVlNWJhNTNlZWY3ZjUwOTUyN2VfMy0zLTEtMS0yOTgwMw_28a9253e-fc40-46bd-8f62-d7ed79f777ec">377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1f68282f0c334dd5b5c7b36cb0d6ba8e_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOjg0Mjg4NWI2MWIwNTRlZTViYTUzZWVmN2Y1MDk1MjdlL3RhYmxlcmFuZ2U6ODQyODg1YjYxYjA1NGVlNWJhNTNlZWY3ZjUwOTUyN2VfNC0xLTEtMS0yOTgwMw_4864376c-5d8d-4c3a-9dfa-268daecd45f7">0.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id704a5defa6d483f841dd1efcd484f49_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOjg0Mjg4NWI2MWIwNTRlZTViYTUzZWVmN2Y1MDk1MjdlL3RhYmxlcmFuZ2U6ODQyODg1YjYxYjA1NGVlNWJhNTNlZWY3ZjUwOTUyN2VfNC0zLTEtMS0yOTgwMw_d36be612-e55a-42c1-b0dd-90f0f14cb778">0.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#8217;s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_70"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 12 &#8211; <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDg3NQ_6ac1d463-f576-42ee-8b0a-12deb584949e" continuedAt="i3cf1c540f29e43198ce1292be729c9ea" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i3cf1c540f29e43198ce1292be729c9ea" continuedAt="i4ded035664524eb9a7f619fcf1d305a9"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="i9a48869ba93a417bb2d014c285a349c6_I20211231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfMTY0OTI2NzQ1Nzg1MQ_dd205326-b5ff-4e99-ab85-17a7dc50436b">281</ix:nonFraction>&#160;million of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an ownership change of greater than 50% over a 3-year testing period on January 25, 2021. As a result, $<ix:nonFraction unitRef="usd" contextRef="i9a48869ba93a417bb2d014c285a349c6_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzY2OQ_924ecbeb-f069-4ee8-8958-3d039618df37">168.8</ix:nonFraction>&#160;million of the $<ix:nonFraction unitRef="usd" contextRef="i9a48869ba93a417bb2d014c285a349c6_I20211231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfMTY0OTI2NzQ1Nzg3Ng_dd205326-b5ff-4e99-ab85-17a7dc50436b">281</ix:nonFraction>&#160;million  of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $112.3&#160;million of remaining Federal NOLs.  The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on January 25, 2021 will be subject to an annual limitation of $173&#160;thousand under Internal Revenue Code Section 382. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="i2dc12ffc2bcf4c17a7efd9e7f1736478_I20221231" decimals="-3" name="clbs:OperatingLossCarryforwardsBeforeWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfMTY0OTI2NzQ1Nzg5OQ_ec4f5be2-450f-4860-b67b-ac63b5e020c6">34.0</ix:nonFraction>&#160;million of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an ownership change of greater than 50% on September 15, 2022. As a result of the ownership change, $<ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzcxNA_d06d5b31-42dd-4fff-b1e1-a2826be21659">88.2</ix:nonFraction>&#160;million of Federal </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><ix:continuation id="i4ded035664524eb9a7f619fcf1d305a9" continuedAt="i1836519b0bc345b68a6310072ee37cb2"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $<ix:nonFraction unitRef="usd" contextRef="i2dc12ffc2bcf4c17a7efd9e7f1736478_I20221231" decimals="-3" name="clbs:OperatingLossCarryforwardsBeforeWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfMTY0OTI2NzQ1NzkyMQ_ec4f5be2-450f-4860-b67b-ac63b5e020c6">34.0</ix:nonFraction>&#160;million of remaining Federal NOLs.  The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on September 15, 2022 will be subject to an annual limitation of zero while losses incurred after September 15, 2022 will not be subject to limitations. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, Cend Therapeutics had approximately $<ix:nonFraction unitRef="usd" contextRef="i1ba87c90863144d990c890ebce4a437a_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzcyOQ_ba9a7786-8dd1-4150-85f6-41fd835544d1">10.9</ix:nonFraction>&#160;million of Federal NOLs available to offset future taxable income. The Company performed an analysis and determined that there was an ownership change of greater than 50% on September 15, 2022. As of September 15, 2022 Cend has approximately $<ix:nonFraction unitRef="usd" contextRef="i3a535f623a624914a6711e4e82eebafc_I20220915" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzc1OQ_146e0158-e3b8-413a-a531-ffac775a2975">10.7</ix:nonFraction>&#160;million of Federal and $<ix:nonFraction unitRef="usd" contextRef="ice2ae4d365344c85a05b88a31a78ac50_I20220915" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzc0NA_03833803-c206-4088-ae45-e58fb2e3511f">15.0</ix:nonFraction>&#160;million of state NOLs. The state NOLs will expire from the 2036 through 2042 tax years.  Using a fair market value of $<ix:nonFraction unitRef="usd" contextRef="i3afe3e21f9e14d83ac8486daad4e1b82_D20220101-20221231" decimals="-5" name="clbs:FairValueMarketOfTaxNOLs" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzc3NA_88f33bfc-6a03-46da-98fc-2b84ef8db6c2">36.1</ix:nonFraction>&#160;million and applying an applicable federal rate of <ix:nonFraction unitRef="number" contextRef="i3afe3e21f9e14d83ac8486daad4e1b82_D20220101-20221231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzc4OQ_754c0e30-df87-415c-9e83-dc7df424c84c">2.54</ix:nonFraction>% Cend will have an annual limitation of approximately $917 thousand each year. The Federal NOL of $<ix:nonFraction unitRef="usd" contextRef="i1ba87c90863144d990c890ebce4a437a_I20221231" decimals="-3" name="clbs:OperatingLossCarryforwardsPostAcquisition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzc5Ng_5191164e-d5d4-4d06-aa66-d0f7413c2455">106</ix:nonFraction>&#160;thousand incurred in the post-acquisition period September 15, 2022 to December 31, 2022 is not subject to limitation, and does not expire. Cend&#8217;s wholly owned Australian subsidiary has $<ix:nonFraction unitRef="usd" contextRef="ia25852cf0b524a4a811255369807adc6_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzgxMQ_b5b4e104-be33-4e2d-8781-cfd8e8e48667">1.8</ix:nonFraction>&#160;million of NOLs which will be carried forward and do not expire. There is a full valuation allowance against the NOLs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the Company had State NOLs available in New Jersey of $<ix:nonFraction unitRef="usd" contextRef="i35714006bb8c4a12bfdea57e263522a5_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzgyNQ_5eb707af-def4-464a-8db5-e7fd3fa2048f">35.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4403bf2ab03749ec86046716a8f3d4ec_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzg0MA_d57d97c2-1baf-4308-b97b-898583bad415">97.0</ix:nonFraction>&#160;million, respectively, California of $<ix:nonFraction unitRef="usd" contextRef="iafb81e753f5344fd8594c25ddabaf02c_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzg1NQ_5bd133d9-c6d2-4f9e-bf22-ab6d8b05bfc8">10.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia9ffa93082d045a0bbf2f1f37390955e_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzg3MA_48c53518-cc9b-4ace-b7cb-78e11db2475e">69.5</ix:nonFraction>&#160;million, respectively, and New York City of $<ix:nonFraction unitRef="usd" contextRef="i128ebe4deb504c3994e29fd10cb3bd21_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzg4NQ_2d2dd157-fb44-4117-9818-91134890a029">1.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i28c8467f29d64fef93f97e7c8af17104_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzg5OQ_3c4c597b-95b4-47ef-893a-2b81c6882009">13.0</ix:nonFraction>&#160;million, respectively, to offset future taxable income expiring from 2032 through 2042. In accordance with Section 382 of the Internal Revenue code, the usage of the Company&#8217;s NOLs is limited given the change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the FASB&#8217;s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with uncertain tax positions as a component of income tax expense.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the Company&#8217;s uncertain tax positions were $<ix:nonFraction unitRef="usd" contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzkxNA_a7927d79-0734-4531-900f-1dd775224a98">344</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="id4046547dd294ad49c799697f6ddb110_I20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzkyOQ_f3ad3a25-fe83-4753-8f5b-9305ca0ef40b">0</ix:nonFraction>, respectively. Due to the acquisition of Cend, the Company&#8217;s uncertain tax positions increased by $<ix:nonFraction unitRef="usd" contextRef="i997e64fe38cd4696b408c8f14ff89821_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzkzMw_53c8a88d-93dd-4bb4-9c23-33c1b1a8c48c">344</ix:nonFraction>&#160;thousand related to Federal and state credits and certain state NOLs. The Company will continue to evaluate its uncertain tax positions in future periods. As of March&#160;31, 2023, the Company does not believe there will be any material changes in its unrecognized tax positions over the next year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For years prior to 2019, the federal statute of limitations is closed for assessing tax. The Company&#8217;s state tax returns remain open to examination for a period of three to four years from the date of filing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2023, Lisata received final approval to sell a portion of their unused New Jersey net operating losses (&#8220;NJ NOLs&#8221;) through the State of New Jersey Economic Development Authority's Technology Business Tax Certificate Transfer Program (the &#8220;Program&#8221;). The Program permits qualified companies to sell a percentage of their NJ NOLs to unrelated profitable corporations. When the NOL&#8217;s are sold it will be a discrete event. The Company will record a deferred income tax benefit and reduce the deferred tax asset (NJ NOLs) when the transaction closes and cash is received.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1836519b0bc345b68a6310072ee37cb2">On August 16, 2022, the Inflation Reduction Act was signed into law. The Inflation Reduction Act includes various tax provisions, which are effective for tax years beginning on or after January 1, 2023. For tax years beginning after December 31, 2021, the Tax Cuts &amp; Jobs Act of 2017 eliminated the option to deduct research and development expenditures as incurred and instead required taxpayers to capitalize and amortize them over five or 15 years beginning in 2022. Since the Company is in a net operating loss position, the capitalization of research and development costs did not have a material impact on the Company&#8217;s results of operations for the year ended December 31, 2022. The Company will continue to monitor possible future impact of changes in tax legislation.</ix:continuation>  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_73"></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 13 &#8211; <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="clbs:ResearchAndDevelopmentTaxIncentiveTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83My9mcmFnOmJmMWU1Y2YzYzQ3MjRlYjViY2IwZjA1M2FmYWI4Y2FlL3RleHRyZWdpb246YmYxZTVjZjNjNDcyNGViNWJjYjBmMDUzYWZhYjhjYWVfNTQz_7bb76a21-14a5-4a84-97cd-c1fd18ce5fbb" continuedAt="ib0dca1dac26a4d0896d8f395fedd1ab2" escape="true">Australia Research and Development Tax Incentive</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib0dca1dac26a4d0896d8f395fedd1ab2">The Company&#8217;s Australian subsidiary, which conducts core research and development activities, is eligible to receive a refundable tax incentive between 43.5% to <ix:nonFraction unitRef="number" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83My9mcmFnOmJmMWU1Y2YzYzQ3MjRlYjViY2IwZjA1M2FmYWI4Y2FlL3RleHRyZWdpb246YmYxZTVjZjNjNDcyNGViNWJjYjBmMDUzYWZhYjhjYWVfMTg0_ffebcd6a-587d-44bb-b787-a94fa59bfe2f">48.5</ix:nonFraction>% (depending upon the income tax rate) for qualified research and development activities. As of the three months ended March&#160;31, 2023, $<ix:nonFraction unitRef="usd" contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83My9mcmFnOmJmMWU1Y2YzYzQ3MjRlYjViY2IwZjA1M2FmYWI4Y2FlL3RleHRyZWdpb246YmYxZTVjZjNjNDcyNGViNWJjYjBmMDUzYWZhYjhjYWVfNDM5ODA0NjUxMjEwNQ_b87ae0c7-49fe-41ff-845b-0dad3aa4ceee">1.0</ix:nonFraction>&#160;million was recorded as an income tax incentive receivable in the consolidated balance sheets, as the Company determined that the expenses met the eligibility criteria and the amounts claimed are expected to be received shortly after the related tax returns are filed.</ix:continuation></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_76"></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 14 &#8211; <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83Ni9mcmFnOjA1ZjE4M2IxOGUzZjRiMGI5YzgzMzIyNDc4YjcyODIyL3RleHRyZWdpb246MDVmMTgzYjE4ZTNmNGIwYjljODMzMjI0NzhiNzI4MjJfMTIwNA_434a29d9-f95a-4418-86ae-8431f74d19a6" continuedAt="icdd1fe6d097044a0b0d3a0121c233e54" escape="true">Contingencies</ix:nonNumeric></span></div><ix:continuation id="icdd1fe6d097044a0b0d3a0121c233e54"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, Cend received a written threat of litigation on behalf of a Chinese entity called Lingmed Limited (&#8220;Lingmed&#8221;) claiming Lingmed was entitled to a success fee based on Cend&#8217;s Collaboration and License Agreement with Qilu Pharmaceuticals. Cend responded by denying that Lingmed is entitled to a success fee under the terms of their agreement. In May 2022, Cend was served with a complaint filed by Lingmed in the San Diego County Superior Court, alleging claims for breach of contract, fraud and declaratory relief. Cend&#8217;s response to the complaint was filed on June 6, 2022. Lingmed filed an answer to Cend&#8217;s response on July 11, 2022. The court held a case management conference on October 7, 2022, which resulted in a continuance until December 16, 2022. On December 16, 2022, the court continued the case management conference until April 7, 2023. At the April 7, 2023 case management conference, based on Lingmed reporting that it had not yet been able to effect service on an individually-named defendant through the Hague Convention, the court continued the conference until August 4, 2023. The Company denies these allegations and intends to vigorously defend against this claim.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_79"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 15 &#8211; <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNzgxNQ_11c98555-8a85-49bd-99d3-ec75939b39a7" continuedAt="i8fd26f43ad464130997b3ba93f566948" escape="true">License Agreements</ix:nonNumeric></span></div><ix:continuation id="i8fd26f43ad464130997b3ba93f566948" continuedAt="i0147ee359bc8429a96a83546d3a763dd"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanford Burnham Prebys</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (&#8220;SBP&#8221;) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of LSTA1. At the time the license agreement was entered into, Cend&#8217;s founding shareholder, now a Lisata board member, was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of <ix:nonFraction unitRef="shares" contextRef="idcc2b98561db4f2c9078a1c50bd84b01_I20161231" decimals="INF" name="clbs:SharesIssuedUnderLicenseAgreement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNjU1_dd76355f-eeec-41ba-92f0-7cd6c833a39f">382,030</ix:nonFraction> shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $<ix:nonFraction unitRef="usd" contextRef="idcc2b98561db4f2c9078a1c50bd84b01_I20161231" decimals="-3" name="clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfODEw_0e461721-8b35-403f-9cab-1f6a2b32af95">10,000</ix:nonFraction> increasing to $<ix:nonFraction unitRef="usd" contextRef="idcc2b98561db4f2c9078a1c50bd84b01_I20161231" decimals="-3" name="clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfODI3_faa87068-cc80-4449-9433-6cdd5f69e78f">20,000</ix:nonFraction> on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $<ix:nonFraction unitRef="usd" contextRef="idcc2b98561db4f2c9078a1c50bd84b01_I20161231" decimals="-5" name="clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfMTA1Nw_eb81d978-2d93-4598-8b7c-f04d4e94ceff">10.6</ix:nonFraction>&#160;million. The Company has also agreed to pay SBP royalties of <ix:nonFraction unitRef="number" contextRef="idcc2b98561db4f2c9078a1c50bd84b01_I20161231" decimals="INF" name="clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfMTExMw_c71bce8c-e1b8-4555-b524-f233402e8da9">4</ix:nonFraction>% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP <ix:nonFraction unitRef="usd" contextRef="idcc2b98561db4f2c9078a1c50bd84b01_I20161231" decimals="INF" name="clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfMTI2OA_d0d4deeb-e584-4178-82c7-4edd98d16af7">25</ix:nonFraction>% of any sublicensing income. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Cend entered into a license agreement with SBP under which Cend was granted an exclusive, royalty-bearing license to certain patent rights and know-how controlled by SBP. The agreement provides Cend with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. The Company is required to pay an annual license maintenance fee of $<ix:nonFraction unitRef="usd" contextRef="i55d91e2a703a41a4b67672acbce81809_I20211031" decimals="-3" name="clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfMTY5MA_d6ee0a58-14a5-4283-8737-8e6713bffe44">20,000</ix:nonFraction>, increasing to $<ix:nonFraction unitRef="usd" contextRef="i55d91e2a703a41a4b67672acbce81809_I20211031" decimals="-3" name="clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfMTcwOA_c153a8b1-bf8f-48a2-8940-3ce43e226444">30,000</ix:nonFraction> on year four of the agreement. Further, the Company could be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $<ix:nonFraction unitRef="usd" contextRef="i55d91e2a703a41a4b67672acbce81809_I20211031" decimals="-5" name="clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfMTk0MQ_7caf30a5-779f-470a-9b4f-f8b82612645c">23.2</ix:nonFraction>&#160;million. The Company is obligated to pay SBP royalties of <ix:nonFraction unitRef="number" contextRef="i55d91e2a703a41a4b67672acbce81809_I20211031" decimals="INF" name="clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfMTk5NA_1d3da558-3e84-49ed-bd88-dbd5fa0799fe">4</ix:nonFraction>% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP varying sublicense fees, ranging from <ix:nonFraction unitRef="usd" contextRef="i9b47136928e3471f891783820d0f46a1_I20211031" decimals="INF" name="clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfMjE4Ng_1c4d5386-dbd1-4d6a-ba58-011ae2e720f8">10</ix:nonFraction>% to <ix:nonFraction unitRef="usd" contextRef="if5743124ce7d40908442e8bd62e47009_I20211031" decimals="INF" name="clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfMjE5Mg_42027c96-ab4d-49b7-b576-1a7f055676cb">25</ix:nonFraction>%, dependent on when the related milestones are reached. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreements will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreements may be terminated in their entirety by the Company at any time by giving SBP sixty days&#8217; prior written notice. The agreements may be terminated in their entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreements may be terminated in their entirety by SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreements for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SBP owned <ix:nonFraction unitRef="shares" contextRef="i1ac540323fe04816bb43b23a4a4cd560_I20230331" decimals="INF" name="clbs:SharesHeldByThirdParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfMzU3MQ_371224e8-8438-42c8-a553-4bde11470bfc">382,030</ix:nonFraction> shares of the Company&#8217;s common stock as of March&#160;31, 2023 and is a related party. </span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><ix:continuation id="i0147ee359bc8429a96a83546d3a763dd" continuedAt="icf4b138879674c61bb3037fde837177e"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">University of California at San Diego</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Cend entered into a license agreement with the University of California at San Diego (&#8220;UCSD&#8221;) under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of nano-particles to modulate immune response. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell and otherwise exploit the patent rights. The Company could be required to make milestone payments to UCSD upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $<ix:nonFraction unitRef="usd" contextRef="i402d926e5cb44e54a8d375857d19b288_I20210930" decimals="-5" name="clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNDMwNQ_1707b4dc-0e2e-477d-b6a3-5e880318f1f3">1.2</ix:nonFraction>&#160;million. The Company has also agreed to pay UCSD royalties of <ix:nonFraction unitRef="number" contextRef="i402d926e5cb44e54a8d375857d19b288_I20210930" decimals="INF" name="clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNDM2Mg_ab4573eb-6a74-4f36-a294-77d293cb0aa7">1.5</ix:nonFraction>% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company agreed to pay UCSD varying sublicense fees, ranging from <ix:nonFraction unitRef="usd" contextRef="i73ca6b3e79144046b283ad153b819bb1_I20210930" decimals="INF" name="clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNDU0OQ_8d36289e-9243-4ff5-a2fe-093722fd3b5f">10</ix:nonFraction>% to <ix:nonFraction unitRef="usd" contextRef="if616b4f4bf5141008e520b036ed05453_I20210930" decimals="INF" name="clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNDU1NQ_8737f257-8af2-4e8e-8c50-8b71bd9742df">20</ix:nonFraction>%, dependent on when the related milestones are reached. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the expiration of the longest-lived patent rights. The agreement may be terminated in its entirety by the Company at any time by giving UCSD ninety days&#8217; prior written notice. The agreement may be terminated in its entirety by UCSD if the Company, at any time, (i) fails to perform or violates any term of the agreement and fails to cure the default within sixty days. Upon termination of the agreement for any reason, UCSD may terminate a sublicensee but will allow the Company to assign any sublicenses to UCSD provided a) that the sublicensee is in good standing upon termination of the agreement with the Company; and b) the sublicensee is not currently involved in litigation as an adverse party to UCSD.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Massachusetts Institute of Technology</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Cend entered into a license agreement with the Massachusetts Institute of Technology ("MIT") under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of tissue specific delivery of interfering RNA. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 43,236 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $<ix:nonFraction unitRef="usd" contextRef="ie64acccae8a54473b4916dda6d9766df_I20211031" decimals="-3" name="clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNTg3OQ_c8adbae2-8b13-44f2-8fdd-26f6a4f29e09">20,000</ix:nonFraction>, increasing to $<ix:nonFraction unitRef="usd" contextRef="ie64acccae8a54473b4916dda6d9766df_I20211031" decimals="-3" name="clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNTg5Nw_cdf7fa8b-1af3-497c-91be-d6e903163329">25,000</ix:nonFraction> for year two and three of the agreement, increasing to $<ix:nonFraction unitRef="usd" contextRef="ie64acccae8a54473b4916dda6d9766df_I20211031" decimals="-3" name="clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNTk1NQ_3bedd683-3290-44af-9b1b-9b6e758acb5e">50,000</ix:nonFraction> on year four of the agreement and thereafter until the first commercial sale, and increasing to $<ix:nonFraction unitRef="usd" contextRef="i3e38bf3272614bd784e0e3713d21241f_I20211031" decimals="-3" name="clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNjA1NA_d1bb6490-8f7f-429e-be6a-9bed562ec5fc">150,000</ix:nonFraction> each year of the agreement after the first sale. Further, the Company could be required to make milestone payments to MIT upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $<ix:nonFraction unitRef="usd" contextRef="ie64acccae8a54473b4916dda6d9766df_I20211031" decimals="-5" name="clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNjMwNQ_199db2b8-fbe2-4831-85b1-493d19224e05">5.0</ix:nonFraction>&#160;million. The Company has also agreed to pay MIT royalties of <ix:nonFraction unitRef="number" contextRef="ie64acccae8a54473b4916dda6d9766df_I20211031" decimals="INF" name="clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNjM2MQ_14b161b6-7adf-4347-88a1-73aa346ae6ea">2</ix:nonFraction>% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay MIT varying sublicense fees, ranging from <ix:nonFraction unitRef="usd" contextRef="ibbe067b5df1b486281624627370f5bc7_I20211031" decimals="INF" name="clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNjU1Mw_46553f5d-ee94-485f-8e99-9c455938bc8d">3</ix:nonFraction>% to <ix:nonFraction unitRef="usd" contextRef="i628328038b2b4904ac047c8f5980356a_I20211031" decimals="INF" name="clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNjU1OQ_623118a8-5008-46d8-a7c3-e9e00c1254c2">20</ix:nonFraction>%, depending on when the related milestones are reached. In connection with the close of the Merger, the Company was required to pay MIT a change of control fee of $<ix:nonFraction unitRef="usd" contextRef="ie64acccae8a54473b4916dda6d9766df_I20211031" decimals="-5" name="clbs:CollaborativeArrangementRightsAndObligationsChangeOfControlFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNjcyNQ_306f1a31-a858-42b7-ac7a-29ed12e78efe">0.3</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the expiration or abandonment of all valid claims. The agreement may be terminated in its entirety by the Company at any time by giving MIT six months prior written notice. The agreement may be terminated in its entirety by MIT if the Company, at any time, (i) defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice, or (ii) commits a material breach of its obligations under the agreement (aside from item (i)) and fails to cure that breach within sixty days after receipt of written notice. Upon termination of the agreement for any reason, the rights and licenses granted to the Company shall terminate and revert to MIT. Upon termination of the agreement for any reason, MIT may terminate a sublicensee but will allow the Company to assign any sublicenses to MIT provided that the sublicensee is in good standing upon termination of the agreement with the Company.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIT owned <ix:nonFraction unitRef="shares" contextRef="i9a3db4b42dc146229cb4171314c0ce3d_I20230331" decimals="INF" name="clbs:SharesHeldByThirdParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNDM5ODA0NjUxOTQzMg_e128f50d-9eab-4552-b834-962be9926b0d">43,236</ix:nonFraction> shares of the Company&#8217;s common stock as of March&#160;31, 2023</span></div></ix:continuation><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_82"></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 16 &#8211; <ix:continuation id="icf4b138879674c61bb3037fde837177e" continuedAt="ibaf2a08ff8aa482a880d2d8525eb53dc">Research Collaboration and License Agreement</ix:continuation></span></div><ix:continuation id="ibaf2a08ff8aa482a880d2d8525eb53dc" continuedAt="id935f0dc6c454000aca381920a805161"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the &#8220;Qilu Agreement&#8221;) in which Cend granted an exclusive license to Qilu for the development and commercialization of LSTA1 in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of LSTA1 in its Territory. In consideration for the license, Qilu made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i8788a48508344937b3068aa082fec1c3_I20210228" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl84Mi9mcmFnOmY3NjRlYzFhZTMxMjQ2NTRiODgxNTU3MmUxOGNhM2E4L3RleHRyZWdpb246Zjc2NGVjMWFlMzEyNDY1NGI4ODE1NTcyZTE4Y2EzYThfNTk2_a145d76c-151d-4bc7-b483-6db53508fd8a">10</ix:nonFraction>&#160;million to Cend, which was recognized as revenue by Cend prior to the Merger. In addition, Cend received and recognized as revenue a $<ix:nonFraction unitRef="usd" contextRef="ic152646f8baa44789d4da65765ea5a4b_D20220914-20220914" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl84Mi9mcmFnOmY3NjRlYzFhZTMxMjQ2NTRiODgxNTU3MmUxOGNhM2E4L3RleHRyZWdpb246Zjc2NGVjMWFlMzEyNDY1NGI4ODE1NTcyZTE4Y2EzYThfNzI0_966e7423-a50f-41a8-b112-afab0631f7e7">5</ix:nonFraction>&#160;million development milestone prior to the Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $<ix:nonFraction unitRef="usd" contextRef="ie65ed995e0f7462e8f1737be572b0839_I20210228" decimals="-6" name="clbs:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl84Mi9mcmFnOmY3NjRlYzFhZTMxMjQ2NTRiODgxNTU3MmUxOGNhM2E4L3RleHRyZWdpb246Zjc2NGVjMWFlMzEyNDY1NGI4ODE1NTcyZTE4Y2EzYThfNDM5ODA0NjUxMjgyNA_75c96fe4-c276-4b80-a429-591497fd2583">95</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0b06f28b1d2f42819f88a1b59197ea04_I20210228" decimals="-6" name="clbs:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl84Mi9mcmFnOmY3NjRlYzFhZTMxMjQ2NTRiODgxNTU3MmUxOGNhM2E4L3RleHRyZWdpb246Zjc2NGVjMWFlMzEyNDY1NGI4ODE1NTcyZTE4Y2EzYThfODc3_93fb20eb-5828-4a53-af20-05323584308b">125</ix:nonFraction>&#160;million, respectively, tiered royalties on net sales ranging from <ix:nonFraction unitRef="number" contextRef="ie65ed995e0f7462e8f1737be572b0839_I20210228" decimals="INF" name="clbs:RevenuePerformanceObligationPercentageOfNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl84Mi9mcmFnOmY3NjRlYzFhZTMxMjQ2NTRiODgxNTU3MmUxOGNhM2E4L3RleHRyZWdpb246Zjc2NGVjMWFlMzEyNDY1NGI4ODE1NTcyZTE4Y2EzYThfOTM4_111f3cde-3900-4b32-a3cd-dbadb41f9c92">10</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i0b06f28b1d2f42819f88a1b59197ea04_I20210228" decimals="INF" name="clbs:RevenuePerformanceObligationPercentageOfNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl84Mi9mcmFnOmY3NjRlYzFhZTMxMjQ2NTRiODgxNTU3MmUxOGNhM2E4L3RleHRyZWdpb246Zjc2NGVjMWFlMzEyNDY1NGI4ODE1NTcyZTE4Y2EzYThfOTQ0_84ee67cc-5c67-4e57-a1f7-93b6d706724a">15</ix:nonFraction>%, and tiered sublicensing revenues ranging from <ix:nonFraction unitRef="number" contextRef="ie65ed995e0f7462e8f1737be572b0839_I20210228" decimals="INF" name="clbs:RevenuePerformanceObligationPercentageOfSublicensingRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl84Mi9mcmFnOmY3NjRlYzFhZTMxMjQ2NTRiODgxNTU3MmUxOGNhM2E4L3RleHRyZWdpb246Zjc2NGVjMWFlMzEyNDY1NGI4ODE1NTcyZTE4Y2EzYThfOTk0_a7e25606-151d-449d-b47b-76ea96f148c9">12</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i0b06f28b1d2f42819f88a1b59197ea04_I20210228" decimals="INF" name="clbs:RevenuePerformanceObligationPercentageOfSublicensingRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl84Mi9mcmFnOmY3NjRlYzFhZTMxMjQ2NTRiODgxNTU3MmUxOGNhM2E4L3RleHRyZWdpb246Zjc2NGVjMWFlMzEyNDY1NGI4ODE1NTcyZTE4Y2EzYThfMTAwMA_92ecf29a-06f5-4104-a41c-dea67ad380a6">35</ix:nonFraction>%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id935f0dc6c454000aca381920a805161">period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate.</ix:continuation></span></div><div><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_1082"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 17 &#8211; <ix:nonNumeric contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xMDgyL2ZyYWc6YjFmODBjNWE1NWJlNDMwZTk0ODI1Yzk1NjkxZmQ0NjkvdGV4dHJlZ2lvbjpiMWY4MGM1YTU1YmU0MzBlOTQ4MjVjOTU2OTFmZDQ2OV80Mzk4MDQ2NTE0Mjk2_59959162-371a-456a-924f-d218be1eeb46" continuedAt="i43fb2c4ecba94c6db5bab4e2ca3820d8" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="i43fb2c4ecba94c6db5bab4e2ca3820d8"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Sale of New Jersey Net Operating Losses </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 19, 2022, the Company received preliminary approval from the New Jersey Economic Development Authority ("NJEDA") to participate in the Technology Business Tax Certificate Transfer Program (the "Program"). The Program permits qualified companies to sell a percentage of their New Jersey net operating losses ("NJ NOLs") to unrelated profitable corporations. On April 5, 2023, the Company received final approval from the NJEDA, and it subsequently sold a portion of its NJ NOLs to a qualifying and approved buyer pursuant to the Program for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i9c7a64d6081c499fbfec9b5f2a137f04_D20230401-20230430" decimals="-5" name="clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xMDgyL2ZyYWc6YjFmODBjNWE1NWJlNDMwZTk0ODI1Yzk1NjkxZmQ0NjkvdGV4dHJlZ2lvbjpiMWY4MGM1YTU1YmU0MzBlOTQ4MjVjOTU2OTFmZDQ2OV80Mzk4MDQ2NTE0Mjk4_42f6bf11-9d5c-4587-b111-5c8244726c45">2.2</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Elimination of President and Chief Business Officer Position </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2023, the Company, after a careful review of capital utilization and prioritization, eliminated the position of President and Chief Business Officer, and terminated the employment of Mr. David Slack, effective immediately. Pursuant to the employment agreement, dated as of September 15, 2022, by and between the Company and Mr. Slack (the &#8220;Slack Employment Agreement&#8221;), the termination of Mr. Slack&#8217;s employment also constituted his resignation from any director, officer, employee or committee position he had with the Company or any of its affiliates and the Slack Employment Agreement served as written notice of resignation upon such termination.  Accordingly, Mr. Slack effectively resigned from the Company&#8217;s Board of Directors as of May 1, 2023 pursuant to the terms of the Slack Employment Agreement.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with Mr. Slack&#8217;s resignation and in accordance with the terms and conditions of the Slack Employment Agreement, Mr. Slack is entitled to receive the following items of compensation: (i) a lump sum payment of $24,134, representing earned but unpaid base salary, earned and vested but unpaid bonus amounts, accrued and unused paid time off, unreimbursed business expenses and other payments and benefits owed to Mr. Slack under the terms of his compensation arrangements with the Company; (ii) severance payments in a total amount of $478,400, to be paid over a period of 12 months following termination (the &#8220;Slack Severance Period&#8221;); (iii) COBRA assistance for the duration of the Slack Severance Period, not including the portion of the monthly premium which Mr. Slack would otherwise have paid if he had not resigned and (iv) a bonus payment equal to $239,200, representing 50% of Mr. Slack&#8217;s base salary at the time of termination, paid in equal installments for the duration of the Slack Severance Period. Also in connection with his termination, the exercise period of each of Mr. Slack&#8217;s vested options was extended to three years following termination or the remaining term of such awards, whichever period is shorter.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24 </span></div></div></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; herein and under &#8220;Risk Factors&#8221; in our 2022 Form 10-K. The following discussion should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report and in our 2022 Form 10-K.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Our lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are not expected to be affected. LSTA1 also has the potential to modify the tumor microenvironment (&#8220;TME&#8221;), with the objective of making tumors more susceptible to immunotherapies. We and our collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. To date, LSTA1 has also demonstrated favorable safety, tolerability, and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. We are exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. In addition, we have development programs based on our autologous CD34+ cell therapy technology platform that we will look to partner while incurring no additional capital outlay.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. Our goal is to develop and commercialize products that address important unmet medical needs. Our current development pipeline includes: </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LSTA1, the subject of Phase 1b/2a and 2b clinical studies being conducted globally in a variety of solid tumor types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a variety of anti-cancer regimens.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Targeted Solid Tumor Penetration via CendR Active Transport</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many solid tumor cancers, including pancreatic ductal adenocarcinoma (&#8220;PDAC&#8221;), are surrounded by dense fibrotic tissue, or stroma. This limits the efficacy of current chemotherapies for these cancers. Emerging immunotherapy treatments, including checkpoint inhibitors, adoptive cell therapies such as chimeric antigen receptor T (&#8220;CAR-T&#8221;) cells, as well as nucleic acid-based therapies, such as short interfering RNA (&#8220;siRNA&#8221;), antisense oligonucleotides (&#8220;ASO&#8221;), and messenger RNAs (&#8220;mRNAs&#8221;) also face challenges in penetrating solid tumors. Many tumors also exhibit an immunosuppressive tumor microenvironment (&#8220;TME&#8221;), which suppresses patients&#8217; immune systems&#8217; ability to fight their cancer and can limit effectiveness of immunotherapies and/or contribute to metastases. These factors negatively impact the ability of many therapeutic agents to effectively treat these cancers.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To address the tumor stroma&#8217;s role as a primary impediment to effective treatment, Lisata&#8217;s approach is to activate the C-end rule (&#8220;CendR&#8221;), or CendR system, a naturally occurring active transport system. Lisata&#8217;s lead investigational drug, LSTA1 (a specific internalizing R-G-D or iRGD peptide) activates this transport system in a tumor-specific manner (Sugahara, Science, 2010). This results in tumors selectively and more efficiently taking up systemically administered anticancer drugs as if they were nutrients. As a result, more drug accumulates in the tumor than would accumulate without LSTA1, while normal tissues are not affected. Moreover, the drugs penetrate tumor cells farther away from blood vessels with LSTA1 present than without. The overall result is enhanced anticancer activity without an increase in side effects. Anticancer drugs can be coupled/tethered or conjugated to LSTA1 or other CendR peptides in Lisata&#8217;s portfolio, but can be also co-administered with LSTA1. Lisata believes that the co-administration option is an advantage because it is not necessary to create a new chemical entity with its attendant development and regulatory hurdles, providing a potentially faster-to-clinic and potentially faster-to-market product opportunity for a range of solid tumor cancers and for co-administration with a range of therapies.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical progress with other approaches to address delivery to highly fibrotic tumors, such as PEGylated hyaluronidase and hedgehog inhibitors, has been limited by toxicity and side effects. LSTA1 has demonstrated favorable safety/tolerability and activity in clinical trials to enhance delivery of standard-of-care chemotherapy for mPDAC. Lisata and its collaborators have also amassed non-clinical data demonstrating enhanced delivery of a range of emerging anticancer therapies, including </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapies, and RNA-based therapeutics. LSTA1&#8217;s cancer-targeted delivery may enable such emerging treatment modalities to treat a range of solid tumors potentially more effectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LSTA1 as a treatment for solid tumor cancers in combination with other anti-cancer agents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LSTA1 is an investigational drug that actuates the CendR active transport mechanism while also having the potential to modify the TME and make it less immunosuppressive, thereby making the tumor more susceptible to attack by the immune system. It is targeted to tumor vasculature, tumor cells and some intratumoral immunosuppressive cells by its affinity for alpha-v, beta-3 and beta-5 integrins that are upregulated on these cells. LSTA1 is a nine amino acid cyclic internalizing RGD (&#8220;iRGD&#8221;) peptide that, once bound to these integrins, is cleaved by proteases expressed in tumors to release a peptide fragment, called a CendR fragment, which binds to a second receptor, called neuropilin-1 receptor, to activate a novel uptake pathway that allows circulating moieties such as anticancer drugs to more selectively penetrate solid tumors. The ability of LSTA1 and iRGD peptides to modify the TME to enhance delivery and efficacy of co-administered drugs has been demonstrated in many preclinical models in a range of solid tumors with the results from Lisata, collaborators and research groups around the world having been the subject of over 200 scientific publications.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to clinical development, LSTA1 is the subject of a completed Phase 1b clinical trial of 31 first-line metastatic pancreatic ductal adenocarcinoma patients, of which 29 were evaluable. Results from the trial showed that the safety profile of the LSTA1 combination regimen was similar to standard of care (&#8220;SoC&#8221;) alone with LSTA1 being well-tolerated with no-dose limiting toxicities. An Objective Response Rate (&#8220;ORR&#8221;) of fifty nine percent was observed, including a rare complete response, which compares favorably to the twenty three percent ORR observed in the &#8220;MPACT&#8221; clinical trial that served as the basis for approval of nab-paclitaxel for use in combination with gemcitabine for the treatment of first line, metastatic pancreatic ductal adenocarcinoma. A Disease Control Rate (&#8220;DCR&#8221;); (partial and complete responses plus stable disease) of over seventy nine percent was observed in comparison to a DCR of forty eight percent observed in the MPACT trial. Reduction in the level of circulating tumor biomarker CA19-9 was observed in 96% of patients versus 61% in the MPACT trial. Importantly, median progression-free survival and median overall survival of nearly ten months and over thirteen months were observed, respectively, vs. less than six months and less than nine months, respectively, in the MPACT trial. These results have been published in The Lancet Gastroenterology and Hepatology (Dean, et al. 2022).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, LSTA1 is the subject of multiple ongoing and planned clinical trials being conducted globally in a variety of solid tumor types and in combination with several chemotherapy and immunotherapy anti-cancer regimens. The following diagram summarizes these studies.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><img src="clbs-20230331_g1.jpg" alt="Slide1.jpg" style="height:371px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><img src="clbs-20230331_g2.jpg" alt="Slide2.jpg" style="height:371px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ischemic Repair (CD34+ Cell Technology)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CD34+ cell was discovered as a result of the deliberate search for a cell capable of stimulating the development and/or repair of blood vessels. All tissues in the body maintain their function by replacing cells over time. In addition to the maintenance function, the body must also be capable of building new blood vessels after injury. A CD34+ cell is an endothelial progenitor cell that has the ability to stimulate new blood vessel formation at the level of the microvasculature. No other native cell discovered to date has demonstrated this same capability.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary cell technology using autologous (a patient&#8217;s own naturally occurring) CD34+ cells has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted or reduced. Through the administration of CD34+ cells, we seek to promote the development and formation of new microvasculature and thereby increase blood flow to the impacted area. We believe that a number of conditions caused by underlying ischemic injury can be improved through our CD34+ cell technology, including, but not limited to, Buerger's disease, critical limb ischemia (&#8220;CLI&#8221;), coronary microvascular dysfunction (&#8220;CMD&#8221;), and diabetic kidney disease (&#8220;DKD&#8221;).</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for Treatment of Critical Limb Ischemia</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our randomized, open-label, registration-eligible study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan for the treatment of CLI and Buerger's disease has, to date, demonstrated positive trends in both safety and efficacy. The HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> study's enrollment, however, has been significantly curtailed by the COVID-19 pandemic's impact in Japan, including the States of Emergency in Japan that have persisted for much of 2020, 2021, and 2022. Due to the significant and continued operational and financial burden incurred as a result of these COVID-19 delays, coupled with the unpredictability of the timing of site enrollment re-initiation, we suspended further enrollment in the fourth quarter of 2021. Following study suspension, we completed all protocol-defined patient observations and completed the clinical study report. Data from the follow-up of all patients completed in the registration-eligible clinical trial in Japan have been compiled and are the subject of discussions with the Pharmaceuticals and Medical Devices Agency (&#8220;PMDA&#8221;) in Japan as part of the Japanese regulatory pre-consultation process and in preparation for the formal clinical consultation meetings which precede a Japanese new drug application. To date, the PMDA has provided advice on how to prepare for the formal consultation meeting, which we expect to occur later this year. Concomitantly, the Company has reinforced its efforts to secure a Japanese partner to complete the remaining steps of development/registration as well as eventual commercialization in Japan.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merger with Cend Therapeutics, Inc. and Name Change</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, the Company, then operating as Caladrius Biosciences, Inc. (&#8220;Caladrius&#8221;), completed its acquisition of Cend Therapeutics, Inc. (&#8220;Cend&#8221;), a Delaware corporation (the &#8220;Merger&#8221;), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), dated as of April 26, 2022, by and among Caladrius, Cend and CS Cedar Merger Sub, Inc. (&#8220;Merger Sub&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms set forth in the Merger Agreement and effective September 15, 2022 (the &#8220;Effective Time&#8221;): (i) Merger Sub merged with and into Cend, with Cend surviving as a wholly owned subsidiary of Caladrius, (ii) Caladrius changed its name to Lisata Therapeutics, Inc. in connection with and immediately following to the Effective Time, and (iii) Caladrius effected a 1:15 reverse stock split of its common stock (&#8220;Reverse Stock Split&#8221;) prior to the Effective Time. At the Effective Time, each share of Cend's common stock outstanding immediately prior to the Effective Time was converted into the right to receive shares of Lisata&#8217;s common stock based on an exchange ratio of 0.5338 (the &#8220;Exchange Ratio&#8221;), after taking into account the Reverse Stock Split. In connection with the Merger close, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Merger Agreement, we assumed all of the outstanding and unexercised options to purchase shares of Cend capital stock under the 2016 Equity Incentive Plan (the &#8220;Cend Plan&#8221;), and, in connection with the Merger, such options were converted into options to purchase shares of Lisata&#8217;s common stock based on the Exchange Ratio. At the closing of the Merger at the Effective Time, we assumed Cend's stock options to purchase an aggregate of 1,227,776 shares of the Company's common stock.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caladrius was considered to be the accounting acquirer based on the terms of the Merger Agreement and certain factors including: (i) Caladrius owned approximately 52% of the Company's outstanding shares of common stock immediately following the close of the Merger; (ii) although both entities contributed to the new management team of Lisata, the Caladrius team has more individuals on the management team and will hold the CEO, CMO and other senior management roles; (iii) Caladrius paid a premium to acquire Cend&#8217;s assets; and (iv) Caladrius was significantly larger than Cend regarding total assets, operations, and research and development activities. The Merger was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;). Cend&#8217;s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;D with no alternative future use being expensed. The prior reported operating results prior to the Merger close are those of Caladrius.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Out-licensing Opportunities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our broad intellectual property portfolio of assets includes notable programs available for out-licensing in order to augment or continue their clinical development. Our current long-term strategy focuses on advancing our therapies through development with the ultimate objective of obtaining market authorizations and entering commercialization, either alone or with partners, to provide treatment options to patients suffering from life-threatening medical conditions. We believe that we are well-positioned to realize potentially meaningful value increases within our own proprietary pipeline if we are successful in advancing our product candidates to their next significant development milestones.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the COVID-19 Pandemic</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to closely monitor the impact of the COVID-19 pandemic on all aspects of our business, including how it has and will continue to impact our operations and the operations of our suppliers, vendors and business partners, and may take further precautionary and preemptive actions as may be required by federal, state or local authorities. In addition, we have taken steps to minimize the current environment&#8217;s impact on our business and strategy, including devising contingency plans and securing additional resources from third party service providers. Our phase 2b trial of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States  experienced delays in enrolling patients as a result of COVID-19. In May 2022, we announced that enrollment in the FREEDOM Trial was suspended and that we intended to conduct an interim analysis of the data from not less than the first 20 patients enrolled using the 6-month follow-up data to evaluate the efficacy and safety of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in subjects with CMD. Following this analysis along with Key Opinion Leaders&#8217; input, we determined that execution of a redesigned FREEDOM-like trial would be the appropriate next step, but the cost of such a trial would be prohibitively expensive to undergo without a strategic partner. Accordingly, our board of directors concluded that XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> development will only be continued if a strategic partner that can contribute the necessary capital for a redesigned trial is identified and secured. There can be no assurance that we will be able to identify such a partner and enter into an agreement with such partner on acceptable terms or at all.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond its impact on our development pipeline described above, the extent to which COVID-19 ultimately impacts our business, results of operations and financial condition will depend on future developments, which remain highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, the emergence of new variants, new information that may emerge concerning the severity of COVID-19 or the effectiveness of actions taken to contain COVID-19 or treat its impact, including vaccination campaigns, among others. If we or any of the third parties with whom we engage, however, were to experience any additional shutdowns or other prolonged business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially or negatively affected, which could have a material adverse impact on our business, financial condition and results of operations. It is possible that our clinical development timelines could continue to be negatively affected by COVID-19, which could materially and adversely affect our business, financial condition and results of operations. See &#8220;Risk Factors&#8221; for additional discussion of the potential adverse impact of the COVID-19 pandemic on our business, financial condition and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_88"></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended March&#160;31, 2023 Compared to Three Months Ended March&#160;31, 2022 </span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended March&#160;31, 2023 and March&#160;31, 2022:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.643%"><tr><td style="width:1.0%"></td><td style="width:52.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.258%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,620&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,844)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,620)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,479)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,479)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,187)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,226)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,961)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, net losses were $6.2 million for the three months ended March&#160;31, 2023, compared to $4.2 million for the three months ended March&#160;31, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, operating expenses totaled $6.8 million compared to $6.6 million for the three months ended March&#160;31, 2022, representing an increase of 3.4%.  Operating expenses comprised the following:&#160;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development expenses were approximately $3.2&#160;million for the three months ended March&#160;31, 2023, compared to $3.3 million for the three months ended March&#160;31, 2022, representing a decrease of $0.1&#160;million or 3.2%. This was primarily due to expenses associated with our XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Phase 2b study (the FREEDOM Trial) in the prior year (study was suspended in 2022), partially offset by study start up activities in the current year associated with the planned LSTA1 Phase 2 proof-of-concept basket trial in various solid tumors in combination with the corresponding standards of care, enrollment activities for the LSTA1 Phase 2b ASCEND study and chemistry, manufacturing and control (CMC) activities for LSTA1. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were approximately $3.7 million for the three months ended March&#160;31, 2023, compared to $3.3 million for the three months ended March&#160;31, 2022, representing an increase of $0.3&#160;million or 9.8%. This was primarily due to the addition of an employee acquired through the Merger with Cend, an increase in external legal fees and an increase in accounting and tax related fees.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, to minimize our use of cash, we have used a variety of equity instruments to compensate employees, consultants and other service providers. The use of these instruments has resulted in charges to the results of operations, which have been significant in the past.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense) is comprised of investment income from cash, cash equivalents and marketable securities for both three months ended March&#160;31, 2023 and 2022 and a loss on sale related to the sale of our NJ NOLs in the three months ended March&#160;31, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Benefit</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we received final approval from the New Jersey Economic Development Authority (&#8220;NJEDA&#8221;) under the Technology Business Tax Certificate Transfer Program (&#8220;Program&#8221;) to sell a percentage of our NJ NOLs, which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $2.3 million. The $2.5 million of our NJ NOL Tax Benefits have been recorded as a benefit from income taxes and the loss on sale of $0.1 million recorded in other income (expense).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30 </span></div></div></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Analysis of Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023, we had cash, cash equivalents and marketable securities of approximately $61.1 million, working capital of approximately $60.0 million, and stockholders&#8217; equity of approximately $61.0 million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we met our immediate cash requirements through existing cash balances.  Additionally, we used equity and equity-linked instruments to pay for services and compensation. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in) or provided by, operating, investing and financing activities were as follows (in thousands):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:66.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,196)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,642)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,090)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Operating Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in operating activities during the three months ended March&#160;31, 2023 was $8.2 million, which is comprised of (i) our net loss of $6.2 million, adjusted for non-cash expenses totaling $0.6&#160;million (which includes adjustments for equity-based compensation, depreciation and amortization, a loss on disposal of fixed assets, and amortization/accretion of marketable securities), and (ii) changes in operating assets and liabilities using approximately $2.6 million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in operating activities during the three months ended March&#160;31, 2022 was $5.6 million, which is comprised of (i) our net loss of $4.2 million, adjusted for non-cash expenses totaling $1.3 million (which includes adjustments for equity-based compensation, depreciation and amortization, and amortization/accretion of marketable securities) and (ii) changes in operating assets and liabilities using approximately $2.7 million.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Investing Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash provided by investing activities during the three months ended March&#160;31, 2023 totaled $4.3 million and was primarily due to net sales of marketable securities (net of purchases of marketable securities).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in investing activities during the three months ended March&#160;31, 2022 totaled $6.1 million and was primarily due to net purchases of marketable securities (net of sales of marketable securities).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Financing Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in financing activities during the three months ended March&#160;31, 2023 totaled $0.1 million and consisted primarily of tax withholding-related payments on net share settlement equity awards to employees. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash provided by financing activities during the three months ended March&#160;31, 2022 totaled $0.2 million and consisted primarily of tax withholding-related payments on net share settlement equity awards to employees. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Requirements Outlook</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To meet our short and long-term liquidity needs, we expect to use existing cash balances, marketable securities and a variety of other means. Other sources of liquidity could include additional potential issuances of debt or equity securities in public or private financings, partnerships and/or collaborations and/or sale of assets. Our history of operating losses and liquidity challenges may make it difficult for us to raise capital on acceptable terms or at all. The demand for the equity and debt of pharmaceutical companies like ours is dependent upon many factors, including the general state of the financial markets. During times of extreme market volatility, capital may not be available on favorable terms, if at all. Our inability to obtain such additional capital could materially and adversely affect our business operations. We will also continue to seek, as appropriate, grants for scientific and clinical studies from various governmental agencies and foundations, and other sources of non-dilutive funding. We believe that our cash on hand and marketable securities will enable us to fund operating expenses for at least the next 12 months following the issuance of our financial statements. Our future capital requirements are difficult to forecast and will depend on many factors including the timing and nature of any other strategic transactions that we undertake; and our ability to establish and maintain collaboration partnerships, in-license/out-license or other similar arrangements and the financial terms of such agreements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, we entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC as sales agent, in connection with an &#8220;at the market offering&#8221; under which we from time to time may offer and sell </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of our common stock having an aggregate offering price of up to $50.0&#160;million. Subsequent to the filing of our Form 10-K on March 22, 2022, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $43.6 million. Pursuant to General Instruction I.B.6 of Form S-3, since the aggregate market value of our outstanding common stock held by non-affiliates was below $75.0 million at the time of such Form 10-K filing, the aggregate amount of securities that we are permitted to offer and sell was reduced to $17,698,943, which was equal to one-third of the aggregate market value of our common stock held by non-affiliates as of September 21, 2022. As of March&#160;31, 2023, we had not issued any shares under the ATM Agreement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and our negotiating position in capital generating efforts may worsen as existing resources are used. Additional equity financing may be dilutive to our stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict our ability to operate as a business; our stock price may not reach levels necessary to induce option or warrant exercises; and asset sales may not be possible on terms we consider acceptable. If we are unable to access capital necessary to meet our long-term liquidity needs, we may have to delay the expansion of our business or raise funds on terms that we currently consider unfavorable. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_94"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our critical accounting policies and estimates during the three months ended March&#160;31, 2023, compared to those reported in our 2022 Form 10-K.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_97"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.<br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_100"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;&#160;Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures are our controls and other procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934), as amended (the &#8220;Exchange Act&#8221;) is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that we file under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer, who serves as our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well-designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Due to the inherent limitations of control systems, not all misstatements may be detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. Controls and procedures can only provide reasonable, not absolute, assurance that the above objectives have been met.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we evaluated, with the participation of our management, including our Chief Executive Officer, the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on that evaluation, our Chief Executive Officer concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms and is accumulated and communicated to management, including the Chief Executive Officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)&#160;&#160;Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15, that occurred during our last quarter to which this Quarterly Report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33 </span></div></div></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_106"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as disclosed in &#8220;Note 14 &#8211; Contingencies&#8221; set forth in the Notes to Unaudited Consolidated Financial Statements, which are included herein, there are no material changes to the disclosures previously reported in our 2022 Form 10-K.<br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_109"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the risk factors previously reported in our 2022 Form 10-K.  See the risk factors set forth in our 2022 Annual Report on Form 10-K under the caption &#8220;Item 1A - Risk Factors.&#8221;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_112"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_115"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_118"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_121"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OTHER INFORMATION</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_124"></div><div style="-sec-extract:summary;margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Exhibit Index appearing immediately after the signature page to this Form 10-Q is incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34 </span></div></div></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LISATA THERAPEUTICS, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> /s/ David J. Mazzo, PhD      </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name: David J. Mazzo, PhD      </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title:   Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer, Principal Financial Officer </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and Principal Accounting Officer)</span></div></td></tr></table></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:15.75pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35 </span></div></div></div><div id="i5bfad0e6eb2d444eb181b61964f9b0c2_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bfad0e6eb2d444eb181b61964f9b0c2_7">Index</a></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:13.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:461.50pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="clbs-ex311_20230331xq1.htm">31.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification of Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></td></tr><tr style="height:27pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="clbs-ex32_20230331q1.htm">32</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification of Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_______________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:16.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:502.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">             </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36 </span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>clbs-ex311_20230331xq1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ibab00307a15848a1a55e70c6ea651cb5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS UNDER SECTION 302</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David J. Mazzo, PhD, certify that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Lisata Therapeutics, Inc.&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by&#160;this report based on such evaluation&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;I have disclosed, based on my most recent evaluation of internal control over financial reporting to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;9, 2023 </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; David J. Mazzo, PhD&#160;&#160;&#160;&#160;       </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; David J. Mazzo, PhD</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; Chief Executive Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>3
<FILENAME>clbs-ex32_20230331q1.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i74d4a66a3faa480faf5981cdd905545f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Lisata Therapeutics, Inc. (the &#8220;Company&#8221;) for the quarter ended March&#160;31, 2023 filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, David J. Mazzo, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of the dates presented and the results of operations of the Company for the periods presented.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;&#160;&#160;May&#160;9, 2023 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:54.834%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; David J. Mazzo, PhD     </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David J. Mazzo, PhD</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>clbs-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8a27d5e7-fe33-4755-a32c-690f224065c0,g:57aefdc3-f3d7-461d-8b12-8991faaa8b7c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:clbs="http://www.caladrius.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.caladrius.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="clbs-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="clbs-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="clbs-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="clbs-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.caladrius.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParentheticals" roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000004 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000005 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofEquity">
        <link:definition>0000006 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheBusiness" roleURI="http://www.caladrius.com/role/TheBusiness">
        <link:definition>0000008 - Disclosure - The Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Merger" roleURI="http://www.caladrius.com/role/Merger">
        <link:definition>0000010 - Disclosure - Merger</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecurities" roleURI="http://www.caladrius.com/role/AvailableforSaleSecurities">
        <link:definition>0000011 - Disclosure - Available-for-Sale-Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNotes" roleURI="http://www.caladrius.com/role/PropertyandEquipmentNotes">
        <link:definition>0000012 - Disclosure - Property and Equipment (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerShare" roleURI="http://www.caladrius.com/role/IncomeLossPerShare">
        <link:definition>0000013 - Disclosure - Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.caladrius.com/role/FairValueMeasurements">
        <link:definition>0000014 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilities" roleURI="http://www.caladrius.com/role/AccruedLiabilities">
        <link:definition>0000015 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeases" roleURI="http://www.caladrius.com/role/OperatingLeases">
        <link:definition>0000016 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.caladrius.com/role/StockholdersEquity">
        <link:definition>0000017 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.caladrius.com/role/ShareBasedCompensation">
        <link:definition>0000018 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.caladrius.com/role/IncomeTaxes">
        <link:definition>0000019 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AustraliaResearchandDevelopmentTaxIncentive" roleURI="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive">
        <link:definition>0000020 - Disclosure - Australia Research and Development Tax Incentive</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.caladrius.com/role/Contingencies">
        <link:definition>0000021 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreements" roleURI="http://www.caladrius.com/role/LicenseAgreements">
        <link:definition>0000022 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreement" roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement">
        <link:definition>0000023 - Disclosure - Research Collaboration and License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.caladrius.com/role/SubsequentEvents">
        <link:definition>0000024 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000025 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerTables" roleURI="http://www.caladrius.com/role/MergerTables">
        <link:definition>0000026 - Disclosure - Merger (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesTables" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables">
        <link:definition>0000027 - Disclosure - Available-for-Sale-Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.caladrius.com/role/PropertyandEquipmentTables">
        <link:definition>0000028 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerShareTables" roleURI="http://www.caladrius.com/role/IncomeLossPerShareTables">
        <link:definition>0000029 - Disclosure - Income (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.caladrius.com/role/FairValueMeasurementsTables">
        <link:definition>0000030 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesTables" roleURI="http://www.caladrius.com/role/AccruedLiabilitiesTables">
        <link:definition>0000031 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesTables" roleURI="http://www.caladrius.com/role/OperatingLeasesTables">
        <link:definition>0000032 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.caladrius.com/role/StockholdersEquityTables">
        <link:definition>0000033 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.caladrius.com/role/ShareBasedCompensationTables">
        <link:definition>0000034 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheBusinessDetails" roleURI="http://www.caladrius.com/role/TheBusinessDetails">
        <link:definition>0000035 - Disclosure - The Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>0000036 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerDetails" roleURI="http://www.caladrius.com/role/MergerDetails">
        <link:definition>0000037 - Disclosure - Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails">
        <link:definition>0000038 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails">
        <link:definition>0000039 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails">
        <link:definition>0000040 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.caladrius.com/role/PropertyandEquipmentDetails">
        <link:definition>0000041 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerShareDetails" roleURI="http://www.caladrius.com/role/IncomeLossPerShareDetails">
        <link:definition>0000042 - Disclosure - Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails">
        <link:definition>0000043 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesDetails" roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails">
        <link:definition>0000044 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesNarrativeDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails">
        <link:definition>0000045 - Disclosure - Operating Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesBalanceSheetPresentationDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails">
        <link:definition>0000046 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesFutureMinimumLeasePaymentsDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>0000047 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1">
        <link:definition>0000047 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityEquityIssuancesDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails">
        <link:definition>0000048 - Disclosure - Stockholders' Equity - Equity Issuances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockOptionsandWarrantsDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails">
        <link:definition>0000049 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails">
        <link:definition>0000050 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>0000051 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationCompensationCostNotYetRecognizedDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails">
        <link:definition>0000052 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails">
        <link:definition>0000053 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.caladrius.com/role/IncomeTaxesDetails">
        <link:definition>0000054 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails_1" roleURI="http://www.caladrius.com/role/IncomeTaxesDetails_1">
        <link:definition>0000055 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsDetails" roleURI="http://www.caladrius.com/role/LicenseAgreementsDetails">
        <link:definition>0000056 - Disclosure - License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementDetails" roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails">
        <link:definition>0000057 - Disclosure - Research Collaboration and License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.caladrius.com/role/SubsequentEventsDetails">
        <link:definition>0000058 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsOutstanding" abstract="false" name="WeightedAverageExercisePriceWarrantsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_OperatingLossCarryforwardsPostAcquisition" abstract="false" name="OperatingLossCarryforwardsPostAcquisition" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WarrantsExpired" abstract="false" name="WarrantsExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_AssetAcquisitionCashAndCashEquivalents" abstract="false" name="AssetAcquisitionCashAndCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_BusinessTextBlock" abstract="false" name="BusinessTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="clbs_RevenuePerformanceObligationPercentageOfNetSale" abstract="false" name="RevenuePerformanceObligationPercentageOfNetSale" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="clbs_PreferredStockLiquidationPreferenceShare" abstract="false" name="PreferredStockLiquidationPreferenceShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" abstract="false" name="ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" abstract="false" name="AggregateIntrinsicValueWarrantsvestedandexpectedtovest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WarrantsWeightedAverageExercisePriceRollForward" abstract="true" name="WarrantsWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="clbs_ClinicalAndRDRelatedLiabilities" abstract="false" name="ClinicalAndRDRelatedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_AssetAcquisitionIntangibles" abstract="false" name="AssetAcquisitionIntangibles" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" abstract="false" name="WeightedAverageRemainingContractualTermwarrantoutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_CENDMember" abstract="true" name="CENDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_AtTheMarketOfferingAgreementMember" abstract="true" name="AtTheMarketOfferingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_AssetAcquisitionSharePrice" abstract="false" name="AssetAcquisitionSharePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_OptionsVestedweightedAverageRemainingContractualTerm" abstract="false" name="OptionsVestedweightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsExercised" abstract="false" name="WeightedAverageExercisePriceWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" abstract="false" name="SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" abstract="false" name="CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="clbs_FairValueMarketOfTaxNOLs" abstract="false" name="FairValueMarketOfTaxNOLs" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_AssetAcquisitionConsiderationTransferredEquityValue" abstract="false" name="AssetAcquisitionConsiderationTransferredEquityValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_ResearchAndDevelopmentTaxIncentiveTextBlock" abstract="false" name="ResearchAndDevelopmentTaxIncentiveTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="clbs_AggregateIntrinsicValueWarrantsvested" abstract="false" name="AggregateIntrinsicValueWarrantsvested" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsGranted" abstract="false" name="WeightedAverageExercisePriceWarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_OperatingLeaseRightOfUseAssetAbstract" abstract="true" name="OperatingLeaseRightOfUseAssetAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="clbs_Sharesvestedandexpectedtovest" abstract="false" name="Sharesvestedandexpectedtovest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues" abstract="false" name="RevenuePerformanceObligationPercentageOfSublicensingRevenues" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees" abstract="false" name="CollaborativeArrangementRightsAndObligationsSublicensingFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WeightedAverageRemainingContractualTermwarrantsvested" abstract="false" name="WeightedAverageRemainingContractualTermwarrantsvested" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_SaleOfStockAvailableForSale" abstract="false" name="SaleOfStockAvailableForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsExpired" abstract="false" name="WeightedAverageExercisePriceWarrantsExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_AssetAcquisitionAcquiredInProcessResearchAndDevelopment" abstract="false" name="AssetAcquisitionAcquiredInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_AggregateIntrinsicValueWarrantsOutstanding" abstract="false" name="AggregateIntrinsicValueWarrantsOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_MassachusettsInstituteOfTechnologyMember" abstract="true" name="MassachusettsInstituteOfTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" abstract="false" name="WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_AssetAcquisitionOtherLiabilities" abstract="false" name="AssetAcquisitionOtherLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_PreferredStockSharesDesignated" abstract="false" name="PreferredStockSharesDesignated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_SharesIssuedUnderLicenseAgreement" abstract="false" name="SharesIssuedUnderLicenseAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsCanceled" abstract="false" name="WeightedAverageExercisePriceWarrantsCanceled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_AccruedGrantFunding" abstract="false" name="AccruedGrantFunding" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_NumberOfOfficesUnderOperatingLeases" abstract="false" name="NumberOfOfficesUnderOperatingLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="clbs_CommonStockWarrantsShares" abstract="false" name="CommonStockWarrantsShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_SharesHeldByThirdParty" abstract="false" name="SharesHeldByThirdParty" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_OperatingLossCarryforwardsBeforeWriteDown" abstract="false" name="OperatingLossCarryforwardsBeforeWriteDown" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" abstract="false" name="WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_WarrantsOtherDisclosuresAbstract" abstract="true" name="WarrantsOtherDisclosuresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="clbs_WarrantsGranted" abstract="false" name="WarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_QiluMember" abstract="true" name="QiluMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsExercisable" abstract="false" name="WeightedAverageExercisePriceWarrantsExercisable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" abstract="false" name="IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WarrantsVested" abstract="false" name="WarrantsVested" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_SanfordBurnhamPrebysMember" abstract="true" name="SanfordBurnhamPrebysMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_WarrantsCanceled" abstract="false" name="WarrantsCanceled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_WarrantsExercised" abstract="false" name="WarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" abstract="false" name="LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="clbs_AssetAcquisitionNetWorkingCapital" abstract="false" name="AssetAcquisitionNetWorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_UniversityOfCaliforniaAtSanDiegoMember" abstract="true" name="UniversityOfCaliforniaAtSanDiegoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee" abstract="false" name="CollaborativeArrangementRightsAndObligationsChangeOfControlFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>clbs-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8a27d5e7-fe33-4755-a32c-690f224065c0,g:57aefdc3-f3d7-461d-8b12-8991faaa8b7c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="clbs-20230331.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ff0c58a2-c136-423a-a8d3-bd106cf5422f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_d986068f-b9e0-478d-b202-6dfa06c774c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff0c58a2-c136-423a-a8d3-bd106cf5422f" xlink:to="loc_us-gaap_PreferredStockValue_d986068f-b9e0-478d-b202-6dfa06c774c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a78bfb2d-5c14-445c-85aa-47d34e1554da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff0c58a2-c136-423a-a8d3-bd106cf5422f" xlink:to="loc_us-gaap_CommonStockValue_a78bfb2d-5c14-445c-85aa-47d34e1554da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a3d49670-9406-47d9-89d1-f1ccaa35b00c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff0c58a2-c136-423a-a8d3-bd106cf5422f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a3d49670-9406-47d9-89d1-f1ccaa35b00c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_01b750d5-70e0-4c1a-8e3f-e9124b751087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff0c58a2-c136-423a-a8d3-bd106cf5422f" xlink:to="loc_us-gaap_TreasuryStockCommonValue_01b750d5-70e0-4c1a-8e3f-e9124b751087" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e5a5db65-c095-4176-8742-7ccd69485904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff0c58a2-c136-423a-a8d3-bd106cf5422f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e5a5db65-c095-4176-8742-7ccd69485904" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_379502fd-0541-4b09-9707-9ff649237caf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff0c58a2-c136-423a-a8d3-bd106cf5422f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_379502fd-0541-4b09-9707-9ff649237caf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ef84dc93-58e5-4f47-a98a-15c88ef2818e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b0765a39-78b5-4ef1-8f44-8770c081b59e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ef84dc93-58e5-4f47-a98a-15c88ef2818e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b0765a39-78b5-4ef1-8f44-8770c081b59e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_bb2c22fa-2c98-487c-af78-eba7c14eb337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ef84dc93-58e5-4f47-a98a-15c88ef2818e" xlink:to="loc_us-gaap_MarketableSecurities_bb2c22fa-2c98-487c-af78-eba7c14eb337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ade9ce57-de1e-4930-9d6d-077707318b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ef84dc93-58e5-4f47-a98a-15c88ef2818e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ade9ce57-de1e-4930-9d6d-077707318b5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c601a2a9-df96-4c60-8460-8ade5817c1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_dae17ac7-70ea-455d-abb9-5552a41a5cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c601a2a9-df96-4c60-8460-8ade5817c1b7" xlink:to="loc_us-gaap_AssetsCurrent_dae17ac7-70ea-455d-abb9-5552a41a5cb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_485c53e0-c13a-4002-a334-3b9252c8930a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c601a2a9-df96-4c60-8460-8ade5817c1b7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_485c53e0-c13a-4002-a334-3b9252c8930a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b67a5366-ac5c-4645-adc8-55fd3fdae89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c601a2a9-df96-4c60-8460-8ade5817c1b7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b67a5366-ac5c-4645-adc8-55fd3fdae89c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_98a99888-38a5-4843-89eb-11cfa0c4a1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c601a2a9-df96-4c60-8460-8ade5817c1b7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_98a99888-38a5-4843-89eb-11cfa0c4a1b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6fc0b7e-f2a6-44de-9f9e-cf0765b3d221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_505939eb-43e4-45c8-823c-b06614806477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6fc0b7e-f2a6-44de-9f9e-cf0765b3d221" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_505939eb-43e4-45c8-823c-b06614806477" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a59e7798-7faa-4e58-b7b0-8ec63f701622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6fc0b7e-f2a6-44de-9f9e-cf0765b3d221" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a59e7798-7faa-4e58-b7b0-8ec63f701622" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e1bdb8ea-f8ec-482a-bcae-d0233834c381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6fc0b7e-f2a6-44de-9f9e-cf0765b3d221" xlink:to="loc_us-gaap_Liabilities_e1bdb8ea-f8ec-482a-bcae-d0233834c381" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d5a85560-10ad-4378-b58a-db71e8ea7710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3cef13d7-0a3e-4564-b102-665cbb4e5aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d5a85560-10ad-4378-b58a-db71e8ea7710" xlink:to="loc_us-gaap_AccountsPayableCurrent_3cef13d7-0a3e-4564-b102-665cbb4e5aee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_16f14851-cc98-4181-8345-41ff83a576d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d5a85560-10ad-4378-b58a-db71e8ea7710" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_16f14851-cc98-4181-8345-41ff83a576d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_da97dc59-a684-434a-bb74-7ee04c977120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3cfe09d5-649b-414f-96c5-66078a22cd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_da97dc59-a684-434a-bb74-7ee04c977120" xlink:to="loc_us-gaap_LiabilitiesCurrent_3cfe09d5-649b-414f-96c5-66078a22cd2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5350ae0e-943f-4e51-b35d-a14c80ec9e12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_da97dc59-a684-434a-bb74-7ee04c977120" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5350ae0e-943f-4e51-b35d-a14c80ec9e12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_29a11e72-4b58-4efa-82c2-abb963464b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_72e375f4-23bc-470d-9bbb-7400194d1ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_29a11e72-4b58-4efa-82c2-abb963464b4d" xlink:to="loc_us-gaap_StockholdersEquity_72e375f4-23bc-470d-9bbb-7400194d1ea8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9cae3e69-9aad-44f0-86b2-8599dad9085e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_29a11e72-4b58-4efa-82c2-abb963464b4d" xlink:to="loc_us-gaap_MinorityInterest_9cae3e69-9aad-44f0-86b2-8599dad9085e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="clbs-20230331.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6e5cf62b-2403-44e4-9aa9-0a05654e71cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_95fdef7d-ff11-4ec4-8543-a4dc8fb635ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_6e5cf62b-2403-44e4-9aa9-0a05654e71cc" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_95fdef7d-ff11-4ec4-8543-a4dc8fb635ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_fab146dc-44aa-4066-b769-183876cea78c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_6e5cf62b-2403-44e4-9aa9-0a05654e71cc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_fab146dc-44aa-4066-b769-183876cea78c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3ca081cb-074b-47b7-a5b2-00dfb859d875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_11409855-86c3-4a65-9282-b94f88486c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3ca081cb-074b-47b7-a5b2-00dfb859d875" xlink:to="loc_us-gaap_OperatingExpenses_11409855-86c3-4a65-9282-b94f88486c1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0b8d88ec-08a9-4f67-95ca-64c6fe9e7fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_63c04784-b9a5-4bac-9aff-80df05c9d10d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0b8d88ec-08a9-4f67-95ca-64c6fe9e7fd0" xlink:to="loc_us-gaap_OperatingIncomeLoss_63c04784-b9a5-4bac-9aff-80df05c9d10d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e42e176b-c36a-44c8-84da-60d725f46b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0b8d88ec-08a9-4f67-95ca-64c6fe9e7fd0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e42e176b-c36a-44c8-84da-60d725f46b3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5ea87f5e-a44b-46ff-bede-22a3fd078e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_486dec0a-d52a-4581-856f-21e1da06366a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5ea87f5e-a44b-46ff-bede-22a3fd078e8c" xlink:to="loc_us-gaap_ProfitLoss_486dec0a-d52a-4581-856f-21e1da06366a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_0de238e6-1269-4139-97f9-977dfb496f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5ea87f5e-a44b-46ff-bede-22a3fd078e8c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_0de238e6-1269-4139-97f9-977dfb496f89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9de39f3c-39b4-472d-92c2-d3f1e7c4cfa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83bb6c41-c05a-4acf-9f8d-0124e8a0adc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_9de39f3c-39b4-472d-92c2-d3f1e7c4cfa4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83bb6c41-c05a-4acf-9f8d-0124e8a0adc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ca447799-0ab8-41b9-81f2-b7c7c63880c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_9de39f3c-39b4-472d-92c2-d3f1e7c4cfa4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ca447799-0ab8-41b9-81f2-b7c7c63880c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0ad8d561-21f5-409b-a745-1a314aad72ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_8e8ca6a8-347a-49ce-817e-d02697ef3b93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0ad8d561-21f5-409b-a745-1a314aad72ad" xlink:to="loc_us-gaap_InvestmentIncomeNet_8e8ca6a8-347a-49ce-817e-d02697ef3b93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_544dbd02-5f7e-43e7-b87c-31ce6c4eec49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0ad8d561-21f5-409b-a745-1a314aad72ad" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_544dbd02-5f7e-43e7-b87c-31ce6c4eec49" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="clbs-20230331.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_61de687e-3638-4e27-80c4-eee3f3d03dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ff399061-3b53-461c-b844-8fcd50666a21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_61de687e-3638-4e27-80c4-eee3f3d03dd5" xlink:to="loc_us-gaap_ProfitLoss_ff399061-3b53-461c-b844-8fcd50666a21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2794dd26-3e6a-472a-a5de-c9b24db7c5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_61de687e-3638-4e27-80c4-eee3f3d03dd5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2794dd26-3e6a-472a-a5de-c9b24db7c5f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9d704cdb-ce43-4be4-a359-19ab8b561fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_57cad484-8bc8-4e6e-97d1-eec5254fc854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9d704cdb-ce43-4be4-a359-19ab8b561fc2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_57cad484-8bc8-4e6e-97d1-eec5254fc854" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fd5cc941-a053-448d-a708-956cd1e3fdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9d704cdb-ce43-4be4-a359-19ab8b561fc2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fd5cc941-a053-448d-a708-956cd1e3fdc6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="clbs-20230331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa659c26-3256-40f5-af78-36e6cd197bde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_da8e5e1b-338b-499b-9429-79bc62dd704e" xlink:href="clbs-20230331.xsd#clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa659c26-3256-40f5-af78-36e6cd197bde" xlink:to="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_da8e5e1b-338b-499b-9429-79bc62dd704e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f7f01adb-0155-450e-a7d7-93ee68674c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa659c26-3256-40f5-af78-36e6cd197bde" xlink:to="loc_us-gaap_ProfitLoss_f7f01adb-0155-450e-a7d7-93ee68674c3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_8622d457-f3e1-4dd6-84ad-699ef9158552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa659c26-3256-40f5-af78-36e6cd197bde" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_8622d457-f3e1-4dd6-84ad-699ef9158552" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_b72a578e-57e9-4ba6-a15f-0549b958762e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa659c26-3256-40f5-af78-36e6cd197bde" xlink:to="loc_us-gaap_DepreciationAndAmortization_b72a578e-57e9-4ba6-a15f-0549b958762e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6a9f5ca3-a3c8-4668-9f2a-0a7c52c679b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa659c26-3256-40f5-af78-36e6cd197bde" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6a9f5ca3-a3c8-4668-9f2a-0a7c52c679b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9e284d4a-1668-44f5-b34b-a485031e7e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa659c26-3256-40f5-af78-36e6cd197bde" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9e284d4a-1668-44f5-b34b-a485031e7e9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ec6815c2-e7ba-4618-b5d9-8f8560840b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa659c26-3256-40f5-af78-36e6cd197bde" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ec6815c2-e7ba-4618-b5d9-8f8560840b7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_50411faf-fab7-405e-9dfd-b21420a39cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa659c26-3256-40f5-af78-36e6cd197bde" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_50411faf-fab7-405e-9dfd-b21420a39cfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d1f82cc-ac6d-445d-ae04-78cafaedb1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_55a355e9-9a8d-489a-96b1-e8626a0751aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d1f82cc-ac6d-445d-ae04-78cafaedb1ee" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_55a355e9-9a8d-489a-96b1-e8626a0751aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2349c0a2-6de5-4d1d-8f24-0c1d267fe804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_974a3187-6c45-4eef-9fdc-199cd11b3bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2349c0a2-6de5-4d1d-8f24-0c1d267fe804" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_974a3187-6c45-4eef-9fdc-199cd11b3bf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_8656ba50-35f3-4963-928a-8beb08f908ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2349c0a2-6de5-4d1d-8f24-0c1d267fe804" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_8656ba50-35f3-4963-928a-8beb08f908ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2fe430e2-43b6-418d-b116-e49e5e991b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3c12281d-28cc-4197-a29e-00d5e4714b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2fe430e2-43b6-418d-b116-e49e5e991b5c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3c12281d-28cc-4197-a29e-00d5e4714b96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d0a5bf21-a40a-4848-b260-bf256df43289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2fe430e2-43b6-418d-b116-e49e5e991b5c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d0a5bf21-a40a-4848-b260-bf256df43289" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_79c8c2e5-3763-4043-bdb5-97cd221a2878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2fe430e2-43b6-418d-b116-e49e5e991b5c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_79c8c2e5-3763-4043-bdb5-97cd221a2878" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0946cabb-a156-4bb7-ac0c-9d9f5a732456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2fe430e2-43b6-418d-b116-e49e5e991b5c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0946cabb-a156-4bb7-ac0c-9d9f5a732456" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d84d59dc-dfbd-4ba0-acdc-955d84e30f40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f276a18f-f967-46cb-8f29-dd2fc25c0850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d84d59dc-dfbd-4ba0-acdc-955d84e30f40" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f276a18f-f967-46cb-8f29-dd2fc25c0850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d563d265-047d-4db9-a3a8-bdd07154c1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d84d59dc-dfbd-4ba0-acdc-955d84e30f40" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d563d265-047d-4db9-a3a8-bdd07154c1b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9dc30a3f-55ad-483d-b566-86f8ed33e213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d84d59dc-dfbd-4ba0-acdc-955d84e30f40" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9dc30a3f-55ad-483d-b566-86f8ed33e213" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_0ef2eade-4ce0-460b-8cc1-965ef5720d30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_b61da93c-2882-4d92-9194-8a025c85aefd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_0ef2eade-4ce0-460b-8cc1-965ef5720d30" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_b61da93c-2882-4d92-9194-8a025c85aefd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_4cc62692-bcbf-455f-9745-57fe87d91ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_0ef2eade-4ce0-460b-8cc1-965ef5720d30" xlink:to="loc_us-gaap_MarketableSecurities_4cc62692-bcbf-455f-9745-57fe87d91ebe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d690a234-e3d8-49d3-b713-10d188437ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_27454282-2aee-43e7-b9e5-5f8dfcbab22c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d690a234-e3d8-49d3-b713-10d188437ce3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_27454282-2aee-43e7-b9e5-5f8dfcbab22c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_6d1424e8-da28-49ec-bb31-bfb981a1c275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d690a234-e3d8-49d3-b713-10d188437ce3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_6d1424e8-da28-49ec-bb31-bfb981a1c275" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a67f0e44-a5b9-49c2-8d1a-b28f1076a239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_f34825a9-31dc-4bef-aaf6-12ea110fba62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a67f0e44-a5b9-49c2-8d1a-b28f1076a239" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_f34825a9-31dc-4bef-aaf6-12ea110fba62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_063397db-b848-4017-a675-875b71cb8060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a67f0e44-a5b9-49c2-8d1a-b28f1076a239" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_063397db-b848-4017-a675-875b71cb8060" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#PropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_761221e3-8263-46c6-bb10-ccd404ee2330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0415b480-e97b-4a8c-a8b9-72d31450d22c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_761221e3-8263-46c6-bb10-ccd404ee2330" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0415b480-e97b-4a8c-a8b9-72d31450d22c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0e188842-73be-4c12-86f5-ae0c71540f20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_761221e3-8263-46c6-bb10-ccd404ee2330" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0e188842-73be-4c12-86f5-ae0c71540f20" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_fed00842-cd20-45c3-bd9a-9268ad53cca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_2c6c35a7-1172-4716-80aa-5827e037a263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_fed00842-cd20-45c3-bd9a-9268ad53cca5" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_2c6c35a7-1172-4716-80aa-5827e037a263" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#AccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_856b9534-54b0-4910-b7e5-f825d407a648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f5812b91-0c37-4830-b526-1ab6170bde5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_856b9534-54b0-4910-b7e5-f825d407a648" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f5812b91-0c37-4830-b526-1ab6170bde5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d0e5e7dd-4fa0-45f5-ac59-0c169da830c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_856b9534-54b0-4910-b7e5-f825d407a648" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d0e5e7dd-4fa0-45f5-ac59-0c169da830c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ClinicalAndRDRelatedLiabilities_92f434b0-91e3-459f-992b-2d160b08ab00" xlink:href="clbs-20230331.xsd#clbs_ClinicalAndRDRelatedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_856b9534-54b0-4910-b7e5-f825d407a648" xlink:to="loc_clbs_ClinicalAndRDRelatedLiabilities_92f434b0-91e3-459f-992b-2d160b08ab00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a67f1756-6af1-4c41-a72e-4f1fdc172826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_856b9534-54b0-4910-b7e5-f825d407a648" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a67f1756-6af1-4c41-a72e-4f1fdc172826" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AccruedGrantFunding_d29a2479-8816-4952-9033-7abe92205ac9" xlink:href="clbs-20230331.xsd#clbs_AccruedGrantFunding"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_856b9534-54b0-4910-b7e5-f825d407a648" xlink:to="loc_clbs_AccruedGrantFunding_d29a2479-8816-4952-9033-7abe92205ac9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#OperatingLeasesBalanceSheetPresentationDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c15c92ab-2a44-47e3-804a-f09ca21ea133" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ec5e3e49-1961-4ddb-b109-f6c96a0fc40a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_c15c92ab-2a44-47e3-804a-f09ca21ea133" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ec5e3e49-1961-4ddb-b109-f6c96a0fc40a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3b6690ea-9109-44b4-ae30-ca85ec673e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_c15c92ab-2a44-47e3-804a-f09ca21ea133" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3b6690ea-9109-44b4-ae30-ca85ec673e70" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d5d59367-6ed5-4fd4-8b2a-25704232a6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d0c34abc-ee45-4498-88a6-364327316338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d5d59367-6ed5-4fd4-8b2a-25704232a6a4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d0c34abc-ee45-4498-88a6-364327316338" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2827de04-ff5d-46e6-986c-f701b3f3b9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d5d59367-6ed5-4fd4-8b2a-25704232a6a4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2827de04-ff5d-46e6-986c-f701b3f3b9a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_623afd8d-42f3-4d7f-b6e1-d6284aa63d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d5d59367-6ed5-4fd4-8b2a-25704232a6a4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_623afd8d-42f3-4d7f-b6e1-d6284aa63d88" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="clbs-20230331.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4894036b-ab25-45a6-b299-09fd7c611c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6ec1adf8-9abe-4a1f-a543-d839728cbe79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4894036b-ab25-45a6-b299-09fd7c611c3d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6ec1adf8-9abe-4a1f-a543-d839728cbe79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d8957de0-6bce-4823-a7ab-881fb4d8de12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4894036b-ab25-45a6-b299-09fd7c611c3d" xlink:to="loc_us-gaap_OperatingLeaseLiability_d8957de0-6bce-4823-a7ab-881fb4d8de12" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>clbs-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8a27d5e7-fe33-4755-a32c-690f224065c0,g:57aefdc3-f3d7-461d-8b12-8991faaa8b7c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="clbs-20230331.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofEquity" xlink:type="extended" id="i5546e972a1544b49b333faf663149e49_ConsolidatedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_48e3bef9-4887-4502-b2e1-c727cc1e42cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4caba145-dbf2-4f94-ad87-4d6eec056ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48e3bef9-4887-4502-b2e1-c727cc1e42cc" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4caba145-dbf2-4f94-ad87-4d6eec056ff8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b29a9a5d-808a-4774-816e-4ee77237be3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4caba145-dbf2-4f94-ad87-4d6eec056ff8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b29a9a5d-808a-4774-816e-4ee77237be3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0b85c3fd-0957-4d9b-a8b6-2bf3b53226d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4caba145-dbf2-4f94-ad87-4d6eec056ff8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0b85c3fd-0957-4d9b-a8b6-2bf3b53226d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8949c823-c002-4484-b7a4-104cc428f562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4caba145-dbf2-4f94-ad87-4d6eec056ff8" xlink:to="loc_us-gaap_ProfitLoss_8949c823-c002-4484-b7a4-104cc428f562" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c0f0001d-a8c0-4c41-ab0a-8336569326c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4caba145-dbf2-4f94-ad87-4d6eec056ff8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c0f0001d-a8c0-4c41-ab0a-8336569326c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3a10dfd1-679e-4cdb-b7d1-85e3e8c04ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4caba145-dbf2-4f94-ad87-4d6eec056ff8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3a10dfd1-679e-4cdb-b7d1-85e3e8c04ddb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_20d90882-4d3c-4ddd-8c6e-383cb04f3af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4caba145-dbf2-4f94-ad87-4d6eec056ff8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_20d90882-4d3c-4ddd-8c6e-383cb04f3af9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3c86fc54-d15f-4977-96e0-8440e6673f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4caba145-dbf2-4f94-ad87-4d6eec056ff8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3c86fc54-d15f-4977-96e0-8440e6673f4a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e2d7dc63-f040-4dad-97b1-4f5a0b23acfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8b84f59c-b838-4a48-b1fd-781474175e50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_80a7a0f8-5728-4e87-84d2-4e956c616c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_48e3bef9-4887-4502-b2e1-c727cc1e42cc" xlink:to="loc_us-gaap_StatementTable_80a7a0f8-5728-4e87-84d2-4e956c616c3e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3411d549-e437-42b0-b213-97e49bc34b65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_80a7a0f8-5728-4e87-84d2-4e956c616c3e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3411d549-e437-42b0-b213-97e49bc34b65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3411d549-e437-42b0-b213-97e49bc34b65_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3411d549-e437-42b0-b213-97e49bc34b65" xlink:to="loc_us-gaap_EquityComponentDomain_3411d549-e437-42b0-b213-97e49bc34b65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_122948c0-5756-4334-b20b-170056f0cc42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3411d549-e437-42b0-b213-97e49bc34b65" xlink:to="loc_us-gaap_EquityComponentDomain_122948c0-5756-4334-b20b-170056f0cc42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_32bfdae4-2fce-4352-92da-b19fafda7ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_122948c0-5756-4334-b20b-170056f0cc42" xlink:to="loc_us-gaap_ParentMember_32bfdae4-2fce-4352-92da-b19fafda7ef9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9b47f4c7-8a98-43f8-92de-8a5f1e197211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_32bfdae4-2fce-4352-92da-b19fafda7ef9" xlink:to="loc_us-gaap_CommonStockMember_9b47f4c7-8a98-43f8-92de-8a5f1e197211" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4c34ce0f-08db-4991-93cc-cf6d05b68700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_32bfdae4-2fce-4352-92da-b19fafda7ef9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4c34ce0f-08db-4991-93cc-cf6d05b68700" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_05680e45-5de0-467a-9ef8-941b35def37b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_32bfdae4-2fce-4352-92da-b19fafda7ef9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_05680e45-5de0-467a-9ef8-941b35def37b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_53cdf0df-b8e0-466e-b770-20e03360b2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_32bfdae4-2fce-4352-92da-b19fafda7ef9" xlink:to="loc_us-gaap_RetainedEarningsMember_53cdf0df-b8e0-466e-b770-20e03360b2f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_6a65bd9c-c8af-40f5-8f6b-749d0b19f637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_32bfdae4-2fce-4352-92da-b19fafda7ef9" xlink:to="loc_us-gaap_TreasuryStockCommonMember_6a65bd9c-c8af-40f5-8f6b-749d0b19f637" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_fb4b1f85-a296-437c-b192-b10f4eab9849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_122948c0-5756-4334-b20b-170056f0cc42" xlink:to="loc_us-gaap_NoncontrollingInterestMember_fb4b1f85-a296-437c-b192-b10f4eab9849" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TheBusinessDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#TheBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/TheBusinessDetails" xlink:type="extended" id="i5132545faef9427ebdde83e39559b3e5_TheBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_d9650918-6f14-4bcc-a689-cbe59cbafd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_65cfe5ee-beb7-4371-8958-1d2cca18bc41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_d9650918-6f14-4bcc-a689-cbe59cbafd7c" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_65cfe5ee-beb7-4371-8958-1d2cca18bc41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_93ca2ad6-1c7b-4c14-bcee-4e520c38e28f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_d9650918-6f14-4bcc-a689-cbe59cbafd7c" xlink:to="loc_us-gaap_SharesIssued_93ca2ad6-1c7b-4c14-bcee-4e520c38e28f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_a585b942-166f-4cd8-a31e-aa109e7ac744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_d9650918-6f14-4bcc-a689-cbe59cbafd7c" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_a585b942-166f-4cd8-a31e-aa109e7ac744" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_5a396dbc-a5dc-49b2-95eb-33b5fbc9a4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_d9650918-6f14-4bcc-a689-cbe59cbafd7c" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_5a396dbc-a5dc-49b2-95eb-33b5fbc9a4e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_72acc5d6-b410-46d7-aff7-90b4cad26678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_d9650918-6f14-4bcc-a689-cbe59cbafd7c" xlink:to="loc_us-gaap_AssetAcquisitionTable_72acc5d6-b410-46d7-aff7-90b4cad26678" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_06544062-a899-4679-945b-faf48d3bf960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_72acc5d6-b410-46d7-aff7-90b4cad26678" xlink:to="loc_us-gaap_AssetAcquisitionAxis_06544062-a899-4679-945b-faf48d3bf960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_06544062-a899-4679-945b-faf48d3bf960_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_06544062-a899-4679-945b-faf48d3bf960" xlink:to="loc_us-gaap_AssetAcquisitionDomain_06544062-a899-4679-945b-faf48d3bf960_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_55ba461b-f2ee-4e75-a69e-a0bd1b87b79c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_06544062-a899-4679-945b-faf48d3bf960" xlink:to="loc_us-gaap_AssetAcquisitionDomain_55ba461b-f2ee-4e75-a69e-a0bd1b87b79c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CENDMember_01f17779-7dfa-4688-a734-273af38acea2" xlink:href="clbs-20230331.xsd#clbs_CENDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_55ba461b-f2ee-4e75-a69e-a0bd1b87b79c" xlink:to="loc_clbs_CENDMember_01f17779-7dfa-4688-a734-273af38acea2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="ib2490f0b8ac8498b858e9d5a20d79feb_SummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76bbb704-c11c-407f-aba2-21800612aeac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_938f7bc5-963c-4f23-a9ca-178149ec50cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76bbb704-c11c-407f-aba2-21800612aeac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_938f7bc5-963c-4f23-a9ca-178149ec50cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_96286ba8-881e-4a83-9733-9fcf043091a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76bbb704-c11c-407f-aba2-21800612aeac" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_96286ba8-881e-4a83-9733-9fcf043091a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b2082892-7f97-48d4-aad1-a49b02d359e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_96286ba8-881e-4a83-9733-9fcf043091a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b2082892-7f97-48d4-aad1-a49b02d359e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b2082892-7f97-48d4-aad1-a49b02d359e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b2082892-7f97-48d4-aad1-a49b02d359e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b2082892-7f97-48d4-aad1-a49b02d359e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8497406-388d-4d95-84ac-d818497f29b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b2082892-7f97-48d4-aad1-a49b02d359e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8497406-388d-4d95-84ac-d818497f29b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_9e4bfe84-3435-41f9-81aa-0acfad5544ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8497406-388d-4d95-84ac-d818497f29b7" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_9e4bfe84-3435-41f9-81aa-0acfad5544ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_4a1c7d3d-5d5c-440a-969e-993b058bbc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8497406-388d-4d95-84ac-d818497f29b7" xlink:to="loc_us-gaap_ComputerEquipmentMember_4a1c7d3d-5d5c-440a-969e-993b058bbc6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_dab2e599-4d33-4641-b4b8-041517fa9e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8497406-388d-4d95-84ac-d818497f29b7" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_dab2e599-4d33-4641-b4b8-041517fa9e46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_9d273726-6fb6-40f3-b599-45295f5e5bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8497406-388d-4d95-84ac-d818497f29b7" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_9d273726-6fb6-40f3-b599-45295f5e5bc2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/MergerDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#MergerDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/MergerDetails" xlink:type="extended" id="i66fa0484933f4d208c5bebd5afd8f1e4_MergerDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_04957421-942a-4520-9725-7fdaa35f0f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_04957421-942a-4520-9725-7fdaa35f0f7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AssetAcquisitionSharePrice_0dcf5231-b7b4-4c21-88dc-6845a748ea15" xlink:href="clbs-20230331.xsd#clbs_AssetAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_clbs_AssetAcquisitionSharePrice_0dcf5231-b7b4-4c21-88dc-6845a748ea15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AssetAcquisitionConsiderationTransferredEquityValue_67589955-041a-4c73-9e64-39a3d43f188a" xlink:href="clbs-20230331.xsd#clbs_AssetAcquisitionConsiderationTransferredEquityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_clbs_AssetAcquisitionConsiderationTransferredEquityValue_67589955-041a-4c73-9e64-39a3d43f188a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_66f90d7e-9467-46ce-af33-7350f4dd26bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_66f90d7e-9467-46ce-af33-7350f4dd26bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_806cbdc4-1f5e-4f3e-8aea-fd2ec7a02e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_806cbdc4-1f5e-4f3e-8aea-fd2ec7a02e6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_45f3c8b0-5050-4f0f-80f4-f6c3f5b85023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_45f3c8b0-5050-4f0f-80f4-f6c3f5b85023" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_b3cb8ed8-e3ef-4746-821a-36b30364ad5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_b3cb8ed8-e3ef-4746-821a-36b30364ad5d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AssetAcquisitionCashAndCashEquivalents_600c40e0-1a01-4c66-bcb4-c5c8cecdf237" xlink:href="clbs-20230331.xsd#clbs_AssetAcquisitionCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_clbs_AssetAcquisitionCashAndCashEquivalents_600c40e0-1a01-4c66-bcb4-c5c8cecdf237" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AssetAcquisitionNetWorkingCapital_1e5ba66b-dcbc-4edb-922e-87f893082641" xlink:href="clbs-20230331.xsd#clbs_AssetAcquisitionNetWorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_clbs_AssetAcquisitionNetWorkingCapital_1e5ba66b-dcbc-4edb-922e-87f893082641" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AssetAcquisitionOtherLiabilities_7226c27f-a949-40ad-b9df-58c40568c032" xlink:href="clbs-20230331.xsd#clbs_AssetAcquisitionOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_clbs_AssetAcquisitionOtherLiabilities_7226c27f-a949-40ad-b9df-58c40568c032" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AssetAcquisitionAcquiredInProcessResearchAndDevelopment_eb2f4ef0-8c07-42cd-8150-6823fb394895" xlink:href="clbs-20230331.xsd#clbs_AssetAcquisitionAcquiredInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_clbs_AssetAcquisitionAcquiredInProcessResearchAndDevelopment_eb2f4ef0-8c07-42cd-8150-6823fb394895" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AssetAcquisitionIntangibles_1954d4e4-b574-4513-95c2-33af55846044" xlink:href="clbs-20230331.xsd#clbs_AssetAcquisitionIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_clbs_AssetAcquisitionIntangibles_1954d4e4-b574-4513-95c2-33af55846044" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_37f90050-f94d-4425-9c12-97600087eac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_us-gaap_AssetAcquisitionTable_37f90050-f94d-4425-9c12-97600087eac3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_0acf1ca9-11f1-46b1-80d7-a407fd8a8ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_37f90050-f94d-4425-9c12-97600087eac3" xlink:to="loc_us-gaap_AssetAcquisitionAxis_0acf1ca9-11f1-46b1-80d7-a407fd8a8ca7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_0acf1ca9-11f1-46b1-80d7-a407fd8a8ca7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_0acf1ca9-11f1-46b1-80d7-a407fd8a8ca7" xlink:to="loc_us-gaap_AssetAcquisitionDomain_0acf1ca9-11f1-46b1-80d7-a407fd8a8ca7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_9178ccc7-639f-4279-b683-0498a9571b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_0acf1ca9-11f1-46b1-80d7-a407fd8a8ca7" xlink:to="loc_us-gaap_AssetAcquisitionDomain_9178ccc7-639f-4279-b683-0498a9571b51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CENDMember_685e9736-5835-4e7b-9fa7-1805996189ff" xlink:href="clbs-20230331.xsd#clbs_CENDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_9178ccc7-639f-4279-b683-0498a9571b51" xlink:to="loc_clbs_CENDMember_685e9736-5835-4e7b-9fa7-1805996189ff" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="extended" id="i7535e97358e44a759899ad271045b5fd_AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fac7569b-5dbd-4c7c-80d8-ab858a93b1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2fb18989-8c64-47da-aa48-4f6b0ce1d7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fac7569b-5dbd-4c7c-80d8-ab858a93b1d0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2fb18989-8c64-47da-aa48-4f6b0ce1d7c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_084d317b-f260-48d1-af62-c39eed71e9df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fac7569b-5dbd-4c7c-80d8-ab858a93b1d0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_084d317b-f260-48d1-af62-c39eed71e9df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_363fb3e6-4739-4d4d-bb09-7f1e9cea015c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fac7569b-5dbd-4c7c-80d8-ab858a93b1d0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_363fb3e6-4739-4d4d-bb09-7f1e9cea015c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0f8b682e-ab3e-4c08-8886-8990dabd91bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fac7569b-5dbd-4c7c-80d8-ab858a93b1d0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0f8b682e-ab3e-4c08-8886-8990dabd91bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5e461888-a7e9-4945-a3f0-55b05dce21de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fac7569b-5dbd-4c7c-80d8-ab858a93b1d0" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5e461888-a7e9-4945-a3f0-55b05dce21de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_db9a07d4-a20e-4298-ae5b-9559008bfc61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5e461888-a7e9-4945-a3f0-55b05dce21de" xlink:to="loc_us-gaap_FinancialInstrumentAxis_db9a07d4-a20e-4298-ae5b-9559008bfc61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_db9a07d4-a20e-4298-ae5b-9559008bfc61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_db9a07d4-a20e-4298-ae5b-9559008bfc61" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_db9a07d4-a20e-4298-ae5b-9559008bfc61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f6738de-4b8d-4ca8-91bc-c21556d5e822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_db9a07d4-a20e-4298-ae5b-9559008bfc61" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f6738de-4b8d-4ca8-91bc-c21556d5e822" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c6225e3a-e878-4150-9d31-ec2c99cc4769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f6738de-4b8d-4ca8-91bc-c21556d5e822" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c6225e3a-e878-4150-9d31-ec2c99cc4769" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_189682b5-4c92-4268-8811-fb73b0558ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f6738de-4b8d-4ca8-91bc-c21556d5e822" xlink:to="loc_us-gaap_CommercialPaperMember_189682b5-4c92-4268-8811-fb73b0558ece" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1855f183-58c5-432b-a577-b729ec3738ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f6738de-4b8d-4ca8-91bc-c21556d5e822" xlink:to="loc_us-gaap_MoneyMarketFundsMember_1855f183-58c5-432b-a577-b729ec3738ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_fd19499c-7026-4b24-9f88-d3177d5e3563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f6738de-4b8d-4ca8-91bc-c21556d5e822" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_fd19499c-7026-4b24-9f88-d3177d5e3563" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#PropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="extended" id="i300279e6f50c42eeb8d0b5236c3428c8_PropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b420eda9-33d5-4ace-8375-ce18fa60fc89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_baff7ca8-d024-44e0-b561-d0f852402a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b420eda9-33d5-4ace-8375-ce18fa60fc89" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_baff7ca8-d024-44e0-b561-d0f852402a2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2fe32ef6-8490-484e-8471-dec8a6cf9e51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b420eda9-33d5-4ace-8375-ce18fa60fc89" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2fe32ef6-8490-484e-8471-dec8a6cf9e51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1ae27bc9-7cf7-41c3-8e68-12b9c601725f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b420eda9-33d5-4ace-8375-ce18fa60fc89" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1ae27bc9-7cf7-41c3-8e68-12b9c601725f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_28c7a76e-a1bd-45fe-bc2e-133b378b9ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b420eda9-33d5-4ace-8375-ce18fa60fc89" xlink:to="loc_us-gaap_Depreciation_28c7a76e-a1bd-45fe-bc2e-133b378b9ffd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b1646de8-2ee4-4628-b62a-09978ca4774f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b420eda9-33d5-4ace-8375-ce18fa60fc89" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b1646de8-2ee4-4628-b62a-09978ca4774f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_10e1e6ca-dcd9-4a85-98b4-7edffd384c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b1646de8-2ee4-4628-b62a-09978ca4774f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_10e1e6ca-dcd9-4a85-98b4-7edffd384c1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_10e1e6ca-dcd9-4a85-98b4-7edffd384c1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_10e1e6ca-dcd9-4a85-98b4-7edffd384c1b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_10e1e6ca-dcd9-4a85-98b4-7edffd384c1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ec2bc5d-0a49-47dc-953f-77c38b10dc93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_10e1e6ca-dcd9-4a85-98b4-7edffd384c1b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ec2bc5d-0a49-47dc-953f-77c38b10dc93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_257eb789-17d9-483c-b0e5-ca11c63a120e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ec2bc5d-0a49-47dc-953f-77c38b10dc93" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_257eb789-17d9-483c-b0e5-ca11c63a120e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_ef6049ef-fc7f-4e25-8b16-a84ded6ad530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ec2bc5d-0a49-47dc-953f-77c38b10dc93" xlink:to="loc_us-gaap_ComputerEquipmentMember_ef6049ef-fc7f-4e25-8b16-a84ded6ad530" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_46fa8ce5-1e6b-41e4-b04a-6188e6b9089f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ec2bc5d-0a49-47dc-953f-77c38b10dc93" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_46fa8ce5-1e6b-41e4-b04a-6188e6b9089f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#IncomeLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="extended" id="i7672bbced5664dbba7050a82f45012e7_IncomeLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_459a1f88-78ba-4fbd-88a4-cec51f8f3bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e224b331-f634-4fdd-8b97-d55bfce21e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_459a1f88-78ba-4fbd-88a4-cec51f8f3bf8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e224b331-f634-4fdd-8b97-d55bfce21e96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_032f296e-f2f8-4c63-b38f-2465f556beca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_459a1f88-78ba-4fbd-88a4-cec51f8f3bf8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_032f296e-f2f8-4c63-b38f-2465f556beca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_62dd8df0-9284-4357-8ca9-4f5f5149a28b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_032f296e-f2f8-4c63-b38f-2465f556beca" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_62dd8df0-9284-4357-8ca9-4f5f5149a28b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_62dd8df0-9284-4357-8ca9-4f5f5149a28b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_62dd8df0-9284-4357-8ca9-4f5f5149a28b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_62dd8df0-9284-4357-8ca9-4f5f5149a28b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4adf764f-504f-4fc5-bef6-c4cd39c15ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_62dd8df0-9284-4357-8ca9-4f5f5149a28b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4adf764f-504f-4fc5-bef6-c4cd39c15ee8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9563f178-389c-4ce4-a2db-4659e9e7f56f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4adf764f-504f-4fc5-bef6-c4cd39c15ee8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9563f178-389c-4ce4-a2db-4659e9e7f56f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_e033bc4f-97e4-4213-9f9a-c055dde0cf30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4adf764f-504f-4fc5-bef6-c4cd39c15ee8" xlink:to="loc_us-gaap_WarrantMember_e033bc4f-97e4-4213-9f9a-c055dde0cf30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d4715eaa-732b-40f6-b838-5abdf8c9454c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4adf764f-504f-4fc5-bef6-c4cd39c15ee8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d4715eaa-732b-40f6-b838-5abdf8c9454c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="i68df383b94d144d9b8a50f91159a7844_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c989521a-0eca-4973-a5ad-25a9bab37181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_cc98eec2-040a-4edc-a3b5-e5f5c6ecfe54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c989521a-0eca-4973-a5ad-25a9bab37181" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_cc98eec2-040a-4edc-a3b5-e5f5c6ecfe54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2f11e8c0-1a3a-4093-afea-c83adeaa8e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c989521a-0eca-4973-a5ad-25a9bab37181" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2f11e8c0-1a3a-4093-afea-c83adeaa8e9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e851d9e-412c-4325-8a6a-58d08cdd39a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c989521a-0eca-4973-a5ad-25a9bab37181" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e851d9e-412c-4325-8a6a-58d08cdd39a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54decc13-3e8f-4163-a3e7-b6c9fcb17780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e851d9e-412c-4325-8a6a-58d08cdd39a1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54decc13-3e8f-4163-a3e7-b6c9fcb17780" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54decc13-3e8f-4163-a3e7-b6c9fcb17780_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54decc13-3e8f-4163-a3e7-b6c9fcb17780" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54decc13-3e8f-4163-a3e7-b6c9fcb17780_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e09726ea-2839-4ddb-9b1a-54a9e57a36b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54decc13-3e8f-4163-a3e7-b6c9fcb17780" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e09726ea-2839-4ddb-9b1a-54a9e57a36b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c5b93146-4ca1-498e-90fd-08a194db3d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e09726ea-2839-4ddb-9b1a-54a9e57a36b9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c5b93146-4ca1-498e-90fd-08a194db3d07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_56218e61-a33a-40f7-afa6-6a4350158768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e09726ea-2839-4ddb-9b1a-54a9e57a36b9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_56218e61-a33a-40f7-afa6-6a4350158768" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_54380989-ec0d-4043-94f6-5059bbf39d66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e09726ea-2839-4ddb-9b1a-54a9e57a36b9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_54380989-ec0d-4043-94f6-5059bbf39d66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_648ece86-408a-4969-8127-7e89298162b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e851d9e-412c-4325-8a6a-58d08cdd39a1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_648ece86-408a-4969-8127-7e89298162b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_648ece86-408a-4969-8127-7e89298162b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_648ece86-408a-4969-8127-7e89298162b0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_648ece86-408a-4969-8127-7e89298162b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_afeb8b0b-8780-4a8d-9f70-af7c200974b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_648ece86-408a-4969-8127-7e89298162b0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_afeb8b0b-8780-4a8d-9f70-af7c200974b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_87b9c260-6735-4423-8a94-53a43ce5ec5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_afeb8b0b-8780-4a8d-9f70-af7c200974b7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_87b9c260-6735-4423-8a94-53a43ce5ec5c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#StockholdersEquityEquityIssuancesDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="extended" id="i018973025fbf4e26bcdfe783c97129f3_StockholdersEquityEquityIssuancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7913e9aa-41e0-4c85-bc1b-5a542b1ac46b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_058bce0c-a61d-43f3-9f52-d1968139e8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7913e9aa-41e0-4c85-bc1b-5a542b1ac46b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_058bce0c-a61d-43f3-9f52-d1968139e8cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_c88a32a4-0c42-4730-afc1-d17d6a759639" xlink:href="clbs-20230331.xsd#clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7913e9aa-41e0-4c85-bc1b-5a542b1ac46b" xlink:to="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_c88a32a4-0c42-4730-afc1-d17d6a759639" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_dddc76ca-177a-4cec-b7e1-f22ea4ce5717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7913e9aa-41e0-4c85-bc1b-5a542b1ac46b" xlink:to="loc_us-gaap_CommonStockValueOutstanding_dddc76ca-177a-4cec-b7e1-f22ea4ce5717" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAvailableForSale_d80bdac9-cea1-4386-abb1-5aea8bd3cb06" xlink:href="clbs-20230331.xsd#clbs_SaleOfStockAvailableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7913e9aa-41e0-4c85-bc1b-5a542b1ac46b" xlink:to="loc_clbs_SaleOfStockAvailableForSale_d80bdac9-cea1-4386-abb1-5aea8bd3cb06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_875ac15e-2b89-4fbb-b0ad-ce8a6a38a1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7913e9aa-41e0-4c85-bc1b-5a542b1ac46b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_875ac15e-2b89-4fbb-b0ad-ce8a6a38a1ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f7590dca-5825-4fac-8ed3-535c34a9dccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_7913e9aa-41e0-4c85-bc1b-5a542b1ac46b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f7590dca-5825-4fac-8ed3-535c34a9dccc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a8d06d34-0fdc-4905-8828-63dc243d5876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f7590dca-5825-4fac-8ed3-535c34a9dccc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a8d06d34-0fdc-4905-8828-63dc243d5876" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a8d06d34-0fdc-4905-8828-63dc243d5876_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a8d06d34-0fdc-4905-8828-63dc243d5876" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a8d06d34-0fdc-4905-8828-63dc243d5876_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ec494b31-bcd2-4ac6-bfbc-dff443487d35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a8d06d34-0fdc-4905-8828-63dc243d5876" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ec494b31-bcd2-4ac6-bfbc-dff443487d35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AtTheMarketOfferingAgreementMember_491e1314-f9e3-4baf-bf46-2a0b52b87215" xlink:href="clbs-20230331.xsd#clbs_AtTheMarketOfferingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ec494b31-bcd2-4ac6-bfbc-dff443487d35" xlink:to="loc_clbs_AtTheMarketOfferingAgreementMember_491e1314-f9e3-4baf-bf46-2a0b52b87215" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_e4e27229-ec86-42cb-8e4b-2efbe13da0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f7590dca-5825-4fac-8ed3-535c34a9dccc" xlink:to="loc_us-gaap_AssetAcquisitionAxis_e4e27229-ec86-42cb-8e4b-2efbe13da0f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_e4e27229-ec86-42cb-8e4b-2efbe13da0f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_e4e27229-ec86-42cb-8e4b-2efbe13da0f0" xlink:to="loc_us-gaap_AssetAcquisitionDomain_e4e27229-ec86-42cb-8e4b-2efbe13da0f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_640c4c0b-a380-4535-9ec8-c3e6dfada278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_e4e27229-ec86-42cb-8e4b-2efbe13da0f0" xlink:to="loc_us-gaap_AssetAcquisitionDomain_640c4c0b-a380-4535-9ec8-c3e6dfada278" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CENDMember_886ae39d-835c-4866-927d-f5a8771f9165" xlink:href="clbs-20230331.xsd#clbs_CENDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_640c4c0b-a380-4535-9ec8-c3e6dfada278" xlink:to="loc_clbs_CENDMember_886ae39d-835c-4866-927d-f5a8771f9165" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="extended" id="i8abb7d8c73d4476a964ac33ea406a962_StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_196b1cb5-152c-4e10-8210-ecf94e05851f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_73580636-9d59-47a5-bf43-62e88b018736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_196b1cb5-152c-4e10-8210-ecf94e05851f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_73580636-9d59-47a5-bf43-62e88b018736" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_103ddc1a-c6c1-4163-bbbe-21267123b9be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_196b1cb5-152c-4e10-8210-ecf94e05851f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_103ddc1a-c6c1-4163-bbbe-21267123b9be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c1329f31-656e-44f9-a156-97885a718288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_196b1cb5-152c-4e10-8210-ecf94e05851f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c1329f31-656e-44f9-a156-97885a718288" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_276c26cf-eba8-4282-abc2-6eb743f255a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_196b1cb5-152c-4e10-8210-ecf94e05851f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_276c26cf-eba8-4282-abc2-6eb743f255a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5004e1f3-60cb-4947-9d45-46417990ce8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_196b1cb5-152c-4e10-8210-ecf94e05851f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5004e1f3-60cb-4947-9d45-46417990ce8d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2b4f629c-5c90-481d-9d3a-e9a950c4edaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5004e1f3-60cb-4947-9d45-46417990ce8d" xlink:to="loc_us-gaap_AwardTypeAxis_2b4f629c-5c90-481d-9d3a-e9a950c4edaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b4f629c-5c90-481d-9d3a-e9a950c4edaa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2b4f629c-5c90-481d-9d3a-e9a950c4edaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b4f629c-5c90-481d-9d3a-e9a950c4edaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_965ef6c8-ff41-4f97-aaa7-e254b15806fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2b4f629c-5c90-481d-9d3a-e9a950c4edaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_965ef6c8-ff41-4f97-aaa7-e254b15806fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_4bb1652f-b983-4f8a-8e44-66a2f6239021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_965ef6c8-ff41-4f97-aaa7-e254b15806fe" xlink:to="loc_us-gaap_RestrictedStockMember_4bb1652f-b983-4f8a-8e44-66a2f6239021" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_74af2460-bb44-4870-a765-672a73d6557a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_965ef6c8-ff41-4f97-aaa7-e254b15806fe" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_74af2460-bb44-4870-a765-672a73d6557a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1a3441f6-33f3-4a64-a22b-e424a78bab1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5004e1f3-60cb-4947-9d45-46417990ce8d" xlink:to="loc_srt_RangeAxis_1a3441f6-33f3-4a64-a22b-e424a78bab1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1a3441f6-33f3-4a64-a22b-e424a78bab1a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1a3441f6-33f3-4a64-a22b-e424a78bab1a" xlink:to="loc_srt_RangeMember_1a3441f6-33f3-4a64-a22b-e424a78bab1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c2251bda-fde6-4c52-8f6e-e878a0b3e226" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1a3441f6-33f3-4a64-a22b-e424a78bab1a" xlink:to="loc_srt_RangeMember_c2251bda-fde6-4c52-8f6e-e878a0b3e226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_283f8553-7c50-479e-85a0-91882e72e754" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c2251bda-fde6-4c52-8f6e-e878a0b3e226" xlink:to="loc_srt_MinimumMember_283f8553-7c50-479e-85a0-91882e72e754" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_93e3e562-6630-4481-900c-6943464657a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c2251bda-fde6-4c52-8f6e-e878a0b3e226" xlink:to="loc_srt_MaximumMember_93e3e562-6630-4481-900c-6943464657a9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" id="if7efbc22a6884d46a661041a59e48b47_ShareBasedCompensationShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c369edf3-61b0-4c6e-a491-7f0d9dacfcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d52f4647-8d80-4ca2-a389-4644c9bc0542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c369edf3-61b0-4c6e-a491-7f0d9dacfcc4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d52f4647-8d80-4ca2-a389-4644c9bc0542" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb64b3d4-724e-4128-9482-5a3a6ea2a35a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c369edf3-61b0-4c6e-a491-7f0d9dacfcc4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb64b3d4-724e-4128-9482-5a3a6ea2a35a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_465ef2f3-58bc-4653-8762-b4f64f16386b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb64b3d4-724e-4128-9482-5a3a6ea2a35a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_465ef2f3-58bc-4653-8762-b4f64f16386b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_465ef2f3-58bc-4653-8762-b4f64f16386b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_465ef2f3-58bc-4653-8762-b4f64f16386b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_465ef2f3-58bc-4653-8762-b4f64f16386b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1aa2fb65-4fd3-452e-998a-def36c87bc78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_465ef2f3-58bc-4653-8762-b4f64f16386b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1aa2fb65-4fd3-452e-998a-def36c87bc78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e1480f25-06b9-409a-b285-5efc22d9724b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1aa2fb65-4fd3-452e-998a-def36c87bc78" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e1480f25-06b9-409a-b285-5efc22d9724b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a605c862-b742-4545-83d9-8ca0bb7e44cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1aa2fb65-4fd3-452e-998a-def36c87bc78" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a605c862-b742-4545-83d9-8ca0bb7e44cb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#ShareBasedCompensationCompensationCostNotYetRecognizedDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="extended" id="ibc89ccd452174e70b6e05024a8a653a0_ShareBasedCompensationCompensationCostNotYetRecognizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a158946-d482-4f29-b74b-f42729413f81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e410abb9-3895-4ed7-8cfc-c43b2e2b2df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a158946-d482-4f29-b74b-f42729413f81" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e410abb9-3895-4ed7-8cfc-c43b2e2b2df3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9c29f1a9-501e-4729-b6c6-b4da0df57b77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a158946-d482-4f29-b74b-f42729413f81" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9c29f1a9-501e-4729-b6c6-b4da0df57b77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a6e0cb8-e6b7-4e56-ad32-4e0da72617ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a158946-d482-4f29-b74b-f42729413f81" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a6e0cb8-e6b7-4e56-ad32-4e0da72617ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_78a1adfb-2f53-46aa-a5cc-68bcb7c8f2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a6e0cb8-e6b7-4e56-ad32-4e0da72617ea" xlink:to="loc_us-gaap_AwardTypeAxis_78a1adfb-2f53-46aa-a5cc-68bcb7c8f2b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78a1adfb-2f53-46aa-a5cc-68bcb7c8f2b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_78a1adfb-2f53-46aa-a5cc-68bcb7c8f2b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78a1adfb-2f53-46aa-a5cc-68bcb7c8f2b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f5ee47e-4256-4eb1-9b58-009ae1980d31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_78a1adfb-2f53-46aa-a5cc-68bcb7c8f2b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f5ee47e-4256-4eb1-9b58-009ae1980d31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f3e6b993-4f19-4f57-ba73-cdea7ba67072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f5ee47e-4256-4eb1-9b58-009ae1980d31" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f3e6b993-4f19-4f57-ba73-cdea7ba67072" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2d074cb2-85c0-4d7e-bcf5-dec6ed709a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f5ee47e-4256-4eb1-9b58-009ae1980d31" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2d074cb2-85c0-4d7e-bcf5-dec6ed709a39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c987befe-636c-4ea3-a4ca-29bfd1190e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f5ee47e-4256-4eb1-9b58-009ae1980d31" xlink:to="loc_us-gaap_RestrictedStockMember_c987befe-636c-4ea3-a4ca-29bfd1190e01" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="extended" id="i4b9339b702d841ef8fd35db2f3a3ae02_ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6480bc1c-d254-41c2-b7d6-0f3943629e22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9c92e838-0e23-4b89-9760-506c77385401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6480bc1c-d254-41c2-b7d6-0f3943629e22" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9c92e838-0e23-4b89-9760-506c77385401" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b1fe62d0-d1d3-4316-a9f1-8df0a3f39d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6480bc1c-d254-41c2-b7d6-0f3943629e22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b1fe62d0-d1d3-4316-a9f1-8df0a3f39d0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5b3fd5ec-ef1f-4fe4-ad0f-0a360f5a221b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6480bc1c-d254-41c2-b7d6-0f3943629e22" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5b3fd5ec-ef1f-4fe4-ad0f-0a360f5a221b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0cedbfaf-e882-431e-b3c9-fcb47ea7c1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5b3fd5ec-ef1f-4fe4-ad0f-0a360f5a221b" xlink:to="loc_us-gaap_AwardTypeAxis_0cedbfaf-e882-431e-b3c9-fcb47ea7c1ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0cedbfaf-e882-431e-b3c9-fcb47ea7c1ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0cedbfaf-e882-431e-b3c9-fcb47ea7c1ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0cedbfaf-e882-431e-b3c9-fcb47ea7c1ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb4dde63-8ee2-4fad-bdf2-36e06b5b4f79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0cedbfaf-e882-431e-b3c9-fcb47ea7c1ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb4dde63-8ee2-4fad-bdf2-36e06b5b4f79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b13feaa4-057b-4921-9e9c-2ba500fae769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb4dde63-8ee2-4fad-bdf2-36e06b5b4f79" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b13feaa4-057b-4921-9e9c-2ba500fae769" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="extended" id="i7e027a9105634158aa1b8c1cdbf086a1_IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_0b69526c-4f61-40c5-aa1d-799d5eff518e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown_c5fc6b26-e887-4e49-afbe-3a96a657fb46" xlink:href="clbs-20230331.xsd#clbs_OperatingLossCarryforwardsBeforeWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0b69526c-4f61-40c5-aa1d-799d5eff518e" xlink:to="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown_c5fc6b26-e887-4e49-afbe-3a96a657fb46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_b3e4b1df-d748-4357-8737-561aad015320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0b69526c-4f61-40c5-aa1d-799d5eff518e" xlink:to="loc_us-gaap_OperatingLossCarryforwards_b3e4b1df-d748-4357-8737-561aad015320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_FairValueMarketOfTaxNOLs_bf089704-4bc4-4484-afd8-f43852bac942" xlink:href="clbs-20230331.xsd#clbs_FairValueMarketOfTaxNOLs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0b69526c-4f61-40c5-aa1d-799d5eff518e" xlink:to="loc_clbs_FairValueMarketOfTaxNOLs_bf089704-4bc4-4484-afd8-f43852bac942" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_76e7ac91-cdc4-4272-9c65-16a2c7f449a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0b69526c-4f61-40c5-aa1d-799d5eff518e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_76e7ac91-cdc4-4272-9c65-16a2c7f449a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsPostAcquisition_37d459a1-c808-40ec-913e-d78b61a8f81c" xlink:href="clbs-20230331.xsd#clbs_OperatingLossCarryforwardsPostAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0b69526c-4f61-40c5-aa1d-799d5eff518e" xlink:to="loc_clbs_OperatingLossCarryforwardsPostAcquisition_37d459a1-c808-40ec-913e-d78b61a8f81c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_76370d31-fd31-45d9-9a78-54a25a42daa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0b69526c-4f61-40c5-aa1d-799d5eff518e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_76370d31-fd31-45d9-9a78-54a25a42daa2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_a96db61c-c5fd-422d-aadd-d77e339ba642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0b69526c-4f61-40c5-aa1d-799d5eff518e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_a96db61c-c5fd-422d-aadd-d77e339ba642" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_087722fa-d18b-4ca0-a261-05bd1d72c4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0b69526c-4f61-40c5-aa1d-799d5eff518e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_087722fa-d18b-4ca0-a261-05bd1d72c4b0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1750ab10-9f74-469b-9d51-bbe223fc6faf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0b69526c-4f61-40c5-aa1d-799d5eff518e" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1750ab10-9f74-469b-9d51-bbe223fc6faf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_746f27fd-fdbf-40db-86d5-30bb1882d5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1750ab10-9f74-469b-9d51-bbe223fc6faf" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_746f27fd-fdbf-40db-86d5-30bb1882d5c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_746f27fd-fdbf-40db-86d5-30bb1882d5c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_746f27fd-fdbf-40db-86d5-30bb1882d5c9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_746f27fd-fdbf-40db-86d5-30bb1882d5c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d4518e4a-5a84-4d9d-95a3-711d602a2eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_746f27fd-fdbf-40db-86d5-30bb1882d5c9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d4518e4a-5a84-4d9d-95a3-711d602a2eb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_db1c5e09-ce56-4b0b-a426-64ba59f2d366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d4518e4a-5a84-4d9d-95a3-711d602a2eb6" xlink:to="loc_us-gaap_DomesticCountryMember_db1c5e09-ce56-4b0b-a426-64ba59f2d366" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_05906d3f-51c7-437d-a7ef-684db1848d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d4518e4a-5a84-4d9d-95a3-711d602a2eb6" xlink:to="loc_us-gaap_ForeignCountryMember_05906d3f-51c7-437d-a7ef-684db1848d23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_3fc689b6-0f02-494b-9049-6953a5527c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d4518e4a-5a84-4d9d-95a3-711d602a2eb6" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_3fc689b6-0f02-494b-9049-6953a5527c8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_7340110b-cca7-4cf6-956f-d1cbd380d620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1750ab10-9f74-469b-9d51-bbe223fc6faf" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_7340110b-cca7-4cf6-956f-d1cbd380d620" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_7340110b-cca7-4cf6-956f-d1cbd380d620_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_7340110b-cca7-4cf6-956f-d1cbd380d620" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_7340110b-cca7-4cf6-956f-d1cbd380d620_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_4cc7f555-5fa5-4c69-a69d-ce30dd32741b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_7340110b-cca7-4cf6-956f-d1cbd380d620" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_4cc7f555-5fa5-4c69-a69d-ce30dd32741b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_1e2c97cb-2184-4d66-bd9f-3c6de3d6b5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_4cc7f555-5fa5-4c69-a69d-ce30dd32741b" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_1e2c97cb-2184-4d66-bd9f-3c6de3d6b5d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_2744a9ef-5913-4c49-b6e1-30dccc87b937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_4cc7f555-5fa5-4c69-a69d-ce30dd32741b" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_2744a9ef-5913-4c49-b6e1-30dccc87b937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_3498f7af-cc1e-4796-b2d5-3d90d3f6f59e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_4cc7f555-5fa5-4c69-a69d-ce30dd32741b" xlink:to="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_3498f7af-cc1e-4796-b2d5-3d90d3f6f59e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_b4d26a73-f0af-4af8-b94f-5aae2b4bc2e8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1750ab10-9f74-469b-9d51-bbe223fc6faf" xlink:to="loc_dei_LegalEntityAxis_b4d26a73-f0af-4af8-b94f-5aae2b4bc2e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b4d26a73-f0af-4af8-b94f-5aae2b4bc2e8_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_b4d26a73-f0af-4af8-b94f-5aae2b4bc2e8" xlink:to="loc_dei_EntityDomain_b4d26a73-f0af-4af8-b94f-5aae2b4bc2e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_43cfab58-a657-44b1-81f0-87d8ef4a3e24" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_b4d26a73-f0af-4af8-b94f-5aae2b4bc2e8" xlink:to="loc_dei_EntityDomain_43cfab58-a657-44b1-81f0-87d8ef4a3e24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CENDMember_a9a1e0cd-4668-46cd-9ac5-fcecd0f3ff75" xlink:href="clbs-20230331.xsd#clbs_CENDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_43cfab58-a657-44b1-81f0-87d8ef4a3e24" xlink:to="loc_clbs_CENDMember_a9a1e0cd-4668-46cd-9ac5-fcecd0f3ff75" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#LicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/LicenseAgreementsDetails" xlink:type="extended" id="iba2959bebd064a9d9d88acf4118fd026_LicenseAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SharesIssuedUnderLicenseAgreement_925cce3f-a7ce-4345-9b63-16c3e54cfbe1" xlink:href="clbs-20230331.xsd#clbs_SharesIssuedUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_clbs_SharesIssuedUnderLicenseAgreement_925cce3f-a7ce-4345-9b63-16c3e54cfbe1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_4e1b6a7a-c95f-4d18-bc3f-3fe2a2ec93d2" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_4e1b6a7a-c95f-4d18-bc3f-3fe2a2ec93d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_c607e371-a792-4f0c-a893-f2c51887ae3f" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_c607e371-a792-4f0c-a893-f2c51887ae3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_c5810b1c-1054-4f37-a0f2-ff01b464e16c" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_c5810b1c-1054-4f37-a0f2-ff01b464e16c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_d9dfb064-dcb7-4dbc-bbf0-b1abba88f4f2" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_d9dfb064-dcb7-4dbc-bbf0-b1abba88f4f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees_a91acb67-5903-47fd-b1ab-3938a7dcd1cd" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees_a91acb67-5903-47fd-b1ab-3938a7dcd1cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour_1ed2815f-b052-4936-b5fb-0e793699e85f" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour_1ed2815f-b052-4936-b5fb-0e793699e85f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SharesHeldByThirdParty_d907eb62-5e5b-43b3-b1d3-d760a16678b3" xlink:href="clbs-20230331.xsd#clbs_SharesHeldByThirdParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_clbs_SharesHeldByThirdParty_d907eb62-5e5b-43b3-b1d3-d760a16678b3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree_fb93348f-3e2e-4db9-90ca-70235e68a168" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree_fb93348f-3e2e-4db9-90ca-70235e68a168" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale_b1d8634e-a2e8-493a-9405-37a215d83c31" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale_b1d8634e-a2e8-493a-9405-37a215d83c31" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee_efafbd7c-8de8-47de-bd97-8bfee07c2523" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee_efafbd7c-8de8-47de-bd97-8bfee07c2523" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_13db0280-0725-4fec-ba25-92bca4d58862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_13db0280-0725-4fec-ba25-92bca4d58862" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c56e4594-a247-4ac9-a1d4-69d417b63387" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_13db0280-0725-4fec-ba25-92bca4d58862" xlink:to="loc_srt_CounterpartyNameAxis_c56e4594-a247-4ac9-a1d4-69d417b63387" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c56e4594-a247-4ac9-a1d4-69d417b63387_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c56e4594-a247-4ac9-a1d4-69d417b63387" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c56e4594-a247-4ac9-a1d4-69d417b63387_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8ca6f37-197f-47eb-923b-48966175175e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c56e4594-a247-4ac9-a1d4-69d417b63387" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8ca6f37-197f-47eb-923b-48966175175e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SanfordBurnhamPrebysMember_e8fcdf11-8e63-477c-ac88-2ddca334754a" xlink:href="clbs-20230331.xsd#clbs_SanfordBurnhamPrebysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8ca6f37-197f-47eb-923b-48966175175e" xlink:to="loc_clbs_SanfordBurnhamPrebysMember_e8fcdf11-8e63-477c-ac88-2ddca334754a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_UniversityOfCaliforniaAtSanDiegoMember_6b613f8d-939a-4831-a4ef-2676de735ae0" xlink:href="clbs-20230331.xsd#clbs_UniversityOfCaliforniaAtSanDiegoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8ca6f37-197f-47eb-923b-48966175175e" xlink:to="loc_clbs_UniversityOfCaliforniaAtSanDiegoMember_6b613f8d-939a-4831-a4ef-2676de735ae0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MassachusettsInstituteOfTechnologyMember_fd606628-7903-46e2-bc64-4f77b80a21a0" xlink:href="clbs-20230331.xsd#clbs_MassachusettsInstituteOfTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8ca6f37-197f-47eb-923b-48966175175e" xlink:to="loc_clbs_MassachusettsInstituteOfTechnologyMember_fd606628-7903-46e2-bc64-4f77b80a21a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5bbd02e3-4dc6-41ea-b34d-f1fb05c13d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_13db0280-0725-4fec-ba25-92bca4d58862" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5bbd02e3-4dc6-41ea-b34d-f1fb05c13d87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5bbd02e3-4dc6-41ea-b34d-f1fb05c13d87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5bbd02e3-4dc6-41ea-b34d-f1fb05c13d87" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5bbd02e3-4dc6-41ea-b34d-f1fb05c13d87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1eab03a4-ea9d-4034-b6d7-2dae9888584d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5bbd02e3-4dc6-41ea-b34d-f1fb05c13d87" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1eab03a4-ea9d-4034-b6d7-2dae9888584d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_0d160409-9fb3-4927-a363-5119ef389c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1eab03a4-ea9d-4034-b6d7-2dae9888584d" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_0d160409-9fb3-4927-a363-5119ef389c1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cb31f77c-b88b-432a-8ee2-976821c3eec8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_13db0280-0725-4fec-ba25-92bca4d58862" xlink:to="loc_srt_RangeAxis_cb31f77c-b88b-432a-8ee2-976821c3eec8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb31f77c-b88b-432a-8ee2-976821c3eec8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cb31f77c-b88b-432a-8ee2-976821c3eec8" xlink:to="loc_srt_RangeMember_cb31f77c-b88b-432a-8ee2-976821c3eec8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_98c08fae-5a29-47e1-a0e5-04e5cd1712d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cb31f77c-b88b-432a-8ee2-976821c3eec8" xlink:to="loc_srt_RangeMember_98c08fae-5a29-47e1-a0e5-04e5cd1712d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6e9d0d7c-79cc-4fd4-9fc5-35edde7316df" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_98c08fae-5a29-47e1-a0e5-04e5cd1712d2" xlink:to="loc_srt_MinimumMember_6e9d0d7c-79cc-4fd4-9fc5-35edde7316df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8cafc404-b2b5-4b38-b717-c5c6c482fd08" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_98c08fae-5a29-47e1-a0e5-04e5cd1712d2" xlink:to="loc_srt_MaximumMember_8cafc404-b2b5-4b38-b717-c5c6c482fd08" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#ResearchCollaborationandLicenseAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" xlink:type="extended" id="i7dfaa1c9dc5444019395a280d51cc793_ResearchCollaborationandLicenseAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e80173f0-0c05-4ef0-bf7e-c3bd720c6a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_19fb6f9f-5871-4936-9afb-6b92c51ad9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e80173f0-0c05-4ef0-bf7e-c3bd720c6a59" xlink:to="loc_us-gaap_ContractWithCustomerLiability_19fb6f9f-5871-4936-9afb-6b92c51ad9d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_36fb329b-9c09-4f05-b99d-b92fbc7ae121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e80173f0-0c05-4ef0-bf7e-c3bd720c6a59" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_36fb329b-9c09-4f05-b99d-b92fbc7ae121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount_e7cc063f-1480-4d1f-a98c-f6a0e5c2dce3" xlink:href="clbs-20230331.xsd#clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e80173f0-0c05-4ef0-bf7e-c3bd720c6a59" xlink:to="loc_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount_e7cc063f-1480-4d1f-a98c-f6a0e5c2dce3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RevenuePerformanceObligationPercentageOfNetSale_ab4d89fd-9bc5-408e-b53d-dc5eda2b5e7f" xlink:href="clbs-20230331.xsd#clbs_RevenuePerformanceObligationPercentageOfNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e80173f0-0c05-4ef0-bf7e-c3bd720c6a59" xlink:to="loc_clbs_RevenuePerformanceObligationPercentageOfNetSale_ab4d89fd-9bc5-408e-b53d-dc5eda2b5e7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues_55efb10c-f652-4601-a256-118a1a50d742" xlink:href="clbs-20230331.xsd#clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e80173f0-0c05-4ef0-bf7e-c3bd720c6a59" xlink:to="loc_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues_55efb10c-f652-4601-a256-118a1a50d742" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ba02d02-4248-477c-88bb-4db11ac8278f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e80173f0-0c05-4ef0-bf7e-c3bd720c6a59" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ba02d02-4248-477c-88bb-4db11ac8278f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cdcdd4ad-9a10-4f76-be4b-b732809e7e28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ba02d02-4248-477c-88bb-4db11ac8278f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cdcdd4ad-9a10-4f76-be4b-b732809e7e28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cdcdd4ad-9a10-4f76-be4b-b732809e7e28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cdcdd4ad-9a10-4f76-be4b-b732809e7e28" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cdcdd4ad-9a10-4f76-be4b-b732809e7e28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6836aa85-c090-4281-baa8-f1e9ee5a4d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cdcdd4ad-9a10-4f76-be4b-b732809e7e28" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6836aa85-c090-4281-baa8-f1e9ee5a4d25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3df63b6e-5ea5-469d-a99d-768afe0c6559" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ba02d02-4248-477c-88bb-4db11ac8278f" xlink:to="loc_srt_CounterpartyNameAxis_3df63b6e-5ea5-469d-a99d-768afe0c6559" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3df63b6e-5ea5-469d-a99d-768afe0c6559_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3df63b6e-5ea5-469d-a99d-768afe0c6559" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3df63b6e-5ea5-469d-a99d-768afe0c6559_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e22bba8c-0f79-4585-a758-c95657bec72e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3df63b6e-5ea5-469d-a99d-768afe0c6559" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e22bba8c-0f79-4585-a758-c95657bec72e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_QiluMember_6a5e5fc6-cfa5-4531-98af-8d9899c6540c" xlink:href="clbs-20230331.xsd#clbs_QiluMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e22bba8c-0f79-4585-a758-c95657bec72e" xlink:to="loc_clbs_QiluMember_6a5e5fc6-cfa5-4531-98af-8d9899c6540c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3cf0fac0-e3e2-4740-b7c4-f2f2eec300bb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ba02d02-4248-477c-88bb-4db11ac8278f" xlink:to="loc_srt_ProductOrServiceAxis_3cf0fac0-e3e2-4740-b7c4-f2f2eec300bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3cf0fac0-e3e2-4740-b7c4-f2f2eec300bb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3cf0fac0-e3e2-4740-b7c4-f2f2eec300bb" xlink:to="loc_srt_ProductsAndServicesDomain_3cf0fac0-e3e2-4740-b7c4-f2f2eec300bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bc526c36-1730-43e5-ae1d-5329009251d6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3cf0fac0-e3e2-4740-b7c4-f2f2eec300bb" xlink:to="loc_srt_ProductsAndServicesDomain_bc526c36-1730-43e5-ae1d-5329009251d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_47d9c105-3679-449b-acac-d0bb1e5b8474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bc526c36-1730-43e5-ae1d-5329009251d6" xlink:to="loc_us-gaap_LicenseMember_47d9c105-3679-449b-acac-d0bb1e5b8474" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0dcdac54-5b27-4f9e-8e40-30d842a791e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ba02d02-4248-477c-88bb-4db11ac8278f" xlink:to="loc_srt_RangeAxis_0dcdac54-5b27-4f9e-8e40-30d842a791e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0dcdac54-5b27-4f9e-8e40-30d842a791e5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0dcdac54-5b27-4f9e-8e40-30d842a791e5" xlink:to="loc_srt_RangeMember_0dcdac54-5b27-4f9e-8e40-30d842a791e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d5795f1a-b3b4-4b77-b93d-e83d45ca512c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0dcdac54-5b27-4f9e-8e40-30d842a791e5" xlink:to="loc_srt_RangeMember_d5795f1a-b3b4-4b77-b93d-e83d45ca512c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c2fb9489-cb8c-417a-aca0-967db9232fd7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d5795f1a-b3b4-4b77-b93d-e83d45ca512c" xlink:to="loc_srt_MinimumMember_c2fb9489-cb8c-417a-aca0-967db9232fd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_103c0ff5-433f-4aed-9819-b55de8309c7e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d5795f1a-b3b4-4b77-b93d-e83d45ca512c" xlink:to="loc_srt_MaximumMember_103c0ff5-433f-4aed-9819-b55de8309c7e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/SubsequentEventsDetails" xlink:type="extended" id="i380efab1a61a4822942e56ac6de5d93a_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_df78a619-c542-44a1-9982-af5668e2f371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_95b12f9b-90ff-491f-8f5f-30ea62b13d03" xlink:href="clbs-20230331.xsd#clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_df78a619-c542-44a1-9982-af5668e2f371" xlink:to="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_95b12f9b-90ff-491f-8f5f-30ea62b13d03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_7bb958f0-8399-4dd1-86e7-2b7c3ff4315d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_df78a619-c542-44a1-9982-af5668e2f371" xlink:to="loc_us-gaap_SubsequentEventTable_7bb958f0-8399-4dd1-86e7-2b7c3ff4315d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_68ddb3e1-ce57-4895-9694-8f3419252431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_7bb958f0-8399-4dd1-86e7-2b7c3ff4315d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_68ddb3e1-ce57-4895-9694-8f3419252431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_68ddb3e1-ce57-4895-9694-8f3419252431_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_68ddb3e1-ce57-4895-9694-8f3419252431" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_68ddb3e1-ce57-4895-9694-8f3419252431_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_28f06df5-8781-40f2-b316-1bf5d8557b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_68ddb3e1-ce57-4895-9694-8f3419252431" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_28f06df5-8781-40f2-b316-1bf5d8557b5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_71ba3ad3-378e-45c0-b65c-0962e1686887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_28f06df5-8781-40f2-b316-1bf5d8557b5f" xlink:to="loc_us-gaap_SubsequentEventMember_71ba3ad3-378e-45c0-b65c-0962e1686887" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>clbs-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8a27d5e7-fe33-4755-a32c-690f224065c0,g:57aefdc3-f3d7-461d-8b12-8991faaa8b7c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_b8299933-0630-44d6-9bad-f92d0cd86f58_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9939b8d5-68a5-4398-b6f3-7ffb8a5b22d1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_daf06b1c-d827-4ce1-b42a-d81be04f5729_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_d851ef3a-368a-42f6-86ee-8a2ba822f167_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Lisata Therapeutics, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_58751dfb-6475-44dd-bb31-5ca618e49d8a_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_45d7ee7c-a377-4524-8a58-88c3603a8de3_periodStartLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_25f97fb1-3612-4e28-be30-f37a556984a1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries, employee benefits and related taxes</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_fcf18771-a96e-499e-bb61-fcaf3457226f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_Sharesvestedandexpectedtovest_497d8c51-96db-4c41-8d68-12dd25eb0c39_terseLabel_en-US" xlink:label="lab_clbs_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_clbs_Sharesvestedandexpectedtovest_label_en-US" xlink:label="lab_clbs_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares, vested and expected to vest</link:label>
    <link:label id="lab_clbs_Sharesvestedandexpectedtovest_documentation_en-US" xlink:label="lab_clbs_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares, vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_Sharesvestedandexpectedtovest" xlink:href="clbs-20230331.xsd#clbs_Sharesvestedandexpectedtovest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_Sharesvestedandexpectedtovest" xlink:to="lab_clbs_Sharesvestedandexpectedtovest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_85d54547-65a2-4741-8e6a-73a36081eac9_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_d2866d55-63f4-4f72-8f7c-d80603c1299a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a0e0830e-f19a-435c-a558-2ebee2dc29d5_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e356d6fd-25e9-40b4-92f5-5473e7eb5cf6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f603842f-58a8-4d2a-8814-7af324632964_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term for operating leases (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_5ac1bc47-e1d6-45e1-bb62-7e789babc81d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Remeasurement</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_cb571658-3723-4a29-8b99-a6b769bd2ad5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ceff9427-d79b-406d-a2a0-2092446384a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c6c2f91-da3e-42b0-a775-17ced5781522_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b180f864-98f6-41f6-9bbf-b0f63d8f9c51_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_6291c556-56e3-4653-a804-9668ffa3bf53_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable_d88f5fea-b22e-4950-9d69-10831e612eba_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercisable</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:href="clbs-20230331.xsd#clbs_WeightedAverageExercisePriceWarrantsExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3889a7c1-0099-4d38-862f-918087354cd1_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4565c3e6-91ba-4329-bddb-b9344111a9fc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate for operating leases (percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_812aad82-3fc4-4204-b555-d265f6b42aba_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_24ea5e18-d30d-4bc5-84de-e6c9c16e9b6b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_47ca87c6-1e51-4eb5-9476-bd968c2e0125_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lisata transaction costs</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Transaction Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_9a359e5f-ecbd-4f60-b9f5-7c41774ee1c7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_f2bc4448-6b46-41de-829f-9074638a7d4d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_e6a9f429-8521-43b7-b19f-b6b0467ade24_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5085ccbf-7978-4149-9444-3c15b06d9bc0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average estimated fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ee92cf76-b22a-41a6-a58a-1424f4e7da00_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities - net unrealized loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_b1b2dc07-2ed0-4fbc-836d-e923a328c02e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97a65795-a6b7-4ca2-9912-d2e6f6f93cc7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_0db1acc0-dde4-47f8-9f24-630f73eda8c2_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_be22c633-4f05-4469-8036-8537d421c082_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_606ba010-05d3-4f00-9ad0-211b7389d768_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees_0a357f59-7cb6-4771-bdce-ef7f4b1145fa_terseLabel_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicensing fee</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees_label_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sublicensing Fees</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees_documentation_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sublicensing Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:to="lab_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_34f72dd0-553f-43a5-8e6f-209a015cf9b1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Weighted Average Contractual Term and Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_8322c773-882c-434e-8917-554986cfc29b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contract</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_1918bbfe-e890-4602-8ca3-c7f3b917fefd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2b76c255-e5ab-4d97-a6cb-4293227ad0b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_3167e541-4fa4-4617-bb8e-9313ee73ba5a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_2a97262b-2340-4b13-9cda-35ecce992827_terseLabel_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal debt securities</link:label>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_label_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US States and Political Subdivisions Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_66a95461-98e2-421b-a1b5-873bc54408b7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_a6cd5aee-3504-40cc-8025-c8fad79b70dd_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:href="clbs-20230331.xsd#clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_37a618e6-30d3-4f4b-ad18-4a8b3c5f8291_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_a1233a50-55a5-4ba9-a292-687149ac04c4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.000067 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at March 31, 2023 and December 31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_b000b355-0697-4205-bb1d-ffcf12d330d6_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_label_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term warrant outstanding</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_documentation_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term warrant outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:href="clbs-20230331.xsd#clbs_WeightedAverageRemainingContractualTermwarrantoutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:to="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4b368c59-e7d9-4916-aafb-772df74f0ba1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, Beginning of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f7fde7bf-dd23-4f8b-ade2-a0933ce0ecc0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, End of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_731ec86c-19ab-4b90-9d5c-02092c86a015_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_64d6fb2d-2dd7-4d43-89dd-c072765d3f43_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_d2af7fec-0dc4-4a26-9c78-6ec899791dc8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_c998dbc6-97d8-4117-b80e-e0e2b5b6a141_terseLabel_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance fee</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_label_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_documentation_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:to="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_47ba063e-7b1d-457c-99f7-89f38499c418_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_62b82ba3-ae2a-4071-a41d-70fb4082fe9a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_21e631d7-7a3b-41d5-bae0-c17744a2fc01_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a7051cfb-59d8-4598-9e9f-feb4c48c7e4d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3941c55a-bc1f-4b89-94fd-c8c6c449f161_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8ebe4b10-70a2-4438-a92f-3f4b3b4dab8d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caladrius Biosciences, Inc. common stockholders - basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_21dce22f-887e-44c9-9439-c0249e52af35_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee_64eec9b6-4bb6-4e5a-a49c-516d36573be9_terseLabel_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change of control fee</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee_label_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Change of Control Fee</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee_documentation_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Change of Control Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee" xlink:to="lab_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c46346bd-84f4-4695-bd37-fc6d2be9b9e6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_a901d127-1876-4994-90d5-66e73838b674_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_4fa4c25c-de99-4ca4-823b-556746da25d6_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_2c72275e-30f2-4256-a9f8-729d24829ff1_terseLabel_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_label_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_documentation_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:to="lab_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AssetAcquisitionOtherLiabilities_76f1b201-5592-4376-9163-b9adb886c890_negatedTerseLabel_en-US" xlink:label="lab_clbs_AssetAcquisitionOtherLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_clbs_AssetAcquisitionOtherLiabilities_label_en-US" xlink:label="lab_clbs_AssetAcquisitionOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Other Liabilities</link:label>
    <link:label id="lab_clbs_AssetAcquisitionOtherLiabilities_documentation_en-US" xlink:label="lab_clbs_AssetAcquisitionOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AssetAcquisitionOtherLiabilities" xlink:href="clbs-20230331.xsd#clbs_AssetAcquisitionOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AssetAcquisitionOtherLiabilities" xlink:to="lab_clbs_AssetAcquisitionOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_17479f87-5cb3-49ec-89fc-7b03817da634_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_19612c9a-3d2a-4983-a0a7-047bf643c2cf_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f346efd4-d4e8-41ce-a763-1a4dc0749402_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6de07054-c98b-4884-952f-c848f3d8f297_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_98a1356c-3ecf-4023-8f61-84e8d99fa4a9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_25d07e4f-53ef-4e2c-846e-068a29f82a31_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_0d6720c7-e507-4df7-9474-08f9ccff8b5f_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SharesHeldByThirdParty_17d21a31-faf6-41bc-a534-1633816b7812_terseLabel_en-US" xlink:label="lab_clbs_SharesHeldByThirdParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares held by third party</link:label>
    <link:label id="lab_clbs_SharesHeldByThirdParty_label_en-US" xlink:label="lab_clbs_SharesHeldByThirdParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Held by Third Party</link:label>
    <link:label id="lab_clbs_SharesHeldByThirdParty_documentation_en-US" xlink:label="lab_clbs_SharesHeldByThirdParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Held by Third Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SharesHeldByThirdParty" xlink:href="clbs-20230331.xsd#clbs_SharesHeldByThirdParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SharesHeldByThirdParty" xlink:to="lab_clbs_SharesHeldByThirdParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_028811cb-458b-4fb9-8625-ed0529426de1_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d1255fb4-c0ec-450c-b973-88ff8d8f9557_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, non-controlling interests and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_54836935-9e6c-48ca-b50a-8fe54b17f7e9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_932ae55a-9435-4453-b63d-aa9754b11efe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_66a6d1c0-22fe-450e-b1f7-2e1cabc920ba_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_543fc7ab-808d-4221-ac24-072d771e57a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_f4ed8517-30a5-4eac-a6aa-ef697bb7c268_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fcfd1cba-5809-491b-b1f5-8cf4934edaf1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsGranted_193dc34a-ef39-4448-a4c9-cdfd01d73182_terseLabel_en-US" xlink:label="lab_clbs_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Granted (in shares)</link:label>
    <link:label id="lab_clbs_WarrantsGranted_label_en-US" xlink:label="lab_clbs_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Granted</link:label>
    <link:label id="lab_clbs_WarrantsGranted_documentation_en-US" xlink:label="lab_clbs_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsGranted" xlink:href="clbs-20230331.xsd#clbs_WarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsGranted" xlink:to="lab_clbs_WarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_4f151bda-1850-4a61-a5cd-f559d428b9a9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_17124c82-36ef-4d6d-a305-738e4cfaff9e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_bc4552be-bc2c-4b39-9ac6-401500314048_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding_d5228df9-2616-455f-a6f1-a340c6dd4612_periodStartLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding, Beginning of Period (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding_6eb28111-a206-4221-9d5f-b03f5eec9b43_periodEndLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding, End of Period (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:href="clbs-20230331.xsd#clbs_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_400494ff-20eb-40b4-9019-7bba29039c7f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research tax credit rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_0f4a1a56-408e-48f8-bdac-7f77dfcb39d9_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7f9d3777-0721-458f-9ce0-7368f4cbb2d3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ac3f1d25-9583-43cb-ace5-64797c017ad7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_ce290ed2-76b5-4365-b3e5-c55838c8d7a1_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_750f0789-6524-4c89-972c-d6b62797f4f0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_a39889f8-e34a-4318-8f16-4eb018956b2d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_245c6aa7-f677-4840-a877-a308ace2e535_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_575614d4-2d5e-40f4-a56e-4dc7c78cf7e7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8e6ee28e-f9cc-4aee-9bfe-d1b018968427_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_57036911-802b-4f39-b77a-60c275818093_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_OperatingLeaseRightOfUseAssetAbstract_a5f7746e-ca71-4fba-ad16-52a5e140cf67_terseLabel_en-US" xlink:label="lab_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Assets:</link:label>
    <link:label id="lab_clbs_OperatingLeaseRightOfUseAssetAbstract_label_en-US" xlink:label="lab_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset [Abstract]</link:label>
    <link:label id="lab_clbs_OperatingLeaseRightOfUseAssetAbstract_documentation_en-US" xlink:label="lab_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:href="clbs-20230331.xsd#clbs_OperatingLeaseRightOfUseAssetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:to="lab_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_0fa77f7c-a0aa-4f3a-a865-0a22e42ad5f2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_d77f2870-ae5c-4920-87d9-c4d5d43c4bd6_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_label_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_documentation_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:href="clbs-20230331.xsd#clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:to="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_160fbbbc-5edb-4a9f-baed-c9407b06572a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_dad4023a-bb3e-49ee-8460-05aae03d89a9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_904089b5-4daf-4ddc-85a6-c93074a5315d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_01c26ab5-604e-431b-baff-35b00aa704c3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9397aedd-08f3-482c-9a8c-7a66d3512152_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_d8dfc4eb-2edc-4bad-a8b7-fed714faa339_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale-Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f5e27148-32e4-4eaa-9b62-25479048878e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_2a0c28f6-74e2-493b-a35e-4d104e1b6171_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_9c5d8892-5a6d-485d-b6fd-58cc1af85b0e_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_ece68be8-cdf1-4ace-86ab-fd4b8fa80819_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, authorized 33,333,333 shares; issued 7,999,080 and 7,866,799 shares at March 31, 2023 and December 31, 2022, respectively; and outstanding, 7,998,342 and 7,866,061 shares at March 31, 2023 and December 31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_f7ad705f-b47d-4c24-87e6-7e7394a06192_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_OperatingLossCarryforwardsPostAcquisition_a7fcd22c-d1be-41fe-b62c-cf75a3fe3c2b_terseLabel_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsPostAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Post Acquisition</link:label>
    <link:label id="lab_clbs_OperatingLossCarryforwardsPostAcquisition_label_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsPostAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Post Acquisition</link:label>
    <link:label id="lab_clbs_OperatingLossCarryforwardsPostAcquisition_documentation_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsPostAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Post Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsPostAcquisition" xlink:href="clbs-20230331.xsd#clbs_OperatingLossCarryforwardsPostAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_OperatingLossCarryforwardsPostAcquisition" xlink:to="lab_clbs_OperatingLossCarryforwardsPostAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_594de45f-75fd-417b-892d-f0b8f342772c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected weighted-average period in years of compensation cost to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_4d085785-688c-46d4-9b81-05329d635b9a_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_61aaf479-2f77-4004-ac31-be50b3897ecc_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_600bb45f-7de7-43a5-bda6-f9a49f774270_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 13)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_a767e89b-6998-43af-8c78-792cd7d4fcc2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_60889243-e0ae-4a26-a146-9162d7dd0bf9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5a9f553f-513f-4de5-a079-f64a63719e79_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding_c0c88418-c6f2-4c5f-b192-a086d1023805_terseLabel_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding_label_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants Outstanding</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding_documentation_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:href="clbs-20230331.xsd#clbs_AggregateIntrinsicValueWarrantsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:to="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1920c866-6ee6-48b3-a0b6-e97561174059_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_508af60b-6da0-4c00-b102-cfd31a6f2b7f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_5bb1909f-1bf2-434e-8d20-cf1190d08bc8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e63f98ef-57ee-4807-8b4e-34ad173c0b8f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Share-based Compensation Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_77d324e7-52b3-46d8-9e4b-ffc46036b0dd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_161a91ac-9f15-4540-b9d9-be9fed7461f5_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_7cf7b063-6ac9-444b-b06b-161e3361b574_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AtTheMarketOfferingAgreementMember_1cba75ec-40a1-4039-937d-25ddb6170d23_terseLabel_en-US" xlink:label="lab_clbs_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Agreement</link:label>
    <link:label id="lab_clbs_AtTheMarketOfferingAgreementMember_label_en-US" xlink:label="lab_clbs_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering Agreement [Member]</link:label>
    <link:label id="lab_clbs_AtTheMarketOfferingAgreementMember_documentation_en-US" xlink:label="lab_clbs_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AtTheMarketOfferingAgreementMember" xlink:href="clbs-20230331.xsd#clbs_AtTheMarketOfferingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AtTheMarketOfferingAgreementMember" xlink:to="lab_clbs_AtTheMarketOfferingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_3f0c5f0e-0cc0-4004-a8cc-bf9c0e641fca_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1ec107a4-45c0-44e3-8236-bbb3bd3ff45e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Amounts representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_8cacfedb-7e06-42ea-b9ae-2c850efa09f6_terseLabel_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey</link:label>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_label_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey Division of Taxation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:to="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_24459b3b-dfd5-4db6-8ec1-a3f070ad3f70_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CommonStockWarrantsShares_8703799c-187b-44b3-9694-ee8775aab282_periodStartLabel_en-US" xlink:label="lab_clbs_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Outstanding, Beginning of Period (in shares)</link:label>
    <link:label id="lab_clbs_CommonStockWarrantsShares_d1822890-8722-463e-b64a-2e99479a6079_periodEndLabel_en-US" xlink:label="lab_clbs_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Outstanding, End of Period (in shares)</link:label>
    <link:label id="lab_clbs_CommonStockWarrantsShares_label_en-US" xlink:label="lab_clbs_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants, Shares</link:label>
    <link:label id="lab_clbs_CommonStockWarrantsShares_documentation_en-US" xlink:label="lab_clbs_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CommonStockWarrantsShares" xlink:href="clbs-20230331.xsd#clbs_CommonStockWarrantsShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CommonStockWarrantsShares" xlink:to="lab_clbs_CommonStockWarrantsShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_ab94e386-a2a4-4c74-935f-f947d3998a2a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of Lisata's cost method investment in Cend</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b3498f15-b46c-457b-ad44-450876729014_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AssetAcquisitionNetWorkingCapital_ee6d0e30-a56b-4ddf-b30f-bc1e3a86258f_negatedTerseLabel_en-US" xlink:label="lab_clbs_AssetAcquisitionNetWorkingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net working capital (excluding cash)</link:label>
    <link:label id="lab_clbs_AssetAcquisitionNetWorkingCapital_label_en-US" xlink:label="lab_clbs_AssetAcquisitionNetWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Net Working Capital</link:label>
    <link:label id="lab_clbs_AssetAcquisitionNetWorkingCapital_documentation_en-US" xlink:label="lab_clbs_AssetAcquisitionNetWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Net Working Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AssetAcquisitionNetWorkingCapital" xlink:href="clbs-20230331.xsd#clbs_AssetAcquisitionNetWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AssetAcquisitionNetWorkingCapital" xlink:to="lab_clbs_AssetAcquisitionNetWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_15712f36-bb1a-468f-b7a8-30281c0a4f7d_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_3549a545-c83b-4286-86ab-93047d1f33d9_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_1c8b5b27-67dd-4880-888e-2d81c2319950_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_32105b96-352d-4ea6-ab88-69342dcd8431_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_b7a908c6-046f-4883-8085-b598a712fea1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental fair value of Cend's fully vested stock options</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_d7117cf3-cd43-47f0-a68b-86e096d62f77_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Greater than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_06c5b183-9f42-400d-83ec-f891056d09ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_bca7ea67-a70b-4212-9f91-d4632fba74ba_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_fa7f5f89-d2be-4843-af26-472bd5580ef0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_1349d135-06fc-4541-a2c5-d7e6bf9e7035_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_c053d73c-b84f-446a-a2ba-b8c8a6d00382_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_a25fd1d8-fc7c-4d18-a8ee-c5f1bc582286_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_fce7a8f8-4306-4a39-b333-cc6a6f84937a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour_70aa7f61-7fad-474b-9c56-98609612009e_terseLabel_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance fee, year four</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour_label_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Four</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour_documentation_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" xlink:to="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_9839b428-c90f-4363-8a31-69f93447a928_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_126d7563-4d71-4e61-a6df-b6dc4e3f3c5b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_de85cab1-0a2e-4ba5-aece-033ef70d659a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities &#8212; current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_aaf3b043-cf3a-450e-84b2-044b59e62c36_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e844a02d-2caf-4741-8490-4e0fb93e3c0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9c8d8138-34ac-4ae4-b6f2-fbcaeb53c0fb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_0a290a3a-b61b-464d-b867-2997df2873e5_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_542b789a-1399-4f7a-b752-20094f471af1_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and License Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_4f827912-5dd1-4ebe-8cfb-ac1b5d15385c_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bbcfa059-876f-4aca-823f-c5426b661890_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_2b79f54a-83c2-4126-98ec-0691612ba3cb_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsOtherDisclosuresAbstract_005ac972-808e-4f2e-a27a-6efaeed67cb8_terseLabel_en-US" xlink:label="lab_clbs_WarrantsOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Weighted Average Contractual Term and Intrinsic Value</link:label>
    <link:label id="lab_clbs_WarrantsOtherDisclosuresAbstract_label_en-US" xlink:label="lab_clbs_WarrantsOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Other Disclosures [Abstract]</link:label>
    <link:label id="lab_clbs_WarrantsOtherDisclosuresAbstract_documentation_en-US" xlink:label="lab_clbs_WarrantsOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Other Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsOtherDisclosuresAbstract" xlink:href="clbs-20230331.xsd#clbs_WarrantsOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract" xlink:to="lab_clbs_WarrantsOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_714e183d-61ab-4a6b-ade4-ecc652bc6d23_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_8b2779a4-2da8-41d0-86a3-2196e6fa5e4b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2893a287-f45c-4641-974f-ad44b564e2c1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_7bd407b0-4a40-46d1-acd1-db6ad452ccba_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c4ab8844-3f45-4ca8-a2a9-6cabfe659e97_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_NumberOfOfficesUnderOperatingLeases_189fc089-0d17-40c6-bbbf-0fa35d5ed32e_terseLabel_en-US" xlink:label="lab_clbs_NumberOfOfficesUnderOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of offices under operating leases</link:label>
    <link:label id="lab_clbs_NumberOfOfficesUnderOperatingLeases_label_en-US" xlink:label="lab_clbs_NumberOfOfficesUnderOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Offices Under Operating Leases</link:label>
    <link:label id="lab_clbs_NumberOfOfficesUnderOperatingLeases_documentation_en-US" xlink:label="lab_clbs_NumberOfOfficesUnderOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Offices Under Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_NumberOfOfficesUnderOperatingLeases" xlink:href="clbs-20230331.xsd#clbs_NumberOfOfficesUnderOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_NumberOfOfficesUnderOperatingLeases" xlink:to="lab_clbs_NumberOfOfficesUnderOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_7dc731f3-3abd-439d-9e3f-0badd2a6d741_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current, balance sheet line item</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e2c417aa-8ebb-44be-9f1f-41f942b1f52c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_PreferredStockSharesDesignated_44f53849-2a99-44fc-ae4d-5978c7d2f99d_terseLabel_en-US" xlink:label="lab_clbs_PreferredStockSharesDesignated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated</link:label>
    <link:label id="lab_clbs_PreferredStockSharesDesignated_label_en-US" xlink:label="lab_clbs_PreferredStockSharesDesignated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated</link:label>
    <link:label id="lab_clbs_PreferredStockSharesDesignated_documentation_en-US" xlink:label="lab_clbs_PreferredStockSharesDesignated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreferredStockSharesDesignated" xlink:href="clbs-20230331.xsd#clbs_PreferredStockSharesDesignated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_PreferredStockSharesDesignated" xlink:to="lab_clbs_PreferredStockSharesDesignated" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_4bc79175-d335-4310-8ec9-ca310d69f649_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_316e1b61-5613-4af4-b963-cfbf0961b8d0_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_8bb59fa3-7dd9-433d-a13f-19c3d8c8a11d_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_39a40975-6b7c-4052-aa39-e2974a347612_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_b7d06cb3-d980-4451-a4e1-40698c17c80a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dffb7a8f-b0e2-463b-b584-bee75c461947_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ae6a7643-9b2d-4645-b6d9-5841305c9565_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_35ddc9b5-7afa-49b1-9664-0cdcf1011374_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_9ace4d6d-ca3e-4ed8-8244-8d77cb6b8ad0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_19f9644c-6bfe-4115-b327-5b1966c2ca1a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_cec4d46c-971b-408a-a64a-dff6b924c7b2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments Under Lease Agreements</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_c7d3bacf-6167-4b55-b601-aa2f8ef7341a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Lisata Therapeutics, Inc. stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_29bd5fed-1f5d-42d6-a9d8-67e02dfa3aa9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_809eb425-5d59-44e1-9687-0704f73522c1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_e662fe40-1e38-4473-a084-ff96e296d7ad_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0ca9f941-ab3f-44bf-8ee4-a1395d935047_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_025dd77a-dbb7-4055-89c8-1877539b9bb9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTableTextBlock_746576b9-deb3-4ca6-89fb-848808213829_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTableTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SharesIssuedUnderLicenseAgreement_28469b27-9763-417d-b95c-fdec0f37ba56_terseLabel_en-US" xlink:label="lab_clbs_SharesIssuedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under license agreement</link:label>
    <link:label id="lab_clbs_SharesIssuedUnderLicenseAgreement_label_en-US" xlink:label="lab_clbs_SharesIssuedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Under License Agreement</link:label>
    <link:label id="lab_clbs_SharesIssuedUnderLicenseAgreement_documentation_en-US" xlink:label="lab_clbs_SharesIssuedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Under License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SharesIssuedUnderLicenseAgreement" xlink:href="clbs-20230331.xsd#clbs_SharesIssuedUnderLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SharesIssuedUnderLicenseAgreement" xlink:to="lab_clbs_SharesIssuedUnderLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockAvailableForSale_e0877f05-2614-4067-b987-d017d7655bd3_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock Available for Sale</link:label>
    <link:label id="lab_clbs_SaleOfStockAvailableForSale_label_en-US" xlink:label="lab_clbs_SaleOfStockAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock Available for Sale</link:label>
    <link:label id="lab_clbs_SaleOfStockAvailableForSale_documentation_en-US" xlink:label="lab_clbs_SaleOfStockAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock Available for Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAvailableForSale" xlink:href="clbs-20230331.xsd#clbs_SaleOfStockAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockAvailableForSale" xlink:to="lab_clbs_SaleOfStockAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_7ff15b63-7dfd-4514-bf59-ab7df23219b6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_37e22389-141e-4ea5-94b4-fea9b729870d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AssetAcquisitionConsiderationTransferredEquityValue_d018b710-bb34-44c5-919c-d2e9f6defddf_terseLabel_en-US" xlink:label="lab_clbs_AssetAcquisitionConsiderationTransferredEquityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_clbs_AssetAcquisitionConsiderationTransferredEquityValue_label_en-US" xlink:label="lab_clbs_AssetAcquisitionConsiderationTransferredEquityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Equity Value</link:label>
    <link:label id="lab_clbs_AssetAcquisitionConsiderationTransferredEquityValue_documentation_en-US" xlink:label="lab_clbs_AssetAcquisitionConsiderationTransferredEquityValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Equity Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AssetAcquisitionConsiderationTransferredEquityValue" xlink:href="clbs-20230331.xsd#clbs_AssetAcquisitionConsiderationTransferredEquityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AssetAcquisitionConsiderationTransferredEquityValue" xlink:to="lab_clbs_AssetAcquisitionConsiderationTransferredEquityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_d3ac54fe-ca5c-4e12-890d-b65d61e782c9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_2fbcb1eb-94f1-49be-a9a4-f8efb211c1bb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Greater than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_fb89d0a1-a59f-4dde-8db7-4068fa3e5534_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Risks</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_03c47c15-8a64-4227-ae53-87e2e8bd4a39_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_38d6ce96-a9ce-453c-b29e-a7eeb43da348_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a72ca3df-1956-47bd-8577-fde7f6c374c8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_a6ca255c-5642-4b02-a342-285f8097590f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_16deeaa2-a03e-4ed8-bbe2-39b856c59c89_terseLabel_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance fee, year seven</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_label_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_documentation_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:to="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_13eb8400-4452-4d11-af88-c3a914f3eb9b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Acquisition</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_533bbf73-15fe-454b-86f7-3def83b94637_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_207ea6ee-e91e-4455-b712-aded5236d4cb_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_bc413b84-10b1-4b81-b401-45af213691a4_terseLabel_en-US" xlink:label="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from sale of NOLs</link:label>
    <link:label id="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_label_en-US" xlink:label="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Net Operating Losses, NJEDA Program</link:label>
    <link:label id="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_documentation_en-US" xlink:label="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Net Operating Losses, NJEDA Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:href="clbs-20230331.xsd#clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:to="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercised_2bab238e-a9ce-41bc-be39-9ad865651889_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Exercised (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercised_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercised</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercised_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:href="clbs-20230331.xsd#clbs_WeightedAverageExercisePriceWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_d50d8400-a3bd-4b5a-a7b5-9510cbe5cf95_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_06c0a7ed-fcb4-44fd-911a-146e871e0a40_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_4d7c708a-db3e-4bf8-9790-65bf576b42e2_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_2987aa82-a6e7-4bcd-a9e8-c24bd3a3e798_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_630a8628-f310-4133-a2ee-af8f44af0c45_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm_0d406b14-58b6-4087-bde1-723648f08ca7_terseLabel_en-US" xlink:label="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested, weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested, weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:href="clbs-20230331.xsd#clbs_OptionsVestedweightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:to="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsExpired_0dc7351b-0431-453e-83b9-e181275a951e_negatedTerseLabel_en-US" xlink:label="lab_clbs_WarrantsExpired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expired (in shares)</link:label>
    <link:label id="lab_clbs_WarrantsExpired_label_en-US" xlink:label="lab_clbs_WarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expired</link:label>
    <link:label id="lab_clbs_WarrantsExpired_documentation_en-US" xlink:label="lab_clbs_WarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsExpired" xlink:href="clbs-20230331.xsd#clbs_WarrantsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsExpired" xlink:to="lab_clbs_WarrantsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_702e0de1-9083-49c6-aa9f-29623017f634_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less - net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsExercised_d2b0f48f-86e8-469e-83f4-74123f1422c3_negatedTerseLabel_en-US" xlink:label="lab_clbs_WarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Exercised (in shares)</link:label>
    <link:label id="lab_clbs_WarrantsExercised_label_en-US" xlink:label="lab_clbs_WarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercised</link:label>
    <link:label id="lab_clbs_WarrantsExercised_documentation_en-US" xlink:label="lab_clbs_WarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsExercised" xlink:href="clbs-20230331.xsd#clbs_WarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsExercised" xlink:to="lab_clbs_WarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_a84618a5-177d-437d-889c-7ce34267df8a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1e151279-d763-45d6-adbb-d684de44e242_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_16b98cd9-501c-40ac-953b-f1917515aecd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a0853ac8-62dc-4b4e-8527-ce67c2303642_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3cc2ce9e-2010-41b6-8c59-b35214d1fa08_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eae7fb36-8571-4285-80cc-51fd7e3bccdc_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_4845976c-2353-481d-86b8-0e64b2b94b7e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_81e29df4-f670-42e3-affa-56e19dcf1d99_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1dfacb93-b867-4d60-a852-9b31ec34d288_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_1829d1b1-b6a4-4a9e-9574-c39e0a245ddb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_afcfbfcf-d2a1-4824-9622-1675d8d9b115_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_cdada828-7d33-47a9-81bc-73ec3b55b5ba_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_0b2d74ea-27cd-4639-abe9-c0f9b5abaf2f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_e8e23014-e15c-40ef-b168-8f76393ae6e1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Name of Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d5efc2f3-1c27-4a37-b0e3-221597e98d10_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_448360d6-b50c-432b-ae9d-c0dc677c7bc8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTable" xlink:to="lab_us-gaap_AssetAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_af5fe3a4-1f76-4cd8-b971-e48d3241e1b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_e20ed215-4266-4e4b-ac60-d106898c49af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_4f133465-9392-4b7f-a641-63afc1f1a6b8_terseLabel_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, net of sales</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_label_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_documentation_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:to="lab_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTextBlock_717cc5a1-821d-4bc2-aa62-9b707a4a328e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b6eaa582-b755-42a1-bf49-02b111b25ef4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2fdb9e3d-b925-43a6-8842-e33603340e9d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_f8fa3a00-9604-4dd8-a82f-efb512bb93f0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_fd2534ad-82e3-4cde-acec-2744be8d10b4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_362d99cd-30b3-4dcb-90da-aa9b0c06f394_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_3a01a3e3-e1b0-4da9-ba6b-dc3579204c14_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_cc04d8a3-85d7-4cb3-b2b0-a20dbfd710f2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsVested_985ff4fd-c2cf-4adc-95e8-94836bdf99ab_terseLabel_en-US" xlink:label="lab_clbs_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested (in shares)</link:label>
    <link:label id="lab_clbs_WarrantsVested_label_en-US" xlink:label="lab_clbs_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested</link:label>
    <link:label id="lab_clbs_WarrantsVested_documentation_en-US" xlink:label="lab_clbs_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsVested" xlink:href="clbs-20230331.xsd#clbs_WarrantsVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsVested" xlink:to="lab_clbs_WarrantsVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_eadf75cf-a75a-4c58-a686-41323619a67e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_85b1804c-5e05-4fb3-8a22-375c200085c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average estimated fair value of shares granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_0b1b78b5-5ebd-414d-9e07-f7e2bdef0abf_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3a5ca987-6b12-473a-88dc-41fce6f1ba2b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_BusinessTextBlock_85e273b1-09c9-4d8d-a42d-2604d3ba2ea4_terseLabel_en-US" xlink:label="lab_clbs_BusinessTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Business</link:label>
    <link:label id="lab_clbs_BusinessTextBlock_label_en-US" xlink:label="lab_clbs_BusinessTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Business [Text Block]</link:label>
    <link:label id="lab_clbs_BusinessTextBlock_documentation_en-US" xlink:label="lab_clbs_BusinessTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Business [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_BusinessTextBlock" xlink:href="clbs-20230331.xsd#clbs_BusinessTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_BusinessTextBlock" xlink:to="lab_clbs_BusinessTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6bb853f2-37c2-456d-b2a2-9ebb2e3c231e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_67b7878a-b034-4dc6-939e-672e3cab464f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_20afffc1-38d6-4207-a999-a1e242afab24_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested_5a532d18-8c5b-4fbe-aa2d-dec6d899e4c9_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested_label_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">weighted Average Remaining Contractual Term, warrants vested</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested_documentation_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">weighted Average Remaining Contractual Term, warrants vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:href="clbs-20230331.xsd#clbs_WeightedAverageRemainingContractualTermwarrantsvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:to="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_135b9fb4-fa69-4529-be34-a835089b861f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5990ea88-6407-43b5-9453-44aca350ac26_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_2fb811af-d68d-42c3-b266-76bd62b798ac_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_acbc07b0-de6f-42fd-9bf6-eb725ede34a7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9c8027d4-bd19-4a29-aa0c-4623035490dc_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2df4911d-bd3d-4162-a5a8-3624486b6f14_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_a9ce2751-b599-4935-ad0d-2ec920bfd653_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_c449c9f2-3df1-4c7f-85b8-cf90f13f01e6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Compensation Cost Related to Nonvested Awards</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_d0076812-22fd-4834-8825-96becd5b2bed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bf11824f-0be9-4402-9e68-48eedc95ca8e_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before benefit from income taxes and noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_cd70d47d-191e-407f-8406-792b858ea126_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_77db1fe7-d9ab-4a8f-a197-46948e6ffcf4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d38fdaf6-b451-4324-8656-b157947818ef_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_d2a5378f-5a37-4d38-8f26-397930f8ca97_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_201557dd-7bf7-4df7-824c-50593c57b189_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_05927a0d-7dfa-4b7b-92da-eecae5833a4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Share-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_UniversityOfCaliforniaAtSanDiegoMember_2e3b9327-a6cd-4258-b92e-8eb2d4f0ea89_terseLabel_en-US" xlink:label="lab_clbs_UniversityOfCaliforniaAtSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of California at San Diego</link:label>
    <link:label id="lab_clbs_UniversityOfCaliforniaAtSanDiegoMember_label_en-US" xlink:label="lab_clbs_UniversityOfCaliforniaAtSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of California at San Diego [Member]</link:label>
    <link:label id="lab_clbs_UniversityOfCaliforniaAtSanDiegoMember_documentation_en-US" xlink:label="lab_clbs_UniversityOfCaliforniaAtSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of California at San Diego</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_UniversityOfCaliforniaAtSanDiegoMember" xlink:href="clbs-20230331.xsd#clbs_UniversityOfCaliforniaAtSanDiegoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_UniversityOfCaliforniaAtSanDiegoMember" xlink:to="lab_clbs_UniversityOfCaliforniaAtSanDiegoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CENDMember_ac3e5452-4515-4845-a62d-73a06582762e_terseLabel_en-US" xlink:label="lab_clbs_CENDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEND</link:label>
    <link:label id="lab_clbs_CENDMember_label_en-US" xlink:label="lab_clbs_CENDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEND [Member]</link:label>
    <link:label id="lab_clbs_CENDMember_documentation_en-US" xlink:label="lab_clbs_CENDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CENDMember" xlink:href="clbs-20230331.xsd#clbs_CENDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CENDMember" xlink:to="lab_clbs_CENDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_273c2380-a89f-40c2-bdb7-63f4e82373de_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_fb525dee-c1a3-4667-b9e5-13efd7ffdaf7_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_dbc38269-3520-4d00-bb29-4d3f85a75ba1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_48274ac9-af5f-4b1f-89e0-88aeb45f73c2_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_4bd2d5ce-f4b6-4a4f-bad6-9bc018ce5c7f_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_70615105-0c03-4b0d-a048-29c7df73ea77_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_95811e6c-0684-494f-b03e-caca9974bf6c_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- Controlling Interest in Subsidiary</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExpired_68b61cc2-5331-40e2-9467-9a449cb0860c_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expired (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExpired_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Expired</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExpired_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:href="clbs-20230331.xsd#clbs_WeightedAverageExercisePriceWarrantsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_111be7c9-1e6d-475f-87aa-1e0bbce18c6d_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d70cdbf7-aed3-4887-855f-a37f31fa3881_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsCanceled_880c709b-5fc3-4ae5-9393-22f60c77772b_negatedLabel_en-US" xlink:label="lab_clbs_WarrantsCanceled" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Forfeited (in shares)</link:label>
    <link:label id="lab_clbs_WarrantsCanceled_label_en-US" xlink:label="lab_clbs_WarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Canceled</link:label>
    <link:label id="lab_clbs_WarrantsCanceled_documentation_en-US" xlink:label="lab_clbs_WarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Canceled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsCanceled" xlink:href="clbs-20230331.xsd#clbs_WarrantsCanceled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsCanceled" xlink:to="lab_clbs_WarrantsCanceled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0df4b255-53d4-43e1-bee5-215e6222b308_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues_b29318ad-95f2-477b-92b9-63ac1633e652_terseLabel_en-US" xlink:label="lab_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sublicensing revenues</link:label>
    <link:label id="lab_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues_label_en-US" xlink:label="lab_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Percentage of Sublicensing Revenues</link:label>
    <link:label id="lab_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues_documentation_en-US" xlink:label="lab_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Percentage of Sublicensing Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:href="clbs-20230331.xsd#clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:to="lab_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_8006a50c-3bc6-4b04-8a67-d9a37f26444c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AssetAcquisitionIntangibles_4261f331-0754-451c-8d8f-2fdb7f0775d6_terseLabel_en-US" xlink:label="lab_clbs_AssetAcquisitionIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_clbs_AssetAcquisitionIntangibles_label_en-US" xlink:label="lab_clbs_AssetAcquisitionIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Intangibles</link:label>
    <link:label id="lab_clbs_AssetAcquisitionIntangibles_documentation_en-US" xlink:label="lab_clbs_AssetAcquisitionIntangibles" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AssetAcquisitionIntangibles" xlink:href="clbs-20230331.xsd#clbs_AssetAcquisitionIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AssetAcquisitionIntangibles" xlink:to="lab_clbs_AssetAcquisitionIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4331b6f8-cff5-488f-8403-1c837b9193ae_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_60e9d846-43a6-4f4e-bcb0-86d733ac18c3_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_RevenuePerformanceObligationPercentageOfNetSale_869d6c16-8ec3-479b-bc59-cb8ac8f6fb4b_terseLabel_en-US" xlink:label="lab_clbs_RevenuePerformanceObligationPercentageOfNetSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net sale</link:label>
    <link:label id="lab_clbs_RevenuePerformanceObligationPercentageOfNetSale_label_en-US" xlink:label="lab_clbs_RevenuePerformanceObligationPercentageOfNetSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Percentage of Net Sale</link:label>
    <link:label id="lab_clbs_RevenuePerformanceObligationPercentageOfNetSale_documentation_en-US" xlink:label="lab_clbs_RevenuePerformanceObligationPercentageOfNetSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Percentage of Net Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RevenuePerformanceObligationPercentageOfNetSale" xlink:href="clbs-20230331.xsd#clbs_RevenuePerformanceObligationPercentageOfNetSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_RevenuePerformanceObligationPercentageOfNetSale" xlink:to="lab_clbs_RevenuePerformanceObligationPercentageOfNetSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_8e950669-5799-48ea-b743-5fafb3f89b4c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_92fe0b67-5bec-4d45-9c40-da326b9992c8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7e035694-b878-4a54-96db-675ca5a4475c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_eb4fb337-4b96-41f7-85c9-4b4e8bb47fef_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caladrius Biosciences, Inc. common stockholders - diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_05fd0a8d-66b5-4e0a-ba9d-660fb9d7452d_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_b4ffef91-4c08-4cd7-b848-103889f1faa6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_637cdbf0-97fe-4a25-81c6-cd98669ff238_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_2639447d-5496-415f-8f6b-6102fc16ea05_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Lisata Therapeutics, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_08f5acdb-619f-4437-acea-dfdfb535cf32_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_cd4685c2-9897-4785-bd06-ee91453466a3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_14eacda6-642d-4bb8-8a66-3fe2cf457bce_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_eda1a8ed-362c-4a21-9463-27c763adf7d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting terms (years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount_a6e91e24-e09c-41a1-9cc9-16f601775cc7_terseLabel_en-US" xlink:label="lab_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable consideration amounts, milestones</link:label>
    <link:label id="lab_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:label id="lab_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="clbs-20230331.xsd#clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_FairValueMarketOfTaxNOLs_a639eb7d-552d-4ad1-8f9f-d0470c64a265_terseLabel_en-US" xlink:label="lab_clbs_FairValueMarketOfTaxNOLs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Market of Tax NOLs</link:label>
    <link:label id="lab_clbs_FairValueMarketOfTaxNOLs_label_en-US" xlink:label="lab_clbs_FairValueMarketOfTaxNOLs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Market of Tax NOLs</link:label>
    <link:label id="lab_clbs_FairValueMarketOfTaxNOLs_documentation_en-US" xlink:label="lab_clbs_FairValueMarketOfTaxNOLs" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Market of Tax NOLs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_FairValueMarketOfTaxNOLs" xlink:href="clbs-20230331.xsd#clbs_FairValueMarketOfTaxNOLs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_FairValueMarketOfTaxNOLs" xlink:to="lab_clbs_FairValueMarketOfTaxNOLs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_9c629364-a898-4729-b29d-61723a6ff2e3_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AssetAcquisitionSharePrice_76824249-9829-4a39-945a-7ecc8a7ce316_terseLabel_en-US" xlink:label="lab_clbs_AssetAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Multiplied by the fair value per share of Lisata common stock on September 15, 2022</link:label>
    <link:label id="lab_clbs_AssetAcquisitionSharePrice_label_en-US" xlink:label="lab_clbs_AssetAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Share Price</link:label>
    <link:label id="lab_clbs_AssetAcquisitionSharePrice_documentation_en-US" xlink:label="lab_clbs_AssetAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AssetAcquisitionSharePrice" xlink:href="clbs-20230331.xsd#clbs_AssetAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AssetAcquisitionSharePrice" xlink:to="lab_clbs_AssetAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_1da957ce-cae0-48c5-a713-bc8e100c1b8f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_84486740-5790-4ce1-bdeb-56bb32177810_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_fb4d2447-9889-4459-8555-6362b662b0f4_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Lisata Therapeutics, Inc. Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_1cefc0dd-2df2-4f64-a839-a058b438e07e_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering amount authorized per agreement</link:label>
    <link:label id="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_label_en-US" xlink:label="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</link:label>
    <link:label id="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_documentation_en-US" xlink:label="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:href="clbs-20230331.xsd#clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:to="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree_d860ef22-e6e9-4db7-a12c-eb2b12930ade_terseLabel_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance fee, years two and three</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree_label_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Two and Three</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree_documentation_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Two and Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" xlink:to="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_723f6e11-92e1-408c-abbc-6ab09c7fa657_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_ae103645-8c34-4e3a-87f9-f006f6f56e9c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f0310d9b-3938-43f8-a1f7-9d486465407e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_f25456d1-9236-427f-8d0f-f3a64efd6541_terseLabel_en-US" xlink:label="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued liabilities and other liabilities</link:label>
    <link:label id="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_label_en-US" xlink:label="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</link:label>
    <link:label id="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_documentation_en-US" xlink:label="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:href="clbs-20230331.xsd#clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:to="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d72db27b-bd96-44aa-9067-0d993b8aa7ac_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares of the combined company owned by Cend stockholders</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_bbc2448a-d884-4537-821f-211e91f83743_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ee1701ef-6932-4d1b-90b4-c73eec5a14c8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_335a6d94-63b7-41bb-9dc4-0721eb78151f_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown_d8617bd6-8d51-4c66-8d94-5d3c2e6cadfa_terseLabel_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards, prior to write down</link:label>
    <link:label id="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown_label_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Before Write Down</link:label>
    <link:label id="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown_documentation_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Before Write Down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:href="clbs-20230331.xsd#clbs_OperatingLossCarryforwardsBeforeWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:to="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_4ac09874-b975-4e27-a950-b53f8c7575c7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward_93fb1c1d-af38-467f-9d6e-b42565152dc9_terseLabel_en-US" xlink:label="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Weighted Average Exercise Price</link:label>
    <link:label id="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:href="clbs-20230331.xsd#clbs_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:to="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_d349b383-31f7-4aae-b42c-c358e19c3ede_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8f927123-54f6-48ef-afb1-5a2d7c7d08dd_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAbstract" xlink:to="lab_us-gaap_AssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3a7dedb7-3ded-4bfd-aeff-68a023deb05a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_14e59f83-622c-413d-b5d5-c2388a7c1b9e_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8b105eb7-0931-44a0-9a20-e9a17da3f785_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_22a12b03-778a-47ed-88a7-de0d61f995fa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c571676e-3738-4d6f-b4d5-25249146df47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_c159b0e4-0b01-4d3a-8ce6-eb11680ffb30_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_dca0f2ef-3927-4652-bad3-5c89d65b10b6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale_1ecb695c-1fa9-4d97-86db-62e6e1682b1d_terseLabel_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance fee, after first sale</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale_label_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee After First Sale</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale_documentation_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee After First Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" xlink:to="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_b679ab21-0873-4cdc-b4dc-9eac1ebba572_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_58784f2d-b490-425f-9860-f37b60b060de_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities - available for sale</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_df4a6252-32f0-4c68-bd0a-fbf730df910f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ffcd3cd8-1320-4d8c-9cf8-796d178fe471_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a9ce65d1-fd0c-4e0f-91de-121ab62df948_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_31e6da3e-61da-419a-b59e-1de23b3c132e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AccruedGrantFunding_0156871e-2d8c-46be-b4ec-64bf5a598703_terseLabel_en-US" xlink:label="lab_clbs_AccruedGrantFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">D&amp;O insurance liabilities</link:label>
    <link:label id="lab_clbs_AccruedGrantFunding_label_en-US" xlink:label="lab_clbs_AccruedGrantFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Grant Funding</link:label>
    <link:label id="lab_clbs_AccruedGrantFunding_documentation_en-US" xlink:label="lab_clbs_AccruedGrantFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Grant Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AccruedGrantFunding" xlink:href="clbs-20230331.xsd#clbs_AccruedGrantFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AccruedGrantFunding" xlink:to="lab_clbs_AccruedGrantFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_27f8e334-0930-40d8-8c31-e1bdcd86d96d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_a7bee1d3-b86c-420e-98f6-03866a5b42a5_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_dca3ccaf-c13b-40d0-b27a-34ebf1b24902_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_05cbeaaa-f9ee-4ddb-ae22-0f7703354dcb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_95e54e31-3558-4247-95c7-dc8af62d6e52_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_784e1800-8451-47c5-b6ea-2c96a775f746_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_76d97387-0c1b-471e-bae1-5f94470ec9b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_5c9f0569-5f2a-48b9-bb24-c2c092efc854_terseLabel_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_label_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested and expected to vest</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_documentation_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:href="clbs-20230331.xsd#clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:to="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled_3afb57ce-7ae0-4e0b-ab21-98f9fc695cef_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Canceled</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Canceled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:href="clbs-20230331.xsd#clbs_WeightedAverageExercisePriceWarrantsCanceled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsGranted_b5bd8aaa-fcff-49d9-af99-0558e4fdccb1_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Granted (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsGranted_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Granted</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsGranted_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:href="clbs-20230331.xsd#clbs_WeightedAverageExercisePriceWarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2c591464-7710-40f7-bbbb-eaf9ceae4eba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SanfordBurnhamPrebysMember_73178fe0-517b-4f86-b869-b9cb72ded7a3_terseLabel_en-US" xlink:label="lab_clbs_SanfordBurnhamPrebysMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanford Burnham Prebys</link:label>
    <link:label id="lab_clbs_SanfordBurnhamPrebysMember_label_en-US" xlink:label="lab_clbs_SanfordBurnhamPrebysMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanford Burnham Prebys [Member]</link:label>
    <link:label id="lab_clbs_SanfordBurnhamPrebysMember_documentation_en-US" xlink:label="lab_clbs_SanfordBurnhamPrebysMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanford Burnham Prebys</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SanfordBurnhamPrebysMember" xlink:href="clbs-20230331.xsd#clbs_SanfordBurnhamPrebysMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SanfordBurnhamPrebysMember" xlink:to="lab_clbs_SanfordBurnhamPrebysMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_42e5bf3f-f7af-4413-a25f-d7b469946dca_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_b8c30efc-b098-4b79-b852-1bf2165974e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost; 738 shares at March 31, 2023 and December 31, 2022</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_3839d49c-8b98-49e6-a2d0-553a4b6e7e66_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9a5c58d0-db08-49b6-a7ec-8bb05680bb54_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding. Beginning of Period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_538b5873-9dfc-4dc9-95a0-07f203a0c05f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, End of Period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_8e06312a-88ff-4b3e-a077-461066530bd4_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_84e5d893-0175-4cfb-ba64-374a67b5f736_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, noncurrent, balance sheet line item</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_97223c9d-6539-4c42-9f19-5a49c9d3cb53_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_ClinicalAndRDRelatedLiabilities_371e0558-909d-4c9a-9634-87be2cce9e39_terseLabel_en-US" xlink:label="lab_clbs_ClinicalAndRDRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical and R&amp;D related liabilities</link:label>
    <link:label id="lab_clbs_ClinicalAndRDRelatedLiabilities_label_en-US" xlink:label="lab_clbs_ClinicalAndRDRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical and R&amp;D Related Liabilities</link:label>
    <link:label id="lab_clbs_ClinicalAndRDRelatedLiabilities_documentation_en-US" xlink:label="lab_clbs_ClinicalAndRDRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical and R&amp;D Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ClinicalAndRDRelatedLiabilities" xlink:href="clbs-20230331.xsd#clbs_ClinicalAndRDRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_ClinicalAndRDRelatedLiabilities" xlink:to="lab_clbs_ClinicalAndRDRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_MassachusettsInstituteOfTechnologyMember_005c642e-1470-4ac9-a153-58ed29ad107b_terseLabel_en-US" xlink:label="lab_clbs_MassachusettsInstituteOfTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts Institute of Technology</link:label>
    <link:label id="lab_clbs_MassachusettsInstituteOfTechnologyMember_label_en-US" xlink:label="lab_clbs_MassachusettsInstituteOfTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts Institute of Technology [Member]</link:label>
    <link:label id="lab_clbs_MassachusettsInstituteOfTechnologyMember_documentation_en-US" xlink:label="lab_clbs_MassachusettsInstituteOfTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts Institute of Technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MassachusettsInstituteOfTechnologyMember" xlink:href="clbs-20230331.xsd#clbs_MassachusettsInstituteOfTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_MassachusettsInstituteOfTechnologyMember" xlink:to="lab_clbs_MassachusettsInstituteOfTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_62c03190-3333-4389-8024-c74606d5449f_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvested_58c894ba-cecf-4701-883a-07cdb0619e88_terseLabel_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvested_label_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvested_documentation_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsvested" xlink:href="clbs-20230331.xsd#clbs_AggregateIntrinsicValueWarrantsvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AggregateIntrinsicValueWarrantsvested" xlink:to="lab_clbs_AggregateIntrinsicValueWarrantsvested" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_22cff288-38c4-473e-81c8-c70493672707_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_418a0897-e109-486d-9991-877f7f34f843_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionLineItems" xlink:to="lab_us-gaap_AssetAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fbeadc39-57a6-4ac7-82d9-dcb7f8f9cb2a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_41f30c4c-334c-44be-8846-b2c5224ab79e_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_948386c5-b3cf-4596-ae4b-d9b82287d390_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AssetAcquisitionAcquiredInProcessResearchAndDevelopment_46eabfa3-8784-4aa0-a217-8c3c04102963_terseLabel_en-US" xlink:label="lab_clbs_AssetAcquisitionAcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_clbs_AssetAcquisitionAcquiredInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_clbs_AssetAcquisitionAcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Acquired In-Process Research And Development</link:label>
    <link:label id="lab_clbs_AssetAcquisitionAcquiredInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_clbs_AssetAcquisitionAcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Acquired In-Process Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AssetAcquisitionAcquiredInProcessResearchAndDevelopment" xlink:href="clbs-20230331.xsd#clbs_AssetAcquisitionAcquiredInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AssetAcquisitionAcquiredInProcessResearchAndDevelopment" xlink:to="lab_clbs_AssetAcquisitionAcquiredInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b4259a47-df49-4b44-8248-e2e1e93c0ae0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_13a1dc81-6e73-4752-a84f-94d89fbb7121_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_0039060e-e7bd-4ec2-9d41-6faa6ce32e2f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_cede9f72-a473-46f6-8b3c-650d9fa9bb7c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8a0e433d-9bbd-4202-9b3e-ce2628b21d3c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on disposal of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b8355495-8791-4b70-a632-fee004c1b7e7_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2ea424d6-09e9-466a-951f-665b9c3804b9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_ab79f0d8-93d4-4804-90e8-036620daaecb_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0c79fc69-db3e-4f4a-ad3b-d3fbeeaf1f82_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7371533c-e0ee-4d46-9b0a-4dd59d927a09_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_96ade105-7c12-4849-9d09-66fb2959cb2a_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7e2d864a-f8bd-44b9-beba-5c6befecad85_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_afa82a63-d9a6-4932-9a5c-9294fdba94c6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_04ffad1b-5481-456a-945f-6020a7f3847b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5a3f4150-e55a-405a-aab8-b199502a28df_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_345892ad-ccaa-4407-b8a4-9dc5dc925376_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_e896f5fc-bd65-47f3-814b-1d6723856c08_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_0974ed34-4091-47c1-a321-3e384208e1a1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_490a1b45-eb17-479a-937a-48e3d717f5d8_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_78bbf36e-1820-437f-84d8-c48e6b1d3622_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option and Warrants Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6af767e6-47a9-410c-8526-43cd715753be_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_642f78c4-5d3d-45ff-a905-ac3afe6e3808_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c285d9a3-be03-4ca3-8c9c-153717d77047_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_c209337a-7ba2-4c81-aac1-81e9f76fa810_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_6691dc51-4dc1-40d0-8549-678513e95dd9_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_a414e282-7cf8-46eb-863c-d6acce225fce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_0ce761e2-1d68-4dee-ae28-eb78e57a9895_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_328c0211-fbff-47da-a15d-c8c7d1e35fab_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_96717a9b-4af5-4dfa-9809-46bede4aa646_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dafdb049-ceb3-41cb-a5a0-fd218d4416ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2070b301-637c-4396-9f46-55de87e06b2d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_PreferredStockLiquidationPreferenceShare_481e6b90-c8b4-46e8-912e-998672e63cd7_terseLabel_en-US" xlink:label="lab_clbs_PreferredStockLiquidationPreferenceShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, liquidation value</link:label>
    <link:label id="lab_clbs_PreferredStockLiquidationPreferenceShare_label_en-US" xlink:label="lab_clbs_PreferredStockLiquidationPreferenceShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference, Share</link:label>
    <link:label id="lab_clbs_PreferredStockLiquidationPreferenceShare_documentation_en-US" xlink:label="lab_clbs_PreferredStockLiquidationPreferenceShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference, Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreferredStockLiquidationPreferenceShare" xlink:href="clbs-20230331.xsd#clbs_PreferredStockLiquidationPreferenceShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_PreferredStockLiquidationPreferenceShare" xlink:to="lab_clbs_PreferredStockLiquidationPreferenceShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_8c296fea-1deb-48c8-99cb-36536eaca0e3_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_29dc760d-7b9e-4a80-b0c6-98ab135bff9f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AssetAcquisitionCashAndCashEquivalents_b0d8bf01-97d3-4cc1-8d3d-83c0610840c0_terseLabel_en-US" xlink:label="lab_clbs_AssetAcquisitionCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_clbs_AssetAcquisitionCashAndCashEquivalents_label_en-US" xlink:label="lab_clbs_AssetAcquisitionCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Cash and Cash Equivalents</link:label>
    <link:label id="lab_clbs_AssetAcquisitionCashAndCashEquivalents_documentation_en-US" xlink:label="lab_clbs_AssetAcquisitionCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AssetAcquisitionCashAndCashEquivalents" xlink:href="clbs-20230331.xsd#clbs_AssetAcquisitionCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AssetAcquisitionCashAndCashEquivalents" xlink:to="lab_clbs_AssetAcquisitionCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_b8cd5144-d7d1-44b6-8b9e-d185b96ce64b_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_ed2d8b4f-3665-468c-82e6-313c1999fa51_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_aa7ae8e4-1d10-4788-a603-5ebe92775560_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock_6b31fcb4-60ec-4def-8db0-5e9325a778b9_terseLabel_en-US" xlink:label="lab_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia Research and Development Tax Incentive</link:label>
    <link:label id="lab_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock_label_en-US" xlink:label="lab_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Tax Incentive [Text Block]</link:label>
    <link:label id="lab_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock_documentation_en-US" xlink:label="lab_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Tax Incentive</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:href="clbs-20230331.xsd#clbs_ResearchAndDevelopmentTaxIncentiveTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:to="lab_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_b92887e0-7057-4c07-8d60-2ed99810d01c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_82debfd7-7649-4169-84ea-10a49dd61d0a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax withholding payments on net share settlement equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_78492c72-9cf2-4f4c-8684-6ab695a70739_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6bf55ff8-842a-4677-819a-70900d202b84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_76ff6217-bfed-4b61-854f-f238755b5dee_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_6cf19798-0cb5-49e5-81a6-37f735aca83d_terseLabel_en-US" xlink:label="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York</link:label>
    <link:label id="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_label_en-US" xlink:label="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York State Division of Taxation and Finance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:to="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_9f61d2c0-0d80-46e8-9589-76fb2203dc18_terseLabel_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_label_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Franchise Tax Board [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_6b03a5b5-784a-4d86-973c-bdb9d58fae51_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_a523d763-4960-4761-bdc9-3d040b8f1051_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a2caf50c-f717-4271-aca0-dfb7636355f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_32e8d5a2-6b43-4321-ac6f-90ff8e96b99c_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0683bdfb-40ff-4631-8546-79f3e8539542_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_b5f1eed8-adbb-4359-bfd4-9dd5be533cb3_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_78240c65-e199-4e54-94d7-2e76c03cb259_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_e3f6885b-0e19-4842-b30c-a0318105c543_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_QiluMember_b590ca12-ce65-4af2-a21b-f1ef10796d3d_terseLabel_en-US" xlink:label="lab_clbs_QiluMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu</link:label>
    <link:label id="lab_clbs_QiluMember_label_en-US" xlink:label="lab_clbs_QiluMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu [Member]</link:label>
    <link:label id="lab_clbs_QiluMember_documentation_en-US" xlink:label="lab_clbs_QiluMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_QiluMember" xlink:href="clbs-20230331.xsd#clbs_QiluMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_QiluMember" xlink:to="lab_clbs_QiluMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_98a40a17-314e-4d5a-8719-5a38daceb2e4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, balance sheet line item</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_7820dbfc-7c03-43c3-a21e-413ce956f886_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_ef03e546-a77d-43a4-9457-ac24918f806a_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_bff4f923-7a58-43f2-8ad8-01a46494f90a_terseLabel_en-US" xlink:label="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet</link:label>
    <link:label id="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_label_en-US" xlink:label="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</link:label>
    <link:label id="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_documentation_en-US" xlink:label="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:href="clbs-20230331.xsd#clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:to="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_2dbde5f8-fd53-4219-bcbb-1026c2412990_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research tax credit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a5137cad-7d08-4a77-8015-688118678f09_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_8430a2cc-f034-44ba-a2cb-e0834a8747b1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_aedab6e5-bc35-423a-ad08-2cc24dfcf5dd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_f33d08ee-cf34-4680-a1ff-201b6b06314f_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dcd20986-d355-488f-9ad5-dca7d6e96c9a_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_d2f4596b-031a-4044-bc23-029b7575cf43_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>clbs-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:8a27d5e7-fe33-4755-a32c-690f224065c0,g:57aefdc3-f3d7-461d-8b12-8991faaa8b7c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.caladrius.com/role/Cover" xlink:type="simple" xlink:href="clbs-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c24fa144-b842-4243-a3f8-0ac03bf06e68" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_DocumentType_c24fa144-b842-4243-a3f8-0ac03bf06e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_db34a3f3-5572-4478-9860-e8474aa326cd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_DocumentQuarterlyReport_db34a3f3-5572-4478-9860-e8474aa326cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_07e734af-88fe-44c7-ba72-8450dbc92fe1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_DocumentPeriodEndDate_07e734af-88fe-44c7-ba72-8450dbc92fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_6a264aba-e6e0-4202-a0c5-2643a47dc4bc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_DocumentTransitionReport_6a264aba-e6e0-4202-a0c5-2643a47dc4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b36e967f-ce43-4f65-ab27-ab44753ae777" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_EntityFileNumber_b36e967f-ce43-4f65-ab27-ab44753ae777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_82eaacf2-0891-463f-ae83-a73d1a38e901" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_EntityRegistrantName_82eaacf2-0891-463f-ae83-a73d1a38e901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_14fbdee6-0be3-4e92-883a-f34e5b9e830b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_EntityIncorporationStateCountryCode_14fbdee6-0be3-4e92-883a-f34e5b9e830b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e64ee9dd-3f31-42ab-8751-147912530eff" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_EntityTaxIdentificationNumber_e64ee9dd-3f31-42ab-8751-147912530eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_18f28fab-b6e6-4501-96f3-46049efc632a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_EntityAddressAddressLine1_18f28fab-b6e6-4501-96f3-46049efc632a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0ee01137-0f22-493d-b5bb-0be147e6584e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_EntityAddressCityOrTown_0ee01137-0f22-493d-b5bb-0be147e6584e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8760d3ea-30da-42e5-a2c2-fd59d8e7e43a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_EntityAddressStateOrProvince_8760d3ea-30da-42e5-a2c2-fd59d8e7e43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_dedc2097-7919-44ef-9930-60c822f73da9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_EntityAddressPostalZipCode_dedc2097-7919-44ef-9930-60c822f73da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_04d05d1c-a775-40dc-b0e4-8cbb2e79c274" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_CityAreaCode_04d05d1c-a775-40dc-b0e4-8cbb2e79c274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_efde51d3-4c88-4f3f-b1b5-ecb187b2873f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_LocalPhoneNumber_efde51d3-4c88-4f3f-b1b5-ecb187b2873f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8ccb6a11-5d70-4487-ad68-50f601880a00" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_Security12bTitle_8ccb6a11-5d70-4487-ad68-50f601880a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_33ab725c-c9ff-42ab-9990-30c3043bda1f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_TradingSymbol_33ab725c-c9ff-42ab-9990-30c3043bda1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d98e4a00-8b38-4b16-90dc-3321f5cdac3c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_SecurityExchangeName_d98e4a00-8b38-4b16-90dc-3321f5cdac3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_52a47e38-9930-49b9-b7ac-a5570c9ba553" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_EntityCurrentReportingStatus_52a47e38-9930-49b9-b7ac-a5570c9ba553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_35844d23-76c7-4aa6-bbc8-a6105c365a8a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_EntityInteractiveDataCurrent_35844d23-76c7-4aa6-bbc8-a6105c365a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_2613fb7f-a7c9-404b-978d-363205b35bfe" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_EntityFilerCategory_2613fb7f-a7c9-404b-978d-363205b35bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f76cff9d-c8a6-425a-a0d7-ee53ba9fa1ca" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_EntitySmallBusiness_f76cff9d-c8a6-425a-a0d7-ee53ba9fa1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b2756841-d782-461e-a3ec-366155adc38e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_EntityEmergingGrowthCompany_b2756841-d782-461e-a3ec-366155adc38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1aa4e423-38a1-477b-83ce-60ee4a8426ee" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_EntityShellCompany_1aa4e423-38a1-477b-83ce-60ee4a8426ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_288fa379-163c-4c45-bc35-360b2c8458fa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_EntityCentralIndexKey_288fa379-163c-4c45-bc35-360b2c8458fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5c82280d-8dba-439e-9320-ddc9b6cea9b2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_CurrentFiscalYearEndDate_5c82280d-8dba-439e-9320-ddc9b6cea9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a0c0d623-b414-4f10-91e4-25545d0baa00" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_DocumentFiscalYearFocus_a0c0d623-b414-4f10-91e4-25545d0baa00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f74d7c2c-a5e7-4784-b988-e66194c39677" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f74d7c2c-a5e7-4784-b988-e66194c39677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0850e072-705d-46b5-a710-6cb367e9c5f7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_AmendmentFlag_0850e072-705d-46b5-a710-6cb367e9c5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7db4eae6-61dc-4f50-905a-8ed816916629" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_924c5960-2f51-47a4-b127-e2adacccbf58" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7db4eae6-61dc-4f50-905a-8ed816916629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="clbs-20230331.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0b57abfb-53bb-4b9b-a332-fa7c99d62464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_9c3e1c77-fae1-4628-8253-5c0650f26a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0b57abfb-53bb-4b9b-a332-fa7c99d62464" xlink:to="loc_us-gaap_AssetsAbstract_9c3e1c77-fae1-4628-8253-5c0650f26a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9c51efe3-c478-4b26-b41a-ad3886df0ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9c3e1c77-fae1-4628-8253-5c0650f26a13" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9c51efe3-c478-4b26-b41a-ad3886df0ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_5999c1f5-1a45-40a2-8c43-70e460dc48ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9c3e1c77-fae1-4628-8253-5c0650f26a13" xlink:to="loc_us-gaap_MarketableSecurities_5999c1f5-1a45-40a2-8c43-70e460dc48ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c8520067-d730-4291-a7b3-9527a23188c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9c3e1c77-fae1-4628-8253-5c0650f26a13" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c8520067-d730-4291-a7b3-9527a23188c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9ea93574-8030-4590-8099-7cd486b9a68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9c3e1c77-fae1-4628-8253-5c0650f26a13" xlink:to="loc_us-gaap_AssetsCurrent_9ea93574-8030-4590-8099-7cd486b9a68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_356e5a8c-866c-471b-81bd-4fc9f67b71bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9c3e1c77-fae1-4628-8253-5c0650f26a13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_356e5a8c-866c-471b-81bd-4fc9f67b71bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bfb4c663-537f-4800-883e-fa4377d0a79a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9c3e1c77-fae1-4628-8253-5c0650f26a13" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bfb4c663-537f-4800-883e-fa4377d0a79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_213469e3-b333-456a-bfb0-98234ea8a036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9c3e1c77-fae1-4628-8253-5c0650f26a13" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_213469e3-b333-456a-bfb0-98234ea8a036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5644b073-26bf-43f9-afa0-724948f3a181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9c3e1c77-fae1-4628-8253-5c0650f26a13" xlink:to="loc_us-gaap_Assets_5644b073-26bf-43f9-afa0-724948f3a181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45c622e7-40dd-4b16-b7c3-2b0d909408af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0b57abfb-53bb-4b9b-a332-fa7c99d62464" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45c622e7-40dd-4b16-b7c3-2b0d909408af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_d65e93f4-49cb-45c4-a5a6-8cef6b01070d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45c622e7-40dd-4b16-b7c3-2b0d909408af" xlink:to="loc_us-gaap_LiabilitiesAbstract_d65e93f4-49cb-45c4-a5a6-8cef6b01070d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_90515d05-a362-47fb-ab3c-e7f8706d729d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_d65e93f4-49cb-45c4-a5a6-8cef6b01070d" xlink:to="loc_us-gaap_AccountsPayableCurrent_90515d05-a362-47fb-ab3c-e7f8706d729d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a3af08f3-1f9f-484f-971b-3f512cf69b84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_d65e93f4-49cb-45c4-a5a6-8cef6b01070d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a3af08f3-1f9f-484f-971b-3f512cf69b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2948b088-d19e-4ce8-9f45-0f5524bf9d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_d65e93f4-49cb-45c4-a5a6-8cef6b01070d" xlink:to="loc_us-gaap_LiabilitiesCurrent_2948b088-d19e-4ce8-9f45-0f5524bf9d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_598afe10-cf8c-4bba-b20e-d3c479754628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_d65e93f4-49cb-45c4-a5a6-8cef6b01070d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_598afe10-cf8c-4bba-b20e-d3c479754628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_61b10e21-846a-49f0-bc4b-0bd03793b7da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_d65e93f4-49cb-45c4-a5a6-8cef6b01070d" xlink:to="loc_us-gaap_Liabilities_61b10e21-846a-49f0-bc4b-0bd03793b7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_fb6b8697-ae96-441a-abc4-a63cbb159110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45c622e7-40dd-4b16-b7c3-2b0d909408af" xlink:to="loc_us-gaap_CommitmentsAndContingencies_fb6b8697-ae96-441a-abc4-a63cbb159110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_245ca0e0-8a00-4404-8c72-b106b4a3e5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45c622e7-40dd-4b16-b7c3-2b0d909408af" xlink:to="loc_us-gaap_StockholdersEquityAbstract_245ca0e0-8a00-4404-8c72-b106b4a3e5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_506a912d-48c6-437e-b04c-12a732dfd875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_245ca0e0-8a00-4404-8c72-b106b4a3e5f6" xlink:to="loc_us-gaap_PreferredStockValue_506a912d-48c6-437e-b04c-12a732dfd875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_758500fc-f1a2-4d23-a348-ff130563b67a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_245ca0e0-8a00-4404-8c72-b106b4a3e5f6" xlink:to="loc_us-gaap_CommonStockValue_758500fc-f1a2-4d23-a348-ff130563b67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f4ad60b4-4131-434f-bd5b-94ef2245a8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_245ca0e0-8a00-4404-8c72-b106b4a3e5f6" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f4ad60b4-4131-434f-bd5b-94ef2245a8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_6fccb49e-e399-47fd-bfa5-235b5d666d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_245ca0e0-8a00-4404-8c72-b106b4a3e5f6" xlink:to="loc_us-gaap_TreasuryStockCommonValue_6fccb49e-e399-47fd-bfa5-235b5d666d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5038aed2-be13-4287-8be3-fbebdc7d7f73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_245ca0e0-8a00-4404-8c72-b106b4a3e5f6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5038aed2-be13-4287-8be3-fbebdc7d7f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e9f98779-2770-4434-a044-0ded1010dd77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_245ca0e0-8a00-4404-8c72-b106b4a3e5f6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e9f98779-2770-4434-a044-0ded1010dd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9ce50fbb-c773-48e4-a517-37ac4c07868b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_245ca0e0-8a00-4404-8c72-b106b4a3e5f6" xlink:to="loc_us-gaap_StockholdersEquity_9ce50fbb-c773-48e4-a517-37ac4c07868b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_b52ae432-61fe-4a64-a021-5b790b4b2e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_245ca0e0-8a00-4404-8c72-b106b4a3e5f6" xlink:to="loc_us-gaap_MinorityInterest_b52ae432-61fe-4a64-a021-5b790b4b2e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d92662ef-fc1e-4800-abd1-2c168f33e4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_245ca0e0-8a00-4404-8c72-b106b4a3e5f6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d92662ef-fc1e-4800-abd1-2c168f33e4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e0bd6074-f50a-48e7-aad5-0f1d96aefdde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45c622e7-40dd-4b16-b7c3-2b0d909408af" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e0bd6074-f50a-48e7-aad5-0f1d96aefdde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="simple" xlink:href="clbs-20230331.xsd#ConsolidatedBalanceSheetsParentheticals"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_917d1308-f3d8-44a9-b28f-aaa2ce2e06e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_eab28c2f-5e1f-4939-bc27-655fc2fc3520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_917d1308-f3d8-44a9-b28f-aaa2ce2e06e8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_eab28c2f-5e1f-4939-bc27-655fc2fc3520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreferredStockLiquidationPreferenceShare_973590f0-2036-49d1-bbd1-cc96f0a6a496" xlink:href="clbs-20230331.xsd#clbs_PreferredStockLiquidationPreferenceShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_917d1308-f3d8-44a9-b28f-aaa2ce2e06e8" xlink:to="loc_clbs_PreferredStockLiquidationPreferenceShare_973590f0-2036-49d1-bbd1-cc96f0a6a496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_447885a0-50d8-4694-afe2-265505701393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_917d1308-f3d8-44a9-b28f-aaa2ce2e06e8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_447885a0-50d8-4694-afe2-265505701393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreferredStockSharesDesignated_b323ef0f-fdb5-4fc8-b348-4982fab70cce" xlink:href="clbs-20230331.xsd#clbs_PreferredStockSharesDesignated"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_917d1308-f3d8-44a9-b28f-aaa2ce2e06e8" xlink:to="loc_clbs_PreferredStockSharesDesignated_b323ef0f-fdb5-4fc8-b348-4982fab70cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_dfed3eb2-c0e6-463b-b44d-ab6d32a2d83c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_917d1308-f3d8-44a9-b28f-aaa2ce2e06e8" xlink:to="loc_us-gaap_PreferredStockSharesIssued_dfed3eb2-c0e6-463b-b44d-ab6d32a2d83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_b42099d8-33c6-4780-8006-98fc794b6068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_917d1308-f3d8-44a9-b28f-aaa2ce2e06e8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_b42099d8-33c6-4780-8006-98fc794b6068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2cff52f7-67cb-4953-a45a-934771d4180f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_917d1308-f3d8-44a9-b28f-aaa2ce2e06e8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2cff52f7-67cb-4953-a45a-934771d4180f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4319ff39-a08c-4953-847f-b5ee4e5e4bce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_917d1308-f3d8-44a9-b28f-aaa2ce2e06e8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4319ff39-a08c-4953-847f-b5ee4e5e4bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_095e7bb0-ca3c-47cb-83fc-fff7ae140355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_917d1308-f3d8-44a9-b28f-aaa2ce2e06e8" xlink:to="loc_us-gaap_CommonStockSharesIssued_095e7bb0-ca3c-47cb-83fc-fff7ae140355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_90733216-0316-4049-b0ca-6109bd397c28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_917d1308-f3d8-44a9-b28f-aaa2ce2e06e8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_90733216-0316-4049-b0ca-6109bd397c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_0a101a59-3607-400d-88a6-61a8c5ae881b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_917d1308-f3d8-44a9-b28f-aaa2ce2e06e8" xlink:to="loc_us-gaap_TreasuryStockCommonShares_0a101a59-3607-400d-88a6-61a8c5ae881b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="clbs-20230331.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_00b2370b-1b90-4672-8e63-cf7f670b7d44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_33d199d5-3250-4ae0-bdb2-77c0ee34fd05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_00b2370b-1b90-4672-8e63-cf7f670b7d44" xlink:to="loc_us-gaap_OperatingExpensesAbstract_33d199d5-3250-4ae0-bdb2-77c0ee34fd05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_380c1e49-98b9-4087-99df-6b58c70e48e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_33d199d5-3250-4ae0-bdb2-77c0ee34fd05" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_380c1e49-98b9-4087-99df-6b58c70e48e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_400ad965-1b8c-4be3-a951-713d54254967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_33d199d5-3250-4ae0-bdb2-77c0ee34fd05" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_400ad965-1b8c-4be3-a951-713d54254967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0e032b56-5902-4083-b628-b1836a27673b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_33d199d5-3250-4ae0-bdb2-77c0ee34fd05" xlink:to="loc_us-gaap_OperatingExpenses_0e032b56-5902-4083-b628-b1836a27673b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_38c010f8-9778-4908-92ce-d43c1993e419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_00b2370b-1b90-4672-8e63-cf7f670b7d44" xlink:to="loc_us-gaap_OperatingIncomeLoss_38c010f8-9778-4908-92ce-d43c1993e419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dd273f35-7be7-428f-92ba-f577612d2e79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_00b2370b-1b90-4672-8e63-cf7f670b7d44" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dd273f35-7be7-428f-92ba-f577612d2e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_ced389a6-10eb-46c5-a04c-9fa3406c4008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dd273f35-7be7-428f-92ba-f577612d2e79" xlink:to="loc_us-gaap_InvestmentIncomeNet_ced389a6-10eb-46c5-a04c-9fa3406c4008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6d690eff-bacd-4e98-aa78-6bc0c5b1b989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dd273f35-7be7-428f-92ba-f577612d2e79" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6d690eff-bacd-4e98-aa78-6bc0c5b1b989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_90f07cbb-28a1-43e2-a5c6-c4ed02ac1a99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dd273f35-7be7-428f-92ba-f577612d2e79" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_90f07cbb-28a1-43e2-a5c6-c4ed02ac1a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a9ca1e95-eb8c-4bcd-b75f-dce2cbca4790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_00b2370b-1b90-4672-8e63-cf7f670b7d44" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a9ca1e95-eb8c-4bcd-b75f-dce2cbca4790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a4da85e7-95e8-4629-a6d4-5844691d637e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_00b2370b-1b90-4672-8e63-cf7f670b7d44" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a4da85e7-95e8-4629-a6d4-5844691d637e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0406d923-7306-4f0b-b565-94f1fb1d0151" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_00b2370b-1b90-4672-8e63-cf7f670b7d44" xlink:to="loc_us-gaap_ProfitLoss_0406d923-7306-4f0b-b565-94f1fb1d0151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_473dbe39-bcde-441f-a088-b80a003d34c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_00b2370b-1b90-4672-8e63-cf7f670b7d44" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_473dbe39-bcde-441f-a088-b80a003d34c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f60ced90-c408-4a99-81fb-5539c146a481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_00b2370b-1b90-4672-8e63-cf7f670b7d44" xlink:to="loc_us-gaap_NetIncomeLoss_f60ced90-c408-4a99-81fb-5539c146a481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_92a0fb7d-8688-46f3-a28c-8da9cbc95469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_00b2370b-1b90-4672-8e63-cf7f670b7d44" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_92a0fb7d-8688-46f3-a28c-8da9cbc95469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9968c081-d7e2-4110-aff6-9d0ab9899475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_92a0fb7d-8688-46f3-a28c-8da9cbc95469" xlink:to="loc_us-gaap_EarningsPerShareBasic_9968c081-d7e2-4110-aff6-9d0ab9899475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5dcf6d6c-a992-48af-b1ba-cde49c833c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_92a0fb7d-8688-46f3-a28c-8da9cbc95469" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5dcf6d6c-a992-48af-b1ba-cde49c833c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ac09a3c3-a195-44b3-ac44-57ac6389172a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_00b2370b-1b90-4672-8e63-cf7f670b7d44" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ac09a3c3-a195-44b3-ac44-57ac6389172a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_34620305-705f-470f-9621-3880edaccd88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ac09a3c3-a195-44b3-ac44-57ac6389172a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_34620305-705f-470f-9621-3880edaccd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_13876d9b-6592-4d69-bba8-543c93befd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ac09a3c3-a195-44b3-ac44-57ac6389172a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_13876d9b-6592-4d69-bba8-543c93befd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="clbs-20230331.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cab37497-aa4a-4305-9ff6-f55c89ed30a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0d4a181c-9391-497a-bc63-58968e629ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cab37497-aa4a-4305-9ff6-f55c89ed30a9" xlink:to="loc_us-gaap_ProfitLoss_0d4a181c-9391-497a-bc63-58968e629ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_df46d4ab-b5a7-4d89-ac0f-62e70ee8612a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cab37497-aa4a-4305-9ff6-f55c89ed30a9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_df46d4ab-b5a7-4d89-ac0f-62e70ee8612a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_50b1e5db-d057-4704-9212-361d451199ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cab37497-aa4a-4305-9ff6-f55c89ed30a9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_50b1e5db-d057-4704-9212-361d451199ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6002572d-f54b-4073-97a6-79e6984c4524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cab37497-aa4a-4305-9ff6-f55c89ed30a9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6002572d-f54b-4073-97a6-79e6984c4524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_21d0c140-ebaf-47a0-b5f5-19516c41f07e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cab37497-aa4a-4305-9ff6-f55c89ed30a9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_21d0c140-ebaf-47a0-b5f5-19516c41f07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="clbs-20230331.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_f5447d97-77ea-4620-9396-05b4bece16fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_80a7a0f8-5728-4e87-84d2-4e956c616c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f5447d97-77ea-4620-9396-05b4bece16fa" xlink:to="loc_us-gaap_StatementTable_80a7a0f8-5728-4e87-84d2-4e956c616c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3411d549-e437-42b0-b213-97e49bc34b65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_80a7a0f8-5728-4e87-84d2-4e956c616c3e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3411d549-e437-42b0-b213-97e49bc34b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_122948c0-5756-4334-b20b-170056f0cc42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3411d549-e437-42b0-b213-97e49bc34b65" xlink:to="loc_us-gaap_EquityComponentDomain_122948c0-5756-4334-b20b-170056f0cc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_32bfdae4-2fce-4352-92da-b19fafda7ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_122948c0-5756-4334-b20b-170056f0cc42" xlink:to="loc_us-gaap_ParentMember_32bfdae4-2fce-4352-92da-b19fafda7ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9b47f4c7-8a98-43f8-92de-8a5f1e197211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_32bfdae4-2fce-4352-92da-b19fafda7ef9" xlink:to="loc_us-gaap_CommonStockMember_9b47f4c7-8a98-43f8-92de-8a5f1e197211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4c34ce0f-08db-4991-93cc-cf6d05b68700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_32bfdae4-2fce-4352-92da-b19fafda7ef9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4c34ce0f-08db-4991-93cc-cf6d05b68700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_05680e45-5de0-467a-9ef8-941b35def37b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_32bfdae4-2fce-4352-92da-b19fafda7ef9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_05680e45-5de0-467a-9ef8-941b35def37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_53cdf0df-b8e0-466e-b770-20e03360b2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_32bfdae4-2fce-4352-92da-b19fafda7ef9" xlink:to="loc_us-gaap_RetainedEarningsMember_53cdf0df-b8e0-466e-b770-20e03360b2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_6a65bd9c-c8af-40f5-8f6b-749d0b19f637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_32bfdae4-2fce-4352-92da-b19fafda7ef9" xlink:to="loc_us-gaap_TreasuryStockCommonMember_6a65bd9c-c8af-40f5-8f6b-749d0b19f637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_fb4b1f85-a296-437c-b192-b10f4eab9849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_122948c0-5756-4334-b20b-170056f0cc42" xlink:to="loc_us-gaap_NoncontrollingInterestMember_fb4b1f85-a296-437c-b192-b10f4eab9849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_48e3bef9-4887-4502-b2e1-c727cc1e42cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_80a7a0f8-5728-4e87-84d2-4e956c616c3e" xlink:to="loc_us-gaap_StatementLineItems_48e3bef9-4887-4502-b2e1-c727cc1e42cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4caba145-dbf2-4f94-ad87-4d6eec056ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48e3bef9-4887-4502-b2e1-c727cc1e42cc" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4caba145-dbf2-4f94-ad87-4d6eec056ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b29a9a5d-808a-4774-816e-4ee77237be3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4caba145-dbf2-4f94-ad87-4d6eec056ff8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b29a9a5d-808a-4774-816e-4ee77237be3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0b85c3fd-0957-4d9b-a8b6-2bf3b53226d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4caba145-dbf2-4f94-ad87-4d6eec056ff8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0b85c3fd-0957-4d9b-a8b6-2bf3b53226d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8949c823-c002-4484-b7a4-104cc428f562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4caba145-dbf2-4f94-ad87-4d6eec056ff8" xlink:to="loc_us-gaap_ProfitLoss_8949c823-c002-4484-b7a4-104cc428f562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c0f0001d-a8c0-4c41-ab0a-8336569326c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4caba145-dbf2-4f94-ad87-4d6eec056ff8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c0f0001d-a8c0-4c41-ab0a-8336569326c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3a10dfd1-679e-4cdb-b7d1-85e3e8c04ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4caba145-dbf2-4f94-ad87-4d6eec056ff8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3a10dfd1-679e-4cdb-b7d1-85e3e8c04ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_20d90882-4d3c-4ddd-8c6e-383cb04f3af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4caba145-dbf2-4f94-ad87-4d6eec056ff8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_20d90882-4d3c-4ddd-8c6e-383cb04f3af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3c86fc54-d15f-4977-96e0-8440e6673f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4caba145-dbf2-4f94-ad87-4d6eec056ff8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3c86fc54-d15f-4977-96e0-8440e6673f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e2d7dc63-f040-4dad-97b1-4f5a0b23acfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4caba145-dbf2-4f94-ad87-4d6eec056ff8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e2d7dc63-f040-4dad-97b1-4f5a0b23acfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8b84f59c-b838-4a48-b1fd-781474175e50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4caba145-dbf2-4f94-ad87-4d6eec056ff8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8b84f59c-b838-4a48-b1fd-781474175e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="clbs-20230331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d4630d79-06d3-4086-8ebc-a408d5a18f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c2af179e-65f2-446f-a30f-817621f11f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d4630d79-06d3-4086-8ebc-a408d5a18f2b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c2af179e-65f2-446f-a30f-817621f11f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f7855146-ef8c-4fcd-9038-69effefb30fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c2af179e-65f2-446f-a30f-817621f11f78" xlink:to="loc_us-gaap_ProfitLoss_f7855146-ef8c-4fcd-9038-69effefb30fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dd93d09-b83d-463a-998e-e03d08d1487d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c2af179e-65f2-446f-a30f-817621f11f78" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dd93d09-b83d-463a-998e-e03d08d1487d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_4bf3dbb5-c1c4-45aa-96cd-c3a7223aa3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dd93d09-b83d-463a-998e-e03d08d1487d" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_4bf3dbb5-c1c4-45aa-96cd-c3a7223aa3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_597d8333-cfae-4198-8587-515700f142d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dd93d09-b83d-463a-998e-e03d08d1487d" xlink:to="loc_us-gaap_DepreciationAndAmortization_597d8333-cfae-4198-8587-515700f142d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_b20a27a7-8e60-40df-8d73-37fdc4f7e2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dd93d09-b83d-463a-998e-e03d08d1487d" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_b20a27a7-8e60-40df-8d73-37fdc4f7e2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6812241f-3df2-4aeb-98f4-a679cd9bce59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dd93d09-b83d-463a-998e-e03d08d1487d" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6812241f-3df2-4aeb-98f4-a679cd9bce59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3b730d40-1491-47ef-90a9-3e081ffd5447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c2af179e-65f2-446f-a30f-817621f11f78" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3b730d40-1491-47ef-90a9-3e081ffd5447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c2fc7905-a99d-4803-b84c-20398332e337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3b730d40-1491-47ef-90a9-3e081ffd5447" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c2fc7905-a99d-4803-b84c-20398332e337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5e148279-bed2-4088-b1c3-1d74cac0ed3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3b730d40-1491-47ef-90a9-3e081ffd5447" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5e148279-bed2-4088-b1c3-1d74cac0ed3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_ded2b80f-8fbf-440e-8e90-a704b76677df" xlink:href="clbs-20230331.xsd#clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3b730d40-1491-47ef-90a9-3e081ffd5447" xlink:to="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_ded2b80f-8fbf-440e-8e90-a704b76677df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14fc59c7-0d56-44f8-a716-7b284f23883b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c2af179e-65f2-446f-a30f-817621f11f78" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14fc59c7-0d56-44f8-a716-7b284f23883b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5912d7bc-f7d8-4a2f-8d31-47a44f1f2d02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d4630d79-06d3-4086-8ebc-a408d5a18f2b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5912d7bc-f7d8-4a2f-8d31-47a44f1f2d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_4abf63bb-2e41-48da-950d-28dfcd82b024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5912d7bc-f7d8-4a2f-8d31-47a44f1f2d02" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_4abf63bb-2e41-48da-950d-28dfcd82b024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_aad3e42a-4857-4e15-95ec-d3ffafa5f1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5912d7bc-f7d8-4a2f-8d31-47a44f1f2d02" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_aad3e42a-4857-4e15-95ec-d3ffafa5f1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2eef3014-4cbc-47fc-bbf4-8b34759653fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5912d7bc-f7d8-4a2f-8d31-47a44f1f2d02" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2eef3014-4cbc-47fc-bbf4-8b34759653fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ed8923d-82f9-412b-b0bf-0cb7b91cc0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d4630d79-06d3-4086-8ebc-a408d5a18f2b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ed8923d-82f9-412b-b0bf-0cb7b91cc0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d9b53f1d-e17c-4589-9239-7356b942446b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ed8923d-82f9-412b-b0bf-0cb7b91cc0b4" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d9b53f1d-e17c-4589-9239-7356b942446b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4c0e861e-4dde-44a9-a559-8dccef1f9fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ed8923d-82f9-412b-b0bf-0cb7b91cc0b4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4c0e861e-4dde-44a9-a559-8dccef1f9fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52b7c0b3-0a6e-42f9-ae8d-983a08edbdd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d4630d79-06d3-4086-8ebc-a408d5a18f2b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52b7c0b3-0a6e-42f9-ae8d-983a08edbdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b35e0c4a-8508-4a34-9865-381735552108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d4630d79-06d3-4086-8ebc-a408d5a18f2b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b35e0c4a-8508-4a34-9865-381735552108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52f0f3e0-65a3-4431-bac9-77e35d710e59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d4630d79-06d3-4086-8ebc-a408d5a18f2b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52f0f3e0-65a3-4431-bac9-77e35d710e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b6cd38c4-fb6e-4cb1-b2f2-1b6f1479bd56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d4630d79-06d3-4086-8ebc-a408d5a18f2b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b6cd38c4-fb6e-4cb1-b2f2-1b6f1479bd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TheBusiness" xlink:type="simple" xlink:href="clbs-20230331.xsd#TheBusiness"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/TheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3af30cee-11bd-4fb8-80c4-054c4802c712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_BusinessTextBlock_59cae4d6-7f58-4745-a218-a9035261e109" xlink:href="clbs-20230331.xsd#clbs_BusinessTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3af30cee-11bd-4fb8-80c4-054c4802c712" xlink:to="loc_clbs_BusinessTextBlock_59cae4d6-7f58-4745-a218-a9035261e109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="clbs-20230331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7eba3841-8a4d-4d90-9634-55b5e17f0910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e30df224-a61c-4bb4-9df1-c8525f2df757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7eba3841-8a4d-4d90-9634-55b5e17f0910" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e30df224-a61c-4bb4-9df1-c8525f2df757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/Merger" xlink:type="simple" xlink:href="clbs-20230331.xsd#Merger"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/Merger" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAbstract_c0932605-9532-4590-ac9a-6016870ed54b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock_cc498edf-6a4d-463b-bc02-bc076ca1a1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAbstract_c0932605-9532-4590-ac9a-6016870ed54b" xlink:to="loc_us-gaap_AssetAcquisitionTextBlock_cc498edf-6a4d-463b-bc02-bc076ca1a1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecurities" xlink:type="simple" xlink:href="clbs-20230331.xsd#AvailableforSaleSecurities"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a67ac305-819d-47f3-8e61-8cf373d8e95e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_0ac35033-721f-434e-9eae-1ab50ebec0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a67ac305-819d-47f3-8e61-8cf373d8e95e" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_0ac35033-721f-434e-9eae-1ab50ebec0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipmentNotes" xlink:type="simple" xlink:href="clbs-20230331.xsd#PropertyandEquipmentNotes"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/PropertyandEquipmentNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c48eee2f-2609-4e64-8568-7d6f43fa2280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9eca29d6-e675-4226-af54-720f126afb3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c48eee2f-2609-4e64-8568-7d6f43fa2280" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9eca29d6-e675-4226-af54-720f126afb3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShare" xlink:type="simple" xlink:href="clbs-20230331.xsd#IncomeLossPerShare"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b735bb92-a96d-4e9b-8d94-ac4fd7673a55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_34e7192d-6bf3-405f-82d6-f264fb8478d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b735bb92-a96d-4e9b-8d94-ac4fd7673a55" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_34e7192d-6bf3-405f-82d6-f264fb8478d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="clbs-20230331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_86344385-3eb1-4385-ae96-8a792533f39e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_729809f9-f13e-4d65-be90-1ecbfe11c6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_86344385-3eb1-4385-ae96-8a792533f39e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_729809f9-f13e-4d65-be90-1ecbfe11c6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="clbs-20230331.xsd#AccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_46bf275b-4664-4c9a-9dd3-8308aa4790a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_a21cbafc-3873-47f3-adc9-47b74d502b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_46bf275b-4664-4c9a-9dd3-8308aa4790a9" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_a21cbafc-3873-47f3-adc9-47b74d502b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeases" xlink:type="simple" xlink:href="clbs-20230331.xsd#OperatingLeases"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_24613b0e-3107-41f5-96ed-7aac3c4a3d08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_fc58b326-612d-4d49-8e95-641c819b1825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_24613b0e-3107-41f5-96ed-7aac3c4a3d08" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_fc58b326-612d-4d49-8e95-641c819b1825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquity" xlink:type="simple" xlink:href="clbs-20230331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_fbd470ef-d5f0-4094-8f16-2f75aea0898b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4fca962f-118e-437c-8cc2-e137f7541375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fbd470ef-d5f0-4094-8f16-2f75aea0898b" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4fca962f-118e-437c-8cc2-e137f7541375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="clbs-20230331.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_21c111fa-11be-49d1-8bca-68ed2686cb14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c4529459-8731-4cd6-a21f-a0e107f90f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_21c111fa-11be-49d1-8bca-68ed2686cb14" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c4529459-8731-4cd6-a21f-a0e107f90f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxes" xlink:type="simple" xlink:href="clbs-20230331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a025c95a-dbd3-4f1d-bf36-ed7553e1dab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_258f08dc-fa70-4137-a936-96c73cb4fde0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a025c95a-dbd3-4f1d-bf36-ed7553e1dab3" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_258f08dc-fa70-4137-a936-96c73cb4fde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive" xlink:type="simple" xlink:href="clbs-20230331.xsd#AustraliaResearchandDevelopmentTaxIncentive"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2140000a-218e-4246-9992-229f733cd1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock_6f4c2a61-ff9c-4e76-abc7-0b31c048da78" xlink:href="clbs-20230331.xsd#clbs_ResearchAndDevelopmentTaxIncentiveTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2140000a-218e-4246-9992-229f733cd1d6" xlink:to="loc_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock_6f4c2a61-ff9c-4e76-abc7-0b31c048da78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/Contingencies" xlink:type="simple" xlink:href="clbs-20230331.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b6d40fec-ff0c-423e-b517-6faafbac7bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_20c14acd-0f6d-4d73-b7dd-121d4f4297d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b6d40fec-ff0c-423e-b517-6faafbac7bd2" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_20c14acd-0f6d-4d73-b7dd-121d4f4297d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/LicenseAgreements" xlink:type="simple" xlink:href="clbs-20230331.xsd#LicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/LicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6fe9f8d6-325c-41b2-87c6-82f7ffdb6488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4b72a55b-351d-4eb2-8220-62b75ba465d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6fe9f8d6-325c-41b2-87c6-82f7ffdb6488" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4b72a55b-351d-4eb2-8220-62b75ba465d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement" xlink:type="simple" xlink:href="clbs-20230331.xsd#ResearchCollaborationandLicenseAgreement"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd862ec6-2bfa-43af-add5-8706fe3bc417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_97dcb828-717b-4ac8-a651-e815f5142a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd862ec6-2bfa-43af-add5-8706fe3bc417" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_97dcb828-717b-4ac8-a651-e815f5142a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SubsequentEvents" xlink:type="simple" xlink:href="clbs-20230331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_79ee48f6-741c-4802-bfbf-eafa40d00642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_0e5b912b-3db0-45f8-b583-6dd4cee20434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_79ee48f6-741c-4802-bfbf-eafa40d00642" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_0e5b912b-3db0-45f8-b583-6dd4cee20434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="clbs-20230331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_204d6c9f-b450-44e9-87ab-190b9c53b1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6f54fa1c-000e-44fd-9706-0b38fa220729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_204d6c9f-b450-44e9-87ab-190b9c53b1c3" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6f54fa1c-000e-44fd-9706-0b38fa220729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_8d86c91f-e018-4d99-bec1-cc5cba131428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_204d6c9f-b450-44e9-87ab-190b9c53b1c3" xlink:to="loc_us-gaap_UseOfEstimates_8d86c91f-e018-4d99-bec1-cc5cba131428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_dd4fad50-fc78-452d-a6ee-640192124f14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_204d6c9f-b450-44e9-87ab-190b9c53b1c3" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_dd4fad50-fc78-452d-a6ee-640192124f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_936c5a54-40f8-4e98-b1b3-bc97c0203ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_204d6c9f-b450-44e9-87ab-190b9c53b1c3" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_936c5a54-40f8-4e98-b1b3-bc97c0203ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_5d583a84-afca-4b9d-88dc-b53598361d41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_204d6c9f-b450-44e9-87ab-190b9c53b1c3" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_5d583a84-afca-4b9d-88dc-b53598361d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7bca23cf-143e-48f3-ac4d-9796d5b0879f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_204d6c9f-b450-44e9-87ab-190b9c53b1c3" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7bca23cf-143e-48f3-ac4d-9796d5b0879f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8af610f5-da94-47d8-8267-92334aacac74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_204d6c9f-b450-44e9-87ab-190b9c53b1c3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8af610f5-da94-47d8-8267-92334aacac74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/MergerTables" xlink:type="simple" xlink:href="clbs-20230331.xsd#MergerTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/MergerTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAbstract_8ec529d1-d284-4d0b-97b4-769e2780c826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTableTextBlock_386eb793-3674-4ea7-a6d4-26851c210c76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAbstract_8ec529d1-d284-4d0b-97b4-769e2780c826" xlink:to="loc_us-gaap_AssetAcquisitionTableTextBlock_386eb793-3674-4ea7-a6d4-26851c210c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" xlink:type="simple" xlink:href="clbs-20230331.xsd#AvailableforSaleSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0d4dfd2c-2b2c-4fe8-a559-eb7a8ff5ac1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_b5181223-ca05-4af8-a09e-24f2014307a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0d4dfd2c-2b2c-4fe8-a559-eb7a8ff5ac1e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_b5181223-ca05-4af8-a09e-24f2014307a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_e726cd2c-1beb-4cc6-b254-b45643ea656b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0d4dfd2c-2b2c-4fe8-a559-eb7a8ff5ac1e" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_e726cd2c-1beb-4cc6-b254-b45643ea656b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_c945d19b-d2a1-43af-8af4-7fed901c821b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0d4dfd2c-2b2c-4fe8-a559-eb7a8ff5ac1e" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_c945d19b-d2a1-43af-8af4-7fed901c821b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="clbs-20230331.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ea4a6aa2-b174-4064-9416-d6a12f3ad1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_8744b17d-9439-4707-9162-86935ed25437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ea4a6aa2-b174-4064-9416-d6a12f3ad1a4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_8744b17d-9439-4707-9162-86935ed25437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareTables" xlink:type="simple" xlink:href="clbs-20230331.xsd#IncomeLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_270fa5e3-9697-4b38-8d9a-7eb5f7ab48e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b727dd20-75c4-4995-a7a0-a43f3b23de4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_270fa5e3-9697-4b38-8d9a-7eb5f7ab48e8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b727dd20-75c4-4995-a7a0-a43f3b23de4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="clbs-20230331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_535f04d1-0234-4f40-a24e-a88c8c53a0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_fed679ef-66d4-4623-9f0a-6ec9f96d558b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_535f04d1-0234-4f40-a24e-a88c8c53a0b0" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_fed679ef-66d4-4623-9f0a-6ec9f96d558b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="clbs-20230331.xsd#AccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_19123126-0a44-4f76-ab43-596ebeb9eda1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_34589530-445a-4a83-a043-6720a0cfbe10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_19123126-0a44-4f76-ab43-596ebeb9eda1" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_34589530-445a-4a83-a043-6720a0cfbe10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesTables" xlink:type="simple" xlink:href="clbs-20230331.xsd#OperatingLeasesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e7bb3352-0f3b-4e9e-a1a0-9c4cca928687" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_30a1e3df-3bd6-4a37-b7f8-81cb23f4dc8e" xlink:href="clbs-20230331.xsd#clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e7bb3352-0f3b-4e9e-a1a0-9c4cca928687" xlink:to="loc_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_30a1e3df-3bd6-4a37-b7f8-81cb23f4dc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ffcf4d7f-612c-4ce3-8a24-56156021d4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e7bb3352-0f3b-4e9e-a1a0-9c4cca928687" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ffcf4d7f-612c-4ce3-8a24-56156021d4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="clbs-20230331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_cb5b51f9-48e1-4194-b050-55c0bdc2dc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ae60f9a6-ba42-478f-8f58-1d6cd7bef50f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_cb5b51f9-48e1-4194-b050-55c0bdc2dc8e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ae60f9a6-ba42-478f-8f58-1d6cd7bef50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_6a8969b9-0cbe-419e-ab70-91b09f18e093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_cb5b51f9-48e1-4194-b050-55c0bdc2dc8e" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_6a8969b9-0cbe-419e-ab70-91b09f18e093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_ea2e53a7-8cfb-4171-a8bc-5bb06c3dbe31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_cb5b51f9-48e1-4194-b050-55c0bdc2dc8e" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_ea2e53a7-8cfb-4171-a8bc-5bb06c3dbe31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="clbs-20230331.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_9f7713e9-bf6f-4d24-9c9e-0f345ccfdb57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_cbc9ef79-bb6b-45aa-b791-abd3f582580c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_9f7713e9-bf6f-4d24-9c9e-0f345ccfdb57" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_cbc9ef79-bb6b-45aa-b791-abd3f582580c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_a5acf830-ce95-4257-979c-aedb025b680c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_9f7713e9-bf6f-4d24-9c9e-0f345ccfdb57" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_a5acf830-ce95-4257-979c-aedb025b680c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_06c54959-8de8-41b4-a4e6-a2243c9d1ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_9f7713e9-bf6f-4d24-9c9e-0f345ccfdb57" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_06c54959-8de8-41b4-a4e6-a2243c9d1ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TheBusinessDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#TheBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/TheBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_92f6c9bb-d3be-421a-9421-8797f4b662c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_72acc5d6-b410-46d7-aff7-90b4cad26678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_92f6c9bb-d3be-421a-9421-8797f4b662c7" xlink:to="loc_us-gaap_AssetAcquisitionTable_72acc5d6-b410-46d7-aff7-90b4cad26678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_06544062-a899-4679-945b-faf48d3bf960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_72acc5d6-b410-46d7-aff7-90b4cad26678" xlink:to="loc_us-gaap_AssetAcquisitionAxis_06544062-a899-4679-945b-faf48d3bf960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_55ba461b-f2ee-4e75-a69e-a0bd1b87b79c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_06544062-a899-4679-945b-faf48d3bf960" xlink:to="loc_us-gaap_AssetAcquisitionDomain_55ba461b-f2ee-4e75-a69e-a0bd1b87b79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CENDMember_01f17779-7dfa-4688-a734-273af38acea2" xlink:href="clbs-20230331.xsd#clbs_CENDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_55ba461b-f2ee-4e75-a69e-a0bd1b87b79c" xlink:to="loc_clbs_CENDMember_01f17779-7dfa-4688-a734-273af38acea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_d9650918-6f14-4bcc-a689-cbe59cbafd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_72acc5d6-b410-46d7-aff7-90b4cad26678" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_d9650918-6f14-4bcc-a689-cbe59cbafd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_65cfe5ee-beb7-4371-8958-1d2cca18bc41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_d9650918-6f14-4bcc-a689-cbe59cbafd7c" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_65cfe5ee-beb7-4371-8958-1d2cca18bc41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_93ca2ad6-1c7b-4c14-bcee-4e520c38e28f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_d9650918-6f14-4bcc-a689-cbe59cbafd7c" xlink:to="loc_us-gaap_SharesIssued_93ca2ad6-1c7b-4c14-bcee-4e520c38e28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_a585b942-166f-4cd8-a31e-aa109e7ac744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_d9650918-6f14-4bcc-a689-cbe59cbafd7c" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_a585b942-166f-4cd8-a31e-aa109e7ac744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_5a396dbc-a5dc-49b2-95eb-33b5fbc9a4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_d9650918-6f14-4bcc-a689-cbe59cbafd7c" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_5a396dbc-a5dc-49b2-95eb-33b5fbc9a4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_af1d7936-aff2-4e30-bb12-26b16570d6be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d0645ee3-65d1-48b6-9f4c-ef04e441677a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af1d7936-aff2-4e30-bb12-26b16570d6be" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d0645ee3-65d1-48b6-9f4c-ef04e441677a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0a2bd19d-b6f9-4c66-847e-8baa183df9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af1d7936-aff2-4e30-bb12-26b16570d6be" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0a2bd19d-b6f9-4c66-847e-8baa183df9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_96286ba8-881e-4a83-9733-9fcf043091a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af1d7936-aff2-4e30-bb12-26b16570d6be" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_96286ba8-881e-4a83-9733-9fcf043091a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b2082892-7f97-48d4-aad1-a49b02d359e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_96286ba8-881e-4a83-9733-9fcf043091a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b2082892-7f97-48d4-aad1-a49b02d359e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8497406-388d-4d95-84ac-d818497f29b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b2082892-7f97-48d4-aad1-a49b02d359e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8497406-388d-4d95-84ac-d818497f29b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_9e4bfe84-3435-41f9-81aa-0acfad5544ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8497406-388d-4d95-84ac-d818497f29b7" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_9e4bfe84-3435-41f9-81aa-0acfad5544ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_4a1c7d3d-5d5c-440a-969e-993b058bbc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8497406-388d-4d95-84ac-d818497f29b7" xlink:to="loc_us-gaap_ComputerEquipmentMember_4a1c7d3d-5d5c-440a-969e-993b058bbc6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_dab2e599-4d33-4641-b4b8-041517fa9e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8497406-388d-4d95-84ac-d818497f29b7" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_dab2e599-4d33-4641-b4b8-041517fa9e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_9d273726-6fb6-40f3-b599-45295f5e5bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8497406-388d-4d95-84ac-d818497f29b7" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_9d273726-6fb6-40f3-b599-45295f5e5bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76bbb704-c11c-407f-aba2-21800612aeac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_96286ba8-881e-4a83-9733-9fcf043091a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76bbb704-c11c-407f-aba2-21800612aeac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_938f7bc5-963c-4f23-a9ca-178149ec50cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76bbb704-c11c-407f-aba2-21800612aeac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_938f7bc5-963c-4f23-a9ca-178149ec50cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/MergerDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#MergerDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/MergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAbstract_e579b342-f791-4a59-8a4c-78bb84d57fca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_37f90050-f94d-4425-9c12-97600087eac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAbstract_e579b342-f791-4a59-8a4c-78bb84d57fca" xlink:to="loc_us-gaap_AssetAcquisitionTable_37f90050-f94d-4425-9c12-97600087eac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_0acf1ca9-11f1-46b1-80d7-a407fd8a8ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_37f90050-f94d-4425-9c12-97600087eac3" xlink:to="loc_us-gaap_AssetAcquisitionAxis_0acf1ca9-11f1-46b1-80d7-a407fd8a8ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_9178ccc7-639f-4279-b683-0498a9571b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_0acf1ca9-11f1-46b1-80d7-a407fd8a8ca7" xlink:to="loc_us-gaap_AssetAcquisitionDomain_9178ccc7-639f-4279-b683-0498a9571b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CENDMember_685e9736-5835-4e7b-9fa7-1805996189ff" xlink:href="clbs-20230331.xsd#clbs_CENDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_9178ccc7-639f-4279-b683-0498a9571b51" xlink:to="loc_clbs_CENDMember_685e9736-5835-4e7b-9fa7-1805996189ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_37f90050-f94d-4425-9c12-97600087eac3" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_04957421-942a-4520-9725-7fdaa35f0f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_04957421-942a-4520-9725-7fdaa35f0f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AssetAcquisitionSharePrice_0dcf5231-b7b4-4c21-88dc-6845a748ea15" xlink:href="clbs-20230331.xsd#clbs_AssetAcquisitionSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_clbs_AssetAcquisitionSharePrice_0dcf5231-b7b4-4c21-88dc-6845a748ea15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AssetAcquisitionConsiderationTransferredEquityValue_67589955-041a-4c73-9e64-39a3d43f188a" xlink:href="clbs-20230331.xsd#clbs_AssetAcquisitionConsiderationTransferredEquityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_clbs_AssetAcquisitionConsiderationTransferredEquityValue_67589955-041a-4c73-9e64-39a3d43f188a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_66f90d7e-9467-46ce-af33-7350f4dd26bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_66f90d7e-9467-46ce-af33-7350f4dd26bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_806cbdc4-1f5e-4f3e-8aea-fd2ec7a02e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_806cbdc4-1f5e-4f3e-8aea-fd2ec7a02e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_45f3c8b0-5050-4f0f-80f4-f6c3f5b85023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_45f3c8b0-5050-4f0f-80f4-f6c3f5b85023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_b3cb8ed8-e3ef-4746-821a-36b30364ad5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_b3cb8ed8-e3ef-4746-821a-36b30364ad5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AssetAcquisitionCashAndCashEquivalents_600c40e0-1a01-4c66-bcb4-c5c8cecdf237" xlink:href="clbs-20230331.xsd#clbs_AssetAcquisitionCashAndCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_clbs_AssetAcquisitionCashAndCashEquivalents_600c40e0-1a01-4c66-bcb4-c5c8cecdf237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AssetAcquisitionNetWorkingCapital_1e5ba66b-dcbc-4edb-922e-87f893082641" xlink:href="clbs-20230331.xsd#clbs_AssetAcquisitionNetWorkingCapital"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_clbs_AssetAcquisitionNetWorkingCapital_1e5ba66b-dcbc-4edb-922e-87f893082641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AssetAcquisitionOtherLiabilities_7226c27f-a949-40ad-b9df-58c40568c032" xlink:href="clbs-20230331.xsd#clbs_AssetAcquisitionOtherLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_clbs_AssetAcquisitionOtherLiabilities_7226c27f-a949-40ad-b9df-58c40568c032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AssetAcquisitionAcquiredInProcessResearchAndDevelopment_eb2f4ef0-8c07-42cd-8150-6823fb394895" xlink:href="clbs-20230331.xsd#clbs_AssetAcquisitionAcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_clbs_AssetAcquisitionAcquiredInProcessResearchAndDevelopment_eb2f4ef0-8c07-42cd-8150-6823fb394895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AssetAcquisitionIntangibles_1954d4e4-b574-4513-95c2-33af55846044" xlink:href="clbs-20230331.xsd#clbs_AssetAcquisitionIntangibles"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_59b150d1-23a1-4dd1-97ad-3e1d3c30259e" xlink:to="loc_clbs_AssetAcquisitionIntangibles_1954d4e4-b574-4513-95c2-33af55846044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_103bf2dc-2d46-4a28-86eb-511bf753fb32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5e461888-a7e9-4945-a3f0-55b05dce21de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_103bf2dc-2d46-4a28-86eb-511bf753fb32" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5e461888-a7e9-4945-a3f0-55b05dce21de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_db9a07d4-a20e-4298-ae5b-9559008bfc61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5e461888-a7e9-4945-a3f0-55b05dce21de" xlink:to="loc_us-gaap_FinancialInstrumentAxis_db9a07d4-a20e-4298-ae5b-9559008bfc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f6738de-4b8d-4ca8-91bc-c21556d5e822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_db9a07d4-a20e-4298-ae5b-9559008bfc61" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f6738de-4b8d-4ca8-91bc-c21556d5e822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c6225e3a-e878-4150-9d31-ec2c99cc4769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f6738de-4b8d-4ca8-91bc-c21556d5e822" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c6225e3a-e878-4150-9d31-ec2c99cc4769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_189682b5-4c92-4268-8811-fb73b0558ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f6738de-4b8d-4ca8-91bc-c21556d5e822" xlink:to="loc_us-gaap_CommercialPaperMember_189682b5-4c92-4268-8811-fb73b0558ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1855f183-58c5-432b-a577-b729ec3738ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f6738de-4b8d-4ca8-91bc-c21556d5e822" xlink:to="loc_us-gaap_MoneyMarketFundsMember_1855f183-58c5-432b-a577-b729ec3738ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_fd19499c-7026-4b24-9f88-d3177d5e3563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f6738de-4b8d-4ca8-91bc-c21556d5e822" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_fd19499c-7026-4b24-9f88-d3177d5e3563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fac7569b-5dbd-4c7c-80d8-ab858a93b1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5e461888-a7e9-4945-a3f0-55b05dce21de" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fac7569b-5dbd-4c7c-80d8-ab858a93b1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2fb18989-8c64-47da-aa48-4f6b0ce1d7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fac7569b-5dbd-4c7c-80d8-ab858a93b1d0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2fb18989-8c64-47da-aa48-4f6b0ce1d7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_084d317b-f260-48d1-af62-c39eed71e9df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fac7569b-5dbd-4c7c-80d8-ab858a93b1d0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_084d317b-f260-48d1-af62-c39eed71e9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_363fb3e6-4739-4d4d-bb09-7f1e9cea015c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fac7569b-5dbd-4c7c-80d8-ab858a93b1d0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_363fb3e6-4739-4d4d-bb09-7f1e9cea015c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0f8b682e-ab3e-4c08-8886-8990dabd91bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fac7569b-5dbd-4c7c-80d8-ab858a93b1d0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0f8b682e-ab3e-4c08-8886-8990dabd91bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2a8143b9-723f-48d7-970e-715ed2899696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_238125a8-1aa8-4b90-9886-64d5612d48cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2a8143b9-723f-48d7-970e-715ed2899696" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_238125a8-1aa8-4b90-9886-64d5612d48cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_96717548-69ae-4792-be8a-a400452e0125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2a8143b9-723f-48d7-970e-715ed2899696" xlink:to="loc_us-gaap_MarketableSecurities_96717548-69ae-4792-be8a-a400452e0125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_1d9fa046-10e6-46b9-8649-87564347cedb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2a8143b9-723f-48d7-970e-715ed2899696" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_1d9fa046-10e6-46b9-8649-87564347cedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_155911ee-c211-4978-8808-85f6a86f9b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_ad440fb1-fdab-4e45-9714-93abc6bbea41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_155911ee-c211-4978-8808-85f6a86f9b59" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_ad440fb1-fdab-4e45-9714-93abc6bbea41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_034ccf9b-a61b-4528-8456-8210f3c389fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_ad440fb1-fdab-4e45-9714-93abc6bbea41" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_034ccf9b-a61b-4528-8456-8210f3c389fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_9514a206-559c-4d4c-a50a-ebea4b7fde8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_ad440fb1-fdab-4e45-9714-93abc6bbea41" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_9514a206-559c-4d4c-a50a-ebea4b7fde8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ca94d5e4-f7f1-4d35-b1b4-63912f143d33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_ad440fb1-fdab-4e45-9714-93abc6bbea41" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ca94d5e4-f7f1-4d35-b1b4-63912f143d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_097e5620-eae3-4758-b899-d8bf8ed94fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_155911ee-c211-4978-8808-85f6a86f9b59" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_097e5620-eae3-4758-b899-d8bf8ed94fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_b922b8ca-0673-4152-b3ae-c55e8c647173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_097e5620-eae3-4758-b899-d8bf8ed94fa4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_b922b8ca-0673-4152-b3ae-c55e8c647173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_ed2a0046-e8b7-41ab-9fed-d494d198a442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_097e5620-eae3-4758-b899-d8bf8ed94fa4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_ed2a0046-e8b7-41ab-9fed-d494d198a442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_22447d04-e725-4390-bc9a-10e30825453a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_097e5620-eae3-4758-b899-d8bf8ed94fa4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_22447d04-e725-4390-bc9a-10e30825453a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_eaecf92e-3787-4af2-bab5-ffd1332e7e90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b1646de8-2ee4-4628-b62a-09978ca4774f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_eaecf92e-3787-4af2-bab5-ffd1332e7e90" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b1646de8-2ee4-4628-b62a-09978ca4774f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_10e1e6ca-dcd9-4a85-98b4-7edffd384c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b1646de8-2ee4-4628-b62a-09978ca4774f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_10e1e6ca-dcd9-4a85-98b4-7edffd384c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ec2bc5d-0a49-47dc-953f-77c38b10dc93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_10e1e6ca-dcd9-4a85-98b4-7edffd384c1b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ec2bc5d-0a49-47dc-953f-77c38b10dc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_257eb789-17d9-483c-b0e5-ca11c63a120e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ec2bc5d-0a49-47dc-953f-77c38b10dc93" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_257eb789-17d9-483c-b0e5-ca11c63a120e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_ef6049ef-fc7f-4e25-8b16-a84ded6ad530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ec2bc5d-0a49-47dc-953f-77c38b10dc93" xlink:to="loc_us-gaap_ComputerEquipmentMember_ef6049ef-fc7f-4e25-8b16-a84ded6ad530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_46fa8ce5-1e6b-41e4-b04a-6188e6b9089f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ec2bc5d-0a49-47dc-953f-77c38b10dc93" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_46fa8ce5-1e6b-41e4-b04a-6188e6b9089f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b420eda9-33d5-4ace-8375-ce18fa60fc89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b1646de8-2ee4-4628-b62a-09978ca4774f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b420eda9-33d5-4ace-8375-ce18fa60fc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_baff7ca8-d024-44e0-b561-d0f852402a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b420eda9-33d5-4ace-8375-ce18fa60fc89" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_baff7ca8-d024-44e0-b561-d0f852402a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2fe32ef6-8490-484e-8471-dec8a6cf9e51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b420eda9-33d5-4ace-8375-ce18fa60fc89" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2fe32ef6-8490-484e-8471-dec8a6cf9e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1ae27bc9-7cf7-41c3-8e68-12b9c601725f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b420eda9-33d5-4ace-8375-ce18fa60fc89" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1ae27bc9-7cf7-41c3-8e68-12b9c601725f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_28c7a76e-a1bd-45fe-bc2e-133b378b9ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b420eda9-33d5-4ace-8375-ce18fa60fc89" xlink:to="loc_us-gaap_Depreciation_28c7a76e-a1bd-45fe-bc2e-133b378b9ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#IncomeLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2841db49-0838-4002-bfed-e1fcfaedffaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_032f296e-f2f8-4c63-b38f-2465f556beca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2841db49-0838-4002-bfed-e1fcfaedffaf" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_032f296e-f2f8-4c63-b38f-2465f556beca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_62dd8df0-9284-4357-8ca9-4f5f5149a28b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_032f296e-f2f8-4c63-b38f-2465f556beca" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_62dd8df0-9284-4357-8ca9-4f5f5149a28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4adf764f-504f-4fc5-bef6-c4cd39c15ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_62dd8df0-9284-4357-8ca9-4f5f5149a28b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4adf764f-504f-4fc5-bef6-c4cd39c15ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9563f178-389c-4ce4-a2db-4659e9e7f56f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4adf764f-504f-4fc5-bef6-c4cd39c15ee8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9563f178-389c-4ce4-a2db-4659e9e7f56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_e033bc4f-97e4-4213-9f9a-c055dde0cf30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4adf764f-504f-4fc5-bef6-c4cd39c15ee8" xlink:to="loc_us-gaap_WarrantMember_e033bc4f-97e4-4213-9f9a-c055dde0cf30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d4715eaa-732b-40f6-b838-5abdf8c9454c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4adf764f-504f-4fc5-bef6-c4cd39c15ee8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d4715eaa-732b-40f6-b838-5abdf8c9454c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_459a1f88-78ba-4fbd-88a4-cec51f8f3bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_032f296e-f2f8-4c63-b38f-2465f556beca" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_459a1f88-78ba-4fbd-88a4-cec51f8f3bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e224b331-f634-4fdd-8b97-d55bfce21e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_459a1f88-78ba-4fbd-88a4-cec51f8f3bf8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e224b331-f634-4fdd-8b97-d55bfce21e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_38ec3b9f-d29a-4c15-9723-a770f8e64a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e851d9e-412c-4325-8a6a-58d08cdd39a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_38ec3b9f-d29a-4c15-9723-a770f8e64a0b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e851d9e-412c-4325-8a6a-58d08cdd39a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54decc13-3e8f-4163-a3e7-b6c9fcb17780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e851d9e-412c-4325-8a6a-58d08cdd39a1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54decc13-3e8f-4163-a3e7-b6c9fcb17780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e09726ea-2839-4ddb-9b1a-54a9e57a36b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54decc13-3e8f-4163-a3e7-b6c9fcb17780" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e09726ea-2839-4ddb-9b1a-54a9e57a36b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c5b93146-4ca1-498e-90fd-08a194db3d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e09726ea-2839-4ddb-9b1a-54a9e57a36b9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c5b93146-4ca1-498e-90fd-08a194db3d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_56218e61-a33a-40f7-afa6-6a4350158768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e09726ea-2839-4ddb-9b1a-54a9e57a36b9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_56218e61-a33a-40f7-afa6-6a4350158768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_54380989-ec0d-4043-94f6-5059bbf39d66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e09726ea-2839-4ddb-9b1a-54a9e57a36b9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_54380989-ec0d-4043-94f6-5059bbf39d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_648ece86-408a-4969-8127-7e89298162b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e851d9e-412c-4325-8a6a-58d08cdd39a1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_648ece86-408a-4969-8127-7e89298162b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_afeb8b0b-8780-4a8d-9f70-af7c200974b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_648ece86-408a-4969-8127-7e89298162b0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_afeb8b0b-8780-4a8d-9f70-af7c200974b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_87b9c260-6735-4423-8a94-53a43ce5ec5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_afeb8b0b-8780-4a8d-9f70-af7c200974b7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_87b9c260-6735-4423-8a94-53a43ce5ec5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c989521a-0eca-4973-a5ad-25a9bab37181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e851d9e-412c-4325-8a6a-58d08cdd39a1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c989521a-0eca-4973-a5ad-25a9bab37181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_cc98eec2-040a-4edc-a3b5-e5f5c6ecfe54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c989521a-0eca-4973-a5ad-25a9bab37181" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_cc98eec2-040a-4edc-a3b5-e5f5c6ecfe54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2f11e8c0-1a3a-4093-afea-c83adeaa8e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c989521a-0eca-4973-a5ad-25a9bab37181" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2f11e8c0-1a3a-4093-afea-c83adeaa8e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#AccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_1fdd6840-eba8-4c93-8e06-3a240fb23ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_72c7ccbc-1214-48d0-b8eb-9ba98c208bea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_1fdd6840-eba8-4c93-8e06-3a240fb23ca5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_72c7ccbc-1214-48d0-b8eb-9ba98c208bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e5768d82-e583-4999-b3d9-9dcd6897cc51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_1fdd6840-eba8-4c93-8e06-3a240fb23ca5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e5768d82-e583-4999-b3d9-9dcd6897cc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AccruedGrantFunding_17721f2d-0e03-4b2b-89c9-44097e072bf0" xlink:href="clbs-20230331.xsd#clbs_AccruedGrantFunding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_1fdd6840-eba8-4c93-8e06-3a240fb23ca5" xlink:to="loc_clbs_AccruedGrantFunding_17721f2d-0e03-4b2b-89c9-44097e072bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ClinicalAndRDRelatedLiabilities_53395426-70c5-44b3-9e57-de3d15a1c47a" xlink:href="clbs-20230331.xsd#clbs_ClinicalAndRDRelatedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_1fdd6840-eba8-4c93-8e06-3a240fb23ca5" xlink:to="loc_clbs_ClinicalAndRDRelatedLiabilities_53395426-70c5-44b3-9e57-de3d15a1c47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_dc59eb7f-2a87-4b16-a916-810a1ea5681d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_1fdd6840-eba8-4c93-8e06-3a240fb23ca5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_dc59eb7f-2a87-4b16-a916-810a1ea5681d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_800bc452-61a1-4fc5-baab-392b1bc56c57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_1fdd6840-eba8-4c93-8e06-3a240fb23ca5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_800bc452-61a1-4fc5-baab-392b1bc56c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#OperatingLeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_19892192-7577-4380-8f35-0fed43bfd821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_NumberOfOfficesUnderOperatingLeases_728d89e6-48ac-4f0f-906f-2ed2922c9064" xlink:href="clbs-20230331.xsd#clbs_NumberOfOfficesUnderOperatingLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19892192-7577-4380-8f35-0fed43bfd821" xlink:to="loc_clbs_NumberOfOfficesUnderOperatingLeases_728d89e6-48ac-4f0f-906f-2ed2922c9064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_dcaf99fe-1c9d-4e34-b769-d303c686de9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19892192-7577-4380-8f35-0fed43bfd821" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_dcaf99fe-1c9d-4e34-b769-d303c686de9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d7e21112-560d-4f9a-b207-652464389999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19892192-7577-4380-8f35-0fed43bfd821" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d7e21112-560d-4f9a-b207-652464389999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#OperatingLeasesBalanceSheetPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c40e7267-14d7-4fa7-b8ef-c19f7c1f33fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLeaseRightOfUseAssetAbstract_009ee934-ef9b-4c74-9420-e5c15207044f" xlink:href="clbs-20230331.xsd#clbs_OperatingLeaseRightOfUseAssetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c40e7267-14d7-4fa7-b8ef-c19f7c1f33fe" xlink:to="loc_clbs_OperatingLeaseRightOfUseAssetAbstract_009ee934-ef9b-4c74-9420-e5c15207044f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8ab68228-68ed-4958-827c-101a8e53fe8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_OperatingLeaseRightOfUseAssetAbstract_009ee934-ef9b-4c74-9420-e5c15207044f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8ab68228-68ed-4958-827c-101a8e53fe8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_9ab7e382-40d7-4566-8436-3d70f5c68129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_OperatingLeaseRightOfUseAssetAbstract_009ee934-ef9b-4c74-9420-e5c15207044f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_9ab7e382-40d7-4566-8436-3d70f5c68129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_d2191336-8c68-4aa7-8f46-d6aa4d32606d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c40e7267-14d7-4fa7-b8ef-c19f7c1f33fe" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_d2191336-8c68-4aa7-8f46-d6aa4d32606d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ad521ce0-c4f1-4b8d-ab1e-bdb8105ed1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_d2191336-8c68-4aa7-8f46-d6aa4d32606d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ad521ce0-c4f1-4b8d-ab1e-bdb8105ed1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b3fb7927-7e34-4ac1-9885-19b754dceb66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_d2191336-8c68-4aa7-8f46-d6aa4d32606d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b3fb7927-7e34-4ac1-9885-19b754dceb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a04a5cbc-98b1-4989-b92d-33726f3b1c78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_d2191336-8c68-4aa7-8f46-d6aa4d32606d" xlink:to="loc_us-gaap_OperatingLeaseLiability_a04a5cbc-98b1-4989-b92d-33726f3b1c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_42b0e075-efba-4406-8ac1-7a6c18002ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_d2191336-8c68-4aa7-8f46-d6aa4d32606d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_42b0e075-efba-4406-8ac1-7a6c18002ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_b608944e-55c6-4272-a0ad-4af806cb6c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_d2191336-8c68-4aa7-8f46-d6aa4d32606d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_b608944e-55c6-4272-a0ad-4af806cb6c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_db571b02-0790-4312-93ba-d4bd613d200b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_91a542ed-5236-46ec-a26f-78ea6eab16fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_db571b02-0790-4312-93ba-d4bd613d200b" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_91a542ed-5236-46ec-a26f-78ea6eab16fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4a3c3b49-61f3-43a7-879f-23905ba2ff7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_91a542ed-5236-46ec-a26f-78ea6eab16fb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4a3c3b49-61f3-43a7-879f-23905ba2ff7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ca6c6523-c150-4a9e-9a56-cfb8b970f7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_91a542ed-5236-46ec-a26f-78ea6eab16fb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ca6c6523-c150-4a9e-9a56-cfb8b970f7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9aad0b11-86f1-4efa-9551-9bacdecfd539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_91a542ed-5236-46ec-a26f-78ea6eab16fb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9aad0b11-86f1-4efa-9551-9bacdecfd539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_43370611-6232-4126-8928-3d66ccc51c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_91a542ed-5236-46ec-a26f-78ea6eab16fb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_43370611-6232-4126-8928-3d66ccc51c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_67877091-461c-4678-ab78-6497901ab36c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_91a542ed-5236-46ec-a26f-78ea6eab16fb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_67877091-461c-4678-ab78-6497901ab36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_93912132-9968-480a-97a3-d72249fc236b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_91a542ed-5236-46ec-a26f-78ea6eab16fb" xlink:to="loc_us-gaap_OperatingLeaseLiability_93912132-9968-480a-97a3-d72249fc236b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="clbs-20230331.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#StockholdersEquityEquityIssuancesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_029f6e01-f0f8-4f44-bb94-500168770dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f7590dca-5825-4fac-8ed3-535c34a9dccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_029f6e01-f0f8-4f44-bb94-500168770dc6" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f7590dca-5825-4fac-8ed3-535c34a9dccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a8d06d34-0fdc-4905-8828-63dc243d5876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f7590dca-5825-4fac-8ed3-535c34a9dccc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a8d06d34-0fdc-4905-8828-63dc243d5876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ec494b31-bcd2-4ac6-bfbc-dff443487d35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a8d06d34-0fdc-4905-8828-63dc243d5876" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ec494b31-bcd2-4ac6-bfbc-dff443487d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AtTheMarketOfferingAgreementMember_491e1314-f9e3-4baf-bf46-2a0b52b87215" xlink:href="clbs-20230331.xsd#clbs_AtTheMarketOfferingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ec494b31-bcd2-4ac6-bfbc-dff443487d35" xlink:to="loc_clbs_AtTheMarketOfferingAgreementMember_491e1314-f9e3-4baf-bf46-2a0b52b87215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_e4e27229-ec86-42cb-8e4b-2efbe13da0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f7590dca-5825-4fac-8ed3-535c34a9dccc" xlink:to="loc_us-gaap_AssetAcquisitionAxis_e4e27229-ec86-42cb-8e4b-2efbe13da0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_640c4c0b-a380-4535-9ec8-c3e6dfada278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_e4e27229-ec86-42cb-8e4b-2efbe13da0f0" xlink:to="loc_us-gaap_AssetAcquisitionDomain_640c4c0b-a380-4535-9ec8-c3e6dfada278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CENDMember_886ae39d-835c-4866-927d-f5a8771f9165" xlink:href="clbs-20230331.xsd#clbs_CENDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_640c4c0b-a380-4535-9ec8-c3e6dfada278" xlink:to="loc_clbs_CENDMember_886ae39d-835c-4866-927d-f5a8771f9165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7913e9aa-41e0-4c85-bc1b-5a542b1ac46b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f7590dca-5825-4fac-8ed3-535c34a9dccc" xlink:to="loc_us-gaap_ClassOfStockLineItems_7913e9aa-41e0-4c85-bc1b-5a542b1ac46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_058bce0c-a61d-43f3-9f52-d1968139e8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7913e9aa-41e0-4c85-bc1b-5a542b1ac46b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_058bce0c-a61d-43f3-9f52-d1968139e8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_c88a32a4-0c42-4730-afc1-d17d6a759639" xlink:href="clbs-20230331.xsd#clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7913e9aa-41e0-4c85-bc1b-5a542b1ac46b" xlink:to="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_c88a32a4-0c42-4730-afc1-d17d6a759639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_dddc76ca-177a-4cec-b7e1-f22ea4ce5717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7913e9aa-41e0-4c85-bc1b-5a542b1ac46b" xlink:to="loc_us-gaap_CommonStockValueOutstanding_dddc76ca-177a-4cec-b7e1-f22ea4ce5717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAvailableForSale_d80bdac9-cea1-4386-abb1-5aea8bd3cb06" xlink:href="clbs-20230331.xsd#clbs_SaleOfStockAvailableForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7913e9aa-41e0-4c85-bc1b-5a542b1ac46b" xlink:to="loc_clbs_SaleOfStockAvailableForSale_d80bdac9-cea1-4386-abb1-5aea8bd3cb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_875ac15e-2b89-4fbb-b0ad-ce8a6a38a1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7913e9aa-41e0-4c85-bc1b-5a542b1ac46b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_875ac15e-2b89-4fbb-b0ad-ce8a6a38a1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#StockholdersEquityStockOptionsandWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c4483cae-aac2-4b13-b8bb-ae3329121ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_235453b7-b538-470c-9c5d-6cea621e9c53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c4483cae-aac2-4b13-b8bb-ae3329121ad3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_235453b7-b538-470c-9c5d-6cea621e9c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85362a9e-2b0b-4599-86a3-19b84973b445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_235453b7-b538-470c-9c5d-6cea621e9c53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85362a9e-2b0b-4599-86a3-19b84973b445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4441e35f-ea04-41d7-b27d-491460009330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85362a9e-2b0b-4599-86a3-19b84973b445" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4441e35f-ea04-41d7-b27d-491460009330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_31ee1041-a1df-4b0c-bd50-2d683e458bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85362a9e-2b0b-4599-86a3-19b84973b445" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_31ee1041-a1df-4b0c-bd50-2d683e458bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_edc0e5b2-7a7f-44dc-b088-78e1959fe0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85362a9e-2b0b-4599-86a3-19b84973b445" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_edc0e5b2-7a7f-44dc-b088-78e1959fe0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2426129d-afa1-427b-aa0a-7414ec10188b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85362a9e-2b0b-4599-86a3-19b84973b445" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2426129d-afa1-427b-aa0a-7414ec10188b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2a35f63f-aa9c-42b6-945e-d98deb8cb441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85362a9e-2b0b-4599-86a3-19b84973b445" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2a35f63f-aa9c-42b6-945e-d98deb8cb441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_23d5ac65-0628-4a73-923f-368233d2b733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85362a9e-2b0b-4599-86a3-19b84973b445" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_23d5ac65-0628-4a73-923f-368233d2b733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_51a92267-e9ce-4700-886a-b27493987e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_235453b7-b538-470c-9c5d-6cea621e9c53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_51a92267-e9ce-4700-886a-b27493987e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_065d1938-367a-4a65-8d78-64ca1bc1fcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_235453b7-b538-470c-9c5d-6cea621e9c53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_065d1938-367a-4a65-8d78-64ca1bc1fcf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4a87ad71-3bdb-4a49-89c2-35d9efe9a681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_235453b7-b538-470c-9c5d-6cea621e9c53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4a87ad71-3bdb-4a49-89c2-35d9efe9a681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dea22c18-161f-4966-b699-2336cbd96032" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4a87ad71-3bdb-4a49-89c2-35d9efe9a681" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dea22c18-161f-4966-b699-2336cbd96032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c2430bf5-1b4b-4a8e-89d6-029c06ce4938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4a87ad71-3bdb-4a49-89c2-35d9efe9a681" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c2430bf5-1b4b-4a8e-89d6-029c06ce4938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2ac0e52f-4ecb-4f35-a41d-d737b27a81ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4a87ad71-3bdb-4a49-89c2-35d9efe9a681" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2ac0e52f-4ecb-4f35-a41d-d737b27a81ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c99d02fc-9a5d-40d2-a22d-b1c65007442b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4a87ad71-3bdb-4a49-89c2-35d9efe9a681" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c99d02fc-9a5d-40d2-a22d-b1c65007442b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_90f89edd-c119-423a-96ef-f865ddc1a819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4a87ad71-3bdb-4a49-89c2-35d9efe9a681" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_90f89edd-c119-423a-96ef-f865ddc1a819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_589532a1-fd58-4a28-9f1d-e80a0479aae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4a87ad71-3bdb-4a49-89c2-35d9efe9a681" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_589532a1-fd58-4a28-9f1d-e80a0479aae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_514af708-0f69-4c67-9fd9-e49962801827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_235453b7-b538-470c-9c5d-6cea621e9c53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_514af708-0f69-4c67-9fd9-e49962801827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_45c30fdb-ca6d-4782-8cda-2a97f989f906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_235453b7-b538-470c-9c5d-6cea621e9c53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_45c30fdb-ca6d-4782-8cda-2a97f989f906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5fdf0dcb-e5ec-4c32-b5d5-d36f4d164a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_235453b7-b538-470c-9c5d-6cea621e9c53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5fdf0dcb-e5ec-4c32-b5d5-d36f4d164a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_52df7afd-34cc-4866-946c-05984106829d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5fdf0dcb-e5ec-4c32-b5d5-d36f4d164a1c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_52df7afd-34cc-4866-946c-05984106829d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a078a404-b3ad-4488-8ce6-468df21e3900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5fdf0dcb-e5ec-4c32-b5d5-d36f4d164a1c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a078a404-b3ad-4488-8ce6-468df21e3900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OptionsVestedweightedAverageRemainingContractualTerm_aa184e95-ddea-45a8-abdf-0a14d6f0782a" xlink:href="clbs-20230331.xsd#clbs_OptionsVestedweightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5fdf0dcb-e5ec-4c32-b5d5-d36f4d164a1c" xlink:to="loc_clbs_OptionsVestedweightedAverageRemainingContractualTerm_aa184e95-ddea-45a8-abdf-0a14d6f0782a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_367b520d-6154-4b68-95c5-353f063f0283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5fdf0dcb-e5ec-4c32-b5d5-d36f4d164a1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_367b520d-6154-4b68-95c5-353f063f0283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6780e40f-e07b-4921-8957-d40b33ce9238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5fdf0dcb-e5ec-4c32-b5d5-d36f4d164a1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6780e40f-e07b-4921-8957-d40b33ce9238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_88581d39-4aea-44df-9486-187d0382f1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5fdf0dcb-e5ec-4c32-b5d5-d36f4d164a1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_88581d39-4aea-44df-9486-187d0382f1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_c74903e3-86c6-46ec-8394-dc7a0510b66c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c4483cae-aac2-4b13-b8bb-ae3329121ad3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_c74903e3-86c6-46ec-8394-dc7a0510b66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ec4413e1-7f08-481a-8b33-3f2f824a1d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_c74903e3-86c6-46ec-8394-dc7a0510b66c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ec4413e1-7f08-481a-8b33-3f2f824a1d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CommonStockWarrantsShares_cfa370e6-6ec1-447e-830c-1833d78b5c98" xlink:href="clbs-20230331.xsd#clbs_CommonStockWarrantsShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ec4413e1-7f08-481a-8b33-3f2f824a1d4c" xlink:to="loc_clbs_CommonStockWarrantsShares_cfa370e6-6ec1-447e-830c-1833d78b5c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsGranted_76901373-f8c7-4c3a-83b1-e0b36ad75d1c" xlink:href="clbs-20230331.xsd#clbs_WarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ec4413e1-7f08-481a-8b33-3f2f824a1d4c" xlink:to="loc_clbs_WarrantsGranted_76901373-f8c7-4c3a-83b1-e0b36ad75d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsExercised_3b2017f3-37ef-453d-babf-cb27e92aa688" xlink:href="clbs-20230331.xsd#clbs_WarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ec4413e1-7f08-481a-8b33-3f2f824a1d4c" xlink:to="loc_clbs_WarrantsExercised_3b2017f3-37ef-453d-babf-cb27e92aa688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsCanceled_94fd4551-0c89-4065-a9f5-345d50375629" xlink:href="clbs-20230331.xsd#clbs_WarrantsCanceled"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ec4413e1-7f08-481a-8b33-3f2f824a1d4c" xlink:to="loc_clbs_WarrantsCanceled_94fd4551-0c89-4065-a9f5-345d50375629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsExpired_ef721dd5-84f0-4b4d-8867-364c1aa364e1" xlink:href="clbs-20230331.xsd#clbs_WarrantsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ec4413e1-7f08-481a-8b33-3f2f824a1d4c" xlink:to="loc_clbs_WarrantsExpired_ef721dd5-84f0-4b4d-8867-364c1aa364e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CommonStockWarrantsShares_22e84564-88c2-412d-8a7f-2c03930c999b" xlink:href="clbs-20230331.xsd#clbs_CommonStockWarrantsShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ec4413e1-7f08-481a-8b33-3f2f824a1d4c" xlink:to="loc_clbs_CommonStockWarrantsShares_22e84564-88c2-412d-8a7f-2c03930c999b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_Sharesvestedandexpectedtovest_57a742df-5f67-4112-b0f9-7632f5237a7c" xlink:href="clbs-20230331.xsd#clbs_Sharesvestedandexpectedtovest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_c74903e3-86c6-46ec-8394-dc7a0510b66c" xlink:to="loc_clbs_Sharesvestedandexpectedtovest_57a742df-5f67-4112-b0f9-7632f5237a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsVested_d732ad71-262a-4bd1-af66-e7bd2f70ab83" xlink:href="clbs-20230331.xsd#clbs_WarrantsVested"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_c74903e3-86c6-46ec-8394-dc7a0510b66c" xlink:to="loc_clbs_WarrantsVested_d732ad71-262a-4bd1-af66-e7bd2f70ab83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_f9a2c3a4-08cf-482c-87b6-5635aaf578ba" xlink:href="clbs-20230331.xsd#clbs_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_c74903e3-86c6-46ec-8394-dc7a0510b66c" xlink:to="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_f9a2c3a4-08cf-482c-87b6-5635aaf578ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_8bc8a89a-2f6b-4b49-b457-2775df535cc7" xlink:href="clbs-20230331.xsd#clbs_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_f9a2c3a4-08cf-482c-87b6-5635aaf578ba" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_8bc8a89a-2f6b-4b49-b457-2775df535cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsGranted_049d5cda-c1a7-43b7-a52d-aec5b2dff2ae" xlink:href="clbs-20230331.xsd#clbs_WeightedAverageExercisePriceWarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_f9a2c3a4-08cf-482c-87b6-5635aaf578ba" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsGranted_049d5cda-c1a7-43b7-a52d-aec5b2dff2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExercised_ffb7c604-ec97-4128-9cb1-8e5a262ce3e4" xlink:href="clbs-20230331.xsd#clbs_WeightedAverageExercisePriceWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_f9a2c3a4-08cf-482c-87b6-5635aaf578ba" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsExercised_ffb7c604-ec97-4128-9cb1-8e5a262ce3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsCanceled_ba2bbcff-396f-4c31-982b-492d136d8651" xlink:href="clbs-20230331.xsd#clbs_WeightedAverageExercisePriceWarrantsCanceled"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_f9a2c3a4-08cf-482c-87b6-5635aaf578ba" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsCanceled_ba2bbcff-396f-4c31-982b-492d136d8651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExpired_047385d9-00bd-4a8a-8150-4dd793909c68" xlink:href="clbs-20230331.xsd#clbs_WeightedAverageExercisePriceWarrantsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_f9a2c3a4-08cf-482c-87b6-5635aaf578ba" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsExpired_047385d9-00bd-4a8a-8150-4dd793909c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_b9d65073-61b1-4412-aad3-639c4983c47d" xlink:href="clbs-20230331.xsd#clbs_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_f9a2c3a4-08cf-482c-87b6-5635aaf578ba" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_b9d65073-61b1-4412-aad3-639c4983c47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_cabb1fa4-664f-4150-83da-950f6fe5bfa5" xlink:href="clbs-20230331.xsd#clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_c74903e3-86c6-46ec-8394-dc7a0510b66c" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_cabb1fa4-664f-4150-83da-950f6fe5bfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExercisable_1781dbbd-4f27-45a5-8e7a-dc9b60a3faf6" xlink:href="clbs-20230331.xsd#clbs_WeightedAverageExercisePriceWarrantsExercisable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_c74903e3-86c6-46ec-8394-dc7a0510b66c" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsExercisable_1781dbbd-4f27-45a5-8e7a-dc9b60a3faf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsOtherDisclosuresAbstract_2c33e2e0-212d-481e-bb82-b7501dfcc9ab" xlink:href="clbs-20230331.xsd#clbs_WarrantsOtherDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_c74903e3-86c6-46ec-8394-dc7a0510b66c" xlink:to="loc_clbs_WarrantsOtherDisclosuresAbstract_2c33e2e0-212d-481e-bb82-b7501dfcc9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_77fd517a-7f6b-438c-9124-30e0c63ab939" xlink:href="clbs-20230331.xsd#clbs_WeightedAverageRemainingContractualTermwarrantoutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_2c33e2e0-212d-481e-bb82-b7501dfcc9ab" xlink:to="loc_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_77fd517a-7f6b-438c-9124-30e0c63ab939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_4136a7d4-c8b7-418e-9675-2d84b041a622" xlink:href="clbs-20230331.xsd#clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_2c33e2e0-212d-481e-bb82-b7501dfcc9ab" xlink:to="loc_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_4136a7d4-c8b7-418e-9675-2d84b041a622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermwarrantsvested_d2b00d10-87dc-48fd-8e2f-3984ad110ae0" xlink:href="clbs-20230331.xsd#clbs_WeightedAverageRemainingContractualTermwarrantsvested"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_2c33e2e0-212d-481e-bb82-b7501dfcc9ab" xlink:to="loc_clbs_WeightedAverageRemainingContractualTermwarrantsvested_d2b00d10-87dc-48fd-8e2f-3984ad110ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsOutstanding_7a3b834f-7e6e-4e6a-86a5-78d053f2688b" xlink:href="clbs-20230331.xsd#clbs_AggregateIntrinsicValueWarrantsOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_2c33e2e0-212d-481e-bb82-b7501dfcc9ab" xlink:to="loc_clbs_AggregateIntrinsicValueWarrantsOutstanding_7a3b834f-7e6e-4e6a-86a5-78d053f2688b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_4c5c4c25-ab6b-42b6-9b1b-6dc288728c6a" xlink:href="clbs-20230331.xsd#clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_2c33e2e0-212d-481e-bb82-b7501dfcc9ab" xlink:to="loc_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_4c5c4c25-ab6b-42b6-9b1b-6dc288728c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsvested_d3c7ba98-03a7-4bc0-80ee-f3f5e70a52be" xlink:href="clbs-20230331.xsd#clbs_AggregateIntrinsicValueWarrantsvested"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_2c33e2e0-212d-481e-bb82-b7501dfcc9ab" xlink:to="loc_clbs_AggregateIntrinsicValueWarrantsvested_d3c7ba98-03a7-4bc0-80ee-f3f5e70a52be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d78c3edb-dea5-40f2-97d7-4076f42d8b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5004e1f3-60cb-4947-9d45-46417990ce8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d78c3edb-dea5-40f2-97d7-4076f42d8b3c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5004e1f3-60cb-4947-9d45-46417990ce8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2b4f629c-5c90-481d-9d3a-e9a950c4edaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5004e1f3-60cb-4947-9d45-46417990ce8d" xlink:to="loc_us-gaap_AwardTypeAxis_2b4f629c-5c90-481d-9d3a-e9a950c4edaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_965ef6c8-ff41-4f97-aaa7-e254b15806fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2b4f629c-5c90-481d-9d3a-e9a950c4edaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_965ef6c8-ff41-4f97-aaa7-e254b15806fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_4bb1652f-b983-4f8a-8e44-66a2f6239021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_965ef6c8-ff41-4f97-aaa7-e254b15806fe" xlink:to="loc_us-gaap_RestrictedStockMember_4bb1652f-b983-4f8a-8e44-66a2f6239021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_74af2460-bb44-4870-a765-672a73d6557a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_965ef6c8-ff41-4f97-aaa7-e254b15806fe" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_74af2460-bb44-4870-a765-672a73d6557a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1a3441f6-33f3-4a64-a22b-e424a78bab1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5004e1f3-60cb-4947-9d45-46417990ce8d" xlink:to="loc_srt_RangeAxis_1a3441f6-33f3-4a64-a22b-e424a78bab1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c2251bda-fde6-4c52-8f6e-e878a0b3e226" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1a3441f6-33f3-4a64-a22b-e424a78bab1a" xlink:to="loc_srt_RangeMember_c2251bda-fde6-4c52-8f6e-e878a0b3e226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_283f8553-7c50-479e-85a0-91882e72e754" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c2251bda-fde6-4c52-8f6e-e878a0b3e226" xlink:to="loc_srt_MinimumMember_283f8553-7c50-479e-85a0-91882e72e754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_93e3e562-6630-4481-900c-6943464657a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c2251bda-fde6-4c52-8f6e-e878a0b3e226" xlink:to="loc_srt_MaximumMember_93e3e562-6630-4481-900c-6943464657a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_196b1cb5-152c-4e10-8210-ecf94e05851f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5004e1f3-60cb-4947-9d45-46417990ce8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_196b1cb5-152c-4e10-8210-ecf94e05851f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_73580636-9d59-47a5-bf43-62e88b018736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_196b1cb5-152c-4e10-8210-ecf94e05851f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_73580636-9d59-47a5-bf43-62e88b018736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_103ddc1a-c6c1-4163-bbbe-21267123b9be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_196b1cb5-152c-4e10-8210-ecf94e05851f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_103ddc1a-c6c1-4163-bbbe-21267123b9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c1329f31-656e-44f9-a156-97885a718288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_196b1cb5-152c-4e10-8210-ecf94e05851f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c1329f31-656e-44f9-a156-97885a718288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_276c26cf-eba8-4282-abc2-6eb743f255a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_196b1cb5-152c-4e10-8210-ecf94e05851f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_276c26cf-eba8-4282-abc2-6eb743f255a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_601b8c15-840f-4ff5-82b9-fd1337762ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb64b3d4-724e-4128-9482-5a3a6ea2a35a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_601b8c15-840f-4ff5-82b9-fd1337762ea0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb64b3d4-724e-4128-9482-5a3a6ea2a35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_465ef2f3-58bc-4653-8762-b4f64f16386b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb64b3d4-724e-4128-9482-5a3a6ea2a35a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_465ef2f3-58bc-4653-8762-b4f64f16386b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1aa2fb65-4fd3-452e-998a-def36c87bc78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_465ef2f3-58bc-4653-8762-b4f64f16386b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1aa2fb65-4fd3-452e-998a-def36c87bc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e1480f25-06b9-409a-b285-5efc22d9724b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1aa2fb65-4fd3-452e-998a-def36c87bc78" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e1480f25-06b9-409a-b285-5efc22d9724b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a605c862-b742-4545-83d9-8ca0bb7e44cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1aa2fb65-4fd3-452e-998a-def36c87bc78" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a605c862-b742-4545-83d9-8ca0bb7e44cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c369edf3-61b0-4c6e-a491-7f0d9dacfcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb64b3d4-724e-4128-9482-5a3a6ea2a35a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c369edf3-61b0-4c6e-a491-7f0d9dacfcc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d52f4647-8d80-4ca2-a389-4644c9bc0542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c369edf3-61b0-4c6e-a491-7f0d9dacfcc4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d52f4647-8d80-4ca2-a389-4644c9bc0542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#ShareBasedCompensationCompensationCostNotYetRecognizedDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_1965ecd0-3c1a-4ca0-9b0c-0bc535c6703b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a6e0cb8-e6b7-4e56-ad32-4e0da72617ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_1965ecd0-3c1a-4ca0-9b0c-0bc535c6703b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a6e0cb8-e6b7-4e56-ad32-4e0da72617ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_78a1adfb-2f53-46aa-a5cc-68bcb7c8f2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a6e0cb8-e6b7-4e56-ad32-4e0da72617ea" xlink:to="loc_us-gaap_AwardTypeAxis_78a1adfb-2f53-46aa-a5cc-68bcb7c8f2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f5ee47e-4256-4eb1-9b58-009ae1980d31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_78a1adfb-2f53-46aa-a5cc-68bcb7c8f2b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f5ee47e-4256-4eb1-9b58-009ae1980d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f3e6b993-4f19-4f57-ba73-cdea7ba67072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f5ee47e-4256-4eb1-9b58-009ae1980d31" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f3e6b993-4f19-4f57-ba73-cdea7ba67072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2d074cb2-85c0-4d7e-bcf5-dec6ed709a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f5ee47e-4256-4eb1-9b58-009ae1980d31" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2d074cb2-85c0-4d7e-bcf5-dec6ed709a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c987befe-636c-4ea3-a4ca-29bfd1190e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f5ee47e-4256-4eb1-9b58-009ae1980d31" xlink:to="loc_us-gaap_RestrictedStockMember_c987befe-636c-4ea3-a4ca-29bfd1190e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a158946-d482-4f29-b74b-f42729413f81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a6e0cb8-e6b7-4e56-ad32-4e0da72617ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a158946-d482-4f29-b74b-f42729413f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e410abb9-3895-4ed7-8cfc-c43b2e2b2df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a158946-d482-4f29-b74b-f42729413f81" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e410abb9-3895-4ed7-8cfc-c43b2e2b2df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9c29f1a9-501e-4729-b6c6-b4da0df57b77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a158946-d482-4f29-b74b-f42729413f81" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9c29f1a9-501e-4729-b6c6-b4da0df57b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e1c8cba-992a-4584-a00e-61d79c1496c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5b3fd5ec-ef1f-4fe4-ad0f-0a360f5a221b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e1c8cba-992a-4584-a00e-61d79c1496c8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5b3fd5ec-ef1f-4fe4-ad0f-0a360f5a221b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0cedbfaf-e882-431e-b3c9-fcb47ea7c1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5b3fd5ec-ef1f-4fe4-ad0f-0a360f5a221b" xlink:to="loc_us-gaap_AwardTypeAxis_0cedbfaf-e882-431e-b3c9-fcb47ea7c1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb4dde63-8ee2-4fad-bdf2-36e06b5b4f79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0cedbfaf-e882-431e-b3c9-fcb47ea7c1ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb4dde63-8ee2-4fad-bdf2-36e06b5b4f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b13feaa4-057b-4921-9e9c-2ba500fae769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb4dde63-8ee2-4fad-bdf2-36e06b5b4f79" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b13feaa4-057b-4921-9e9c-2ba500fae769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6480bc1c-d254-41c2-b7d6-0f3943629e22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5b3fd5ec-ef1f-4fe4-ad0f-0a360f5a221b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6480bc1c-d254-41c2-b7d6-0f3943629e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9c92e838-0e23-4b89-9760-506c77385401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6480bc1c-d254-41c2-b7d6-0f3943629e22" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9c92e838-0e23-4b89-9760-506c77385401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b1fe62d0-d1d3-4316-a9f1-8df0a3f39d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6480bc1c-d254-41c2-b7d6-0f3943629e22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b1fe62d0-d1d3-4316-a9f1-8df0a3f39d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0e87b700-5e3f-48e1-8677-5c034d8f79c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1750ab10-9f74-469b-9d51-bbe223fc6faf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0e87b700-5e3f-48e1-8677-5c034d8f79c4" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1750ab10-9f74-469b-9d51-bbe223fc6faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_746f27fd-fdbf-40db-86d5-30bb1882d5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1750ab10-9f74-469b-9d51-bbe223fc6faf" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_746f27fd-fdbf-40db-86d5-30bb1882d5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d4518e4a-5a84-4d9d-95a3-711d602a2eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_746f27fd-fdbf-40db-86d5-30bb1882d5c9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d4518e4a-5a84-4d9d-95a3-711d602a2eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_db1c5e09-ce56-4b0b-a426-64ba59f2d366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d4518e4a-5a84-4d9d-95a3-711d602a2eb6" xlink:to="loc_us-gaap_DomesticCountryMember_db1c5e09-ce56-4b0b-a426-64ba59f2d366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_05906d3f-51c7-437d-a7ef-684db1848d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d4518e4a-5a84-4d9d-95a3-711d602a2eb6" xlink:to="loc_us-gaap_ForeignCountryMember_05906d3f-51c7-437d-a7ef-684db1848d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_3fc689b6-0f02-494b-9049-6953a5527c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d4518e4a-5a84-4d9d-95a3-711d602a2eb6" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_3fc689b6-0f02-494b-9049-6953a5527c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_7340110b-cca7-4cf6-956f-d1cbd380d620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1750ab10-9f74-469b-9d51-bbe223fc6faf" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_7340110b-cca7-4cf6-956f-d1cbd380d620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_4cc7f555-5fa5-4c69-a69d-ce30dd32741b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_7340110b-cca7-4cf6-956f-d1cbd380d620" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_4cc7f555-5fa5-4c69-a69d-ce30dd32741b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_1e2c97cb-2184-4d66-bd9f-3c6de3d6b5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_4cc7f555-5fa5-4c69-a69d-ce30dd32741b" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_1e2c97cb-2184-4d66-bd9f-3c6de3d6b5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_2744a9ef-5913-4c49-b6e1-30dccc87b937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_4cc7f555-5fa5-4c69-a69d-ce30dd32741b" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_2744a9ef-5913-4c49-b6e1-30dccc87b937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_3498f7af-cc1e-4796-b2d5-3d90d3f6f59e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_4cc7f555-5fa5-4c69-a69d-ce30dd32741b" xlink:to="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_3498f7af-cc1e-4796-b2d5-3d90d3f6f59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_b4d26a73-f0af-4af8-b94f-5aae2b4bc2e8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1750ab10-9f74-469b-9d51-bbe223fc6faf" xlink:to="loc_dei_LegalEntityAxis_b4d26a73-f0af-4af8-b94f-5aae2b4bc2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_43cfab58-a657-44b1-81f0-87d8ef4a3e24" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_b4d26a73-f0af-4af8-b94f-5aae2b4bc2e8" xlink:to="loc_dei_EntityDomain_43cfab58-a657-44b1-81f0-87d8ef4a3e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CENDMember_a9a1e0cd-4668-46cd-9ac5-fcecd0f3ff75" xlink:href="clbs-20230331.xsd#clbs_CENDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_43cfab58-a657-44b1-81f0-87d8ef4a3e24" xlink:to="loc_clbs_CENDMember_a9a1e0cd-4668-46cd-9ac5-fcecd0f3ff75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_0b69526c-4f61-40c5-aa1d-799d5eff518e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1750ab10-9f74-469b-9d51-bbe223fc6faf" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_0b69526c-4f61-40c5-aa1d-799d5eff518e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown_c5fc6b26-e887-4e49-afbe-3a96a657fb46" xlink:href="clbs-20230331.xsd#clbs_OperatingLossCarryforwardsBeforeWriteDown"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0b69526c-4f61-40c5-aa1d-799d5eff518e" xlink:to="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown_c5fc6b26-e887-4e49-afbe-3a96a657fb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_b3e4b1df-d748-4357-8737-561aad015320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0b69526c-4f61-40c5-aa1d-799d5eff518e" xlink:to="loc_us-gaap_OperatingLossCarryforwards_b3e4b1df-d748-4357-8737-561aad015320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_FairValueMarketOfTaxNOLs_bf089704-4bc4-4484-afd8-f43852bac942" xlink:href="clbs-20230331.xsd#clbs_FairValueMarketOfTaxNOLs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0b69526c-4f61-40c5-aa1d-799d5eff518e" xlink:to="loc_clbs_FairValueMarketOfTaxNOLs_bf089704-4bc4-4484-afd8-f43852bac942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_76e7ac91-cdc4-4272-9c65-16a2c7f449a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0b69526c-4f61-40c5-aa1d-799d5eff518e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_76e7ac91-cdc4-4272-9c65-16a2c7f449a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsPostAcquisition_37d459a1-c808-40ec-913e-d78b61a8f81c" xlink:href="clbs-20230331.xsd#clbs_OperatingLossCarryforwardsPostAcquisition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0b69526c-4f61-40c5-aa1d-799d5eff518e" xlink:to="loc_clbs_OperatingLossCarryforwardsPostAcquisition_37d459a1-c808-40ec-913e-d78b61a8f81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_76370d31-fd31-45d9-9a78-54a25a42daa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0b69526c-4f61-40c5-aa1d-799d5eff518e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_76370d31-fd31-45d9-9a78-54a25a42daa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_a96db61c-c5fd-422d-aadd-d77e339ba642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0b69526c-4f61-40c5-aa1d-799d5eff518e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_a96db61c-c5fd-422d-aadd-d77e339ba642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_087722fa-d18b-4ca0-a261-05bd1d72c4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0b69526c-4f61-40c5-aa1d-799d5eff518e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_087722fa-d18b-4ca0-a261-05bd1d72c4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesDetails_1" xlink:type="simple" xlink:href="clbs-20230331.xsd#IncomeTaxesDetails_1"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_152b9a1a-d581-4078-bb2d-03654d39a188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_77a500c0-f064-4988-bfe8-e88c787cb0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_152b9a1a-d581-4078-bb2d-03654d39a188" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_77a500c0-f064-4988-bfe8-e88c787cb0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_67270eae-5211-4ac4-b6d7-5ccc47f3bb89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_152b9a1a-d581-4078-bb2d-03654d39a188" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_67270eae-5211-4ac4-b6d7-5ccc47f3bb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#LicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/LicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9085c78-0882-4045-8819-0c422bb01101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_13db0280-0725-4fec-ba25-92bca4d58862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9085c78-0882-4045-8819-0c422bb01101" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_13db0280-0725-4fec-ba25-92bca4d58862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c56e4594-a247-4ac9-a1d4-69d417b63387" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_13db0280-0725-4fec-ba25-92bca4d58862" xlink:to="loc_srt_CounterpartyNameAxis_c56e4594-a247-4ac9-a1d4-69d417b63387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8ca6f37-197f-47eb-923b-48966175175e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c56e4594-a247-4ac9-a1d4-69d417b63387" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8ca6f37-197f-47eb-923b-48966175175e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SanfordBurnhamPrebysMember_e8fcdf11-8e63-477c-ac88-2ddca334754a" xlink:href="clbs-20230331.xsd#clbs_SanfordBurnhamPrebysMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8ca6f37-197f-47eb-923b-48966175175e" xlink:to="loc_clbs_SanfordBurnhamPrebysMember_e8fcdf11-8e63-477c-ac88-2ddca334754a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_UniversityOfCaliforniaAtSanDiegoMember_6b613f8d-939a-4831-a4ef-2676de735ae0" xlink:href="clbs-20230331.xsd#clbs_UniversityOfCaliforniaAtSanDiegoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8ca6f37-197f-47eb-923b-48966175175e" xlink:to="loc_clbs_UniversityOfCaliforniaAtSanDiegoMember_6b613f8d-939a-4831-a4ef-2676de735ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MassachusettsInstituteOfTechnologyMember_fd606628-7903-46e2-bc64-4f77b80a21a0" xlink:href="clbs-20230331.xsd#clbs_MassachusettsInstituteOfTechnologyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8ca6f37-197f-47eb-923b-48966175175e" xlink:to="loc_clbs_MassachusettsInstituteOfTechnologyMember_fd606628-7903-46e2-bc64-4f77b80a21a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5bbd02e3-4dc6-41ea-b34d-f1fb05c13d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_13db0280-0725-4fec-ba25-92bca4d58862" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5bbd02e3-4dc6-41ea-b34d-f1fb05c13d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1eab03a4-ea9d-4034-b6d7-2dae9888584d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5bbd02e3-4dc6-41ea-b34d-f1fb05c13d87" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1eab03a4-ea9d-4034-b6d7-2dae9888584d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_0d160409-9fb3-4927-a363-5119ef389c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1eab03a4-ea9d-4034-b6d7-2dae9888584d" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_0d160409-9fb3-4927-a363-5119ef389c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cb31f77c-b88b-432a-8ee2-976821c3eec8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_13db0280-0725-4fec-ba25-92bca4d58862" xlink:to="loc_srt_RangeAxis_cb31f77c-b88b-432a-8ee2-976821c3eec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_98c08fae-5a29-47e1-a0e5-04e5cd1712d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cb31f77c-b88b-432a-8ee2-976821c3eec8" xlink:to="loc_srt_RangeMember_98c08fae-5a29-47e1-a0e5-04e5cd1712d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6e9d0d7c-79cc-4fd4-9fc5-35edde7316df" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_98c08fae-5a29-47e1-a0e5-04e5cd1712d2" xlink:to="loc_srt_MinimumMember_6e9d0d7c-79cc-4fd4-9fc5-35edde7316df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8cafc404-b2b5-4b38-b717-c5c6c482fd08" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_98c08fae-5a29-47e1-a0e5-04e5cd1712d2" xlink:to="loc_srt_MaximumMember_8cafc404-b2b5-4b38-b717-c5c6c482fd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_13db0280-0725-4fec-ba25-92bca4d58862" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SharesIssuedUnderLicenseAgreement_925cce3f-a7ce-4345-9b63-16c3e54cfbe1" xlink:href="clbs-20230331.xsd#clbs_SharesIssuedUnderLicenseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_clbs_SharesIssuedUnderLicenseAgreement_925cce3f-a7ce-4345-9b63-16c3e54cfbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_4e1b6a7a-c95f-4d18-bc3f-3fe2a2ec93d2" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_4e1b6a7a-c95f-4d18-bc3f-3fe2a2ec93d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_c607e371-a792-4f0c-a893-f2c51887ae3f" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_c607e371-a792-4f0c-a893-f2c51887ae3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_c5810b1c-1054-4f37-a0f2-ff01b464e16c" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_c5810b1c-1054-4f37-a0f2-ff01b464e16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_d9dfb064-dcb7-4dbc-bbf0-b1abba88f4f2" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_d9dfb064-dcb7-4dbc-bbf0-b1abba88f4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees_a91acb67-5903-47fd-b1ab-3938a7dcd1cd" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees_a91acb67-5903-47fd-b1ab-3938a7dcd1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour_1ed2815f-b052-4936-b5fb-0e793699e85f" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour_1ed2815f-b052-4936-b5fb-0e793699e85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SharesHeldByThirdParty_d907eb62-5e5b-43b3-b1d3-d760a16678b3" xlink:href="clbs-20230331.xsd#clbs_SharesHeldByThirdParty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_clbs_SharesHeldByThirdParty_d907eb62-5e5b-43b3-b1d3-d760a16678b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree_fb93348f-3e2e-4db9-90ca-70235e68a168" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree_fb93348f-3e2e-4db9-90ca-70235e68a168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale_b1d8634e-a2e8-493a-9405-37a215d83c31" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale_b1d8634e-a2e8-493a-9405-37a215d83c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee_efafbd7c-8de8-47de-bd97-8bfee07c2523" xlink:href="clbs-20230331.xsd#clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae22050c-7202-420c-8983-ed2a51cbe37a" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee_efafbd7c-8de8-47de-bd97-8bfee07c2523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#ResearchCollaborationandLicenseAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_591ee9a0-eb2e-4c8a-b005-7a568c01da3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ba02d02-4248-477c-88bb-4db11ac8278f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_591ee9a0-eb2e-4c8a-b005-7a568c01da3d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ba02d02-4248-477c-88bb-4db11ac8278f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cdcdd4ad-9a10-4f76-be4b-b732809e7e28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ba02d02-4248-477c-88bb-4db11ac8278f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cdcdd4ad-9a10-4f76-be4b-b732809e7e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6836aa85-c090-4281-baa8-f1e9ee5a4d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cdcdd4ad-9a10-4f76-be4b-b732809e7e28" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6836aa85-c090-4281-baa8-f1e9ee5a4d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3df63b6e-5ea5-469d-a99d-768afe0c6559" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ba02d02-4248-477c-88bb-4db11ac8278f" xlink:to="loc_srt_CounterpartyNameAxis_3df63b6e-5ea5-469d-a99d-768afe0c6559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e22bba8c-0f79-4585-a758-c95657bec72e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3df63b6e-5ea5-469d-a99d-768afe0c6559" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e22bba8c-0f79-4585-a758-c95657bec72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_QiluMember_6a5e5fc6-cfa5-4531-98af-8d9899c6540c" xlink:href="clbs-20230331.xsd#clbs_QiluMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e22bba8c-0f79-4585-a758-c95657bec72e" xlink:to="loc_clbs_QiluMember_6a5e5fc6-cfa5-4531-98af-8d9899c6540c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3cf0fac0-e3e2-4740-b7c4-f2f2eec300bb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ba02d02-4248-477c-88bb-4db11ac8278f" xlink:to="loc_srt_ProductOrServiceAxis_3cf0fac0-e3e2-4740-b7c4-f2f2eec300bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bc526c36-1730-43e5-ae1d-5329009251d6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3cf0fac0-e3e2-4740-b7c4-f2f2eec300bb" xlink:to="loc_srt_ProductsAndServicesDomain_bc526c36-1730-43e5-ae1d-5329009251d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_47d9c105-3679-449b-acac-d0bb1e5b8474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bc526c36-1730-43e5-ae1d-5329009251d6" xlink:to="loc_us-gaap_LicenseMember_47d9c105-3679-449b-acac-d0bb1e5b8474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0dcdac54-5b27-4f9e-8e40-30d842a791e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ba02d02-4248-477c-88bb-4db11ac8278f" xlink:to="loc_srt_RangeAxis_0dcdac54-5b27-4f9e-8e40-30d842a791e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d5795f1a-b3b4-4b77-b93d-e83d45ca512c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0dcdac54-5b27-4f9e-8e40-30d842a791e5" xlink:to="loc_srt_RangeMember_d5795f1a-b3b4-4b77-b93d-e83d45ca512c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c2fb9489-cb8c-417a-aca0-967db9232fd7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d5795f1a-b3b4-4b77-b93d-e83d45ca512c" xlink:to="loc_srt_MinimumMember_c2fb9489-cb8c-417a-aca0-967db9232fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_103c0ff5-433f-4aed-9819-b55de8309c7e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d5795f1a-b3b4-4b77-b93d-e83d45ca512c" xlink:to="loc_srt_MaximumMember_103c0ff5-433f-4aed-9819-b55de8309c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e80173f0-0c05-4ef0-bf7e-c3bd720c6a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ba02d02-4248-477c-88bb-4db11ac8278f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e80173f0-0c05-4ef0-bf7e-c3bd720c6a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_19fb6f9f-5871-4936-9afb-6b92c51ad9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e80173f0-0c05-4ef0-bf7e-c3bd720c6a59" xlink:to="loc_us-gaap_ContractWithCustomerLiability_19fb6f9f-5871-4936-9afb-6b92c51ad9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_36fb329b-9c09-4f05-b99d-b92fbc7ae121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e80173f0-0c05-4ef0-bf7e-c3bd720c6a59" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_36fb329b-9c09-4f05-b99d-b92fbc7ae121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount_e7cc063f-1480-4d1f-a98c-f6a0e5c2dce3" xlink:href="clbs-20230331.xsd#clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e80173f0-0c05-4ef0-bf7e-c3bd720c6a59" xlink:to="loc_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount_e7cc063f-1480-4d1f-a98c-f6a0e5c2dce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RevenuePerformanceObligationPercentageOfNetSale_ab4d89fd-9bc5-408e-b53d-dc5eda2b5e7f" xlink:href="clbs-20230331.xsd#clbs_RevenuePerformanceObligationPercentageOfNetSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e80173f0-0c05-4ef0-bf7e-c3bd720c6a59" xlink:to="loc_clbs_RevenuePerformanceObligationPercentageOfNetSale_ab4d89fd-9bc5-408e-b53d-dc5eda2b5e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues_55efb10c-f652-4601-a256-118a1a50d742" xlink:href="clbs-20230331.xsd#clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e80173f0-0c05-4ef0-bf7e-c3bd720c6a59" xlink:to="loc_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues_55efb10c-f652-4601-a256-118a1a50d742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="clbs-20230331.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0138dc66-b3ce-464d-9858-1a49f659d077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_7bb958f0-8399-4dd1-86e7-2b7c3ff4315d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0138dc66-b3ce-464d-9858-1a49f659d077" xlink:to="loc_us-gaap_SubsequentEventTable_7bb958f0-8399-4dd1-86e7-2b7c3ff4315d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_68ddb3e1-ce57-4895-9694-8f3419252431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_7bb958f0-8399-4dd1-86e7-2b7c3ff4315d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_68ddb3e1-ce57-4895-9694-8f3419252431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_28f06df5-8781-40f2-b316-1bf5d8557b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_68ddb3e1-ce57-4895-9694-8f3419252431" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_28f06df5-8781-40f2-b316-1bf5d8557b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_71ba3ad3-378e-45c0-b65c-0962e1686887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_28f06df5-8781-40f2-b316-1bf5d8557b5f" xlink:to="loc_us-gaap_SubsequentEventMember_71ba3ad3-378e-45c0-b65c-0962e1686887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_df78a619-c542-44a1-9982-af5668e2f371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_7bb958f0-8399-4dd1-86e7-2b7c3ff4315d" xlink:to="loc_us-gaap_SubsequentEventLineItems_df78a619-c542-44a1-9982-af5668e2f371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_95b12f9b-90ff-491f-8f5f-30ea62b13d03" xlink:href="clbs-20230331.xsd#clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_df78a619-c542-44a1-9982-af5668e2f371" xlink:to="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_95b12f9b-90ff-491f-8f5f-30ea62b13d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>clbs-20230331_g1.jpg
<TEXT>
begin 644 clbs-20230331_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0!0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV/N\H01BO?/^"C_A+X@W'@>Y\4:+XF73_ VGV,=MK&CB[E1[QY;E$0B-4*.
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M6OSB\+W_ ,:?V\/BAK$NF>)IM"TFQ_?&/[9+!9:=$[$1QJD?+R,%/.,G:22
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MHESK%S=I((HW _?1RS,LI9#]Z,[L@-@$E37VE0 4444""BBB@ HHHH ****
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MY<XZUZ%_P48^"/COXK>-/"%WX2\,7VO6]II\L4\EHH(C8R9 .2.U'0?4[O\
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M,9. 65MWRD\AN.1@@]-C-\ _ 7]HKXGZ/8^(?&?QNU'PD][&+A-,TF &1%8
M@.(VB1#C!P-V,^N:^?\ ]G/0;CPK_P %%K/1KO7+KQ+=6&I:K;3:M>L6FNG2
MRN59W)9CNR#G)/2O7_ ?Q<_:X\2:/9>#;?P!;Z1>1Q+9OXHUK3Y8&B0*!YQ+
MOY;.!@_*C9P?D)KG/AE^R_X\^#?[:VBZO;:-JFN^%[2Y_?>(Y@&6<SV12>9C
MG.?,EDS]/QH T/\ @K/_ ,TK_P"XK_[9U]:^'?M?_#+NF?8/^/[_ (0V+R/^
MNGV(;?UQ7E/_  4 _9[\1_'+P#H-UX4M1J.LZ#<RR?8-ZHTT,JJ'V%B!N!1#
M@D9&>^ >9_8N\8?'B/7-.\$>/?"=UIW@[1],:VBU"_TQX)<QA%AC\TD*X"\9
M .0O7K0+H?)O[%_PN\>_$[6O%$'@/Q])X%N[2W@>Y>)Y%:Y1F< ?(>BD=_[U
M?2'C#]A_XU^-M$?2O$OQO&KZ5)(A:UU!KB2)G##9PQQG.,>]8/C;]F/XM_LQ
M_&.]\>?!.T36=#O7DSI<*AVAB=@QMI82P+Q@@;60[AM'W2,FAXVL_P!I_P#;
M#2P\*Z[X0C\#>&1,LMW)+:RV4+%3]^3S7:23!R51!C.">FX SUGQ-\%=<^ O
M[ _CSP?=ZM;ZO=6\,UPEQ:QLB"!Y8V=<'G./,_.N<_X)2_9O^$ \=[=OVO\
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MO#X6\07HF\/:HL=E<7VSRXIK>4@PW(!)QLDX;DX D%>R_P#!5K[7_P *_P#
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MC9^Q+XK\9V]M]C_M/PCJIEMMV[RIDMYHY5![@.C8/<8->#?\$G_^1?\ B/\
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M[>1]GS)LQC_:\NE_;=LXM1_;@T2TG7?!.=)BD7U5G (_(U]0_L0_LCW'[/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \(_;2^%/B/XR_ ^Z\-^%;
M2.]U:2^MYUBDG2$;$8ECN8@5-^QG\+O$7P=^!6F^&O%%I'9:O#=W,KPQS)*
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M'M(_R+\?\SS_ /X69XC_ .B3>,/_  +T;_Y84?\ "S/$?_1)O&'_ (%Z-_\
M+"O0**/K-+_GQ'[Y_P#R8>TC_(OQ_P SS_\ X69XC_Z)-XP_\"]&_P#EA1_P
MLSQ'_P!$F\8?^!>C?_+"O0**/K-+_GQ'[Y__ "8>TC_(OQ_S//\ _A9GB/\
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M/^>G_CH_PH_M"X_YZ?\ CH_PH]K3_P"?$/OG_P#)AS1_D7X_YG,_\+,\1_\
M1)O&'_@7HW_RPH_X69XC_P"B3>,/_ O1O_EA73?VA<?\]/\ QT?X4?VA<?\
M/3_QT?X4>UI_\^(??/\ ^3#FC_(OQ_S.9_X69XC_ .B3>,/_  +T;_Y84?\
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M6%=-_:%Q_P ]/_'1_A1_:%Q_ST_\='^%'M:?_/B'WS_^3#FC_(OQ_P SF?\
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M_"CVM/\ Y\0^^?\ \F'-'^1?C_F<S_PLSQ'_ -$F\8?^!>C?_+"C_A9GB/\
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MSNT/]I+Q5X?_ &/+F\M?%=UJ'B^X\0_89;V[O3<W=G;O&75OG+,H;RG52?\
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M^93D(=VXMD=O\6K[XDR^ 9_B7XD^*6I^'M4\0VUC)X.\(>$K^>+S6EVLT4L
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M"7MOX\O$FMIS-_8=_)ILTL9<^5]HGV,B/A<[I5)*D=SFCG\@/T1HKYM_8O\
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MSX'O-7&EZ-XEUEFDNFYD+-#*XR<I'@D8QD$!6/#E+EW _2ZBOA&'5OBO\/\
MXV-\+?#'C^_\03^(M$2XM[[Q5,]Q]AG,)D:16*NR_P"K<  8_>#(8KDUK-OB
M7X1^+UIX9\'?$'Q)\0KRST61_%"S7DEY9VMSY<A,<3-]ULA0G&_=@9^\H7/Y
M ?>]%?FQX=\7>./AO#X8UCXIR?%S2]-N-1\F34&\4O%$Q5MVTV<D)DV[1R#(
M-P#%?2OTECD6:-)$8,C ,K#H0>AJHRY@+>G_ /'Y'^/\C6U6+I__ !^1_C_(
MUM5C4W(EN%%5M2^U_P!G77]G^3]O\I_L_P!ISY7F8.W?CG;G&<<XKXH^#_C#
MXH1?MQ7OA3QWXN?56@TQY9M/TN:6/2T9H$D41PG .T/C<R[CC)-9"/N"BOA#
M^U_&W[0_Q<^-$!^(OB+P3IW@J.>+3+#1+UK5"R-(H:;;@NN82S9Y^? ( Q7K
MG[('Q8\8_&;]G&^N[BZBE\6Z?+<:9;:G?K^[GD6-6AED"CG'F*&P,G83U)H"
MQ])T5^>7BFW^+7PQ^(G@C1]*^*6N^-OB?=7,UYK^AVU])=:3:6V]2I:-E C4
MH6R"HP.5"_+NY!OBM\3?%7PG\5_&M/B1X@TW5-+\1PV5MH=M/C35A8 [3!]Q
ML;U'S*<A#NW%LA#L?IY17Y]?%J^^),O@&?XE^)/BEJ?A[5/$-M8R>#O"'A*_
MGB\UI=K-%+ %4N0K<L">>I/RH>3\3?%;XY>-/B+I/@O4F\5'4M$T..ZU+3/"
M^K)HUW*QA65II9A&R@@2("A4C(PH!- K'Z8T5X9^QS\2-.^)GP=AO;'5/$&I
M36ER]K=?\)+=I=W<,@56V>>L:>8F&!#%<\D'I7N=,04444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!6U#_CSD_#^8K%K
M:U#_ (\Y/P_F*Q:Z*>Q<=BEK6FOK&CWMC'?76FO<PM$+RR95GAW#&]"RL PZ
M@D'FO#?!_P"QOH?@76CJ>D^/_B!;RRW:7EW"NM(D=[(K;OWX2)3(#R#DY()Y
MKW^BM&DRCY\^,W['^B?$.^\0^(/#^KZIX5\5:M:M#.UE=F.SO6( Q<1A22IV
M@$*0#U()Z]3\#_A1K7@'X+CP9J\FFZ)>J)84O/";R9"N!^^WW"D^<26))7:.
M,  8KUJBERJ]P/ /!_[&^A^!=:.IZ3X_^($$DMVMY=PKK2)'>NK;OWX2)3(#
MR#DY()YJ'5OV&?AOJ_B"ZOVFUVVTR[O!?7'A^VU#9ITLHS\Q3;O'WF^ZXP&(
M7 XKZ%HHY5V \!US]CG0=;\:2^*?^$Z\=:=K!!CAETW5(;?[+#T$$.V#*1J.
M H/3UY-+K7[&?A36+XW\?BGQIIFISV2V.H7UEK.)M20  FX9D;>6V@D#"D\D
M9KWVBCE0'*?#'X8Z!\(?"-MX<\-VSV^GPLTA,LA>261L;G=CU8X'3 XP !75
MT450!1110!X!XF_8K\%>(M7UJ[AUSQ5H5IK4HFU'2=*U01V=TX8G+QLC$C).
M!G _A K=\9?LI> _%V@^&M,BBU'P\_AM/+TO4-%NS#=6Z[MQ =@V<MSD@D$D
M@C)KV*BERKL!\]?LS_L]^(_@?XI\63:K<Z+K%CJCM)%K"R7$FJS'?E5G+CRP
MN"Q.W)+'))XQ<\2?L@Z-XG\>77C&?Q]X\L]?F+!+FQU6* V\9)_=1%8,I& <
M!0?KDY->\T4N56L!X5XS_8[\'^-YM.O+O6_%%KK5M8#3;C6;74P+S4(=FPBY
M=D8.2I() &0<'(  I>(/V)_!6N:'H>B0ZWXGT;1='&ZVT_3;^-8C.6+-</OB
M8M*2?O9X  4*.*^@J*.5 >#ZE^Q]X<UK3;.+4_&'CC4]5L;K[59:[=ZV9+^T
M.%^2-RFT+E<CY2022",UU7PA_9Y\,?!K4-6U/3+C5-8US5#_ *7J^MW?VBYE
M7.=I8*HQGG.,GN3@5Z=13Y4 4444P"N.\8?!_P %>/&O)M<\+:/J%_<P&!M1
MN-/@DND7:5!61T)!7/'I78T4 >*>&_V0?AWX=^&>J>!S97&I:;J4XN+B]NVC
M%Z77F/\ >QHAPASM!!QN8<AB*X'PS^R#K7P]^.'A[Q1H^L6OBGP[I\,=N%\7
MW4\]]9(,AOLWEJL9(4G8&X7<>,X-?5-%3RH#R/XT?LVZ/\<]2L+G7/$WB:PM
M[$ V]AI5Y%%;I("3YNUHF/F<XW9X XQSG-U;]DOPQXE\&_V!XA\1^+?$CQW?
MVVTU?5M6\^^LGVA2(9"FT*0/NE2,\]0,>W44^5 > VO[%_@^Q\,ZUI-MX@\5
M07&N3>9JNL+J,9OKY/F/DR.T1'EDL6("@L<;BV *71_V,_"FFZ!<:!>>*?&F
MN>'I+<VZ:/J6LYM(/F#"2.-$0*X(X[?,P(.:]]HI<J \-\$?L@^$/!OBW2/$
M5QK/B;Q3?Z/&L>FKX@U$7$=F%^[Y:JBX"]E.5'IG%>Y444TDM@-'1_\ EM^'
M]:TJS='_ .6WX?UK2KFG\3,WN<C\3OAW_P +,\/Q:5_PDWB+PKY=PMQ]M\,W
M_P!CN6PK+L9]K90[LD8ZJOI7EGPM_8N\+?"/6/MFC>+?&4UE(SF[T:[U.(V%
M]NC9")X4A42<,>IZ@5] T5 CXT^*'_!/J!K.Q7X=:Q(MC%J0OIO"WBC49WT=
MAC'RB%?,#<8)+%B"1N%?0OC[X0CXK?#.Q\*:WK.H>'(C#$M^GA29;>.7$>UH
M09(W/DYSA< D  ]Q7HU% SP?P9^QYX7\(Z/>:'<>*?&7B3PQ=6,E@WA[6M8\
MRP1&(.Y(HT38X(RK C!)(YYK.\'_ +#?@;P7J\>JVFN>*;O4;.UDM=*N+W4(
MY#I(;?\ -;#R@JLN]BNX, 3NQNYKZ)HH"Y\Y>%/V'_#?@W5)KS3_ !_\0@EU
M<K<W]HVM1B#46!RRW*K"/-5LD-N/(8C/-;?Q(_8R^%OQ&CTM/^$?MO"_V"?S
M]WANRM;0W'3Y)OW+;TXZ<=37N5% 7*^G:=::/86UC86L-E96T:PP6UO&(XXD
M48554#"@   #@58HHH$%4=<TQ]:T:^L([^ZTM[F%H1>V+*L\&X8WQEE8!AU!
M(//:KU% 'SMX+_8IT'P#KAU31_B)\1;>66[2]NX5UQ$COI%;=^_"0J9 W(.3
MD@GGFH_C=^QCH7Q(OO$GB+P[K.J^$O%NL6K0W#6-X8[*]8@#%S&%)*D* 0I
M/4@GK]&T4#N>/? ?X1:Y\/?@@O@C6)=+T*^030I?>$))<JK@?O\ ?<*29RQ8
MDE=H^7  &!R_@O\ 8HT'P#KAU32/B)\1+>66[2]NX5UQ$BOI%;<?/"0J9 W(
M.3D@GGFOHFB@#YPUC]@GX9:QXCN]0:;7[72KR\%_<^'+74=FFS3#=\Q39O'W
MF^ZXP&(7 XJQKW[%/A_7?'$OBS_A/O'VF:T5,4$VF:K#;_9(>0((=L&4B4'
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M/^%1^&_^>>I_^#F]_P#CU=E10%V<;_PJ/PW_ ,\]3_\ !S>__'J/^%1^&_\
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M )YZG_X.;W_X]7944!=G&_\ "H_#?_//4_\ P<WO_P >H_X5'X;_ .>>I_\
M@YO?_CU=E10%V<;_ ,*C\-_\\]3_ /!S>_\ QZC_ (5'X;_YYZG_ .#F]_\
MCU=E10%V<;_PJ/PW_P \]3_\'-[_ /'J/^%1^&_^>>I_^#F]_P#CU=E10%V<
M;_PJ/PW_ ,\]3_\ !S>__'J/^%1^&_\ GGJ?_@YO?_CU=E10%V<;_P *C\-_
M\\]3_P#!S>__ !ZC_A4?AO\ YYZG_P"#F]_^/5V5% 79QO\ PJ/PW_SSU/\
M\'-[_P#'JJ:G\)_#D=NI$>I9W=]8O#V/_36N]JEJW_'NO^__ $-5'=#3U///
M^%5^'O\ GGJ/_@WO/_CM'_"J_#W_ #SU'_P;WG_QVNMHKJLC0Y+_ (57X>_Y
MYZC_ .#>\_\ CM'_  JOP]_SSU'_ ,&]Y_\ ':ZVBBR Y+_A5?A[_GGJ/_@W
MO/\ X[1_PJOP]_SSU'_P;WG_ ,=KK:*+(#DO^%5^'O\ GGJ/_@WO/_CM'_"J
M_#W_ #SU'_P;WG_QVNMHHL@.2_X57X>_YYZC_P"#>\_^.T?\*K\/?\\]1_\
M!O>?_':ZVBBR Y+_ (57X>_YYZC_ .#>\_\ CM'_  JOP]_SSU'_ ,&]Y_\
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MZFN+^#UO\1O'GA?PCJV@R>,&U:/Q+,VH^(M3\3&32Y;".XE62(VCW+ECM"H
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ME6;H_P#RV_#^M:5<L_B9F]PHHHJ!!1110 4444 %%%% !1110 4444 %%%%
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M\.-.NK+P_8&SBNKE[RYDDGDN)KB9_O222RLSNQ]68UT=?SU45^P?ZC_]1/\
MY)_]L<7]D_W_ ,/^"?T*T5_/511_J/\ ]1/_ ))_]L']D_W_ ,/^"?T*T5_/
M511_J/\ ]1/_ ))_]L']D_W_ ,/^"?T*T5_/511_J/\ ]1/_ ))_]L']D_W_
M ,/^"?T*T5_/511_J/\ ]1/_ ))_]L']D_W_ ,/^"?T*T5_/511_J/\ ]1/_
M ))_]L']D_W_ ,/^"?T*T5_/511_J/\ ]1/_ ))_]L']D_W_ ,/^"?T3:/\
M\MOP_K6E7\X]%92X#YG?ZS_Y)_\ ;$O*/^GGX?\ !/Z.**_G'HJ?]0O^HK_R
M3_[8/['_ .GGX?\ !/Z.**_G'HH_U"_ZBO\ R3_[8/['_P"GGX?\$_HXHK^<
M>BC_ %"_ZBO_ "3_ .V#^Q_^GGX?\$_HXHK^<>BC_4+_ *BO_)/_ +8/['_Z
M>?A_P3^CBBOYQZ*/]0O^HK_R3_[8/['_ .GGX?\ !/Z.**_G'HH_U"_ZBO\
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M.HK]\?\ AFOX1?\ 1*_!7_A.V?\ \;H_X9K^$7_1*_!7_A.V?_QNC_7K#?\
M/B7WH/[7A_(S\#J*_?'_ (9K^$7_ $2OP5_X3MG_ /&Z/^&:_A%_T2OP5_X3
MMG_\;H_UZPW_ #XE]Z#^UX?R,_ ZBOWQ_P"&:_A%_P!$K\%?^$[9_P#QNC_A
MFOX1?]$K\%?^$[9__&Z/]>L-_P ^)?>@_M>'\C/P.HK]\?\ AFOX1?\ 1*_!
M7_A.V?\ \;H_X9K^$7_1*_!7_A.V?_QNC_7K#?\ /B7WH/[7A_(S\#J*_?'_
M (9K^$7_ $2OP5_X3MG_ /&Z/^&:_A%_T2OP5_X3MG_\;H_UZPW_ #XE]Z#^
MUX?R,_*']G7Q1;ZAX3;12X6\L'9_+/5HW;=N'T8D'\/6O6J_0BW_ &=OA79L
MSVOPV\)V4Q4IYUIHEM#(H(P=KH@93[@UQUQ^QSX%FO#.ESK,$1;=]FCN8S&!
MZ9:,MC_@6:NEQG@:C?M(2C^)_,?%O >*S#-*N/RQKEJMR:D[-2>_JF]>ZO8_
M/#XR>)[;PYX$U%)6'VB_B>TAC[L7!#'Z!23^7K7R57[Y+^SG\+FM+:"[^'_A
MO53;IL2?5-+@NYL9SS)(K,>?>D_X9K^$7_1*_!7_ (3MG_\ &ZR7'&%C=*C)
M_-'ZSP1E=/A/+GAI^_4F^:36U[627DN_5W/P.HK]\?\ AFOX1?\ 1*_!7_A.
MV?\ \;H_X9K^$7_1*_!7_A.V?_QNJ_UZPW_/B7WH_0_[7A_(S\#J*_?'_AFO
MX1?]$K\%?^$[9_\ QNC_ (9K^$7_ $2OP5_X3MG_ /&Z/]>L-_SXE]Z#^UX?
MR,_ ZBOWQ_X9K^$7_1*_!7_A.V?_ ,;H_P"&:_A%_P!$K\%?^$[9_P#QNC_7
MK#?\^)?>@_M>'\C/P.HK]\?^&:_A%_T2OP5_X3MG_P#&Z/\ AFOX1?\ 1*_!
M7_A.V?\ \;H_UZPW_/B7WH/[7A_(S\#J*_?'_AFOX1?]$K\%?^$[9_\ QNC_
M (9K^$7_ $2OP5_X3MG_ /&Z/]>L-_SXE]Z#^UX?R,_ ZBOWQ_X9K^$7_1*_
M!7_A.V?_ ,;H_P"&:_A%_P!$K\%?^$[9_P#QNC_7K#?\^)?>@_M>'\C/P.HK
M]\?^&:_A%_T2OP5_X3MG_P#&Z/\ AFOX1?\ 1*_!7_A.V?\ \;H_UZPW_/B7
MWH/[7A_(S\#J*_?'_AFOX1?]$K\%?^$[9_\ QNC_ (9K^$7_ $2OP5_X3MG_
M /&Z/]>L-_SXE]Z#^UX?R,_ ZBOWQ_X9K^$7_1*_!7_A.V?_ ,;H_P"&:_A%
M_P!$K\%?^$[9_P#QNC_7K#?\^)?>@_M>'\C/P.HK]\?^&:_A%_T2OP5_X3MG
M_P#&Z/\ AFOX1?\ 1*_!7_A.V?\ \;H_UZPW_/B7WH/[7A_(S\#J*_?'_AFO
MX1?]$K\%?^$[9_\ QNC_ (9K^$7_ $2OP5_X3MG_ /&Z/]>L-_SXE]Z#^UX?
MR,_ ZBOWQ_X9K^$7_1*_!7_A.V?_ ,;H_P"&:_A%_P!$K\%?^$[9_P#QNC_7
MK#?\^)?>@_M>'\C/P.HK]\?^&:_A%_T2OP5_X3MG_P#&Z/\ AFOX1?\ 1*_!
M7_A.V?\ \;H_UZPW_/B7WH/[7A_(S\#J*_?'_AFOX1?]$K\%?^$[9_\ QNJ>
MI_LW_"2.W4K\+?!:G=V\/6@['_IG37'6&;M[&7WH/[6A_(S\&J*_=+_AG7X4
M?]$Q\&_^""T_^-T?\,Z_"C_HF/@W_P $%I_\;K3_ %VP_P#SYE]Z*_M6'\K/
MPMHK]TO^&=?A1_T3'P;_ .""T_\ C='_  SK\*/^B8^#?_!!:?\ QNC_ %VP
M_P#SYE]Z#^U8?RL_"VBOW2_X9U^%'_1,?!O_ ((+3_XW1_PSK\*/^B8^#?\
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M-_\ !!:?_&Z/]=L/_P ^9?>@_M6'\K/PMHK]TO\ AG7X4?\ 1,?!O_@@M/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"SI__ !^1_C_(
MUM5BZ?\ \?D?X_R-;5<]3<B6X4445D2%%%% !1110 4444 %%%% &'_PF-A_
MS[ZK_P""B[_^-4?\)C8?\^^J_P#@HN__ (U6Y10!A_\ "8V'_/OJO_@HN_\
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MS[ZK_P""B[_^-4?\)C8?\^^J_P#@HN__ (U6Y10!A_\ "8V'_/OJO_@HN_\
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M?_QJMRB@##_X3&P_Y]]5_P#!1=__ !JC_A,;#_GWU7_P47?_ ,:K<HH P_\
MA,;#_GWU7_P47?\ \:H_X3&P_P"??5?_  47?_QJMRB@##_X3&P_Y]]5_P#!
M1=__ !JC_A,;#_GWU7_P47?_ ,:K<HH P_\ A,;#_GWU7_P47?\ \:H_X3&P
M_P"??5?_  47?_QJMRB@##_X3&P_Y]]5_P#!1=__ !JC_A,;#_GWU7_P47?_
M ,:K<HH P_\ A,;#_GWU7_P47?\ \:H_X3&P_P"??5?_  47?_QJMRB@##_X
M3&P_Y]]5_P#!1=__ !JC_A,;#_GWU7_P47?_ ,:K<HH P_\ A,;#_GWU7_P4
M7?\ \:H_X3&P_P"??5?_  47?_QJMRB@##_X3&P_Y]]5_P#!1=__ !JC_A,;
M#_GWU7_P47?_ ,:K<HH P_\ A,;#_GWU7_P47?\ \:H_X3&P_P"??5?_  47
M?_QJMRB@##_X3&P_Y]]5_P#!1=__ !JC_A,;#_GWU7_P47?_ ,:K<HH P_\
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M4O\ P67/_P ;K7HKJU-#(_X2FR_YXZE_X++G_P"-T?\ "4V7_/'4O_!9<_\
MQNM>BC4#(_X2FR_YXZE_X++G_P"-T?\ "4V7_/'4O_!9<_\ QNM>BC4#(_X2
MFR_YXZE_X++G_P"-T?\ "4V7_/'4O_!9<_\ QNM>BC4#(_X2FR_YXZE_X++G
M_P"-T?\ "4V7_/'4O_!9<_\ QNM>BC4#(_X2FR_YXZE_X++G_P"-T?\ "4V7
M_/'4O_!9<_\ QNM>BC4#(_X2FR_YXZE_X++G_P"-T?\ "4V7_/'4O_!9<_\
MQNM>BC4#(_X2FR_YXZE_X++G_P"-T?\ "4V7_/'4O_!9<_\ QNM>BC4#(_X2
MFR_YXZE_X++G_P"-T?\ "4V7_/'4O_!9<_\ QNM>BC4#(_X2FR_YXZE_X++G
M_P"-T?\ "4V7_/'4O_!9<_\ QNM>BC4#(_X2FR_YXZE_X++G_P"-T?\ "4V7
M_/'4O_!9<_\ QNM>BC4#(_X2FR_YXZE_X++G_P"-T?\ "4V7_/'4O_!9<_\
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M!UCQ=?ZEHQU_[+9+#";>T#%=TAFD0!RX*A%R3C/3!)S>8'I__"4V7_/'4O\
MP67/_P ;H_X2FR_YXZE_X++G_P"-UY9\./VK?#7Q:\50:'X4T+Q#JQ:UAN[B
M_6"WCMK-'XQ*SS!@RL&4JJL<J=NX#-6_V@/BQXH^%L?AV;1-#L;K3[[5;.QN
M]1U"8E8Q-+L*1Q(0Q?'.XD*,=&/%%]+@>D?\)39?\\=2_P#!9<__ !NC_A*;
M+_GCJ7_@LN?_ (W6O13U R/^$ILO^>.I?^"RY_\ C='_  E-E_SQU+_P67/_
M ,;KSG]I3X@>+OA3X#N?%?ARYT5H+-H(I;'5-.FG:5I9DC#+(EQ&$ #YP4;.
M.HK4MOBI_P (WXIA\'>))?[3\1G1I]=:\TK3_LMH;>-]I0(]Q(XDY]2#UR.E
M*X'9?\)39?\ /'4O_!9<_P#QNC_A*;+_ )XZE_X++G_XW7CJ_MA>&KJQT.XT
MWPKXKU<ZMHT^NQPV5K;%X;6%W21I-UPH!!0\*3G*@<G%6_#O[77@S7E2>XL-
M=T+3YM)N-;M+_5+1$BN[6 D2M'LD9LC!X=5SQC.1DYO,#U?_ (2FR_YXZE_X
M++G_ .-T?\)39?\ /'4O_!9<_P#QNO%-7_;,\/>%=(L]4\2^%O$6@V.J:<VJ
M:0TRVTCZA"I7*JJS'8^UU?:Y'RYYSP>^OOB!XHU[X2W?B/PEX+OQXBFA#:9H
MNO26\#R%MNV23;,550&+%2ZL=I& 2*+@=;_PE-E_SQU+_P %ES_\;H_X2FR_
MYXZE_P""RY_^-UY1X;^(7C/1OC?HW@+7M1TGQ*+[1'U&^?3+%[>32Y4( +_O
M'!CD)*KD!L@?C[%K$6H3:;<)I5S;6>H,N(9[RW:XB1O5HUDC+#V#K]:-6!4_
MX2FR_P">.I?^"RY_^-T?\)39?\\=2_\ !9<__&Z\*\'?M ^);'P?X\\9^-9]
M*N/#_A/5KK2)K+0='ECNKAHI$19E>6\90"7Y0C_@5=?XU_:;\+^!-0\16=_8
M:O-+H>C0:Y<FVAB8/!+(L:JF9!EP6&0<#'<T<P'IMCXKLEND)@U+'/32[H]C
M_P!,ZU_^$QL/^??5?_!1=_\ QJO ?^&R_#^CZAJ45_X(\:6<^D6<>I:C%)8V
MQ-K:2*I6=R+@@K\X^527&&^7Y3CK/$O[5>B:3?>(4T?P[K?BG3_#=C;ZCK>H
MZ:L"164,R"1,++(C2/Y>7*JIP!SSQ6%1ZDR/4O\ A,;#_GWU7_P47?\ \:H_
MX3&P_P"??5?_  47?_QJN ^$_P"TGH7QJ\1ZKIWA;0M>N],TV3RY_$$L5NE@
M6*;TVDS>8VX$8 CR,C=MKC/CK\=?%_P@_MJ\?7_A_%-;R0OI/@^7[1/J^JP-
M($R&65#&['<%"P2*".6(!(S)/<O^$QL/^??5?_!1=_\ QJC_ (3&P_Y]]5_\
M%%W_ /&JT],NI;[3;2YFMVM)IHDD>W<@M$Q4$J2.I!X_"K- C#_X3&P_Y]]5
M_P#!1=__ !JC_A,;#_GWU7_P47?_ ,:K<HH P_\ A,;#_GWU7_P47?\ \:H_
MX3&P_P"??5?_  47?_QJMRB@##_X3&P_Y]]5_P#!1=__ !JC_A,;#_GWU7_P
M47?_ ,:K<HH **P?'VO7'A;P-XBUFT2.2ZT[3KB[B28$HSQQLRA@""1D#."*
M\;^'OQ\U'7M8\-I)XN\&^-;34;:2XU.#PM9R1S:*JV[2^;.WVNX79N4188(2
MSC&<$4 ?05%>):?\4O&*>$=#^(>I'1XO"&JS6SMHZV<B7MG9W,BI!,UP9BKN
MOF([IY2C!(!RN7[[X?\ C"\\5:;KUS>0Q*^GZQ?:?&ELK#='#*R(3DG+$#G&
M!GL* .OHKP3X9_&OQ-\0+K2KNSU/P?JWVB11JGA"S9X-8T1&;:S2O).?,:(Y
MWH88B<':20 VOHGB+XEW'Q<U'PK>>(/"DMCIMA9ZI--!X<N8Y9XYI9D:)2;]
M@C 0'#D,,M]WCD&>R45X+\$?C)K'Q2?39I_B!X"FNY5EFN_"NG6#G4H41F7!
M8W[%2/E)8PXYZ#-0>'?BYX['@?PMXVUB^\-76E:UJ-O8G1++2;BWNQY]SY"^
M7.UW(KLN=Y'E#(5N5ZT ?0-%>>?'+Q%XJ\&?#_6?$OAB^T>W.C6%S?3VNK:;
M+=_:?+3<J(T=Q%Y?W6!)#]1P,<U(OB1JO@^+0M.\3[?%'B+7A)-IUOX:TO[&
MK*BQ%HR)[MQN D9MY=5VJ>A W CTZBO-=-^+5U<Z;(]KX<UKQ5>C4]0LO)T>
MRAMUC6VN&A.]Y[D1 \ #,@:3!81J 55=$^+@\5>*O!EMI<'EZ3KFG:G<SK>1
M%+JWGM9;>(Q$!MH*M)*K#YLE1@XY(!Z317EGCCX@>)-#\3^+HM.DTM=*\/>%
MUUHP75G+)/<3O]K"CS5F5413;*2-C%MQ^9>M:FM_$#4-,D^'(CM[>0>([LP7
M:[&+*HL)[C]U\W!WQ*.<\$]^0 =_17@GPR^-GB;X@76DW=IJ?@_5A<2*-4\'
MV3/!K&B(S;6:5Y)SYC1'.]##$3@[22 &Z>?XJ:O#\9(-$%K9'P:\YT5[PJ_V
MD:K]G^U!=V[9Y1B^7[N?,XSVH&>J45Q?P]\1ZUK&K>,].UN:PN9=%U<6=O-I
M]J]N&A>UMYUWJ\LF7'GE2P(!V@[1TKM*!!1110 4444 %%%% %;4/^/.3\/Y
MBL6MK4/^/.3\/YBL6NBGL7'8****U*"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -'1_\ EM^'
M]:TJS='_ .6WX?UK2KEG\3,WN%%%%0(**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ JEJW_'NO\ O_T-7:I:M_Q[K_O_ -#51^)#6YDT445U
MF@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)ED"$,555)P""?6O,O'G[07C_P"%.I^*_#%_I6F^+?$-GHT&MZ5>Z78SP0O
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M4?,RXHT0'1?"'X1>(/A=(Z3:_H>K073F?4KM=$N(]1U"8K@22W,E[+DY[;,
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M6^4]1Q@G'% 'GOB#X3^,O'<FAVWB2Q\)&]TJ\M;E?&UF\@U1U@F20^5;^0!
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MMM<<D[GPK^">L> KCP0;J?26BT&UUJWF33D:&,_:[N*:'R8MN$15C(*Y^7@
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MV]XZ_P"@3X>_\!I__CU>O_JKF79?>?0?\0XS[^6/_@2/MZBOB'_AM[QU_P!
MGP]_X#3_ /QZC_AM[QU_T"?#W_@-/_\ 'J/]5<R[+[P_XAQGW\L?_ D?;U%?
M$/\ PV]XZ_Z!/A[_ ,!I_P#X]1_PV]XZ_P"@3X>_\!I__CU'^JN9=E]X?\0X
MS[^6/_@2/MZBOB'_ (;>\=?] GP]_P" T_\ \>H_X;>\=?\ 0)\/?^ T_P#\
M>H_U5S+LOO#_ (AQGW\L?_ D?;U%?$/_  V]XZ_Z!/A[_P !I_\ X]1_PV]X
MZ_Z!/A[_ ,!I_P#X]1_JKF79?>'_ !#C/OY8_P#@2/MZBO@7QM^WU\0?#?AF
M]U&VT?PR\\.S:LMK<%3EU4YQ..Q/>O+/^'I_Q7_Z%_P;_P" 5W_\E52X3S.6
MR7WGS69\,YAE-94,4ES-7T=]+M?H?J;17YK7_P#P4$_:&TO7=-T2]^&FD6>L
MZFB26.G7&@ZBEQ=JY(1HHS/N<,00"H.<&L"\_P""HGQ>T^ZFM;KPQX1MKF!V
MBEAFT^\1XW4X964W.00000:4>%<QG\/*_P#MY'CK+Z[VM]Y^I%%?F%H'_!2[
MXV>*]7M]*T3P9X9UC5+@D0V.GZ5>SSRD DA42Y+' !/ Z UK>$O^"@'[0_CW
M5KO3/#GPWT37-0L\FYM[#1;^5[?!(/F!;CY.01\V.>.M*7"N84[N?*K?WD#R
M^M'>WWGZ3T5^=>G_ +;'[3VK>)+_ ,/V?PCT^XUNP"M=V,?A_43+;JV=ID7S
M_E#8.">#VS7*Z]_P4P^-7A?5[K2M9\'>%])U.U;9/97VF7L,T38SAD:Y!!P1
MU'>ICPOCZCY8.+>_Q+82R^M)V5OO/T^HK\LO^'I_Q7_Z%_P;_P" 5W_\E4?\
M/3_BO_T+_@W_ , KO_Y*K;_5'-.T?O*_LW$=E]Y^IM%?EE_P]/\ BO\ ]"_X
M-_\  *[_ /DJC_AZ?\5_^A?\&_\ @%=__)5'^J.:=H_>']FXCLOO/U-HK\LO
M^'I_Q7_Z%_P;_P" 5W_\E4?\/3_BO_T+_@W_ , KO_Y*H_U1S3M'[P_LW$=E
M]Y^IM%?EE_P]/^*__0O^#?\ P"N__DJC_AZ?\5_^A?\ !O\ X!7?_P E4?ZH
MYIVC]X?V;B.R^\_4VBORR_X>G_%?_H7_  ;_ . 5W_\ )5'_  ]/^*__ $+_
M (-_\ KO_P"2J/\ 5'-.T?O#^S<1V7WGZFT5^67_  ]/^*__ $+_ (-_\ KO
M_P"2J/\ AZ?\5_\ H7_!O_@%=_\ R51_JCFG:/WA_9N([+[S]3:*_++_ (>G
M_%?_ *%_P;_X!7?_ ,E4?\/3_BO_ -"_X-_\ KO_ .2J/]4<T[1^\/[-Q'9?
M>?J]H_\ RV_#^M:5?DK;?\%6OBU:[MGAWP6=W7=97?\ \E5/_P /9/B[_P!"
MYX*_\ ;S_P"2JPEP?FK=^6/WDO+,1?9?>?K'17Y.?\/9/B[_ -"YX*_\ ;S_
M .2J/^'LGQ=_Z%SP5_X WG_R54_ZFYK_ "Q_\"%_9F([+[S]8Z*_)S_A[)\7
M?^A<\%?^ -Y_\E4?\/9/B[_T+G@K_P  ;S_Y*H_U-S7^6/\ X$']F8CLOO/U
MCHK\G/\ A[)\7?\ H7/!7_@#>?\ R51_P]D^+O\ T+G@K_P!O/\ Y*H_U-S7
M^6/_ ($']F8CLOO/UCHK\G/^'LGQ=_Z%SP5_X WG_P E4?\ #V3XN_\ 0N>"
MO_ &\_\ DJC_ %-S7^6/_@0?V9B.R^\_6.BOR<_X>R?%W_H7/!7_ ( WG_R5
M1_P]D^+O_0N>"O\ P!O/_DJC_4W-?Y8_^!!_9F([+[S]8Z*_)S_A[)\7?^A<
M\%?^ -Y_\E4?\/9/B[_T+G@K_P  ;S_Y*H_U-S7^6/\ X$']F8CLOO/UCHK\
MG/\ A[)\7?\ H7/!7_@#>?\ R51_P]D^+O\ T+G@K_P!O/\ Y*H_U-S7^6/_
M ($']F8CLOO/UCHK\G/^'LGQ=_Z%SP5_X WG_P E4?\ #V3XN_\ 0N>"O_ &
M\_\ DJC_ %-S7^6/_@0?V9B.R^\_6.BOR<_X>R?%W_H7/!7_ ( WG_R51_P]
MD^+O_0N>"O\ P!O/_DJC_4W-?Y8_^!!_9F([+[S]8Z*_)S_A[)\7?^A<\%?^
M -Y_\E4?\/9/B[_T+G@K_P  ;S_Y*H_U-S7^6/\ X$']F8CLOO/UCHK\G/\
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MJCFG:/WE_P!FXCLOO/U-HK\LO^'I_P 5_P#H7_!O_@%=_P#R51_P]/\ BO\
M]"_X-_\  *[_ /DJC_5'-.T?O#^S<1V7WGZFT5^67_#T_P"*_P#T+_@W_P
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M_P"'I_Q7_P"A?\&_^ 5W_P#)5'^J.:=H_>']FXCLOO/U-HK\LO\ AZ?\5_\
MH7_!O_@%=_\ R51_P]/^*_\ T+_@W_P"N_\ Y*H_U1S3M'[P_LW$=E]Y^IM%
M?EE_P]/^*_\ T+_@W_P"N_\ Y*H_X>G_ !7_ .A?\&_^ 5W_ /)5'^J.:=H_
M>']FXCLOO/U-HK\LO^'I_P 5_P#H7_!O_@%=_P#R51_P]/\ BO\ ]"_X-_\
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M,/CZW)-U')+ED].6*O[L6MTSY-HKZR_X8._ZGC_RD?\ V^C_ (8._P"IX_\
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MU4?ZT91_S^_\EE_\B'U_#?S?@_\ (_/6BOT*_P"'2O\ U57_ ,MW_P"ZJ/\
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M_P .??\ JK7_ );?_P!UT?\ #GW_ *JU_P"6W_\ =='^M>3?\_\ _P EG_\
M(A_:.%_G_!_Y'YQT5^CG_#GW_JK7_EM__=='_#GW_JK7_EM__=='^M>3?\__
M /R6?_R(?VCA?Y_P?^1^<=%?HY_PY]_ZJU_Y;?\ ]UT?\.??^JM?^6W_ /==
M'^M>3?\ /_\ \EG_ /(A_:.%_G_!_P"1^<=%?HY_PY]_ZJU_Y;?_ -UT?\.?
M?^JM?^6W_P#=='^M>3?\_P#_ ,EG_P#(A_:.%_G_  ?^1^<=%?HY_P .??\
MJK7_ );?_P!UT?\ #GW_ *JU_P"6W_\ =='^M>3?\_\ _P EG_\ (A_:.%_G
M_!_Y'YQT5^CG_#GW_JK7_EM__=='_#GW_JK7_EM__=='^M>3?\__ /R6?_R(
M?VCA?Y_P?^1^<=%?HY_PY]_ZJU_Y;?\ ]UT?\.??^JM?^6W_ /=='^M>3?\
M/_\ \EG_ /(A_:.%_G_!_P"1^<=%?HY_PY]_ZJU_Y;?_ -UT?\.??^JM?^6W
M_P#=='^M>3?\_P#_ ,EG_P#(A_:.%_G_  ?^1^<=%?HY_P .??\ JK7_ );?
M_P!UT?\ #GW_ *JU_P"6W_\ =='^M>3?\_\ _P EG_\ (A_:.%_G_!_Y'YQT
M5^CG_#GW_JK7_EM__=='_#GW_JK7_EM__=='^M>3?\__ /R6?_R(?VCA?Y_P
M?^1^>WA>2"'Q-I+W./LRW<+2[NFT.,Y_#-?;5=?_ ,.??^JM?^6W_P#==>AM
M^PWXK\&^%;2VT_Q3;^,KNW'EGS;/[!(R ?+RTLBL>V25[=:7^LV45I*,:ZOY
MJ27WM)'X)XIY-7SRGA\9EUZCI73BD[V=G==]K-+7;L>&UX#^T])";[P^BX^T
MK',S^NTE-OZAOUK[F\-_LE^/-7U)(=3M;?0;3/SW4UQ',0/]E(V))]B0/>N>
M\6?\$IKWQEKMQJE]\7!YLIPL:^&SMC4=%7_2^@_Q/>JJ<195AYVG77RO+\8I
MH^*\->',;A,XAFF.@Z4*:E9233DY)QM;>R3O=]E;R_,NBOT<_P"'/O\ U5K_
M ,MO_P"ZZ/\ AS[_ -5:_P#+;_\ NNE_K7DW_/\ _P#)9_\ R)_6']HX7^?\
M'_D?G'17Z.?\.??^JM?^6W_]UT?\.??^JM?^6W_]UT?ZUY-_S_\ _)9__(A_
M:.%_G_!_Y'YQT5^CG_#GW_JK7_EM_P#W71_PY]_ZJU_Y;?\ ]UT?ZUY-_P _
M_P#R6?\ \B']HX7^?\'_ )'YQT5^CG_#GW_JK7_EM_\ W71_PY]_ZJU_Y;?_
M -UT?ZUY-_S_ /\ R6?_ ,B']HX7^?\ !_Y'YQT5^CG_  Y]_P"JM?\ EM__
M '71_P .??\ JK7_ );?_P!UT?ZUY-_S_P#_ "6?_P B']HX7^?\'_D?G'17
MZ.?\.??^JM?^6W_]UT?\.??^JM?^6W_]UT?ZUY-_S_\ _)9__(A_:.%_G_!_
MY'YQT5^CG_#GW_JK7_EM_P#W71_PY]_ZJU_Y;?\ ]UT?ZUY-_P __P#R6?\
M\B']HX7^?\'_ )'YQT5^CG_#GW_JK7_EM_\ W71_PY]_ZJU_Y;?_ -UT?ZUY
M-_S_ /\ R6?_ ,B']HX7^?\ !_Y'YQT5^CG_  Y]_P"JM?\ EM__ '74%W_P
M2&^RQA_^%L;LG&/^$<Q_[=T_]:LG?_+_ /\ )9__ "(?VAAOY_P?^1^=5%?H
M5_PZ5_ZJK_Y;O_W51_PZ5_ZJK_Y;O_W55?ZT91_S^_\ )9?_ "(_K^&_F_!_
MY'YZT5^A7_#I7_JJO_EN_P#W51_PZ5_ZJK_Y;O\ ]U4?ZT91_P _O_)9?_(A
M]?PW\WX/_(_/6BOT*_X=*_\ 55?_ "W?_NJC_ATK_P!55_\ +=_^ZJ/]:,H_
MY_?^2R_^1#Z_AOYOP?\ D?GK17Z%?\.E?^JJ_P#EN_\ W51_PZ5_ZJK_ .6[
M_P#=5'^M&4?\_O\ R67_ ,B'U_#?S?@_\C\]:*_0K_ATK_U57_RW?_NJC_AT
MK_U57_RW?_NJC_6C*/\ G]_Y++_Y$/K^&_F_!_Y'YZT5^A7_  Z5_P"JJ_\
MEN__ '51_P .E?\ JJO_ );O_P!U4?ZT91_S^_\ )9?_ "(?7\-_-^#_ ,C\
M]:*_0K_ATK_U57_RW?\ [JH_X=*_]55_\MW_ .ZJ/]:,H_Y_?^2R_P#D0^OX
M;^;\'_D?GK17Z%?\.E?^JJ_^6[_]U4?\.E?^JJ_^6[_]U4?ZT91_S^_\EE_\
MB'U_#?S?@_\ (_/6BOT*_P"'2O\ U57_ ,MW_P"ZJ/\ ATK_ -55_P#+=_\
MNJC_ %HRC_G]_P"2R_\ D0^OX;^;\'_D?GK17Z%?\.E?^JJ_^6[_ /=5'_#I
M7_JJO_EN_P#W51_K1E'_ #^_\EE_\B'U_#?S?@_\C\]:*_0K_ATK_P!55_\
M+=_^ZJ/^'2O_ %57_P MW_[JH_UHRC_G]_Y++_Y$/K^&_F_!_P"1^>M%?H5_
MPZ5_ZJK_ .6[_P#=5'_#I7_JJO\ Y;O_ -U4?ZT91_S^_P#)9?\ R(?7\-_-
M^#_R/SUHK]"O^'2O_55?_+=_^ZJ/^'2O_55?_+=_^ZJ/]:,H_P"?W_DLO_D0
M^OX;^;\'_D?GK6WX)LM9U#Q5ID/A_P P:P9E-NT9P48<[B>P R3GC&:^[_\
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M;W)&=C$<'V^O;.>U=O'^R#XK^%UOJGB34/B=<^-((X,/ILVEFW5?G7,BD3N
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M/#'Q*CA\0W_@ZYE&B:GI>HW=K(D(<&"0F-HV24*$& 6"[ 0QI#/G;P[XT@^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *I:M_Q[K_ +_]#5VJ6K?\>Z_[_P#0U4?B0UN9-%%%=9H%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% $-Y:0W]K-;7$:S6\R&.2-NC*1@@_A4H 4  8 Z"EHI^0[NUN@4444A!1
M110 4444 %0O9P27D5TT2M<1(T:2$<JK%2P'U*K^5344]AIM;!1112$%%%%
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M .H;_P"1*TN4:]%9'_$__P"H;_Y$H_XG_P#U#?\ R)1<#7HK(_XG_P#U#?\
MR)1_Q/\ _J&_^1*+@:]%9'_$_P#^H;_Y$H_XG_\ U#?_ ")1<#7HK(_XG_\
MU#?_ ")1_P 3_P#ZAO\ Y$HN!KT5D?\ $_\ ^H;_ .1*/^)__P!0W_R)1<#7
MHK(_XG__ %#?_(E'_$__ .H;_P"1*+@:]%9'_$__ .H;_P"1*/\ B?\ _4-_
M\B47 UZ*R/\ B?\ _4-_\B4?\3__ *AO_D2BX&O161_Q/_\ J&_^1*/^)_\
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M !4G_4+_ /(E &Y16'_Q4G_4+_\ (E'_ !4G_4+_ /(E &Y16'_Q4G_4+_\
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M-_\ (E%P->BLC_B?_P#4-_\ (E'_ !/_ /J&_P#D2BX&O161_P 3_P#ZAO\
MY$H_XG__ %#?_(E%P->BLC_B?_\ 4-_\B4?\3_\ ZAO_ )$HN!KT5D?\3_\
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M^1K:KC+'_A(/M2;?[-SSU\ST-:__ !4G_4+_ /(E85-R)&Y16'_Q4G_4+_\
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M%% !1110!HZ/_P MOP_K6E6;H_\ RV_#^M:5<L_B9F]PHHHJ!!1110 4444
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M?%.X\#S>(O EI)X0TRWT-_L$:PW3);%4MG>XA=@R8"G8RNI)R<BM/P'I-O\
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MYX"TWPW;:SJ^F^(M#@OM+_M;38;^Q02ZC%YBQ[80DC ON91ABH((8$KS7<^
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MZJ<CG@U';2YS.N?MK:]XC\66FB>"O"5W8FVBU!M8;5[.VNYX9;14,T<<*ZA
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MN'9V4/@':%X'R], ]#J/AE^U-K7B;X9Z)KVK?#/Q5>WUQICZG=7&AVEL-/\
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M&G3LCSV=G#;R-&25+(@4D9 XR/2K3=R33HHHJ@"BBB@ HHHH **** "BBB@
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MN?Q-X>^Q00VNJ:9<1K(;@1XV2LC,0V1D@X.?W8/R5J'[/O@[7M=UV\F\:1Z
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MX*5?#CPCJ\NFZEX9\90W,?/%G:%74]&4_:N0:R_^'I_PH_Z%_P 9?^ 5I_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOQ.N/%$?B66]%OX?T>R-I+<$;DOQJ4UO@*1A6)N,]MN*8K'W0GQ>\"2>(O\
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ML0\9S^UJVLFU913WLKO5[7OMIW/QO_X=_P#Q[_Z$/_RL6'_Q^C_AW_\ 'O\
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MA]TO_DC#^UJ_9?C_ )GXJ_\ #N[]H/\ Z)__ .5K3_\ Y(H_X=W?M!_]$_\
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M_P#_ "M:?_\ )%)_P[U^/MNR-<> &\K=@[=9T_)]O^/BOVKJEJW_ ![K_O\
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M HHHH **** +.G_\?D?X_P C6U6+I_\ Q^1_C_(UM5SU-R);A11161(4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ JEJW_'NO^_\ T-7:I:M_Q[K_ +_]
M#51^)#6YDT445UF@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!9T__ (_(_P ?Y&MJL73_ /C\C_'^1K:KGJ;D2W"BBBLB0HHHH **
M** "BBB@ HHHH P_^$,TO^[=?^!T_P#\71_PAFE_W;K_ ,#I_P#XNMRB@9A_
M\(9I?]VZ_P# Z?\ ^+H_X0S2_P"[=?\ @=/_ /%UN44 8?\ PAFE_P!VZ_\
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M-+_NW7_@=/\ _%T?\(9I?]VZ_P# Z?\ ^+K<HH P_P#A#-+_ +MU_P"!T_\
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M_P 71_PBNG?W;G_P,F_^+K7HHL@,C_A%=._NW/\ X&3?_%T?\(KIW]VY_P#
MR;_XNM>BBR R/^$5T[^[<_\ @9-_\71_PBNG?W;G_P #)O\ XNM>BBR R/\
MA%=._NW/_@9-_P#%T?\ "*Z=_=N?_ R;_P"+K7HHL@,C_A%=._NW/_@9-_\
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M3?\ Q='_  BNG?W;G_P,F_\ BZUZ*+("A8^$]->Z0%;G'/\ R^3>A_VZUO\
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M2"4<=4)QD9QD9Z"SU*&^N+R"-+A7M)!%(9K:2)6)4-E&90)!AA\R$@'(SD$
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M+73>$]%-\)1?&R@,XF!#^9Y:[MP/(.<YS5J5V!K44450!1110 4444 %%%%
M!1110 4444 %%%% !1110!HZ/_RV_#^M:59NC_\ +;\/ZUI5RS^)F;W"BBBH
M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<_X=\>:%XL
MUC7]*TJ^^U7^@W*VFHP^3(GD2L@<+EE ;Y2#E217E'[7'AO6/$?AGP>MKI6H
M:]X;M?$EI<^(])TQ&EENK!=VX&%?FF0,4)C ).!P<<?.>E^"KG1](\?PZ+\)
MM5E\(:IXYLY;6SUG1=16&UM!&=UT=/BV2W4*MG$/097(&, &?<?C;QYH7PZT
M>/5?$-]_9]A)<PVBS>3)+F65PD:X16/+$#.,#OBN@K\Z6^$NL^(/A7\0GD^'
M=Y-!9>,;*_TFQ'A2:P*V;/']K:RLI3)(D;A!NC1CD 9 Z#2^/FA3^)I/'/\
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MROPMHH_U)P__ #^E]R#^RH?S,_>+2_VD/A+'YN_XH^"USC&[Q!:#U_Z:5?\
M^&E/A%_T5/P5_P"%#9__ !ROP.HK.7 V&D[^VE]R%_9,/YV?OC_PTI\(O^BI
M^"O_  H;/_XY1_PTI\(O^BI^"O\ PH;/_P".5^!U%+_47#?\_P"7W(7]D0_G
M9^^/_#2GPB_Z*GX*_P#"AL__ (Y1_P -*?"+_HJ?@K_PH;/_ ..5^!U%'^HN
M&_Y_R^Y!_9$/YV?OC_PTI\(O^BI^"O\ PH;/_P".4?\ #2GPB_Z*GX*_\*&S
M_P#CE?@=11_J+AO^?\ON0?V1#^=G[X_\-*?"+_HJ?@K_ ,*&S_\ CE'_  TI
M\(O^BI^"O_"AL_\ XY7X'44?ZBX;_G_+[D']D0_G9^^/_#2GPB_Z*GX*_P#"
MAL__ (Y1_P -*?"+_HJ?@K_PH;/_ ..5^!U%'^HN&_Y_R^Y!_9$/YV?OC_PT
MI\(O^BI^"O\ PH;/_P".4?\ #2GPB_Z*GX*_\*&S_P#CE?@=11_J+AO^?\ON
M0?V1#^=G[X_\-*?"+_HJ?@K_ ,*&S_\ CE'_  TI\(O^BI^"O_"AL_\ XY7X
M'44?ZBX;_G_+[D']D0_G9^^/_#2GPB_Z*GX*_P#"AL__ (Y1_P -*?"+_HJ?
M@K_PH;/_ ..5^!U%'^HN&_Y_R^Y!_9$/YV?OC_PTI\(O^BI^"O\ PH;/_P".
M4?\ #2GPB_Z*GX*_\*&S_P#CE?@=11_J+AO^?\ON0?V1#^=G[X_\-*?"+_HJ
M?@K_ ,*&S_\ CE'_  TI\(O^BI^"O_"AL_\ XY7X'44?ZBX;_G_+[D']D0_G
M9^^/_#2GPB_Z*GX*_P#"AL__ (Y37_:6^$:(S#XH^#9"!G9%KUJ[M[!1(23[
M#DU^"UG=-9W"2JJOM/*N,AAZ&N\TRSTO4HX;V"UC1U.?E&-K#M@5\'Q1EN&X
M8A&M6C4G3EHI1Y;*7123M9/O=]>VOV_#7 =/B2<J5+%*$XZN+6KCU<6KW:[6
M[=S]?OV1OCY)\=_"/B"YO"%U+3]6G'DG&Y+65VDM\X]%+1_]LJ]XK\4/A[\6
M_%_PIDU"3PGKD^BR:A&L-RT"HQ=5)*_>4X()/(P>3S7Z0_LD_"SQGIVCIXV^
M)'B#6=7\1ZE%FST[4KV21-/@89SY;':LC#KQ\HXX)85^693FD\5&-%Q;DMWT
M/=\0> \/D%6MF<:\:=&;_=TTFYMV5U;1))W=[NRMULG]'4445]4?@@4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !5+5O^/=?]_^AJ[5+5O^/=?]
M_P#H:J/Q(:W,FBBBNLT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** +.G_\?D?X_P C6U6+I_\ Q^1_C_(UM5SU-R);A11161(4444
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M'BC]H3XN65A\:M?L/';65AX'U*QMM/TE=)LFBD2:;8RR,8=^T*.,,#SUK?\
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MMHB@&#G<7SD<C'/FU?T*T5V4>,X4*<:5/#>ZM%[[?YQN:QS10BHQIZ+S_P"
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MX!_/517]"M%'^O'_ %#?^3__ &H?VM_<_'_@'\]5%?T*T4?Z\?\ 4-_Y/_\
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M=_C_ , _G'HK^CBBC_7W_J&_\G_^U#^V/^G?X_\  /YQZ*_HXHH_U]_ZAO\
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH T='_P"6WX?UK2K-T?\
MY;?A_6M*N6?Q,S>X4445 @HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "J6K?\>Z_P"__0U=JEJW_'NO^_\ T-5'XD-;F311176:!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %G3_ /C\C_'^1K:K
M%T__ (_(_P ?Y&MJN>IN1+<****R)"BBB@ HHHH **** "BBB@##_P"$QL/^
M??5?_!1=_P#QJC_A,;#_ )]]5_\ !1=__&JW** ,/_A,;#_GWU7_ ,%%W_\
M&J/^$QL/^??5?_!1=_\ QJMRB@##_P"$QL/^??5?_!1=_P#QJC_A,;#_ )]]
M5_\ !1=__&JW** ,/_A,;#_GWU7_ ,%%W_\ &J/^$QL/^??5?_!1=_\ QJMR
MB@##_P"$QL/^??5?_!1=_P#QJC_A,;#_ )]]5_\ !1=__&JW** ,/_A,;#_G
MWU7_ ,%%W_\ &J/^$QL/^??5?_!1=_\ QJMRB@##_P"$QL/^??5?_!1=_P#Q
MJC_A,;#_ )]]5_\ !1=__&JW** ,/_A,;#_GWU7_ ,%%W_\ &J/^$QL/^??5
M?_!1=_\ QJMRB@##_P"$QL/^??5?_!1=_P#QJC_A,;#_ )]]5_\ !1=__&JW
M** ,/_A,;#_GWU7_ ,%%W_\ &J/^$QL/^??5?_!1=_\ QJMRB@##_P"$QL/^
M??5?_!1=_P#QJC_A,;#_ )]]5_\ !1=__&JW** ,/_A,;#_GWU7_ ,%%W_\
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M=2_\%ES_ /&ZUZ*UU-3(_P"$ILO^>.I?^"RY_P#C='_"4V7_ #QU+_P67/\
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M_P#QNM>BC4#(_P"$ILO^>.I?^"RY_P#C='_"4V7_ #QU+_P67/\ \;K7HHU
MKZ7XML8_-S!J9Z?=TJZ/KZ1U?_X3&P_Y]]5_\%%W_P#&JM:/_P MOP_K6E7-
M/XB'N8?_  F-A_S[ZK_X*+O_ .-4?\)C8?\ /OJO_@HN_P#XU6Y14$F'_P )
MC8?\^^J_^"B[_P#C5'_"8V'_ #[ZK_X*+O\ ^-5N44 8?_"8V'_/OJO_ (*+
MO_XU1_PF-A_S[ZK_ ."B[_\ C5;E% &'_P )C8?\^^J_^"B[_P#C5'_"8V'_
M #[ZK_X*+O\ ^-5N44 8?_"8V'_/OJO_ (*+O_XU1_PF-A_S[ZK_ ."B[_\
MC5;E% &'_P )C8?\^^J_^"B[_P#C5'_"8V'_ #[ZK_X*+O\ ^-5N44 8?_"8
MV'_/OJO_ (*+O_XU1_PF-A_S[ZK_ ."B[_\ C5;E% &'_P )C8?\^^J_^"B[
M_P#C5'_"8V'_ #[ZK_X*+O\ ^-5N44 8?_"8V'_/OJO_ (*+O_XU1_PF-A_S
M[ZK_ ."B[_\ C5;E% &'_P )C8?\^^J_^"B[_P#C5'_"8V'_ #[ZK_X*+O\
M^-5N44 8?_"8V'_/OJO_ (*+O_XU1_PF-A_S[ZK_ ."B[_\ C5;E% &'_P )
MC8?\^^J_^"B[_P#C5'_"8V'_ #[ZK_X*+O\ ^-5N44 8?_"8V'_/OJO_ (*+
MO_XU1_PF-A_S[ZK_ ."B[_\ C5;E% &'_P )C8?\^^J_^"B[_P#C5'_"8V'_
M #[ZK_X*+O\ ^-5N44 8?_"8V'_/OJO_ (*+O_XU1_PF-A_S[ZK_ ."B[_\
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M@\N*3A&WE=ASZ!B1W% B;_A,;#_GWU7_ ,%%W_\ &J/^$QL/^??5?_!1=_\
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M_C='_"4V7_/'4O\ P67/_P ;K7HHU S['Q79+=(3!J6.>FEW1['_ *9UK_\
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MC_P\1_9\_P"B@?\ E%U#_P"1Z/\ AXC^SY_T4#_RBZA_\CT?V1F7_0-/_P
ME_D'U:O_ "/[F?1U%?./_#Q']GS_ **!_P"474/_ )'H_P"'B/[/G_10/_*+
MJ'_R/1_9&9?] T__  "7^0?5J_\ (_N9]'45\X_\/$?V?/\ HH'_ )1=0_\
MD>C_ (>(_L^?]% _\HNH?_(]']D9E_T#3_\  )?Y!]6K_P C^YGT=17SC_P\
M1_9\_P"B@?\ E%U#_P"1Z/\ AXC^SY_T4#_RBZA_\CT?V1F7_0-/_P  E_D'
MU:O_ "/[F?1U%?./_#Q']GS_ **!_P"474/_ )'H_P"'B/[/G_10/_*+J'_R
M/1_9&9?] T__  "7^0?5J_\ (_N9]'45\X_\/$?V?/\ HH'_ )1=0_\ D>C_
M (>(_L^?]% _\HNH?_(]']D9E_T#3_\  )?Y!]6K_P C^YGT=17SC_P\1_9\
M_P"B@?\ E%U#_P"1Z/\ AXC^SY_T4#_RBZA_\CT?V1F7_0-/_P  E_D'U:O_
M "/[F4I/A#K?CC]HSXP>?JWB;PGX>U;2=-M/MNE001QZ@ODR)(BS3V\G*YQF
M(JPW<GIBMX%^!^I^'/VA/%MEX=U'Q)X(\+67AW2;&QOM/M;>2.Z$:N#'YMU;
MS*S+U.W!RW/:M;_AXC^SY_T4#_RBZA_\CT?\/$?V?/\ HH'_ )1=0_\ D>C^
MR,Q_Z!I_^ 2_R']7K_R/[F<_\2-+F\$^)?&FK^$3\4-"\>RV<1-WI^@KJ>F>
M([B.(+%(ZQPR0HWRA6/^CXR3@"MWP'=Z_P#M!>-O#]SXEABL]+\"1Q-JEI:N
M?*NO$9B4R)P2#';;CP&/[Q\9(6G_ /#Q']GS_HH'_E%U#_Y'JCHW[>7[-7AN
MQ%GI/B^UTNSWO*+>S\/WT,>]F+.VU;8#)8DD]R2:/[(S'_H&G_X!+_(/JU?_
M )]O[F<7NU+X=?#GX[> -6\+:WJGB;Q)K&IW&D"RTJXN8=42]C"Q2"=4:,;,
M_-N8;=GK6'X4\-^*O@C\-;?2_AQ8_$71?'T$MI%=>%[[1/MVA:A=8C6XG6Y*
M/%%&_P S%UN4QC[HZ#HOVA?VX/".I?"S3;_X7^)X-8U&76H%D5(Y8)8HX&6=
MMT<BJX5BL:9QA@SC)P17UOX7\0VGB[PWI6N:>_F6.I6L5W WJCH&7\<&O$E/
MDQ,\)-.,X6NGH]?+^MSUL5DN+P>74,SK1M3K2G%?]N6W]6W;_"SP3]I+PO>:
M[\1?A=?^(?#FI>*?AW:?;1K>EZ;:2WZ)<O"HMY);:-6>55.X A3M//&>? _
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M+.G_ /'Y'^/\C6U6+I__ !^1_C_(UM5SU-R);A11161(4444 %%%% !1110
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M[G&""#C!KX/D^'OC;X%^$OAG\<KW3;.*9M2;4-:U"TOI9+V[AOR& FA,"+$
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M .-T?6\/_P _(_>@]I#^9'GM%>A?\,Z_%?\ Z)CXR_\ !!=__&Z/^&=?BO\
M]$Q\9?\ @@N__C='UO#_ //R/WH/:0_F1Y[17H7_  SK\5_^B8^,O_!!=_\
MQNC_ (9U^*__ $3'QE_X(+O_ .-T?6\/_P _(_>@]I#^9'GM%>A?\,Z_%?\
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M_>@]I#^9'G%%>C_\,U_%W_HE?C7_ ,)V\_\ C='_  S7\7?^B5^-?_"=O/\
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M._\ UZ.>(71G45H_V/\ ]-O_ !W_ .O1_8__ $V_\=_^O1SQ"Z,ZBM'^Q_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 45YWXB^.6@^&?C#X<^&]U9ZK)KNO6TEU;7$%INM45 Y(=\Y!^0]%(&1N(
MS7HE !17B/[7GQ$U_P"&?PLLM5\.:I-I%]-K5E9R75O:QW,HAD<APD;QN"V.
MF%)STKR3X@?%KXJ>#]-^(FH^']6\2:EX0TSPTMY;>(/%OAR+3;FVU+SPOEPQ
MM:P"9#&23NB(!_BZ @['V317RX_C#XA:E\*[W5? ?B3QIXJ\;_V5%<1:9XD\
M,Q:?8EG,8E>*1M/MQ*Z*S,B"4AL#AQP7_#'XN>+)_B,F@'Q5-K-S=Z0TZ>&?
MB#I3:!JBW:$G,,D%GY4D)4-NP)&7;D9% 6/J"BO!_P!JCXD>+/AQ\&])UC3;
MP>'==N-7L+2[?3474/+21\2I%YL'[SV/E G ^7M7F'B[]HSX@_!O7M7UB'3O
M$GQ#^'L-E:QK<>+-+70+I=1EG\L10M]CA,B[#DYA(!_C'0@6/L>BOF.X_:C\
M?&7QZD/PXTB*3P'917NN0/XB=V;?%YWDPL+4 NL8;)(V[A@%AR<7XC?MWII,
M>I0^%= L)KB/0K35[*7Q%J?V1[TW2*T26MLJ,UR5W ,H=#E6 /&: L?6U%?&
M&L?MY^)/"NIRZ-J/@*PDFMK^RTFXUJ^U4Z5;I=7,/FJ98'CE:%4 ;?F5MNT_
M-SBM$?M^1V_BR;PM+H?A^[O8+Q89?$EMXDSX=6)XO,CD-XMN[*Q.4V&/&Y3\
MW4 "S/KZBOEN\_;6N;6^TJRD\)Z+IKWMC-=C5-6\701:/.Z2%!#;7\44L<KL
M!G#^5M_B K(U?]LG4='^)D>A6^@WE_J^N6VEQZ5H\VKV3V$=Q=9R?/@@9MBA
M22_G2ALC:JYX L?7=%?+.J?MD>(-#^(B?#B?P%8WOCS^V8M+:"'7&BLFBFA$
ML5PLK6Y;&W=N79D;1C=NP.DD_:RL+;1_&]AJ[>&?"GCOPW<O:#2=:\1I%:WC
M!%<20S&)9'4JV<>4#NPIQG< +'T%17Q1\'?VHOB<+#P);ZMH\7CC5_&]I<ZA
M;S7&L06-O8P6[L)&*1:>&08!)4O,3L&#EMM6K7_@HI96_AO3/%>JZ-H4>A7]
MU-:G2M.\1+<ZW:[5?9-):F)?D=HR.HP'0]Z L?9M%?-'PE_;$3Q_XV\&Z%J%
MIX<B'BVSFN;--#\0"_N=/DC3S!!>1>6OENR$X.?O*RX]*?QB\??$[P[\1/%B
MWFJ:]X+\&6]C')H&L:%X>BU>R>01EI9-0/DS31J'P,*J?*"<]"0+'U'17SK\
M.?VIY_$D/B"RNK+2=:N_#WA2+Q!/J^AW[FSOY"K%HXE>(-&,H1ELD'(*\5@Z
M7^V;XE\4WEO;>&_A?'JLG_"*)XKNO-\0>2(8F5CY*_Z,Q=\@*N ,EN=H!- 6
M/JBBOCOXD?MO2W&F^%CX0T6\G%_8Z=J=[=6FJ00?99+F4Q)9.9;2=6)8-N(5
M6PN0170+^VY+J/AWPS+H_@8:AXDU(:B=2T6?78+-=(%F^QVEN)D5,%BN"VW@
M]S@$"Q]245\C^+_VQ;_5_ GQ0L]$&D:;XI\.:+%JMGJWAW6(=<L75Y%0XD,*
M*'4M@HR'KGTKZ?\ !>H7&K>#M"OKN3S;JZL()I9-H&YVC4L<#@9)/2@#9HHK
MS;]HSQ?J_@/X->(==T*[^PZK:_9_)N/+23;NN(D;Y7!4Y5F'([UT8>C+$UH4
M(;R:2OYNQUX+"SQV*I82FTI5)**OM>3LK[Z:]CTFBOS;_P"&N_BU_P!#9_Y3
M;3_XU1_PUW\6O^AL_P#*;:?_ !JOMO\ 4O,/YX??+_Y$_5O^(6YU_P _:7_@
M4_\ Y _22BOS;_X:[^+7_0V?^4VT_P#C5>D_LY_M&?$/QY\9?#VA:[XA^W:5
M=?:/.M_L5O'NVV\KK\R1AAAE4\'M7/B.$<=AJ,Z\YPM%-NS?17_E./&^&^;8
M'"U<74JTW&G%R=G*]HJ[M[BUT[GVW17 ZY\<O"7A_P 77OAB:;5KW7;*&.XN
M;/2= O\ 4&ACDSL9C;P.H!P>_:NB\/\ C*P\33-%9V^JPLL*3DZAI%W9+M;.
M &FB0%N.4^\O&0,BOB3\I-RBBN?\.^/-"\6:QK^E:5??:K_0;E;348?)D3R)
M60.%RR@-\I!RI(H Z"BBH+Z\ATZSN+NX?R[>"-I9'P3M51DG Y/ [4 3T5RW
MA/XF>'_'%GH]YH<]Y?V.K6AO;.]73KE;=X@VWYI6C"(V>B.0QZ@$5T5I?6VH
M1F2UN(KF-6VEH7# 'TR._- $]%<_XE\>:%X0U/0=/U>^^R7FNW?V'3H_)D?S
MYMI;9E5(7@$Y8@>]:$NN6\.N0:2T=X;J:%IUD6RF:W"J<$-.$\M6YX1F#'J
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M/ 'CSQDFM?#6?P7K&HBTETPQZ3+-;V]N;1#- M^$9!AU^97D#,W7<V:^NZ*
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M2?M0#Q5?^&HIO"__  F%UJ_VF:YMG7R&LPD4OE[RV?- P-NX$ X'6O9OV5_
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M8)'S[FYY8U\J>$_VQ/%>L>#? VNQZSX'\3Z]KU_%:7'@/1+.9-5A5G968/\
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MC_AXQ\-O^@)XJ_\  2V_^2*/^'C'PV_Z GBK_P !+;_Y(H^JUOY0_P!3\_\
M^@27X?YGU/17RQ_P\8^&W_0$\5?^ EM_\D4?\/&/AM_T!/%7_@);?_)%'U6M
M_*'^I^?_ /0)+\/\SZGHKY8_X>,?#;_H">*O_ 2V_P#DBC_AXQ\-O^@)XJ_\
M!+;_ .2*/JM;^4/]3\__ .@27X?YGU/17RQ_P\8^&W_0$\5?^ EM_P#)%'_#
MQCX;?] 3Q5_X"6W_ ,D4?5:W\H?ZGY__ - DOP_S/J>BOEC_ (>,?#;_ * G
MBK_P$MO_ )(H_P"'C'PV_P"@)XJ_\!+;_P"2*/JM;^4/]3\__P"@27X?YGU/
M17RQ_P /&/AM_P! 3Q5_X"6W_P D4?\ #QCX;?\ 0$\5?^ EM_\ )%'U6M_*
M'^I^?_\ 0)+\/\SZGHKY8_X>,?#;_H">*O\ P$MO_DBC_AXQ\-O^@)XJ_P#
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M_P#)%'U6M_*'^I^?_P#0)+\/\SZGHKY8_P"'C'PV_P"@)XJ_\!+;_P"2*/\
MAXQ\-O\ H">*O_ 2V_\ DBCZK6_E#_4_/_\ H$E^'^9]3T5\L?\ #QCX;?\
M0$\5?^ EM_\ )%'_  \8^&W_ $!/%7_@);?_ "11]5K?RA_J?G__ $"2_#_,
M^IZ*^6/^'C'PV_Z GBK_ ,!+;_Y(H_X>,?#;_H">*O\ P$MO_DBCZK6_E#_4
M_/\ _H$E^'^9]3T5\L?\/&/AM_T!/%7_ ("6W_R11_P\8^&W_0$\5?\ @);?
M_)%'U6M_*'^I^?\ _0)+\/\ ,^IZ*^6/^'C'PV_Z GBK_P !+;_Y(H_X>,?#
M;_H">*O_  $MO_DBCZK6_E#_ %/S_P#Z!)?A_F?4]%?+'_#QCX;?] 3Q5_X"
M6W_R11_P\8^&W_0$\5?^ EM_\D4?5:W\H?ZGY_\ ] DOP_S/J>BOEC_AXQ\-
MO^@)XJ_\!+;_ .2*/^'C'PV_Z GBK_P$MO\ Y(H^JUOY0_U/S_\ Z!)?A_F?
M4]%?+'_#QCX;?] 3Q5_X"6W_ ,D4?\/&/AM_T!/%7_@);?\ R11]5K?RA_J?
MG_\ T"2_#_,^IZ*^6/\ AXQ\-O\ H">*O_ 2V_\ DBC_ (>,?#;_ * GBK_P
M$MO_ )(H^JUOY0_U/S__ *!)?A_F?4]%?+'_  \8^&W_ $!/%7_@);?_ "11
M_P /&/AM_P! 3Q5_X"6W_P D4?5:W\H?ZGY__P! DOP_S/J>BOEC_AXQ\-O^
M@)XJ_P# 2V_^2*/^'C'PV_Z GBK_ ,!+;_Y(H^JUOY0_U/S_ /Z!)?A_F?4]
M%?+'_#QCX;?] 3Q5_P" EM_\D4?\/&/AM_T!/%7_ ("6W_R11]5K?RA_J?G_
M /T"2_#_ #/J>BOEC_AXQ\-O^@)XJ_\  2V_^2*/^'C'PV_Z GBK_P !+;_Y
M(H^JUOY0_P!3\_\ ^@27X?YGU/17RQ_P\8^&W_0$\5?^ EM_\D4?\/&/AM_T
M!/%7_@);?_)%'U6M_*'^I^?_ /0)+\/\SZGHKY8_X>,?#;_H">*O_ 2V_P#D
MBC_AXQ\-O^@)XJ_\!+;_ .2*/JM;^4/]3\__ .@27X?YGU/17RQ_P\8^&W_0
M$\5?^ EM_P#)%'_#QCX;?] 3Q5_X"6W_ ,D4?5:W\H?ZGY__ - DOP_S/J>B
MOEC_ (>,?#;_ * GBK_P$MO_ )(H_P"'C'PV_P"@)XJ_\!+;_P"2*/JM;^4/
M]3\__P"@27X?YGU/17RQ_P /&/AM_P! 3Q5_X"6W_P D4?\ #QCX;?\ 0$\5
M?^ EM_\ )%'U6M_*'^I^?_\ 0)+\/\SZGHKY8_X>,?#;_H">*O\ P$MO_DBC
M_AXQ\-O^@)XJ_P# 2V_^2*/JM;^4/]3\_P#^@27X?YGU/17RQ_P\8^&W_0$\
M5?\ @);?_)%'_#QCX;?] 3Q5_P" EM_\D4?5:W\H?ZGY_P#] DOP_P SZGHK
MY8_X>,?#;_H">*O_  $MO_DBC_AXQ\-O^@)XJ_\  2V_^2*/JM;^4/\ 4_/_
M /H$E^'^9]3T5\L?\/&/AM_T!/%7_@);?_)%'_#QCX;?] 3Q5_X"6W_R11]5
MK?RA_J?G_P#T"2_#_,^IZ*^6/^'C'PV_Z GBK_P$MO\ Y(H_X>,?#;_H">*O
M_ 2V_P#DBCZK6_E#_4_/_P#H$E^'^9]3T5\L?\/&/AM_T!/%7_@);?\ R11_
MP\8^&W_0$\5?^ EM_P#)%'U6M_*'^I^?_P#0)+\/\SZGHKY8_P"'C'PV_P"@
M)XJ_\!+;_P"2*/\ AXQ\-O\ H">*O_ 2V_\ DBCZK6_E#_4_/_\ H$E^'^9]
M3T5\L?\ #QCX;?\ 0$\5?^ EM_\ )%'_  \8^&W_ $!/%7_@);?_ "11]5K?
MRA_J?G__ $"2_#_,^IZ*^6/^'C'PV_Z GBK_ ,!+;_Y(H_X>,?#;_H">*O\
MP$MO_DBCZK6_E#_4_/\ _H$E^'^9]3T5\L?\/&/AM_T!/%7_ ("6W_R11_P\
M8^&W_0$\5?\ @);?_)%'U6M_*'^I^?\ _0)+\/\ ,^IZ*^6/^'C'PV_Z GBK
M_P !+;_Y(H_X>,?#;_H">*O_  $MO_DBCZK6_E#_ %/S_P#Z!)?A_F?4]%?+
M'_#QCX;?] 3Q5_X"6W_R11_P\8^&W_0$\5?^ EM_\D4?5:W\H?ZGY_\ ] DO
MP_S/J>BOEC_AXQ\-O^@)XJ_\!+;_ .2*/^'C'PV_Z GBK_P$MO\ Y(H^JUOY
M0_U/S_\ Z!)?A_F?4]%?+'_#QCX;?] 3Q5_X"6W_ ,D4?\/&/AM_T!/%7_@)
M;?\ R11]5K?RA_J?G_\ T"2_#_,^IZ*^6/\ AXQ\-O\ H">*O_ 2V_\ DBC_
M (>,?#;_ * GBK_P$MO_ )(H^JUOY0_U/S__ *!)?A_F?4]%?+'_  \8^&W_
M $!/%7_@);?_ "11_P /&/AM_P! 3Q5_X"6W_P D4?5:W\H?ZGY__P! DOP_
MS/J>BOEC_AXQ\-O^@)XJ_P# 2V_^2*/^'C'PV_Z GBK_ ,!+;_Y(H^JUOY0_
MU/S_ /Z!)?A_F?4]%?+'_#QCX;?] 3Q5_P" EM_\D4?\/&/AM_T!/%7_ ("6
MW_R11]5K?RA_J?G_ /T"2_#_ #/J>BOEC_AXQ\-O^@)XJ_\  2V_^2*/^'C'
MPV_Z GBK_P !+;_Y(H^JUOY0_P!3\_\ ^@27X?YGU/17RQ_P\8^&W_0$\5?^
M EM_\D4?\/&/AM_T!/%7_@);?_)%'U6M_*'^I^?_ /0)+\/\SZGHKY8_X>,?
M#;_H">*O_ 2V_P#DBC_AXQ\-O^@)XJ_\!+;_ .2*/JM;^4/]3\__ .@27X?Y
MGU/17RQ_P\8^&W_0$\5?^ EM_P#)%'_#QCX;?] 3Q5_X"6W_ ,D4?5:W\H?Z
MGY__ - DOP_S/J>BOEC_ (>,?#;_ * GBK_P$MO_ )(H_P"'C'PV_P"@)XJ_
M\!+;_P"2*/JM;^4/]3\__P"@27X?YGU/17RQ_P /&/AM_P! 3Q5_X"6W_P D
M4?\ #QCX;?\ 0$\5?^ EM_\ )%'U6M_*'^I^?_\ 0)+\/\SZGHKY8_X>,?#;
M_H">*O\ P$MO_DBC_AXQ\-O^@)XJ_P# 2V_^2*/JM;^4/]3\_P#^@27X?YGU
M/17RQ_P\8^&W_0$\5?\ @);?_)%'_#QCX;?] 3Q5_P" EM_\D4?5:W\H?ZGY
M_P#] DOP_P SZGHKY8_X>,?#;_H">*O_  $MO_DBC_AXQ\-O^@)XJ_\  2V_
M^2*/JM;^4/\ 4_/_ /H$E^'^9]3T5\L?\/&/AM_T!/%7_@);?_)%'_#QCX;?
M] 3Q5_X"6W_R11]5K?RA_J?G_P#T"2_#_,^IZ*^6/^'C'PV_Z GBK_P$MO\
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MC'PV_P"@)XJ_\!+;_P"2*/\ AXQ\-O\ H">*O_ 2V_\ DBCZK6_E#_4_/_\
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M^)'Q^_X0W1_",G@*[O;T0MHEY)+(-*C5 TKR/+\^Q%#R$M_".,\5WGQE\&^
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M=4-?+5>Q@\#@,90CB%A^52U2>]OOZ[G32XGS>K!3]O)7]#KO^%FZI_SPL_\
MOA__ (JC_A9NJ?\ /"S_ .^'_P#BJY&BNW^R,!_SZ1K_ *R9O_T$2.N_X6;J
MG_/"S_[X?_XJC_A9NJ?\\+/_ +X?_P"*KD:*/[(P'_/I!_K)F_\ T$2.N_X6
M;JG_ #PL_P#OA_\ XJC_ (6;JG_/"S_[X?\ ^*KD:*/[(P'_ #Z0?ZR9O_T$
M2.N_X6;JG_/"S_[X?_XJC_A9NJ?\\+/_ +X?_P"*KD:*/[(P'_/I!_K)F_\
MT$2.N_X6;JG_ #PL_P#OA_\ XJC_ (6;JG_/"S_[X?\ ^*KD:*/[(P'_ #Z0
M?ZR9O_T$2.N_X6;JG_/"S_[X?_XJC_A9NJ?\\+/_ +X?_P"*KD:*/[(P'_/I
M!_K)F_\ T$2.N_X6;JG_ #PL_P#OA_\ XJC_ (6;JG_/"S_[X?\ ^*KD:*/[
M(P'_ #Z0?ZR9O_T$2.N_X6;JG_/"S_[X?_XJC_A9NJ?\\+/_ +X?_P"*KD:*
M/[(P'_/I!_K)F_\ T$2.N_X6;JG_ #PL_P#OA_\ XJC_ (6;JG_/"S_[X?\
M^*KD:*/[(P'_ #Z0?ZR9O_T$2.N_X6;JG_/"S_[X?_XJC_A9NJ?\\+/_ +X?
M_P"*KD:*/[(P'_/I!_K)F_\ T$2.N_X6;JG_ #PL_P#OA_\ XJC_ (6;JG_/
M"S_[X?\ ^*KD:*/[(P'_ #Z0?ZR9O_T$2.N_X6;JG_/"S_[X?_XJC_A9NJ?\
M\+/_ +X?_P"*KD:*/[(P'_/I!_K)F_\ T$2.N_X6;JG_ #PL_P#OA_\ XJC_
M (6;JG_/"S_[X?\ ^*KD:*/[(P'_ #Z0?ZR9O_T$2.N_X6;JG_/"S_[X?_XJ
MC_A9NJ?\\+/_ +X?_P"*KD:*/[(P'_/I!_K)F_\ T$2.N_X6;JG_ #PL_P#O
MA_\ XJC_ (6;JG_/"S_[X?\ ^*KD:*/[(P'_ #Z0?ZR9O_T$2.N_X6;JG_/"
MS_[X?_XJC_A9NJ?\\+/_ +X?_P"*KD:*/[(P'_/I!_K)F_\ T$2.N_X6;JG_
M #PL_P#OA_\ XJC_ (6;JG_/"S_[X?\ ^*KD:*/[(P'_ #Z0?ZR9O_T$2.N_
MX6;JG_/"S_[X?_XJC_A9NJ?\\+/_ +X?_P"*KD:*/[(P'_/I!_K)F_\ T$2.
MN_X6;JG_ #PL_P#OA_\ XJC_ (6;JG_/"S_[X?\ ^*KD:*/[(P'_ #Z0?ZR9
MO_T$2.N_X6;JG_/"S_[X?_XJC_A9NJ?\\+/_ +X?_P"*KD:*/[(P'_/I!_K)
MF_\ T$2.N_X6;JG_ #PL_P#OA_\ XJC_ (6;JG_/"S_[X?\ ^*KD:*/[(P'_
M #Z0?ZR9O_T$2.N_X6;JG_/"S_[X?_XJC_A9NJ?\\+/_ +X?_P"*KD:*/[(P
M'_/I!_K)F_\ T$2.N_X6;JG_ #PL_P#OA_\ XJC_ (6;JG_/"S_[X?\ ^*KD
M:*/[(P'_ #Z0?ZR9O_T$2.N_X6;JG_/"S_[X?_XJC_A9NJ?\\+/_ +X?_P"*
MKD:*/[(P'_/I!_K)F_\ T$2.N_X6;JG_ #PL_P#OA_\ XJC_ (6;JG_/"S_[
MX?\ ^*KD:*/[(P'_ #Z0?ZR9O_T$2.N_X6;JG_/"S_[X?_XJC_A9NJ?\\+/_
M +X?_P"*KD:*/[(P'_/I!_K)F_\ T$2.N_X6;JG_ #PL_P#OA_\ XJC_ (6;
MJG_/"S_[X?\ ^*KD:*/[(P'_ #Z0?ZR9O_T$2.N_X6;JG_/"S_[X?_XJC_A9
MNJ?\\+/_ +X?_P"*KD:*/[(P'_/I!_K)F_\ T$2.N_X6;JG_ #PL_P#OA_\
MXJC_ (6;JG_/"S_[X?\ ^*KD:*/[(P'_ #Z0?ZR9O_T$2.N_X6;JG_/"S_[X
M?_XJC_A9NJ?\\+/_ +X?_P"*KD:*/[(P'_/I!_K)F_\ T$2.N_X6;JG_ #PL
M_P#OA_\ XJC_ (6;JG_/"S_[X?\ ^*KD:*/[(P'_ #Z0?ZR9O_T$2.N_X6;J
MG_/"S_[X?_XJC_A9NJ?\\+/_ +X?_P"*KD:*/[(P'_/I!_K)F_\ T$2.N_X6
M;JG_ #PL_P#OA_\ XJC_ (6;JG_/"S_[X?\ ^*KD:*/[(P'_ #Z0?ZR9O_T$
M2.N_X6;JG_/"S_[X?_XJC_A9NJ?\\+/_ +X?_P"*KD:*/[(P'_/I!_K)F_\
MT$2.N_X6;JG_ #PL_P#OA_\ XJC_ (6;JG_/"S_[X?\ ^*KD:*/[(P'_ #Z0
M?ZR9O_T$2.N_X6;JG_/"S_[X?_XJC_A9NJ?\\+/_ +X?_P"*KD:*/[(P'_/I
M!_K)F_\ T$2.N_X6;JG_ #PL_P#OA_\ XJC_ (6;JG_/"S_[X?\ ^*KD:*/[
M(P'_ #Z0?ZR9O_T$2.N_X6;JG_/"S_[X?_XJC_A9NJ?\\+/_ +X?_P"*KD:*
M/[(P'_/I!_K)F_\ T$2.N_X6;JG_ #PL_P#OA_\ XJC_ (6;JG_/"S_[X?\
M^*KD:*/[(P'_ #Z0?ZR9O_T$2.N_X6;JG_/"S_[X?_XJC_A9NJ?\\+/_ +X?
M_P"*KD:*/[(P'_/I!_K)F_\ T$2.N_X6;JG_ #PL_P#OA_\ XJC_ (6;JG_/
M"S_[X?\ ^*KD:*/[(P'_ #Z0?ZR9O_T$2.N_X6;JG_/"S_[X?_XJC_A9NJ?\
M\+/_ +X?_P"*KD:*/[(P'_/I!_K)F_\ T$2.N_X6;JG_ #PL_P#OA_\ XJC_
M (6;JG_/"S_[X?\ ^*KD:*/[(P'_ #Z0?ZR9O_T$2.N_X6;JG_/"S_[X?_XJ
MC_A9NJ?\\+/_ +X?_P"*KD:*/[(P'_/I!_K)F_\ T$2.N_X6;JG_ #PL_P#O
MA_\ XJC_ (6;JG_/"S_[X?\ ^*KD:*/[(P'_ #Z0?ZR9O_T$2.N_X6;JG_/"
MS_[X?_XJC_A9NJ?\\+/_ +X?_P"*KD:*/[(P'_/I!_K)F_\ T$2.N_X6;JG_
M #PL_P#OA_\ XJC_ (6;JG_/"S_[X?\ ^*KD:*/[(P'_ #Z0?ZR9O_T$2.N_
MX6;JG_/"S_[X?_XJC_A9NJ?\\+/_ +X?_P"*KD:*/[(P'_/I!_K)F_\ T$2.
MN_X6;JG_ #PL_P#OA_\ XJC_ (6;JG_/"S_[X?\ ^*KD:*/[(P'_ #Z0?ZR9
MO_T$2.N_X6;JG_/"S_[X?_XJC_A9NJ?\\+/_ +X?_P"*KD:*/[(P'_/I!_K)
MF_\ T$2.N_X6;JG_ #PL_P#OA_\ XJC_ (6;JG_/"S_[X?\ ^*KD:*/[(P'_
M #Z0?ZR9O_T$2.N_X6;JG_/"S_[X?_XJC_A9NJ?\\+/_ +X?_P"*KD:*/[(P
M'_/I!_K)F_\ T$2.N_X6;JG_ #PL_P#OA_\ XJC_ (6;JG_/"S_[X?\ ^*KD
M:*/[(P'_ #Z0?ZR9O_T$2.N_X6;JG_/"S_[X?_XJC_A9NJ?\\+/_ +X?_P"*
MKD:*/[(P'_/I!_K)F_\ T$2.N_X6;JG_ #PL_P#OA_\ XJC_ (6;JG_/"S_[
MX?\ ^*KD:*/[(P'_ #Z0?ZR9O_T$2.N_X6;JG_/"S_[X?_XJC_A9NJ?\\+/_
M +X?_P"*KD:*/[(P'_/I!_K)F_\ T$2.N_X6;JG_ #PL_P#OA_\ XJC_ (6;
MJG_/"S_[X?\ ^*KD:*/[(P'_ #Z0?ZR9O_T$2.N_X6;JG_/"S_[X?_XJC_A9
MNJ?\\+/_ +X?_P"*KD:*/[(P'_/I!_K)F_\ T$2.N_X6;JG_ #PL_P#OA_\
MXJC_ (6;JG_/"S_[X?\ ^*KD:*/[(P'_ #Z0?ZR9O_T$2.N_X6;JG_/"S_[X
M?_XJC_A9NJ?\\+/_ +X?_P"*KD:*/[(P'_/I!_K)F_\ T$2.N_X6;JG_ #PL
M_P#OA_\ XJC_ (6;JG_/"S_[X?\ ^*KD:*/[(P'_ #Z0?ZR9O_T$2.N_X6;J
MG_/"S_[X?_XJC_A9NJ?\\+/_ +X?_P"*KD:*/[(P'_/I!_K)F_\ T$2.N_X6
M;JG_ #PL_P#OA_\ XJC_ (6;JG_/"S_[X?\ ^*KD:*/[(P'_ #Z0?ZR9O_T$
M2.N_X6;JG_/"S_[X?_XJC_A9NJ?\\+/_ +X?_P"*KD:*/[(P'_/I!_K)F_\
MT$2.N_X6;JG_ #PL_P#OA_\ XJC_ (6;JG_/"S_[X?\ ^*KD:*/[(P'_ #Z0
M?ZR9O_T$2.N_X6;JG_/"S_[X?_XJC_A9NJ?\\+/_ +X?_P"*KD:*/[(P'_/I
M!_K)F_\ T$2.N_X6;JG_ #PL_P#OA_\ XJC_ (6;JG_/"S_[X?\ ^*KD:*/[
M(P'_ #Z0?ZR9O_T$2.N_X6;JG_/"S_[X?_XJC_A9NJ?\\+/_ +X?_P"*KD:*
M/[(P'_/I!_K)F_\ T$2.N_X6;JG_ #PL_P#OA_\ XJC_ (6;JG_/"S_[X?\
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MXFGB*<K)+E<6KKE5[6OJK-_H8_54JBFGMI;=6_0I$EB23DFBBBOI#N"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
8* "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>clbs-20230331_g2.jpg
<TEXT>
begin 644 clbs-20230331_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0!0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV/N\H01BO?/^"C_A+X@W'@>Y\4:+XF73_ VGV,=MK&CB[E1[QY;E$0B-4*.
M9$SN8< ]:0['M?[*/QWOOVB/AA-XJU#2K?1YDU&:R%O;2,Z[45&!R>_S_I7E
M?[;'B#XZZ-XH\-I\)(M<DTY[.0WW]DV"7"^;O^7<2C8.WM7@'[#/PG^,'B33
M_#_B;POXX@TCP#8^(HVU+1'U"XB:Y6-XGG B2,HV^/"\L,]#@<UWW_!2/XO>
M-OAOXV\'6WA;Q3JOA^WN=.FDFCT^Z:)9&$N 2 >3B@.I]X:2T[:79M<[OM)A
M0R[A@[MHSD?6K=</XV^)6G_"WX17GC+7)&>UTW3DN)!GYYI"JA$!/\3NRJ/=
MJ_/KX?ZM^TC^VEKVLZWH'C:X\(:'93>7FUU"?3[.)B,B%! "\C!2"2V<9&3R
M!3%8_3VOCOX[>(OCY8_M/:'9^#8M>;X>M-IXNVL]/26VVF0>?ND*$CY<YYXK
MCOV<_CU\3OA/^T(OP8^+NI/K?VQO)L]1GE\YTE9=\3+,0&DCD'R@-R&('RX8
M5E_M0?&/QSX7_;6\->'-(\5ZMIN@SW&DK+IMM=.D#B250X* X.X=?6@=C]":
M*^<_V]_&FO> ?V>[O5O#FKWFB:FNHVL8N[&4Q2!68[AN'8U\Q?!OQ=^T/^U%
M\-[+PYX1\43:%8Z+YJZOXKU"^DCN+VY>5W2)9D5I $B:,87&/XCRHH%8_2FB
MOS(^%/[1'Q5_9F_:"C\!_%7Q#>:WH\UU';7SZI>/=B%),>7=0S/E]@W!B.FW
M<"H8<?77[8GQH\9?!_X?VK^!/#M]K&NZE*\0OH+&2ZAT^-0"TCA5*[CD!0W!
MPQYVD$"Q[[17PCI'[+'[27C;P_#KFM_'/5= UF[B$_\ 94%]=(D1;YMCF)T5
M",\A5('09 JC^Q_^T1\2-%_: O/@Q\1M3D\0RK)=6L5U<2>;-!<0(\C8FQND
MC9(VQOY^[TY%(+'T%^UY^TK=?LT^#M&U:QT:WUN[U*]-JL-S.8E11&6+\ D]
M ,<=>M>O>!?$$GBSP3X>UR:)8)=3TZWO7B0DJC21*Y4$]@6Q7YC?\%$O"7Q!
M\+^/K>]\3^)EU;PMKE]>7.A:8EW++]A2/R@P9'0*A(E7&TMT/X_3_P"Q=\*?
MC!X.N+#Q!XU\<0:]X*OO#D:Z;I*:A<3-;,Y@>$F-XU1=L2NO#'&[ R.: Z'U
MM17Y[>*OCM\4OVNOC=J7@/X0^(&\*^$=-#F76;:1H6EC1MIN&E4;P&8X1$(R
M"">Y7*^*=C^T+^Q?=:5XNE^(]]\0/#$MPL%RFI7$UQ&&()$<D<K,45@" Z-G
M(P<'&0+'Z/45Y_X3^-7A_P 4?!6V^)BS?9]!;3'U*XRP9H/+4F6,],LC*Z^Y
M6OSB\+W_ ,:?V\/BAK$NF>)IM"TFQ_?&/[9+!9:=$[$1QJD?+R,%/.,G:22
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M[5'QPN? 7P?UF?0]!MWD6&ZL+AK4RQ1D![J:=?G5"?NA>S*,%C4?B#QK\?\
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M5>B2,@+K^#;A^% '5T444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM\*X]$O)X;S7[Z=K[4[F#)0RD!1&I(R515 R>I+' SBO:Z*!W"BBB@04444
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MSQ'_ -$F\8?^!>C?_+"C_A9GB/\ Z)-XP_\  O1O_EA7H%%'UFE_SXC]\_\
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M^%7&O3EJJ$?OG_\ )C4XO["_'_,YG_A9GB/_ *)-XP_\"]&_^6%'_"S/$?\
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M%'_"S/$?_1)O&'_@7HW_ ,L*Z;^T+C_GI_XZ/\*/[0N/^>G_ (Z/\*/:T_\
MGQ#[Y_\ R8<T?Y%^/^9S/_"S/$?_ $2;QA_X%Z-_\L*/^%F>(_\ HDWC#_P+
MT;_Y85TW]H7'_/3_ ,='^%']H7'_ #T_\='^%'M:?_/B'WS_ /DPYH_R+\?\
MSF?^%F>(_P#HDWC#_P "]&_^6%'_  LSQ'_T2;QA_P"!>C?_ "PKIO[0N/\
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MS.9_X69XC_Z)-XP_\"]&_P#EA1_PLSQ'_P!$F\8?^!>C?_+"NF_M"X_YZ?\
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M_ O1O_EA1_PLSQ'_ -$F\8?^!>C?_+"O0**7UFE_SXC]\_\ Y,7M(_R+\?\
M,\__ .%F>(_^B3>,/_ O1O\ Y84?\+,\1_\ 1)O&'_@7HW_RPKT"BCZS2_Y\
M1^^?_P F'M(_R+\?\SS_ /X69XC_ .B3>,/_  +T;_Y84?\ "S/$?_1)O&'_
M (%Z-_\ +"O0**/K-+_GQ'[Y_P#R8>TC_(OQ_P SS_\ X69XC_Z)-XP_\"]&
M_P#EA1_PLSQ'_P!$F\8?^!>C?_+"O0**/K-+_GQ'[Y__ "8>TC_(OQ_S//\
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M'M(_R+\?\SS_ /X69XC_ .B3>,/_  +T;_Y84?\ "S/$?_1)O&'_ (%Z-_\
M+"O0**/K-+_GQ'[Y_P#R8>TC_(OQ_P SS_\ X69XC_Z)-XP_\"]&_P#EA1_P
MLSQ'_P!$F\8?^!>C?_+"O0**/K-+_GQ'[Y__ "8>TC_(OQ_S//\ _A9GB/\
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M"]&_^6%'_"S/$?\ T2;QA_X%Z-_\L*Z;^T+C_GI_XZ/\*/[0N/\ GI_XZ/\
M"CVM/_GQ#[Y__)AS1_D7X_YG,_\ "S/$?_1)O&'_ (%Z-_\ +"C_ (69XC_Z
M)-XP_P# O1O_ )85TW]H7'_/3_QT?X4?VA<?\]/_ !T?X4>UI_\ /B'WS_\
MDPYH_P B_'_,YG_A9GB/_HDWC#_P+T;_ .6%'_"S/$?_ $2;QA_X%Z-_\L*Z
M;^T+C_GI_P".C_"C^T+C_GI_XZ/\*/:T_P#GQ#[Y_P#R8<T?Y%^/^9S/_"S/
M$?\ T2;QA_X%Z-_\L*/^%F>(_P#HDWC#_P "]&_^6%=-_:%Q_P ]/_'1_A1_
M:%Q_ST_\='^%'M:?_/B'WS_^3#FC_(OQ_P SF?\ A9GB/_HDWC#_ ,"]&_\
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M_1)O&'_@7HW_ ,L*Z;^T+C_GI_XZ/\*/[0N/^>G_ (Z/\*/:T_\ GQ#[Y_\
MR8<T?Y%^/^9S/_"S/$?_ $2;QA_X%Z-_\L*/^%F>(_\ HDWC#_P+T;_Y85TW
M]H7'_/3_ ,='^%']H7'_ #T_\='^%'M:?_/B'WS_ /DPYH_R+\?\SF?^%F>(
M_P#HDWC#_P "]&_^6%'_  LSQ'_T2;QA_P"!>C?_ "PKIO[0N/\ GI_XZ/\
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M'M(_R+\?\PHHHKSS **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ]X3?Q3XHUKXIZEI5Y>7,5MX.\->%KZ:,W&9,%)80J[V"D98$\GDGY4)S:7
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MR45^76L?'GXJ^ ?!/C>?P[XPU_6_ =YK(TK1/%&MLTMTPS(6:"5QDY2/!(P
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MOBNLT-FBOCW]D?QGXVU/XY?%32?&'B:]\13Z2&B,9F?[,LB3LC&&'A4!V\
M<5YKH_B;Q]\7/A;\2_BK-\2O$.@WV@W9^PZ-IMZT%DD:[7V/&N W#A0>I*_-
MNS6?.!^AE%>'?#_QEXX^-'[+FG:QH-Y9Z3XWU*S:%+^]4B)94E,;S85#@L$9
MAA2 6'&!7S7J'B;XB_"#XD"U\+?$#7/B')H6AR7OBQ=0O)+W3K2=4=GC5F!V
M_=7 P&SP3RRJW+J!^@M%?FXOQ/\ B/X*^'/@7XN_\+ U[6=0UK6;BWN]"O)R
MU@\:.1L6+[J;@C#Y5&-XV[2O/6_&2P^*O@)[.[N?BEK&I?%'6]85]+\+>&[R
M5[+['M)RUL54#! '(*D YW?,P7/Y ?>U%?G?XZO/C-I_B_QOK/B*T^)']AZ<
M$G>;0/$4FDV4*JH$CQ[X9%D3(SB,#:,DYZU]G?L_^*],\:?!_P -:KI%]JFH
MV<EOY?VC6Y_/O2Z,5<32?Q,&!^8<$8(IQE=V ]"HHHJP"BD;=M.T MCC/2O@
MSXT:;\5?A]/:W-S\4]8U/XHZSK(;2_"_AJ\E>R^QA3\S6Q50,$ <@J0#G=\S
M"92Y0/O2BOC76-;\<_&/]I@?#74/&6L>"['1M$BN;K_A'+G[-)<71@B:1@Z\
ME=\W .1M3@ G-=9^Q-\4/$WB_3_&WA?Q%J<WB"X\,WX@MM6NG+//&QD7:S<E
ML&(G)).'QV%)2UL!]/45\%_&C3?BK\/I[6YN?BGK&I_%'6=9#:7X7\-7DKV7
MV,*?F:V*J!@@#D%2 <[OF88MYXZ^)7Q.F^+FN:AX\UKPS>^ [:/[/IFAW#06
MCRI(RR!U7&\$Q/R<G+C^$;2N?R _0ZBO@ZX\0_$'XA?"6V^*'C/XH77@OPU%
MHTL.GV?AZ\DM+R]U%&,:M(BJJOYC(6PK< \; ":Y^XD_:&\1:3\.$O;?QY>)
M-;3F;^P[^339I8RY\K[1/L9$?"YW2J25([G-'/Y ?HC17S;^Q?\ $"T\5Z3X
MJTN6]\6R^(-,O56_L_%NK_VE);_>0"*7RX\#*/N7:""._%?256G=7 ****8!
M17R9^UYH7BO3=2N/$$/BCX@3Z;)I\XT_2/!5DT=M831HI$M[.LG^K))))3.
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M <QQQG(7Y25SC()!7;TJ.<#]!Z*\B_: \*>-?&FDZ+!X;\8P^!] BG^T:_J
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MN[AD"JVSSUC3S$PP(8KGD@]*]SIB"BBB@ HHHH **** "BBB@ HHHH ****
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M_P#8Y^&_P]T_Q;8P6$VK6_B9&AN_[2$)>*%B2887CC1HTSM. >J(>JBO<**
M/C7Q%^P?J'AWQEX/U3P-K4&O:+HD[3#0?'E[/-:VQ+A@;=8$' /.UN"5!8L,
MBO?/CE\ ],^/ND6FDZWXA\0Z5I4+%Y++1;F*&*Y;(*F4/$^[;C@= 3G&<8].
MHH'<\)M/V/O"TG@S5?"VN^)O&/C#1KV.%(8/$&L>>-/:+.Q[8*BB-AG'0@@
M$8R#G^&_V)/!WA6/5YK+Q+XO.NZC:K8_\)!-J<;7]M;@*#%"_E;4!5%3.TL%
M&%*@FOH:B@#Y\^'_ .Q7X4^'LD$%MXK\8ZKH"NTD_AK5=2BETJ[+ @^=;"%5
MD&<'GNH]*TO%'[&?PN\3>-- \1#0+;2#I!!_LK2[.U@L+S#;O](B\D^9Z=1Q
M7N-% "*H50 , < "J>K?\>Z_[_\ 0U=JEJW_ ![K_O\ ]#51^) MS)K#\;>%
MO^$T\,WNC?VOJN@_:@H_M#1+G[-=Q;7#?NY,';G&#QR"16Y176:'S[X1_8Q\
M/>"?%A\1Z9XZ\>1ZG+<+<W;G5XQ]N(?>5N"L(,BL<Y!/.37-_&+]AS3?$ECK
MUSX%UF]\/:CJUPES<Z1<7KKI%RP<LWF1JI<'))&"0O8"OJ:BIY5L!YOHGPRO
M[KX*V'@O4[U?"ETEHMK-+X+F:)(55ONP/.K. 5 #,PW$EN><UR7P\_9#\/?#
M6XA73O%_C2ZTA3(9M!O-50Z=<^8A5A+"D2A@0?S KW6BGRH#Y[T/]AWX=Z'X
MALM1CN=?NK*PN6O++1;O4!)8VLI*G<B;-QP57[S'=M ;<.*;#^Q=HUMXBU#7
M[?XC_$6TUK4#_I=_:ZU%#-,/1F2 $@8&!T&!BOH:BERKL!X!XF_8K\%^(M8U
MB^AUWQ5H<>L[?[3L=*U01V]Z5.<RJT;%LG)QG ). *]D\%>#-'^'OA?3_#V@
MV:V.E6,?EPPJ2>Y)8D\EB222>I)-;=%.R6P!1113 ;(I>-E#,A(P&7&1[C-?
M/</[%VC6WB+4-?M_B/\ $6TUK4#_ *7?VNM10S3#T9D@!(&!@=!@8KZ&HI-)
M[@>-?%3]EWPY\3-8M_$":IK7AWQ5:VGV2/6=(O3%-(H0JHE)!W#GDC:Q'&<5
M3_97^"?B#X(>#M6T'6QH&Z:X\Z&_T1IVGN,@@O.9AC<!M"A1M !X)))]QHHY
M5>X'SS#^Q=HUMXBU#7[?XC_$6TUK4#_I=_:ZU%#-,/1F2 $@8&!T&!BKGCC]
MB_P)XZ\17VL2W_B#29M25%U*#3+\1PZ@5*G=,K(V22JDX(R1N^]S7O5%+E0'
M@/B;]C+PIXCU?2;V+Q/XNT2/1H4@TFSTG48XH=.15 _<YB9U8XW,Q8LQ)))J
MSK'[(7AO7%T2YN/%GC0>(M)$BP^)5UG_ (F;HY8['E*$8&X@84'!QDBO=:*.
M5 >>?!OX%^&/@?I=]:^'TNI[F_E\Z\U'4)1+<W+#.-[  8&6P !]XGJ2:]#H
MHJMM@"BBB@#Q3X@?LG>%?'GB[4?$D>M^)O#&IZE ;?4&\/ZD+=+M#@%9%9&X
M.!E1@$\D$\U)J/[(_P .M0^%]AX&^PW=MIMC.UW;WL%R1=QW###2[R""Q&,@
MKMX'R\#'L]%+E0'S5\'?V8_$7PE^.6J^)WU/3_$^AWD)B35-;N+B?6XEV8"@
MX$1R0H+'G:N!MY!ZKXF?LKZ-\5/&\/BG4_&7C&QU"U(-E'IFH10Q6. !F$>2
M60DC).<D]^F/:Z*7*K6 \0\1?LD^%_%6CZ%!J?B+Q9=:WHKNUIXGDU;=J@5G
M+;&F*$%03\ORY7L1DYRKK]B/P/)X%A\)6FL^)M+T@SM=7HL[Z(/J,QVA7N"T
M3!MH4;54*HR3C)S7T)11RKL!X._['?A;4/"-[X<UOQ1XR\2Z=,(OLPUC5_..
MGF/(5K<! J<-@@@@@#CBM?X<?LN>%?AWXT/BUM3U_P 5>(UA\B#4/$E\+J2W
M3;MPA"+CY<KDYP"0,9->PT4^5 %%%%, KGO$WPZ\*>-+B&?Q#X8T;7IX5V12
MZGI\5RT:DY(4NI(&>PKH:* /%_ ?[(_P\\ Z?XJLH+&;5(/$:-#=?V@(B\4+
M$DQ0O'&C(F=IP#U13U KROQ!^Q!?^'_%_A/4_!6L0:YH^C3M,-#\;WD\UM;D
MN&!@6%!P#SM;@E1N+#(KZ\HJ>5 >;?&KX%Z;\=-)M=+UG7]>TO3(6+R6>CW,
M44=RV0090\;[MN.!T&<XSBN:M?V2_#+^#]4\,:WXD\6^+-'O(XDB@UW5O/%@
M8\['M@$41L,XZ$$#!&,@^W44^5;@>!^'?V,_"7AB/5IK/Q'XL.MZA:K9?V]+
MJ*-?6UN H,4+^5M4%45<[2P7A2H)I?!'[&_AGP*HM;3Q=XUO-#;S1/H-UJZC
M3[GS$*MYD4<:9ZYR"#D ]J][HI<J ^=M,_89\ V-UIBW6K>*-8T73;AKFU\/
MZEJ2R:?$S-N($0C!P3U^;YN^:^B% 4  8 X %+1322V LZ?_ ,?D?X_R-;58
MNG_\?D?X_P C6U6%3<B6Y0U[2O[=T/4--^V7>G_;+>2W^V6$OE7$&]2N^-\'
M:XSD''! KYVC_8/\.0^*)/$J?$CXE)XBD3RWU===C%VZ[0NTS>1O(V@#&>@
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M     !BNSHHH$<;_ ,*C\-_\\]3_ /!S>_\ QZC_ (5'X;_YYZG_ .#F]_\
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M_P#!S>__ !ZNRHH"[.-_X5'X;_YYZG_X.;W_ ./4?\*C\-_\\]3_ /!S>_\
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MS_X[1_PJOP]_SSU'_P &]Y_\=KK:*+(#DO\ A5?A[_GGJ/\ X-[S_P".T?\
M"J_#W_//4?\ P;WG_P =KK:*+(#DO^%5^'O^>>H_^#>\_P#CM'_"J_#W_//4
M?_!O>?\ QVNMHHL@.2_X57X>_P">>H_^#>\_^.T?\*K\/?\ //4?_!O>?_':
MZVBBR Y+_A5?A[_GGJ/_ (-[S_X[1_PJOP]_SSU'_P &]Y_\=KK:*+(#DO\
MA5?A[_GGJ/\ X-[S_P".T?\ "J_#W_//4?\ P;WG_P =KK:*+(#DO^%5^'O^
M>>H_^#>\_P#CM'_"J_#W_//4?_!O>?\ QVNMHHL@.2_X57X>_P">>H_^#>\_
M^.T?\*K\/?\ //4?_!O>?_':ZVBBR Y+_A5?A[_GGJ/_ (-[S_X[1_PJOP]_
MSSU'_P &]Y_\=KK:*+(#DO\ A5?A[_GGJ/\ X-[S_P".T?\ "J_#W_//4?\
MP;WG_P =KK:*+(#DO^%5^'O^>>H_^#>\_P#CM'_"J_#W_//4?_!O>?\ QVNM
MHHL@.2_X57X>_P">>H_^#>\_^.T?\*K\/?\ //4?_!O>?_':ZVBBR Y+_A5?
MA[_GGJ/_ (-[S_X[1_PJOP]_SSU'_P &]Y_\=KK:*+(#DO\ A5?A[_GGJ/\
MX-[S_P".T?\ "J_#W_//4?\ P;WG_P =KK:*+(#DO^%5^'O^>>H_^#>\_P#C
MM'_"J_#W_//4?_!O>?\ QVNMHHL@.2_X57X>_P">>H_^#>\_^.T?\*K\/?\
M//4?_!O>?_':ZVBBR Y+_A5?A[_GGJ/_ (-[S_X[1_PJOP]_SSU'_P &]Y_\
M=KK:*+(#F;'X4^'6ND!CU+'/_,8O!V/_ $UK7_X5'X;_ .>>I_\ @YO?_CU;
M&G_\?D?X_P C6U7/4W,Y'&_\*C\-_P#//4__  <WO_QZC_A4?AO_ )YZG_X.
M;W_X]7945F*[.-_X5'X;_P">>I_^#F]_^/4?\*C\-_\ //4__!S>_P#QZNRH
MH"[.-_X5'X;_ .>>I_\ @YO?_CU'_"H_#?\ SSU/_P '-[_\>KLJ* NSC?\
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M)(R&.""2IZ+19O$]Q8_"EO%;7,FH#Q;>K;RW\217<MH++41;O.D8"K*T00L
M%Z\@'(H ]XHHHH$%%%% !1110 4444 %%%% !1110!6U#_CSD_#^8K%K:U#_
M (\Y/P_F*Q:Z*>Q<=@HHHK4H**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH T='_ .6WX?UK2K-T
M?_EM^']:TJY9_$S-[A1114""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH YCQ5\4?!G@6\AM/$OB[0O#UU,GFQ0:KJ4-L[IG&Y5D8$C((R/2
MLKQ1\8O 6C:=IUQJ'C?PY8P:@@N+.6YU:WC6YBY'F1EG =<_Q#(KR/XAV6NZ
MA^VAX?A\/:EIVE7S>"+G=/JFG/?1;/M:Y'EI/"<YQR6(X/!SQYWI?P=U/X.?
M'GX<>$?#/B&S;4+?POJ<\NI:II;30R-)=AY EO%/%Y8W-\H#D*!WZU4=RD?0
MLWQL^'=M86U]-X]\,165T76"Y?6+<1RE2 P1B^&()&<=,UU:ZI9OIHU%;N!M
M/,7GBZ$BF+R\;M^_.-N.<YQBOFKXE6^F^%?BE#XAU7XE^'_#OCS^P6L;J+7]
M"=-&U&U\QG"Q>;-E6R0&$<[DXY7G%9GA+Q=>?'+X?^"OA]I/A^V\%V^I0-?^
M)+?28!!;VNF+,ZJD494%!=LN5!'W&<G<#D]',6>_ZY\7/ &@QZ9=:MXP\/6*
M7T0GL9KK48$$\9Z21DM\R'^\./>K.L?%7P5X?OK:RU3QAH&FWMRB2P6]YJ<$
M4DJ/]QE5F!8-V(ZUX!I&L>$_AE\=OC,OCR33]&M+S2[ :3_:#)''<:8ENT;P
M6X.,@.-IC7DG'!Q7AOP=_L_X5_"?6]2E\7:):>(]0TP3:GX'\?:,\@OX5+_9
M([=F,<CJT.P!4$RY/3L%S ?HUG/(Y%96CZEHEY?:G;Z7=:?/>6LP2_BLY$:2
M&4C<!*%.58@YPW/->!?&7QEK-K\&_A;?Q07_ ,/]!U+4=-3Q$FF;K>32;%XR
M6BWJ%:!%;:I8!2HP.,XKQ'P[XVT;PK:_$E]*\0Z_J^B7_CJSM(-:M?$#6:.A
MB/\ Q]ZDRO(EN,;3(AW,%7#8/+<K ?>.HZ]IFCW-C;W^HVEE<7\OD6D5Q.L;
MW$F"=D8)R[8!.!D\5?K\VH?%%MXG\66&KZ[XDU.X\+:/XX%G'?P^*;^ZM[*W
M:UD;$=W(T;??!"S$*Q'&XK78_#?XVOK'Q(^%4F@^)=5E36M7N8KRSU;QA-JE
MY/;'>!]JLA$MO:D$ H$;.".#U"YP/O2BBBM "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH LZ?\ \?D?X_R-;58NG_\ 'Y'^/\C6U7/4W(EN%%%%9$A1110 4444
M %%%% !1110!1US7M-\,Z7<:GK&HVNDZ;;C=->7TZPPQ D %G8@ 9(')[UG_
M /"?>&#;Z+./$>D^3K3!-+D^W1;;]B,@0'=^])]%S7E?[;G_ ":SX_\ ^O2/
M_P!'QU\9:''XF^&/Q4^"_P ,M4275-,L=<MO$'AV^D(7S+6YC4M![;90P^I;
MH-M ['Z?T5^;[?%GQJOP3L_BA_PG&N/\3)?&_P#9[>&QJ,HM%7E?L!L=WEXP
M V=F[YNN>:B^(WB[QD%_:.\31>//%EC=^%-<LH=(L[76[F.VMA)<E77R@^QE
MV@ *1@<\4!8_26BO$/$/Q4\477PCU.?_ (0CQ-:S/H,LW_"0PW.FQP(_V8M]
MH4+>><JY^88CWCCY0>*^*? OB+XF-X?^#5_<_$?Q3J%IX\U&ZM;V/4_$D]I:
M@6]P%BMQ=*DDL+R$/ETR6#*H QF@+'ZBUC^+/">F>-]#FTC5XII;&62*4BWN
M9;:17CD62-EEB971E=%8%6!R*^#]4MOBY8^,K;0;+XHZ#XOTZWUF:5? NE?$
MEX]<<$-FU:]=(9F"$' )R,<CC(Q?A_\ '+Q-\7OB9X3\ :/K7B6'1;"UO!-#
MXD\6OI]U?WR;MT9U*S@9YEC0JRKMR<'<2,90['Z.6=JEC:06T;2-'"BQJTTK
M2N0!@%G8EF/'+,23U)-4E\4:,WB)M &K6)UU;?[6VEBY3[4(-VWS3%G=LW<;
ML8SQ7PA\,_%'C?7/C/X-^&GC7XK0ZQX3AL;V]AU;PKXDEW:DRA@MO-?Q"*22
M2(#<1QP,G.0!@^&X_"7A?]J#Q[?0?$?Q3XUT;1?!,VHPZ_9^)3=Z@9(VB<QI
M-&RI*$^8B&0-'Q\ZD"@+'Z/].:\Z\(ZYX#^.EU8>,-!O[G6O^$>O9[:"59;N
MVAAN1&4DS;L421@DK .R-@.=IKXX\"_%;Q$WQ<^!MQI6O:Y;Z/XFDN!=6NJ>
M,Y=;GOH<X5[FV9%BMGX.!&.Q'RE37G'@?7M2^'/P,U#QCX7\8:M8^+(OB%]D
M@T.VU.06MS&R@F-[3=L<OR2Q7)"@=J L?I3X ^*7ACXH0ZM+X8U/^TX]*OI-
M.O#]GEB\JX3&Y/WBKNQD<C(]ZZNORR^'_CSQ;I>NKX3T:\DT;2?$?Q(U%=0N
MDU272_/=!"8[4WD2.\(<L02@+'@#')KZH^']K\0](^&OQHTM?&NF>*[^UAN3
MH=GI?B%]:U#2)VCES;33RQ1N6#!=F\;N#TQRQ6/>D^+/@>3Q)_PCR>,O#[:_
MYGD_V4NJ0&Z\S&=GE;]V[';&:9XD^,'@/P;JC:;K_C;P[H>HJJNUGJ6K06\P
M4C()1W!P>QQ7PCX>\6>!?"?[#/A6^U7PAH?C'38]0>34;6;7IM-U+^U!.X4Q
M^5"S%A&=Q)D0A!T(KT3PS<:]XD_;JU.\\,W^GZ'>77@.TN"VKV4NI((V^S$I
MA9X6+9*_.6/0Y'.0@L?8WAWQ-H_B[28M4T+5;'6M,E+".\TZY2XA<J2& ="0
M<$$'GJ*TJJ:3'?PZ;;)J=S;WFH*@$\]I;M!$[]RL;.Y4>Q=OK5NF(**** "B
MBB@ HHHH K:A_P ><GX?S%8M;6H?\><GX?S%8M=%/8N.P4445J4%%%% !17Q
M#^V]_P E7TG_ + D7_H^>OGJOOL#PK]=PT,1[>W,KVY;_P#MQ^T9/X<?VM@*
M..^M\O.KVY+V^?.K_<?K'17Y.45W?ZE_]1'_ )+_ /;'L?\ $*/^H[_RG_\
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MKJ8:NE3K05[+52C>UUK=6;2:=]UKV_H>HK^<>BE_J%_U%?\ DG_VQ^M_V/\
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MP1R,K2&V8R2#>!N.-Q!/%=1H_P"VU)X^BO#X!\#/XC?2O#RZ_K O=5%DMKE
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MG_QNC_7;#_\ /F7WH/[5A_*S\+:*_>+2_P!G#X2R>;O^%W@ML8QN\/VA]?\
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M#%U*-:O.IAZ?)!NZC>]O*]E=+I?6V]]PHHHK0XPHHHH **** "BBB@ HHHH
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M_P %%W_\:H_X3&P_Y]]5_P#!1=__ !JMRB@##_X3&P_Y]]5_\%%W_P#&J/\
MA,;#_GWU7_P47?\ \:K<HH P_P#A,;#_ )]]5_\ !1=__&J/^$QL/^??5?\
MP47?_P :K<HH P_^$QL/^??5?_!1=_\ QJC_ (3&P_Y]]5_\%%W_ /&JW**
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M /C5;E% &'_PF-A_S[ZK_P""B[_^-4?\)C8?\^^J_P#@HN__ (U6Y10!A_\
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M /C5;E% &'_PF-A_S[ZK_P""B[_^-4?\)C8?\^^J_P#@HN__ (U6Y10!A_\
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M"B[_ /C5;E% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\&L__P 71_J;7_Y_+[F'_$*\;_T$Q^YGZ;45^9/_  MSQU_T.GB'_P &L_\
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M ,H]A_\ &*/]2\P_GA]\O_D0_LNMW7X_Y'[(45^-_P#P\ ^/?_0^?^4>P_\
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M_'_(_:JBOQ5_X>(_M!_]% _\HNG_ /R/1_P\1_:#_P"B@?\ E%T__P"1Z/\
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M .B@?^473_\ Y'H_U'S+_GY#[Y?_ "(?V37[K\?\C]JJ*_%7_AXC^T'_ -%
M_P#*+I__ ,CT?\/$?V@_^B@?^473_P#Y'H_U'S+_ )^0^^7_ ,B']DU^Z_'_
M "/VJHK\5?\ AXC^T'_T4#_RBZ?_ /(]'_#Q']H/_HH'_E%T_P#^1Z/]1\R_
MY^0^^7_R(?V37[K\?\C]JJI:M_Q[K_O_ -#7XQ?\/$?V@_\ HH'_ )1=/_\
MD>HYO^"A7[0$ZA7\?;AG/_(&T_\ ^1Z<>!\Q3O[2'WR_^1'_ &37[K\?\C]B
MZ*_&_P#X> ?'O_H?/_*/8?\ QBC_ (> ?'O_ *'S_P H]A_\8K?_ %+S#^>'
MWR_^1*_LNMW7X_Y'[(45^-__  \ ^/?_ $/G_E'L/_C%'_#P#X]_]#Y_Y1[#
M_P",4?ZEYA_/#[Y?_(A_9=;NOQ_R/V0HK\;_ /AX!\>_^A\_\H]A_P#&*/\
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M_P",4?ZEYA_/#[Y?_(A_9=;NOQ_R/V0HK\;_ /AX!\>_^A\_\H]A_P#&*/\
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M_P",4?ZEYA_/#[Y?_(A_9=;NOQ_R/V0HK\;_ /AX!\>_^A\_\H]A_P#&*/\
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M?VGA^[^X_)RBOUC_ .'3?PB_Z&/QK_X'6?\ \BT?\.F_A%_T,?C7_P #K/\
M^1:/]<LJ_FE_X"']IX?N_N/R<HK]8_\ ATW\(O\ H8_&O_@=9_\ R+1_PZ;^
M$7_0Q^-?_ ZS_P#D6C_7+*OYI?\ @(?VGA^[^X_)RBOUC_X=-_"+_H8_&O\
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M!UG_ /(M3_KEE7\TO_ 3^WO[3P_=_<?DY17ZQ_\ #IOX1?\ 0Q^-?_ ZS_\
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M:KWW_!*/X26T(9?$7C0DMCF^M/\ Y%IKC'*GIS2_\!#^T\/W?W'Y245^IO\
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M7_@;:?\ R+1_PZP^%'_0P>,O_ VT_P#D6C_6[*^\ON#^TL/W?W'Y945^IO\
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MI_\ (M'_  ZP^%'_ $,'C+_P-M/_ )%H_P!;LK[R^X/[2P_=_<?EE17ZF_\
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M %NROO+[@_M+#]W]Q^65%?J;_P .L/A1_P!#!XR_\#;3_P"1:/\ AUA\*/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *I:M_Q[K_O_ -#5VJ6K?\>Z_P"__0U4?B0UN9-%
M%%=9H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 3:3
M#';W$211K&@+$*@ '.2>/K6[6+I__'Y'^/\ (UM5SU-R9:N["BBBLB HHHH
M**** "BBB@ HHHH **P_^*D_ZA?_ )$H_P"*D_ZA?_D2@#<HK#_XJ3_J%_\
MD2C_ (J3_J%_^1* -RBL/_BI/^H7_P"1*/\ BI/^H7_Y$H W**P_^*D_ZA?_
M )$H_P"*D_ZA?_D2@#<HK#_XJ3_J%_\ D2C_ (J3_J%_^1* -RBL/_BI/^H7
M_P"1*/\ BI/^H7_Y$H W**P_^*D_ZA?_ )$H_P"*D_ZA?_D2@#<HK#_XJ3_J
M%_\ D2C_ (J3_J%_^1* -RBL/_BI/^H7_P"1*/\ BI/^H7_Y$H W**P_^*D_
MZA?_ )$H_P"*D_ZA?_D2@#<HK#_XJ3_J%_\ D2C_ (J3_J%_^1* -RBL/_BI
M/^H7_P"1*/\ BI/^H7_Y$H T]0_X\Y/P_F*Q:+[_ (2+[*^[^R\<=/,]161_
MQ/\ _J&_^1*Z*>Q<37HK(_XG_P#U#?\ R)1_Q/\ _J&_^1*TN4:]%9'_ !/_
M /J&_P#D2C_B?_\ 4-_\B47 UZ*R/^)__P!0W_R)1_Q/_P#J&_\ D2BX&O16
M1_Q/_P#J&_\ D2C_ (G_ /U#?_(E%P->BLC_ (G_ /U#?_(E'_$__P"H;_Y$
MHN!KT5D?\3__ *AO_D2C_B?_ /4-_P#(E%P->BLC_B?_ /4-_P#(E'_$_P#^
MH;_Y$HN!KT5D?\3_ /ZAO_D2C_B?_P#4-_\ (E%P->BLC_B?_P#4-_\ (E'_
M !/_ /J&_P#D2BX&O161_P 3_P#ZAO\ Y$H_XG__ %#?_(E%P->BLC_B?_\
M4-_\B4?\3_\ ZAO_ )$HN!KT5D?\3_\ ZAO_ )$H_P")_P#]0W_R)1<#7HK(
M_P")_P#]0W_R)1_Q/_\ J&_^1*+@:]%9'_$__P"H;_Y$H_XG_P#U#?\ R)1<
M#7HK(_XG_P#U#?\ R)1_Q/\ _J&_^1*+@:]%9'_$_P#^H;_Y$H_XG_\ U#?_
M ")1<#J-'_Y;?A_6M*N4TK_A(?WNW^S.W7S/>K__ !4G_4+_ /(E<T_B(>YN
M45A_\5)_U"__ ")1_P 5)_U"_P#R)4$FY16'_P 5)_U"_P#R)1_Q4G_4+_\
M(E &Y16'_P 5)_U"_P#R)1_Q4G_4+_\ (E &Y16'_P 5)_U"_P#R)1_Q4G_4
M+_\ (E &Y16'_P 5)_U"_P#R)1_Q4G_4+_\ (E &Y16'_P 5)_U"_P#R)1_Q
M4G_4+_\ (E &Y16'_P 5)_U"_P#R)1_Q4G_4+_\ (E &Y16'_P 5)_U"_P#R
M)1_Q4G_4+_\ (E &Y16'_P 5)_U"_P#R)1_Q4G_4+_\ (E &Y16'_P 5)_U"
M_P#R)1_Q4G_4+_\ (E &Y16'_P 5)_U"_P#R)1_Q4G_4+_\ (E &Y16'_P 5
M)_U"_P#R)1_Q4G_4+_\ (E &Y16'_P 5)_U"_P#R)1_Q4G_4+_\ (E &Y16'
M_P 5)_U"_P#R)1_Q4G_4+_\ (E &Y16'_P 5)_U"_P#R)1_Q4G_4+_\ (E &
MY16'_P 5)_U"_P#R)1_Q4G_4+_\ (E &Y16'_P 5)_U"_P#R)1_Q4G_4+_\
M(E &Y16'_P 5)_U"_P#R)1_Q4G_4+_\ (E &Y16'_P 5)_U"_P#R)1_Q4G_4
M+_\ (E &Y16'_P 5)_U"_P#R)1_Q4G_4+_\ (E &Y16'_P 5)_U"_P#R)1_Q
M4G_4+_\ (E &Y5+5O^/=?]_^AJA_Q4G_ %"__(E5-4_X2+[.N[^S,;NWF>AJ
MH[H:W)**R/\ B?\ _4-_\B4?\3__ *AO_D2NJYH:]%9'_$__ .H;_P"1*/\
MB?\ _4-_\B47 UZ*R/\ B?\ _4-_\B4?\3__ *AO_D2BX&O161_Q/_\ J&_^
M1*/^)_\ ]0W_ ,B47 UZ*R/^)_\ ]0W_ ,B4?\3_ /ZAO_D2BX&O161_Q/\
M_J&_^1*/^)__ -0W_P B47 UZ*R/^)__ -0W_P B4?\ $_\ ^H;_ .1*+@:]
M%9'_ !/_ /J&_P#D2C_B?_\ 4-_\B47 UZ*R/^)__P!0W_R)1_Q/_P#J&_\
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MA[5SO@?]DN3P_>KHVB?$"S_X2#0(-0MKV6?P\/LTL.I+DJD$=RGEE,<$.5Y
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MX))#* PSUX&.$UK]E_P?X%\,OJUKXG\3>'X]&\-2Z/<W]C<6WGS6"%I6#-)
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M_J]DW_0%2_\ !</\CUG_ (:J^*7_ $-'_E/M?_C5'_#57Q2_Z&C_ ,I]K_\
M&J\FHH_LO ?\^(?^ Q_R#_5[)O\ H"I?^"X?Y'K/_#57Q2_Z&C_RGVO_ ,:H
M_P"&JOBE_P!#1_Y3[7_XU7DU%']EX#_GQ#_P&/\ D'^KV3?] 5+_ ,%P_P C
MUG_AJKXI?]#1_P"4^U_^-4?\-5?%+_H:/_*?:_\ QJO)J*/[+P'_ #XA_P"
MQ_R#_5[)O^@*E_X+A_D>L_\ #57Q2_Z&C_RGVO\ \:H_X:J^*7_0T?\ E/M?
M_C5>344?V7@/^?$/_ 8_Y!_J]DW_ $!4O_!</\CUG_AJKXI?]#1_Y3[7_P"-
M5YY\6_VUOC/X8_LK^S/&7V;S_-\S_B5V3[MNS'WH3ZFLFO)OCU_S _\ MO\
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MV_P]_:,_:C^(_AO5?$=CX[T[3/#>ERQV]UK&M6^E65JLSD;8@\D(W,<@X&<
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M&BC^R,N_Z!H?^ 1_R#ZM0_D7W(^CO^'B/[0?_10/_*+I_P#\CT?\/$?V@_\
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M $4#_P HNG__ "/6!^T])";[P^BX^TK',S^NTE-OZAOUKQ"MHY3ES5_JT/\
MP"/^1_;'"&,_MO(L-C\332J33OHM7%N-_G:_S/H[_AXC^T'_ -% _P#*+I__
M ,CT?\/$?V@_^B@?^473_P#Y'KYQHJO[(R[_ *!H?^ 1_P C['ZM0_D7W(^C
MO^'B/[0?_10/_*+I_P#\CT?\/$?V@_\ HH'_ )1=/_\ D>OG&BC^R,N_Z!H?
M^ 1_R#ZM0_D7W(^CO^'B/[0?_10/_*+I_P#\CT?\/$?V@_\ HH'_ )1=/_\
MD>OG&BC^R,N_Z!H?^ 1_R#ZM0_D7W(^CO^'B/[0?_10/_*+I_P#\CT?\/$?V
M@_\ HH'_ )1=/_\ D>OG&BC^R,N_Z!H?^ 1_R#ZM0_D7W(^CO^'B/[0?_10/
M_*+I_P#\CT?\/$?V@_\ HH'_ )1=/_\ D>OG&BC^R,N_Z!H?^ 1_R#ZM0_D7
MW(^CO^'B/[0?_10/_*+I_P#\CT?\/$?V@_\ HH'_ )1=/_\ D>OG&BC^R,N_
MZ!H?^ 1_R#ZM0_D7W(^CO^'B/[0?_10/_*+I_P#\CT?\/$?V@_\ HH'_ )1=
M/_\ D>OG&BC^R,N_Z!H?^ 1_R#ZM0_D7W(^CO^'B/[0?_10/_*+I_P#\CTZ/
M_@HE^T#YB^9X_8ID;@NC:<#COC_1Z^;Z*/[(R[_H&A_X!'_(/JU#^1?<C] -
M,^/'[0/B[0;;6/#'QHM[VTN4W(EYX>L(F1NZ,5A;D'@\5T^J^./B7865WJ/A
M;Q<NF^,KL1BYU6XM()$N.5\PM&T3(N<$C:@P0 , FO#/V6O!>L>'_#=UJE_/
M)#9:EM>VL&'&!_RV.>A8<#U !.>,>XU\;B</AZ-5TZ=.%EVC%7\G9:GZ9EV4
MX)X5R]@H^T5FO+_@[G _$;]J/XZ_"WP^MWJOQB%UJEP=EK86OAW3QO(ZL6,/
MW1G^[Z#OQY-_P\1_:#_Z*!_Y1=/_ /D>L+]J3P7K%AXL7Q#-/)?:3>!8HF8<
M6K ?ZKC@ \L#WR>XR?#J^DP65Y?4HJ<J,)-_W(_=L?#9C@L-1Q,J4**BEY;^
M?S/H[_AXC^T'_P!% _\ *+I__P CT?\ #Q']H/\ Z*!_Y1=/_P#D>OG&BN[^
MR,N_Z!H?^ 1_R/,^K4/Y%]R/H[_AXC^T'_T4#_RBZ?\ _(]'_#Q']H/_ **!
M_P"473__ )'KYQHH_LC+O^@:'_@$?\@^K4/Y%]R/H[_AXC^T'_T4#_RBZ?\
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M<1M\"?C6WP#'PECO/ -OH\6ESZ:=49[V6XNE+?N?W8C18#M^\V9>>0M?6%%
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M]'_#!W_4\?\ E(_^WU]8T4?ZR9K_ ,_O_)8_Y!_K]Q)_T%?^24__ )$^3O\
MA@[_ *GC_P I'_V^C_A@[_J>/_*1_P#;Z^L:*/\ 63-?^?W_ )+'_(/]?N)/
M^@K_ ,DI_P#R)\G?\,'?]3Q_Y2/_ +?1_P ,'?\ 4\?^4C_[?7UC11_K)FO_
M #^_\EC_ )!_K]Q)_P!!7_DE/_Y$^3O^&#O^IX_\I'_V^N2\>?\ !-'_ (3?
M[#_Q<?[%]E\S_F!^9NW;?^GD8QM_6OMZBFN)<V6JK?\ DL?\CCQG&6>X^A+#
M8G$<T)6NN6"V=^D4]T?GI_PZ5_ZJK_Y;O_W51_PZ5_ZJK_Y;O_W57Z%T5?\
MK1F__/[_ ,EC_P#(GS?U_$_S?@O\C\]/^'2O_55?_+=_^ZJ/^'2O_55?_+=_
M^ZJ_0NBC_6C-_P#G]_Y+'_Y$/K^)_F_!?Y'YZ?\ #I7_ *JK_P"6[_\ =5'_
M  Z5_P"JJ_\ EN__ '57Z%T4?ZT9O_S^_P#)8_\ R(?7\3_-^"_R/ST_X=*_
M]55_\MW_ .ZJ/^'2O_55?_+=_P#NJOT+HH_UHS?_ )_?^2Q_^1#Z_B?YOP7^
M1^>G_#I7_JJO_EN__=5'_#I7_JJO_EN__=5?H711_K1F_P#S^_\ )8__ "(?
M7\3_ #?@O\C\_;/_ ()$_:M__%V-NW'_ #+F?_;NK/\ PY]_ZJU_Y;?_ -UU
M^A6C_P#+;\/ZUI5SRXJSA.RK_P#DL?\ Y$AYAB;_ !_@O\C\X_\ AS[_ -5:
M_P#+;_\ NNC_ (<^_P#56O\ RV__ +KK]'**G_6O.?\ G_\ ^2P_^1%_:.*_
MG_!?Y'YQ_P##GW_JK7_EM_\ W71_PY]_ZJU_Y;?_ -UU^CE%'^M><_\ /_\
M\EA_\B']HXK^?\%_D?G'_P .??\ JK7_ );?_P!UT?\ #GW_ *JU_P"6W_\
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MLY_Y_P#_ )+#_P"1/U##XFIA*,,/0:C"*2225DELMC\X_P#AS[_U5K_RV_\
M[KH_X<^_]5:_\MO_ .ZZ_1RBG_K7G/\ S_\ _)8?_(G1_:.*_G_!?Y'YQ_\
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M_1RBC_6O.?\ G_\ ^2P_^1#^T<5_/^"_R/SC_P"'/O\ U5K_ ,MO_P"ZZ/\
MAS[_ -5:_P#+;_\ NNOT<HH_UKSG_G__ .2P_P#D0_M'%?S_ (+_ "/SC_X<
M^_\ 56O_ "V__NNH+O\ X)#?98P__"V-V3C'_".8_P#;NOTCJEJW_'NO^_\
MT-./%6<-_P ?_P EA_\ (C688G^?\%_D?F]_PZ5_ZJK_ .6[_P#=5'_#I7_J
MJO\ Y;O_ -U5^A=%=/\ K1F__/[_ ,EC_P#(E_7\3_-^"_R/ST_X=*_]55_\
MMW_[JH_X=*_]55_\MW_[JK]"Z*/]:,W_ .?W_DL?_D0^OXG^;\%_D?GI_P .
ME?\ JJO_ );O_P!U4?\ #I7_ *JK_P"6[_\ =5?H711_K1F__/[_ ,EC_P#(
MA]?Q/\WX+_(_/3_ATK_U57_RW?\ [JH_X=*_]55_\MW_ .ZJ_0NBC_6C-_\
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M-RY')N*UNK*]M-D%%%%=Y\L%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 6=/\ ^/R/\?Y&MJL73_\ C\C_ !_D:VJY
MZFY$MPHHHK(D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** *VH?\><GX?S%8M;6H?\><GX
M?S%8M=%/8N.P4445J4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 :.C_\ +;\/ZUI5FZ/_ ,MO
MP_K6E7+/XF9O<****@04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !5+5O\ CW7_ '_Z&KM4M6_X]U_W_P"AJH_$AK<R:***ZS0**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH LZ?\ \?D?X_R-;58N
MG_\ 'Y'^/\C6U7/4W(EN%%%%9$A1110 4444 %%%% !1110!A_\ "&:7_=NO
M_ Z?_P"+H_X0S2_[MU_X'3__ !=;E% S#_X0S2_[MU_X'3__ !='_"&:7_=N
MO_ Z?_XNMRB@##_X0S2_[MU_X'3_ /Q='_"&:7_=NO\ P.G_ /BZW** ,/\
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M?_%T?\(KIW]VY_\  R;_ .+K7HK6R&9'_"*Z=_=N?_ R;_XNC_A%=._NW/\
MX&3?_%UKT460&1_PBNG?W;G_ ,#)O_BZ/^$5T[^[<_\ @9-_\76O119 9'_"
M*Z=_=N?_  ,F_P#BZ/\ A%=._NW/_@9-_P#%UKT460&1_P (KIW]VY_\#)O_
M (NC_A%=._NW/_@9-_\ %UKT460&1_PBNG?W;G_P,F_^+H_X173O[MS_ .!D
MW_Q=:]%%D!D?\(KIW]VY_P# R;_XNC_A%=._NW/_ (&3?_%UKT460&1_PBNG
M?W;G_P #)O\ XNC_ (173O[MS_X&3?\ Q=:]%%D!D?\ "*Z=_=N?_ R;_P"+
MH_X173O[MS_X&3?_ !=:]%%D!D?\(KIW]VY_\#)O_BZ/^$5T[^[<_P#@9-_\
M76O119 9'_"*Z=_=N?\ P,F_^+H_X173O[MS_P"!DW_Q=:]%%D!D?\(KIW]V
MY_\  R;_ .+H_P"$5T[^[<_^!DW_ ,76O119 9'_  BNG?W;G_P,F_\ BZ/^
M$5T[^[<_^!DW_P 76O119 9'_"*Z=_=N?_ R;_XNC_A%=._NW/\ X&3?_%UK
MT460&1_PBNG?W;G_ ,#)O_BZ/^$5T[^[<_\ @9-_\76O119 9'_"*Z=_=N?_
M  ,F_P#BZ/\ A%=._NW/_@9-_P#%UKT460%?2_".F2>;N6ZXQTO9AZ_[=7_^
M$,TO^[=?^!T__P 75K1_^6WX?UK2KEG\1#W,/_A#-+_NW7_@=/\ _%T?\(9I
M?]VZ_P# Z?\ ^+K<HJ!&'_PAFE_W;K_P.G_^+H_X0S2_[MU_X'3_ /Q=;E%
M&'_PAFE_W;K_ ,#I_P#XNC_A#-+_ +MU_P"!T_\ \76Y10!A_P#"&:7_ ';K
M_P #I_\ XNC_ (0S2_[MU_X'3_\ Q=;E% &'_P (9I?]VZ_\#I__ (NC_A#-
M+_NW7_@=/_\ %UN44 8?_"&:7_=NO_ Z?_XNC_A#-+_NW7_@=/\ _%UN44 8
M?_"&:7_=NO\ P.G_ /BZ/^$,TO\ NW7_ ('3_P#Q=;E% &'_ ,(9I?\ =NO_
M  .G_P#BZ/\ A#-+_NW7_@=/_P#%UN44 8?_  AFE_W;K_P.G_\ BZ/^$,TO
M^[=?^!T__P 76Y10!A_\(9I?]VZ_\#I__BZ/^$,TO^[=?^!T_P#\76Y10!A_
M\(9I?]VZ_P# Z?\ ^+H_X0S2_P"[=?\ @=/_ /%UN44 8?\ PAFE_P!VZ_\
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M_P"[=?\ @=/_ /%T?\(9I?\ =NO_  .G_P#BZW** ,/_ (0S2_[MU_X'3_\
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MTN#@R,=L9Z!R"!Z?X/L]-T[PGHUIHUM+9:3!9PQ6EO/#)#)%"J (K)( ZL%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!P_QB^,?_  I'P?#KO]D?VU]HOX[+[/\ :?(V[HY7W;MC
M9_U>,8[]>*\7_P"'A'_4@_\ E9_^YZW_ -MW_DC^F_\ 8=@_])[FOAVOTS(,
MDR_'X)5L13YI7>MY+\FC^@^"N%,FS?*5BL;0YIN4E?FFM%MHI)'V'_P\(_ZD
M'_RL_P#W/1_P\(_ZD'_RL_\ W/7QY17T?^J^4?\ /G_R:7_R1]Y_J!PW_P!
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M?_+D_P#N2OSCHH_U4R;_ )\?^33_ /D@_L["_P GXO\ S/T<_P"'P7_5)?\
MRY/_ +DH_P"'P7_5)?\ RY/_ +DK\XZ*/]5,F_Y\?^33_P#D@_L["_R?B_\
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M*_..BC_53)O^?'_DT_\ Y(/[.PO\GXO_ #/T<_X?!?\ 5)?_ "Y/_N2H+O\
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M -RT?\/:O^J5?^7%_P#<M?GK11_JOE'_ #Y_\FE_\D']GX;^7\7_ )GZ%?\
M#VK_ *I5_P"7%_\ <M'_  ]J_P"J5?\ EQ?_ '+7YZT4?ZKY1_SY_P#)I?\
MR0?V?AOY?Q?^9^A7_#VK_JE7_EQ?_<M'_#VK_JE7_EQ?_<M?GK11_JOE'_/G
M_P FE_\ )!_9^&_E_%_YGZ%?\/:O^J5?^7%_]RT?\/:O^J5?^7%_]RU^>M%'
M^J^4?\^?_)I?_)!_9^&_E_%_YGZ%?\/:O^J5?^7%_P#<M'_#VK_JE7_EQ?\
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M:7_R0?V?AOY?Q?\ F?H5_P /:O\ JE7_ )<7_P!RT?\ #VK_ *I5_P"7%_\
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MW:QRRVCG&6B9@2A^5>5QT'I67)\)_!$NFW.GOX-\/O87-W]OGM6TN Q2W/\
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M ,K6G_\ R17[544?Z\9E_P ^X?=+_P"2#^UJ_9?C_F?BK_P[N_:#_P"B?_\
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M.W.B^(OA/INI6LR\21:Q8PRHXZ.I^TD!@?;VZ&O)O^'=W[0?_1/_ /RM:?\
M_)%?M51713XRQU%-4Z4$O27_ ,D>36S[&8AIU;-KR_X)^*O_  [N_:#_ .B?
M_P#E:T__ .2*/^'=W[0?_1/_ /RM:?\ _)%?M516W^O&9?\ /N'W2_\ DCG_
M +6K]E^/^9^*O_#N[]H/_HG_ /Y6M/\ _DBC_AW=^T'_ -$__P#*UI__ ,D5
M^U5%'^O&9?\ /N'W2_\ D@_M:OV7X_YGXJ_\.[OV@_\ HG__ )6M/_\ DBHY
MO^">O[0$"AG\ [1G'_(9T_\ ^2*_:ZJ6K?\ 'NO^_P#T-./'&8MV]G#[I?\
MR0_[6K]E^/\ F?BS_P ._P#X]_\ 0A_^5BP_^/T?\.__ (]_]"'_ .5BP_\
MC]?LA16_^NF8?R0^Z7_R17]J5NR_'_,_&_\ X=__ ![_ .A#_P#*Q8?_ !^C
M_AW_ /'O_H0__*Q8?_'Z_9"BC_73,/Y(?=+_ .2#^U*W9?C_ )GXW_\ #O\
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MF'\D/NE_\D']J5NR_'_,_&__ (=__'O_ *$/_P K%A_\?H_X=_\ Q[_Z$/\
M\K%A_P#'Z_9"BC_73,/Y(?=+_P"2#^U*W9?C_F?C?_P[_P#CW_T(?_E8L/\
MX_1_P[_^/?\ T(?_ )6+#_X_7[(44?ZZ9A_)#[I?_)!_:E;LOQ_S/QO_ .'?
M_P >_P#H0_\ RL6'_P ?H_X=_P#Q[_Z$/_RL6'_Q^OV0HH_UTS#^2'W2_P#D
M@_M2MV7X_P"9^-__  [_ /CW_P!"'_Y6+#_X_1_P[_\ CW_T(?\ Y6+#_P"/
MU^R%%'^NF8?R0^Z7_P D']J5NR_'_,_&_P#X=_\ Q[_Z$/\ \K%A_P#'Z/\
MAW_\>_\ H0__ "L6'_Q^OV0HH_UTS#^2'W2_^2#^U*W9?C_F?C?_ ,.__CW_
M -"'_P"5BP_^/T?\._\ X]_]"'_Y6+#_ ./U^R%%'^NF8?R0^Z7_ ,D']J5N
MR_'_ #/QO_X=_P#Q[_Z$/_RL6'_Q^C_AW_\ 'O\ Z$/_ ,K%A_\ 'Z_9"BC_
M %TS#^2'W2_^2#^U*W9?C_F?C?\ \.__ (]_]"'_ .5BP_\ C]'_  [_ /CW
M_P!"'_Y6+#_X_7[(44?ZZ9A_)#[I?_)!_:E;LOQ_S/QO_P"'?_Q[_P"A#_\
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M #[ZK_X*+O\ ^-5N44 8?_"8V'_/OJO_ (*+O_XU1_PF-A_S[ZK_ ."B[_\
MC5;E% &'_P )C8?\^^J_^"B[_P#C5'_"8V'_ #[ZK_X*+O\ ^-5N44 8?_"8
MV'_/OJO_ (*+O_XU1_PF-A_S[ZK_ ."B[_\ C5;E% &'_P )C8?\^^J_^"B[
M_P#C5'_"8V'_ #[ZK_X*+O\ ^-5N44 8?_"8V'_/OJO_ (*+O_XU1_PF-A_S
M[ZK_ ."B[_\ C5;E% &'_P )C8?\^^J_^"B[_P#C5'_"8V'_ #[ZK_X*+O\
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M9?\ /'4O_!9<_P#QNM>BO=U/HC(_X2FR_P">.I?^"RY_^-T?\)39?\\=2_\
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M'_"4V7_/'4O_  67/_QNM>BC4#(_X2FR_P">.I?^"RY_^-T?\)39?\\=2_\
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M_C5;E% &'_PF-A_S[ZK_ ."B[_\ C5'_  F-A_S[ZK_X*+O_ .-5N44 8?\
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M\=2_\%ES_P#&Z/\ A*;+_GCJ7_@LN?\ XW6O11J!D?\ "4V7_/'4O_!9<_\
MQNC_ (2FR_YXZE_X++G_ .-UKT4:@9'_  E-E_SQU+_P67/_ ,;H_P"$ILO^
M>.I?^"RY_P#C=:]%&H&1_P )39?\\=2_\%ES_P#&Z/\ A*;+_GCJ7_@LN?\
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MI_\ Q^1_C_(UM5A4W(D8?_"8V'_/OJO_ (*+O_XU1_PF-A_S[ZK_ ."B[_\
MC5;E%9$F'_PF-A_S[ZK_ ."B[_\ C5'_  F-A_S[ZK_X*+O_ .-5N44 8?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *I:M_Q[K_O_ -#5VJ6K?\>Z_P"__0U4?B0UN9-%
M%%=9H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 6=/
M_P"/R/\ '^1K:K%T_P#X_(_Q_D:VJYZFY$MPHHHK(D**** "BBB@ HHHH **
M** .<^(?C#_A _!]_KOV3[=]E,0^S^9Y>[?*J?>P<8W9Z=JK>)_'B>&?&7A3
M0I+021ZX;L-=M-L%L((3*25VG=G&.HQUYJE\;?"MWXV^%^MZ'962:C<7@A3[
M+(4"R*)D9P=Y"XVAN#UZ5QNM?L^^'M-^)'@S4?"O@O1="T^%-1@U:ZT>RM[-
MQ'+:F.,-L"L^6/& <=>*!E_2OC7J]]I>C^*KCPU;6W@'5[F*&UU)=19KU(II
M!';W,ML80JQNS)TE8JKJQ'W@M[PG\;H?$7BWQEX>N]);2[[0WF>R\RX#KJEM
M$VR29,*-A60;60Y*[D.2'%<?!X1\7:M\-_#OPMO_  U>6T.G26-I>^)3<VIL
MYK2TEC?S(E60R^9*L2KL,:["S$G"J6O>)OA7X@O?">MWVE0+:^+[#7;[5='W
MS(JW4,K$/;NPSM2:,E3G[K;&(R@H U+?XQ>)O$6M:'IGAGPII-Y/J'AVV\0S
M-JVN2VBPK,VT1+Y=I,7(/\1"_2M'5/B!XTA\56'AO3?"F@W>KMI(U.]^U>(9
MH+>$^:8_+C=;)VDY&=S(GTKS*\^%,T/B3PE=^)?A-_PL'3[+P;9Z2T&S2[G[
M'>1N2XQ=SQCIQN3(-=O>7/B/1_B+IWB>S^'6NWNGS>'AI[6%G<Z8DUE*+@N$
M</=HF-N.8V<4 .U'X[7T>BV:V/AF(^*G\01^'+O1M2U+R([6X>,R!S/'%+NC
M*;&5@F2'&0I!4;6C_%:YM;SQ18>,-+L] U#0-.CU>X.GZBU];/:/YN'$C0Q,
M&!@D!5D'8@G/'GFL?!GQ#XN6#5M5L)K._P!;\8VFM:C8Z=JC02Z=9PVIMT47
M$3HQD"HI8Q-U<A2P&XOD^">NV%QXP\+V(U%]%\2:G93-XIN-02\O8+%4)EMG
M:Z:2238T.Q-ZNNV[Y!VO0!TMG\9-3U[X6ZMK%UIB^#]>L+I[&^M;BX6Y%@^T
M2(V\JH)>-XBN5P&E4$, 06?L\^/-<\6:;/#K5[<ZA<(&=C?1A+FWY7:K_P"B
M6AVMN;;NMT.8GP9%*M6AX1^&^K^%/B%KKW^J7_C#0/$6FH;ZZUA+)3'<PGRU
MC,<$42LLD4F"=A_U.">5%=[X9\(Z%X*TW^SO#VBZ?H.G[S)]ETRUCMHMQZML
M0 9.!SB@#'7QAJ5Q\4;CPO;Z5:OIMGID&H7>I2WS),IFDG2-(X!$0XS;G+&1
M<;A@'%<GJGQMU)9+ZTTCPY:WNI0^*?\ A&(8[W4VMH9#]F$_G,ZP2%!@E=H1
MNG6K<^I7.C_&3QE=VFDWFN7$?AO1]MA8/"LTN;K4 =IFDCCX!S\SC@'&3@'C
M'^$6N>);&"?4M-O-,_M7QM_PD%W9VVJ?9[JQM?LIA&9[>0$/E4)$3M]_ )&:
M -;Q-^T)J_@W2]275?!7G^(-+U"UMKO3=+U/[1&UM-&\OVB"5H4:0JD4O[IH
MT8LF!U4GM9_B,VI:E8V?AJULM:_M+0Y=:L+N6^:&WF57A5%+K%(0K"8-O"G&
M/NG/&3?_  GLO#__  CZ>&[":3;X@AU/4KJ\OI+JYE589(S))-/(TDA V* 6
M)   &!6+X%^&6N>!_C%J;QQ+)X%CTRY.DR^<NZT>XGADDM/+^]L5HW=". L@
M3C:* /1_A_XJ/CKP+X>\1M:"Q;5K""^-J)?,$7F1A]F_:N[&<9P,XZ"N@K@O
M@%_R0[X?_P#8!LO_ $0E=[0(**** "BBB@ HHHH **** *VH?\><GX?S%?GA
M<-;Q_M[_ !^:[BEGM%\"SF:*&01R.G]G66X*Y5@I(S@E3CT/2OT/U#_CSD_#
M^8K\5?\ @H!_R=SX\_[</_2"VK[KA/#_ %NO6H7MS0>O_;T3U\NA[2<H7W7Z
MH^A_V,_VEK"ZUJT\/:)X6NM-\-^!/">LZG%'J.K?;KRZD:2*5E,PAB5%XP%6
M/'?FO</A]HO@+X:ZIX@U+PK-'?W/Q>LK[Q';C 4V-C':>88^"<YGF?T'S8Q\
MG/Y!UTUO\+_&=VEF\'A'79DO;-]1M6CTV9A/:IC?.F%^:-<C+CY1D9-?H>,X
M=HU*DIQK<D9[K>^\M6WK[WO?AL>S5P492;4K)_\ #]^^I]VV/@GQ[JGCK]E;
MQ)X5M-0M-'TKPGI[ZMKJJT5E;6JR%[A)ICA,&+=E"<D'I796OQ,^'7P!U33-
M#:[EM-,^*?B"]UJZM[/3(KBWFTFY9[:V621YD:",@B8,BR<!AMP<'\NJTO$'
MAG6/"6H"QUS2;[1KTQK,+;4+9X)#&PRK[7 .TCD'H:UJ9 JS4*M;2ST2LWJW
MK=N]G+333YE2P:EI*6G]?E<^QOV4?#.H_!7]KCXA^!7BM9$T_3=4C$MW8P32
MND43-"ZNZ%D5T9695(#@@," ,>N>'_"]CXA\6?#VS_X0SPY-\$-;\#-J?B36
MX-!M+>V^V>3(TTSW$<*^1*DBQ@(I3;V48X_,NM[Q!I/B?P8O]AZW9ZMH2S*E
MW_9NH12VXD5A\LOEN!D$ 8;'.*UQ63/$5?:.JE.44MNJ37,M=U>Z[%5,*YRY
MN;5K^GN?HCK=CX3LOVFO&'A6V^'?@?\ X1_PWX!FUFUM7\,V1\^[$$4@EE;R
MMS??(VY [XSS2>$?#_@_QY<_"_0]0^'?@>&/Q=X O=9U6ZAT*WM7:Z1%"2))
M&H: +M8GRROWR>PQ^:-%9_ZOOE259II)7L][-7^+N^;U0OJ;MI+^K>OS/U2T
M/X!66F+XI_MOPQH+)HL>CW&F:EH?@N#2[&&X66)]UG?F9[F[!! =G&TD'GDB
MO;O@C_R-GQH_['B;_P!-]A7X?U^IO_!+#_DWWQ!_V-%Q_P"DEI7R^?934P>#
ME7J5N>]E;EM_+KN_Y?Q.#&8>5*DYRE?Y>G^1]D4445^8G@!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!HZ/_ ,MOP_K6E6;H_P#R
MV_#^M:5<L_B9F]PHHHJ!!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %4M6_X]U_W_Z&KM4M6_X]U_W_ .AJH_$AK<R:***ZS0**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH LZ?_Q^1_C_ "-;58NG
M_P#'Y'^/\C6U7/4W(EN%%%%9$A1110 4444 %%%% !1110!5U35+/1--NM0U
M"ZAL;"UB::>YN'"1Q1J,LS,>  !G)KS7PO\ M0?#/QAK&E:9IOB1C<ZL773F
MO-.NK2&^*-M80331+'*<\81B3VK(_;+\(ZYXX_9M\9:3X=MIKW5)(8I5M;?/
MF3)',DCJH'+$JK?*.O3O7D?A_P",'PR\9^ ?@IX2LO#'_"=>(X/LB)HUBY2?
M0I8(UCEN)L8\L(W]XC/4>M SZ7^&OQ<\)_%[3]0OO"6J_P!K6NGW;6-S)]FF
MA\N90"5Q(BD\$<C(YZU+X ^*7ACXH0ZM+X8U/^TX]*OI-.O#]GEB\JX3&Y/W
MBKNQD<C(]Z^1_P#@GU\2O"/A'PKXWTS7?%6B:+J5UXIF:WL]1U&&WFF!2-04
M1V!8%@1P.HQ7:?L&2-#X?^+TBQM*R^-+]A&O5B%3@>YH"Q]7T5^4WB_Q%;75
MKX5\0P:)I/@3Q%'XW036*P7\FOVX).Y[O4;B4E@W.$*CIP>& O\ Q3\(Z3>1
M_M4>)YK-)->TCQ%8KIU\>)+3?=MO,9ZJ2  2.PI#L?I?XV\66G@/P?K7B34(
MYIK'2;.6]GCME#2LD:%F"@D G XR0/>N(?\ :4\#:?\ "'1/B5K5]=:!X9U?
M8+=[RT>68,^[:K) ),'Y#TR/>OBKXG7FEZQXV^)\GQ6E6XO)/ 5M-X-;5BWE
MLYMHV=K<GCS3-R2.>).P:M+XV?\ *-?X9\X_TBSY_P"_] K'VOX5^.O@OQCX
MN?PK8:C=V_B-;;[8-+U;2KO3IWASC>B7,49<<'[N>AKOJ_/O7K@>)/VEKH>%
MO$;_ !B6X\!7UI<:L/(G;2,P7&Q$>T2.'+OM7!0M^\(SDUPWPO\ %&GZG>?L
MIZ/IE];W&NZ/=ZI'>66[Y[:5IB460?PDXSCKC![B@=C])YO">AW7B2W\0S:-
MI\NOV\)MX=5>UC:ZBB.<HLI&X*=S< X^8^M:U?F+X!\,V_B?2TD\8?$"S\&_
M&!?%3RR-_P (W>7WB87('RJK17(9K9D["'RQTSGFO-[;P#HL'[.'C/QO<3WT
M/B%_&?\ 84=U%)*+:.V95>59D1A^[?/S':YRD8 Y)H"Q^L[>-_#B^*%\-'7]
M+'B-H_-&CF\C^V%,9W"'=OQ@$YQC J_J^CV'B#3+G3M4L;?4M/N4,<]I>1++
M%*IZJR,"&'L17Y.>*O$&EZB?$U[X$\4Z+I6C:U=V*:WX1\(VFH&VATV)2);E
M_-@MF<;OOI$!\KG+#)-:W[1GA7PYIO@OQ1J'@[Q]I&M:5<ZA8)?:%X3\/W-E
MHT$^P[)HYFN)H?-V9#(C9^8D@8- 6/T0\'_%KPQ=?%/7/A/H^E76G7_A?3X)
MV6.WBBL5@9(_+CAVOD8$BC&Q0,'%>DU\B_%3]E?X;_"OX!^*Y=!N[WP3>ZEI
M\-KJ/B-?MVHM+&)$=Q+%&SE4<KAV50 &.>.#C_L=^($L?B)XM\,Z/X=\,SL-
M(AN'\4^!;NZ;1IY%5%BCDAD/E)<%6!8J V0^0>2&(^DOC%\:M#^".EZ)?:[:
MZA=PZMJ<6DP+I\:.RRR!BK-O=<+\IR1D^U;NA>,)-;\3:WH[>'M:TQ-,9 NI
M7UNB6E[N!Y@8.68#'.Y5Z]Z_+J^/A^X^'/A6;7/+;XSCXB8U]K[<-1";NC[N
M?+XCP.F0V.=U=A\5M%LM>^-GQQM]0\50^%K5/$.D3%M1L;FXTZ[94DVP7;0J
M?+B+$'<_RY7\0AV/TXHK\K)?$E_JVM:+H+Z'H/AGX8V/B@OKFN:-]NU#PE?7
M3D>4WE/*BB!64Y1'6/Y@2  ,]5<6N@^%=2T_3M*OM)\?^!]5\122B_OM$U2W
M\)^';@$B0) +AHKM7S\N9"B;#@X8D 6/TIHK\CO!>GV.JZYJEI/XT\.Z78Z-
MXMNI-/\ #_BO3+V+PQ=EU;!?[RVP 0[4D;=@]>.>D\&^()/&/B[P/:>)M)TC
MP%\*[&VO+72V\1Q7NJ^'+F\^8M*GG7$1 9&Q'ND*J5^49/ %C]3:*\0_8]\/
MVGAOX.PVNE^,+GQIH1O)9--O;C2KG3UA@(7$,27#,[1*=Q5\D'=@9P37M],D
MK:A_QYR?A_,5^*O_  4 _P"3N?'G_;A_Z06U?M5J'_'G)^'\Q7XJ_P#!0#_D
M[GQY_P!N'_I!;5^C<#_[_4_P/_TJ)[>4_P 9^GZH]R^"/PYTF_\ @[\*KOPY
M\/\ P=XQTG48M7;QQJWB$(C64B*WE+)>>5+)9A4 92B_,0O][=7>^%_">@>+
M/^%)6.KZ1I^N:;#\,-5G@@U"!+J-70Q;) '7[P[-M!Y[5^9=%?H-;(YU92E[
M:S;D]G?7F_O=.:UTEHDCV981R;?/W_&_GYGZ,>"_A[X,\47'PG\$7G@CPS]@
MU_X92ZK?:A'I427[W83Y)OM"@.&!7.003N.XGC'HGQ$^#?AS2K'PU+\-_A;X
M+\1^)[C4=(AU[3[[3+=H[;3GMR3(4,;"!';=NN%0MP>3M 'Y1T5C4R"K*HIK
M$.ROI9V;;;U]Y>2^2]"7@Y-WY_Z^\_4_3_V=]"N]6U"PNO!OA:7PA-X6O;N+
M_A&_"\-U86[,7\IAKTT@N)KE2O2.,+M(RJ\&N!\<>'M*\5_\%$?A9I6MZ99Z
MSI=QX=LQ-8ZA;I/!*!9SD!D<%3@@'D=0*^ O#OA76O%][)9Z%H]_K=W'"UP]
MOIUJ]Q(L:_><J@)"C/)Z"M[0=6\;? 7QSI6N6EO?>%/$UK&+NRDU"P"N(Y$9
M1((YD(965FP2I!ZBLXY+5IRG_M'--PE%*UM9+=N[?J[79*PLHM^_=V:^\_0#
MP7\+?#>H^+OA]#\1OA_X/\/>+[GQGJ-M8:#I^F6J)>Z.MG,P-Q!'E)%255VR
M.">%Y.XDS^%Y=$\9>$/ ^K^%? FEW:3:K?0>*]+\+>"-(N8GCCG94M+J26>#
M[(GDL=LA!R"&+<?-^<EMX7\2^*K>[UNTT34M3M6NT@GOK6R>2(7$K?)&65=H
M=R?E7J<\"L[6M%U'PWJESIFK6%UI>I6K^7/9WL+0S1,.JNC %3[$53R)U):U
M_>72UTOBNK<VWO+K=-)]K/ZIS/X]?^'\_,[3XP:;X L?$>J-X*U'6G5M0F T
MS4-.MHX+2'<VU([F&\G$^WA0V & W9K]#/\ @EA_R;[X@_[&BX_])+2ORRK]
M3?\ @EA_R;[X@_[&BX_])+2LN*8.GE/*Y-V<=63F"Y<-9N^Q]D4445^)'RH4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 :.C_ /+;
M\/ZUI5FZ/_RV_#^M:5<L_B9F]PHHHJ!!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %4M6_X]U_W_P"AJ[5+5O\ CW7_ '_Z&JC\2&MS)HHH
MKK- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"SI__
M !^1_C_(UM5BZ?\ \?D?X_R-;5<]3<B6X4445D2%%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 6=/\ ^/R/\?Y&MJL7
M3_\ C\C_ !_D:VJYZFY$MPHHHK(D**** "BBB@ HHHH **** "BBB@ HHHH
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M8T8=%:/]C_\ 3;_QW_Z]']C_ /3;_P =_P#KUT<\2[HSJ*T?['_Z;?\ CO\
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M_P =_P#KT?V/_P!-O_'?_KT<\0NC.HK1_L?_ *;?^.__ %Z/['_Z;?\ CO\
M]>CGB%T9U%:/]C_]-O\ QW_Z]']C_P#3;_QW_P"O1SQ"Z,ZBM'^Q_P#IM_X[
M_P#7H_L?_IM_X[_]>CGB%T9U%:/]C_\ 3;_QW_Z]']C_ /3;_P =_P#KT<\0
MNC.HK1_L?_IM_P"._P#UZ/['_P"FW_CO_P!>CGB%T9U%:/\ 8_\ TV_\=_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK
MSOQ%\<M!\,_&'PY\-[JSU637=>MI+JVN(+3=:HJ!R0[YR#\AZ*0,C<1FO1*
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M8SSSQ76?LH_$+7_B5\-=0U7Q)?\ ]HW\6N7]FDWDQQ8BCE*HN$51P.^,GN:
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M->V:+I46A:/8:;;L[P6<$=O&TA!8JBA03@ 9P/2KM% @KQW]KO\ Y-X\6?\
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M\3.UM.L8N@JO&+DGA9 ^0H?D#Y1@  ?8E%% @HHHH *QO&>GSZOX/UVPM?\
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MO&EM;B5(_,(E1C\SLJC@$\D5ZE)&DT921%D1N"K#(/X4L<:QHJ(H1%& JC
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M1B"/)4*0LASG/I0&IMS_ ++.EWWA.?PQ?^./&M_X?.G/I5MITNI0I#:P,H4
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M27X?YGU/17RQ_P /&/AM_P! 3Q5_X"6W_P D4?\ #QCX;?\ 0$\5?^ EM_\
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M_P"2*/\ AXQ\-O\ H">*O_ 2V_\ DBCZK6_E#_4_/_\ H$E^'^9]3T5\L?\
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MEC_AXQ\-O^@)XJ_\!+;_ .2*/^'C'PV_Z GBK_P$MO\ Y(H^JUOY0_U/S_\
MZ!)?A_F?4]%?+'_#QCX;?] 3Q5_X"6W_ ,D4?\/&/AM_T!/%7_@);?\ R11]
M5K?RA_J?G_\ T"2_#_,^IZ*^6/\ AXQ\-O\ H">*O_ 2V_\ DBC_ (>,?#;_
M * GBK_P$MO_ )(H^JUOY0_U/S__ *!)?A_F?4]%?+'_  \8^&W_ $!/%7_@
M);?_ "11_P /&/AM_P! 3Q5_X"6W_P D4?5:W\H?ZGY__P! DOP_S/J>BOEC
M_AXQ\-O^@)XJ_P# 2V_^2*/^'C'PV_Z GBK_ ,!+;_Y(H^JUOY0_U/S_ /Z!
M)?A_F?4]%?+'_#QCX;?] 3Q5_P" EM_\D4?\/&/AM_T!/%7_ ("6W_R11]5K
M?RA_J?G_ /T"2_#_ #/J>BOEC_AXQ\-O^@)XJ_\  2V_^2*/^'C'PV_Z GBK
M_P !+;_Y(H^JUOY0_P!3\_\ ^@27X?YGU/17RQ_P\8^&W_0$\5?^ EM_\D4?
M\/&/AM_T!/%7_@);?_)%'U6M_*'^I^?_ /0)+\/\SZGHKY8_X>,?#;_H">*O
M_ 2V_P#DBC_AXQ\-O^@)XJ_\!+;_ .2*/JM;^4/]3\__ .@27X?YGU/17RQ_
MP\8^&W_0$\5?^ EM_P#)%'_#QCX;?] 3Q5_X"6W_ ,D4?5:W\H?ZGY__ - D
MOP_S/J>BOEC_ (>,?#;_ * GBK_P$MO_ )(H_P"'C'PV_P"@)XJ_\!+;_P"2
M*/JM;^4/]3\__P"@27X?YGU/17RQ_P /&/AM_P! 3Q5_X"6W_P D4?\ #QCX
M;?\ 0$\5?^ EM_\ )%'U6M_*'^I^?_\ 0)+\/\SZGHKY8_X>,?#;_H">*O\
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MC'PV_P"@)XJ_\!+;_P"2*/\ AXQ\-O\ H">*O_ 2V_\ DBCZK6_E#_4_/_\
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MY_\ ] DOP_S/J>BOEC_AXQ\-O^@)XJ_\!+;_ .2*/^'C'PV_Z GBK_P$MO\
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M)+\/\SZGHKY8_P"'C'PV_P"@)XJ_\!+;_P"2*/\ AXQ\-O\ H">*O_ 2V_\
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MKUGKESI%A<:U91M%:ZE+;(US C9W*DA&Y0<G(!YS6I7RQ_P\8^&W_0$\5?\
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MYINM0_&"VU;5?MUG\0I8I_*%IL;3GCCVHRMO/F$-M<'"_=Q7$?\ #QCX;?\
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MAF  5(81]U0  79W]6/%>)_\/&/AM_T!/%7_ ("6W_R11_P\8^&W_0$\5?\
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M9R3T&*P_@3\$_!FN>"3J7Q!NO[%O?'EU)H/@TDD);3J=S7T@SDPK,(K?//\
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M4?V1@/\ GT@_UDS?_H(D==_PLW5/^>%G_P!\/_\ %4?\+-U3_GA9_P#?#_\
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M11_9& _Y](/]9,W_ .@B1UW_  LW5/\ GA9_]\/_ /%4?\+-U3_GA9_]\/\
M_%5R-%']D8#_ )](/]9,W_Z")'7?\+-U3_GA9_\ ?#__ !5'_"S=4_YX6?\
MWP__ ,57(T4?V1@/^?2#_63-_P#H(D==_P +-U3_ )X6?_?#_P#Q5'_"S=4_
MYX6?_?#_ /Q5<C11_9& _P"?2#_63-_^@B1UW_"S=4_YX6?_ 'P__P 51_PL
MW5/^>%G_ -\/_P#%5R-%']D8#_GT@_UDS?\ Z")'7?\ "S=4_P">%G_WP_\
M\51_PLW5/^>%G_WP_P#\57(T4?V1@/\ GT@_UDS?_H(D==_PLW5/^>%G_P!\
M/_\ %4?\+-U3_GA9_P#?#_\ Q5<C11_9& _Y](/]9,W_ .@B1UW_  LW5/\
MGA9_]\/_ /%4?\+-U3_GA9_]\/\ _%5R-%']D8#_ )](/]9,W_Z")'7?\+-U
M3_GA9_\ ?#__ !5'_"S=4_YX6?\ WP__ ,57(T4?V1@/^?2#_63-_P#H(D==
M_P +-U3_ )X6?_?#_P#Q5'_"S=4_YX6?_?#_ /Q5<C11_9& _P"?2#_63-_^
M@B1UW_"S=4_YX6?_ 'P__P 51_PLW5/^>%G_ -\/_P#%5R-%']D8#_GT@_UD
MS?\ Z")'7?\ "S=4_P">%G_WP_\ \51_PLW5/^>%G_WP_P#\57(T4?V1@/\
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MPLW5/^>%G_WP_P#\57(T4?V1@/\ GT@_UDS?_H(D==_PLW5/^>%G_P!\/_\
M%4?\+-U3_GA9_P#?#_\ Q5<C11_9& _Y](/]9,W_ .@B1UW_  LW5/\ GA9_
M]\/_ /%4?\+-U3_GA9_]\/\ _%5R-%']D8#_ )](/]9,W_Z")'7?\+-U3_GA
M9_\ ?#__ !5'_"S=4_YX6?\ WP__ ,57(T4?V1@/^?2#_63-_P#H(D==_P +
M-U3_ )X6?_?#_P#Q5'_"S=4_YX6?_?#_ /Q5<C11_9& _P"?2#_63-_^@B1U
MW_"S=4_YX6?_ 'P__P 51_PLW5/^>%G_ -\/_P#%5R-%']D8#_GT@_UDS?\
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M /%4?\+-U3_GA9_]\/\ _%5R-%']D8#_ )](/]9,W_Z")'7?\+-U3_GA9_\
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MX6?_ 'P__P 51_PLW5/^>%G_ -\/_P#%5R-%']D8#_GT@_UDS?\ Z")'7?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
%110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713879790192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LISATA THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-2343568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">110 Allen Road, 2nd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Basking Ridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">842-0100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LSTA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000320017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,974,464<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713881470704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 28,155<span></span>
</td>
<td class="nump">$ 32,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">32,940<span></span>
</td>
<td class="nump">37,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">4,203<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">65,298<span></span>
</td>
<td class="nump">71,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">262<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">66,326<span></span>
</td>
<td class="nump">73,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,341<span></span>
</td>
<td class="nump">2,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">3,945<span></span>
</td>
<td class="nump">3,728<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,286<span></span>
</td>
<td class="nump">6,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">5,623<span></span>
</td>
<td class="nump">6,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, authorized 33,333,333 shares; issued 7,999,080 and 7,866,799 shares at March 31, 2023 and December 31, 2022, respectively; and outstanding, 7,998,342 and 7,866,061 shares at March 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">575,137<span></span>
</td>
<td class="nump">574,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost; 738 shares at March 31, 2023 and December 31, 2022</a></td>
<td class="num">(708)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(513,428)<span></span>
</td>
<td class="num">(507,241)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Lisata Therapeutics, Inc. stockholders' equity</a></td>
<td class="nump">60,957<span></span>
</td>
<td class="nump">66,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests</a></td>
<td class="num">(254)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">60,703<span></span>
</td>
<td class="nump">66,324<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, non-controlling interests and stockholders' equity</a></td>
<td class="nump">$ 66,326<span></span>
</td>
<td class="nump">$ 73,034<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713879749088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">33,333,333<span></span>
</td>
<td class="nump">33,333,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">7,999,080<span></span>
</td>
<td class="nump">7,866,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of common shares of the combined company owned by Cend stockholders</a></td>
<td class="nump">7,998,342<span></span>
</td>
<td class="nump">7,866,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (shares)</a></td>
<td class="nump">738<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713879641312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 3,179<span></span>
</td>
<td class="nump">$ 3,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,665<span></span>
</td>
<td class="nump">3,337<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">6,844<span></span>
</td>
<td class="nump">6,620<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(6,844)<span></span>
</td>
<td class="num">(6,620)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income, net</a></td>
<td class="nump">670<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(148)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">657<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before benefit from income taxes and noncontrolling interests</a></td>
<td class="num">(6,187)<span></span>
</td>
<td class="num">(6,705)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,479)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(6,187)<span></span>
</td>
<td class="num">(4,226)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Less - net income attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Lisata Therapeutics, Inc. common stockholders</a></td>
<td class="num">$ (6,187)<span></span>
</td>
<td class="num">$ (4,226)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Basic and diluted loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Caladrius Biosciences, Inc. common stockholders - basic (in usd per share)</a></td>
<td class="num">$ (0.77)<span></span>
</td>
<td class="num">$ (1.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Caladrius Biosciences, Inc. common stockholders - diluted (in usd per share)</a></td>
<td class="num">$ (0.77)<span></span>
</td>
<td class="num">$ (1.05)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic shares</a></td>
<td class="nump">7,987<span></span>
</td>
<td class="nump">4,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares</a></td>
<td class="nump">7,987<span></span>
</td>
<td class="nump">4,037<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713884659344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (6,187)<span></span>
</td>
<td class="num">$ (4,226)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Available for sale securities - net unrealized loss</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Lisata Therapeutics, Inc. common stockholders</a></td>
<td class="num">$ (6,210)<span></span>
</td>
<td class="num">$ (4,352)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713880857472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Total Lisata Therapeutics, Inc. Stockholders' Equity</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Non- Controlling Interest in Subsidiary</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 92,000<span></span>
</td>
<td class="nump">$ 92,254<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 546,044<span></span>
</td>
<td class="num">$ (70)<span></span>
</td>
<td class="num">$ (453,016)<span></span>
</td>
<td class="num">$ (708)<span></span>
</td>
<td class="num">$ (254)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,986,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(4,226)<span></span>
</td>
<td class="num">(4,226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">593<span></span>
</td>
<td class="nump">593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">88,241<span></span>
</td>
<td class="nump">88,495<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">546,637<span></span>
</td>
<td class="num">(196)<span></span>
</td>
<td class="num">(457,242)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 66,324<span></span>
</td>
<td class="nump">66,578<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">574,548<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(507,241)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">7,866,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,867,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (6,187)<span></span>
</td>
<td class="num">(6,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">589<span></span>
</td>
<td class="nump">589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">$ (11)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">7,998,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,999,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 60,703<span></span>
</td>
<td class="nump">$ 60,957<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 575,137<span></span>
</td>
<td class="num">$ (52)<span></span>
</td>
<td class="num">$ (513,428)<span></span>
</td>
<td class="num">$ (708)<span></span>
</td>
<td class="num">$ (254)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713881585616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (6,187)<span></span>
</td>
<td class="num">$ (4,226)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Share-based compensation</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Gain) loss on disposal of fixed assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion on marketable securities</a></td>
<td class="num">(167)<span></span>
</td>
<td class="nump">515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="num">(1,652)<span></span>
</td>
<td class="num">(969)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities', window );">Accounts payable, accrued liabilities and other liabilities</a></td>
<td class="num">(1,083)<span></span>
</td>
<td class="num">(1,786)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(8,196)<span></span>
</td>
<td class="num">(5,642)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(30,121)<span></span>
</td>
<td class="num">(26,546)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sale of marketable securities</a></td>
<td class="nump">34,410<span></span>
</td>
<td class="nump">20,456<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">4,289<span></span>
</td>
<td class="num">(6,090)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding payments on net share settlement equity awards</a></td>
<td class="num">(85)<span></span>
</td>
<td class="num">(168)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(85)<span></span>
</td>
<td class="num">(168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(3,999)<span></span>
</td>
<td class="num">(11,900)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">32,154<span></span>
</td>
<td class="nump">24,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 28,155<span></span>
</td>
<td class="nump">$ 12,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713883442752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_BusinessTextBlock', window );">The Business</a></td>
<td class="text">The Business<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lisata Therapeutics, Inc. (together with its subsidiaries, the &#8220;Company&#8221;) is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The Company's lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are not expected to be affected. LSTA1 also has the potential to modify the tumor microenvironment (&#8220;TME&#8221;), with the objective of making tumors more susceptible to immunotherapies. The Company and its collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. To date, LSTA1 has also demonstrated favorable safety, tolerability, and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. The Company is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. In addition, the Company has development programs based on its autologous CD34+ cell therapy technology platform that it will look to partner while incurring no additional capital outlay.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. Its goal is to develop and commercialize products that address important unmet medical needs. The Company&#8217;s current development pipeline includes: </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LSTA1, the subject of Phase 1b/2a and 2b clinical studies being conducted globally in a variety of solid tumor types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a variety of anti-cancer regimens.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merger with Cend Therapeutics, Inc. and Name Change</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, the Company, then operating as Caladrius Biosciences, Inc. (&#8220;Caladrius&#8221;), completed its acquisition of Cend Therapeutics, Inc. (&#8220;Cend&#8221;), a Delaware corporation (the &#8220;Merger&#8221;), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), dated as of April 26, 2022, by and among Caladrius, Cend and CS Cedar Merger Sub, Inc. (&#8220;Merger Sub&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms set forth in the Merger Agreement and effective September 15, 2022 (the &#8220;Effective Time&#8221;): (i) Merger Sub merged with and into Cend, with Cend surviving as a wholly owned subsidiary of Caladrius, (ii) Caladrius changed its name to Lisata Therapeutics, Inc., and (iii) Caladrius effected a 1:15 reverse stock split of its common stock (&#8220;Reverse Stock Split&#8221;) prior to the Effective Time. At the Effective Time, each share of Cend's common stock outstanding immediately prior to the Effective Time was converted into the right to receive shares of Lisata&#8217;s common stock based on an exchange ratio of 0.5338, after taking into account the Reverse Stock Split (the &#8220;Exchange Ratio&#8221;). In connection with the Merger close, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Merger Agreement, Lisata assumed all of the outstanding and unexercised options to purchase shares of Cend capital stock under the 2016 Equity Incentive Plan (the &#8220;Cend Plan&#8221;), and, in connection with the Merger, such options were converted into options to purchase shares of Lisata&#8217;s common stock based on the Exchange Ratio. At the closing of the Merger at the Effective Time, the Company assumed Cend's stock options to purchase an aggregate of 1,227,776 shares of the Company's common stock. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caladrius was considered to be the accounting acquirer based on the terms of the Merger Agreement and certain factors including: (i) Caladrius owned approximately 52% of the Company's outstanding shares of common stock immediately following the close of the Merger; (ii) although both entities contributed to the new management team of Lisata, the Caladrius team had more individuals on the management team and holds the chief executive officer (&#8220;CEO&#8221;), chief medical officer (&#8220;CMO&#8221;) and other senior management roles; (iii) Caladrius paid a premium to acquire Cend&#8217;s assets; and (iv) Caladrius was significantly larger than Cend regarding total assets, operations, and research and development activities. The Merger was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;). Cend&#8217;s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;D with no </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alternative future use being expensed as reported in the consolidated statement of operations. Operating results presented in the consolidated statements of operations and comprehensive loss prior to the Merger are solely related to Caladrius Biosciences, Inc. and subsidiaries.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coronavirus Considerations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lisata's Phase 2b FREEDOM Trial of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. experienced delays in enrolling patients as a result of COVID-19. While early enrollment proceeded to plan with the first patient treated in January 2021, the impact of the COVID-19 pandemic contributed to a general slowing of enrollment, including supply chain disruptions affecting the availability of qualified catheters used in the diagnosis of CMD and/or administration of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as with a contrast agent typically used in many catheter laboratories. In May 2022, the Company announced that enrollment in the FREEDOM Trial was suspended and that it intended to conduct an interim analysis of the data from not less than the first 20 patients enrolled using the 6-month follow-up data to evaluate the efficacy and safety of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in subjects with CMD. Following this analysis along with Key Opinion Leaders&#8217; input, the Company determined that execution of a redesigned FREEDOM-like trial would be the appropriate next step, but the cost of such a trial would be prohibitively expensive to undergo without a strategic partner. Accordingly, the Company&#8217;s board of directors concluded that XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> development will only be continued if a strategic partner that can contribute the necessary capital for a redesigned trial is identified and secured. There can be no assurance that we will be able to identify such a partner and enter into an agreement with such partner on acceptable terms or at all.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2022, in connection with the Merger, the Company implemented the Reverse Stock Split, as authorized at the annual meeting of stockholders on September 13, 2022. The Reverse Stock Split became effective on September 14, 2022 at 5:00 pm and the Company's common stock began trading on The Nasdaq Capital Market on a post-split basis at the open of business on September 15, 2022. As of September 14, 2022, every fifteen shares of the Company&#8217;s issued and outstanding common stock (and such shares held in treasury) were automatically converted into one share of common stock, without any change in the par value per share. In addition, proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options, stock appreciation rights, convertible notes and warrants to purchase shares of common stock, the number of shares issuable upon the vesting of all restricted stock awards, and the number of shares of common stock reserved for issuance pursuant to the Company&#8217;s equity incentive compensation plans. Any stockholder who would otherwise be entitled to a fractional share of common stock created as a result of the Reverse Stock Split received a cash payment equal to the product of such resulting fractional interest in one share of common stock multiplied by the closing trading price of the common stock on September 15, 2022. The Reverse Stock Split was effectuated in order to increase the per share trading price of our common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from &#8220;common stock&#8221; to &#8220;additional paid-in capital&#8221; in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2023, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2022 and 2021 included in our 2022 Form 10-K. Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and the valuation of the Merger which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;). Accordingly, actual results could differ from those estimates and assumptions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd. which is a foreign subsidiary of the Company is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_BusinessTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Business [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_BusinessTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713965391504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of lease</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (&#8220;R&amp;D&#8221;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further drive the Company&#8217;s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company&#8217;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#8220;business&#8221; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Asset</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible asset consists of a single asset, Cend&#8217;s license agreement with Qilu Pharmaceutical, Co., Ltd. (&#8220;Qilu&#8221;) acquired in the Merger, with a value of $0.4&#160;million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of 5 years. Amortization expense was $18 thousand for the three months ended March&#160;31, 2023. The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.  The projected amortization expense is $71&#160;thousand per year for the next five years. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestones</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#8217;s collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#8217;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three months ended March&#160;31, 2023 and March&#160;31, 2022, the Company has not recognized revenue related to milestones.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713882733696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAbstract', window );"><strong>Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">Merger</a></td>
<td class="text">Merger<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger was accounted for as an asset acquisition as substantially all of the fair value was concentrated in IPR&amp;D. Cend&#8217;s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;D being expensed. The fair value of total consideration was $36.1&#160;million. The following table is a summary of the purchase price calculation (in thousands except per share data).</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:448.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of common shares of the combined company owned by Cend stockholders</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,772,768&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multiplied by the fair value per share of Lisata common stock on September 15, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.25</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$23,580</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of Lisata's cost method investment in Cend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental fair value of Cend's fully vested stock options</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,136&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisata transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$36,098</span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The allocation of the purchase price was as follows (amounts in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:448.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7,062</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net working capital (excluding cash)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,690)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$36,098</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713882688736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale-Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Available-for-Sale-Securities</a></td>
<td class="text">Available-for-Sale-Securities<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,581&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,758&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:360.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,641&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,581&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:361.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,581&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713882640560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Notes)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:505.50pt"><tr><td style="width:1.0pt"/><td style="width:363.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results included depreciation expense of approximately $30&#160;thousand and $7&#160;thousand for the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713882623616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Income (Loss) Per Share</a></td>
<td class="text">Income (Loss) Per Share<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023 and 2022, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive. At March&#160;31, 2023 and 2022, the Company excluded the following potentially dilutive securities (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713882605248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 inputs are defined as unobservable inputs for the assets or liabilities. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of March&#160;31, 2023 and December&#160;31, 2022 (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:116.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:12.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,940&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,940&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,072&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,072&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash, cash equivalents, accounts payable and accrued expenses approximate fair value as of March&#160;31, 2023 and December&#160;31, 2022, due to the short maturity nature of these items.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713882536752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">Accrued Liabilities<div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of March&#160;31, 2023 and December&#160;31, 2022 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"/><td style="width:313.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities &#8212; current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D&amp;O insurance liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and R&amp;D related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,728&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713882548848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text">Operating LeasesThe Company adopted ASU No. 2016-02, Leases (Topic 842) on January 1, 2019 and recognized leases with duration greater than 12 months on the balance sheet using the modified retrospective approach. The Company has operating leases for two offices, one of which expired on March 31, 2023 and the other expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. Each of the Company's leases includes options for the Company to extend the lease term and/or sub-lease space in whole or in part.<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfMi0wLTEtMS0yOTgwMw_684390b7-3bb3-42c7-8a83-13f2f83e10e2"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfMi0wLTEtMS0yOTgwMw_7e944932-8384-4e08-8716-1c2ac79100ed">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNi0wLTEtMS0yOTgwMw_37de52d8-2557-479d-bbaf-f29481bcc474"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNi0wLTEtMS0yOTgwMw_69afedb4-8e13-45d2-80d7-456feaf20302">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNy0wLTEtMS0yOTgwMw_16c9c39d-ad71-40ba-bf95-bdb2e5413413"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNy0wLTEtMS0yOTgwMw_bcfccd01-1243-450c-981b-7940b87eb256">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the weighted average remaining lease term for our operating lease was 2.5 years, and the weighted average discount rate for our operating lease was 9.625%. As of December&#160;31, 2022, the weighted average remaining lease term for our operating leases was 1.50 years, and the weighted average discount rate for our operating leases was 9.625%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under the lease agreement as of March&#160;31, 2023 were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:448.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713882640560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2022, in connection with the merger, we implemented the Reverse Stock Split, as described in Note 1. All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from &#8220;common stock&#8221; to &#8220;additional paid-in capital&#8221; in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Issuances</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">At The Market Offering Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC, as sales agent, in connection with an &#8220;at the market offering&#8221; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0&#160;million. Subsequent to the filing of our Form 10-K on March 22, 2022, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $43.6&#160;million. Pursuant to General Instruction I.B.6 of Form S-3, since the aggregate market value of our outstanding common stock held by non-affiliates was below $75.0&#160;million at the time of such Form 10-K filing, the aggregate amount of securities that we are permitted to offer and sell was reduced to $17,698,943, which was equal to one-third of the aggregate market value of our common stock held by non-affiliates as of September 21, 2022. During the three months ended March&#160;31, 2023 and since inception, the Company has not issued any shares under the ATM Agreement. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger closing, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Warrants</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger and after giving effect to the Reverse Stock Split, the Company assumed 1,227,776 options outstanding of Cend. The options granted under the Cend Plan are exercisable at various dates as determined upon grant and will expire no more than ten years from their original date of grant. The Cend Plan stock options generally vest over a four-year term. The following table summarizes the activity for stock options and warrants for the three months ended March&#160;31, 2023:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,391,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.03</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,423,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.37</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">224.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,492,682&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.94&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">359.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,423,774&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.57&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2023<br/>or expected to vest in the future</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,486,393&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.96&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,423,774&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.57&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,207,228&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.90&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.64</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">344.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,423,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.57&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, the Company issued restricted stock for services as follows ($ in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"><tr><td style="width:1.0pt"/><td style="width:322.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:4.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vesting terms of restricted stock issuances are generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNTcyMQ_03645692-ddcc-455a-9649-721f44f866fe">one</span> and four years.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, the Company issued restricted stock units for services as follows ($ in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"><tr><td style="width:1.0pt"/><td style="width:343.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The weighted average estimated fair value of restricted stock issued for services in the three months ended March&#160;31, 2023 and 2022 was $3.00 and $13.76 per share, respectively. The fair value of the restricted stock units was determined using the Company&#8217;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713882724016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize share-based compensation in the form of stock options, restricted stock, and restricted stock units.&#160;The following table summarizes the components of share-based compensation expense for the three months ended March&#160;31, 2023 and 2022 (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:70.349%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:2.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.477%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March&#160;31, 2023 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.42</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March&#160;31, 2023 and 2022 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:378.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#8217;s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713882634704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had approximately $281&#160;million of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an ownership change of greater than 50% over a 3-year testing period on January 25, 2021. As a result, $168.8&#160;million of the $281&#160;million  of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $112.3&#160;million of remaining Federal NOLs.  The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on January 25, 2021 will be subject to an annual limitation of $173&#160;thousand under Internal Revenue Code Section 382. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had approximately $34.0&#160;million of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an ownership change of greater than 50% on September 15, 2022. As a result of the ownership change, $88.2&#160;million of Federal </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $34.0&#160;million of remaining Federal NOLs.  The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on September 15, 2022 will be subject to an annual limitation of zero while losses incurred after September 15, 2022 will not be subject to limitations. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, Cend Therapeutics had approximately $10.9&#160;million of Federal NOLs available to offset future taxable income. The Company performed an analysis and determined that there was an ownership change of greater than 50% on September 15, 2022. As of September 15, 2022 Cend has approximately $10.7&#160;million of Federal and $15.0&#160;million of state NOLs. The state NOLs will expire from the 2036 through 2042 tax years.  Using a fair market value of $36.1&#160;million and applying an applicable federal rate of 2.54% Cend will have an annual limitation of approximately $917 thousand each year. The Federal NOL of $106&#160;thousand incurred in the post-acquisition period September 15, 2022 to December 31, 2022 is not subject to limitation, and does not expire. Cend&#8217;s wholly owned Australian subsidiary has $1.8&#160;million of NOLs which will be carried forward and do not expire. There is a full valuation allowance against the NOLs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the Company had State NOLs available in New Jersey of $35.5&#160;million and $97.0&#160;million, respectively, California of $10.0&#160;million and $69.5&#160;million, respectively, and New York City of $1.9&#160;million and $13.0&#160;million, respectively, to offset future taxable income expiring from 2032 through 2042. In accordance with Section 382 of the Internal Revenue code, the usage of the Company&#8217;s NOLs is limited given the change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the FASB&#8217;s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with uncertain tax positions as a component of income tax expense.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the Company&#8217;s uncertain tax positions were $344&#160;thousand and $0, respectively. Due to the acquisition of Cend, the Company&#8217;s uncertain tax positions increased by $344&#160;thousand related to Federal and state credits and certain state NOLs. The Company will continue to evaluate its uncertain tax positions in future periods. As of March&#160;31, 2023, the Company does not believe there will be any material changes in its unrecognized tax positions over the next year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For years prior to 2019, the federal statute of limitations is closed for assessing tax. The Company&#8217;s state tax returns remain open to examination for a period of three to four years from the date of filing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2023, Lisata received final approval to sell a portion of their unused New Jersey net operating losses (&#8220;NJ NOLs&#8221;) through the State of New Jersey Economic Development Authority's Technology Business Tax Certificate Transfer Program (the &#8220;Program&#8221;). The Program permits qualified companies to sell a percentage of their NJ NOLs to unrelated profitable corporations. When the NOL&#8217;s are sold it will be a discrete event. The Company will record a deferred income tax benefit and reduce the deferred tax asset (NJ NOLs) when the transaction closes and cash is received.</span></div>On August 16, 2022, the Inflation Reduction Act was signed into law. The Inflation Reduction Act includes various tax provisions, which are effective for tax years beginning on or after January 1, 2023. For tax years beginning after December 31, 2021, the Tax Cuts &amp; Jobs Act of 2017 eliminated the option to deduct research and development expenditures as incurred and instead required taxpayers to capitalize and amortize them over five or 15 years beginning in 2022. Since the Company is in a net operating loss position, the capitalization of research and development costs did not have a material impact on the Company&#8217;s results of operations for the year ended December 31, 2022. The Company will continue to monitor possible future impact of changes in tax legislation.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713882684016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Australia Research and Development Tax Incentive<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock', window );">Australia Research and Development Tax Incentive</a></td>
<td class="text">Australia Research and Development Tax IncentiveThe Company&#8217;s Australian subsidiary, which conducts core research and development activities, is eligible to receive a refundable tax incentive between 43.5% to 48.5% (depending upon the income tax rate) for qualified research and development activities. As of the three months ended March&#160;31, 2023, $1.0&#160;million was recorded as an income tax incentive receivable in the consolidated balance sheets, as the Company determined that the expenses met the eligibility criteria and the amounts claimed are expected to be received shortly after the related tax returns are filed.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Tax Incentive</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_ResearchAndDevelopmentTaxIncentiveTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713882613424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, Cend received a written threat of litigation on behalf of a Chinese entity called Lingmed Limited (&#8220;Lingmed&#8221;) claiming Lingmed was entitled to a success fee based on Cend&#8217;s Collaboration and License Agreement with Qilu Pharmaceuticals. Cend responded by denying that Lingmed is entitled to a success fee under the terms of their agreement. In May 2022, Cend was served with a complaint filed by Lingmed in the San Diego County Superior Court, alleging claims for breach of contract, fraud and declaratory relief. Cend&#8217;s response to the complaint was filed on June 6, 2022. Lingmed filed an answer to Cend&#8217;s response on July 11, 2022. The court held a case management conference on October 7, 2022, which resulted in a continuance until December 16, 2022. On December 16, 2022, the court continued the case management conference until April 7, 2023. At the April 7, 2023 case management conference, based on Lingmed reporting that it had not yet been able to effect service on an individually-named defendant through the Hague Convention, the court continued the conference until August 4, 2023. The Company denies these allegations and intends to vigorously defend against this claim.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713882623616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text">License Agreements<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanford Burnham Prebys</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (&#8220;SBP&#8221;) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of LSTA1. At the time the license agreement was entered into, Cend&#8217;s founding shareholder, now a Lisata board member, was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10,000 increasing to $20,000 on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6&#160;million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Cend entered into a license agreement with SBP under which Cend was granted an exclusive, royalty-bearing license to certain patent rights and know-how controlled by SBP. The agreement provides Cend with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $30,000 on year four of the agreement. Further, the Company could be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $23.2&#160;million. The Company is obligated to pay SBP royalties of 4% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP varying sublicense fees, ranging from 10% to 25%, dependent on when the related milestones are reached. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreements will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreements may be terminated in their entirety by the Company at any time by giving SBP sixty days&#8217; prior written notice. The agreements may be terminated in their entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreements may be terminated in their entirety by SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreements for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SBP owned 382,030 shares of the Company&#8217;s common stock as of March&#160;31, 2023 and is a related party. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">University of California at San Diego</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Cend entered into a license agreement with the University of California at San Diego (&#8220;UCSD&#8221;) under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of nano-particles to modulate immune response. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell and otherwise exploit the patent rights. The Company could be required to make milestone payments to UCSD upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $1.2&#160;million. The Company has also agreed to pay UCSD royalties of 1.5% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company agreed to pay UCSD varying sublicense fees, ranging from 10% to 20%, dependent on when the related milestones are reached. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the expiration of the longest-lived patent rights. The agreement may be terminated in its entirety by the Company at any time by giving UCSD ninety days&#8217; prior written notice. The agreement may be terminated in its entirety by UCSD if the Company, at any time, (i) fails to perform or violates any term of the agreement and fails to cure the default within sixty days. Upon termination of the agreement for any reason, UCSD may terminate a sublicensee but will allow the Company to assign any sublicenses to UCSD provided a) that the sublicensee is in good standing upon termination of the agreement with the Company; and b) the sublicensee is not currently involved in litigation as an adverse party to UCSD.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Massachusetts Institute of Technology</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Cend entered into a license agreement with the Massachusetts Institute of Technology ("MIT") under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of tissue specific delivery of interfering RNA. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 43,236 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $25,000 for year two and three of the agreement, increasing to $50,000 on year four of the agreement and thereafter until the first commercial sale, and increasing to $150,000 each year of the agreement after the first sale. Further, the Company could be required to make milestone payments to MIT upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $5.0&#160;million. The Company has also agreed to pay MIT royalties of 2% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay MIT varying sublicense fees, ranging from 3% to 20%, depending on when the related milestones are reached. In connection with the close of the Merger, the Company was required to pay MIT a change of control fee of $0.3&#160;million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the expiration or abandonment of all valid claims. The agreement may be terminated in its entirety by the Company at any time by giving MIT six months prior written notice. The agreement may be terminated in its entirety by MIT if the Company, at any time, (i) defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice, or (ii) commits a material breach of its obligations under the agreement (aside from item (i)) and fails to cure that breach within sixty days after receipt of written notice. Upon termination of the agreement for any reason, the rights and licenses granted to the Company shall terminate and revert to MIT. Upon termination of the agreement for any reason, MIT may terminate a sublicensee but will allow the Company to assign any sublicenses to MIT provided that the sublicensee is in good standing upon termination of the agreement with the Company.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIT owned 43,236 shares of the Company&#8217;s common stock as of March&#160;31, 2023</span></div>Research Collaboration and License Agreement<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the &#8220;Qilu Agreement&#8221;) in which Cend granted an exclusive license to Qilu for the development and commercialization of LSTA1 in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of LSTA1 in its Territory. In consideration for the license, Qilu made an upfront payment of $10&#160;million to Cend, which was recognized as revenue by Cend prior to the Merger. In addition, Cend received and recognized as revenue a $5&#160;million development milestone prior to the Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $95&#160;million and $125&#160;million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time </span></div>period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713882630976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Research Collaboration and License Agreement</a></td>
<td class="text">License Agreements<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanford Burnham Prebys</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (&#8220;SBP&#8221;) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of LSTA1. At the time the license agreement was entered into, Cend&#8217;s founding shareholder, now a Lisata board member, was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10,000 increasing to $20,000 on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6&#160;million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Cend entered into a license agreement with SBP under which Cend was granted an exclusive, royalty-bearing license to certain patent rights and know-how controlled by SBP. The agreement provides Cend with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $30,000 on year four of the agreement. Further, the Company could be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $23.2&#160;million. The Company is obligated to pay SBP royalties of 4% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP varying sublicense fees, ranging from 10% to 25%, dependent on when the related milestones are reached. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreements will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreements may be terminated in their entirety by the Company at any time by giving SBP sixty days&#8217; prior written notice. The agreements may be terminated in their entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreements may be terminated in their entirety by SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreements for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SBP owned 382,030 shares of the Company&#8217;s common stock as of March&#160;31, 2023 and is a related party. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">University of California at San Diego</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Cend entered into a license agreement with the University of California at San Diego (&#8220;UCSD&#8221;) under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of nano-particles to modulate immune response. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell and otherwise exploit the patent rights. The Company could be required to make milestone payments to UCSD upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $1.2&#160;million. The Company has also agreed to pay UCSD royalties of 1.5% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company agreed to pay UCSD varying sublicense fees, ranging from 10% to 20%, dependent on when the related milestones are reached. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the expiration of the longest-lived patent rights. The agreement may be terminated in its entirety by the Company at any time by giving UCSD ninety days&#8217; prior written notice. The agreement may be terminated in its entirety by UCSD if the Company, at any time, (i) fails to perform or violates any term of the agreement and fails to cure the default within sixty days. Upon termination of the agreement for any reason, UCSD may terminate a sublicensee but will allow the Company to assign any sublicenses to UCSD provided a) that the sublicensee is in good standing upon termination of the agreement with the Company; and b) the sublicensee is not currently involved in litigation as an adverse party to UCSD.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Massachusetts Institute of Technology</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Cend entered into a license agreement with the Massachusetts Institute of Technology ("MIT") under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of tissue specific delivery of interfering RNA. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 43,236 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $25,000 for year two and three of the agreement, increasing to $50,000 on year four of the agreement and thereafter until the first commercial sale, and increasing to $150,000 each year of the agreement after the first sale. Further, the Company could be required to make milestone payments to MIT upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $5.0&#160;million. The Company has also agreed to pay MIT royalties of 2% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay MIT varying sublicense fees, ranging from 3% to 20%, depending on when the related milestones are reached. In connection with the close of the Merger, the Company was required to pay MIT a change of control fee of $0.3&#160;million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the expiration or abandonment of all valid claims. The agreement may be terminated in its entirety by the Company at any time by giving MIT six months prior written notice. The agreement may be terminated in its entirety by MIT if the Company, at any time, (i) defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice, or (ii) commits a material breach of its obligations under the agreement (aside from item (i)) and fails to cure that breach within sixty days after receipt of written notice. Upon termination of the agreement for any reason, the rights and licenses granted to the Company shall terminate and revert to MIT. Upon termination of the agreement for any reason, MIT may terminate a sublicensee but will allow the Company to assign any sublicenses to MIT provided that the sublicensee is in good standing upon termination of the agreement with the Company.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIT owned 43,236 shares of the Company&#8217;s common stock as of March&#160;31, 2023</span></div>Research Collaboration and License Agreement<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the &#8220;Qilu Agreement&#8221;) in which Cend granted an exclusive license to Qilu for the development and commercialization of LSTA1 in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of LSTA1 in its Territory. In consideration for the license, Qilu made an upfront payment of $10&#160;million to Cend, which was recognized as revenue by Cend prior to the Merger. In addition, Cend received and recognized as revenue a $5&#160;million development milestone prior to the Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $95&#160;million and $125&#160;million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time </span></div>period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713882578384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Sale of New Jersey Net Operating Losses </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 19, 2022, the Company received preliminary approval from the New Jersey Economic Development Authority ("NJEDA") to participate in the Technology Business Tax Certificate Transfer Program (the "Program"). The Program permits qualified companies to sell a percentage of their New Jersey net operating losses ("NJ NOLs") to unrelated profitable corporations. On April 5, 2023, the Company received final approval from the NJEDA, and it subsequently sold a portion of its NJ NOLs to a qualifying and approved buyer pursuant to the Program for net proceeds of $2.2&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713879633008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2023, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2022 and 2021 included in our 2022 Form 10-K. Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the </span></div>circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and the valuation of the Merger which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;). Accordingly, actual results could differ from those estimates and assumptions.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">Principles of ConsolidationThe Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Remeasurement</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd. which is a foreign subsidiary of the Company is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risks</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#8220;business&#8221; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Asset</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible asset consists of a single asset, Cend&#8217;s license agreement with Qilu Pharmaceutical, Co., Ltd. (&#8220;Qilu&#8221;) acquired in the Merger, with a value of $0.4&#160;million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of 5 years. Amortization expense was $18 thousand for the three months ended March&#160;31, 2023. The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.  The projected amortization expense is $71&#160;thousand per year for the next five years. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestones</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#8217;s collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#8217;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three months ended March&#160;31, 2023 and March&#160;31, 2022, the Company has not recognized revenue related to milestones.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three months ended March&#160;31, 2023 and 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713879719568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAbstract', window );"><strong>Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Asset Acquisition</a></td>
<td class="text">The following table is a summary of the purchase price calculation (in thousands except per share data).<div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:448.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of common shares of the combined company owned by Cend stockholders</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,772,768&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multiplied by the fair value per share of Lisata common stock on September 15, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.25</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$23,580</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of Lisata's cost method investment in Cend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental fair value of Cend's fully vested stock options</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,136&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisata transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$36,098</span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The allocation of the purchase price was as follows (amounts in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:448.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7,062</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net working capital (excluding cash)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,690)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$36,098</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713881575904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale-Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-sale Securities Reconciliation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,581&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,758&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:360.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,641&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,581&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Investments Classified by Contractual Maturity Date</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:361.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,581&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713882536752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:505.50pt"><tr><td style="width:1.0pt"/><td style="width:363.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713882613424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">At March&#160;31, 2023 and 2022, the Company excluded the following potentially dilutive securities (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713882607248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text">as of March&#160;31, 2023 and December&#160;31, 2022 (in thousands):<div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:116.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:12.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,940&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,940&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,072&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,072&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash, cash equivalents, accounts payable and accrued expenses approximate fair value as of March&#160;31, 2023 and December&#160;31, 2022, due to the short maturity nature of these items.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713882578384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of March&#160;31, 2023 and December&#160;31, 2022 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"/><td style="width:313.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities &#8212; current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D&amp;O insurance liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and R&amp;D related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,728&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713882566320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock', window );">Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfMi0wLTEtMS0yOTgwMw_684390b7-3bb3-42c7-8a83-13f2f83e10e2"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfMi0wLTEtMS0yOTgwMw_7e944932-8384-4e08-8716-1c2ac79100ed">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNi0wLTEtMS0yOTgwMw_37de52d8-2557-479d-bbaf-f29481bcc474"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNi0wLTEtMS0yOTgwMw_69afedb4-8e13-45d2-80d7-456feaf20302">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNy0wLTEtMS0yOTgwMw_16c9c39d-ad71-40ba-bf95-bdb2e5413413"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNy0wLTEtMS0yOTgwMw_bcfccd01-1243-450c-981b-7940b87eb256">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments Under Lease Agreements</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under the lease agreement as of March&#160;31, 2023 were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:448.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713884630448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option and Warrants Activity</a></td>
<td class="text">The following table summarizes the activity for stock options and warrants for the three months ended March&#160;31, 2023:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,391,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.03</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,423,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.37</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">224.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,492,682&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.94&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">359.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,423,774&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.57&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2023<br/>or expected to vest in the future</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,486,393&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.96&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,423,774&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.57&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,207,228&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.90&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.64</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">344.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,423,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.57&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, the Company issued restricted stock for services as follows ($ in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"><tr><td style="width:1.0pt"/><td style="width:322.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:4.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, the Company issued restricted stock units for services as follows ($ in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"><tr><td style="width:1.0pt"/><td style="width:343.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713879790704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule Share-based Compensation Expense</a></td>
<td class="text">The following table summarizes the components of share-based compensation expense for the three months ended March&#160;31, 2023 and 2022 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:70.349%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:2.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.477%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Total Compensation Cost Related to Nonvested Awards</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March&#160;31, 2023 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.42</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Share-based Compensation Awards</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March&#160;31, 2023 and 2022 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:378.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713879908560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The Business (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 15, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</a></td>
<td class="nump">1,227,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Sale of Stock, Percentage of Ownership after Transaction</a></td>
<td class="nump">52.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=clbs_CENDMember', window );">CEND</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Conversion ratio</a></td>
<td class="nump">0.5338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, Issued</a></td>
<td class="nump">3,772,768<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=clbs_CENDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=clbs_CENDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713879563552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net (Excluding Goodwill)</a></td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Five</a></td>
<td class="nump">$ 71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer Software, Intangible Asset</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713876061568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Merger (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of common shares of the combined company owned by Cend stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,998,342<span></span>
</td>
<td class="nump">7,866,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=clbs_CENDMember', window );">CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of common shares of the combined company owned by Cend stockholders</a></td>
<td class="nump">3,772,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_AssetAcquisitionSharePrice', window );">Multiplied by the fair value per share of Lisata common stock on September 15, 2022</a></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_AssetAcquisitionConsiderationTransferredEquityValue', window );">Total</a></td>
<td class="nump">$ 23,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Carrying value of Lisata's cost method investment in Cend</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable', window );">Incremental fair value of Cend's fully vested stock options</a></td>
<td class="nump">2,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Lisata transaction costs</a></td>
<td class="nump">382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total purchase price</a></td>
<td class="nump">36,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_AssetAcquisitionCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">7,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_AssetAcquisitionNetWorkingCapital', window );">Net working capital (excluding cash)</a></td>
<td class="num">(1,690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_AssetAcquisitionOtherLiabilities', window );">Other liabilities</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_AssetAcquisitionAcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">30,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_AssetAcquisitionIntangibles', window );">License</a></td>
<td class="nump">$ 355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AssetAcquisitionAcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Acquired In-Process Research And Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AssetAcquisitionAcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AssetAcquisitionCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Cash and Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AssetAcquisitionCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AssetAcquisitionConsiderationTransferredEquityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Consideration Transferred, Equity Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AssetAcquisitionConsiderationTransferredEquityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AssetAcquisitionIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Intangibles</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AssetAcquisitionIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AssetAcquisitionNetWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Net Working Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AssetAcquisitionNetWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AssetAcquisitionOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Other Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AssetAcquisitionOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AssetAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Share Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AssetAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=clbs_CENDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=clbs_CENDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713880391312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 55,610<span></span>
</td>
<td class="nump">$ 64,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">55,581<span></span>
</td>
<td class="nump">64,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">37,267<span></span>
</td>
<td class="nump">44,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">37,238<span></span>
</td>
<td class="nump">44,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">5,328<span></span>
</td>
<td class="nump">7,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">5,328<span></span>
</td>
<td class="nump">7,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">12,666<span></span>
</td>
<td class="nump">4,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">12,666<span></span>
</td>
<td class="nump">4,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">349<span></span>
</td>
<td class="nump">7,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 349<span></span>
</td>
<td class="nump">$ 7,625<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713879560576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 22,641<span></span>
</td>
<td class="nump">$ 27,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">32,940<span></span>
</td>
<td class="nump">37,072<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total</a></td>
<td class="nump">$ 55,581<span></span>
</td>
<td class="nump">$ 64,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713879893344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis', window );">Less than one year</a></td>
<td class="nump">$ 55,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis', window );">Greater than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">55,610<span></span>
</td>
<td class="nump">$ 64,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue', window );">Less than one year</a></td>
<td class="nump">55,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Greater than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total estimated fair value</a></td>
<td class="nump">$ 55,581<span></span>
</td>
<td class="nump">$ 64,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713881626224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(399)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(417)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713880249936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">1,493<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">1,424<span></span>
</td>
<td class="nump">1,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713879845360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">$ 32,940<span></span>
</td>
<td class="nump">$ 37,072<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">32,940<span></span>
</td>
<td class="nump">37,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">32,940<span></span>
</td>
<td class="nump">37,072<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">32,940<span></span>
</td>
<td class="nump">37,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713880221248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Salaries, employee benefits and related taxes</a></td>
<td class="nump">$ 1,173<span></span>
</td>
<td class="nump">$ 2,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities &#8212; current</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_AccruedGrantFunding', window );">D&amp;O insurance liabilities</a></td>
<td class="nump">956<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_ClinicalAndRDRelatedLiabilities', window );">Clinical and R&amp;D related liabilities</a></td>
<td class="nump">1,334<span></span>
</td>
<td class="nump">785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 3,945<span></span>
</td>
<td class="nump">$ 3,728<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AccruedGrantFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Grant Funding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AccruedGrantFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_ClinicalAndRDRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical and R&amp;D Related Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_ClinicalAndRDRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713884630576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>office</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_NumberOfOfficesUnderOperatingLeases', window );">Number of offices under operating leases</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term for operating leases (in years)</a></td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate for operating leases (percent)</a></td>
<td class="nump">9.625%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_NumberOfOfficesUnderOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Offices Under Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_NumberOfOfficesUnderOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713879553264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Balance Sheet Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_OperatingLeaseRightOfUseAssetAbstract', window );"><strong>Right-of-Use Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 425<span></span>
</td>
<td class="nump">$ 487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Right-of-use assets, balance sheet line item</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">265<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 421<span></span>
</td>
<td class="nump">$ 485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease liabilities, current, balance sheet line item</a></td>
<td class="text">Accrued liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease liabilities, noncurrent, balance sheet line item</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_OperatingLeaseRightOfUseAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_OperatingLeaseRightOfUseAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713880162992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Minimum Lease Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amounts representing interest</a></td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 421<span></span>
</td>
<td class="nump">$ 485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713879833952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Equity Issuances (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of common shares of the combined company owned by Cend stockholders</a></td>
<td class="nump">7,998,342<span></span>
</td>
<td class="nump">7,866,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=clbs_CENDMember', window );">CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of common shares of the combined company owned by Cend stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,772,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_AtTheMarketOfferingAgreementMember', window );">ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement', window );">Aggregate offering amount authorized per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common Stock, Value, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_SaleOfStockAvailableForSale', window );">Sale of Stock Available for Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,698,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock Available for Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=clbs_CENDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=clbs_CENDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_AtTheMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=clbs_AtTheMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713880623824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Options and Warrants (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding, Beginning of Period (in shares)</a></td>
<td class="nump">1,391,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options, Granted (in shares)</a></td>
<td class="nump">103,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,227,776)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, Expired (in shares)</a></td>
<td class="num">(2,520)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding, End of Period (in shares)</a></td>
<td class="nump">1,492,682<span></span>
</td>
<td class="nump">1,391,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options, Vested and expected to vest (in shares)</a></td>
<td class="nump">1,486,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options, Vested (in shares)</a></td>
<td class="nump">1,207,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Stock Options, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options, Outstanding. Beginning of Period (in dollars per share)</a></td>
<td class="nump">$ 10.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options, Granted (in dollars per share)</a></td>
<td class="nump">3.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options, Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options, Forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options, Expired (in dollars per share)</a></td>
<td class="nump">224.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options, Outstanding, End of Period (in dollars per share)</a></td>
<td class="nump">9.94<span></span>
</td>
<td class="nump">$ 10.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options, Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">9.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options, Vested (in dollars per share)</a></td>
<td class="nump">$ 10.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Weighted Average Contractual Term and Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 3 days<span></span>
</td>
<td class="text">7 years 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options, Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_OptionsVestedweightedAverageRemainingContractualTerm', window );">Options, Vested, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 7 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options, Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 359,400<span></span>
</td>
<td class="nump">$ 187,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options, Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">358,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options, Vested, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 344,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Warrants, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CommonStockWarrantsShares', window );">Warrants, Outstanding, Beginning of Period (in shares)</a></td>
<td class="nump">1,423,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WarrantsGranted', window );">Warrants, Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WarrantsExercised', window );">Warrants, Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WarrantsCanceled', window );">Warrants, Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WarrantsExpired', window );">Warrants, Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CommonStockWarrantsShares', window );">Warrants, Outstanding, End of Period (in shares)</a></td>
<td class="nump">1,423,774<span></span>
</td>
<td class="nump">1,423,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_Sharesvestedandexpectedtovest', window );">Warrants, Vested and expected to vest (in shares)</a></td>
<td class="nump">1,423,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WarrantsVested', window );">Warrants, Vested (in shares)</a></td>
<td class="nump">1,423,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WarrantsWeightedAverageExercisePriceRollForward', window );"><strong>Warrants, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsOutstanding', window );">Warrants Outstanding, Beginning of Period (in dollars per share)</a></td>
<td class="nump">$ 42.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsGranted', window );">Warrants, Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsExercised', window );">Warrants, Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsCanceled', window );">Warrants, Forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsExpired', window );">Warrants, Expired (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsOutstanding', window );">Warrants Outstanding, End of Period (in dollars per share)</a></td>
<td class="nump">42.57<span></span>
</td>
<td class="nump">$ 42.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest', window );">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</a></td>
<td class="nump">42.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsExercisable', window );">Warrants, Vested, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 42.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WarrantsOtherDisclosuresAbstract', window );"><strong>Warrants, Weighted Average Contractual Term and Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding', window );">Warrants, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">3 years 1 month 17 days<span></span>
</td>
<td class="text">3 years 4 months 13 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest', window );">Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">3 years 1 month 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WeightedAverageRemainingContractualTermwarrantsvested', window );">Warrants, Vested, Weighted Average Remaining Contractual Term</a></td>
<td class="text">3 years 1 month 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_AggregateIntrinsicValueWarrantsOutstanding', window );">Warrants Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest', window );">Warrants, Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_AggregateIntrinsicValueWarrantsvested', window );">Warrants, Vested, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AggregateIntrinsicValueWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AggregateIntrinsicValueWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AggregateIntrinsicValueWarrantsvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants vested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AggregateIntrinsicValueWarrantsvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants vested and expected to vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CommonStockWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Warrants, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CommonStockWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_OptionsVestedweightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options, Vested, weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_OptionsVestedweightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_Sharesvestedandexpectedtovest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>shares, vested and expected to vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_Sharesvestedandexpectedtovest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Canceled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Other Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, Vested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Weighted Average Exercise Price [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Canceled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Exercisable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Vested And Expected To Vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term warrant outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageRemainingContractualTermwarrantoutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageRemainingContractualTermwarrantsvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>weighted Average Remaining Contractual Term, warrants vested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageRemainingContractualTermwarrantsvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713876343856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of shares issued</a></td>
<td class="nump">159,950<span></span>
</td>
<td class="nump">70,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Value of shares issued</a></td>
<td class="nump">$ 480<span></span>
</td>
<td class="nump">$ 973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 13.76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms (years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms (years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of shares issued</a></td>
<td class="nump">188,850<span></span>
</td>
<td class="nump">91,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Value of shares issued</a></td>
<td class="nump">$ 567<span></span>
</td>
<td class="nump">$ 1,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms (years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713880184304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 675<span></span>
</td>
<td class="nump">$ 760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 488<span></span>
</td>
<td class="nump">$ 542<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713877090928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 1,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">1 year 5 months 1 day<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">1 year 2 months 19 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">1 year 5 months 19 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713881751088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details) - Stock Options - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of shares vested</a></td>
<td class="nump">$ 324<span></span>
</td>
<td class="nump">$ 377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value of shares granted</a></td>
<td class="nump">$ 0.78<span></span>
</td>
<td class="nump">$ 0.62<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713875754896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="nump">$ 344,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition', window );">Unrecognized Tax Benefits, Increase Resulting from Acquisition</a></td>
<td class="nump">344,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</a></td>
<td class="nump">88,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=clbs_CENDMember', window );">CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_FairValueMarketOfTaxNOLs', window );">Fair Value Market of Tax NOLs</a></td>
<td class="nump">$ 36,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent</a></td>
<td class="nump">2.54%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_OperatingLossCarryforwardsBeforeWriteDown', window );">Net operating loss carryforwards, prior to write down</a></td>
<td class="nump">$ 34,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">10,900,000<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_OperatingLossCarryforwardsPostAcquisition', window );">Operating Loss Carryforwards, Post Acquisition</a></td>
<td class="nump">106,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority | CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">35,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_FairValueMarketOfTaxNOLs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Market of Tax NOLs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_FairValueMarketOfTaxNOLs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_OperatingLossCarryforwardsBeforeWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Before Write Down</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_OperatingLossCarryforwardsBeforeWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_OperatingLossCarryforwardsPostAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Post Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_OperatingLossCarryforwardsPostAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=clbs_CENDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=clbs_CENDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713876184496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research tax credit rate</a></td>
<td class="nump">48.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Research tax credit</a></td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713875899760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale', window );">Annual license maintenance fee, after first sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=clbs_SanfordBurnhamPrebysMember', window );">Sanford Burnham Prebys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_SharesIssuedUnderLicenseAgreement', window );">Shares issued under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee', window );">Annual license maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven', window );">Annual license maintenance fee, year seven</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales', window );">Royalties, net of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour', window );">Annual license maintenance fee, year four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_SharesHeldByThirdParty', window );">Shares held by third party</a></td>
<td class="nump">382,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=clbs_SanfordBurnhamPrebysMember', window );">Sanford Burnham Prebys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=clbs_SanfordBurnhamPrebysMember', window );">Sanford Burnham Prebys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=clbs_UniversityOfCaliforniaAtSanDiegoMember', window );">University of California at San Diego | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales', window );">Royalties, net of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=clbs_UniversityOfCaliforniaAtSanDiegoMember', window );">University of California at San Diego | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=clbs_UniversityOfCaliforniaAtSanDiegoMember', window );">University of California at San Diego | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=clbs_MassachusettsInstituteOfTechnologyMember', window );">Massachusetts Institute of Technology | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee', window );">Annual license maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales', window );">Royalties, net of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour', window );">Annual license maintenance fee, year four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_SharesHeldByThirdParty', window );">Shares held by third party</a></td>
<td class="nump">43,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree', window );">Annual license maintenance fee, years two and three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee', window );">Change of control fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=clbs_MassachusettsInstituteOfTechnologyMember', window );">Massachusetts Institute of Technology | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=clbs_MassachusettsInstituteOfTechnologyMember', window );">Massachusetts Institute of Technology | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee After First Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Two and Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Change of Control Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Sublicensing Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SharesHeldByThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Held by Third Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SharesHeldByThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SharesIssuedUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued Under License Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SharesIssuedUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=clbs_SanfordBurnhamPrebysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=clbs_SanfordBurnhamPrebysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=clbs_UniversityOfCaliforniaAtSanDiegoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=clbs_UniversityOfCaliforniaAtSanDiegoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=clbs_MassachusettsInstituteOfTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=clbs_MassachusettsInstituteOfTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713876345104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Research Collaboration and License Agreement (Details) - Qilu - License - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 14, 2022</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from contract</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=clbs_QiluMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Variable consideration amounts, milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_RevenuePerformanceObligationPercentageOfNetSale', window );">Percentage of net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues', window );">Percentage of sublicensing revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=clbs_QiluMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Variable consideration amounts, milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_RevenuePerformanceObligationPercentageOfNetSale', window );">Percentage of net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues', window );">Percentage of sublicensing revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_RevenuePerformanceObligationPercentageOfNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Percentage of Net Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_RevenuePerformanceObligationPercentageOfNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Percentage of Sublicensing Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123385629&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=clbs_QiluMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=clbs_QiluMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140713880444640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram', window );">Net proceeds from sale of NOLs</a></td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Net Operating Losses, NJEDA Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>clbs-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:clbs="http://www.caladrius.com/20230331"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="clbs-20230331.xsd" xlink:type="simple"/>
    <context id="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i81865228b8a54f5ea02f2339cdf0bacf_I20230509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2023-05-09</instant>
        </period>
    </context>
    <context id="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i724c150ab27c43fb92268e63a43d2567_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idccd6d8b24e84252b1bfbf4c82909880_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i83c32766e7f045148be714d2464b2a0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i172b6566e2954903a795810c0f7faea8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i659cc88ca4174728b2be88034cec77d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i167ad6f9efc349e8aeb1f3afc4eb06f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3016a907934548cf89814e3cc5065bb5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61be37acd3b24fdd8277d7ebcc1a2524_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id4046547dd294ad49c799697f6ddb110_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c1e7ed7cdb0485db6a09b8f120ae70a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i30dbc205504449d38986e42bcedd9a11_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia5530dc46c414ce092189cff88a3f7dd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7e1630a3383b43cb9dd10a9949f9a4e4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic5e281aca39d4be8a4acaf10e78a17c4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i57742d73f1a641e6869962f1ae17f160_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i38bd3b8625604395bc59611e78cb1d4c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9b6d5d55db744ce2adef5755fc8dcf38_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia56329ac6bf74270be8df5d045aa6494_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i12937a3ada6d4dd2b874669455d35962_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1bb37f6848ed455f8b7792e91866123b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9619f9b64ebe471ca599503ec1560977_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5ce139ad8e764eb2804ef24019b88cdc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3fd2bb5d543d427ca3beb6d8dae402ca_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8d1ce795a4ca4649ac9b72bf8edca70d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i800befd23f3841569b227ba2e2d706d1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3d5c507b54c44f3382ccc7e3b5440bb2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i79e1062c1f414381a135b2e72a0a68df_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iac1d983470804b2cac2936f1132412ae_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic0482b3971ec42ce8127564740a1f058_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id7ee28bcb50447fd965f5db978a79599_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i13d0c68aceb945648fc95a868eb9e3ef_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic9347bcc62e74b129f2045c4859eb549_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if20c8a9a03b14863bb4789b2d34ee496_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic8cc3ac77efa48088686b917cb62e54f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1083fcdc93504069ab0c6b8124da6c36_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7bf4f3fb7021489abb1e920d657cfc55_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iffe6cb540c934ae58b0986186454ad7d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6da0050ca7b24feeba54e912cec8a0d6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1306a47c84604f74bccf2442a61ec582_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i50382c5190684ed1bbbe023c4f418b3e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iee22d1576f8f42cfbcb560d4e1373257_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iac5cf83f8935401bb2f5aca604012ece_D20220915-20220915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">clbs:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="icbaa2961421947beb045865325d7915f_I20220915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">clbs:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="ic072dd5659984964b08dc7870ffd5237_I20220915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="ie18f40d4e2884dbfaf339b40535a723f_D20220915-20220915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="i9fba73856db44b87a21cac709470eda2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5ee0cb91c75d458c950b56f03890e10c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ied9953ef26fe438b9a0b57d97f79bdea_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib7bcd8f5631a452dbabbd9fc97bbc4d8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ied1922d4661541beb53e95573627a550_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iab073f0d92e84ba6a575d902b1c5e90b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib5bdf116a27d45e4852970a908a1c9d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4fe5dff51cd045c6a67c3d6af3c855d4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i66c395e4236040e08deda6719527e329_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3379968f199147d999b83005f594ec07_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib8ffd44b3aa94c9a96419561b18f7289_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idb513457df6349bbb925697c05f89164_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if531ec7b0d1a4289a1d93db89b2325ff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if3aa127bddd44877959f1946f1b707a1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iea3f0934334b47bfbb1b2334acb69624_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i19bc8aae9d6b47a3a7633a871fba31ca_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iae124bfea4fe4e4d85a6e62fb5a67fa4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic3f5e8fd57334737879297c5b890af27_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i94a5f2f4d8634a6482193404d866f108_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1aa2ff8c93a14a628ddf610567129143_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3f52a94bfea84193af9a8db010f1aa88_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if3d4362e69d54f54aaad194fd8645f31_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i239efe19fad74784b328fdf62d219847_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5c17a022357047ff92faad6cb21667dd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i504afb254cc84fff8865bdb6c94dc145_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i014d15d0d777404b8e448a8905b727ad_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i039c3f49b8da4f2d9b6cefb4c7bdaac6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if6f24ed5b4964736968a44cdbb684fbc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic3c9472dfe66456db347e101f7b9c855_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i71685748225c4034a7cebd3a48175ca9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i51755cafee74432a96fde0a4fb4c5bfb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2d6b8752305947b19367c1e2776a4b9b_I20210604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-04</instant>
        </period>
    </context>
    <context id="i8175b9d271b74085bb0ba378fb359200_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i35acb9e033324b219fe3495ddd939d9c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6e7ec6bf429543dd8edca7c206e09fd8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i997e64fe38cd4696b408c8f14ff89821_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifcccbb1ec967438ca65784bea06bd71c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if9391ecdb3584403a88b94bdd91f8a15_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie5c1886b35e84c7695a04666f5e1137b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0bf2527917654f82a4c8b3249bbddab5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i123fae5df7b2491e87422b22888cdec1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6cd4f16a626841558cb57f42b71c9c60_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i787b9e2301e54c9785a066d7cd81323f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id03152d7237c4f9b90a0fc7dd766e90b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2c93ce6862cc404f9f8ce8668c15838a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i83f0c391f25941a899f1eb4e31178bdd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6d650d9bcb5a4a57b8d4315548c62afd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8c3f59edeb884c01895f1ea44c1ef3d9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i93afe9d3f6ed4cb09390722746228408_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1f68282f0c334dd5b5c7b36cb0d6ba8e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id704a5defa6d483f841dd1efcd484f49_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9a48869ba93a417bb2d014c285a349c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2dc12ffc2bcf4c17a7efd9e7f1736478_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1ba87c90863144d990c890ebce4a437a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clbs:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3a535f623a624914a6711e4e82eebafc_I20220915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clbs:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="ice2ae4d365344c85a05b88a31a78ac50_I20220915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clbs:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="i3afe3e21f9e14d83ac8486daad4e1b82_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clbs:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia25852cf0b524a4a811255369807adc6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clbs:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i35714006bb8c4a12bfdea57e263522a5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4403bf2ab03749ec86046716a8f3d4ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iafb81e753f5344fd8594c25ddabaf02c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia9ffa93082d045a0bbf2f1f37390955e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i128ebe4deb504c3994e29fd10cb3bd21_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i28c8467f29d64fef93f97e7c8af17104_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idcc2b98561db4f2c9078a1c50bd84b01_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:SanfordBurnhamPrebysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i55d91e2a703a41a4b67672acbce81809_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:SanfordBurnhamPrebysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i9b47136928e3471f891783820d0f46a1_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:SanfordBurnhamPrebysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="if5743124ce7d40908442e8bd62e47009_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:SanfordBurnhamPrebysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i1ac540323fe04816bb43b23a4a4cd560_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:SanfordBurnhamPrebysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i402d926e5cb44e54a8d375857d19b288_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:UniversityOfCaliforniaAtSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i73ca6b3e79144046b283ad153b819bb1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:UniversityOfCaliforniaAtSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if616b4f4bf5141008e520b036ed05453_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:UniversityOfCaliforniaAtSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie64acccae8a54473b4916dda6d9766df_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i3e38bf3272614bd784e0e3713d21241f_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="ibbe067b5df1b486281624627370f5bc7_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i628328038b2b4904ac047c8f5980356a_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i9a3db4b42dc146229cb4171314c0ce3d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8788a48508344937b3068aa082fec1c3_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="ic152646f8baa44789d4da65765ea5a4b_D20220914-20220914">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-14</startDate>
            <endDate>2022-09-14</endDate>
        </period>
    </context>
    <context id="ie65ed995e0f7462e8f1737be572b0839_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i0b06f28b1d2f42819f88a1b59197ea04_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i9c7a64d6081c499fbfec9b5f2a137f04_D20230401-20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="office">
        <measure>clbs:office</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80L2ZyYWc6ZmRjMWY3YTk2OWIyNDk1ZjlhZDMxOTdlMmUyZjdiYWEvdGFibGU6NWY5ZTNkNTQ2MDEzNDViNzk0MmY0N2EzYzMwMWRkM2YvdGFibGVyYW5nZTo1ZjllM2Q1NDYwMTM0NWI3OTQyZjQ3YTNjMzAxZGQzZl8zLTEtMS0xLTI5ODAz_036ae607-7bd7-4e8d-8019-0932d2d567b6">0000320017</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80L2ZyYWc6ZmRjMWY3YTk2OWIyNDk1ZjlhZDMxOTdlMmUyZjdiYWEvdGFibGU6NWY5ZTNkNTQ2MDEzNDViNzk0MmY0N2EzYzMwMWRkM2YvdGFibGVyYW5nZTo1ZjllM2Q1NDYwMTM0NWI3OTQyZjQ3YTNjMzAxZGQzZl80LTEtMS0xLTI5ODAz_18bf34f5-7e2f-46d1-9b67-ea7b218f677b">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80L2ZyYWc6ZmRjMWY3YTk2OWIyNDk1ZjlhZDMxOTdlMmUyZjdiYWEvdGFibGU6NWY5ZTNkNTQ2MDEzNDViNzk0MmY0N2EzYzMwMWRkM2YvdGFibGVyYW5nZTo1ZjllM2Q1NDYwMTM0NWI3OTQyZjQ3YTNjMzAxZGQzZl81LTEtMS0xLTI5ODAz_0810a67a-36f8-4790-ac7b-6f7df54aab79">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80L2ZyYWc6ZmRjMWY3YTk2OWIyNDk1ZjlhZDMxOTdlMmUyZjdiYWEvdGFibGU6NWY5ZTNkNTQ2MDEzNDViNzk0MmY0N2EzYzMwMWRkM2YvdGFibGVyYW5nZTo1ZjllM2Q1NDYwMTM0NWI3OTQyZjQ3YTNjMzAxZGQzZl82LTEtMS0xLTI5ODAz_35ea7e08-0d04-4630-9bb4-58752f916127">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80L2ZyYWc6ZmRjMWY3YTk2OWIyNDk1ZjlhZDMxOTdlMmUyZjdiYWEvdGFibGU6NWY5ZTNkNTQ2MDEzNDViNzk0MmY0N2EzYzMwMWRkM2YvdGFibGVyYW5nZTo1ZjllM2Q1NDYwMTM0NWI3OTQyZjQ3YTNjMzAxZGQzZl83LTEtMS0xLTI5ODAz_04bb1053-b145-4153-b607-dedc460a0195">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfMi0wLTEtMS0yOTgwMw_684390b7-3bb3-42c7-8a83-13f2f83e10e2">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfMi0wLTEtMS0yOTgwMw_7e944932-8384-4e08-8716-1c2ac79100ed">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNi0wLTEtMS0yOTgwMw_37de52d8-2557-479d-bbaf-f29481bcc474">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNi0wLTEtMS0yOTgwMw_69afedb4-8e13-45d2-80d7-456feaf20302">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNy0wLTEtMS0yOTgwMw_16c9c39d-ad71-40ba-bf95-bdb2e5413413">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNy0wLTEtMS0yOTgwMw_bcfccd01-1243-450c-981b-7940b87eb256">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie5c1886b35e84c7695a04666f5e1137b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNTcyMQ_03645692-ddcc-455a-9649-721f44f866fe">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGV4dHJlZ2lvbjo4N2I2ZGU1MWM2NGU0MmM4OTA1NmJjYzZmODQxYWNlMV8yMDYx_98ce9706-e546-40f0-8502-9b242444c05d">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6YTBhM2MyM2RjYjg3NDBiMjlkN2QzZmI4YTUxNGIyODEvdGFibGVyYW5nZTphMGEzYzIzZGNiODc0MGIyOWQ3ZDNmYjhhNTE0YjI4MV8wLTAtMS0xLTI5ODAz_f175b077-6fad-4407-9301-c3b7e6bf3528">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGV4dHJlZ2lvbjo4N2I2ZGU1MWM2NGU0MmM4OTA1NmJjYzZmODQxYWNlMV80Mzk4MDQ2NTEzMzMy_7f4c5602-60a4-4224-bab4-42be3bebb027">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6Mzk4OGZlZDUxNDI5NDcyYWFkMTQ2ZTBkMDgyMzU2YWIvdGFibGVyYW5nZTozOTg4ZmVkNTE0Mjk0NzJhYWQxNDZlMGQwODIzNTZhYl8wLTAtMS0xLTI5ODAz_dfc0531e-98dd-4df2-b094-a9a30e99ea9f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGV4dHJlZ2lvbjo4N2I2ZGU1MWM2NGU0MmM4OTA1NmJjYzZmODQxYWNlMV8yMDUz_3a4932e9-576c-4128-9bce-9fe1c3e24d2a">001-33650</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGV4dHJlZ2lvbjo4N2I2ZGU1MWM2NGU0MmM4OTA1NmJjYzZmODQxYWNlMV8yMDU3_1bba046f-5340-4916-9181-127575b93486">LISATA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6NzgzYmFiMzIxOWExNDVmZThhZmQ4ZjEwNDE0ZGM0NWYvdGFibGVyYW5nZTo3ODNiYWIzMjE5YTE0NWZlOGFmZDhmMTA0MTRkYzQ1Zl8wLTAtMS0xLTI5ODAz_3344ba09-b0cf-42ee-b86e-b02f264ff74b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6NzgzYmFiMzIxOWExNDVmZThhZmQ4ZjEwNDE0ZGM0NWYvdGFibGVyYW5nZTo3ODNiYWIzMjE5YTE0NWZlOGFmZDhmMTA0MTRkYzQ1Zl8wLTEtMS0xLTI5ODAz_b6c0cb41-857f-4fc9-ad8b-e172558dca02">22-2343568</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6NzgzYmFiMzIxOWExNDVmZThhZmQ4ZjEwNDE0ZGM0NWYvdGFibGVyYW5nZTo3ODNiYWIzMjE5YTE0NWZlOGFmZDhmMTA0MTRkYzQ1Zl8zLTAtMS0xLTI5ODAzL3RleHRyZWdpb246NDIwZDhlNzVjNTQ3NGU4MWFlZmUzMGNlOTk3YjdlZWFfNA_30128fe0-dcca-435a-9e61-f693b8169a5c">110 Allen Road, 2nd Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6NzgzYmFiMzIxOWExNDVmZThhZmQ4ZjEwNDE0ZGM0NWYvdGFibGVyYW5nZTo3ODNiYWIzMjE5YTE0NWZlOGFmZDhmMTA0MTRkYzQ1Zl8zLTAtMS0xLTI5ODAzL3RleHRyZWdpb246NDIwZDhlNzVjNTQ3NGU4MWFlZmUzMGNlOTk3YjdlZWFfOA_642db119-96a5-4bf2-b849-fa9be90c9a45">Basking Ridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6NzgzYmFiMzIxOWExNDVmZThhZmQ4ZjEwNDE0ZGM0NWYvdGFibGVyYW5nZTo3ODNiYWIzMjE5YTE0NWZlOGFmZDhmMTA0MTRkYzQ1Zl8zLTAtMS0xLTI5ODAzL3RleHRyZWdpb246NDIwZDhlNzVjNTQ3NGU4MWFlZmUzMGNlOTk3YjdlZWFfMTI_23308f61-e1f1-4117-ad13-9476aeb72096">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6NzgzYmFiMzIxOWExNDVmZThhZmQ4ZjEwNDE0ZGM0NWYvdGFibGVyYW5nZTo3ODNiYWIzMjE5YTE0NWZlOGFmZDhmMTA0MTRkYzQ1Zl8zLTEtMS0xLTI5ODAz_c5087235-9dd3-4aa3-8813-113a25f924b1">07920</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGV4dHJlZ2lvbjo4N2I2ZGU1MWM2NGU0MmM4OTA1NmJjYzZmODQxYWNlMV8yMDU4_4c89f554-9c98-4428-a166-4fe3a38669c2">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGV4dHJlZ2lvbjo4N2I2ZGU1MWM2NGU0MmM4OTA1NmJjYzZmODQxYWNlMV8yMDU0_a79f5668-5cb5-4b3a-ab2d-8b9d4250bdc7">842-0100</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6MjAwMTNkYTJhN2FlNGZmOTk3ZGYzZGRjN2U3MTA3M2MvdGFibGVyYW5nZToyMDAxM2RhMmE3YWU0ZmY5OTdkZjNkZGM3ZTcxMDczY18yLTAtMS0xLTI5ODAz_89430b85-3ea4-421b-88fb-47cca76971c9">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6MjAwMTNkYTJhN2FlNGZmOTk3ZGYzZGRjN2U3MTA3M2MvdGFibGVyYW5nZToyMDAxM2RhMmE3YWU0ZmY5OTdkZjNkZGM3ZTcxMDczY18yLTEtMS0xLTI5ODAz_3a0e8105-ff18-4815-8210-138ae41cab95">LSTA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6MjAwMTNkYTJhN2FlNGZmOTk3ZGYzZGRjN2U3MTA3M2MvdGFibGVyYW5nZToyMDAxM2RhMmE3YWU0ZmY5OTdkZjNkZGM3ZTcxMDczY18yLTItMS0xLTI5ODAzL3RleHRyZWdpb246YTYyNTQwODBjNjY1NDkxMGIyOWFlNDBlZDY0NjFhZTFfOA_de42c332-f079-40eb-bc39-5b1b10cc860f">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGV4dHJlZ2lvbjo4N2I2ZGU1MWM2NGU0MmM4OTA1NmJjYzZmODQxYWNlMV8yMDUy_244acbd3-9138-4eba-8609-4fe6f5b22007">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGV4dHJlZ2lvbjo4N2I2ZGU1MWM2NGU0MmM4OTA1NmJjYzZmODQxYWNlMV8yMDU5_b0adb9c8-66ef-4f00-9986-7259afda1f92">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6YTA0OWUwZWJhYTc1NGE0ODkxMzNmOTVlODYzYjc0YTMvdGFibGVyYW5nZTphMDQ5ZTBlYmFhNzU0YTQ4OTEzM2Y5NWU4NjNiNzRhM18xLTAtMS0xLTI5ODAz_f7cebbce-a6e4-464d-837e-8249b1f5f75f">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6YTA0OWUwZWJhYTc1NGE0ODkxMzNmOTVlODYzYjc0YTMvdGFibGVyYW5nZTphMDQ5ZTBlYmFhNzU0YTQ4OTEzM2Y5NWU4NjNiNzRhM18xLTQtMS0xLTI5ODAz_c82a404b-9922-4034-8b23-8f3365334e61">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6YTA0OWUwZWJhYTc1NGE0ODkxMzNmOTVlODYzYjc0YTMvdGFibGVyYW5nZTphMDQ5ZTBlYmFhNzU0YTQ4OTEzM2Y5NWU4NjNiNzRhM18yLTQtMS0xLTI5ODAz_d6ae17a9-db25-462f-af86-7f20043eb94e">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGV4dHJlZ2lvbjo4N2I2ZGU1MWM2NGU0MmM4OTA1NmJjYzZmODQxYWNlMV8yMDYw_80326170-8eb5-4b99-9afe-c53f6dc573d1">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i81865228b8a54f5ea02f2339cdf0bacf_I20230509"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xL2ZyYWc6ODdiNmRlNTFjNjRlNDJjODkwNTZiY2M2Zjg0MWFjZTEvdGFibGU6NTk5Y2M4NjhlM2NkNGY2MmIzNWQxYTNjNjY1ZDQ1NzUvdGFibGVyYW5nZTo1OTljYzg2OGUzY2Q0ZjYyYjM1ZDFhM2M2NjVkNDU3NV8xLTEtMS0xLTI5ODAz_5aef65cc-b9b1-455e-9128-81af4f7d9286"
      unitRef="shares">7974464</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMi0xLTEtMS0yOTgwMw_7db614e5-e345-4fa2-9086-180d7446db68"
      unitRef="usd">28155000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMi0zLTEtMS0yOTgwMw_bf11aa2f-8cdc-45d5-95a0-a42fae646952"
      unitRef="usd">32154000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMy0xLTEtMS0yOTgwMw_3f1257bb-744b-4299-b69c-7fa41c18383c"
      unitRef="usd">32940000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMy0zLTEtMS0yOTgwMw_cafb9e0b-1502-44db-abb6-ebd90dd2711d"
      unitRef="usd">37072000</us-gaap:MarketableSecurities>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfNC0xLTEtMS0yOTgwMw_764ac289-efa7-44f0-b9b0-7c985b54acba"
      unitRef="usd">4203000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfNC0zLTEtMS0yOTgwMw_9a62a0c2-b7b1-4f83-ae75-f787ec686a69"
      unitRef="usd">2650000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfNS0xLTEtMS0yOTgwMw_8f7109b5-afae-4d7f-9f7f-fc8c839f5e8a"
      unitRef="usd">65298000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfNS0zLTEtMS0yOTgwMw_c8cd0b51-7407-4cf8-9f2f-f1c68fce112a"
      unitRef="usd">71876000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfNi0xLTEtMS0yOTgwMw_3470e8c7-2283-4444-8f1a-2d372829ba7e"
      unitRef="usd">262000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfNi0zLTEtMS0yOTgwMw_567c4e11-4418-4055-943c-4e2416606fa1"
      unitRef="usd">296000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfNy0xLTEtMS0yOTgwMw_a18c3884-10af-4601-8f5b-9aaac877f4b1"
      unitRef="usd">317000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfNy0zLTEtMS0yOTgwMw_183862b6-fdcb-4b7c-8925-08a38d56dfc4"
      unitRef="usd">334000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfOC0xLTEtMS0yOTgwMw_cf2acf4f-5cb5-4ba4-bf68-edf898627072"
      unitRef="usd">449000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfOC0zLTEtMS0yOTgwMw_c77b7bc2-e866-44d9-a554-32f63ba7e2ad"
      unitRef="usd">528000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfOS0xLTEtMS0yOTgwMw_5621b9fc-7084-472a-b5d5-2aea550ea918"
      unitRef="usd">66326000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfOS0zLTEtMS0yOTgwMw_2987fe9b-bef7-46d1-92f3-dc1d1d38064f"
      unitRef="usd">73034000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTMtMS0xLTEtMjk4MDM_e0b3446c-eb6a-4223-9209-7d243c2bfce8"
      unitRef="usd">1341000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTMtMy0xLTEtMjk4MDM_36a52505-a95b-4f62-87a0-38f56d4540e2"
      unitRef="usd">2655000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTQtMS0xLTEtMjk4MDM_1e219fc3-ca4a-4e9f-b1a7-d67587d6f165"
      unitRef="usd">3945000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTQtMy0xLTEtMjk4MDM_d6095233-375c-4091-a86d-29fbffd62634"
      unitRef="usd">3728000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTUtMS0xLTEtMjk4MDM_bfbe367e-576a-44fa-a53c-e026819a6a1c"
      unitRef="usd">5286000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTUtMy0xLTEtMjk4MDM_7e910ac3-9a48-4949-86f0-2961ad08765e"
      unitRef="usd">6383000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTYtMS0xLTEtMjk4MDM_cc2cd460-43b4-43d6-9822-724e3c319145"
      unitRef="usd">337000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTYtMy0xLTEtMjk4MDM_6716a7eb-9467-41a9-bcf1-9e9d8e12bef4"
      unitRef="usd">327000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTctMS0xLTEtMjk4MDM_7dd7a968-8cab-4cb7-9b4d-ae61ce59e499"
      unitRef="usd">5623000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTctMy0xLTEtMjk4MDM_10318444-e07f-4dd4-80ff-4105a2317c6f"
      unitRef="usd">6710000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTgtMS0xLTEtMjk4MDM_dcb3b903-7b8a-4b0f-a0a6-02479080e7d9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMTgtMy0xLTEtMjk4MDM_d8e4cedb-8dd0-4851-9b1e-1dacf33c54f4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjItMC0xLTEtMjk4MDMvdGV4dHJlZ2lvbjpiZWVkNTJhM2M5ZTE0MWY2YjAyN2Y5Yzg4NDcxZDMzOV8xOA_0c2376ac-224e-4e4e-a334-e404335045cb"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjItMC0xLTEtMjk4MDMvdGV4dHJlZ2lvbjpiZWVkNTJhM2M5ZTE0MWY2YjAyN2Y5Yzg4NDcxZDMzOV8xOA_5ade6d5a-fb4a-4d68-9cea-faaba2ebb9cc"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjItMC0xLTEtMjk4MDMvdGV4dHJlZ2lvbjpiZWVkNTJhM2M5ZTE0MWY2YjAyN2Y5Yzg4NDcxZDMzOV80Mw_59572931-458a-436d-b30a-a4dda3f9919b"
      unitRef="shares">33333333</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjItMC0xLTEtMjk4MDMvdGV4dHJlZ2lvbjpiZWVkNTJhM2M5ZTE0MWY2YjAyN2Y5Yzg4NDcxZDMzOV80Mw_852bbd37-01fd-48be-a8fb-f49178f4334b"
      unitRef="shares">33333333</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjItMC0xLTEtMjk4MDMvdGV4dHJlZ2lvbjpiZWVkNTJhM2M5ZTE0MWY2YjAyN2Y5Yzg4NDcxZDMzOV82MQ_9b71aab0-d304-4110-961c-7337294c8181"
      unitRef="shares">7999080</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjItMC0xLTEtMjk4MDMvdGV4dHJlZ2lvbjpiZWVkNTJhM2M5ZTE0MWY2YjAyN2Y5Yzg4NDcxZDMzOV82OA_81607cee-25c6-4272-a231-7310b1bd365c"
      unitRef="shares">7866799</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjItMC0xLTEtMjk4MDMvdGV4dHJlZ2lvbjpiZWVkNTJhM2M5ZTE0MWY2YjAyN2Y5Yzg4NDcxZDMzOV8xNTU_2a8d912a-89ec-4702-b2f3-ade8db99320e"
      unitRef="shares">7998342</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjItMC0xLTEtMjk4MDMvdGV4dHJlZ2lvbjpiZWVkNTJhM2M5ZTE0MWY2YjAyN2Y5Yzg4NDcxZDMzOV8xNjI_01649941-73fa-4caa-a462-843fc229d0c5"
      unitRef="shares">7866061</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjItMS0xLTEtMjk4MDM_d923915c-4c30-4b6b-9890-8077bfb8bf44"
      unitRef="usd">8000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjItMy0xLTEtMjk4MDM_8930496f-69a4-4a51-99b5-3ad8c3d923d0"
      unitRef="usd">8000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjMtMS0xLTEtMjk4MDM_27be3862-633a-4a1d-89bb-c989f1747c2c"
      unitRef="usd">575137000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjMtMy0xLTEtMjk4MDM_d98f222e-d6a8-4e95-a61a-6b580c9dccad"
      unitRef="usd">574548000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjQtMC0xLTEtMjk4MDMvdGV4dHJlZ2lvbjozMmE0ODEzZTM0MDE0YzVlOWU3Njc3NGZmZjczODgwY18yOQ_6502dc8b-1ffe-4ea7-bab5-62489344ffde"
      unitRef="shares">738</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjQtMC0xLTEtMjk4MDMvdGV4dHJlZ2lvbjozMmE0ODEzZTM0MDE0YzVlOWU3Njc3NGZmZjczODgwY18yOQ_7852bb53-3a93-4956-85a2-7ade82e5d79d"
      unitRef="shares">738</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjQtMS0xLTEtMjk4MDM_bcee2ad6-d391-43ea-96a8-c28d8f31d598"
      unitRef="usd">708000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjQtMy0xLTEtMjk4MDM_a50375e7-7152-4afc-8993-e8676f4ba7fb"
      unitRef="usd">708000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjUtMS0xLTEtMjk4MDM_0ac481e3-a56f-4c51-9b95-82377a916fed"
      unitRef="usd">-513428000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjUtMy0xLTEtMjk4MDM_085e2168-add7-4bed-9e06-1ad92f8cda67"
      unitRef="usd">-507241000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjYtMS0xLTEtMjk4MDM_e9e590ec-3b54-417d-9445-968844c693be"
      unitRef="usd">-52000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjYtMy0xLTEtMjk4MDM_7e1da76f-6990-4892-90aa-c1f1b8256285"
      unitRef="usd">-29000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjctMS0xLTEtMjk4MDM_548c15ac-5e15-4e50-8c24-226f56563b55"
      unitRef="usd">60957000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjctMy0xLTEtMjk4MDM_e7768e33-d819-4896-b5e6-5050b9a84b74"
      unitRef="usd">66578000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjgtMS0xLTEtMjk4MDM_0f79c4d6-6bc1-4507-94f8-d9077da9365c"
      unitRef="usd">-254000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjgtMy0xLTEtMjk4MDM_6336b2b6-b3be-4e61-a9c6-cf214b51d206"
      unitRef="usd">-254000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjktMS0xLTEtMjk4MDM_4ed68879-35a8-49a3-8e9d-00271d55acea"
      unitRef="usd">60703000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMjktMy0xLTEtMjk4MDM_f6b6616e-2141-4715-85b1-1696b829efc9"
      unitRef="usd">66324000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMzAtMS0xLTEtMjk4MDM_3ebdc6d1-8a34-48a4-a15b-49107218497e"
      unitRef="usd">66326000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xNi9mcmFnOjMwNjg4ZGEyMzBmZTQ3MTJiZDMzYWEzYWRjNTQ3Y2UyL3RhYmxlOjUwMjY0NDYwMjNhMzRhMWFiYWVkZTMwN2M5NjEwYjI4L3RhYmxlcmFuZ2U6NTAyNjQ0NjAyM2EzNGExYWJhZWRlMzA3Yzk2MTBiMjhfMzAtMy0xLTEtMjk4MDM_d79570cf-a34d-4836-9010-b4efae50274a"
      unitRef="usd">73034000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMy01LTEtMS0yOTgwMw_a78d663f-4412-44c8-acab-eb00e28f9a4e"
      unitRef="usd">3179000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMy03LTEtMS0yOTgwMw_22c78d16-4cc2-4a9a-bfb1-59b64f86b46a"
      unitRef="usd">3283000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfNS01LTEtMS0yOTgwMw_e0cce1ff-5e00-401a-ae4b-9d0234d9d211"
      unitRef="usd">3665000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfNS03LTEtMS0yOTgwMw_9c3ac61f-a381-4a72-8f34-e02a2db2f1ff"
      unitRef="usd">3337000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfNi01LTEtMS0yOTgwMw_477e6199-9e71-4cec-a1a7-1fcce623670b"
      unitRef="usd">6844000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfNi03LTEtMS0yOTgwMw_739786ed-d83c-4932-9a6c-79f3fc0d3f47"
      unitRef="usd">6620000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfOC01LTEtMS0yOTgwMw_b1e4255e-8718-4870-9f40-cf42c59aaa55"
      unitRef="usd">-6844000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfOC03LTEtMS0yOTgwMw_7886ab4c-1eb5-4d50-8b0b-9ddc8b2630b8"
      unitRef="usd">-6620000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTEtNS0xLTEtMjk4MDM_ffd17a0c-8071-4f62-9674-6af1e35701dd"
      unitRef="usd">670000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTEtNy0xLTEtMjk4MDM_45f376e8-1662-4e6b-9bc3-faa046da55d3"
      unitRef="usd">63000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTItNS0xLTEtMjk4MDM_e511c4c0-8fb0-400c-8ed9-36a68d1c0dd0"
      unitRef="usd">-13000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTItNy0xLTEtMjk4MDM_b468a745-d9e5-4a46-8833-f60081c5ebf1"
      unitRef="usd">-148000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTMtNS0xLTEtMjk4MDM_648cfd63-8676-403e-9caf-3db8a542214b"
      unitRef="usd">657000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTMtNy0xLTEtMjk4MDM_123320cb-e8cf-4d55-814a-6617bafd54ac"
      unitRef="usd">-85000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTUtNS0xLTEtMjk4MDM_57b88eec-ffbd-4d78-8dfe-e8125925b85b"
      unitRef="usd">-6187000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTUtNy0xLTEtMjk4MDM_e7c50d56-b2ad-44cc-991c-7b53f15b21e5"
      unitRef="usd">-6705000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTYtNS0xLTEtMjk4MDM_7354c5a0-2ec3-4a70-815d-2d21927588c5"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTYtNy0xLTEtMjk4MDM_65057c12-e65e-4f73-b7c3-cc67af42e2f2"
      unitRef="usd">-2479000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTctNS0xLTEtMjk4MDM_18917001-e73d-42d4-b039-e58c390afdbf"
      unitRef="usd">-6187000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTctNy0xLTEtMjk4MDM_ae3c5eeb-35f7-41dc-acfc-21b318114545"
      unitRef="usd">-4226000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTgtNS0xLTEtMjk4MDM_7c4cb063-1787-4d7d-b903-da87089d7efe"
      unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTgtNy0xLTEtMjk4MDM_18fb4ed3-697b-4722-9573-976de35fe794"
      unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:NetIncomeLoss
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTktNS0xLTEtMjk4MDM_31b0405e-6a7c-4774-849f-49d816196adc"
      unitRef="usd">-6187000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMTktNy0xLTEtMjk4MDM_1360eec6-caa7-4dcf-8880-bc31f8100324"
      unitRef="usd">-4226000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMjMtNS0xLTEtMjk4MDM_1e35bca2-7fba-45c6-b5d9-2ff6391c8b1c"
      unitRef="usdPerShare">-0.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMjMtNS0xLTEtMjk4MDM_4b81915e-280a-4a78-ac26-191ccca7dff5"
      unitRef="usdPerShare">-0.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMjMtNy0xLTEtMjk4MDM_1a1e6490-5038-4120-90fe-f7615976e913"
      unitRef="usdPerShare">-1.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMjMtNy0xLTEtMjk4MDM_58fc1a97-ad5c-4a17-947e-4fd3de0999ab"
      unitRef="usdPerShare">-1.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMjYtNS0xLTEtMjk4MDM_831a0cef-cd2c-477b-b2b0-9ca7dc364c02"
      unitRef="shares">7987000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMjYtNS0xLTEtMjk4MDM_e9176691-7381-420b-af75-ed31d4156e16"
      unitRef="shares">7987000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMjYtNy0xLTEtMjk4MDM_1681825c-d6bd-4651-8794-95ede7e8b4d9"
      unitRef="shares">4037000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xOS9mcmFnOjJjMTdiMmI3NTJlZDRjMGQ5OWQ3OTg5NDU0OTI0ZmRhL3RhYmxlOjc0NDAzMWZkYTFhMzQwNTdhNDI5YTI0YjY4ZTgwYmIyL3RhYmxlcmFuZ2U6NzQ0MDMxZmRhMWEzNDA1N2E0MjlhMjRiNjhlODBiYjJfMjYtNy0xLTEtMjk4MDM_ca30b010-861b-4984-9bc5-8a38d1e10fac"
      unitRef="shares">4037000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yMi9mcmFnOmU3ZGEwOTZiYTQ2YjRmMDViOWFlNTAwMjMyNTE5MmM2L3RhYmxlOjQ2MjdlN2YzM2FlYzQwN2I5ZDQ4MDBmNzIxNjE3MzBmL3RhYmxlcmFuZ2U6NDYyN2U3ZjMzYWVjNDA3YjlkNDgwMGY3MjE2MTczMGZfMi01LTEtMS0yOTgwMw_02047a2f-beab-4e5a-897b-4016b2321205"
      unitRef="usd">-6187000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yMi9mcmFnOmU3ZGEwOTZiYTQ2YjRmMDViOWFlNTAwMjMyNTE5MmM2L3RhYmxlOjQ2MjdlN2YzM2FlYzQwN2I5ZDQ4MDBmNzIxNjE3MzBmL3RhYmxlcmFuZ2U6NDYyN2U3ZjMzYWVjNDA3YjlkNDgwMGY3MjE2MTczMGZfMi03LTEtMS0yOTgwMw_578dcf90-4e1b-4e01-8fd5-630b7d18e79a"
      unitRef="usd">-4226000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yMi9mcmFnOmU3ZGEwOTZiYTQ2YjRmMDViOWFlNTAwMjMyNTE5MmM2L3RhYmxlOjQ2MjdlN2YzM2FlYzQwN2I5ZDQ4MDBmNzIxNjE3MzBmL3RhYmxlcmFuZ2U6NDYyN2U3ZjMzYWVjNDA3YjlkNDgwMGY3MjE2MTczMGZfNS01LTEtMS0yOTgwMw_514e1ae6-2b33-4a98-adbd-9a4ef2c12c78"
      unitRef="usd">-11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yMi9mcmFnOmU3ZGEwOTZiYTQ2YjRmMDViOWFlNTAwMjMyNTE5MmM2L3RhYmxlOjQ2MjdlN2YzM2FlYzQwN2I5ZDQ4MDBmNzIxNjE3MzBmL3RhYmxlcmFuZ2U6NDYyN2U3ZjMzYWVjNDA3YjlkNDgwMGY3MjE2MTczMGZfNS03LTEtMS0yOTgwMw_ea36ee45-c1bb-4e49-a66b-fde279ff2e5b"
      unitRef="usd">-126000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yMi9mcmFnOmU3ZGEwOTZiYTQ2YjRmMDViOWFlNTAwMjMyNTE5MmM2L3RhYmxlOjQ2MjdlN2YzM2FlYzQwN2I5ZDQ4MDBmNzIxNjE3MzBmL3RhYmxlcmFuZ2U6NDYyN2U3ZjMzYWVjNDA3YjlkNDgwMGY3MjE2MTczMGZfNi01LTEtMS0yOTgwMw_dd06a293-f19a-455c-a8ce-713891583223"
      unitRef="usd">-12000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yMi9mcmFnOmU3ZGEwOTZiYTQ2YjRmMDViOWFlNTAwMjMyNTE5MmM2L3RhYmxlOjQ2MjdlN2YzM2FlYzQwN2I5ZDQ4MDBmNzIxNjE3MzBmL3RhYmxlcmFuZ2U6NDYyN2U3ZjMzYWVjNDA3YjlkNDgwMGY3MjE2MTczMGZfNi03LTEtMS0yOTgwMw_983d03f1-31d3-406a-ad3c-0277c755bfa6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yMi9mcmFnOmU3ZGEwOTZiYTQ2YjRmMDViOWFlNTAwMjMyNTE5MmM2L3RhYmxlOjQ2MjdlN2YzM2FlYzQwN2I5ZDQ4MDBmNzIxNjE3MzBmL3RhYmxlcmFuZ2U6NDYyN2U3ZjMzYWVjNDA3YjlkNDgwMGY3MjE2MTczMGZfNy01LTEtMS0yOTgwMw_e91f84bc-3646-4ee8-94b7-4bc68d67b18d"
      unitRef="usd">-23000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yMi9mcmFnOmU3ZGEwOTZiYTQ2YjRmMDViOWFlNTAwMjMyNTE5MmM2L3RhYmxlOjQ2MjdlN2YzM2FlYzQwN2I5ZDQ4MDBmNzIxNjE3MzBmL3RhYmxlcmFuZ2U6NDYyN2U3ZjMzYWVjNDA3YjlkNDgwMGY3MjE2MTczMGZfNy03LTEtMS0yOTgwMw_8dbe7973-ccbc-4a3c-8139-9dc8dfaa90fd"
      unitRef="usd">-126000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yMi9mcmFnOmU3ZGEwOTZiYTQ2YjRmMDViOWFlNTAwMjMyNTE5MmM2L3RhYmxlOjQ2MjdlN2YzM2FlYzQwN2I5ZDQ4MDBmNzIxNjE3MzBmL3RhYmxlcmFuZ2U6NDYyN2U3ZjMzYWVjNDA3YjlkNDgwMGY3MjE2MTczMGZfMTMtNS0xLTEtMjk4MDM_5e88cd90-b6cb-48ce-9ff2-93b939a862da"
      unitRef="usd">-6210000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yMi9mcmFnOmU3ZGEwOTZiYTQ2YjRmMDViOWFlNTAwMjMyNTE5MmM2L3RhYmxlOjQ2MjdlN2YzM2FlYzQwN2I5ZDQ4MDBmNzIxNjE3MzBmL3RhYmxlcmFuZ2U6NDYyN2U3ZjMzYWVjNDA3YjlkNDgwMGY3MjE2MTczMGZfMTMtNy0xLTEtMjk4MDM_da1c9924-92a1-48a7-a331-0fca931931e6"
      unitRef="usd">-4352000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idccd6d8b24e84252b1bfbf4c82909880_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMi01LTEtMS0yOTgwMw_da5e5980-530c-44c7-ac2f-89774c5d55ff"
      unitRef="shares">3986000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idccd6d8b24e84252b1bfbf4c82909880_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMi03LTEtMS0yOTgwMw_ab423787-dedc-405a-bda9-c0a4d3e16ac9"
      unitRef="usd">4000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i83c32766e7f045148be714d2464b2a0f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMi05LTEtMS0yOTgwMw_0f82ba03-a9e3-4bc0-a303-df8fadba4f10"
      unitRef="usd">546044000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i172b6566e2954903a795810c0f7faea8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMi0xMS0xLTEtMjk4MDM_8c926559-9f52-4b64-9b11-8b14cbaeb23c"
      unitRef="usd">-70000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i659cc88ca4174728b2be88034cec77d9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMi0xMy0xLTEtMjk4MDM_64d3b8d8-ea55-48a6-9d31-5697ddb5592c"
      unitRef="usd">-453016000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i167ad6f9efc349e8aeb1f3afc4eb06f1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMi0xNS0xLTEtMjk4MDM_f948bfed-dcee-498d-85cb-91151981abff"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3016a907934548cf89814e3cc5065bb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMi0xNy0xLTEtMjk4MDM_68cc6149-776f-44df-aa34-a4337ef61e55"
      unitRef="usd">92254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i61be37acd3b24fdd8277d7ebcc1a2524_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMi0xOS0xLTEtMjk4MDM_02172db1-22b7-4b16-8eaa-a7e97261804c"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id4046547dd294ad49c799697f6ddb110_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMi0yMS0xLTEtMjk4MDM_ecf7cc78-fa84-4c6e-8eb9-4afc1ae6f811"
      unitRef="usd">92000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i3c1e7ed7cdb0485db6a09b8f120ae70a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMy0xMy0xLTEtMjk4MDM_f0b51f40-e88c-48a2-abfa-471352048541"
      unitRef="usd">-4226000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i30dbc205504449d38986e42bcedd9a11_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMy0xNy0xLTEtMjk4MDM_76ff2bc1-7635-4e73-8211-04c96be81ce4"
      unitRef="usd">-4226000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMy0yMS0xLTEtMjk4MDM_f207fc61-0204-458e-9455-769a21bf1606"
      unitRef="usd">-4226000</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ia5530dc46c414ce092189cff88a3f7dd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfNC01LTEtMS0yOTgwMw_24585502-f9e9-4df9-ac9e-3a6a6f545c3a"
      unitRef="shares">49000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7e1630a3383b43cb9dd10a9949f9a4e4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfNC05LTEtMS0yOTgwMw_881b7d57-ebad-468f-a8e0-c30eb161de7e"
      unitRef="usd">593000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i30dbc205504449d38986e42bcedd9a11_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfNC0xNy0xLTEtMjk4MDM_8ac503a4-fea2-4868-a9cf-f3239e0a5dac"
      unitRef="usd">593000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfNC0yMS0xLTEtMjk4MDM_761d4117-743c-454b-a33a-add5f393b58f"
      unitRef="usd">593000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ic5e281aca39d4be8a4acaf10e78a17c4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOC0xMS0xLTEtMjk4MDM_4490453b-2237-454c-a4d0-ebf8f348671a"
      unitRef="usd">-126000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i30dbc205504449d38986e42bcedd9a11_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOC0xNy0xLTEtMjk4MDM_ae42fd83-2c84-4987-930e-4714c25481a0"
      unitRef="usd">-126000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOC0yMS0xLTEtMjk4MDM_863af76a-4abe-4458-99b8-c9c0f7f13203"
      unitRef="usd">-126000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i57742d73f1a641e6869962f1ae17f160_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOS01LTEtMS0yOTgwMw_de47eea6-1b2a-4079-91b3-1a4d7839dca1"
      unitRef="shares">4035000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i57742d73f1a641e6869962f1ae17f160_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOS03LTEtMS0yOTgwMw_b6d9b220-6606-4ee2-ac0c-7c489b33ed2f"
      unitRef="usd">4000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i38bd3b8625604395bc59611e78cb1d4c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOS05LTEtMS0yOTgwMw_5a46514a-4887-4a51-897e-d6f3c35e0871"
      unitRef="usd">546637000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9b6d5d55db744ce2adef5755fc8dcf38_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOS0xMS0xLTEtMjk4MDM_71e3e1be-c93f-4e03-a474-f564f101beef"
      unitRef="usd">-196000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia56329ac6bf74270be8df5d045aa6494_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOS0xMy0xLTEtMjk4MDM_d416f003-63a2-42ea-b9bd-c6b480a3000f"
      unitRef="usd">-457242000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12937a3ada6d4dd2b874669455d35962_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOS0xNS0xLTEtMjk4MDM_308106fc-0c3c-4b88-93c2-f4eb2fafe6e3"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12937a3ada6d4dd2b874669455d35962_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOS0xNS0xLTEtMjk4MDM_6aed78d0-6771-4f0d-95bb-0016a18daf74"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1bb37f6848ed455f8b7792e91866123b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOS0xNy0xLTEtMjk4MDM_6b31f0c3-e674-40e4-8c9d-1d5de08a4ddf"
      unitRef="usd">88495000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9619f9b64ebe471ca599503ec1560977_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOS0xOS0xLTEtMjk4MDM_7f33ffec-97ac-406e-b590-738ec3379be7"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5ce139ad8e764eb2804ef24019b88cdc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfOS0yMS0xLTEtMjk4MDM_5f9fe031-6ee7-4b4b-a94d-21fbb8f7da85"
      unitRef="usd">88241000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3fd2bb5d543d427ca3beb6d8dae402ca_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTMtNS0xLTEtMjk4MDM_d98f8dbe-238d-429c-9cde-e69309c4609e"
      unitRef="shares">7867000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3fd2bb5d543d427ca3beb6d8dae402ca_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTMtNy0xLTEtMjk4MDM_2628ce51-8d03-4eef-bdf3-5d48a1c976e8"
      unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8d1ce795a4ca4649ac9b72bf8edca70d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTMtOS0xLTEtMjk4MDM_247bbb40-a6a6-4022-bffa-e0e7b9d4bef7"
      unitRef="usd">574548000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i800befd23f3841569b227ba2e2d706d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTMtMTEtMS0xLTI5ODAz_2a2be77b-d408-4f05-a92a-68b387ccfe31"
      unitRef="usd">-29000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3d5c507b54c44f3382ccc7e3b5440bb2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTMtMTMtMS0xLTI5ODAz_cb4bf56f-177d-4728-b363-dff9e45c15a5"
      unitRef="usd">-507241000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i79e1062c1f414381a135b2e72a0a68df_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTMtMTUtMS0xLTI5ODAz_e642026a-803e-4596-97f5-34f8782870e0"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iac1d983470804b2cac2936f1132412ae_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTMtMTctMS0xLTI5ODAz_b5872176-20de-423a-89e8-91434d6584d4"
      unitRef="usd">66578000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic0482b3971ec42ce8127564740a1f058_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTMtMTktMS0xLTI5ODAz_d1f90a97-d8f0-42be-86ee-953e987a268b"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTMtMjEtMS0xLTI5ODAz_529ebd1b-4c7a-4df9-bff1-81ad4308f6cc"
      unitRef="usd">66324000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="id7ee28bcb50447fd965f5db978a79599_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTUtMTMtMS0xLTI5ODAz_f3519a00-c389-4a94-88b5-271e22a643a5"
      unitRef="usd">-6187000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i13d0c68aceb945648fc95a868eb9e3ef_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTUtMTctMS0xLTI5ODAz_c68862c8-9a5f-492d-8738-1e0f287113ed"
      unitRef="usd">-6187000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTUtMjEtMS0xLTI5ODAz_33e2a5be-c2e9-4b85-8d23-a252dd309b1d"
      unitRef="usd">-6187000</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic9347bcc62e74b129f2045c4859eb549_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTYtNS0xLTEtMjk4MDM_8e34bef9-0f5d-401d-a3ed-c929bc6ebf65"
      unitRef="shares">132000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if20c8a9a03b14863bb4789b2d34ee496_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTYtOS0xLTEtMjk4MDM_ffaded0f-dcc3-427b-83e6-433ff826d74c"
      unitRef="usd">589000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i13d0c68aceb945648fc95a868eb9e3ef_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTYtMTctMS0xLTI5ODAz_6004e2b6-b3bc-4f0c-8845-676992761e55"
      unitRef="usd">589000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTYtMjEtMS0xLTI5ODAz_b809ac91-c166-4cf2-8485-1a5955c6b41f"
      unitRef="usd">589000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ic8cc3ac77efa48088686b917cb62e54f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTktMTEtMS0xLTQyOTQ4_c5ac4a75-b956-4963-b2a6-96e18916ba7b"
      unitRef="usd">-12000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i13d0c68aceb945648fc95a868eb9e3ef_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTktMTctMS0xLTQyOTQ4_68b11189-b58e-4f0d-9c25-48b601fdbf0e"
      unitRef="usd">-12000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMTktMjEtMS0xLTQyOTQ4_161af1ac-1e36-4643-8b6a-6792b761707c"
      unitRef="usd">-12000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ic8cc3ac77efa48088686b917cb62e54f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjAtMTEtMS0xLTI5ODAz_cc4bba6e-a0ba-46e8-903c-4c2e9ec111cc"
      unitRef="usd">-11000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i13d0c68aceb945648fc95a868eb9e3ef_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjAtMTctMS0xLTI5ODAz_7b254b99-3a41-418d-99b2-f58808b336a9"
      unitRef="usd">-11000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjAtMjEtMS0xLTI5ODAz_726ecbfc-2437-41d2-81e1-f113c88039c6"
      unitRef="usd">-11000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1083fcdc93504069ab0c6b8124da6c36_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjEtNS0xLTEtMjk4MDM_1b3f86af-46d7-457c-a511-138810b94668"
      unitRef="shares">7999000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1083fcdc93504069ab0c6b8124da6c36_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjEtNy0xLTEtMjk4MDM_fef12001-9596-4190-9e4a-67d8c53f4e08"
      unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7bf4f3fb7021489abb1e920d657cfc55_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjEtOS0xLTEtMjk4MDM_cf359a52-86dc-44c1-9b53-cd549c1674c3"
      unitRef="usd">575137000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iffe6cb540c934ae58b0986186454ad7d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjEtMTEtMS0xLTI5ODAz_6d4dbc4a-5544-4e27-a458-88a9e863a6de"
      unitRef="usd">-52000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6da0050ca7b24feeba54e912cec8a0d6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjEtMTMtMS0xLTI5ODAz_ae9a7862-8cde-4f55-a902-d70600d7cf40"
      unitRef="usd">-513428000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1306a47c84604f74bccf2442a61ec582_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjEtMTUtMS0xLTI5ODAz_48dbe205-0f10-427a-afd6-bb112e78b701"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i50382c5190684ed1bbbe023c4f418b3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjEtMTctMS0xLTI5ODAz_a845a989-d246-4911-ab55-970331df7e7c"
      unitRef="usd">60957000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iee22d1576f8f42cfbcb560d4e1373257_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjEtMTktMS0xLTI5ODAz_10885861-bb33-4a4f-a1f8-2d6f56f251bd"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yNS9mcmFnOjViZTc5NjNjNjAwZTRjN2Q5MGFiYzgyNWVlYTlhMTQyL3RhYmxlOjExZTEzYjA2ZDIxNjRkODI5N2E4NmNlZDAwZWUwMjQyL3RhYmxlcmFuZ2U6MTFlMTNiMDZkMjE2NGQ4Mjk3YTg2Y2VkMDBlZTAyNDJfMjEtMjEtMS0xLTI5ODAz_c3ea4ba9-7b92-4751-9b29-6e8da030f848"
      unitRef="usd">60703000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMy0xLTEtMS0yOTgwMw_a0fc73e5-4705-4788-a175-dab0c5c92f29"
      unitRef="usd">-6187000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMy0zLTEtMS0yOTgwMw_883474be-2e67-4f29-bd77-3f443eddad62"
      unitRef="usd">-4226000</us-gaap:ProfitLoss>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfNS0xLTEtMS0yOTgwMw_685f1a6d-7e1f-454a-ba9e-16c80db706fa"
      unitRef="usd">675000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfNS0zLTEtMS0yOTgwMw_ae64d0d2-8c7d-4534-9f1d-76f2a4106af4"
      unitRef="usd">760000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:DepreciationAndAmortization
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfNi0xLTEtMS0yOTgwMw_71226f95-5653-461e-bfc9-7f318e4ce8f6"
      unitRef="usd">48000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfNi0zLTEtMS0yOTgwMw_ad167424-536b-4d1c-b54a-41abe5ac2c94"
      unitRef="usd">7000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfNy0xLTEtMS0yOTgwMw_8357cb18-234d-4091-b004-e59b58f9f87c"
      unitRef="usd">-3000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfNy0zLTEtMS0yOTgwMw_9ae57018-516b-4b3a-8591-83194f5d2a7b"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTAtMS0xLTEtMjk4MDM_533e8733-a28e-4930-962a-cd3e34f38a13"
      unitRef="usd">167000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTAtMy0xLTEtMjk4MDM_6b415275-c116-4d54-84fb-c529f9bdb070"
      unitRef="usd">-515000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTItMS0xLTEtMjk4MDM_542a6189-abda-4873-a294-df5edc4268b6"
      unitRef="usd">1652000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTItMy0xLTEtMjk4MDM_1942af8e-00ff-4261-80c4-d6faf97566c2"
      unitRef="usd">969000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTMtMS0xLTEtMjk4MDM_1f687cc9-8615-4916-ac99-89c207674a5f"
      unitRef="usd">-167000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTMtMy0xLTEtMjk4MDM_07f84d19-3539-4325-ba78-b39959cef443"
      unitRef="usd">-57000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTQtMS0xLTEtMjk4MDM_a7d42f92-6c07-4354-8478-f70780941ab4"
      unitRef="usd">-1083000</clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities>
    <clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTQtMy0xLTEtMjk4MDM_76616228-f5fa-4ae5-b6f6-82d43ed61138"
      unitRef="usd">-1786000</clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTUtMS0xLTEtMjk4MDM_3dbb574e-dc67-429f-ad13-ed57133d7f42"
      unitRef="usd">-8196000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTUtMy0xLTEtMjk4MDM_192fb3c9-eae4-42f7-aaec-d12ca757fe71"
      unitRef="usd">-5642000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTctMS0xLTEtMjk4MDM_bb9f41c8-1c40-43d9-9cd3-156c66999f92"
      unitRef="usd">30121000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTctMy0xLTEtMjk4MDM_5c4312c4-9daa-441a-8c14-2bbd3692304d"
      unitRef="usd">26546000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTgtMS0xLTEtMjk4MDM_a8c024ab-ea25-4523-bd87-5af1e05981e7"
      unitRef="usd">34410000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMTgtMy0xLTEtMjk4MDM_22884777-9de6-46b0-8277-edcf3a1c0bc6"
      unitRef="usd">20456000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMjQtMS0xLTEtMjk4MDM_0dedb1c1-23a1-4726-a7cf-76b742a7bf01"
      unitRef="usd">4289000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMjQtMy0xLTEtMjk4MDM_7d890bad-d0ee-4e75-ac45-788ccbffb7bf"
      unitRef="usd">-6090000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMjctMS0xLTEtMjk4MDM_4453ddd9-298f-4be5-972e-1262456a6b69"
      unitRef="usd">85000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMjctMy0xLTEtMjk4MDM_a3f6c9fd-c251-433b-9107-548b02f04268"
      unitRef="usd">168000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMzAtMS0xLTEtMjk4MDM_1620d447-dbce-4a53-b2bc-fe4e24bc7dae"
      unitRef="usd">-85000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMzAtMy0xLTEtMjk4MDM_357a5c66-0636-45cc-97e8-759050fbaac2"
      unitRef="usd">-168000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMzEtMS0xLTEtMjk4MDM_59300e83-f33d-4d94-b907-c0ca13fcafce"
      unitRef="usd">-7000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMzEtMy0xLTEtMjk4MDM_5b789eec-fd66-4192-bdfe-e074cbe72a66"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMzItMS0xLTEtMjk4MDM_9538c7bd-e6f2-4375-a333-1484b575403c"
      unitRef="usd">-3999000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMzItMy0xLTEtMjk4MDM_5440fb07-cb7a-465c-96e9-c7177f132e99"
      unitRef="usd">-11900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMzMtMS0xLTEtMjk4MDM_cabd7464-cc90-4f1d-be26-7d5570366cd0"
      unitRef="usd">32154000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id4046547dd294ad49c799697f6ddb110_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMzMtMy0xLTEtMjk4MDM_06c4e295-7025-4614-84da-2abc7c925fcb"
      unitRef="usd">24647000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMzQtMS0xLTEtMjk4MDM_baa05d08-76e9-4d5b-90c4-cce0811b6f14"
      unitRef="usd">28155000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5ce139ad8e764eb2804ef24019b88cdc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8yOC9mcmFnOjNhMjNiZTBjNmUyZTRhZTFhMTkzOGY2OWM1NWUxNTY3L3RhYmxlOjY0ZTlmOTJmZWExMDRkNmU5MzlhYTllNWNiM2IyNWVlL3RhYmxlcmFuZ2U6NjRlOWY5MmZlYTEwNGQ2ZTkzOWFhOWU1Y2IzYjI1ZWVfMzQtMy0xLTEtMjk4MDM_136156dd-9c4c-4742-9722-0322e277a2ac"
      unitRef="usd">12747000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <clbs:BusinessTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNC9mcmFnOjU5NDM4OWM1ZWY1MDRjMWRhYjc2YjlkYTcwMTZkYmZmL3RleHRyZWdpb246NTk0Mzg5YzVlZjUwNGMxZGFiNzZiOWRhNzAxNmRiZmZfMTQ3MDE_b83c6259-d7c1-451e-88e0-fb0a2dbc649e">The Business&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lisata Therapeutics, Inc. (together with its subsidiaries, the &#x201c;Company&#x201d;) is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The Company's lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are not expected to be affected. LSTA1 also has the potential to modify the tumor microenvironment (&#x201c;TME&#x201d;), with the objective of making tumors more susceptible to immunotherapies. The Company and its collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. To date, LSTA1 has also demonstrated favorable safety, tolerability, and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. The Company is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. In addition, the Company has development programs based on its autologous CD34+ cell therapy technology platform that it will look to partner while incurring no additional capital outlay.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. Its goal is to develop and commercialize products that address important unmet medical needs. The Company&#x2019;s current development pipeline includes: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;LSTA1, the subject of Phase 1b/2a and 2b clinical studies being conducted globally in a variety of solid tumor types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a variety of anti-cancer regimens.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Merger with Cend Therapeutics, Inc. and Name Change&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 15, 2022, the Company, then operating as Caladrius Biosciences, Inc. (&#x201c;Caladrius&#x201d;), completed its acquisition of Cend Therapeutics, Inc. (&#x201c;Cend&#x201d;), a Delaware corporation (the &#x201c;Merger&#x201d;), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the &#x201c;Merger Agreement&#x201d;), dated as of April 26, 2022, by and among Caladrius, Cend and CS Cedar Merger Sub, Inc. (&#x201c;Merger Sub&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms set forth in the Merger Agreement and effective September 15, 2022 (the &#x201c;Effective Time&#x201d;): (i) Merger Sub merged with and into Cend, with Cend surviving as a wholly owned subsidiary of Caladrius, (ii) Caladrius changed its name to Lisata Therapeutics, Inc., and (iii) Caladrius effected a 1:15 reverse stock split of its common stock (&#x201c;Reverse Stock Split&#x201d;) prior to the Effective Time. At the Effective Time, each share of Cend's common stock outstanding immediately prior to the Effective Time was converted into the right to receive shares of Lisata&#x2019;s common stock based on an exchange ratio of 0.5338, after taking into account the Reverse Stock Split (the &#x201c;Exchange Ratio&#x201d;). In connection with the Merger close, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Merger Agreement, Lisata assumed all of the outstanding and unexercised options to purchase shares of Cend capital stock under the 2016 Equity Incentive Plan (the &#x201c;Cend Plan&#x201d;), and, in connection with the Merger, such options were converted into options to purchase shares of Lisata&#x2019;s common stock based on the Exchange Ratio. At the closing of the Merger at the Effective Time, the Company assumed Cend's stock options to purchase an aggregate of 1,227,776 shares of the Company's common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Caladrius was considered to be the accounting acquirer based on the terms of the Merger Agreement and certain factors including: (i) Caladrius owned approximately 52% of the Company's outstanding shares of common stock immediately following the close of the Merger; (ii) although both entities contributed to the new management team of Lisata, the Caladrius team had more individuals on the management team and holds the chief executive officer (&#x201c;CEO&#x201d;), chief medical officer (&#x201c;CMO&#x201d;) and other senior management roles; (iii) Caladrius paid a premium to acquire Cend&#x2019;s assets; and (iv) Caladrius was significantly larger than Cend regarding total assets, operations, and research and development activities. The Merger was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;). Cend&#x2019;s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;amp;D with no &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;alternative future use being expensed as reported in the consolidated statement of operations. Operating results presented in the consolidated statements of operations and comprehensive loss prior to the Merger are solely related to Caladrius Biosciences, Inc. and subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Coronavirus Considerations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lisata's Phase 2b FREEDOM Trial of XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the U.S. experienced delays in enrolling patients as a result of COVID-19. While early enrollment proceeded to plan with the first patient treated in January 2021, the impact of the COVID-19 pandemic contributed to a general slowing of enrollment, including supply chain disruptions affecting the availability of qualified catheters used in the diagnosis of CMD and/or administration of XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as well as with a contrast agent typically used in many catheter laboratories. In May 2022, the Company announced that enrollment in the FREEDOM Trial was suspended and that it intended to conduct an interim analysis of the data from not less than the first 20 patients enrolled using the 6-month follow-up data to evaluate the efficacy and safety of XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in subjects with CMD. Following this analysis along with Key Opinion Leaders&#x2019; input, the Company determined that execution of a redesigned FREEDOM-like trial would be the appropriate next step, but the cost of such a trial would be prohibitively expensive to undergo without a strategic partner. Accordingly, the Company&#x2019;s board of directors concluded that XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; development will only be continued if a strategic partner that can contribute the necessary capital for a redesigned trial is identified and secured. There can be no assurance that we will be able to identify such a partner and enter into an agreement with such partner on acceptable terms or at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 14, 2022, in connection with the Merger, the Company implemented the Reverse Stock Split, as authorized at the annual meeting of stockholders on September 13, 2022. The Reverse Stock Split became effective on September 14, 2022 at 5:00 pm and the Company's common stock began trading on The Nasdaq Capital Market on a post-split basis at the open of business on September 15, 2022. As of September 14, 2022, every fifteen shares of the Company&#x2019;s issued and outstanding common stock (and such shares held in treasury) were automatically converted into one share of common stock, without any change in the par value per share. In addition, proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options, stock appreciation rights, convertible notes and warrants to purchase shares of common stock, the number of shares issuable upon the vesting of all restricted stock awards, and the number of shares of common stock reserved for issuance pursuant to the Company&#x2019;s equity incentive compensation plans. Any stockholder who would otherwise be entitled to a fractional share of common stock created as a result of the Reverse Stock Split received a cash payment equal to the product of such resulting fractional interest in one share of common stock multiplied by the closing trading price of the common stock on September 15, 2022. The Reverse Stock Split was effectuated in order to increase the per share trading price of our common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from &#x201c;common stock&#x201d; to &#x201c;additional paid-in capital&#x201d; in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of March&#160;31, 2023, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2022 and 2021 included in our 2022 Form 10-K. Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and the valuation of the Merger which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;). Accordingly, actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Remeasurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd. which is a foreign subsidiary of the Company is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.&lt;/span&gt;&lt;/div&gt;</clbs:BusinessTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="iac5cf83f8935401bb2f5aca604012ece_D20220915-20220915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNC9mcmFnOjU5NDM4OWM1ZWY1MDRjMWRhYjc2YjlkYTcwMTZkYmZmL3RleHRyZWdpb246NTk0Mzg5YzVlZjUwNGMxZGFiNzZiOWRhNzAxNmRiZmZfNTQ5NzU1ODQ3MzY3_96e9c084-a54e-460c-8371-99917853503a"
      unitRef="number">0.5338</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:SharesIssued
      contextRef="icbaa2961421947beb045865325d7915f_I20220915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNC9mcmFnOjU5NDM4OWM1ZWY1MDRjMWRhYjc2YjlkYTcwMTZkYmZmL3RleHRyZWdpb246NTk0Mzg5YzVlZjUwNGMxZGFiNzZiOWRhNzAxNmRiZmZfNTQ5NzU1ODQ3NTE4_7ec92184-c9cd-492b-a449-efe8313e8bd7"
      unitRef="shares">3772768</us-gaap:SharesIssued>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="ic072dd5659984964b08dc7870ffd5237_I20220915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNC9mcmFnOjU5NDM4OWM1ZWY1MDRjMWRhYjc2YjlkYTcwMTZkYmZmL3RleHRyZWdpb246NTk0Mzg5YzVlZjUwNGMxZGFiNzZiOWRhNzAxNmRiZmZfNTQ5NzU1ODQ4MTY1_409da001-fff1-4575-ab55-1cf355aedd17"
      unitRef="shares">1227776</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="ie18f40d4e2884dbfaf339b40535a723f_D20220915-20220915"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNC9mcmFnOjU5NDM4OWM1ZWY1MDRjMWRhYjc2YjlkYTcwMTZkYmZmL3RleHRyZWdpb246NTk0Mzg5YzVlZjUwNGMxZGFiNzZiOWRhNzAxNmRiZmZfNTQ5NzU1ODQ4Mzcx_782090f5-1a7c-4d58-a270-2e58c865ddf5"
      unitRef="number">0.52</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNC9mcmFnOjU5NDM4OWM1ZWY1MDRjMWRhYjc2YjlkYTcwMTZkYmZmL3RleHRyZWdpb246NTk0Mzg5YzVlZjUwNGMxZGFiNzZiOWRhNzAxNmRiZmZfMTQ2ODk_aa8f323f-e1c4-474e-94fb-83acc580c1d3">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of March&#160;31, 2023, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2022 and 2021 included in our 2022 Form 10-K. Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNC9mcmFnOjU5NDM4OWM1ZWY1MDRjMWRhYjc2YjlkYTcwMTZkYmZmL3RleHRyZWdpb246NTk0Mzg5YzVlZjUwNGMxZGFiNzZiOWRhNzAxNmRiZmZfMTQ2OTc_b65ecc0e-8d62-4b0f-aaad-8aa51e366577">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the &lt;/span&gt;&lt;/div&gt;circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and the valuation of the Merger which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;). Accordingly, actual results could differ from those estimates and assumptions.</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNC9mcmFnOjU5NDM4OWM1ZWY1MDRjMWRhYjc2YjlkYTcwMTZkYmZmL3RleHRyZWdpb246NTk0Mzg5YzVlZjUwNGMxZGFiNzZiOWRhNzAxNmRiZmZfMTQ2OTg_5ac7a4af-f18f-4c33-a671-33be381656e9">Principles of ConsolidationThe Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNC9mcmFnOjU5NDM4OWM1ZWY1MDRjMWRhYjc2YjlkYTcwMTZkYmZmL3RleHRyZWdpb246NTk0Mzg5YzVlZjUwNGMxZGFiNzZiOWRhNzAxNmRiZmZfMTQ2OTU_629db4bd-e96d-4c0e-8527-92378ea898f8">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Remeasurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd. which is a foreign subsidiary of the Company is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNy9mcmFnOjlmNWU1MzEzYzkzMDQyZmJiZTExODUyZDE2OWU4YWEyL3RleHRyZWdpb246OWY1ZTUzMTNjOTMwNDJmYmJlMTE4NTJkMTY5ZThhYTJfMTI2MjA_47f79cc2-25d4-445c-8887-4b1b0a464b75">Summary of Significant Accounting Policies&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Life of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#x2019;s restricted stock and restricted stock units is based on the closing market price of the Company&#x2019;s common stock on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To further drive the Company&#x2019;s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company&#x2019;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-process Research and Development Expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#x201c;business&#x201d; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible asset consists of a single asset, Cend&#x2019;s license agreement with Qilu Pharmaceutical, Co., Ltd. (&#x201c;Qilu&#x201d;) acquired in the Merger, with a value of $0.4&#160;million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of 5 years. Amortization expense was $18 thousand for the three months ended March&#160;31, 2023. The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.  The projected amortization expense is $71&#160;thousand per year for the next five years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#x2019;s collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#x2019;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three months ended March&#160;31, 2023 and March&#160;31, 2022, the Company has not recognized revenue related to milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNy9mcmFnOjlmNWU1MzEzYzkzMDQyZmJiZTExODUyZDE2OWU4YWEyL3RleHRyZWdpb246OWY1ZTUzMTNjOTMwNDJmYmJlMTE4NTJkMTY5ZThhYTJfMTI2MTg_7aeda70f-7f4f-4fcd-90f6-558a345f22ec">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i9fba73856db44b87a21cac709470eda2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNy9mcmFnOjlmNWU1MzEzYzkzMDQyZmJiZTExODUyZDE2OWU4YWEyL3RhYmxlOjQwYTE3YTZkZmUzYTQ0MjFhYzk5YjkwZGU0Yjg5MDQyL3RhYmxlcmFuZ2U6NDBhMTdhNmRmZTNhNDQyMWFjOTliOTBkZTRiODkwNDJfMC0xLTEtMS00NTg0MA_9294499d-00d8-45f9-ba8a-ca2a06cb4fbc">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i5ee0cb91c75d458c950b56f03890e10c_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNy9mcmFnOjlmNWU1MzEzYzkzMDQyZmJiZTExODUyZDE2OWU4YWEyL3RhYmxlOjQwYTE3YTZkZmUzYTQ0MjFhYzk5YjkwZGU0Yjg5MDQyL3RhYmxlcmFuZ2U6NDBhMTdhNmRmZTNhNDQyMWFjOTliOTBkZTRiODkwNDJfMS0xLTEtMS00NTg0MA_b7b48265-614b-43b7-9a2f-ccf9f1b00d89">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ied9953ef26fe438b9a0b57d97f79bdea_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNy9mcmFnOjlmNWU1MzEzYzkzMDQyZmJiZTExODUyZDE2OWU4YWEyL3RhYmxlOjQwYTE3YTZkZmUzYTQ0MjFhYzk5YjkwZGU0Yjg5MDQyL3RhYmxlcmFuZ2U6NDBhMTdhNmRmZTNhNDQyMWFjOTliOTBkZTRiODkwNDJfMi0xLTEtMS00NTg0MA_5b745664-49a6-4110-a5cd-bfc1a9918d49">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNy9mcmFnOjlmNWU1MzEzYzkzMDQyZmJiZTExODUyZDE2OWU4YWEyL3RleHRyZWdpb246OWY1ZTUzMTNjOTMwNDJmYmJlMTE4NTJkMTY5ZThhYTJfMTI2MTM_8c7ec0ff-0c00-44a1-81fd-f5fb32820a2c">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-process Research and Development Expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#x201c;business&#x201d; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible asset consists of a single asset, Cend&#x2019;s license agreement with Qilu Pharmaceutical, Co., Ltd. (&#x201c;Qilu&#x201d;) acquired in the Merger, with a value of $0.4&#160;million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of 5 years. Amortization expense was $18 thousand for the three months ended March&#160;31, 2023. The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.  The projected amortization expense is $71&#160;thousand per year for the next five years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#x2019;s collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#x2019;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three months ended March&#160;31, 2023 and March&#160;31, 2022, the Company has not recognized revenue related to milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNy9mcmFnOjlmNWU1MzEzYzkzMDQyZmJiZTExODUyZDE2OWU4YWEyL3RleHRyZWdpb246OWY1ZTUzMTNjOTMwNDJmYmJlMTE4NTJkMTY5ZThhYTJfNzk5NQ_ed1af4ba-74e5-45c7-b7c4-510c35b87dfe"
      unitRef="usd">400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNy9mcmFnOjlmNWU1MzEzYzkzMDQyZmJiZTExODUyZDE2OWU4YWEyL3RleHRyZWdpb246OWY1ZTUzMTNjOTMwNDJmYmJlMTE4NTJkMTY5ZThhYTJfNTQ5NzU1ODM3MDky_db2137de-7c2f-4859-bbd4-c661536de9a0"
      unitRef="usd">71000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8zNy9mcmFnOjlmNWU1MzEzYzkzMDQyZmJiZTExODUyZDE2OWU4YWEyL3RleHRyZWdpb246OWY1ZTUzMTNjOTMwNDJmYmJlMTE4NTJkMTY5ZThhYTJfMTI2MTU_04e567e3-4fb9-4166-9162-b0179cd15fdc">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:AssetAcquisitionTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RleHRyZWdpb246NjhlMjk0ZTI4ZTEyNDY3MmEzODdjNmIxYTZhYWRkNTlfNjE2_2bc8cc7f-7a99-4283-aae5-f894dac73d14">Merger&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Merger was accounted for as an asset acquisition as substantially all of the fair value was concentrated in IPR&amp;amp;D. Cend&#x2019;s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;amp;D being expensed. The fair value of total consideration was $36.1&#160;million. The following table is a summary of the purchase price calculation (in thousands except per share data).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:448.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of common shares of the combined company owned by Cend stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,772,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Multiplied by the fair value per share of Lisata common stock on September 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$23,580&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of Lisata's cost method investment in Cend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incremental fair value of Cend's fully vested stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lisata transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$36,098&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The allocation of the purchase price was as follows (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:448.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$7,062&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net working capital (excluding cash)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$36,098&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="iac5cf83f8935401bb2f5aca604012ece_D20220915-20220915"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RleHRyZWdpb246NjhlMjk0ZTI4ZTEyNDY3MmEzODdjNmIxYTZhYWRkNTlfNDIy_6741fe89-7d72-45f8-992d-1d8a328a052f"
      unitRef="usd">36100000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionTableTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RleHRyZWdpb246NjhlMjk0ZTI4ZTEyNDY3MmEzODdjNmIxYTZhYWRkNTlfNDM5ODA0NjUxMTg0MA_0a660f7f-b111-493b-89d9-6cda9e05037e">The following table is a summary of the purchase price calculation (in thousands except per share data).&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:448.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of common shares of the combined company owned by Cend stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,772,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Multiplied by the fair value per share of Lisata common stock on September 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$23,580&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of Lisata's cost method investment in Cend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incremental fair value of Cend's fully vested stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lisata transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$36,098&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The allocation of the purchase price was as follows (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:448.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$7,062&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net working capital (excluding cash)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$36,098&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AssetAcquisitionTableTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icbaa2961421947beb045865325d7915f_I20220915"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmNhZTQ3Yjg3ODcwNDQ5NzI5NjIzOWUyMjk3MGMwYTI3L3RhYmxlcmFuZ2U6Y2FlNDdiODc4NzA0NDk3Mjk2MjM5ZTIyOTcwYzBhMjdfNC0xLTEtMS0yOTgwMw_821b22bb-68a8-463e-9ffd-a417c8b69c4d"
      unitRef="shares">3772768</us-gaap:CommonStockSharesOutstanding>
    <clbs:AssetAcquisitionSharePrice
      contextRef="icbaa2961421947beb045865325d7915f_I20220915"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmNhZTQ3Yjg3ODcwNDQ5NzI5NjIzOWUyMjk3MGMwYTI3L3RhYmxlcmFuZ2U6Y2FlNDdiODc4NzA0NDk3Mjk2MjM5ZTIyOTcwYzBhMjdfNS0xLTEtMS0yOTgwMw_c314fec9-017d-447e-929c-9ddd48d05515"
      unitRef="usdPerShare">6.25</clbs:AssetAcquisitionSharePrice>
    <clbs:AssetAcquisitionConsiderationTransferredEquityValue
      contextRef="icbaa2961421947beb045865325d7915f_I20220915"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmNhZTQ3Yjg3ODcwNDQ5NzI5NjIzOWUyMjk3MGMwYTI3L3RhYmxlcmFuZ2U6Y2FlNDdiODc4NzA0NDk3Mjk2MjM5ZTIyOTcwYzBhMjdfNi0xLTEtMS0yOTgwMw_1b9530cd-d5cf-49f0-9bff-ee7d8cee561d"
      unitRef="usd">23580000</clbs:AssetAcquisitionConsiderationTransferredEquityValue>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="iac5cf83f8935401bb2f5aca604012ece_D20220915-20220915"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmNhZTQ3Yjg3ODcwNDQ5NzI5NjIzOWUyMjk3MGMwYTI3L3RhYmxlcmFuZ2U6Y2FlNDdiODc4NzA0NDk3Mjk2MjM5ZTIyOTcwYzBhMjdfNy0xLTEtMS0yOTgwMw_3dfdc463-35e1-4134-bfc1-7b21c4538fb8"
      unitRef="usd">10000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="iac5cf83f8935401bb2f5aca604012ece_D20220915-20220915"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmNhZTQ3Yjg3ODcwNDQ5NzI5NjIzOWUyMjk3MGMwYTI3L3RhYmxlcmFuZ2U6Y2FlNDdiODc4NzA0NDk3Mjk2MjM5ZTIyOTcwYzBhMjdfOC0xLTEtMS0yOTgwMw_61adb8c1-2efc-4add-a6cd-e913ecf93507"
      unitRef="usd">2136000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="iac5cf83f8935401bb2f5aca604012ece_D20220915-20220915"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmNhZTQ3Yjg3ODcwNDQ5NzI5NjIzOWUyMjk3MGMwYTI3L3RhYmxlcmFuZ2U6Y2FlNDdiODc4NzA0NDk3Mjk2MjM5ZTIyOTcwYzBhMjdfOS0xLTEtMS0yOTgwMw_13091b82-67cf-428b-b8ca-889cb04dfddd"
      unitRef="usd">382000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="iac5cf83f8935401bb2f5aca604012ece_D20220915-20220915"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmNhZTQ3Yjg3ODcwNDQ5NzI5NjIzOWUyMjk3MGMwYTI3L3RhYmxlcmFuZ2U6Y2FlNDdiODc4NzA0NDk3Mjk2MjM5ZTIyOTcwYzBhMjdfMTAtMS0xLTEtMjk4MDM_4dc5ad98-4edd-41c6-a0c6-d16496720b8c"
      unitRef="usd">36098000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <clbs:AssetAcquisitionCashAndCashEquivalents
      contextRef="icbaa2961421947beb045865325d7915f_I20220915"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmU2MTliNGY1MGJlODRhYWZhMzFhNjZhYTJlZDlmZDllL3RhYmxlcmFuZ2U6ZTYxOWI0ZjUwYmU4NGFhZmEzMWE2NmFhMmVkOWZkOWVfNC0xLTEtMS0yOTgwMw_3d7f05db-5327-45ee-a115-18a4fae90b50"
      unitRef="usd">7062000</clbs:AssetAcquisitionCashAndCashEquivalents>
    <clbs:AssetAcquisitionNetWorkingCapital
      contextRef="icbaa2961421947beb045865325d7915f_I20220915"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmU2MTliNGY1MGJlODRhYWZhMzFhNjZhYTJlZDlmZDllL3RhYmxlcmFuZ2U6ZTYxOWI0ZjUwYmU4NGFhZmEzMWE2NmFhMmVkOWZkOWVfNS0xLTEtMS0yOTgwMw_384f19d3-5402-4919-97d4-154038f95449"
      unitRef="usd">1690000</clbs:AssetAcquisitionNetWorkingCapital>
    <clbs:AssetAcquisitionOtherLiabilities
      contextRef="icbaa2961421947beb045865325d7915f_I20220915"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmU2MTliNGY1MGJlODRhYWZhMzFhNjZhYTJlZDlmZDllL3RhYmxlcmFuZ2U6ZTYxOWI0ZjUwYmU4NGFhZmEzMWE2NmFhMmVkOWZkOWVfNi0xLTEtMS0yOTgwMw_ca645968-5a39-44ba-af29-cb30ecd52560"
      unitRef="usd">22000</clbs:AssetAcquisitionOtherLiabilities>
    <clbs:AssetAcquisitionAcquiredInProcessResearchAndDevelopment
      contextRef="icbaa2961421947beb045865325d7915f_I20220915"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmU2MTliNGY1MGJlODRhYWZhMzFhNjZhYTJlZDlmZDllL3RhYmxlcmFuZ2U6ZTYxOWI0ZjUwYmU4NGFhZmEzMWE2NmFhMmVkOWZkOWVfNy0xLTEtMS0yOTgwMw_35ae0649-ebdd-44ff-ae2b-77a42ba82bb0"
      unitRef="usd">30393000</clbs:AssetAcquisitionAcquiredInProcessResearchAndDevelopment>
    <clbs:AssetAcquisitionIntangibles
      contextRef="icbaa2961421947beb045865325d7915f_I20220915"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmU2MTliNGY1MGJlODRhYWZhMzFhNjZhYTJlZDlmZDllL3RhYmxlcmFuZ2U6ZTYxOWI0ZjUwYmU4NGFhZmEzMWE2NmFhMmVkOWZkOWVfOC0xLTEtMS0yOTgwMw_5bff1f5c-8103-4ebd-96cf-c0fea66ef47c"
      unitRef="usd">355000</clbs:AssetAcquisitionIntangibles>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="iac5cf83f8935401bb2f5aca604012ece_D20220915-20220915"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80MC9mcmFnOjY4ZTI5NGUyOGUxMjQ2NzJhMzg3YzZiMWE2YWFkZDU5L3RhYmxlOmU2MTliNGY1MGJlODRhYWZhMzFhNjZhYTJlZDlmZDllL3RhYmxlcmFuZ2U6ZTYxOWI0ZjUwYmU4NGFhZmEzMWE2NmFhMmVkOWZkOWVfMTAtMS0xLTEtMjk4MDM_ae5babd8-ed89-4cbd-8ac4-bc4bcf475290"
      unitRef="usd">36098000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RleHRyZWdpb246ZDQ0NTRhMTQ3NjU5NDkxM2IyMTlmNTA3MDc5M2JmMGFfNjM3_8bc0ea79-acbe-420c-98d9-c386eed8a33c">Available-for-Sale-Securities&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:360.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:361.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RleHRyZWdpb246ZDQ0NTRhMTQ3NjU5NDkxM2IyMTlmNTA3MDc5M2JmMGFfNjMx_8535841a-4219-4b82-a52a-7e5e5c1e83fc">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib7bcd8f5631a452dbabbd9fc97bbc4d8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfMy0xLTEtMS0yOTgwMw_3e378253-eb68-45de-b46d-c01fbd1080ad"
      unitRef="usd">37267000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib7bcd8f5631a452dbabbd9fc97bbc4d8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfMy0zLTEtMS0yOTgwMw_77a32c04-161e-4a3f-8fba-975a3cfdb91f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib7bcd8f5631a452dbabbd9fc97bbc4d8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfMy01LTEtMS0yOTgwMw_b24cf3dc-6aad-4d09-8351-c7ff03f918d5"
      unitRef="usd">29000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib7bcd8f5631a452dbabbd9fc97bbc4d8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfMy03LTEtMS0yOTgwMw_db975066-debb-4a0c-a543-15f617ec1326"
      unitRef="usd">37238000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ied1922d4661541beb53e95573627a550_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfMy05LTEtMS0yOTgwMw_1163ebad-a610-4d9b-9341-a7352fcab800"
      unitRef="usd">44308000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ied1922d4661541beb53e95573627a550_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfMy0xMS0xLTEtMjk4MDM_2eb1a808-d1ce-4466-b282-615fe20464b0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ied1922d4661541beb53e95573627a550_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfMy0xMy0xLTEtMjk4MDM_776d0e9d-55b4-414b-8bae-fa7672efc7a1"
      unitRef="usd">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ied1922d4661541beb53e95573627a550_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfMy0xNS0xLTEtMjk4MDM_e51691e7-8c69-425b-95ae-17c30b8edcc6"
      unitRef="usd">44291000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iab073f0d92e84ba6a575d902b1c5e90b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNC0xLTEtMS0yOTgwMw_8e092d23-3e54-48db-b0fd-5b8e70843681"
      unitRef="usd">5328000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iab073f0d92e84ba6a575d902b1c5e90b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNC0zLTEtMS0yOTgwMw_298f8035-dc8a-437b-8ea1-e50b1bb117bd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iab073f0d92e84ba6a575d902b1c5e90b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNC01LTEtMS0yOTgwMw_5b6270a9-26e6-47ea-9e94-304090bd3486"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iab073f0d92e84ba6a575d902b1c5e90b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNC03LTEtMS0yOTgwMw_2278e9dd-4d40-4a9a-b372-9d8a7433f00b"
      unitRef="usd">5328000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib5bdf116a27d45e4852970a908a1c9d5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNC05LTEtMS0yOTgwMw_70a044e7-96dd-4d23-ba94-f4d96dce96dc"
      unitRef="usd">7953000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib5bdf116a27d45e4852970a908a1c9d5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNC0xMS0xLTEtMjk4MDM_dff32b6d-78e9-4a3d-8c7c-3b07fbcf6ba1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib5bdf116a27d45e4852970a908a1c9d5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNC0xMy0xLTEtMjk4MDM_33771511-3257-4ef0-be1d-fe6b08f8fa1b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib5bdf116a27d45e4852970a908a1c9d5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNC0xNS0xLTEtMjk4MDM_5c9dee7a-8fc8-48a4-aefa-6f9a8457988c"
      unitRef="usd">7953000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4fe5dff51cd045c6a67c3d6af3c855d4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNS0xLTEtMS0yOTgwMw_4cb75444-c61b-491c-bebc-b22b38ddbb00"
      unitRef="usd">12666000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4fe5dff51cd045c6a67c3d6af3c855d4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNS0zLTEtMS0yOTgwMw_1e4bc7e1-68be-4692-a416-0ac917fa8d61"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4fe5dff51cd045c6a67c3d6af3c855d4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNS01LTEtMS0yOTgwMw_7cba934b-efc6-4b52-840e-5efbfddfb4b3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4fe5dff51cd045c6a67c3d6af3c855d4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNS03LTEtMS0yOTgwMw_f5499d4f-8938-4c10-8e6d-37f939b1d2fb"
      unitRef="usd">12666000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i66c395e4236040e08deda6719527e329_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNS05LTEtMS0yOTgwMw_09b1c6e0-e367-430f-a425-e23de0f0d36e"
      unitRef="usd">4871000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i66c395e4236040e08deda6719527e329_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNS0xMS0xLTEtMjk4MDM_c3f1214a-38dd-423b-8fe0-2c6112439b69"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i66c395e4236040e08deda6719527e329_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNS0xMy0xLTEtMjk4MDM_1422072c-fd78-47a7-95e0-997bb3777ea0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i66c395e4236040e08deda6719527e329_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNS0xNS0xLTEtMjk4MDM_e6fa9e32-0f97-47fd-a2e6-4aa27a0cd4ae"
      unitRef="usd">4871000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3379968f199147d999b83005f594ec07_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNi0xLTEtMS0yOTgwMw_5d40633a-f7af-4d18-a12a-afa9760be6dd"
      unitRef="usd">349000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3379968f199147d999b83005f594ec07_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNi0zLTEtMS0yOTgwMw_68f98f40-7f06-40fc-b1a6-1699c9b0adc9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3379968f199147d999b83005f594ec07_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNi01LTEtMS0yOTgwMw_e3a46c05-6d91-453e-93ab-a244809bd40e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3379968f199147d999b83005f594ec07_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNi03LTEtMS0yOTgwMw_1a12ff00-acd6-4a3d-943f-2646ec7c882b"
      unitRef="usd">349000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib8ffd44b3aa94c9a96419561b18f7289_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNi05LTEtMS0yOTgwMw_8c1bf105-d6d0-4440-80d5-a23377976d3a"
      unitRef="usd">7626000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib8ffd44b3aa94c9a96419561b18f7289_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNi0xMS0xLTEtMjk4MDM_e6bbf29f-9dea-41fa-b9e7-bdb36bf2fb29"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib8ffd44b3aa94c9a96419561b18f7289_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNi0xMy0xLTEtMjk4MDM_59787819-5c12-4d2b-acc1-9fdfa23c721d"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib8ffd44b3aa94c9a96419561b18f7289_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfNi0xNS0xLTEtMjk4MDM_707e6235-1e0d-4265-bed1-b3d98746a243"
      unitRef="usd">7625000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfOC0xLTEtMS0yOTgwMw_eb2b7500-eded-4f09-835a-47eeb197ad64"
      unitRef="usd">55610000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfOC0zLTEtMS0yOTgwMw_60ab006b-4c5a-4e8a-b2e0-03b2789b5cb2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfOC01LTEtMS0yOTgwMw_69005b4c-9943-41c1-80ee-fc94893b8ae6"
      unitRef="usd">29000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfOC03LTEtMS0yOTgwMw_9f42ad13-0ba6-4fd6-bd85-864b5596c03f"
      unitRef="usd">55581000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfOC05LTEtMS0yOTgwMw_1cf19b8e-452d-45a2-890d-31421677ae63"
      unitRef="usd">64758000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfOC0xMS0xLTEtMjk4MDM_6a4881b2-20c7-4d7f-ac2b-0a2f8d4f4edc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfOC0xMy0xLTEtMjk4MDM_392f82c5-491c-46ac-8c78-00fdeb16a33e"
      unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjlmYWU2YzE3Mjg2ODQ1YzE4ODk4YjgxNzlkYTc4YTNlL3RhYmxlcmFuZ2U6OWZhZTZjMTcyODY4NDVjMTg4OThiODE3OWRhNzhhM2VfOC0xNS0xLTEtMjk4MDM_fdf87a98-efb8-4dd8-8aaf-78e8ccf95f95"
      unitRef="usd">64740000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RleHRyZWdpb246ZDQ0NTRhMTQ3NjU5NDkxM2IyMTlmNTA3MDc5M2JmMGFfNjMy_64009e95-d378-4241-9cb0-9b12bb406b30">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:360.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjk5NWE5OGQ5YmU2YzRjMmE4ODkyMDY5ZmM1MGQzNWU0L3RhYmxlcmFuZ2U6OTk1YTk4ZDliZTZjNGMyYTg4OTIwNjlmYzUwZDM1ZTRfMS0xLTEtMS0yOTgwMw_48015862-ffd2-4825-9c28-dc9271356e7b"
      unitRef="usd">22641000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjk5NWE5OGQ5YmU2YzRjMmE4ODkyMDY5ZmM1MGQzNWU0L3RhYmxlcmFuZ2U6OTk1YTk4ZDliZTZjNGMyYTg4OTIwNjlmYzUwZDM1ZTRfMS0zLTEtMS0yOTgwMw_37740375-ac82-4f4f-837a-300623beff8c"
      unitRef="usd">27668000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjk5NWE5OGQ5YmU2YzRjMmE4ODkyMDY5ZmM1MGQzNWU0L3RhYmxlcmFuZ2U6OTk1YTk4ZDliZTZjNGMyYTg4OTIwNjlmYzUwZDM1ZTRfMi0xLTEtMS0yOTgwMw_78fe2543-e610-4125-b5dd-a5c672688387"
      unitRef="usd">32940000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjk5NWE5OGQ5YmU2YzRjMmE4ODkyMDY5ZmM1MGQzNWU0L3RhYmxlcmFuZ2U6OTk1YTk4ZDliZTZjNGMyYTg4OTIwNjlmYzUwZDM1ZTRfMi0zLTEtMS0yOTgwMw_072d11ce-840b-415f-91b4-ffe0bfee1bb5"
      unitRef="usd">37072000</us-gaap:MarketableSecurities>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjk5NWE5OGQ5YmU2YzRjMmE4ODkyMDY5ZmM1MGQzNWU0L3RhYmxlcmFuZ2U6OTk1YTk4ZDliZTZjNGMyYTg4OTIwNjlmYzUwZDM1ZTRfMy0xLTEtMS0yOTgwMw_3cfc1401-e836-497f-8705-96cea39d3575"
      unitRef="usd">55581000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjk5NWE5OGQ5YmU2YzRjMmE4ODkyMDY5ZmM1MGQzNWU0L3RhYmxlcmFuZ2U6OTk1YTk4ZDliZTZjNGMyYTg4OTIwNjlmYzUwZDM1ZTRfMy0zLTEtMS0yOTgwMw_987d85cc-400b-4d1d-aa1b-9899b3d88fd7"
      unitRef="usd">64740000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RleHRyZWdpb246ZDQ0NTRhMTQ3NjU5NDkxM2IyMTlmNTA3MDc5M2JmMGFfNjI2_bfd66f61-cc9c-45ea-9669-6152424a8bee">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:361.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjE1ZjcxYjZhNzRhZTRjNGRhOTMxNWUxNmE5MTUwMzFlL3RhYmxlcmFuZ2U6MTVmNzFiNmE3NGFlNGM0ZGE5MzE1ZTE2YTkxNTAzMWVfMi0xLTEtMS0yOTgwMw_d881a086-98a4-4d69-9077-77601f1389f9"
      unitRef="usd">55610000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjE1ZjcxYjZhNzRhZTRjNGRhOTMxNWUxNmE5MTUwMzFlL3RhYmxlcmFuZ2U6MTVmNzFiNmE3NGFlNGM0ZGE5MzE1ZTE2YTkxNTAzMWVfMi0zLTEtMS0yOTgwMw_b37efac4-f6d7-4d72-b545-d1b9e37fedde"
      unitRef="usd">55581000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjE1ZjcxYjZhNzRhZTRjNGRhOTMxNWUxNmE5MTUwMzFlL3RhYmxlcmFuZ2U6MTVmNzFiNmE3NGFlNGM0ZGE5MzE1ZTE2YTkxNTAzMWVfMy0xLTEtMS0yOTgwMw_c9a4cf4b-a2a2-4b28-9bf8-6d0f71a61ff9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjE1ZjcxYjZhNzRhZTRjNGRhOTMxNWUxNmE5MTUwMzFlL3RhYmxlcmFuZ2U6MTVmNzFiNmE3NGFlNGM0ZGE5MzE1ZTE2YTkxNTAzMWVfMy0zLTEtMS0yOTgwMw_41edf229-93f4-480b-abc8-9589dc7d15d2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjE1ZjcxYjZhNzRhZTRjNGRhOTMxNWUxNmE5MTUwMzFlL3RhYmxlcmFuZ2U6MTVmNzFiNmE3NGFlNGM0ZGE5MzE1ZTE2YTkxNTAzMWVfNC0xLTEtMS0yOTgwMw_91d222cc-9bfc-46bf-887e-09ec6a583149"
      unitRef="usd">55610000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80My9mcmFnOmQ0NDU0YTE0NzY1OTQ5MTNiMjE5ZjUwNzA3OTNiZjBhL3RhYmxlOjE1ZjcxYjZhNzRhZTRjNGRhOTMxNWUxNmE5MTUwMzFlL3RhYmxlcmFuZ2U6MTVmNzFiNmE3NGFlNGM0ZGE5MzE1ZTE2YTkxNTAzMWVfNC0zLTEtMS0yOTgwMw_198d64ac-0850-4456-9712-4fa208152c27"
      unitRef="usd">55581000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RleHRyZWdpb246MDBkYTA3NTMxZWI5NDkxYzk1YzczODc3OGFiZjFiZmZfNDM5ODA0NjUxMTU3Mg_2a526786-3764-44ad-b6e0-15e8d0fd2fc2">Property and Equipment&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:505.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:363.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(417)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s results included depreciation expense of approximately $30&#160;thousand and $7&#160;thousand for the three months ended March&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RleHRyZWdpb246MDBkYTA3NTMxZWI5NDkxYzk1YzczODc3OGFiZjFiZmZfNDM5ODA0NjUxMTU3Mw_7d60e38a-48e5-4690-a1ed-0b6310089b28">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:505.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:363.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(417)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idb513457df6349bbb925697c05f89164_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfMi0xLTEtMS00MjU5Nw_7ca6dacd-678a-43f1-883b-e1e88d868e49"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if531ec7b0d1a4289a1d93db89b2325ff_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfMi0zLTEtMS00MjU4OA_5d41bd85-d9f3-4b20-8a38-b09387680bdd"
      unitRef="usd">25000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if3aa127bddd44877959f1946f1b707a1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfMy0xLTEtMS00MjU5Nw_17da85c8-f7de-4c52-9fd6-3d5fbc2d890a"
      unitRef="usd">589000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iea3f0934334b47bfbb1b2334acb69624_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfMy0zLTEtMS00MjU4OA_7d5b7e91-81f7-4b5a-986c-57d467cf6bef"
      unitRef="usd">589000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i19bc8aae9d6b47a3a7633a871fba31ca_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfNC0xLTEtMS00MjU5Nw_ce074fa1-816c-4499-8a5c-821235313e22"
      unitRef="usd">72000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iae124bfea4fe4e4d85a6e62fb5a67fa4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfNC0zLTEtMS00MjU4OA_7f94f88f-ecf0-45e0-8d52-77dba189589e"
      unitRef="usd">99000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfNS0xLTEtMS00MjU5Nw_79809b63-dd23-4eca-8925-5b34a0c5c10f"
      unitRef="usd">661000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfNS0zLTEtMS00MjU4OA_ff0b85c9-cdb1-4727-8df0-9b986020a700"
      unitRef="usd">713000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfNi0xLTEtMS00MjU5Nw_08f36585-464a-4316-a263-7c119d015713"
      unitRef="usd">399000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfNi0zLTEtMS00MjU4OA_4625e40a-db95-4894-a63f-f5082e54244b"
      unitRef="usd">417000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfNy0xLTEtMS00MjU5Nw_681fc4a9-5883-4a99-9d9a-4e72b8792deb"
      unitRef="usd">262000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RhYmxlOjJiYmMyMDQyYmE0MTQ3OTNhNTBkMGE2NWFjOTg1ZDgwL3RhYmxlcmFuZ2U6MmJiYzIwNDJiYTQxNDc5M2E1MGQwYTY1YWM5ODVkODBfNy0zLTEtMS00MjU4OA_db5fba9b-ed58-48d9-bcd2-345364904349"
      unitRef="usd">296000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RleHRyZWdpb246MDBkYTA3NTMxZWI5NDkxYzk1YzczODc3OGFiZjFiZmZfMTY0OTI2NzQ0MjY5OQ_55dcf44b-c2ce-4a0e-85ca-b43a918d8fb4"
      unitRef="usd">30000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80Ni9mcmFnOjAwZGEwNzUzMWViOTQ5MWM5NWM3Mzg3NzhhYmYxYmZmL3RleHRyZWdpb246MDBkYTA3NTMxZWI5NDkxYzk1YzczODc3OGFiZjFiZmZfMTY0OTI2NzQ0MjcwNw_be3926df-8885-434e-b56e-01350fbff007"
      unitRef="usd">7000</us-gaap:Depreciation>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80OS9mcmFnOmI2NzY1ODIyMTkyYTQxNWJhZjE3NTNjOTk4ODFiYmE5L3RleHRyZWdpb246YjY3NjU4MjIxOTJhNDE1YmFmMTc1M2M5OTg4MWJiYTlfMzIz_258a0b9b-7349-4e5e-a56a-e0d5e608cbc3">Income (Loss) Per Share&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2023 and 2022, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive. At March&#160;31, 2023 and 2022, the Company excluded the following potentially dilutive securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80OS9mcmFnOmI2NzY1ODIyMTkyYTQxNWJhZjE3NTNjOTk4ODFiYmE5L3RleHRyZWdpb246YjY3NjU4MjIxOTJhNDE1YmFmMTc1M2M5OTg4MWJiYTlfMzMy_3102e226-12a5-4661-b2ab-c2e0782f058c">At March&#160;31, 2023 and 2022, the Company excluded the following potentially dilutive securities (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic3f5e8fd57334737879297c5b890af27_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80OS9mcmFnOmI2NzY1ODIyMTkyYTQxNWJhZjE3NTNjOTk4ODFiYmE5L3RhYmxlOjU2NjNkOWJiZDgzNTRhMDFhZmVkNmU4YzEyNGE1MmU5L3RhYmxlcmFuZ2U6NTY2M2Q5YmJkODM1NGEwMWFmZWQ2ZThjMTI0YTUyZTlfMi0xLTEtMS0yOTgwMw_a4766968-7aee-4fb0-b4b0-2be6e132606e"
      unitRef="shares">1493000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i94a5f2f4d8634a6482193404d866f108_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80OS9mcmFnOmI2NzY1ODIyMTkyYTQxNWJhZjE3NTNjOTk4ODFiYmE5L3RhYmxlOjU2NjNkOWJiZDgzNTRhMDFhZmVkNmU4YzEyNGE1MmU5L3RhYmxlcmFuZ2U6NTY2M2Q5YmJkODM1NGEwMWFmZWQ2ZThjMTI0YTUyZTlfMi0zLTEtMS0yOTgwMw_d53f6f90-edd6-41d7-9327-18d93e21caac"
      unitRef="shares">176000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1aa2ff8c93a14a628ddf610567129143_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80OS9mcmFnOmI2NzY1ODIyMTkyYTQxNWJhZjE3NTNjOTk4ODFiYmE5L3RhYmxlOjU2NjNkOWJiZDgzNTRhMDFhZmVkNmU4YzEyNGE1MmU5L3RhYmxlcmFuZ2U6NTY2M2Q5YmJkODM1NGEwMWFmZWQ2ZThjMTI0YTUyZTlfMy0xLTEtMS0yOTgwMw_1d48f9d1-7e8b-40e2-a733-cd25589be9d4"
      unitRef="shares">1424000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3f52a94bfea84193af9a8db010f1aa88_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80OS9mcmFnOmI2NzY1ODIyMTkyYTQxNWJhZjE3NTNjOTk4ODFiYmE5L3RhYmxlOjU2NjNkOWJiZDgzNTRhMDFhZmVkNmU4YzEyNGE1MmU5L3RhYmxlcmFuZ2U6NTY2M2Q5YmJkODM1NGEwMWFmZWQ2ZThjMTI0YTUyZTlfMy0zLTEtMS0yOTgwMw_741101ec-ccdb-40bd-b02e-7a8922a5ecf5"
      unitRef="shares">1424000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if3d4362e69d54f54aaad194fd8645f31_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80OS9mcmFnOmI2NzY1ODIyMTkyYTQxNWJhZjE3NTNjOTk4ODFiYmE5L3RhYmxlOjU2NjNkOWJiZDgzNTRhMDFhZmVkNmU4YzEyNGE1MmU5L3RhYmxlcmFuZ2U6NTY2M2Q5YmJkODM1NGEwMWFmZWQ2ZThjMTI0YTUyZTlfNS0xLTEtMS0yOTgwMw_182acfb7-fad1-42e9-befc-5fe38cbf7d3f"
      unitRef="shares">237000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i239efe19fad74784b328fdf62d219847_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl80OS9mcmFnOmI2NzY1ODIyMTkyYTQxNWJhZjE3NTNjOTk4ODFiYmE5L3RhYmxlOjU2NjNkOWJiZDgzNTRhMDFhZmVkNmU4YzEyNGE1MmU5L3RhYmxlcmFuZ2U6NTY2M2Q5YmJkODM1NGEwMWFmZWQ2ZThjMTI0YTUyZTlfNS0zLTEtMS0yOTgwMw_000121e1-1ce0-4a03-99c8-3d9c24589a6c"
      unitRef="shares">97000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RleHRyZWdpb246OTQzZTJmNWZhZGVmNGRiMThkYTczMjY5YjZlNWUzNTBfMTQ3MA_48376114-12fc-41ab-b608-63e6a00a19e1">Fair Value Measurements&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 inputs are defined as unobservable inputs for the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of March&#160;31, 2023 and December&#160;31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:116.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:12.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities - available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of cash, cash equivalents, accounts payable and accrued expenses approximate fair value as of March&#160;31, 2023 and December&#160;31, 2022, due to the short maturity nature of these items.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RleHRyZWdpb246OTQzZTJmNWZhZGVmNGRiMThkYTczMjY5YjZlNWUzNTBfMTQ3Mw_6af68cdf-d327-4c99-815d-fb4a6cbc85a5">as of March&#160;31, 2023 and December&#160;31, 2022 (in thousands):&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:116.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:12.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities - available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of cash, cash equivalents, accounts payable and accrued expenses approximate fair value as of March&#160;31, 2023 and December&#160;31, 2022, due to the short maturity nature of these items.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i5c17a022357047ff92faad6cb21667dd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfMy0yLTEtMS0yOTgwMw_25053d46-224d-4fb8-9cba-bc948ee24315"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i504afb254cc84fff8865bdb6c94dc145_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfMy00LTEtMS0yOTgwMw_2ee141c8-3921-4786-bdbf-1f81438e9f8f"
      unitRef="usd">32940000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i014d15d0d777404b8e448a8905b727ad_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfMy02LTEtMS0yOTgwMw_8109806c-8c93-42ae-9d67-c4418ae5c7af"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i039c3f49b8da4f2d9b6cefb4c7bdaac6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfMy04LTEtMS0yOTgwMw_5274424a-971b-40c3-ad19-9e5c129dd46d"
      unitRef="usd">32940000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if6f24ed5b4964736968a44cdbb684fbc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfMy0xMC0xLTEtMjk4MDM_56b5a014-bffc-4517-a2ce-e644ac544144"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ic3c9472dfe66456db347e101f7b9c855_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfMy0xMi0xLTEtMjk4MDM_db56ced5-3688-4777-965b-e2f29e77d4a2"
      unitRef="usd">37072000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i71685748225c4034a7cebd3a48175ca9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfMy0xNC0xLTEtMjk4MDM_723f0736-eaca-4821-b135-df13a0fa7592"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i51755cafee74432a96fde0a4fb4c5bfb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfMy0xNi0xLTEtMjk4MDM_c2298950-2cb8-4618-bd19-35626f57307c"
      unitRef="usd">37072000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5c17a022357047ff92faad6cb21667dd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfNS0yLTEtMS0yOTgwMw_daf23c95-ce4f-42d4-8955-9e27bb877901"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i504afb254cc84fff8865bdb6c94dc145_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfNS00LTEtMS0yOTgwMw_4cb7c312-fdff-4ec9-b0a7-29b21cf54f6d"
      unitRef="usd">32940000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i014d15d0d777404b8e448a8905b727ad_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfNS02LTEtMS0yOTgwMw_05443ef6-6c53-4db0-a3a3-58a917124ed1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i039c3f49b8da4f2d9b6cefb4c7bdaac6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfNS04LTEtMS0yOTgwMw_3bf85a21-017f-4b04-91a9-2402181ce3fe"
      unitRef="usd">32940000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if6f24ed5b4964736968a44cdbb684fbc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfNS0xMC0xLTEtMjk4MDM_68fe1ec8-bbdf-4bdc-90df-8da955e6484e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic3c9472dfe66456db347e101f7b9c855_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfNS0xMi0xLTEtMjk4MDM_ad837ebd-a316-4b7a-97fd-4fd7733b825e"
      unitRef="usd">37072000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i71685748225c4034a7cebd3a48175ca9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfNS0xNC0xLTEtMjk4MDM_f4c0a359-f882-40bf-8f32-8fc2f1710a5f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i51755cafee74432a96fde0a4fb4c5bfb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81Mi9mcmFnOjk0M2UyZjVmYWRlZjRkYjE4ZGE3MzI2OWI2ZTVlMzUwL3RhYmxlOjEwMmQ5Zjk5MGMzZTRkMjViYWZiMzAzYTE0ZTU2MzEyL3RhYmxlcmFuZ2U6MTAyZDlmOTkwYzNlNGQyNWJhZmIzMDNhMTRlNTYzMTJfNS0xNi0xLTEtMjk4MDM_71b61321-d5d6-44ef-b516-9c5181a49bac"
      unitRef="usd">37072000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RleHRyZWdpb246ZGIxODU3MjllOTdiNDc4ODkwOGZkNzYwM2IyYmUyZjlfMTE1_2c665b88-9e9c-4793-9668-ac2aad0fb431">Accrued Liabilities&lt;div style="margin-bottom:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities as of March&#160;31, 2023 and December&#160;31, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:313.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries, employee benefits and related taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities &#x2014; current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;D&amp;amp;O insurance liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical and R&amp;amp;D related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RleHRyZWdpb246ZGIxODU3MjllOTdiNDc4ODkwOGZkNzYwM2IyYmUyZjlfMTA5_09cba4b5-213f-456c-ae69-376387b26fbb">&lt;div style="margin-bottom:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities as of March&#160;31, 2023 and December&#160;31, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:313.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries, employee benefits and related taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities &#x2014; current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;D&amp;amp;O insurance liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical and R&amp;amp;D related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfMS0xLTEtMS0yOTgwMw_1f77495e-2b36-451c-bc63-64dab7352c42"
      unitRef="usd">1173000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfMS0zLTEtMS0yOTgwMw_958ad543-6171-4e54-a876-8fa2088f2c2b"
      unitRef="usd">2586000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfMi0xLTEtMS0yOTgwMw_3c63dc53-5449-4691-8592-149db33102a8"
      unitRef="usd">156000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfMi0zLTEtMS0yOTgwMw_e2517739-f94d-45e3-9a96-afd738f943e7"
      unitRef="usd">180000</us-gaap:OperatingLeaseLiabilityCurrent>
    <clbs:AccruedGrantFunding
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfMy0xLTEtMS0yOTgwMw_7f013256-89c3-4803-a631-58d541cd4d44"
      unitRef="usd">956000</clbs:AccruedGrantFunding>
    <clbs:AccruedGrantFunding
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfMy0zLTEtMS0yOTgwMw_256c0cca-c5b7-401b-8932-14a177b020d5"
      unitRef="usd">0</clbs:AccruedGrantFunding>
    <clbs:ClinicalAndRDRelatedLiabilities
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfNC0xLTEtMS0yOTgwMw_86e107af-61b5-402b-a5a4-a94443f9f4f2"
      unitRef="usd">1334000</clbs:ClinicalAndRDRelatedLiabilities>
    <clbs:ClinicalAndRDRelatedLiabilities
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfNC0zLTEtMS0yOTgwMw_b3e39fb7-3429-47aa-91aa-7feafea57b3b"
      unitRef="usd">785000</clbs:ClinicalAndRDRelatedLiabilities>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfNS0xLTEtMS0yOTgwMw_cbd90762-0aee-4b2a-8972-26475ed3b5ea"
      unitRef="usd">326000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfNS0zLTEtMS0yOTgwMw_4d277cf2-a54d-4552-8d92-e23cf3d92c68"
      unitRef="usd">177000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfNi0xLTEtMS0yOTgwMw_69afb331-dcfe-4be9-bee0-b30352e99648"
      unitRef="usd">3945000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81NS9mcmFnOmRiMTg1NzI5ZTk3YjQ3ODg5MDhmZDc2MDNiMmJlMmY5L3RhYmxlOmM0ZDQ3ZmNiMjQ3MjQ5ZGE4MTliMjQ0NTI1OTE0YmYzL3RhYmxlcmFuZ2U6YzRkNDdmY2IyNDcyNDlkYTgxOWIyNDQ1MjU5MTRiZjNfNi0zLTEtMS0yOTgwMw_2746322f-7818-4a9f-906c-572aff5f132c"
      unitRef="usd">3728000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RleHRyZWdpb246YmJmMThlNGYyZGRlNGIxODg3YzQxODQyZDQwMTQzNWFfMTE3MQ_8cbacbf3-5e04-4e69-82b0-63a1c094a6a4">Operating LeasesThe Company adopted ASU No. 2016-02, Leases (Topic 842) on January 1, 2019 and recognized leases with duration greater than 12 months on the balance sheet using the modified retrospective approach. The Company has operating leases for two offices, one of which expired on March 31, 2023 and the other expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. Each of the Company's leases includes options for the Company to extend the lease term and/or sub-lease space in whole or in part.&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-Use Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfMi0wLTEtMS0yOTgwMw_684390b7-3bb3-42c7-8a83-13f2f83e10e2"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfMi0wLTEtMS0yOTgwMw_7e944932-8384-4e08-8716-1c2ac79100ed"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Right-of-Use Asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating Lease Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNi0wLTEtMS0yOTgwMw_37de52d8-2557-479d-bbaf-f29481bcc474"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNi0wLTEtMS0yOTgwMw_69afedb4-8e13-45d2-80d7-456feaf20302"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNy0wLTEtMS0yOTgwMw_16c9c39d-ad71-40ba-bf95-bdb2e5413413"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNy0wLTEtMS0yOTgwMw_bcfccd01-1243-450c-981b-7940b87eb256"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Operating Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the weighted average remaining lease term for our operating lease was 2.5 years, and the weighted average discount rate for our operating lease was 9.625%. As of December&#160;31, 2022, the weighted average remaining lease term for our operating leases was 1.50 years, and the weighted average discount rate for our operating leases was 9.625%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under the lease agreement as of March&#160;31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:448.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <clbs:NumberOfOfficesUnderOperatingLeases
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RleHRyZWdpb246YmJmMThlNGYyZGRlNGIxODg3YzQxODQyZDQwMTQzNWFfNjg_f9f34e50-1003-4de7-992e-4696dfdb7a6c"
      unitRef="office">2</clbs:NumberOfOfficesUnderOperatingLeases>
    <clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RleHRyZWdpb246YmJmMThlNGYyZGRlNGIxODg3YzQxODQyZDQwMTQzNWFfMTE3Mg_985b9f39-e417-461a-997d-da34fcf923de">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-Use Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfMi0wLTEtMS0yOTgwMw_684390b7-3bb3-42c7-8a83-13f2f83e10e2"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfMi0wLTEtMS0yOTgwMw_7e944932-8384-4e08-8716-1c2ac79100ed"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Right-of-Use Asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating Lease Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNi0wLTEtMS0yOTgwMw_37de52d8-2557-479d-bbaf-f29481bcc474"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNi0wLTEtMS0yOTgwMw_69afedb4-8e13-45d2-80d7-456feaf20302"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNy0wLTEtMS0yOTgwMw_16c9c39d-ad71-40ba-bf95-bdb2e5413413"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNy0wLTEtMS0yOTgwMw_bcfccd01-1243-450c-981b-7940b87eb256"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Operating Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfMi0xLTEtMS0yOTgwMw_2b33a763-3004-47f6-a434-30af7830d071"
      unitRef="usd">425000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfMi0zLTEtMS0yOTgwMw_5fa8bcf6-17ff-41a9-9178-eee19a93c71b"
      unitRef="usd">487000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfMy0xLTEtMS0yOTgwMw_d32d6a32-255f-4563-b080-2b39ca5ea087"
      unitRef="usd">425000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfMy0zLTEtMS0yOTgwMw_4e7895cb-462c-4355-bd25-385519727d05"
      unitRef="usd">487000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNi0xLTEtMS0yOTgwMw_15946c5d-cfef-41c6-a20c-c374c5090fa5"
      unitRef="usd">156000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNi0zLTEtMS0yOTgwMw_5af0ee4e-f682-4f73-84a6-7502268faf1b"
      unitRef="usd">180000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNy0xLTEtMS0yOTgwMw_407b5fe9-3aed-45a7-9f79-90442310c76a"
      unitRef="usd">265000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfNy0zLTEtMS0yOTgwMw_0706f4fc-c303-43bf-a533-92f9ad03aa45"
      unitRef="usd">305000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfOC0xLTEtMS0yOTgwMw_31c1b0f0-f986-41df-9d5b-d80f46acf070"
      unitRef="usd">421000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOmNkNDNiZTA4NTk1ODRkY2U4N2EyNzY0MDg1NWQzOTkwL3RhYmxlcmFuZ2U6Y2Q0M2JlMDg1OTU4NGRjZTg3YTI3NjQwODU1ZDM5OTBfOC0zLTEtMS0yOTgwMw_a9560b05-ee44-4843-9c26-b95e990fcc17"
      unitRef="usd">485000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RleHRyZWdpb246YmJmMThlNGYyZGRlNGIxODg3YzQxODQyZDQwMTQzNWFfOTky_8e6d15d0-2143-41dc-997d-b694e4ee4696">P2Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RleHRyZWdpb246YmJmMThlNGYyZGRlNGIxODg3YzQxODQyZDQwMTQzNWFfMTA2NA_cf9c1116-1f3e-440d-826b-c8830f04cb6c"
      unitRef="number">0.09625</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RleHRyZWdpb246YmJmMThlNGYyZGRlNGIxODg3YzQxODQyZDQwMTQzNWFfMTE2OA_18736b3b-1736-4db4-a49c-e3bc43160940">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under the lease agreement as of March&#160;31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:448.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOjg2NTBlYzY2NWJkNDQ2Yjk5MGU0ZDJhMjA1NDUyMjc5L3RhYmxlcmFuZ2U6ODY1MGVjNjY1YmQ0NDZiOTkwZTRkMmEyMDU0NTIyNzlfNC0xLTEtMS0yOTgwMw_4027e585-ce44-406e-9ee3-34129a9af345"
      unitRef="usd">143000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOjg2NTBlYzY2NWJkNDQ2Yjk5MGU0ZDJhMjA1NDUyMjc5L3RhYmxlcmFuZ2U6ODY1MGVjNjY1YmQ0NDZiOTkwZTRkMmEyMDU0NTIyNzlfNS0xLTEtMS0yOTgwMw_c520725f-3bbf-4f68-b65e-aac1016aa650"
      unitRef="usd">190000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOjg2NTBlYzY2NWJkNDQ2Yjk5MGU0ZDJhMjA1NDUyMjc5L3RhYmxlcmFuZ2U6ODY1MGVjNjY1YmQ0NDZiOTkwZTRkMmEyMDU0NTIyNzlfNi0xLTEtMS0yOTgwMw_5ccd12de-f405-4ad3-9b7b-e4e727295fe1"
      unitRef="usd">143000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOjg2NTBlYzY2NWJkNDQ2Yjk5MGU0ZDJhMjA1NDUyMjc5L3RhYmxlcmFuZ2U6ODY1MGVjNjY1YmQ0NDZiOTkwZTRkMmEyMDU0NTIyNzlfNy0xLTEtMS0yOTgwMw_14dc4701-8eef-4922-b317-334559799f1f"
      unitRef="usd">476000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOjg2NTBlYzY2NWJkNDQ2Yjk5MGU0ZDJhMjA1NDUyMjc5L3RhYmxlcmFuZ2U6ODY1MGVjNjY1YmQ0NDZiOTkwZTRkMmEyMDU0NTIyNzlfOC0xLTEtMS0yOTgwMw_17a2d68f-7ef0-4d32-b57d-3e8e5386d17a"
      unitRef="usd">55000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl81OC9mcmFnOmJiZjE4ZTRmMmRkZTRiMTg4N2M0MTg0MmQ0MDE0MzVhL3RhYmxlOjg2NTBlYzY2NWJkNDQ2Yjk5MGU0ZDJhMjA1NDUyMjc5L3RhYmxlcmFuZ2U6ODY1MGVjNjY1YmQ0NDZiOTkwZTRkMmEyMDU0NTIyNzlfOS0xLTEtMS0yOTgwMw_67b041da-bc13-4297-ae79-e39e2bf4c242"
      unitRef="usd">421000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNjI4Mg_6d1ea461-815f-4fc0-a60a-3e107bf4c5c6">Stockholders' Equity&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 14, 2022, in connection with the merger, we implemented the Reverse Stock Split, as described in Note 1. All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from &#x201c;common stock&#x201d; to &#x201c;additional paid-in capital&#x201d; in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Issuances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;At The Market Offering Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 4, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;ATM Agreement&#x201d;) with H.C. Wainwright &amp;amp; Co., LLC, as sales agent, in connection with an &#x201c;at the market offering&#x201d; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0&#160;million. Subsequent to the filing of our Form 10-K on March 22, 2022, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $43.6&#160;million. Pursuant to General Instruction I.B.6 of Form S-3, since the aggregate market value of our outstanding common stock held by non-affiliates was below $75.0&#160;million at the time of such Form 10-K filing, the aggregate amount of securities that we are permitted to offer and sell was reduced to $17,698,943, which was equal to one-third of the aggregate market value of our common stock held by non-affiliates as of September 21, 2022. During the three months ended March&#160;31, 2023 and since inception, the Company has not issued any shares under the ATM Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Merger closing, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options and Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Merger and after giving effect to the Reverse Stock Split, the Company assumed 1,227,776 options outstanding of Cend. The options granted under the Cend Plan are exercisable at various dates as determined upon grant and will expire no more than ten years from their original date of grant. The Cend Plan stock options generally vest over a four-year term. The following table summarizes the activity for stock options and warrants for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,391,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,423,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the period:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;224.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,492,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;359.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,423,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at March 31, 2023&lt;br/&gt;or expected to vest in the future&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,486,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,423,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,207,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;344.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,423,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023 and 2022, the Company issued restricted stock for services as follows ($ in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:322.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:4.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The vesting terms of restricted stock issuances are generally between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNTcyMQ_03645692-ddcc-455a-9649-721f44f866fe"&gt;one&lt;/span&gt; and four years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023 and 2022, the Company issued restricted stock units for services as follows ($ in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:343.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock units issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock units issued &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The weighted average estimated fair value of restricted stock issued for services in the three months ended March&#160;31, 2023 and 2022 was $3.00 and $13.76 per share, respectively. The fair value of the restricted stock units was determined using the Company&#x2019;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement
      contextRef="i2d6b8752305947b19367c1e2776a4b9b_I20210604"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNDY0NQ_c387e7a6-336d-497f-b85a-25a0caf7d8f4"
      unitRef="usd">50000000</clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i8175b9d271b74085bb0ba378fb359200_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNTQ5NzU1ODIwMzU4_66614f23-6d57-494e-939c-cc883d7ee6cd"
      unitRef="usd">43600000</us-gaap:CommonStockValueOutstanding>
    <clbs:SaleOfStockAvailableForSale
      contextRef="i35acb9e033324b219fe3495ddd939d9c_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNTQ5NzU1ODIwNjU0_72e0aebf-3115-4236-8153-bc4ebea88b23"
      unitRef="usd">17698943</clbs:SaleOfStockAvailableForSale>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i6e7ec6bf429543dd8edca7c206e09fd8_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNDcwNA_c0bf2f4b-b4ef-4f65-aed3-92aed2777a77"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icbaa2961421947beb045865325d7915f_I20220915"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNDM5ODA0NjUyNDA5MA_7fcbf966-d337-4547-b035-1e29a2c491f8"
      unitRef="shares">3772768</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i997e64fe38cd4696b408c8f14ff89821_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNDM5ODA0NjUyNDEwMQ_fc8e8b6a-f62d-408a-8e89-93b838a43fd8"
      unitRef="shares">1227776</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNjI4NA_061aaa7e-97d3-463d-8f92-dfe30e2e3bd5">The following table summarizes the activity for stock options and warrants for the three months ended March&#160;31, 2023:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,391,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,423,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the period:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;224.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,492,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;359.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,423,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at March 31, 2023&lt;br/&gt;or expected to vest in the future&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,486,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,423,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,207,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;344.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,423,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMi0yLTEtMS0yOTgwMw_53874520-5cb8-4cd1-b10d-717a3940a9ac"
      unitRef="shares">1391352</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMi00LTEtMS0yOTgwMw_661c3d87-42ed-4d47-ba7a-b66f75a9914e"
      unitRef="usdPerShare">10.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i997e64fe38cd4696b408c8f14ff89821_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMi02LTEtMS0yOTgwMw_e1e0d258-589e-49b8-aafd-820be32ae753">P7Y10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMi04LTEtMS0yOTgwMw_cd4a372b-f6ed-4184-bea8-bbade034c831"
      unitRef="usd">187600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <clbs:CommonStockWarrantsShares
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMi0xMC0xLTEtMjk4MDM_633e68eb-ce38-497e-8860-5d3440f09c5b"
      unitRef="shares">1423774</clbs:CommonStockWarrantsShares>
    <clbs:WeightedAverageExercisePriceWarrantsOutstanding
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMi0xMi0xLTEtMjk4MDM_9b7ddd00-09bf-447d-8f9c-58b3b9fe4f17"
      unitRef="usdPerShare">42.57</clbs:WeightedAverageExercisePriceWarrantsOutstanding>
    <clbs:WeightedAverageRemainingContractualTermwarrantoutstanding
      contextRef="i997e64fe38cd4696b408c8f14ff89821_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMi0xNC0xLTEtMjk4MDM_67ea26a2-129a-48c0-92e1-af51473ad5c1">P3Y4M13D</clbs:WeightedAverageRemainingContractualTermwarrantoutstanding>
    <clbs:AggregateIntrinsicValueWarrantsOutstanding
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMi0xNi0xLTEtMjk4MDM_1b6a071c-2093-4a82-afc4-638391e7e5ee"
      unitRef="usd">0</clbs:AggregateIntrinsicValueWarrantsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfNS0yLTEtMS0yOTgwMw_e0b725c2-4417-4da6-b24f-0fbb79f8388f"
      unitRef="shares">103850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfNS00LTEtMS0yOTgwMw_668f4a60-7269-4520-9b53-4daf2b752fc9"
      unitRef="usdPerShare">3.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <clbs:WarrantsGranted
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfNS0xMC0xLTEtMjk4MDM_2b273b0e-5e3a-4305-8d8f-b9434f3cd5be"
      unitRef="shares">0</clbs:WarrantsGranted>
    <clbs:WeightedAverageExercisePriceWarrantsGranted
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfNS0xMi0xLTEtMjk4MDM_bbedad18-6b22-4c16-b8bd-a4a656d5a840"
      unitRef="usdPerShare">0</clbs:WeightedAverageExercisePriceWarrantsGranted>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfNy0yLTEtMS0yOTgwMw_92bba47c-728e-4a18-860d-47c179f4b009"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfNy00LTEtMS0yOTgwMw_51fcceef-dfb5-4049-aa58-f6cf5b0b10e8"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <clbs:WarrantsExercised
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfNy0xMC0xLTEtMjk4MDM_8a28983c-5179-4d66-a6c8-c4228084149f"
      unitRef="shares">0</clbs:WarrantsExercised>
    <clbs:WeightedAverageExercisePriceWarrantsExercised
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfNy0xMi0xLTEtMjk4MDM_8ec0b18e-6499-4e7e-a8cd-0477594c373e"
      unitRef="usdPerShare">0</clbs:WeightedAverageExercisePriceWarrantsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfOC0yLTEtMS0yOTgwMw_3619e71b-11ad-40be-a9c7-7674cd325d5e"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfOC00LTEtMS0yOTgwMw_a3f016f8-fda2-46dd-ab07-3954ed4c3a76"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <clbs:WarrantsCanceled
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfOC0xMC0xLTEtMjk4MDM_28c5efcf-9aca-40ae-8d13-3ca714f1eb20"
      unitRef="shares">0</clbs:WarrantsCanceled>
    <clbs:WeightedAverageExercisePriceWarrantsCanceled
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfOC0xMi0xLTEtMjk4MDM_e5123428-51cd-4d3b-a95e-86caf538fe7a"
      unitRef="usdPerShare">0</clbs:WeightedAverageExercisePriceWarrantsCanceled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfOS0yLTEtMS0yOTgwMw_a549a26a-4776-4f39-8bcf-4ffad36fb545"
      unitRef="shares">2520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfOS00LTEtMS0yOTgwMw_d297351f-d70c-4b92-ac31-27afefbd54a4"
      unitRef="usdPerShare">224.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <clbs:WarrantsExpired
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfOS0xMC0xLTEtMjk4MDM_6edaa803-13cf-4bac-b3af-25c7d7910f60"
      unitRef="shares">0</clbs:WarrantsExpired>
    <clbs:WeightedAverageExercisePriceWarrantsExpired
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfOS0xMi0xLTEtMjk4MDM_96adb97e-7c42-4513-ae34-8a57815b95ca"
      unitRef="usdPerShare">0</clbs:WeightedAverageExercisePriceWarrantsExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTAtMi0xLTEtMjk4MDM_20717567-25b1-4f6f-8bbb-859a5986fea0"
      unitRef="shares">1492682</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTAtNC0xLTEtMjk4MDM_ca0333df-82f5-4022-aad3-ba5408106032"
      unitRef="usdPerShare">9.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTAtNi0xLTEtMjk4MDM_744844b7-8cc7-496c-8e7e-ac599b0b578a">P7Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTAtOC0xLTEtMjk4MDM_711ca45b-1edf-4381-bec5-e3f7bd9f5dda"
      unitRef="usd">359400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <clbs:CommonStockWarrantsShares
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTAtMTAtMS0xLTI5ODAz_8f079c96-6a2b-4487-b7be-2daa0d1cf1ba"
      unitRef="shares">1423774</clbs:CommonStockWarrantsShares>
    <clbs:WeightedAverageExercisePriceWarrantsOutstanding
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTAtMTItMS0xLTI5ODAz_a63f5387-2c8a-40a2-9dcc-ef5813e2cc76"
      unitRef="usdPerShare">42.57</clbs:WeightedAverageExercisePriceWarrantsOutstanding>
    <clbs:WeightedAverageRemainingContractualTermwarrantoutstanding
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTAtMTQtMS0xLTI5ODAz_465cedfd-ceef-4c3c-a6b7-9e8113d46a7e">P3Y1M17D</clbs:WeightedAverageRemainingContractualTermwarrantoutstanding>
    <clbs:AggregateIntrinsicValueWarrantsOutstanding
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTAtMTYtMS0xLTI5ODAz_39617fd2-783a-4cd4-ab89-dfa7da6734b7"
      unitRef="usd">0</clbs:AggregateIntrinsicValueWarrantsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTEtMi0xLTEtMjk4MDM_54f36e11-e554-4deb-b552-9dea3dc09f83"
      unitRef="shares">1486393</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTEtNC0xLTEtMjk4MDM_ef92ba85-a368-4b72-8ee4-8bb810983a1f"
      unitRef="usdPerShare">9.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTEtNi0xLTEtMjk4MDM_f536beea-5847-4496-b4df-0ecd3631e36e">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTEtOC0xLTEtMjk4MDM_f7861414-edac-4b85-ac7d-f4a6da3c5924"
      unitRef="usd">358200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <clbs:Sharesvestedandexpectedtovest
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTEtMTAtMS0xLTI5ODAz_9f6a1190-8423-4111-8b7b-a60c1c25576b"
      unitRef="shares">1423774</clbs:Sharesvestedandexpectedtovest>
    <clbs:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTEtMTItMS0xLTI5ODAz_11e6f390-0fbb-4441-80b1-686db81ebe39"
      unitRef="usdPerShare">42.57</clbs:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest>
    <clbs:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTEtMTQtMS0xLTI5ODAz_c689ae4e-0066-407d-b7f2-4a7a7867cf3b">P3Y1M17D</clbs:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest>
    <clbs:AggregateIntrinsicValueWarrantsvestedandexpectedtovest
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTEtMTYtMS0xLTI5ODAz_7b178f4a-2560-4bb9-ac54-4bc8b82357d6"
      unitRef="usd">0</clbs:AggregateIntrinsicValueWarrantsvestedandexpectedtovest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTItMi0xLTEtMjk4MDM_745ad601-33d0-48d2-8cbb-ff02c2653832"
      unitRef="shares">1207228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTItNC0xLTEtMjk4MDM_adc94ea1-adf0-4ced-9917-2950e7e750d9"
      unitRef="usdPerShare">10.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <clbs:OptionsVestedweightedAverageRemainingContractualTerm
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTItNi0xLTEtMjk4MDM_51770c4b-6de0-40e1-b29b-2a71d01fd05d">P6Y7M20D</clbs:OptionsVestedweightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTItOC0xLTEtMjk4MDM_06e241f5-8227-420d-b6e9-b567c99e4111"
      unitRef="usd">344400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <clbs:WarrantsVested
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTItMTAtMS0xLTI5ODAz_41389543-1697-4418-aca4-04a157fcba74"
      unitRef="shares">1423774</clbs:WarrantsVested>
    <clbs:WeightedAverageExercisePriceWarrantsExercisable
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTItMTItMS0xLTI5ODAz_cdacd9c7-b858-44f0-8612-b1ef3b49b596"
      unitRef="usdPerShare">42.57</clbs:WeightedAverageExercisePriceWarrantsExercisable>
    <clbs:WeightedAverageRemainingContractualTermwarrantsvested
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTItMTQtMS0xLTI5ODAz_f2c14f2c-58da-462b-9fd6-9e16aa4f95e1">P3Y1M17D</clbs:WeightedAverageRemainingContractualTermwarrantsvested>
    <clbs:AggregateIntrinsicValueWarrantsvested
      contextRef="i8f8fffeb19c041f6af85130f51bfd2b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOjI4MTEzNmY3NTQwZTQyOTE5N2ZkZmJjZjYyY2Y5MTk5L3RhYmxlcmFuZ2U6MjgxMTM2Zjc1NDBlNDI5MTk3ZmRmYmNmNjJjZjkxOTlfMTItMTYtMS0xLTI5ODAz_4c863d55-b789-4836-ae6e-5899ceab3f04"
      unitRef="usd">0</clbs:AggregateIntrinsicValueWarrantsvested>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNjI4MQ_ac25a340-6d1f-47f7-9582-a34cf01a86a6">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023 and 2022, the Company issued restricted stock for services as follows ($ in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:322.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:4.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ifcccbb1ec967438ca65784bea06bd71c_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOmYwNWFkM2FiZjM1YTRhZTc4MTBiNjg3MmMzOWRlZDAzL3RhYmxlcmFuZ2U6ZjA1YWQzYWJmMzVhNGFlNzgxMGI2ODcyYzM5ZGVkMDNfMi0yLTEtMS0yOTgwMw_4cc81a3a-3490-4dbd-8fc8-8974f244f61b"
      unitRef="shares">159950</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="if9391ecdb3584403a88b94bdd91f8a15_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOmYwNWFkM2FiZjM1YTRhZTc4MTBiNjg3MmMzOWRlZDAzL3RhYmxlcmFuZ2U6ZjA1YWQzYWJmMzVhNGFlNzgxMGI2ODcyYzM5ZGVkMDNfMi00LTEtMS0yOTgwMw_80061ab6-ad9a-4992-881a-9f141c089151"
      unitRef="shares">70745</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ifcccbb1ec967438ca65784bea06bd71c_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOmYwNWFkM2FiZjM1YTRhZTc4MTBiNjg3MmMzOWRlZDAzL3RhYmxlcmFuZ2U6ZjA1YWQzYWJmMzVhNGFlNzgxMGI2ODcyYzM5ZGVkMDNfMy0yLTEtMS0yOTgwMw_b91f1169-0bba-40f8-ac49-a64ee6d4ae94"
      unitRef="usd">480000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="if9391ecdb3584403a88b94bdd91f8a15_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOmYwNWFkM2FiZjM1YTRhZTc4MTBiNjg3MmMzOWRlZDAzL3RhYmxlcmFuZ2U6ZjA1YWQzYWJmMzVhNGFlNzgxMGI2ODcyYzM5ZGVkMDNfMy00LTEtMS0yOTgwMw_fe1a31e2-3409-4bc4-a8d8-b1fbe23eaea8"
      unitRef="usd">973000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i0bf2527917654f82a4c8b3249bbddab5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNTcyOA_a3e74e5a-bf64-459d-842e-50764e290486">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNjI4OA_a6860201-1ced-4a8e-8a2d-7418415f3124">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023 and 2022, the Company issued restricted stock units for services as follows ($ in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:343.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock units issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock units issued &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i123fae5df7b2491e87422b22888cdec1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOmI5MTcyZmUwZTFjOTQ2ZTlhYmU0MWVkY2VhYTcwMjFmL3RhYmxlcmFuZ2U6YjkxNzJmZTBlMWM5NDZlOWFiZTQxZWRjZWFhNzAyMWZfMi0xLTEtMS0yOTgwMw_37168da3-c014-4c2b-98ea-7e18cd2eaec3"
      unitRef="shares">188850</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i6cd4f16a626841558cb57f42b71c9c60_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOmI5MTcyZmUwZTFjOTQ2ZTlhYmU0MWVkY2VhYTcwMjFmL3RhYmxlcmFuZ2U6YjkxNzJmZTBlMWM5NDZlOWFiZTQxZWRjZWFhNzAyMWZfMi0zLTEtMS0yOTgwMw_375a3cd4-3adc-42fe-b532-1155edec1c6e"
      unitRef="shares">91990</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i123fae5df7b2491e87422b22888cdec1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOmI5MTcyZmUwZTFjOTQ2ZTlhYmU0MWVkY2VhYTcwMjFmL3RhYmxlcmFuZ2U6YjkxNzJmZTBlMWM5NDZlOWFiZTQxZWRjZWFhNzAyMWZfMy0xLTEtMS0yOTgwMw_20fb614e-885f-4a77-b5af-92bdd0a922cc"
      unitRef="usd">567000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i6cd4f16a626841558cb57f42b71c9c60_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RhYmxlOmI5MTcyZmUwZTFjOTQ2ZTlhYmU0MWVkY2VhYTcwMjFmL3RhYmxlcmFuZ2U6YjkxNzJmZTBlMWM5NDZlOWFiZTQxZWRjZWFhNzAyMWZfMy0zLTEtMS0yOTgwMw_f2a6fa68-005b-43f9-b372-9bbae5dd36fb"
      unitRef="usd">1265000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ifcccbb1ec967438ca65784bea06bd71c_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNTk5Mg_4e2429b9-7ab9-4e45-930a-f9996a404462"
      unitRef="usdPerShare">3.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if9391ecdb3584403a88b94bdd91f8a15_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNTk5OQ_14e0edf7-24f0-4772-a7ec-77c495219f9f"
      unitRef="usdPerShare">13.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i123fae5df7b2491e87422b22888cdec1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82MS9mcmFnOjc5NGEwMDY5NzQwMjQ2YjhiOTRlNjI4NGIzYTA4ZmE1L3RleHRyZWdpb246Nzk0YTAwNjk3NDAyNDZiOGI5NGU2Mjg0YjNhMDhmYTVfNjIxOQ_6cc55a34-4dbf-46d3-8fdb-1701b3a7cc4f">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RleHRyZWdpb246NTM4YzI4Y2RkN2ZjNDQ3YjhmODM5YWU4YzY5MTg0NTFfMTE0Mw_2f0f7aef-f111-46a9-9a4a-04d1afaba990">Share-Based Compensation&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize share-based compensation in the form of stock options, restricted stock, and restricted stock units.&#160;The following table summarizes the components of share-based compensation expense for the three months ended March&#160;31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.166%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March&#160;31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized compensation cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected weighted-average period in years of compensation cost to be recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.47&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March&#160;31, 2023 and 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:378.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares vested&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average estimated fair value of shares granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#x2019;s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RleHRyZWdpb246NTM4YzI4Y2RkN2ZjNDQ3YjhmODM5YWU4YzY5MTg0NTFfMTE0NA_5e0edfe5-1d0b-43ca-8f3b-4a8561492949">The following table summarizes the components of share-based compensation expense for the three months ended March&#160;31, 2023 and 2022 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.166%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i787b9e2301e54c9785a066d7cd81323f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOjg2M2U5ZmY1MmVmZTQ2MTJhM2RjMTEwZmM5MGFmNjY0L3RhYmxlcmFuZ2U6ODYzZTlmZjUyZWZlNDYxMmEzZGMxMTBmYzkwYWY2NjRfMi01LTEtMS0yOTgwMw_27634cc5-bfec-4d66-b6b7-d87883e1434d"
      unitRef="usd">187000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id03152d7237c4f9b90a0fc7dd766e90b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOjg2M2U5ZmY1MmVmZTQ2MTJhM2RjMTEwZmM5MGFmNjY0L3RhYmxlcmFuZ2U6ODYzZTlmZjUyZWZlNDYxMmEzZGMxMTBmYzkwYWY2NjRfMi03LTEtMS0yOTgwMw_482d577e-258e-453d-bc44-f1bd5e2c200d"
      unitRef="usd">218000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2c93ce6862cc404f9f8ce8668c15838a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOjg2M2U5ZmY1MmVmZTQ2MTJhM2RjMTEwZmM5MGFmNjY0L3RhYmxlcmFuZ2U6ODYzZTlmZjUyZWZlNDYxMmEzZGMxMTBmYzkwYWY2NjRfMy01LTEtMS0yOTgwMw_ee0d53c7-8987-4685-b663-8df64c6438bb"
      unitRef="usd">488000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i83f0c391f25941a899f1eb4e31178bdd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOjg2M2U5ZmY1MmVmZTQ2MTJhM2RjMTEwZmM5MGFmNjY0L3RhYmxlcmFuZ2U6ODYzZTlmZjUyZWZlNDYxMmEzZGMxMTBmYzkwYWY2NjRfMy03LTEtMS0yOTgwMw_6ac22f3a-ea0d-4b19-ba55-083f8a888715"
      unitRef="usd">542000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOjg2M2U5ZmY1MmVmZTQ2MTJhM2RjMTEwZmM5MGFmNjY0L3RhYmxlcmFuZ2U6ODYzZTlmZjUyZWZlNDYxMmEzZGMxMTBmYzkwYWY2NjRfNC01LTEtMS0yOTgwMw_3deb9475-9e0f-41a5-8fff-fd97661f58f2"
      unitRef="usd">675000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9fafc530df874dedad6abc6ed00315a3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOjg2M2U5ZmY1MmVmZTQ2MTJhM2RjMTEwZmM5MGFmNjY0L3RhYmxlcmFuZ2U6ODYzZTlmZjUyZWZlNDYxMmEzZGMxMTBmYzkwYWY2NjRfNC03LTEtMS0yOTgwMw_4e06b8a4-298a-4c9c-8dcb-44377e7225e0"
      unitRef="usd">760000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RleHRyZWdpb246NTM4YzI4Y2RkN2ZjNDQ3YjhmODM5YWU4YzY5MTg0NTFfMTE1NA_1a0dc195-0df5-4e5a-bfd5-52120ed91d51">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March&#160;31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized compensation cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected weighted-average period in years of compensation cost to be recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.47&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i6d650d9bcb5a4a57b8d4315548c62afd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOmZiZjk4N2U2NDA3OTQwMDRiYjcxZmQ1NmM2N2I2MzQxL3RhYmxlcmFuZ2U6ZmJmOTg3ZTY0MDc5NDAwNGJiNzFmZDU2YzY3YjYzNDFfMS0xLTEtMS0yOTgwMw_f1bd3d5f-4bc5-42de-ac68-1bbf33ab54dd"
      unitRef="usd">1042000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i8c3f59edeb884c01895f1ea44c1ef3d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOmZiZjk4N2U2NDA3OTQwMDRiYjcxZmQ1NmM2N2I2MzQxL3RhYmxlcmFuZ2U6ZmJmOTg3ZTY0MDc5NDAwNGJiNzFmZDU2YzY3YjYzNDFfMS0zLTEtMS0yOTgwMw_b281ac99-91e7-4fd7-931b-bacfca98fa8f"
      unitRef="usd">378000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i93afe9d3f6ed4cb09390722746228408_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOmZiZjk4N2U2NDA3OTQwMDRiYjcxZmQ1NmM2N2I2MzQxL3RhYmxlcmFuZ2U6ZmJmOTg3ZTY0MDc5NDAwNGJiNzFmZDU2YzY3YjYzNDFfMS01LTEtMS0yOTgwMw_060a428d-c33d-4b29-a697-bc29e51ab916"
      unitRef="usd">459000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i1f68282f0c334dd5b5c7b36cb0d6ba8e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOmZiZjk4N2U2NDA3OTQwMDRiYjcxZmQ1NmM2N2I2MzQxL3RhYmxlcmFuZ2U6ZmJmOTg3ZTY0MDc5NDAwNGJiNzFmZDU2YzY3YjYzNDFfMi0xLTEtMS0yOTgwMw_3d245b8b-811a-4a6f-8314-c8c61cbafc83">P1Y5M1D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i123fae5df7b2491e87422b22888cdec1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOmZiZjk4N2U2NDA3OTQwMDRiYjcxZmQ1NmM2N2I2MzQxL3RhYmxlcmFuZ2U6ZmJmOTg3ZTY0MDc5NDAwNGJiNzFmZDU2YzY3YjYzNDFfMi0zLTEtMS0yOTgwMw_b73a1dc8-e871-43fd-9fc7-dd3eeff72e48">P1Y2M19D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ifcccbb1ec967438ca65784bea06bd71c_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOmZiZjk4N2U2NDA3OTQwMDRiYjcxZmQ1NmM2N2I2MzQxL3RhYmxlcmFuZ2U6ZmJmOTg3ZTY0MDc5NDAwNGJiNzFmZDU2YzY3YjYzNDFfMi01LTEtMS0yOTgwMw_aa357cd9-e3ee-48cd-942c-c0a3f8b4f4bf">P1Y5M19D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RleHRyZWdpb246NTM4YzI4Y2RkN2ZjNDQ3YjhmODM5YWU4YzY5MTg0NTFfMTE0Nw_e6aa29c4-a05a-439a-b162-8394b3ef99ee">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March&#160;31, 2023 and 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:378.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares vested&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average estimated fair value of shares granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i1f68282f0c334dd5b5c7b36cb0d6ba8e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOjg0Mjg4NWI2MWIwNTRlZTViYTUzZWVmN2Y1MDk1MjdlL3RhYmxlcmFuZ2U6ODQyODg1YjYxYjA1NGVlNWJhNTNlZWY3ZjUwOTUyN2VfMy0xLTEtMS0yOTgwMw_9f2d0dce-de3c-42a6-b2c9-2fccfec538ef"
      unitRef="usd">324000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="id704a5defa6d483f841dd1efcd484f49_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOjg0Mjg4NWI2MWIwNTRlZTViYTUzZWVmN2Y1MDk1MjdlL3RhYmxlcmFuZ2U6ODQyODg1YjYxYjA1NGVlNWJhNTNlZWY3ZjUwOTUyN2VfMy0zLTEtMS0yOTgwMw_28a9253e-fc40-46bd-8f62-d7ed79f777ec"
      unitRef="usd">377000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1f68282f0c334dd5b5c7b36cb0d6ba8e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOjg0Mjg4NWI2MWIwNTRlZTViYTUzZWVmN2Y1MDk1MjdlL3RhYmxlcmFuZ2U6ODQyODg1YjYxYjA1NGVlNWJhNTNlZWY3ZjUwOTUyN2VfNC0xLTEtMS0yOTgwMw_4864376c-5d8d-4c3a-9dfa-268daecd45f7"
      unitRef="usdPerShare">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id704a5defa6d483f841dd1efcd484f49_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl82Ny9mcmFnOjUzOGMyOGNkZDdmYzQ0N2I4ZjgzOWFlOGM2OTE4NDUxL3RhYmxlOjg0Mjg4NWI2MWIwNTRlZTViYTUzZWVmN2Y1MDk1MjdlL3RhYmxlcmFuZ2U6ODQyODg1YjYxYjA1NGVlNWJhNTNlZWY3ZjUwOTUyN2VfNC0zLTEtMS0yOTgwMw_d36be612-e55a-42c1-b0dd-90f0f14cb778"
      unitRef="usdPerShare">0.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDg3NQ_6ac1d463-f576-42ee-8b0a-12deb584949e">Income Taxes&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had approximately $281&#160;million of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an ownership change of greater than 50% over a 3-year testing period on January 25, 2021. As a result, $168.8&#160;million of the $281&#160;million  of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $112.3&#160;million of remaining Federal NOLs.  The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on January 25, 2021 will be subject to an annual limitation of $173&#160;thousand under Internal Revenue Code Section 382. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had approximately $34.0&#160;million of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an ownership change of greater than 50% on September 15, 2022. As a result of the ownership change, $88.2&#160;million of Federal &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $34.0&#160;million of remaining Federal NOLs.  The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on September 15, 2022 will be subject to an annual limitation of zero while losses incurred after September 15, 2022 will not be subject to limitations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, Cend Therapeutics had approximately $10.9&#160;million of Federal NOLs available to offset future taxable income. The Company performed an analysis and determined that there was an ownership change of greater than 50% on September 15, 2022. As of September 15, 2022 Cend has approximately $10.7&#160;million of Federal and $15.0&#160;million of state NOLs. The state NOLs will expire from the 2036 through 2042 tax years.  Using a fair market value of $36.1&#160;million and applying an applicable federal rate of 2.54% Cend will have an annual limitation of approximately $917 thousand each year. The Federal NOL of $106&#160;thousand incurred in the post-acquisition period September 15, 2022 to December 31, 2022 is not subject to limitation, and does not expire. Cend&#x2019;s wholly owned Australian subsidiary has $1.8&#160;million of NOLs which will be carried forward and do not expire. There is a full valuation allowance against the NOLs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and 2021, the Company had State NOLs available in New Jersey of $35.5&#160;million and $97.0&#160;million, respectively, California of $10.0&#160;million and $69.5&#160;million, respectively, and New York City of $1.9&#160;million and $13.0&#160;million, respectively, to offset future taxable income expiring from 2032 through 2042. In accordance with Section 382 of the Internal Revenue code, the usage of the Company&#x2019;s NOLs is limited given the change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the FASB&#x2019;s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with uncertain tax positions as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and 2021, the Company&#x2019;s uncertain tax positions were $344&#160;thousand and $0, respectively. Due to the acquisition of Cend, the Company&#x2019;s uncertain tax positions increased by $344&#160;thousand related to Federal and state credits and certain state NOLs. The Company will continue to evaluate its uncertain tax positions in future periods. As of March&#160;31, 2023, the Company does not believe there will be any material changes in its unrecognized tax positions over the next year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For years prior to 2019, the federal statute of limitations is closed for assessing tax. The Company&#x2019;s state tax returns remain open to examination for a period of three to four years from the date of filing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 5, 2023, Lisata received final approval to sell a portion of their unused New Jersey net operating losses (&#x201c;NJ NOLs&#x201d;) through the State of New Jersey Economic Development Authority's Technology Business Tax Certificate Transfer Program (the &#x201c;Program&#x201d;). The Program permits qualified companies to sell a percentage of their NJ NOLs to unrelated profitable corporations. When the NOL&#x2019;s are sold it will be a discrete event. The Company will record a deferred income tax benefit and reduce the deferred tax asset (NJ NOLs) when the transaction closes and cash is received.&lt;/span&gt;&lt;/div&gt;On August 16, 2022, the Inflation Reduction Act was signed into law. The Inflation Reduction Act includes various tax provisions, which are effective for tax years beginning on or after January 1, 2023. For tax years beginning after December 31, 2021, the Tax Cuts &amp;amp; Jobs Act of 2017 eliminated the option to deduct research and development expenditures as incurred and instead required taxpayers to capitalize and amortize them over five or 15 years beginning in 2022. Since the Company is in a net operating loss position, the capitalization of research and development costs did not have a material impact on the Company&#x2019;s results of operations for the year ended December 31, 2022. The Company will continue to monitor possible future impact of changes in tax legislation.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i9a48869ba93a417bb2d014c285a349c6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfMTY0OTI2NzQ1Nzg1MQ_dd205326-b5ff-4e99-ab85-17a7dc50436b"
      unitRef="usd">281000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="i9a48869ba93a417bb2d014c285a349c6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzY2OQ_924ecbeb-f069-4ee8-8958-3d039618df37"
      unitRef="usd">168800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i9a48869ba93a417bb2d014c285a349c6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfMTY0OTI2NzQ1Nzg3Ng_dd205326-b5ff-4e99-ab85-17a7dc50436b"
      unitRef="usd">281000000</us-gaap:OperatingLossCarryforwards>
    <clbs:OperatingLossCarryforwardsBeforeWriteDown
      contextRef="i2dc12ffc2bcf4c17a7efd9e7f1736478_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfMTY0OTI2NzQ1Nzg5OQ_ec4f5be2-450f-4860-b67b-ac63b5e020c6"
      unitRef="usd">34000000</clbs:OperatingLossCarryforwardsBeforeWriteDown>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzcxNA_d06d5b31-42dd-4fff-b1e1-a2826be21659"
      unitRef="usd">88200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <clbs:OperatingLossCarryforwardsBeforeWriteDown
      contextRef="i2dc12ffc2bcf4c17a7efd9e7f1736478_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfMTY0OTI2NzQ1NzkyMQ_ec4f5be2-450f-4860-b67b-ac63b5e020c6"
      unitRef="usd">34000000</clbs:OperatingLossCarryforwardsBeforeWriteDown>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i1ba87c90863144d990c890ebce4a437a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzcyOQ_ba9a7786-8dd1-4150-85f6-41fd835544d1"
      unitRef="usd">10900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i3a535f623a624914a6711e4e82eebafc_I20220915"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzc1OQ_146e0158-e3b8-413a-a531-ffac775a2975"
      unitRef="usd">10700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ice2ae4d365344c85a05b88a31a78ac50_I20220915"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzc0NA_03833803-c206-4088-ae45-e58fb2e3511f"
      unitRef="usd">15000000</us-gaap:OperatingLossCarryforwards>
    <clbs:FairValueMarketOfTaxNOLs
      contextRef="i3afe3e21f9e14d83ac8486daad4e1b82_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzc3NA_88f33bfc-6a03-46da-98fc-2b84ef8db6c2"
      unitRef="usd">36100000</clbs:FairValueMarketOfTaxNOLs>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i3afe3e21f9e14d83ac8486daad4e1b82_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzc4OQ_754c0e30-df87-415c-9e83-dc7df424c84c"
      unitRef="number">0.0254</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <clbs:OperatingLossCarryforwardsPostAcquisition
      contextRef="i1ba87c90863144d990c890ebce4a437a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzc5Ng_5191164e-d5d4-4d06-aa66-d0f7413c2455"
      unitRef="usd">106000</clbs:OperatingLossCarryforwardsPostAcquisition>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ia25852cf0b524a4a811255369807adc6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzgxMQ_b5b4e104-be33-4e2d-8781-cfd8e8e48667"
      unitRef="usd">1800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i35714006bb8c4a12bfdea57e263522a5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzgyNQ_5eb707af-def4-464a-8db5-e7fd3fa2048f"
      unitRef="usd">35500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i4403bf2ab03749ec86046716a8f3d4ec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzg0MA_d57d97c2-1baf-4308-b97b-898583bad415"
      unitRef="usd">97000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="iafb81e753f5344fd8594c25ddabaf02c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzg1NQ_5bd133d9-c6d2-4f9e-bf22-ab6d8b05bfc8"
      unitRef="usd">10000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ia9ffa93082d045a0bbf2f1f37390955e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzg3MA_48c53518-cc9b-4ace-b7cb-78e11db2475e"
      unitRef="usd">69500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i128ebe4deb504c3994e29fd10cb3bd21_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzg4NQ_2d2dd157-fb44-4117-9818-91134890a029"
      unitRef="usd">1900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i28c8467f29d64fef93f97e7c8af17104_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzg5OQ_3c4c597b-95b4-47ef-893a-2b81c6882009"
      unitRef="usd">13000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i724c150ab27c43fb92268e63a43d2567_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzkxNA_a7927d79-0734-4531-900f-1dd775224a98"
      unitRef="usd">344000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id4046547dd294ad49c799697f6ddb110_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzkyOQ_f3ad3a25-fe83-4753-8f5b-9305ca0ef40b"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
      contextRef="i997e64fe38cd4696b408c8f14ff89821_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83MC9mcmFnOmFjMDY1OTM1ZjQ4MTQ2MjQ4ZjMyMmVkYjc2Y2RhMDU2L3RleHRyZWdpb246YWMwNjU5MzVmNDgxNDYyNDhmMzIyZWRiNzZjZGEwNTZfNDM5ODA0NjUzNzkzMw_53c8a88d-93dd-4bb4-9c23-33c1b1a8c48c"
      unitRef="usd">344000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition>
    <clbs:ResearchAndDevelopmentTaxIncentiveTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83My9mcmFnOmJmMWU1Y2YzYzQ3MjRlYjViY2IwZjA1M2FmYWI4Y2FlL3RleHRyZWdpb246YmYxZTVjZjNjNDcyNGViNWJjYjBmMDUzYWZhYjhjYWVfNTQz_7bb76a21-14a5-4a84-97cd-c1fd18ce5fbb">Australia Research and Development Tax IncentiveThe Company&#x2019;s Australian subsidiary, which conducts core research and development activities, is eligible to receive a refundable tax incentive between 43.5% to 48.5% (depending upon the income tax rate) for qualified research and development activities. As of the three months ended March&#160;31, 2023, $1.0&#160;million was recorded as an income tax incentive receivable in the consolidated balance sheets, as the Company determined that the expenses met the eligibility criteria and the amounts claimed are expected to be received shortly after the related tax returns are filed.</clbs:ResearchAndDevelopmentTaxIncentiveTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83My9mcmFnOmJmMWU1Y2YzYzQ3MjRlYjViY2IwZjA1M2FmYWI4Y2FlL3RleHRyZWdpb246YmYxZTVjZjNjNDcyNGViNWJjYjBmMDUzYWZhYjhjYWVfMTg0_ffebcd6a-587d-44bb-b787-a94fa59bfe2f"
      unitRef="number">0.485</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83My9mcmFnOmJmMWU1Y2YzYzQ3MjRlYjViY2IwZjA1M2FmYWI4Y2FlL3RleHRyZWdpb246YmYxZTVjZjNjNDcyNGViNWJjYjBmMDUzYWZhYjhjYWVfNDM5ODA0NjUxMjEwNQ_b87ae0c7-49fe-41ff-845b-0dad3aa4ceee"
      unitRef="usd">1000000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83Ni9mcmFnOjA1ZjE4M2IxOGUzZjRiMGI5YzgzMzIyNDc4YjcyODIyL3RleHRyZWdpb246MDVmMTgzYjE4ZTNmNGIwYjljODMzMjI0NzhiNzI4MjJfMTIwNA_434a29d9-f95a-4418-86ae-8431f74d19a6">Contingencies&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, Cend received a written threat of litigation on behalf of a Chinese entity called Lingmed Limited (&#x201c;Lingmed&#x201d;) claiming Lingmed was entitled to a success fee based on Cend&#x2019;s Collaboration and License Agreement with Qilu Pharmaceuticals. Cend responded by denying that Lingmed is entitled to a success fee under the terms of their agreement. In May 2022, Cend was served with a complaint filed by Lingmed in the San Diego County Superior Court, alleging claims for breach of contract, fraud and declaratory relief. Cend&#x2019;s response to the complaint was filed on June 6, 2022. Lingmed filed an answer to Cend&#x2019;s response on July 11, 2022. The court held a case management conference on October 7, 2022, which resulted in a continuance until December 16, 2022. On December 16, 2022, the court continued the case management conference until April 7, 2023. At the April 7, 2023 case management conference, based on Lingmed reporting that it had not yet been able to effect service on an individually-named defendant through the Hague Convention, the court continued the conference until August 4, 2023. The Company denies these allegations and intends to vigorously defend against this claim.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNzgxNQ_11c98555-8a85-49bd-99d3-ec75939b39a7">License Agreements&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sanford Burnham Prebys&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (&#x201c;SBP&#x201d;) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of LSTA1. At the time the license agreement was entered into, Cend&#x2019;s founding shareholder, now a Lisata board member, was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10,000 increasing to $20,000 on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6&#160;million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, Cend entered into a license agreement with SBP under which Cend was granted an exclusive, royalty-bearing license to certain patent rights and know-how controlled by SBP. The agreement provides Cend with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $30,000 on year four of the agreement. Further, the Company could be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $23.2&#160;million. The Company is obligated to pay SBP royalties of 4% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP varying sublicense fees, ranging from 10% to 25%, dependent on when the related milestones are reached. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreements will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreements may be terminated in their entirety by the Company at any time by giving SBP sixty days&#x2019; prior written notice. The agreements may be terminated in their entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreements may be terminated in their entirety by SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreements for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SBP owned 382,030 shares of the Company&#x2019;s common stock as of March&#160;31, 2023 and is a related party. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;University of California at San Diego&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, Cend entered into a license agreement with the University of California at San Diego (&#x201c;UCSD&#x201d;) under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of nano-particles to modulate immune response. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell and otherwise exploit the patent rights. The Company could be required to make milestone payments to UCSD upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $1.2&#160;million. The Company has also agreed to pay UCSD royalties of 1.5% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company agreed to pay UCSD varying sublicense fees, ranging from 10% to 20%, dependent on when the related milestones are reached. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement will expire upon the expiration of the longest-lived patent rights. The agreement may be terminated in its entirety by the Company at any time by giving UCSD ninety days&#x2019; prior written notice. The agreement may be terminated in its entirety by UCSD if the Company, at any time, (i) fails to perform or violates any term of the agreement and fails to cure the default within sixty days. Upon termination of the agreement for any reason, UCSD may terminate a sublicensee but will allow the Company to assign any sublicenses to UCSD provided a) that the sublicensee is in good standing upon termination of the agreement with the Company; and b) the sublicensee is not currently involved in litigation as an adverse party to UCSD.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Massachusetts Institute of Technology&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, Cend entered into a license agreement with the Massachusetts Institute of Technology ("MIT") under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of tissue specific delivery of interfering RNA. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 43,236 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $25,000 for year two and three of the agreement, increasing to $50,000 on year four of the agreement and thereafter until the first commercial sale, and increasing to $150,000 each year of the agreement after the first sale. Further, the Company could be required to make milestone payments to MIT upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $5.0&#160;million. The Company has also agreed to pay MIT royalties of 2% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay MIT varying sublicense fees, ranging from 3% to 20%, depending on when the related milestones are reached. In connection with the close of the Merger, the Company was required to pay MIT a change of control fee of $0.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement will expire upon the expiration or abandonment of all valid claims. The agreement may be terminated in its entirety by the Company at any time by giving MIT six months prior written notice. The agreement may be terminated in its entirety by MIT if the Company, at any time, (i) defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice, or (ii) commits a material breach of its obligations under the agreement (aside from item (i)) and fails to cure that breach within sixty days after receipt of written notice. Upon termination of the agreement for any reason, the rights and licenses granted to the Company shall terminate and revert to MIT. Upon termination of the agreement for any reason, MIT may terminate a sublicensee but will allow the Company to assign any sublicenses to MIT provided that the sublicensee is in good standing upon termination of the agreement with the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MIT owned 43,236 shares of the Company&#x2019;s common stock as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;Research Collaboration and License Agreement&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exclusive License and Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the &#x201c;Qilu Agreement&#x201d;) in which Cend granted an exclusive license to Qilu for the development and commercialization of LSTA1 in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of LSTA1 in its Territory. In consideration for the license, Qilu made an upfront payment of $10&#160;million to Cend, which was recognized as revenue by Cend prior to the Merger. In addition, Cend received and recognized as revenue a $5&#160;million development milestone prior to the Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $95&#160;million and $125&#160;million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time &lt;/span&gt;&lt;/div&gt;period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <clbs:SharesIssuedUnderLicenseAgreement
      contextRef="idcc2b98561db4f2c9078a1c50bd84b01_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNjU1_dd76355f-eeec-41ba-92f0-7cd6c833a39f"
      unitRef="shares">382030</clbs:SharesIssuedUnderLicenseAgreement>
    <clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee
      contextRef="idcc2b98561db4f2c9078a1c50bd84b01_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfODEw_0e461721-8b35-403f-9cab-1f6a2b32af95"
      unitRef="usd">10000000</clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee>
    <clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven
      contextRef="idcc2b98561db4f2c9078a1c50bd84b01_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfODI3_faa87068-cc80-4449-9433-6cdd5f69e78f"
      unitRef="usd">20000000</clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven>
    <clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct
      contextRef="idcc2b98561db4f2c9078a1c50bd84b01_I20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfMTA1Nw_eb81d978-2d93-4598-8b7c-f04d4e94ceff"
      unitRef="usd">10600000</clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct>
    <clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales
      contextRef="idcc2b98561db4f2c9078a1c50bd84b01_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfMTExMw_c71bce8c-e1b8-4555-b524-f233402e8da9"
      unitRef="number">0.04</clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales>
    <clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="idcc2b98561db4f2c9078a1c50bd84b01_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfMTI2OA_d0d4deeb-e584-4178-82c7-4edd98d16af7"
      unitRef="usd">0.25</clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee
      contextRef="i55d91e2a703a41a4b67672acbce81809_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfMTY5MA_d6ee0a58-14a5-4283-8737-8e6713bffe44"
      unitRef="usd">20000000</clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee>
    <clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour
      contextRef="i55d91e2a703a41a4b67672acbce81809_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfMTcwOA_c153a8b1-bf8f-48a2-8940-3ce43e226444"
      unitRef="usd">30000000</clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour>
    <clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct
      contextRef="i55d91e2a703a41a4b67672acbce81809_I20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfMTk0MQ_7caf30a5-779f-470a-9b4f-f8b82612645c"
      unitRef="usd">23200000</clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct>
    <clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales
      contextRef="i55d91e2a703a41a4b67672acbce81809_I20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfMTk5NA_1d3da558-3e84-49ed-bd88-dbd5fa0799fe"
      unitRef="number">0.04</clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales>
    <clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="i9b47136928e3471f891783820d0f46a1_I20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfMjE4Ng_1c4d5386-dbd1-4d6a-ba58-011ae2e720f8"
      unitRef="usd">0.10</clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="if5743124ce7d40908442e8bd62e47009_I20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfMjE5Mg_42027c96-ab4d-49b7-b576-1a7f055676cb"
      unitRef="usd">0.25</clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <clbs:SharesHeldByThirdParty
      contextRef="i1ac540323fe04816bb43b23a4a4cd560_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfMzU3MQ_371224e8-8438-42c8-a553-4bde11470bfc"
      unitRef="shares">382030</clbs:SharesHeldByThirdParty>
    <clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct
      contextRef="i402d926e5cb44e54a8d375857d19b288_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNDMwNQ_1707b4dc-0e2e-477d-b6a3-5e880318f1f3"
      unitRef="usd">1200000</clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct>
    <clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales
      contextRef="i402d926e5cb44e54a8d375857d19b288_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNDM2Mg_ab4573eb-6a74-4f36-a294-77d293cb0aa7"
      unitRef="number">0.015</clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales>
    <clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="i73ca6b3e79144046b283ad153b819bb1_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNDU0OQ_8d36289e-9243-4ff5-a2fe-093722fd3b5f"
      unitRef="usd">0.10</clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="if616b4f4bf5141008e520b036ed05453_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNDU1NQ_8737f257-8af2-4e8e-8c50-8b71bd9742df"
      unitRef="usd">0.20</clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee
      contextRef="ie64acccae8a54473b4916dda6d9766df_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNTg3OQ_c8adbae2-8b13-44f2-8fdd-26f6a4f29e09"
      unitRef="usd">20000000</clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee>
    <clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree
      contextRef="ie64acccae8a54473b4916dda6d9766df_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNTg5Nw_cdf7fa8b-1af3-497c-91be-d6e903163329"
      unitRef="usd">25000000</clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree>
    <clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour
      contextRef="ie64acccae8a54473b4916dda6d9766df_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNTk1NQ_3bedd683-3290-44af-9b1b-9b6e758acb5e"
      unitRef="usd">50000000</clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour>
    <clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale
      contextRef="i3e38bf3272614bd784e0e3713d21241f_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNjA1NA_d1bb6490-8f7f-429e-be6a-9bed562ec5fc"
      unitRef="usd">150000000</clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale>
    <clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct
      contextRef="ie64acccae8a54473b4916dda6d9766df_I20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNjMwNQ_199db2b8-fbe2-4831-85b1-493d19224e05"
      unitRef="usd">5000000</clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct>
    <clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales
      contextRef="ie64acccae8a54473b4916dda6d9766df_I20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNjM2MQ_14b161b6-7adf-4347-88a1-73aa346ae6ea"
      unitRef="number">0.02</clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales>
    <clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="ibbe067b5df1b486281624627370f5bc7_I20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNjU1Mw_46553f5d-ee94-485f-8e99-9c455938bc8d"
      unitRef="usd">0.03</clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="i628328038b2b4904ac047c8f5980356a_I20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNjU1OQ_623118a8-5008-46d8-a7c3-e9e00c1254c2"
      unitRef="usd">0.20</clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <clbs:CollaborativeArrangementRightsAndObligationsChangeOfControlFee
      contextRef="ie64acccae8a54473b4916dda6d9766df_I20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNjcyNQ_306f1a31-a858-42b7-ac7a-29ed12e78efe"
      unitRef="usd">300000</clbs:CollaborativeArrangementRightsAndObligationsChangeOfControlFee>
    <clbs:SharesHeldByThirdParty
      contextRef="i9a3db4b42dc146229cb4171314c0ce3d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl83OS9mcmFnOjliMzk0MWZiMDAxMTQyZTRiZWQ1MTEwYThiZjkwOWFlL3RleHRyZWdpb246OWIzOTQxZmIwMDExNDJlNGJlZDUxMTBhOGJmOTA5YWVfNDM5ODA0NjUxOTQzMg_e128f50d-9eab-4552-b834-962be9926b0d"
      unitRef="shares">43236</clbs:SharesHeldByThirdParty>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8788a48508344937b3068aa082fec1c3_I20210228"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl84Mi9mcmFnOmY3NjRlYzFhZTMxMjQ2NTRiODgxNTU3MmUxOGNhM2E4L3RleHRyZWdpb246Zjc2NGVjMWFlMzEyNDY1NGI4ODE1NTcyZTE4Y2EzYThfNTk2_a145d76c-151d-4bc7-b483-6db53508fd8a"
      unitRef="usd">10000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ic152646f8baa44789d4da65765ea5a4b_D20220914-20220914"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl84Mi9mcmFnOmY3NjRlYzFhZTMxMjQ2NTRiODgxNTU3MmUxOGNhM2E4L3RleHRyZWdpb246Zjc2NGVjMWFlMzEyNDY1NGI4ODE1NTcyZTE4Y2EzYThfNzI0_966e7423-a50f-41a8-b112-afab0631f7e7"
      unitRef="usd">5000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <clbs:RevenueRemainingPerformanceObligationVariableConsiderationAmount
      contextRef="ie65ed995e0f7462e8f1737be572b0839_I20210228"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl84Mi9mcmFnOmY3NjRlYzFhZTMxMjQ2NTRiODgxNTU3MmUxOGNhM2E4L3RleHRyZWdpb246Zjc2NGVjMWFlMzEyNDY1NGI4ODE1NTcyZTE4Y2EzYThfNDM5ODA0NjUxMjgyNA_75c96fe4-c276-4b80-a429-591497fd2583"
      unitRef="usd">95000000</clbs:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <clbs:RevenueRemainingPerformanceObligationVariableConsiderationAmount
      contextRef="i0b06f28b1d2f42819f88a1b59197ea04_I20210228"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl84Mi9mcmFnOmY3NjRlYzFhZTMxMjQ2NTRiODgxNTU3MmUxOGNhM2E4L3RleHRyZWdpb246Zjc2NGVjMWFlMzEyNDY1NGI4ODE1NTcyZTE4Y2EzYThfODc3_93fb20eb-5828-4a53-af20-05323584308b"
      unitRef="usd">125000000</clbs:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <clbs:RevenuePerformanceObligationPercentageOfNetSale
      contextRef="ie65ed995e0f7462e8f1737be572b0839_I20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl84Mi9mcmFnOmY3NjRlYzFhZTMxMjQ2NTRiODgxNTU3MmUxOGNhM2E4L3RleHRyZWdpb246Zjc2NGVjMWFlMzEyNDY1NGI4ODE1NTcyZTE4Y2EzYThfOTM4_111f3cde-3900-4b32-a3cd-dbadb41f9c92"
      unitRef="number">0.10</clbs:RevenuePerformanceObligationPercentageOfNetSale>
    <clbs:RevenuePerformanceObligationPercentageOfNetSale
      contextRef="i0b06f28b1d2f42819f88a1b59197ea04_I20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl84Mi9mcmFnOmY3NjRlYzFhZTMxMjQ2NTRiODgxNTU3MmUxOGNhM2E4L3RleHRyZWdpb246Zjc2NGVjMWFlMzEyNDY1NGI4ODE1NTcyZTE4Y2EzYThfOTQ0_84ee67cc-5c67-4e57-a1f7-93b6d706724a"
      unitRef="number">0.15</clbs:RevenuePerformanceObligationPercentageOfNetSale>
    <clbs:RevenuePerformanceObligationPercentageOfSublicensingRevenues
      contextRef="ie65ed995e0f7462e8f1737be572b0839_I20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl84Mi9mcmFnOmY3NjRlYzFhZTMxMjQ2NTRiODgxNTU3MmUxOGNhM2E4L3RleHRyZWdpb246Zjc2NGVjMWFlMzEyNDY1NGI4ODE1NTcyZTE4Y2EzYThfOTk0_a7e25606-151d-449d-b47b-76ea96f148c9"
      unitRef="number">0.12</clbs:RevenuePerformanceObligationPercentageOfSublicensingRevenues>
    <clbs:RevenuePerformanceObligationPercentageOfSublicensingRevenues
      contextRef="i0b06f28b1d2f42819f88a1b59197ea04_I20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl84Mi9mcmFnOmY3NjRlYzFhZTMxMjQ2NTRiODgxNTU3MmUxOGNhM2E4L3RleHRyZWdpb246Zjc2NGVjMWFlMzEyNDY1NGI4ODE1NTcyZTE4Y2EzYThfMTAwMA_92ecf29a-06f5-4104-a41c-dea67ad380a6"
      unitRef="number">0.35</clbs:RevenuePerformanceObligationPercentageOfSublicensingRevenues>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xMDgyL2ZyYWc6YjFmODBjNWE1NWJlNDMwZTk0ODI1Yzk1NjkxZmQ0NjkvdGV4dHJlZ2lvbjpiMWY4MGM1YTU1YmU0MzBlOTQ4MjVjOTU2OTFmZDQ2OV80Mzk4MDQ2NTE0Mjk2_59959162-371a-456a-924f-d218be1eeb46">Subsequent Events&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; Sale of New Jersey Net Operating Losses &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 19, 2022, the Company received preliminary approval from the New Jersey Economic Development Authority ("NJEDA") to participate in the Technology Business Tax Certificate Transfer Program (the "Program"). The Program permits qualified companies to sell a percentage of their New Jersey net operating losses ("NJ NOLs") to unrelated profitable corporations. On April 5, 2023, the Company received final approval from the NJEDA, and it subsequently sold a portion of its NJ NOLs to a qualifying and approved buyer pursuant to the Program for net proceeds of $2.2&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgram
      contextRef="i9c7a64d6081c499fbfec9b5f2a137f04_D20230401-20230430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViZmFkMGU2ZWIyZDQ0NGViMTgxYjYxOTY0ZjliMGMyL3NlYzo1YmZhZDBlNmViMmQ0NDRlYjE4MWI2MTk2NGY5YjBjMl8xMDgyL2ZyYWc6YjFmODBjNWE1NWJlNDMwZTk0ODI1Yzk1NjkxZmQ0NjkvdGV4dHJlZ2lvbjpiMWY4MGM1YTU1YmU0MzBlOTQ4MjVjOTU2OTFmZDQ2OV80Mzk4MDQ2NTE0Mjk4_42f6bf11-9d5c-4587-b111-5c8244726c45"
      unitRef="usd">2200000</clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgram>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M00>;Q2QTG:%9PWOTAT>IX#.GMSP;K#JU]PL1PDM%.\RU93T\RCC+RR01)5
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MJ"A7=ES'R*)ZN1?28!VHFAE6:E V .>74IJGCBT&3>V?_ 502P,$%     @
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MH,:, /R_%D(?'\P'FF.S^?]02P,$%     @ -8&I5CB(<;XD P  KP@  !@
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M,,,_"E#6 +_/I32;B=V@^4>)_P!02P,$%     @ -8&I5M1=+^'H!@  KC4
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M:,D(E!9#T?K?@]T;]/K3&/2&\@NRL@GN>)YKB);AY?"@3MVWJ<LJOHD!6C8
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M]DN1C63I\3*&[L@^A:C,ZR:TSG<J[+%NC:U"5I[I.+2FL!M;0$--8_P"L!P
M?[;9TEOR/MFRVM^1_:Z\22I;6)@#0Y+T-!T90Q=%7_>53O.S^4B.A;K=V<I
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M970Y+GAM;+5;;7,;-Y+^*RAM*K&K*$J6G4W*;U6RD^RZ*J[36<GMAZO[ ,Z
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M;<9*GHT0!YL"G@8\_,4T%),@:N>(N\ '^/[>8HF5R8Q;GUIV9=:T##WUIJ*
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M-.47A'Z6C<>M[4.2\]FEVAN-T[Q/9_>C)9[+5[=N'>]IO?S@5P,*W#(=(KQ
M^8FV?K5KQD=#7ZM?7;<Y)REK=<WZ'C])%DBL])BAT^%E-!^IN!&%SF(AQ19*
M2,]@@*?@A#O#5?A$;8>TG,BX.1*/\#O0(F?_Q%$*_]!Y\2U,UVT2OU76(_J&
M2%B@!S6% C-X<?&CP1O@OPD+*7$-,_$IYN,OU8>U!/5_^_9E4%8)P;#"%D D
MFYEL0J&"DFQ"]*HP'"4NTRJ#V3+#5;@[!W;*87H&8<EC@VR6\ ^#]4U,B0Y/
M#5,MD"07+E4[K(8>_H35ATB2:0@EY1^&&7(P()'2-,S/?5DHF"7"43L#E0;F
MQGO70QTK(@.=2@L).*)5E#3W6PN..Z'R.*#Y3]@<0+T%-YCS=YQRD(;!#HFN
M?CLP5T>Y$>43@6>D)&6G]XD,X+XUFQ,TW[B]H?A9(Y95T7FI'L@7H7O-Z=>0
M &R\9K!)4JC<CK:G\(O3Z5)[4,;G+9N1QRT&3N:P"?-0T/!W%DP)1[>NGB92
MO ^G^'/:8/FYWA89\Y&($Z@($FMPU9!28A)>-HI;5*J;K:)0B<=+]0L@) MP
MY8]QW&V$[XCF9"AR'PB.RF>*\0SO9#U0UTJO;",5'$2P)G%BEG^T?EEQBM04
M?(IU<QS($0N60_ )61,3GR%1EX^5;U-])@/FA?J0L[QWC:Z^G-]6<'@*+#SJ
M'$5?10-:5YM&H-T3TE:@(H5T O@!T:0"E^-5%Z4.(EMJAMR8"Z99*V5>'%6Y
MJO"4@9!2[S3,U@=R@KY->$N9@S@;E<WG:U20I=C@&G<QJ.7.06]LD='#7(^H
MO35":N6[1F(7+2\0)X+-((<C,OH3.&9-I9O@AIP;Q)//O1"]T6%U;0ZKX@+^
M1?XT9-#9;XF?4R4XF!TD!$RM#35"DOF/_48 \>U??KQZ]L.K<.2ELZX+ON:"
MY*#2J4"0#(5D74+&R7V@H);JM,08:7XM70@^ZQ+) !+$&QR3&4Z!X5!$I:H
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MJ$C@EQTX2TR)C$B9;\&D&RCQ?-VD3NO1'1UF#JW$F<;L*I4)L4D.;QY2,UC
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;+5666_;.!#^*P,U*!)
MC21*/I+:!G*TV04:(&C:[L-B'VAY;!&A2)6DXGI__0XEV7%BQ\$"NR\V.<<W
M-S6CI38/MD!T\*N4RHZ#PKGJ/(IL7F#)[:FN4!%GKDW)'5W-(K*503YKE$H9
ML3CN1R47*IB,&MJ=F8QT[:10>&? UF7)S>H2I5Z.@R18$[Z*1>$\(9J,*K[
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M2M1SKXR&+KR6MI&/UMJ*[V6C.:_NC7(3B3F7!@3.*#3J]$\#T(T:-ANK*J]
M4V5)S_RRH \(:N= YS-%:K/>N 3M)VG\%U!+ P04    "  U@:E65 *C(MP"
M  !G!@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6R555UOVC 4_2M7
MF32U4D="0DO+  FZ3JVT:JBHZ\.T!Y-<B%7'3FVGE/WZ73LA91*@[2&)/\X]
M]QQ_W S72C^;'-'"6R&D&06YM>4@#$V:8\%,1Y4H:6:I=,$L=?4J-*5&EOF@
M0H1Q%%V$!>,R& _]V$R/AZJR@DN<:3!543"]F:)0ZU'0#;8##WR56S<0CH<E
M6^$<[6,YT]0+6Y:,%R@-5Q(T+D?!I#N8]AS> WYP7)N=-C@G"Z6>7><N&P61
M$X0"4^L8&'U>\1J%<$0DXZ7A#-J4+G"WO67_ZKV3EP4S>*W$$\]L/@HN \AP
MR2IA']3Z%AL_YXXO5<+X-ZQK;!(%D%;&JJ())@4%E_67O37KL!-P>2@@;@)B
MK[M.Y%5^89:-AUJM03LTL;F&M^JC21R7;E/F5M,LIS@[OI.I*A!.OBEC3F&&
M&N8YTS@,+9$[2)@V1-.:*#Y E,"]DC8W<",SS/Z.#TE4JRS>*IO&1PGOF>Y
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MI0F$D&"8>B4)P$ +&!R0^MK26[65>D?5W\(U7A6,457"W\;K&%G ,7&C$#3
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M1B'-'2W \Y7% 2#]( ;M]YDG_P%02P,$%     @ -8&I5B4N!6J)"P  WRD
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M+W=O<FMS:&5E=',O<VAE970R-"YX;6R55>]OVS80_5<.VC"T0&#9<M*UF6W
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MLH1KW'$-L#H26[:A(2?# =YDMY]NKI?96P@$5K@@2VE%0) F(3U@V1A2M#W
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MY"^"AN7RAU4X=F60![5>8NOI_/&CH\+)WRK)+\%V_/=!"QM0X/C'M5:H[K0
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M>1S=J3V/QQ7"0@FJ:"Z78-WFP VP76T[6NR0EMG3TD1+DS* 2TB860&3\W*
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M*DOSPYL9#6S4+H#V5TK9_<(5J/\"IO\!4$L#!!0    ( #6!J58)UUK=G (
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MELK2@/';@B8Z:N= ]RNE[,YP =IOQ/0W4$L#!!0    ( #6!J5914;C$4 ,
M $8(   9    >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;(U6;6_;-A#^*P>M
M*!I@B639<C+/-F"W*S:@08VFZ5 4^T!+9XLH1:HD%;?_?D=24A-7%?I%YLO=
M<\_QGB.]/"G]V92(%KY60II55%I;+^+8Y"56S%RI&B7M')2NF*6I/L:FUL@*
M[U2).$V2>5PQ+J/UTJ_M]'JI&BNXQ)T&TU05T]^V*-1I%4VB;N$=/Y;6+<3K
M9<V.>(?VOMYIFL4]2L$KE(8K"1H/JV@S66PS9^\-/G \F4=C<)GLE?KL)O\4
MJRAQA%!@;AT"HY\'?(E".""B\:7%C/J0SO'QN$-_[7.G7/;,X$LE_N6%+5?1
M300%'E@C[#MU^AO;?#S!7 GCOW!J;9,(\L985;7.Q*#B,ORRK^TY_(I#VCJD
MGG<(Y%F^8I:MEUJ=0#MK0G,#GZKW)G)<NJ+<64V[G/SL^FV-FEDNC_ &*3D#
M+]ZSO4!SL8PMP3NC.&^AM@$J_0G4%&Z5M*6!OV2!Q5/_F&CUW-*.VS8=!;QE
M^@JFD]\A3=+I"-ZTSW7J\:8_P6LS_+39&ZM)#O\-Y1@@9L,0KD46IF8YKB+J
M 8/Z :/U\]\F\^3/$8*SGN!L#'U]1RU7- )!'>"L,/"&LST7W'+*@,D"?/M<
MJL/E/6UNC$%K@%2^98+)'.'.*6(HOU$&P_E]IR(\%7%&17=4&MID@<H)-5+3
MYDJ3%H!+L"7"00FZ!!Q0SFK7E,9EJAK76(%VN(B8:4U)CMY5-88"F8L%D";R
MLA<%O,(<JSWJ;B4=.I<%O*7HNJ/V#&9IYKXWU_!>628&?)X8C91B 9L\UPVE
M^/A0GL$DF[OO3=*&%DH>+RWJZHE=.L]@FF0MB[&*.SH33R>#$:%EO="R7Q;:
MZ\8V5*M;+GG55&WL'?M&-R\=UCWULFX7-T>-Z)>'A#4:<5A8;>BJ#1W457>A
M&Q_:Z29LL"Z\TP<1/Y."5]R(<CXBTP;0W4WG1VT"PF0V=8,93/Y(W"#S*Z$X
M9]QFUW-R-:[^E6K<BD:?E_2H7%*MT5AXD647L L;\,!$XX_\QS8*]1VJ;/SH
M;J]0'_T+9B!W4<,UWZ_VC^0FO W?S<,+2P=VY-1S @_DFEQ=4\ET>+7"Q*K:
MOQ1[9>G=\<.2'GK4SH#V#TK9;N("]'\=UO\#4$L#!!0    ( #6!J5:G)/_[
M100  !T,   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;,U7;4_C1A#^
M*R,?NH(4.7Z+[>222.'E6CY<#P$'JJI^V-B3V,+V^G;7!/KK.[M.3("00VU5
M]0-XUSOSS#,[+YZ,5US<R0Q1P4-95')B94K5HWY?)AF63-J\QHI.%ER43-%6
M+/NR%LA2HU06?<]QPG[)\LJ:CLV["S$=\T85>847 F13EDP\'F/!5Q/+M38O
M+O-EIO2+_G1<LR5>H?I67PC:]3N4-"^QDCFO0.!B8LW<T7&HY8W 38XKN;4&
M[<F<\SN].4\GEJ,)88&)T@B,'O=X@D6A@8C&]S6FU9G4BMOK#?IGXSOY,F<2
M3WAQFZ<JFUBQ!2DN6%.H2[[Z!=?^##1>P@MI_L.JE0TB"Y)&*EZNE8E!F5?M
MDSVL[V%+(7;>4/#6"I[AW1HR+$^98M.QX"L06IK0],*X:K2)7%[IH%PI0:<Y
MZ:GIE>+)7<:+%(7\"<Z^-[EZA,-K-B]0'HW[BDQHP7ZRACMNX;PWX'SXPBN5
M23BK4DR?Z_>)6L?/V_ []O8"?F'"!M_M@>=X_AX\O_/7-WC^&WAK#W^?S:42
ME!)_[/*QA0AV0^@R&<F:)3BQJ XDBGNTIA\_N*'S:0_!H",8[$.?7E'9I4V!
MP!=@@@-?ZS9_JQ1NF1"L4A)F.IG)D5WL]^+O9G^=(2QX016:5TM0.OKK,LW_
M1 F*CMG:(LE131MBW!"3AMEJPTP?:WF5"40HVVQ G0U L4RR+IBC9^[))]^N
M,D;$X-84%*G-[E%0?X"S!Q1)+A$N1)[@Z_-+U$U(.W!"5G5P&U; -8H2#G]#
M)N01S)9+@4NF$,Y)(J?6DL -*QJ$P_,*KC/>2'*&!/\/'+XV2BI::C2FX!03
M+.<H-A?H@=OSA_0W\.  7,>.?8ALQ]>;.+)#.@X\OQ=% ;T)/'L0@6_[$6T^
M?H@]U_L$)QFKEN1EV@@3=HI:C2+GZ0A^UJ$@OUS'[\4#AS1=M]/;/#>7D;XZ
M>?FD!KK 7+U#\NRAS@7)'7J]@><<@><%FO1+L1=W\SRSM.=#KQ?&^F*&]C#0
M]^+2VA\,[6#GO;C^UKW<H-14=^+&(5VZW^*&&M<QN+'M_2-<SXEZGA>W@1PZ
M$-JAAO&#X#V$][2=0==V!N]N.Y?$D]);<VU+=%^WV0N[N]N</N7;#[N$:2XZ
MVWM&_H27-:L>(9>R(5GQQ+1M2:8YD14J3NI+<MW4)!P>0%X1PJ:X1E1HVO+V
MU^JE95-COS:FYNA67ME:<W 'P]Z02B1R>E$P6)?R'GF*8:R39ACY^P(7=H$+
M_W[@OE7Y#SX6>\'_\_ UAN\[@]@#?$BP5B!ULX:4QI]_):XMB4UTX]@T0&JT
M0ZK+MZ/[3.L !J'NM%38X6!GE/M;(UN)8FD&4PD);RK53F_=VV[VG;4CWY-X
M.SB3>TOZC$"!"U)U[(A*4K3#:+M1O#8#X)PK&B?-,J/Y'846H/,%YVJST0:Z
M7P33OP!02P,$%     @ -8&I5E$1@^C5 P  B@H  !D   !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&ULE5;;<MLV$/V5'=;3268<D:*N=27-2&Z2]B&MQW*2
MATX?(')%8DP"+ ")=KX^"Y"B*5MBG!<2E[V=W8.=G952W>L4T<!#G@D]]U)C
MBBO?UU&*.=,]6:"@FZU4.3.T58FO"X4L=DIYYH=!,/9SQH6WF+FS&[68R9W)
MN, ;!7J7YTP]KC"3Y=SK>X>#6YZDQA[XBUG!$ERC^5S<*-KYC968YR@TEP(4
M;N?>LG^U&EMY)_"%8ZE;:[!(-E+>V\U?\=P+;$"8862L!4:_/5YCEEE#%,;_
MM4VO<6D5V^N#]0\..V'9,(W7,OO*8Y/.O:D',6[9+C.WLOP3:SPC:R^2F79?
M*"O9\="#:*>-S&MEBB#GHOJSASH/+85I<$8AK!5"%W?ER$7Y!S-L,5.R!&6E
MR9I=.*A.FX+CPA9E;13=<M(SBW7*%+Y;$:X8KF5.M=;,I>O-'=MDJ-_.?$-N
MK+ ?U297E<GPC,D!?)+"I!K>BQCC8WV?PFMB# \QKL).@Y^8ZL&@?PEA$ XZ
M[ T:S -G;]")>>,PW[!'HIB!I5),)&C7E_"W%!'3*;Q_L/E ^'>YT481@?X[
ME8W*V?"T,_NHKG3!(IQ[]&HTJCUZBU]_Z8^#WSN@#!LHPR[KBS4]TGB7(;0Q
M'=6QQG J\$[3IP._2Q&V,J.GS$4"QE*D?L_\&VHP=!V1=RDHCQKD%G0KKJ@=
M%]:YI;[BU$RJ$"&OF(.6.4!UC]*F\,!$;!<AO.&"Q.5.TXE^>P5W3K5-NN>J
M3NV60+AC:RC&/36DPM7^ OK3"7W#_A0^HD#%,B?#8GIPW%;>=@X83J<P&H9P
M)PT)_!#8!8PG(_I.Q@%T5'K45'KTNDI34JL(CLI\+;4AA!DS%(^1EL)[U':S
M+)F*]:GZ=SNLG!Q!BZP3]>1D=_#!G \0TL C6I%()H(8$;L\VO*6KCUB_([M
M*;\)0H&*2]*1M(<RY507*U=;*E&ARV14N]K@D57SO,).@>F:G/H%1]9&1O?P
M3V%Q:$L%H[BS75U\%MR</&XY?9D*(LYE0(RX@,%D2M_AZ#?WWIR%,XB! GLD
M'KK7\=+D"ZC]'CGH]T+[&4XZB#1NB#1^-9$^,*[@"\MV;G>VAYRG4*>K,RW$
M\6IK/>\/GMUCTG!@TS/.P"&#=,US1[XG==W23ZB'N]N?[RD_QY]7=IP?0R7F
MA$/'GPE\?0W<$V@O(.@Y^@6]<7BRU?BM^2!'E;@I2!/A=L)4HT)SV@Q:RVJ^
M>!*OIC2"F7#*0(9;4B7'U$14-?E4&R,+-VULI*'9Q2U3&A9160&ZWTII#AOK
MH!D_%]\!4$L#!!0    ( #6!J59,JR/[J0(  !P'   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,U+GAM;+65WV_3,!#'_Q4K2 BDJDG<-0FCC=1N("K!J-8!
M#X@'-[DTUI(X\SG-X*_'=KK00=8'!'UH_./N>Y^SS_:L%?(6<P!%[LNBPKF3
M*U6?NRXF.90,QZ*&2L]D0I9,Z:[<N5A+8*EU*@N7>E[@EHQ73CRS8VL9ST2C
M"E[!6A)LRI+)[TLH1#MW?.=AX)KO<F4&W'A6LQUL0'VJUU+WW%XEY254R$5%
M)&1S9^&?+R-C;PT^<VCQJ$U,)ELA;DUGE<X=SP!! 8DR"DQ_]G !16&$-,;=
M0=/I0QK'X_:#^EN;N\YERQ N1/&%IRJ?.Y%#4LA84ZAKT;Z#0SY3HY>( NT_
M:3O;D#HD:5")\N"L"4I>=5]V?UB'(P?J/^% #P[4<G>!+.4E4RR>2=$2::RU
MFFG85*VWAN.5V92-DGJ6:S\5W^1 E@WJ443RXA(4XP6^G+E*:QL+-SGH+#L=
M^H3.!NHQ\:<C0CU*">9, CY6<359CT=[/&IE)T_(+A!U82Z2NX8CM]OX];TV
M(2L%)7X;PNSTSH;U3(F?8\T2F#NZAA'D'ISX^3,_\%Z?H)WTM)-3ZO%&B>26
M7$/=R"37I4+64NPD*T?DJBFW((G(R,8N#5DT*A>2_X"4*$&V<.25#J75!9[:
MP.:@[6.?TC ,@YF['R ^ZXG/3A.S BR5(1^1-<@$*J5/HQG\V%8@,><U89G2
M]#>25<CL:1I"["*].D+TQE,ZS#?M^:8G^2[>7%T.Q3KI]9>['/1,P3^NR> _
MT(8];7AZ!46UU[MH[U"F:8?X.@7?>[QUDTGD_?KYPQL9]1C1Z4*S93\B*\1F
MN,*C/RI\$H8T#*+? KM'EYUY-SXPN>,5D@(R[>F-0RTAN[NXZRA1V_MO*Y2^
M36TSU\\72&.@YS,AU$/'7*G]@QC_!%!+ P04    "  U@:E6<M6%-4<#  "E
M"P  &0   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6RUEFUOVS80Q[_*02N&
M!/"B!SMVFMD&G*<N0%H8];)A*/:"EDXV48I422IV]NE[E!S9VQ1V2)<W-DGQ
M_OP=>>3=>*/T9[-&M+ MA#238&UM>1Z&)EUCP<R)*E'2EUSI@EGJZE5H2HTL
MJXT*$291- P+QF4P'==C<ST=J\H*+G&NP51%P?3C!0JUF01Q\#3PD:_6U@V$
MTW')5KA >U_.-?7"5B7C!4K#E02-^228Q><7\< 9U#-^X[@Q!VUPKBR5^NPZ
MM]DDB!P1"DRMDV#T]X"7*(13(HXO.]&@7=,9'K:?U&]JY\F9)3-XJ<3O/+/K
M27 60(8YJX3]J#:_X,ZA4Z>7*F'J7]@T<X<T.:V,5<7.F @*+IM_MMUMQ(%!
MDCQCD.P,DIJ[6:BFO&*63<=:;4"[V:3F&K6KM37!<>E.96$U?>5D9Z>+YC1
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MJ-T$^IXK99\Z;H&V,I]^!5!+ P04    "  U@:E63\KX9[,$  #,%@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6S%F&]OZC84QK^*E5UMK73;_(,
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MYFUS-$:=.L<NQ>8=B35H]6M:_8[KL]\EQR[%YAV)-3@&-<?@?ZS/X*A4_,'
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M/;:]]^90O^>]IV+%,DD26**\<SG 7UJ4KT[+"\7SXF7B@BO%TZ(9 \63G7X
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M,N2GK^E/-Y+M\F^Z5TQ*EN276X+7A&< ]?F&,?E\DWUY7OY8,O\/4$L#!!0
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MCP!I"G ]%T*_3$P;ZO\ZZ5]02P,$%     @ -8&I5IELRP'6 @  VPD  !D
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MY^YY?(Z.V8[Q!Q$#2/28)E3,K5C*[-2V11A#BL4)RX"J-VO&4RS5EF]LD7'
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MJB'7+&/U'0)<.ZCW:\;D?J,35%\VP5]02P,$%     @ -8&I5N=4=A-@ P
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M(6G3W=UT&QVWMMW6MEOI>?]@^^?U7&F)^^I7G[U:;]BO9VKM4A4T@;&%Q:1
MKL&*CS\XP>"JS^Q_$MNQ[K76O4/J\8QR*M'O&8&LX.(%@,PAAR73BN#:8FER
MJG%J-'V&WH6NY8-*WAP2Z]AQ0ES3];;#;I#K1T$;M$,^;,F'!\EO"Y!4LWQ%
M.&#E$KZU>,<?(M=QK[!DI(1<]W'7XOXVMQ_L8??$1(-^:K^E]@]23X]I5ES=
M8OVH4M(\V>'NX_0[#!<=SF[,&Y1!2QD<I)Q@!TLHK[; ?84\;;?".\!!=](\
M;[A'W T*([^?.6R9P\/[0:<@^X#"SEB>NS^#W1@G#/MYHI8G.LCS(+29P.9H
M>6?2HDZ!>!=#?P^R)RATHSU*>^OT-S<O'K4KW&Q8)$M,&YR':%+6MUG=T**H
M+H2YT'B]5(\I?@" - 'X?BF$?FV8.Z;]I(C_ %!+ P04    "  U@:E62\/O
MRU4"  "+!0  &0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6R55%UOTS 4
M_2M6D-"0H/GHQZ"DD=9-""08U2;8 ^+!36X::[$=[)MV^_=<.VE4H*W$2^)[
M[7/N.;:OTYTVC[8"0/8D:V470878S,/0YA5(;D>Z 44SI3:2(X5F$]K& "\\
M2-9A$D6S4'*A@BSUN97)4MUB+12L#+.ME-P\+Z'6NT40!_O$G=A4Z!)AEC9\
M _> WYJ5H2@<6 HA05FA%3-0+H*K>+Z<NO5^P7<!.WLP9L[)6NM'%WPJ%D'D
M!$$-.3H&3K\M7$-=.R*2\:OG#(:2#G@XWK-_\-[)RYI;N-;U@RBP6@1O U9
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MQ@3+%US505Y?4RH.)RI L_<Y^P]02P,$%     @ -8&I5O.,,=H$!P  +#(
M !D   !X;"]W;W)K<VAE971S+W-H965T-#DN>&ULM9M9;]LX$,>_"N%=[+9
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M-DUU OQH 7[XC/D13\";.\K]($S>BF;?'N_ FS_?7DZX""4U.)D7;F]RM^B
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MF'3H77B0X(*M,G,OUU^PUN,2C&6FW1?6M6_'@WBEC<QK,&60<U']V4M=ART
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M]-=[U1J]D[00?[O0U])]M[1>(]Z(=9+2TYY:! 3E][0W_>F':!C^XL(&*4:
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MH-1LKL9A8'B'@?<=1CP8.'=@T(<9CKPG(]\=%6P<!O8[C'9W3?),#;W,$N?
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MU2Y!!Z50-#?+5F]'?KU]O';9?FW!O\F=JPJZG &41J%H;O&MZH_(T=LEJ%$
M2HM!:12*YM9RX^D'?C=AKW8):B/4-._5@!AT2 I%6^6XO_%LG/+11[=,SM)"
MH8Q/#3XX/3-GSG+U-*'5&RWFU>-R'H36(J]>)IQ-N"P_8/X^%4(_ORF?P+-^
MIM/H/U!+ P04    "  U@:E6GHF<67T#  "5#P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970U-RYX;6S%5VMOTS 4_2M60 BDT3SZV#K:2K ),0G$V'A\0'QP
MT]O&PK&+[;3CWW.=I%G*7(M )?JAB1.?XWN.[9OKR5:J[SH#,.0NYT)/@\R8
M]7D8ZC2#G.J>7(/ -TNI<FJPJ5:A7BN@BQ*4\S")HE&84R:"V:1\=JUF$UD8
MS@1<*Z*+/*?JYRO@<CL-XF#WX(:M,F,?A+/)FJ[@%LRG];7"5MBP+%@.0C,I
MB(+E-'@9GU_$ PLH>WQFL-6M>V*ES*7\;AM7BVD0V8B 0VHL!<7+!BZ <\N$
M<?RH28-F3 MLW^_87Y?B4<R<:KB0_ M;F&P:G 5D 4M:<',CMV^@%C2T?*GD
MNOPGV[IO%)"TT$;F-1@CR)FHKO2N-J(%0*%N0%(#DC\%]&M OQ1:15;*NJ2&
MSB9*;HFRO9'-WI3>E&A4PX2=QENC\"U#G)G=@ :JTHR@#YS.I:*5NV)!WK(4
MIPO(RY4"P)DSY.DE&,JX?D:>DP^,%WC9=7I./MU>DJ>/GY''A GR,9.%1A(]
M"0U&:<<*TSJB5U5$R8&(;F'=(_'@A"11DCC@%W[X:YCW2')6PN-]>(C>- 8E
MC4%)R=<_P-?R98->*$7%JG+#>M1NOS<9*&(R*L@^Z.M;Y"17!G+]S>5'%<#
M'8#=Q^=Z35.8!KA1-:@-!+,GC^)1],+ESI'(]KSJ-U[U?>SHE3 *-R:N89/5
MJQ?4">&,SAEGYJ=+O9>RJ_J*;%22V0RVF<41_B;AQB%KT,@:>&7=P 9$ 62I
M9$[26J-+RN#!Z,/VX%6(WK'^<H*&C9*A5\D[)EA>Y*[8O<"NTW DLCV-HT;C
MZ']OV-$QO3H2V9Y7IXU7I][U\)DJW)H<[*K6; &[[)_+0AA]@A\<#KB)!3CS
MN)>[JPVG#_;.>'APYYXU^LZ\^JY!X>?)8#U"Y)((K(HTY>#2XN7IJJ4B&[>T
M1+W8K63<*!EW4**+.2\_O$RLL)@JTY-SBKRD766-7;(2MZXXNB] (G].HG>'
M<I(?V37\8['MZVP56O'_SDMU!,?RZTAL^W[=UUVQMU3YQ]SD)^]L1?*PKD@.
MIZ?XOF"*_173GR<H/U%G07W77AX>D'-?*,7^2NDOLY2?M;.V@4-;_W=M8>O,
M9 ^L[ZA:,:$)AR7"HMXIUC"J.@-6#2/7Y3%J+@V6M>5MAN=F4+8#OE]*:78-
M>S)K3N*S7U!+ P04    "  U@:E6$+W&T3X"  !-!0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970U."YX;6RU5-]OTS 0_E=.84*;A)HT;0<J2:1V&V+2.JI5
M@P?$@YM<&FO^D=E.,_Y[;*<-1>H*+[S8/ON^S]^=?9>T4CWI"M' "V="IT%E
M3#T-0YU7R(D>R!J%/2FEXL184VU"72LDA0=Q%L91=!ER0D60)7YOJ;)$-H91
M@4L%NN&<J)]S9+)-@V&PWWB@F\JXC3!+:K+!%9K'>JFL%?8L!>4H-)4"%)9I
M,!M.YQ/G[QV^4FSUP1I<)&LIGYQQ6Z1!Y 0AP]PX!F*G+5XA8X[(RGC><0;]
ME0YXN-ZS?_*QVUC61..59-]H8:HT^!! @25IF'F0[6?<Q>,%YI)I/T+;^8[C
M /)&&\EW8*N 4]'-Y&67AP- _!H@W@%BK[N[R*N\)H9DB9(M*.=MV=S"A^K1
M5AP5[E%61ME3:G$F6S5KC<\-"@,W6SMJ.+]&0RC3%W &5,"",F;3IY/0V.L<
M*,QWU/...GZ%>@@+*4REX4846/R)#ZW,7FN\USJ/3Q+.:C6 4?0.XB@>P>/J
M&L[/+D[PCOH<C#SO^.\Y0)>#8Z&>9'"5,]4UR3$-;&EH5%L,LK=OAI?1QQ/Z
MQKV^L6<?_>,;P?<[ZP&W!KG^<4SL^#^(G?1B)R>3>6\;2:UDCEAH*)7DH E#
MD"7<?[D[^HLZOF%'Z)K(-HL'<1)N#U6$!U^<H]KX0M:0RT:8[K?WNWVOF'4E
M\MN]:S0+HC94:&!86F@T>&\%J*YX.\/(VA?,6AI;?GY9V7Z'RCG8\U)*LS?<
M!7T'S7X!4$L#!!0    ( #6!J58G'9)940,  +05   -    >&PO<W1Y;&5S
M+GAM;-U876_:,!3]*Y&[3JTT-82,E*R M"%5FK1-E=J'O56&.&#)<3+'=+!?
M/U\[A(_Z5JP/&RRHC7V/S[G']@UQ.ZCU2K#[.6,Z6!9"UD,RU[KZ$(;U=,X*
M6E^5%9,&R4M54&VZ:A;6E6(TJX%4B+#;Z21A0;DDHX%<%+>%KH-IN9!Z2/IM
M*'"WS]F01,E[$CBY<9FQ(7F\>/MC4>J;-X&[G[T[.^L\7M[LQR\L<$E"KVCO
M -&K3@<7!A 33PX3?TD;D[[>E;;#SXV0(YYCM+Z'!C/HM%3;P^@I0C_?H6/9
MKSM^^@X;)4<'+>8+:VF%PZ;61H.\E)N2BXD+F,RT8,$3%4,RIH)/% =63@LN
M5B[<A<"T%*4*M*EU8R6"2/W+P9'KP6/0Z!1<ELKF=AG<[TDS? ]8]\ @%Z(U
MV"4N,!I45&NFY*WIV,$V^ P*FO;#JC(.9XJNHFZ/; CV9I),2I4QU::)R#HT
M&@B6@QW%9W.XZ[(* =2Z+$PCXW162FH]K!E-P\A.F1#W\!WQ/=_17N9;>VK+
M0;9-8ZAI.AG7 ?UM-:>]+=M[E6Y0\:=2?UJ8Z4C;AUIA=XKE?&G[R[PU@*E'
MN#JM*K'Z*/A,%LQ-_N"$HP%=\X)YJ?@ODPU*96H"3)'@B2G-I]N1GXI6#VRI
MU^6TS''/W1/T_'?7><8D4U1LFS:U?\RK_&K'\?6_LFR_5?8->STV+_YC-]D[
M!9/)*9@\B9KLGX+)]/A-QB?@L3FX'KO)Z"A-ALUQ;>M,N',B;*,!G+R'Y!N<
M\<4F:3!9<*&Y;'ISGF5,/CL8&GE-)^9/TAU],SYC.5T(_=""0[)I?V497Q1I
M.^H.%J(9M6E_@>E%27OL-[FXS-B29>.FJV83VPQ,PV1M+B#L([?V\B,8QV%^
M!# L#^8 XS@6EN=_FD\?G8_#,&]]+])'.7V4XU@^9&P_6!X_)S67?Z9I&L=)
M@JWH>.QU,,;6+4G@QZ^&>0,&E@<R_=E:X[N-5\C+=8#MZ4L5@LT4KT1LIOA:
M ^)?-V"DJ7^WL3S P'8!JQW([\\#->7GQ#'L*N8->X)Q)$TQ!&K17Z-)@JQ.
M A___F!/21RGJ1\!S.\@CC$$GD8<P1R !PR)8_L>W'L?A>OW5+CY/^WH-U!+
M P04    "  U@:E6EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P
M#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TX
MI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606
MIW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E
M_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU
M@LD/['X 4$L#!!0    ( #6!J58CR_20J00  $4F   /    >&PO=V]R:V)O
M;VLN>&ULQ9I+;]LX$(#_"J'+N@>OK5?:!G6!/)K= 'DA#G(M:&EL$Y%(EZ2<
MIK^^I!SO4K8\Z&62DRWJ]6DH\AN2^O*L]--,J2?VLZZDF41+:U?'HY$IEE!S
M\[=:@71[YDK7W+I-O1B9E09>FB6 K:M1,AX?C6HN9/3UR_9:=WH4;B@+A15*
MND)?\"C@V?R_WV^RM3!B)BIA7R91^[^"B-5"BEK\@G(2C2-FENKY7Z7%+R4M
MKZ:%5E4UB>+-CD?05A1[Q5,/^<!GIBVQ?';/'<@D.AJ["\Z%-K8]HKT^=XQK
M< =OMAJK+D1E09]S"_]HU:R$7/C+N*<8!8_1QF'[NPGBL?Z3,*KY7!1PKHJF
M!FDW<=10>4!IEF)E(B9Y#9/H3*U!^^=Q-[@L-\]F'500*7TLW Y]6;9XE"C2
MJ$J4[NXE.^45EP6P-H0F $P0P.3= -G@C@>0*0*9OB'DU$/X$PQ3<W:[ZE1U
MAD!F[P9YINI5 )DCD/F[07[[T8@ \@B!/'J_2'*S#" _(I ?:2$?EL!.&R,D
MF+ I?T*(/M$239NZYOK%AVDJ%E*XT[BT[*0H5"-M6+>?$<C/M)#7H!?=SGF,
M]<YC6IJ3-1<5=_<<NM.'4^[^3*%HM+ "PEJ-4840.\3E ZZ3LR^,R[)MI2M_
M AO<N#3!? @I,8_$Q"*YE(6J@0VNE#$?V!UH9Q&N(<3##!(3*^2""\T>>=4
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M]<G:]5__V]#?\];4W7L^&WX@N7H%4$L! A0#%     @ -8&I5@=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    "  U@:E6OYAZE^\    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    "  U@:E6F5R<(Q &  "<)P  $P
M        @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( #6!
MJ58Q+"$@V 4  -,>   8              " @0X(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    "  U@:E6,+G]',$%  #N%@  &
M        @($<#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ -8&I5D'2%+SA @  !P@  !@              ("!$Q0  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( #6!J58O$:0-T00  $(3   8
M              " @2H7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    "  U@:E6.(AQOB0#  "O"   &               @($Q'   >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ -8&I5M1=+^'H!@
MKC4  !@              ("!BQ\  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( #6!J58XA'%,:@4  /X5   8              " @:DF
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  U@:E6!C?I
M70(4  #P-@  &               @(%)+   >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ -8&I5L[]@W8H$P  '3<  !@
M ("!@4   'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( #6!
MJ5;<B^&)/00  !D)   9              " @=]3  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ -8&I5L?'EP("!   <@H  !D
M         ("!4U@  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    "  U@:E6"OG(E?8"  ">!@  &0              @(&,7   >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( #6!J594 J,BW (  &<&
M   9              " @;E?  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ -8&I5K-EUFV^!   &0P  !D              ("!S&(
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  U@:E6G[YA
M1[8"   N!@  &0              @('!9P  >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( #6!J5:Z]^(4 04  %X,   9
M  " @:YJ  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
M-8&I5F/?X1#?!P  S10  !D              ("!YF\  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    "  U@:E6"8D&MF,$  !2"P  &0
M            @('\=P  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( #6!J5:]I,K15@D  -L:   9              " @99\  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ -8&I5I!F]&4Y P
M2P<  !D              ("!(X8  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    "  U@:E6'-ZM[.<$   &"P  &0              @(&3
MB0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( #6!J58V
M6(>K@@L  *LI   9              " @;&.  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ -8&I5B4N!6J)"P  WRD  !D
M     ("!:IH  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #6!J5:&,B6KLP(   X&   9              "
M@0["  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ -8&I
M5@G76MV< @  P 4  !D              ("!^,0  'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    "  U@:E69%]G._$"  #V!@  &0
M        @('+QP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   ( #6!J5:EHB!>Q0(  "\&   9              " @?/*  !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ -8&I5E%1N,10 P  1@@
M !D              ("![\T  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q0
M2P$"% ,4    "  U@:E6IR3_^T4$   =#   &0              @(%VT0
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( #6!J591$8/H
MU0,  (H*   9              " @?+5  !X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L! A0#%     @ -8&I5DRK(_NI @  ' <  !D
M ("!_MD  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  U
M@:E6<M6%-4<#  "E"P  &0              @('>W   >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( #6!J59/ROAGLP0  ,P6   9
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M970T,2YX;6Q02P$"% ,4    "  U@:E6R].<L1X#  #E#   &0
M    @('H\P  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (
M #6!J5;G5'838 ,  )00   9              " @3WW  !X;"]W;W)K<VAE
M971S+W-H965T-#,N>&UL4$L! A0#%     @ -8&I5F+N-]OE @  7@@  !D
M             ("!U/H  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"
M% ,4    "  U@:E62\/ORU4"  "+!0  &0              @('P_0  >&PO
M=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( #6!J58W\O7R^@(
M "L+   9              " @7P  0!X;"]W;W)K<VAE971S+W-H965T-#8N
M>&UL4$L! A0#%     @ -8&I5M/Y[\J\ @  [P@  !D              ("!
MK0,! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    "  U@:E6
MICT!+VT$   ''0  &0              @(&@!@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0X+GAM;%!+ 0(4 Q0    ( #6!J5;SC#':! <  "PR   9
M      " @40+ 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%
M  @ -8&I5@VC587] P  PQ(  !D              ("!?Q(! 'AL+W=O<FMS
M:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    "  U@:E6N6&+ZA$#  "T"P
M&0              @(&S%@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+
M 0(4 Q0    ( #6!J59O,:/+. ,  %4,   9              " @?L9 0!X
M;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ -8&I5F]/P+37
M @  )@<  !D              ("!:AT! 'AL+W=O<FMS:&5E=',O<VAE970U
M,RYX;6Q02P$"% ,4    "  U@:E6\/>__M8%  "(*P  &0
M@(%X( $ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( #6!
MJ58\2\E7/@(  !\%   9              " @84F 0!X;"]W;W)K<VAE971S
M+W-H965T-34N>&UL4$L! A0#%     @ -8&I5FOP@TIT!P  WTD  !D
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M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  U@:E6EXJ[',     3 @  "P
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52P4&     $( 0@ %$@  .40!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>131</ContextCount>
  <ElementCount>268</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>45</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - The Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/TheBusiness</Role>
      <ShortName>The Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Merger</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/Merger</Role>
      <ShortName>Merger</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Available-for-Sale-Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecurities</Role>
      <ShortName>Available-for-Sale-Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Property and Equipment (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.caladrius.com/role/PropertyandEquipmentNotes</Role>
      <ShortName>Property and Equipment (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeLossPerShare</Role>
      <ShortName>Income (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Australia Research and Development Tax Incentive</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive</Role>
      <ShortName>Australia Research and Development Tax Incentive</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Research Collaboration and License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement</Role>
      <ShortName>Research Collaboration and License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Merger (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/MergerTables</Role>
      <ShortName>Merger (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/Merger</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Available-for-Sale-Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesTables</Role>
      <ShortName>Available-for-Sale-Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AvailableforSaleSecurities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/PropertyandEquipmentNotes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Income (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeLossPerShareTables</Role>
      <ShortName>Income (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeLossPerShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/FairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AccruedLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/OperatingLeases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/StockholdersEquity</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/ShareBasedCompensation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - The Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/TheBusinessDetails</Role>
      <ShortName>The Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/TheBusiness</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/MergerDetails</Role>
      <ShortName>Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/MergerTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails</Role>
      <ShortName>Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeLossPerShareDetails</Role>
      <ShortName>Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeLossPerShareTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Operating Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesNarrativeDetails</Role>
      <ShortName>Operating Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails</Role>
      <ShortName>Operating Leases - Balance Sheet Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Operating Leases - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Stockholders' Equity - Equity Issuances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails</Role>
      <ShortName>Stockholders' Equity - Equity Issuances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Stock Options and Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails</Role>
      <ShortName>Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails</Role>
      <ShortName>Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails</Role>
      <ShortName>Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeTaxes</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxesDetails_1</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeTaxes</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/LicenseAgreementsDetails</Role>
      <ShortName>License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/LicenseAgreements</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Research Collaboration and License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails</Role>
      <ShortName>Research Collaboration and License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="clbs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/SubsequentEvents</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  clbs-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="clbs-20230331.htm">clbs-20230331.htm</File>
    <File>clbs-20230331.xsd</File>
    <File>clbs-20230331_cal.xml</File>
    <File>clbs-20230331_def.xml</File>
    <File>clbs-20230331_lab.xml</File>
    <File>clbs-20230331_pre.xml</File>
    <File>clbs-ex311_20230331xq1.htm</File>
    <File>clbs-ex32_20230331q1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>clbs-20230331_g1.jpg</File>
    <File>clbs-20230331_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="442">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "clbs-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2021-01-31": 442,
    "http://xbrl.sec.gov/dei/2021q4": 29
   },
   "contextCount": 131,
   "dts": {
    "calculationLink": {
     "local": [
      "clbs-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "clbs-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "clbs-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "clbs-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "clbs-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "clbs-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 423,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 7,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 12
   },
   "keyCustom": 55,
   "keyStandard": 213,
   "memberCustom": 6,
   "memberStandard": 36,
   "nsprefix": "clbs",
   "nsuri": "http://www.caladrius.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.caladrius.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Merger",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.caladrius.com/role/Merger",
     "shortName": "Merger",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Available-for-Sale-Securities",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecurities",
     "shortName": "Available-for-Sale-Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Property and Equipment (Notes)",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.caladrius.com/role/PropertyandEquipmentNotes",
     "shortName": "Property and Equipment (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Income (Loss) Per Share",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.caladrius.com/role/IncomeLossPerShare",
     "shortName": "Income (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.caladrius.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Accrued Liabilities",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.caladrius.com/role/AccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Operating Leases",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.caladrius.com/role/OperatingLeases",
     "shortName": "Operating Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.caladrius.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Share-Based Compensation",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.caladrius.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.caladrius.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.caladrius.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:ResearchAndDevelopmentTaxIncentiveTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Australia Research and Development Tax Incentive",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive",
     "shortName": "Australia Research and Development Tax Incentive",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:ResearchAndDevelopmentTaxIncentiveTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Contingencies",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.caladrius.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - License Agreements",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.caladrius.com/role/LicenseAgreements",
     "shortName": "License Agreements",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Research Collaboration and License Agreement",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement",
     "shortName": "Research Collaboration and License Agreement",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.caladrius.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "25",
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Merger (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.caladrius.com/role/MergerTables",
     "shortName": "Merger (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Available-for-Sale-Securities (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables",
     "shortName": "Available-for-Sale-Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.caladrius.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Income (Loss) Per Share (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.caladrius.com/role/IncomeLossPerShareTables",
     "shortName": "Income (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.caladrius.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Accrued Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.caladrius.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Operating Leases (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.caladrius.com/role/OperatingLeasesTables",
     "shortName": "Operating Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.caladrius.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Share-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.caladrius.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ic072dd5659984964b08dc7870ffd5237_I20220915",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - The Business (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.caladrius.com/role/TheBusinessDetails",
     "shortName": "The Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ic072dd5659984964b08dc7870ffd5237_I20220915",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Merger (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.caladrius.com/role/MergerDetails",
     "shortName": "Merger (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "icbaa2961421947beb045865325d7915f_I20220915",
      "decimals": "2",
      "lang": "en-US",
      "name": "clbs:AssetAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails",
     "shortName": "Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails",
     "shortName": "Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.caladrius.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails",
     "shortName": "Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.caladrius.com/role/PropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ic3f5e8fd57334737879297c5b890af27_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Income (Loss) Per Share (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.caladrius.com/role/IncomeLossPerShareDetails",
     "shortName": "Income (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ic3f5e8fd57334737879297c5b890af27_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i039c3f49b8da4f2d9b6cefb4c7bdaac6_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Fair Value Measurements (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.caladrius.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i039c3f49b8da4f2d9b6cefb4c7bdaac6_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "clbs:NumberOfOfficesUnderOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "office",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Operating Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails",
     "shortName": "Operating Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "clbs:NumberOfOfficesUnderOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "office",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails",
     "shortName": "Operating Leases - Balance Sheet Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails",
     "shortName": "Operating Leases - Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8f8fffeb19c041f6af85130f51bfd2b0_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Stockholders' Equity - Equity Issuances (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails",
     "shortName": "Stockholders' Equity - Equity Issuances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i2d6b8752305947b19367c1e2776a4b9b_I20210604",
      "decimals": "-5",
      "lang": "en-US",
      "name": "clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i724c150ab27c43fb92268e63a43d2567_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails",
     "shortName": "Stockholders' Equity - Stock Options and Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ifcccbb1ec967438ca65784bea06bd71c_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails",
     "shortName": "Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ifcccbb1ec967438ca65784bea06bd71c_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
     "shortName": "Share-Based Compensation - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i6d650d9bcb5a4a57b8d4315548c62afd_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
     "shortName": "Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i6d650d9bcb5a4a57b8d4315548c62afd_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i1f68282f0c334dd5b5c7b36cb0d6ba8e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
     "shortName": "Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i1f68282f0c334dd5b5c7b36cb0d6ba8e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i724c150ab27c43fb92268e63a43d2567_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.caladrius.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i724c150ab27c43fb92268e63a43d2567_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.caladrius.com/role/IncomeTaxesDetails_1",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i3e38bf3272614bd784e0e3713d21241f_I20211031",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - License Agreements (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.caladrius.com/role/LicenseAgreementsDetails",
     "shortName": "License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i3e38bf3272614bd784e0e3713d21241f_I20211031",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8788a48508344937b3068aa082fec1c3_I20210228",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Research Collaboration and License Agreement (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
     "shortName": "Research Collaboration and License Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i8788a48508344937b3068aa082fec1c3_I20210228",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i9c7a64d6081c499fbfec9b5f2a137f04_D20230401-20230430",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgram",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.caladrius.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "i9c7a64d6081c499fbfec9b5f2a137f04_D20230401-20230430",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgram",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "id4046547dd294ad49c799697f6ddb110_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.caladrius.com/role/ConsolidatedStatementsofEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "id4046547dd294ad49c799697f6ddb110_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:BusinessTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - The Business",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.caladrius.com/role/TheBusiness",
     "shortName": "The Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:BusinessTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20230331.htm",
      "contextRef": "ia7ecf23dd01f4cd49c40d16569bb9bda_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 45,
   "tag": {
    "clbs_AccruedGrantFunding": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Grant Funding",
        "label": "Accrued Grant Funding",
        "terseLabel": "D&amp;O insurance liabilities"
       }
      }
     },
     "localname": "AccruedGrantFunding",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AggregateIntrinsicValueWarrantsOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value, Warrants Outstanding",
        "label": "Aggregate Intrinsic Value, Warrants Outstanding",
        "terseLabel": "Warrants Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueWarrantsOutstanding",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AggregateIntrinsicValueWarrantsvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value, Warrants vested",
        "label": "Aggregate Intrinsic Value, Warrants vested",
        "terseLabel": "Warrants, Vested, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueWarrantsvested",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value, Warrants vested and expected to vest",
        "label": "Aggregate Intrinsic Value, Warrants vested and expected to vest",
        "terseLabel": "Warrants, Vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueWarrantsvestedandexpectedtovest",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AssetAcquisitionAcquiredInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Acquired In-Process Research And Development",
        "label": "Asset Acquisition, Acquired In-Process Research And Development",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "AssetAcquisitionAcquiredInProcessResearchAndDevelopment",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AssetAcquisitionCashAndCashEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Cash and Cash Equivalents",
        "label": "Asset Acquisition, Cash and Cash Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "AssetAcquisitionCashAndCashEquivalents",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AssetAcquisitionConsiderationTransferredEquityValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Consideration Transferred, Equity Value",
        "label": "Asset Acquisition, Consideration Transferred, Equity Value",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredEquityValue",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AssetAcquisitionIntangibles": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Intangibles",
        "label": "Asset Acquisition, Intangibles",
        "terseLabel": "License"
       }
      }
     },
     "localname": "AssetAcquisitionIntangibles",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AssetAcquisitionNetWorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Net Working Capital",
        "label": "Asset Acquisition, Net Working Capital",
        "negatedTerseLabel": "Net working capital (excluding cash)"
       }
      }
     },
     "localname": "AssetAcquisitionNetWorkingCapital",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AssetAcquisitionOtherLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Other Liabilities",
        "label": "Asset Acquisition, Other Liabilities",
        "negatedTerseLabel": "Other liabilities"
       }
      }
     },
     "localname": "AssetAcquisitionOtherLiabilities",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AssetAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Share Price",
        "label": "Asset Acquisition, Share Price",
        "terseLabel": "Multiplied by the fair value per share of Lisata common stock on September 15, 2022"
       }
      }
     },
     "localname": "AssetAcquisitionSharePrice",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_AtTheMarketOfferingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering Agreement",
        "label": "At The Market Offering Agreement [Member]",
        "terseLabel": "ATM Agreement"
       }
      }
     },
     "localname": "AtTheMarketOfferingAgreementMember",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_BusinessTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Business [Text Block]",
        "label": "The Business [Text Block]",
        "terseLabel": "The Business"
       }
      }
     },
     "localname": "BusinessTextBlock",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/TheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clbs_CENDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CEND",
        "label": "CEND [Member]",
        "terseLabel": "CEND"
       }
      }
     },
     "localname": "CENDMember",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails",
      "http://www.caladrius.com/role/MergerDetails",
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails",
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_ClinicalAndRDRelatedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical and R&amp;D Related Liabilities",
        "label": "Clinical and R&amp;D Related Liabilities",
        "terseLabel": "Clinical and R&amp;D related liabilities"
       }
      }
     },
     "localname": "ClinicalAndRDRelatedLiabilities",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee",
        "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee",
        "terseLabel": "Annual license maintenance fee"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee After First Sale",
        "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee After First Sale",
        "terseLabel": "Annual license maintenance fee, after first sale"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven",
        "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven",
        "terseLabel": "Annual license maintenance fee, year seven"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Four",
        "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Four",
        "terseLabel": "Annual license maintenance fee, year four"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Two and Three",
        "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Two and Three",
        "terseLabel": "Annual license maintenance fee, years two and three"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Change of Control Fee",
        "label": "Collaborative Arrangement, Rights and Obligations, Change of Control Fee",
        "terseLabel": "Change of control fee"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsChangeOfControlFee",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product",
        "label": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales",
        "label": "Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales",
        "terseLabel": "Royalties, net of sales"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Sublicensing Fees",
        "label": "Collaborative Arrangement, Rights and Obligations, Sublicensing Fees",
        "terseLabel": "Sublicensing fee"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSublicensingFees",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_CommonStockWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants, Shares",
        "label": "Common Stock Warrants, Shares",
        "periodEndLabel": "Warrants, Outstanding, End of Period (in shares)",
        "periodStartLabel": "Warrants, Outstanding, Beginning of Period (in shares)"
       }
      }
     },
     "localname": "CommonStockWarrantsShares",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_FairValueMarketOfTaxNOLs": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Market of Tax NOLs",
        "label": "Fair Value Market of Tax NOLs",
        "terseLabel": "Fair Value Market of Tax NOLs"
       }
      }
     },
     "localname": "FairValueMarketOfTaxNOLs",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities",
        "label": "Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities",
        "terseLabel": "Accounts payable, accrued liabilities and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]",
        "label": "Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet"
       }
      }
     },
     "localname": "LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clbs_MassachusettsInstituteOfTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Massachusetts Institute of Technology",
        "label": "Massachusetts Institute of Technology [Member]",
        "terseLabel": "Massachusetts Institute of Technology"
       }
      }
     },
     "localname": "MassachusettsInstituteOfTechnologyMember",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_NumberOfOfficesUnderOperatingLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Offices Under Operating Leases",
        "label": "Number Of Offices Under Operating Leases",
        "terseLabel": "Number of offices under operating leases"
       }
      }
     },
     "localname": "NumberOfOfficesUnderOperatingLeases",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "clbs_OperatingLeaseRightOfUseAssetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Right-Of-Use Asset",
        "label": "Operating Lease, Right-Of-Use Asset [Abstract]",
        "terseLabel": "Right-of-Use Assets:"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAbstract",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clbs_OperatingLossCarryforwardsBeforeWriteDown": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Before Write Down",
        "label": "Operating Loss Carryforwards, Before Write Down",
        "terseLabel": "Net operating loss carryforwards, prior to write down"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsBeforeWriteDown",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_OperatingLossCarryforwardsPostAcquisition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Post Acquisition",
        "label": "Operating Loss Carryforwards, Post Acquisition",
        "terseLabel": "Operating Loss Carryforwards, Post Acquisition"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsPostAcquisition",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_OptionsVestedweightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options, Vested, weighted Average Remaining Contractual Term",
        "label": "Options, Vested, weighted Average Remaining Contractual Term",
        "terseLabel": "Options, Vested, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "OptionsVestedweightedAverageRemainingContractualTerm",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "clbs_PreferredStockLiquidationPreferenceShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Liquidation Preference, Share",
        "label": "Preferred Stock, Liquidation Preference, Share",
        "terseLabel": "Preferred stock, liquidation value"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceShare",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_PreferredStockSharesDesignated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock, shares designated",
        "label": "Preferred stock, shares designated",
        "terseLabel": "Preferred stock, shares designated"
       }
      }
     },
     "localname": "PreferredStockSharesDesignated",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Sale Of Net Operating Losses, NJEDA Program",
        "label": "Proceeds From Sale Of Net Operating Losses, NJEDA Program",
        "terseLabel": "Net proceeds from sale of NOLs"
       }
      }
     },
     "localname": "ProceedsFromSaleOfNetOperatingLossesNJEDAProgram",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_QiluMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qilu",
        "label": "Qilu [Member]",
        "terseLabel": "Qilu"
       }
      }
     },
     "localname": "QiluMember",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_ResearchAndDevelopmentTaxIncentiveTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Tax Incentive",
        "label": "Research and Development Tax Incentive [Text Block]",
        "terseLabel": "Australia Research and Development Tax Incentive"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxIncentiveTextBlock",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clbs_RevenuePerformanceObligationPercentageOfNetSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Percentage of Net Sale",
        "label": "Revenue, Performance Obligation, Percentage of Net Sale",
        "terseLabel": "Percentage of net sale"
       }
      }
     },
     "localname": "RevenuePerformanceObligationPercentageOfNetSale",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Percentage of Sublicensing Revenues",
        "label": "Revenue, Performance Obligation, Percentage of Sublicensing Revenues",
        "terseLabel": "Percentage of sublicensing revenues"
       }
      }
     },
     "localname": "RevenuePerformanceObligationPercentageOfSublicensingRevenues",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "terseLabel": "Variable consideration amounts, milestones"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement",
        "label": "Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement",
        "terseLabel": "Aggregate offering amount authorized per agreement"
       }
      }
     },
     "localname": "SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_SaleOfStockAvailableForSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock Available for Sale",
        "label": "Sale of Stock Available for Sale",
        "terseLabel": "Sale of Stock Available for Sale"
       }
      }
     },
     "localname": "SaleOfStockAvailableForSale",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_SanfordBurnhamPrebysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanford Burnham Prebys",
        "label": "Sanford Burnham Prebys [Member]",
        "terseLabel": "Sanford Burnham Prebys"
       }
      }
     },
     "localname": "SanfordBurnhamPrebysMember",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_SharesHeldByThirdParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Held by Third Party",
        "label": "Shares Held by Third Party",
        "terseLabel": "Shares held by third party"
       }
      }
     },
     "localname": "SharesHeldByThirdParty",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_SharesIssuedUnderLicenseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued Under License Agreement",
        "label": "Shares Issued Under License Agreement",
        "terseLabel": "Shares issued under license agreement"
       }
      }
     },
     "localname": "SharesIssuedUnderLicenseAgreement",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_Sharesvestedandexpectedtovest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "shares, vested and expected to vest",
        "label": "shares, vested and expected to vest",
        "terseLabel": "Warrants, Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "Sharesvestedandexpectedtovest",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_UniversityOfCaliforniaAtSanDiegoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of California at San Diego",
        "label": "University of California at San Diego [Member]",
        "terseLabel": "University of California at San Diego"
       }
      }
     },
     "localname": "UniversityOfCaliforniaAtSanDiegoMember",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_WarrantsCanceled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Canceled",
        "label": "Warrants Canceled",
        "negatedLabel": "Warrants, Forfeited (in shares)"
       }
      }
     },
     "localname": "WarrantsCanceled",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Exercised",
        "label": "Warrants Exercised",
        "negatedTerseLabel": "Warrants, Exercised (in shares)"
       }
      }
     },
     "localname": "WarrantsExercised",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expired",
        "label": "Warrants Expired",
        "negatedTerseLabel": "Warrants, Expired (in shares)"
       }
      }
     },
     "localname": "WarrantsExpired",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Granted",
        "label": "Warrants Granted",
        "terseLabel": "Warrants, Granted (in shares)"
       }
      }
     },
     "localname": "WarrantsGranted",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Other Disclosures",
        "label": "Warrants Other Disclosures [Abstract]",
        "terseLabel": "Warrants, Weighted Average Contractual Term and Intrinsic Value"
       }
      }
     },
     "localname": "WarrantsOtherDisclosuresAbstract",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clbs_WarrantsVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Vested",
        "label": "Warrants, Vested",
        "terseLabel": "Warrants, Vested (in shares)"
       }
      }
     },
     "localname": "WarrantsVested",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsWeightedAverageExercisePriceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Weighted Average Exercise Price [Roll Forward]",
        "label": "Warrants Weighted Average Exercise Price [Roll Forward]",
        "terseLabel": "Warrants, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "WarrantsWeightedAverageExercisePriceRollForward",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsCanceled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Canceled",
        "label": "Weighted Average Exercise Price, Warrants Canceled",
        "terseLabel": "Warrants, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsCanceled",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Exercisable",
        "label": "Weighted Average Exercise Price, Warrants Exercisable",
        "terseLabel": "Warrants, Vested, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsExercisable",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Exercised",
        "label": "Weighted Average Exercise Price, Warrants Exercised",
        "terseLabel": "Warrants, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsExercised",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Expired",
        "label": "Weighted Average Exercise Price, Warrants Expired",
        "terseLabel": "Warrants, Expired (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsExpired",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Granted",
        "label": "Weighted Average Exercise Price, Warrants Granted",
        "terseLabel": "Warrants, Granted (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsGranted",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Outstanding",
        "label": "Weighted Average Exercise Price, Warrants Outstanding",
        "periodEndLabel": "Warrants Outstanding, End of Period (in dollars per share)",
        "periodStartLabel": "Warrants Outstanding, Beginning of Period (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsOutstanding",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest",
        "label": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest",
        "terseLabel": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest",
        "label": "Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest",
        "terseLabel": "Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "clbs_WeightedAverageRemainingContractualTermwarrantoutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Contractual Term warrant outstanding",
        "label": "Weighted Average Remaining Contractual Term warrant outstanding",
        "terseLabel": "Warrants, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermwarrantoutstanding",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "clbs_WeightedAverageRemainingContractualTermwarrantsvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "weighted Average Remaining Contractual Term, warrants vested",
        "label": "weighted Average Remaining Contractual Term, warrants vested",
        "terseLabel": "Warrants, Vested, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermwarrantsvested",
     "nsuri": "http://www.caladrius.com/20230331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r190",
      "r191",
      "r260",
      "r265",
      "r419",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r298",
      "r391",
      "r405",
      "r416",
      "r417",
      "r430",
      "r435",
      "r443",
      "r467",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r298",
      "r391",
      "r405",
      "r416",
      "r417",
      "r430",
      "r435",
      "r443",
      "r467",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r231",
      "r392",
      "r431",
      "r442",
      "r468",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r231",
      "r392",
      "r431",
      "r442",
      "r468",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r291",
      "r298",
      "r367",
      "r391",
      "r405",
      "r416",
      "r417",
      "r430",
      "r435",
      "r443",
      "r467",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r291",
      "r298",
      "r367",
      "r391",
      "r405",
      "r416",
      "r417",
      "r430",
      "r435",
      "r443",
      "r467",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r190",
      "r191",
      "r260",
      "r265",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r21",
      "r441"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Accretion on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Abstract]",
        "terseLabel": "Accrued Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r19",
      "r78"
     ],
     "calculation": {
      "http://www.caladrius.com/role/PropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r166",
      "r400",
      "r410",
      "r411"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r34",
      "r37",
      "r137",
      "r406",
      "r407",
      "r418",
      "r451",
      "r452",
      "r453",
      "r456",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r10",
      "r302",
      "r441"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r456",
      "r457",
      "r458",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r101",
      "r124",
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "AssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails",
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails",
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r437",
      "r475",
      "r476",
      "r477"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Total purchase price"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": {
     "auth_ref": [
      "r475",
      "r476",
      "r477"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable",
        "terseLabel": "Incremental fair value of Cend's fully vested stock options"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "auth_ref": [
      "r437",
      "r475",
      "r476",
      "r477"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Transaction Cost",
        "terseLabel": "Lisata transaction costs"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails",
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails",
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Asset Acquisition [Line Items]",
        "terseLabel": "Asset Acquisition [Line Items]"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails",
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]",
        "terseLabel": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails",
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTableTextBlock": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of asset acquisition.",
        "label": "Asset Acquisition [Table Text Block]",
        "terseLabel": "Asset Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for asset acquisition.",
        "label": "Asset Acquisition [Text Block]",
        "terseLabel": "Merger"
       }
      }
     },
     "localname": "AssetAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Merger"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r145",
      "r155",
      "r187",
      "r225",
      "r227",
      "r229",
      "r236",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r324",
      "r328",
      "r340",
      "r441",
      "r465",
      "r466",
      "r483"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r32",
      "r187",
      "r236",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r324",
      "r328",
      "r340",
      "r441",
      "r465",
      "r466",
      "r483"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.caladrius.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Assets, fair value disclosure"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r233",
      "r243"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails",
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year",
        "verboseLabel": "Less than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year",
        "terseLabel": "Less than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost",
        "verboseLabel": "Greater than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value",
        "terseLabel": "Greater than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r62",
      "r232",
      "r243",
      "r394"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "totalLabel": "Total estimated fair value",
        "verboseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails",
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r103",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of California.",
        "label": "California Franchise Tax Board [Member]",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r0",
      "r17",
      "r53"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Available-for-Sale-Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r48",
      "r53",
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r48",
      "r143"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License Agreements",
        "verboseLabel": "Research Collaboration and License Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreements",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r27",
      "r82",
      "r148",
      "r160"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 13)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r81",
      "r83",
      "r249",
      "r250",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r456",
      "r457",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r9",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common stock, ending balance (in shares)",
        "periodStartLabel": "Common stock, beginning balance (in shares)",
        "terseLabel": "Number of common shares of the combined company owned by Cend stockholders"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals",
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity",
      "http://www.caladrius.com/role/MergerDetails",
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r9",
      "r441"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, authorized 33,333,333 shares; issued 7,999,080 and 7,866,799 shares at March 31, 2023 and December 31, 2022, respectively; and outstanding, 7,998,342 and 7,866,061 shares at March 31, 2023 and December 31, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common Stock, Value, Outstanding"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r38",
      "r172",
      "r174",
      "r179",
      "r396",
      "r402"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Lisata Therapeutics, Inc. common stockholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r436",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Computer Software, Intangible Asset"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r154",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r136",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r279",
      "r280",
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract with customer, liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r432",
      "r434",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r51",
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r51",
      "r76"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r103",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of Total Compensation Cost Related to Nonvested Awards"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r180",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r205",
      "r207",
      "r209",
      "r210",
      "r211",
      "r215",
      "r332",
      "r333",
      "r397",
      "r403",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Caladrius Biosciences, Inc. common stockholders - basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Basic and diluted loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r180",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r207",
      "r209",
      "r210",
      "r211",
      "r215",
      "r332",
      "r333",
      "r397",
      "r403",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Caladrius Biosciences, Inc. common stockholders - diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research tax credit rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails_1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Salaries, employee benefits and related taxes"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r125"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected weighted-average period in years of compensation cost to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r88",
      "r163",
      "r175",
      "r176",
      "r177",
      "r192",
      "r193",
      "r194",
      "r196",
      "r202",
      "r204",
      "r217",
      "r237",
      "r278",
      "r299",
      "r300",
      "r301",
      "r310",
      "r311",
      "r331",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r406",
      "r407",
      "r408",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r139",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Assets Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r261",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r335",
      "r364",
      "r365",
      "r366",
      "r428",
      "r429",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r334",
      "r335",
      "r336",
      "r337",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r261",
      "r292",
      "r297",
      "r335",
      "r364",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r261",
      "r292",
      "r297",
      "r335",
      "r365",
      "r428",
      "r429",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r261",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r335",
      "r366",
      "r428",
      "r429",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r141",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r261",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r364",
      "r365",
      "r366",
      "r428",
      "r429",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance Minimum Lease Payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r234",
      "r235",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r262",
      "r276",
      "r330",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r427",
      "r459",
      "r460",
      "r461",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Five"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r74",
      "r393"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Finite-Lived Intangible Assets, Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Remeasurement"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "(Gain) loss on disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "auth_ref": [
      "r133",
      "r135"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Less - net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r40",
      "r144",
      "r150",
      "r162",
      "r225",
      "r226",
      "r228",
      "r230",
      "r398",
      "r426"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before benefit from income taxes and noncontrolling interests"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r188",
      "r306",
      "r308",
      "r309",
      "r312",
      "r314",
      "r316",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r189",
      "r203",
      "r204",
      "r224",
      "r304",
      "r313",
      "r315",
      "r404"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Benefit from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r472"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "terseLabel": "Research tax credit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails_1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r72",
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible Assets, Net (Excluding Goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r44",
      "r46"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Investment income, net"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Investments Classified by Contractual Maturity Date"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.caladrius.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Marketable securities - available for sale"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments Under Lease Agreements"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: Amounts representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r23",
      "r187",
      "r236",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r325",
      "r328",
      "r329",
      "r340",
      "r425",
      "r465",
      "r483",
      "r484"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r14",
      "r147",
      "r158",
      "r441",
      "r455",
      "r462",
      "r481"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, non-controlling interests and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r25",
      "r187",
      "r236",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r325",
      "r328",
      "r329",
      "r340",
      "r441",
      "r465",
      "r483",
      "r484"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      },
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails",
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r31",
      "r146",
      "r157",
      "r187",
      "r236",
      "r251",
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r340"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r48",
      "r49",
      "r52"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r41",
      "r52",
      "r151",
      "r161",
      "r165",
      "r170",
      "r173",
      "r177",
      "r187",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r203",
      "r204",
      "r208",
      "r225",
      "r226",
      "r228",
      "r230",
      "r236",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r333",
      "r340",
      "r426",
      "r465"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to Lisata Therapeutics, Inc. common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewJerseyDivisionOfTaxationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of New Jersey.",
        "label": "New Jersey Division of Taxation [Member]",
        "terseLabel": "New Jersey"
       }
      }
     },
     "localname": "NewJerseyDivisionOfTaxationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of New York.",
        "label": "New York State Division of Taxation and Finance [Member]",
        "terseLabel": "New York"
       }
      }
     },
     "localname": "NewYorkStateDivisionOfTaxationAndFinanceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r133",
      "r278",
      "r456",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- Controlling Interest in Subsidiary"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating Expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r225",
      "r226",
      "r228",
      "r230",
      "r426"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Operating lease liabilities",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails",
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Operating Lease Liabilities:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities \u2014 current",
        "verboseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating lease liabilities, current, balance sheet line item"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating lease liabilities, noncurrent, balance sheet line item"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Right-of-use assets, balance sheet line item"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r355",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate for operating leases (percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r354",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term for operating leases (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r131"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r24"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r167",
      "r168",
      "r169"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r39",
      "r88",
      "r171",
      "r174",
      "r178",
      "r342",
      "r347",
      "r348",
      "r395",
      "r401",
      "r451",
      "r452"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r167",
      "r169"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Available for sale securities - net unrealized loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Total Lisata Therapeutics, Inc. Stockholders' Equity"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r182"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Tax withholding payments on net share settlement equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r181",
      "r475",
      "r476",
      "r477"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Carrying value of Lisata's cost method investment in Cend"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r8",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodStartLabel": "Preferred stock, beginning balance (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r8",
      "r441"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.000067 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at March 31, 2023 and December 31, 2022, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r1",
      "r15",
      "r16"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r165",
      "r170",
      "r173",
      "r183",
      "r187",
      "r195",
      "r203",
      "r204",
      "r225",
      "r226",
      "r228",
      "r230",
      "r236",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r323",
      "r326",
      "r327",
      "r333",
      "r340",
      "r398",
      "r426",
      "r438",
      "r439",
      "r453",
      "r465"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity",
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r19",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r80",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r18",
      "r77"
     ],
     "calculation": {
      "http://www.caladrius.com/role/PropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r6",
      "r7",
      "r79",
      "r159",
      "r399",
      "r441"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.caladrius.com/role/PropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets",
      "http://www.caladrius.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r6",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment [Table Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r6",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, Plant and Equipment, Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r11",
      "r95",
      "r156",
      "r302",
      "r409",
      "r411",
      "r441"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r163",
      "r192",
      "r193",
      "r194",
      "r196",
      "r202",
      "r204",
      "r237",
      "r299",
      "r300",
      "r301",
      "r310",
      "r311",
      "r331",
      "r406",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "auth_ref": [
      "r319",
      "r478"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "terseLabel": "Revenue from contract"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock, Name of Transaction [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.",
        "label": "Sale of Stock, Percentage of Ownership after Transaction",
        "terseLabel": "Sale of Stock, Percentage of Ownership after Transaction"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Available-for-sale Securities Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r70",
      "r152",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r101",
      "r123",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule Share-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r19",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r103",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r108",
      "r117",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option and Warrants Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Share-based Compensation Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r28",
      "r85",
      "r86",
      "r87",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r218",
      "r263",
      "r264",
      "r265",
      "r267",
      "r271",
      "r276",
      "r430",
      "r450",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]",
        "terseLabel": "Share-based Payment Arrangement, Noncash Expense [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting terms (years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average estimated fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Warrants, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock Options, Weighted Average Contractual Term and Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Options, Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options, Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Options, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average estimated fair value of shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options, Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r110",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options, Outstanding, End of Period (in shares)",
        "periodStartLabel": "Options, Outstanding, Beginning of Period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options, Outstanding, End of Period (in dollars per share)",
        "periodStartLabel": "Options, Outstanding. Beginning of Period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Stock Options, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Options, Vested, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options, Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Options, Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options, Vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options, Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options, Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r100",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r103",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options, Vested and expected to vest, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Shares, Issued"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r55",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r29",
      "r88",
      "r163",
      "r175",
      "r176",
      "r177",
      "r192",
      "r193",
      "r194",
      "r196",
      "r202",
      "r204",
      "r217",
      "r237",
      "r278",
      "r299",
      "r300",
      "r301",
      "r310",
      "r311",
      "r331",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r406",
      "r407",
      "r408",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Statement, Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r217",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r8",
      "r9",
      "r88",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock issued (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r88",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r8",
      "r9",
      "r88",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r8",
      "r9",
      "r88",
      "r95",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options, Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r8",
      "r9",
      "r88",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Value of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r8",
      "r9",
      "r95",
      "r102",
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased",
        "terseLabel": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased"
       }
      }
     },
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r9",
      "r12",
      "r13",
      "r60",
      "r441",
      "r455",
      "r462",
      "r481"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Lisata Therapeutics, Inc. stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r133",
      "r134",
      "r138",
      "r163",
      "r164",
      "r176",
      "r192",
      "r193",
      "r194",
      "r196",
      "r202",
      "r237",
      "r278",
      "r299",
      "r300",
      "r301",
      "r310",
      "r311",
      "r331",
      "r342",
      "r343",
      "r348",
      "r407",
      "r408",
      "r418",
      "r455",
      "r462",
      "r481"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets",
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r99",
      "r186",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r349",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r349",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r349",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r349",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r358",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r234",
      "r235",
      "r262",
      "r276",
      "r330",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r459",
      "r460",
      "r461",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury stock (shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r30",
      "r97",
      "r98"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "negatedTerseLabel": "Treasury stock, at cost; 738 shares at March 31, 2023 and December 31, 2022"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "auth_ref": [
      "r432",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "terseLabel": "Municipal debt securities"
       }
      }
     },
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r303",
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition",
        "terseLabel": "Unrecognized Tax Benefits, Increase Resulting from Acquisition"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r57",
      "r58",
      "r59",
      "r219",
      "r220",
      "r222",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r206",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted shares"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r205",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic shares"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=123385629&loc=SL5834089-161433",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r444": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r445": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r446": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r447": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r448": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r449": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0000320017-23-000028-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000320017-23-000028-xbrl.zip
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MYTOH)78L8S+X97F*5'>'/'7D>.W#YEEUH\%KEY_/JD>?2>/H,-^N[S1K1UM
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M#0:V(,J#OX@1%Q(3C1E=HL5-MOAJTFF9"[E8"GJ#&%UH><4 '$S41GD+M(_
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M2DP] =\63Y&=7FH&K U(2,M]Q)8I0<!?(DP0226*W#JY%*BY$*C9-5 FQ:C
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M;6Q.TY0.T>[W@S?^S2+CK78J$R*D#'J$,JV5R"3AVD1O<-1D"6]+>/LU> -
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M)UP@UZ\=/?3][5+32+F])Y_P18\Q))7O)_XNDW@7*HGW_ES3%TLM#?<@2\H
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MD%?TF R'>0EY_+XB/RE+92GRSR7R=P(ARGED.<XD0^!AN*A Y F(/ :#)+J
M,0&1EWA523$O(O_;14DZ)]";BR),DK)U3E+!^-5*._27 9)G#Y"4<_^I:=I]
M\*@V1]-?"_TE-#T&FNXFKU F45!.9H2 I\3@OTQ%;#+BJ22*:&MD '=)/#E
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M0@NKB [1Z2)H0LE=2VA&P>)W/WAQM=+^7DREV"7S$+/J@6=3E>-^36&V?&<
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MGJL3!W3AU&>@?.CL"]7YJBX&6[_-O%.WW0-S8SC_^E>^I/<_\Y+B!N]8Z7_
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M:("4T "N*?:0:@1=F=W/\Q4X&&NW6(W7.UC[YU6T;@.9V[->^'K<;+P:<NN
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M[W__P7EJ3S#I_Z>&X,GXI_<7EEKBFBY?(4@[ >ZP$Z"U>$ )=4(8*W.@F=&
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M,"'@<T) 1J4Q0AA%("<<!2=9N^ 28V*<X=S*1T/ Q!17"(\7L_#(@J.LA17
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M"$BE0([&/E4"H)\ H,8"E8">"6Z,!()!&L^I8$ 9&?Z4!N6<<:*H7QXA3"O
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M-1@5]1)PX4P_C//W*N08WS/8@)FD@U19'Q.<BE3>N!D@;\=P?Y7^//76@SJ
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M:PW] 6 ^C=2KO<Y81\O=8)-!5MVXD+?$QL?9/C/@4"/C3-V@916"JJVD.LX
M40O59*4P]*(J/#T=0@YB/(EV6;AAT:\W"E>Z,M;Y)1JUQ*OX00RZQH#"^4YY
MVX6 T])9.EY@.H&:!D%6!A8\]7K9<7JTZI7'V-OZVZF]B7&Q%Y1'JY5:-6[;
M+I.CJ^&?,_#)O#..$M2'\M@Q+DZ;?+][Y0@M%%6XARH:XX2./R.+./)[DZR6
M-T$2YJ+Z^8RK:Z"C_<^?E!(>(^R!@X;$DJ(.2.(U$#A8$A6Y@7:A6L;&>A^E
M)I0;]BH#+Z?9)X&AK7GH&_74*-AY3)2<AIY7$T0\7H:( ?B"B5=SX/P6JJFL
ML#!WA9L$?V4P#G7'#(K2=[T,0K_KE8\OGU-MB"K-6TVR(_[:VWLS254I:5,=
MBKR$[7:ORG\<[[V=>%#MN(M^9"99GZ_B+FV8@[_+9GLQY!'H'LSC<]^ZD[*8
M0J0%X/^-D>OXX.7U#UU$\HO,]LN(:+W?=CIQ9+ZWOM\?5C2VGN9++K-DQ)8/
M;<4'JHUTRXO=1<I?N495U*ZLOC#.\-E>G ^O5X59;VA2C&&VW,G7TW8,<\25
MW+&6;<^,1UV?HLY1J;?%3_L@4VF'EQ&;<M-U:9=E,DKG8BEEOAR(<=BK3E=I
MQ%2<JCP3AB7GPY?\?;PX7.^&FEOW+3=(15;KR_(CXY(I"W2@XI"7IG5M.<(L
MAI)B0/9T'*\L8A&5V7HR\5&G@>WUB[H<S'4WG1/2N+L73A4Q$A\#D_MA5"/]
MG1D/5&U.SA$<2ZLBNX&[EM^.C>C_+EM6G]21.2U<\!]C:'_\L"4C/ZE),A9O
MN]SI7!:XJ>N$3(NE#*QU51G[FU0QF7ZO^*38F_%[9>,'[2SF%TW7;KI?9O%N
MX([\09@(8N+JX#DRB);YI!EUQN0.",L0(#KW0"EE@5"*0H<9HYS/9[>$D<<>
M4>X%QH1)*WCX TL7B(B"&ODGPSC>52&1B8X\&;)1,87).O)2G*JBGW%.C Y.
MB77E<G^<^,=3XF F,[8?JP<%"!@/5[5C.N[X&&_P*$MHU Y8"2!UTM"4LUAG
M59:U.MK5JOFX&DBLJ-7IQPS*RJLLY]PRH?2*:X;CM="I2,-U)6@OI5T5_;FF
MNW4.U""SHTE)G:I=R0?*.6BV D]<PQF4D];E0 4Q3,TAT_52)CG T^.H7:?M
MODRR_J,/UZ\*]ESN/_HQLJ9,SOE,3I@R.=>B*_>=R?E4,C.7O]ZU4_.N:1=F
MU(WA?3,N?CA%KROGH*Z:Y>HE'%_N/2CSV<]&]J2:'I3NCY?X55&4#LHDMG0%
M'E?P7U/+2*4CK53GT6<=EW.J]SL$4FOF2\O%N240_:)=%9JZ>I:)R5AU>L-D
M :.N\U8M#$P2Y6OWHDIHF<J['V](* =C [8ES+BY97G$SD2HIO1=;#M,8\4X
MJA>WUUPY?CM+)H<GL7I]S^[$I7L>ABR%)X]:)Y^H,EP1Y4& 5P^(P1@HQB'
M6#LLXO Z.>]<&$4Y5&&D23P(2UJI$5*24"FAI0:*>>?BS67():9+3@OAQ[6
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M2V9UP?,+E<^*>I=.H0IE@:X'(96YTEU?ND'#8:?(,*M.>=R\0E1N\52PY6;
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M&JEJI+H]4MFR]+1W>9\PW2:D#=<?/J*6;^L?\_ 5.C^\ ^=^.*B1ZV;(=;Z
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M <'RXXJ/?S_MN/'!*X;02P:+!P]GD;?X&+V$JUS!XD/"X4O,+O[\TB]?^J&
M.<-A_3=&=W3?FS3X@NP0?$EVR)7IB<N7KG"DRSEW+QZC7( ,L5IF5 _M08.@
MK49:42[4%GWZ';'MK>\9/ZSZ L_UQ04SACW:6K-7KRBY5_[4HX.&_]^33EQ+
MXI MB<]>TTG<^'WG-;OCMAO/S=U77O/%'X#CDZ;>V^G,>S/^4P^'9[&__DUN
MS7/83AZQUM>W;.?]1[;;2]O*3X?-7MY.GC6W=]E>KXF:[S^>M[Y^@4O;R?81
MVFT?T;WM;B=M*UNQ_;MY._GAM)6VJ>=?3O>VFVBO_2DT5Y38E1 QR3$(<<0
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M%Y'!ZLS8IV'=F"@?/%)Q&@@J)#4$RQ"W4]AAI"05=>SG,5CWHL<49QC"R".
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M@$X5"SVG5%L6729*:V>I!J4->+4;@)(E5E&!7?"<4\:=(51X!%$01EG)V%V
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M\M(#XN<\><D'18R6'&F:2P3Z*D'2>Q9YGA)G"O1:'!)Y*7]KT+G*/59ZJ9<
M),^5OK0R6ESEA<.UT^V>0#*GB 5.<^.]1EPR@1A3.3+,!91YZVA.L0<U+;&:
ML@?QN=5Z3ZWWO$A>T\T(=H5GKW;7K8A0\[RG(&2.&6;(.QV+-T2EQPJ'8CMU
MIZGEBK#(>Y(;]\YD>;&Z3NU^>A+F4T%S^I&@ #9]Y6\<]>-'M</H01U&\^PG
M!8N&L<J09(0BAC$&8T<8I//,8DLX%[EY0/;32X."6G.J-:>?3("Z0D6JH6]E
MZ)LC0V'L\T !^K)@(O&3 ?1E!J-<YLY([(VGZH'(4"\-]FIOST^B0\UN>EUM
M^E&YY6LGS?T08(X997.IM&<>95F>(Y:!^6-$((AIH<$\$C90\X#,J%K7J'6-
MY\>-NI7=5?.D[H$Z<SPI8;"0@6E$>)XA!N='3'9E\#<KC224"_=P36&>3/-X
M R69KB1*/8]J3,74+%O?VDGUG#E2I=6G84UJCM1#X^_V D=*,*Y=#GHZI0[@
M5SJ"I 4#,(2,6))S*F.!$KQ.,K%.B'Q8HNI#[-&7D1'X:&CTW$Z%NU+\'V2"
M7B9,OU0:UA12US2L!X3H>1J6=E8QKS'2+@!$6S ]E,("$<4S+[S@F5, T=F&
M6NPP\=;A^0Z)C _TUB\!BQ[%MS<#&J>W<_35OKQ[0L8\\QT+D5EF4.X\0$;F
M,3)$&42TP'%=7<;=VKM\(V?/*,FQUI%J'>FU4+:F=*.:LO4P&#=/V<IR3V#A
M.9*$",1(YI#)O4*&Y\(JY2-[8^T=9>RA2U6])K6H]J?]='_:3$^; DYJE]>#
MNKSF65X,4ZDXHPCG*M+1L43::H8RIC$7P1HMV*/5N'H%Z/&S$:/6YUZ#/O>3
MB613&EJ-J"LCZAQYS#IMG;("&<DE(&K(D,PQ00;[0 U3AJO'J:3U"M"T=E$]
M5_K9Z0PGI/91W1<TYOAF@5C,X _$I=.(Y<0@%5R.E,>YUBPH[O&SJ\15*S6U
M4O,<&6LU0>W!8&J.H,:LS*GC'!DA%6*2YDC[W -J*66]-C1D[)$*>?U,[28Q
MV/X]BOKQN_164;#;O7'RC\(GKOWCW7_#']6[3-W=>M@"@W)SODN%LR83<,W/
MCL?#43N<%^-L]QS<Y3<L$TC?XD9=/3AL]ZHID[/@6M[ZH?$"9Q5@I#O^UA[!
MX^P,A(AY""$10C[#GH6#+/+G4HGSV;=ZW#(+K7ZO@(S+0:0Q%'F'FR"V/]JC
M\]VX\+OPW#\Z\-W+Q(Z._Y_/Y_O?W(DA+&]=?,_@N]/6\7?:VMH\;VWMMW?^
MW(;[?26 $=G><>NHN774W=O])\1[-3\=:$NXIBQ#N<,!,1$$4EP2!)_9D&$M
M<YVO-3P [$F4Y,'8KZTLDE=)^R/(Z%6'6I+(K?$@]M:,E>Q&1P/O&UWXR=&P
MX6%DKF!X%E!6T3P;NN?B7\AZ^E&,GNC>>:,]'([A!X-+ 1]&X8JG4P.&]@,L
M\&%##^'?G4[_=-CXY;^* GK],8S>#7_][39(40#,LJE+>#6!UP(D80H[^F3H
M?ZO^\KMK#T\Z^ORW=B]-1/K1[[.KQ4\6\#$]KOCZ]].V&QW]!H?!AN#%@P?3
MP%Y\C3>R92IF\24E9".[YOMK?WS#E^68'OB^@FR01[DQ>ZP!T]O/<$G8KJZ8
M[(UB<9>:&"L8]#=>JA8N76(BE&+_)*JPFD.-A7,LJ<*["2J:!51\N(2*2 :?
MT7GN,;T_U5:ZW304R+A<U;N?X-RUN/KS$Y7;I@;<YH7?VL21V^PE?LU>>MZ%
M>>?G8;G9760#-/IA4;DHE(YG5'OW>7=]NMU\KQ8&#]9:8["W*A>,2JMS+B0S
M7F>Y<0+;I8;)]?DE<6FWT\H6RNG?\!I]5Y@I<[9+8N3\.>@/WT)[J.[>:>L;
MC(U\;.\?-_'>[N>C_5W+FKM_M%O'A[39;5[L?/O<V=_:O)AWANP?;^*];Y\N
M]K[]!5?]<]3Z\V.G=7%XUOQSF^QLV?.]BR;?__.?[\VM5FBVL_/$M_F2G>_L
M'IXV3P^8M1)KJA%E*D/,&8=DL!)))5@@C(4<Q_(H7*TK?F\N\JJ[ZKD4":B1
MX@:D4%0!3CA#N60LHUI*HYAQ3N$@->8)*4B%%*1&BI> %-D<4L@LR[$V.=).
M:<24(D@"=" 5,,,VDPISO/9.9.N"\9<"% ^B=SVG/-_;[>X4;'AHM:L.QJVT
M!F\Q&'?/LV<Q&'=/%?4R*G?#N9,VS#7'SFL(R#W5R7*^H(,:4!,PSA7*C(E-
M^T(D;S*%=,Z\SQW37K&U=TS6N7 UJ-:@^OB@>C]MO@;5GP*J\^IZ\&#68T_
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MN'G>[/[S?>_8DCWR^:BY]97,<P?WOC5/6\=?>?,"](&MP[/6UMYY:^NHV[R
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M_$]WSH>P XN^L5$#!)&.!/)"&2_%% 9W"@ T/&J?-.Q1]$D4&JH'P8TJ)ES
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M/8U+;+045F42S@/&G%*9E2KSQGH&6K70MU6I:W_;O=3E<S HC89C7,@<2>=
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MH(S1C%N=^< RL_9N4?6:U;8V&EMC7[$_IX-  "8Q2K,:8@"XPE&0ZAZM6/@
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MU*.2;I0HG;'9]*MP0LP8\G.-M:NDTTZJ% I0_4O[UZ*N4U$WR(#"V>]5- R
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M"5[+ZV)6D* GJE!"U'G-Y][,_SJU_<K4=E*GMC^+H3Q<:OM2TOZ-)/SY7.7
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MUYI^@:CM3EZ@<@1<1P1*S^IJYU.-AA-0@2-]Z5*/7\6^ET)*  6>P=G&%!6
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MCK&+R6'F,^BI*)TA#QNUP(6($"F%-573[GG;&,4)V%^5BGWY>.=2^GJL;L(
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M]YP:$F#QCFTO8\+E% $V/:*YA9XA=F'BYEBFP1Y5^@#60?WH%>A($Q!.KX1
MHUZ%R*=YL9-+T#;/+YU6KIF*D=LZSV)GENSCC)I ,PY\,ZV!)!4ATM/:.O=D
MR4!I@\?-,(8R<90=VI%/>*9\:N(KJ>GF+',P:+6*]1Y+F:HIZJ$8KQMDYW+Z
M4+KV:$K"5PL)BDO;YV83N'[).L$]@OJ&CC*N.W48;Q]3>K#FA)(&@H28I*EE
M@MNJG8SW;D_K3*=7UW_W1^./-O@\#XK>#DA34&FY(X2?\7JW24K:@O#Q-\Q-
M1\K/BE0\LJ#,) #G/\6;'E-165":/T&5D3*"#@1NH$K7,4P][>=R3JW'^$P_
MW].=6&AN$0,(3I $H2UU,2?6E2]X3; 0D-]14/(#UG1PLK9,:.DQ%EDC8&^W
MC27 SW0^?4EE<#4A<4[+536TN"'%PS97WKLLL+8*Q_\B7"Y-UQ&X"1LA8S#,
MW$T3ZK$$W!C+' M.-P-BP)(NW:6&@AY\?72?3$Q(H3PWTPG6O_'#B#["JY64
M8(=MT],>.[C]8L AU=2$LN1ZS*N2*[?NC,#*K]*(% ZP#E""! 7F-B72YH:2
M^C"O)C>]R'2VC<LU;(PKRDF@E5LJ)]U<'._2>\;GD:%_.F$D\BIS%<24EQT,
MKI D =>M)>(8$R\_!XLE7.'&F!U52$>7LJ(O3>TH%!6%?57%,C&</\T-+7LZ
MKB()2;.)2[=\8ZE83OO/]4PJ::GJ]@10/JZ,,_.$+4O&%$>=I $^)K*YR7"V
MCVI?OP^T4V3<N% XC9LYB6O,:$*<[GF7EX*>+MK@%BC0(N*E2CC6AK><<AQ9
M*TTZ_GHED>:-8"J_*>=:)RPQJ-4$)[#:1+L9,.B .UUE"F1A (ZD(]*,GC3F
M1M\QP!=R+JS1S-RWZS<AQ=HQ'WKFG_.1O(.2'$.ZHC>8@2OUSF;(F;W!W+^
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MTF(L,0<:&&6+5[7&7S)&0Q.%T6),A[;@[B E9[I%>#2QK4JT#N8,V4Q2=\2
M[EIN.S,5W+0,DW+U4^BRHDR!^89R92YM2R!E]C;H'H0@XS)N68A41//7YG@]
MG?/QWERG!FH#LV=!)X(FFO*Y'#!0JA0?RSSZN%.UE7IHY"=I/99,G.&>0H:V
M1^0TN!_P#CUFQ]\U[WG!<=/O?UAH/_()*M7UQCH-,IX[37<)0+_DP98=B$0]
MVLX3ZEYU0NZ*<PQ+\A#G9IU2Y)H<$)=P_4*/-):9.[8&A+#(J.9<FA:;'DQX
M;^?K"J;BCF ES<'4O>"E,I=9&'YX; A2=JSM$@Q95:G]Y3A3'_0?/@(7 UDS
M^1#&! %Z:)5>*X>[M8.])JKV>0K_]O2+1>NOD=;_-N_-?K??J!TV&_=^O5NK
MW_O=0\O6F[7&_MY*RS[\RL;^JD]NTF;?+[3L6R(&)@@@.23H__JA:1K\R%R]
M#XWQG5<OTS&.VIOQLQ#!/34[./P6-]CE(81X.<V=E(.;,QV:,W7]X.N >LA6
M96M]^N?C X=EN_]ECCLC&G8?$@T>L*=[@3"+V%T\Z0_+__0O0S?V3,*A20Z.
M<VDUB-M[782#(NU)3KL Z6P.R!I/>Z?N!<RK@\U4>=4"O&$5_OMR3&/^J2]-
M ML)Y[EE'Q:Y4_>=?"%R6(2LO@7:QZRQH9M<FEJ#0*EUI=:'1!S_]_J>S-9I
M\EWF^+O>*P#"CX\ZH7LR*CE:IZ,U*_5WA_/UF"6IV%ORL$M=T:E73E_S+<6]
M)HIKO&]N*6Y+<=_M:#OUW;TW+T%KW] /M'LN3BA&_0!YON9?;I1*_VTEZ2<5
MTW  CF#9OJ$WZEXMO[$<,.:RD[6[=,W*P<'^DFQ^/N:?E<TO:C]L*(Z:S7=;
M'*TWCAKO7PY#3V3@,J ;M<;^Z^'CL__M4%6JK3^4,L5L);XN@%K8F?<ZB/6@
M\GYO;S7=?AFWYDLJ_G]I[!XT=K?8W5#L-AKK>G/_8A;$69))(5HRFZ/TE]!Y
M=DB.+&ZR;W72[XX?D 1;_*PM?H"7OPAVM@ZO+1"V0-@"X5'^W]?M0Q O 566
MA-AW76$G)_(4S+#DO["U<;"_K.-Q:TF^%MSNO-]?.MRV1>O:H_7=7F--K^Q6
MSFZ!L 7"%@A;(&R!\&P)**_% /FD8M4/<_8@BP62^W<KQBF7R8U^/:H,=6-J
M?%PML+XVJNH3^C@W#+\[C<K>N\.E7:!;S&XQ^[*9,NLL6-P8Y87"'L?9C$Q9
MT!24XO,F +N7%%C*KG?_.')=-Y MG53]A/!9[VM\4*F_?[>JE^@)P+/FY0/;
M>[*])W1/]BJ-QL'VGFSOR?:>/%SB4SD\J+_">[+UT&R!L 7"%@A;(&R!L 7"
M%@A;(&R!L 7"%@A;(&R!L 7"%@A;(&R!L 7"%@A;(&R!\$1 >$M]X/_Y6L8(
MS1]O4$[=>MX=W#.4^@;[/$4X=H=S(7 Z#<Z?^?&@UL#YOQ'.]UAN7D %$&GG
M,?RXM^I"C>>9'O*]0?QY2>#-]F8!,.8^3M,$I+PWL"P!^:!VL"*0<9Z43/6A
M@;*Q&4&-0R.:M;V_U3SO<G9/^/HTS!0/]S5C*#Y,I2-^&W,2@*IBF/)#\^#;
MN*R^(#)ITL[!"U[9,KCJ>SCMD4;"S&UJ:]%%EYIF;-[IZ6(_-FM2"_,D][Q9
M:SX1"<()+ 7^N%NKEW<):\/._X8C&\.,)MP"(>+0$SA3KS"CL^C8?I8E <X4
ME7%E.!-E.[ESU<F=5WI@=)87O8FW,S-O^(V>(088 31-@"B]'?YQ>1(Q_ PQ
M_Z;",]%X:EB_GX$4ZDYD^2R'K[QB3&/;;F@HMUY>3]JF%TSCF-XOT\G.VIU6
M7>\;AZ0E_2K\CX;(C>%=?O857BG#06,:0Y<4F83(\V*$@U]#XK5=/??-O"-(
M8!/9&*=@ =7";N.>G_9HUDX MZ+B#F=VCJ#O1FEK7:_5/CJY.):CT\B]H1IA
MV\5)!2>R%7U80F9^XY> +%C<VSDZ/WHSO3JM7%MFQ-&6!S^>!]_?,_-;7/C=
MTRA:3\> RSH <.#F# <^K+U_D /32&<914>C%V-/C<91,H'M^,$?14B['J9)
M,>#;=([3'5,940T[K92V@5/3[W*5XEB[2 UPPJ]2//1RZF=^$"2%/D</BT8\
M8K/P.GQD,W3*GX&VDA3%! ZL!G CN8U@ 1)P!>,M\+,A#>FF48L%JFH^<3B9
MJ:X "_"G, 8Z+6@2*$^&'"&QXAANC; ,"2W&06(^S:K'P9#4&@!V?Q,&-'[[
M)NS1\$N<22;OAY\02NSRP.MD(AF+@& (,"?]EDA@[K R/5V1#M%5"F -" EQ
M2KP=>C_VLWP[*[DT*_EP.RMY+;;R8K.27\BG<4F<X52:AIQ,-PUYS5SWH:XH
M.&W6FL3 P<+X1F4Y*7_R6ZIE9*:,_R7^>P-VO>:I  I01GDF(DZEMPH=0&>X
MS+!&FG!)LI%\.CC$-8,7&4$H_)8^0V8+,N/B%^_B\LPHV-_#0?-"!"JDV0'%
M0*I,-X(X3V/OL^JFA9].1*>[180'"@0<3P:/6/.\0>4)21'QC"__!0<!3[P3
MD/$)COP]=OP'K2(?)C1?>T?F#E_\<G+<DH'#;SSB<[121P7#&,XZF'B?]$!I
MA/$1VK,HK4&AZ*1PP#X\<)4F@]0?F47E[V99(% P>V'#'N@!*$=!3$U1JM8+
M2*7.BFX&UXDG4X.$)A+WO3\*0%5_HG5!/CZ-R)[@R.PBS0J?9[#C"?2F^C2^
M.D>M)E"*#;H?&U:Y9B4'/MDWZG9I:RYI98[>DJ)XP)L$6I /']U3X<QJ*[RA
M='7%$V+>:!:#"SN?(WW?V<M_856KN?N JK7X7.K#^@];_6RKGSVW^&N!()AD
M(7&ULQ!4D!YR=^0Y1_X8!W-[URH#9A:H96:*KZ]<;.%)OX^O:%V#?'-=1^07
MZ"VOCZ(OI^S .JA;N03K)NE7%+B!4-.<W^_6=NWO\4U9G@1?AR"V01.AKA;O
M/FKOQ-S7F<<WPYMSS'[=91Q_@+T1J"BH=(2CD>JA^YNQF"IRKHD_1QQLZB[,
M<L8*_*3K1WX,][OF>2UQT;$CZ5;<1 )[1 W_L0J;_DK*1LE7-/8GI"V)'R@3
MU[0XD$A5V@@$8:, @MP.@2>,WZ +5+Q>H$Y.G*AM12P_K72BYAT']#?KI6<_
M<"9AT\S;(;,K*6"3O>S-@C%4#!J1Y_G_RR75FA15^P%L(G^<J0_Z#Q]U+D48
MTPGIH8]E-,P)0!$*^&M1*@X/:^]VWZ%>(9DH\N)OSV4_.*CM'>[?^_7*X][W
M:N^:JRW[\'?[S>;S;/;=0LN^AAGCW[Y!RPVG7Y/9S]-*Y2-GT/]U,&D/]1I&
M?"^&YL=.C'</O"&ST1<&7&.9>[#>#886O"!&61!=P4GHLAK LW6??>$.$ O"
M:-46$.O;X6'!@^^\K]0/5VZ%LBF=3K9D_-K)>+]RL-=8/S)^U4.VEI4OCOWI
M&*:.]7FOM#&@>66#@Q:$T%ZE\?YP.Q%VO9&T<U#9/7R9\5M_22UTGA_J,:-<
M7B/)K3#28XV4JTW'3OW@_8N@9WX]V4OE-B]7/?-\N*(5/V ()PP>%>JUM4.M
M6<;SFJ,"ET7Z;4/?ZRT;W*%\ZA_?VZHYG>DRG6&V$[ZA ) NW:,<D0/W.;^'
M(,/T'TQI2>(JQ_E*966XN1]W:P?E#.\=>64<1$4/ SNT$@=^<#$)"V%U2CGB
M4_%ZF$J.]1BX#J7=C!*X?7_*US8E#>,12<8APGYX1XDQF<JSRLQ3;_T@2)5.
M)9\;EWS#3^V$ )1@Z,<#+A9Q4$)KTX^BT.^&$:,'4Y4&TR'&AJVFVXP(X_.0
M:H-)==]":RE2W5N)5.M.E<,S4ND*%/BD!/CN:0CP%<B'4V.P;JI\< WU>>;Y
M"C+"5 3O.=<!26MN,0Y>.\PBS.XE7F\'?P/?C@MXF9\]\--G2BQ\<9;X))AI
MN+7:]<4P\VV0&^P\C,1'8N85\(K/QHC=5%[QD+G^&#ZQ.T6-6- 5DL"U-(DU
M6_X=E>!A,A96..J*@;$_8;$*CQ,W&?J8=JWR/%)<:"XI0[=4 HLEV+IX;$-R
M@.9R\R?!4L/%4N-U8NF%DEGO2V!U4N NBSQ*DJ\;08.=Q!LI2?O+AJ"=LC:9
M  GD*AV!7JG!$6/A B7TH0H=4(T#EF7.3P2LW"-VN(3(*1GE2H.1@C/4/*[T
MDEQA_-:^/DB*J*?U<E,'#*@9)SD6&6.U?8;%%_)D3W5SSRCL[A: %8Z++L@-
MSK@+;S#1T5R[C/L'Q"K-AN&8-OP6?D<I;UV1'^9374?!BCCL'Z XI$+:B5-R
M"K"1/CBLJ9LC#?TH4J36C_P)_/M5>6$.1FR_'P9%E)/!4="E2GVP>VP"+-4D
MJS%#%_&4X5E\0%X4<2U)3XTH55"*MIWT2P8,J&5PDT=^H IR8W'==XSPB<*O
M5/2;H<T%1HTB(O6*,;P6%@46!9PI2;.*8$-SIH%4JV<Y I2K=35<X6.F!P"2
MSDTE,L:BX;L<;Y;\P+M)L*X#3)E)Q1P8P1,GN=<%S-_X843GQIIT_P908H
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MD"0J4;A@+E_J2,H)I8Q&''*:?J"RW/%G>?I"3<*W_<>?5I8TGZ3_>'VWN6U
MOBD2Z/O3YGQQ<]6Z[GBGI_?>U_OV^8UKOB['N^S\?'+MG5Y\OKP^;W5.+R^>
M[*"+WMF#M8\KU&O>V<E/K3..(IP<GU[\M'08X>7U!2YV 5E+638EOZ<>C)*
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MR ]\VTUZ$_B_83Z*_OF_4$L#!!0    ( #6!J589QW_><P\  %NN   1
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MRB5JLM0H^IQCN=%BXG<2RNW"H1:*N:&GW'Q>?T1ZUR\__#]02P,$%     @
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MH*T7-<0,2E81TMVX]C_?'8Y[RY-CAQJKD=31B&<5,)X9 QM+7R6!P*C#,6?
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M]2N'Z(=PC^/^2!>'.0)F:<"J]E@S&&]2=\ ,OT4#OCE =W]A*O7DO,H=QII
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M*+61>SW^*:2?J?T5-" +35HY;HS!)1? RWE4+7 CRMN<"K_VMZ4[,T U(-&
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M%0QD5E;^K>Q)WY;?.,;8!_YGEO\/JQSB[^<Z2O__%PO_-;L1O)8NP:&6!KS
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M RG/EC!+%'@9D&#IM,)?N=3ER":5?K]H4OZE[;TTO;L=Z_7B)_G!9@_3BFB
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M,7/BMWOM)\X#>'GCA@P5E=X@>U GGA0S&5E6'>6*4\SN+Q 0R3G_)H@[XJ'
MX^TW1FP\*8_<5-1F#^O+_(@)"$E+@-8)"T2WPZ\YV9\Y"F?V435+Z:6CI-^#
M+/:':SV%9-L>##+E7<M6G:^3U"7L#4]?-DF5BD1YN*,&66GI'*\J1W04%1,
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M<K8H,QE+YJGP\J*C;FVQ[X(FP<]UPUM)+]YA=S<F &A MH,7B"#] 0-V\B,
MHIM4/AU==.+D:69^9)([6Z=$Y_YCZ9E'L-KEWC++CS"!/_F\@3S*-<*<$9/3
M(8Z-:&>5_"PG6''=2UY!\"<47#!3)Y$/\[SUD"P&2WN@BO5=X !UZC\T["]4
M1-UR<(%7D2JCPJ)X^<UO#R>*5RUPYN?E7UH*XCJ-%,6!4 0 Q7K0A0FNR5N!
MK$0@"))JR@2#GYG>N"'$?YLLHZ150(J)Y=+^TB6Y?%I)[#A:5 N[EHU8\QN
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M;.@_&\W__A^5"XA4F&O1VJ2^E/M13:W.+0;5NM+O3_3"%7MZ^')L5_%DP[>
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MS_O[<^]M:LV5JU1\IY[$O>8]C4G5FV[A;9I&)G3"6"'V2(6<0J<YL:%M%Y<
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M9C@CM *L1"'.:U&4=MIIS2TU+J^_\$XMI?AI3ZSM(9E+7VSFV)E%<RK,2GC
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MP Q9HMN-OY+@.^)Y:H78=I;I/^-0/*3R_65P94][>.+,Z5#=5M 9:"\-%DH
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M7T!K*\1P3HJ/YR];X8R&[5/B/\)_:.._@<H)@+][!!H3/8XF 'I!)T_PW01
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MJP<V/+5R=G #.#(CB!$Z+(9VQ9,+@["S0/0 _ )H]356BL@=F6 XEXJ\#J-
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M ]3N+7D<7YN_5G16V9:JA^>^4 6W&M[<M+"@A7VWTU)G_7["H]\#M3K:%P1
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M3^[<,5JL%ZVJ>I="01(?G+G/N<KA$PFR2\!J2H" O<2L#3@%18H,"5?)!49
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M<UAO!7M[>47JLS=IWOF92,);>\B ]7F_58GBO:J9X,\/P>_-:8EL=5C'B-W
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M>G22(!])V*D=<E6M<LO*8BB@//8;C\CV=BNR7#.6J!A<=15#M\M.$@G22L'
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MWYG+QY&.>(Z&(.B,^%=/;T2TQ\RL']3*)3\S\55N/>2Y\;FJYV\:#_@$(CO
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ML&Y9BV'XRJ0[;U6R(&0,69"B254)*\G/ B6(0M:<A*(C+3\]-!GP!IHNW"[
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MPJ2*^=GM7P=?@O]2X*0">/&7,CX\,UE:)"KND_)1) O8,4KS]^\/40FP03*
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M]U>18)RN?RH>=QR2K,-D*&"6PRVL>)3%W?D$U5/H0P=R7D^6"+R+6G>S('&
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MBWJ@BV>6U'B)_+B<%N7 -'>Z[]/.QB8,5H6P\N*<RNA(CLL*=G'Q%[45OQ?
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M=2,@6WB$VA5""CZP@_-P;$07(I<4/=\AU^Q::G^VG>>9T9DM+'Y ^W*CO.B
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M1<H6SOLF 58+144_>K0DU3UE=%@;;_+>9M%JXD;H(]ZJ4(H].N;GLLPT3F3
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M))Z.%NM16EI7ZHO*0ES,7*HQ-&[B\,WF=V[T):/-2:$()CNG02*KLPDB7%%
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M\#][&?SM3< "$Q !Q(F'1Q;FK>16TTS=3@ON_/C'WW<1=&CXIN,<F WZ9IC
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M-_-EP]U6B"+>(HJX;AK,_XX8-!_TU F;_81+:D0Y!WZ_9:'G[1(2SM_M:RJ
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MB?D%M6N'O;3GB][UL 63W+F>5,T\Y]M+ IP'4Z_*TZ)#:XJJ\PQ^39C4**V
M;1C)+E!O6>A,;3T,+;W-+!M%ZKD;@;-"^@'WGM>QG@)\CS4(4L8(/)WP/<8-
MNX5A=CKK1LO)9Q6(-L\3\@"(6ZR#7XS'L*.-FO6OE#4O27XZ1]&IR8KLK3B\
M*+@YXNC.#.4IH.DD^Q3 EDY@$4(IG=!M7SH%S!&&3@'A>BM"0<A7]=Q(R]GS
M..+!=U2.32V8-IA8D^<<R(KG@0CP>*=8OZ<GX>6\1.JV)>PDSG:XTBXT'N]
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MX\0?7G)30!C65G[3O,%U?%4-1FXP+9;4_"0/4;93),SDR;(MVB,GI!7.^E/
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M(O+VQ_JF>ICTW FD%9 >9\8C2I?4BKO&/F);]YPB H'U< :H+T:J+QS&E[N
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M:[]KK(J?^1=?2F\(2I.P^S&+6"!OPPEG6_9AI<\4(=/JLTCK.VZ94\C;!.A
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M  'Y* 1-+-?F(\A'I.:IG(^LTOJ>:M;P5Q>T)VF212D(>F6T4=8"R(I^@HE
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MHPL1\5IY>.G=%.SW#B^$8$\-<U3WSY>71V1:;Y@^)WT:'? ^\DHV2C^5CT+
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MHA>*.#6V?,6#7/5$VDM(]?>Q&RS[MR[L[*CLEG,S][YT;W1"1Z@&GJ*XX&S
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MJA?6!B2&@E_[D$AG5U@?@ZZRYWX,YOPD!^I7BY_?1VU,OT5V^,^I;$[>:3U
M1*.\LJPI0@^(,TFXZ7/RF7#=>Q$!>2ZOFT5T()5W$WG74W/Z*O0OE98)'G_0
MO_%WPCP#<_5T*W6;$4<+='W3S@/R'&8QH22BSXB&G-T_=BU?IY]7P8BXN1:
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MJCF*@[09:>!'@@/0CDY^F=/+H]O+EC$I.2?.3]C<OAFG.O8S.^=BT*T30%?
MNG-1 AA' +(W+K'@BV@G*AB ^8A_$*P<%"!^:V$/(;T,P!(7+&P?\Z ?)H/&
MMFL)H?O.M\$H+' &H(O['P0OS"NWP@XP& :@3[R1<ULK^VO#(P8@+ JER@!\
MEHQH)')-,@!Q4O^)Z.\7<NZ"P4="_4#@P@N(-JJ8 >#DIQSAWH3PH.<D*AD
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M+22IQQN8$/Q2;<_7-V(1_BOQ"M<TYF1??WYEP&CB]F>O$G6+VE&P=5_Z% W
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MDH<(+ZG R XY+D:%6S'B%INI:JFPXJ43#*OS24J3D@SN.ZADL'$Q/HML05$
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MT=L&=.>M3Y)ZNR'L%)5WB/#EJ)ZD0C<?DH7/VUZ==A</N41BB63H\FC5'#V
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MVMB11="A'TV/1V]S*R.!-P$J.*FVP\L'/S<9?M#=/54OK/NY..;-P_2%3XW
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M[$G_^V9/MDF'_Y&OU_ZS8OX/;VM;^]#(_/N#N9^2__AQ7D8B"S?CKZ,)!-;
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MM7]/GVR_TD@ .H\^R+XBG(QGSE63\8_7OKFNCJ'LX9LT@]4Z(ADA"6S+VT=
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M88!E_Q(*L@*UST$TPGYACNHM8 ;2"ZJR7@!3K%H4T*0OM,>_C1RHM)Q$ 9V
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MJX6BP[?5G\KVSFZ4';_:46/U>3+D0,JQ8$5''?'::7G/B?"N;"8KW?'L19?
M1W)I'P9@N[[B"QQ/CL_*NG=OOEPL-[XY1S#^VHE?5-Y! K](]&=E:6U/)0"2
M*"P3P>]?#A] T4V#;QD<O"@/]=J$Q#\VF(?\8C._ZHO\S@K6+D;<"RW%DJB
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MQ2/%:$;Q@ GUJ<+^A@I11)X]@QKPJL2H8]^JM;H/[\T'5G?.8$)Y$Z8C !K
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M;(""U]KW-)8X^%Z+-QZV9_%UO#$XN*#_<6'$KN'V_;:<5A[S>ST+?'@Z"S[
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M S>K#I#Y(C2BA608$P[R7;*S2#0DFZV^=*S":BI;^._'=R"\J;,]5!.= ,&
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M;RUU8?<NOU&"G53D0?4XK<V??(2TU5%)OLQZ*.^][)(N6VO=UPH_.%JN5N8
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M3/(\HO/#Z8E&]JI CCYJ=MD1VS/&=O%X_!QLB0+B787_<'/F+X]20'U5TV2
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M76]A$C&Z^5K&>)'A!57J.V<>GHI$>I?HM#H)EN-?DP'>J6;XSLEJ,M K I&
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M-?Y2H\I<8G'J_4QF[H'JH8"=G6_V;:A_,"0&RHJBK=H:][*/UEZD4(A;P^&
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M$5R3UJ();L8L<.K>"POW7JTQ6/+^ZBZM^WY0.0,RZP[!;I&!,#*P)8*7(@-
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MBWRV]PXL+&7";RO#-OXY36U3L#M(3 FC==(,GXB6(ESA4NRH+_=6OU&J7GG
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MA#G"B-#KEO6ZF$,;E1VGXHRG$-9!,)EW>)%F]I"G-;Y9]L9Z7>GW$T=9GA'
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MXTUKWQ< T>NZ^Z*0IE-HU.B391$Y]QZ(3J(46+$NU7/-KQ*_7(_[M@\*K>%
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M),D9000W1=KL2<.7_GJ>$FTR!<_W#=UMW4XZ!]P-1)T#J*ODS@'(BB;\O7/
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M,LY<0)A@+M1&I=9?Q\+BUB'3@TJ>D(DWU_5E]1<7?#*J8*RD/^C(7N+[>7"
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MK(=(%NBN)9ZK%<0"S;48DISR];303NW1]N=XK)U='?.PY\ZG"AKFB;#FY\S
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MB0$T@0I)S\[X^$">]=&B>UJF[# D2)E.:OL6L4GM0ZN'T['.>!"\]$\3]EX
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M:J9::D]%KBXY[L-+ M)L7;]S)/5>?MS"JW]CGE-PV_DB:@"@XP<&Q$@"W8]
MCD'DX[';(S#!G"+I0I3S\1-S6+5C?8\C;=]<;RP/S:)4:\[0)5G>PEDE2B)_
MV\#9P)DDH?@B=54 9JS["2=\INGU=1#LE=18X75=>E/_@G+_)O#J? !0[=*;
MC @!ZG]KKU;+P%*"?PLKL$V1^\=D2 U55<2^H[F_L&QLS],//O)!FY9_7*[=
M_LIN7W<3L- H"+LWT"@&U:O@\'6C94B7KP/WL-2GIFI_E-7*@'$4USQ\R!W_
M"1QG,X%LK:TLS5N??3#J!>=REDFQ3+G?BU8 6)@K^13=@] _C?JQRR=#:&:
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MQ5ZJG B??KC'L+!G#+SRM*]/J[% OZZLLOAX5:,4@9SMS[4_14LEC==#%A!
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MU=-/ZM;Z9?TGTC_"YL?Z+3W[T%%>USZ3-N]M[W7V+_#;9:4>IA=%ZX?5NG;
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M:B=/E_MO8N6N"B >-&2IH%$>AFJ,HB!M(E<P5^-&@U@F0C!,4=P.V=LEG\*
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MZV>Y6NLCR/+SJJQNV#\?B\:AFI-,,A[IHN\A%1"%4J@%COJ5R2PAL10QB^B
MRAH]8J?F$756];IVUI[J,Z"5!QWM!U6)Z!N(R_3B#][Q]DM>"ME!-3@<(CQ^
M'8YKD!Y:DL,0,,.R''U/>XG2'(86GBG/87KWP$YV]P^+U;,07\7ZJ6!BER72
M#5%14\U3G9E71Z.4M=/4_;M.,/FXJOY35%^V1<*;8]]WJW7[D;XNG"<8<8&4
MHYDE4CF:849ACB,.9: 6S&JQEF41LVIR-ZKZ4YM]WFZ2V']KPX$@:4/@'FKU
ME4L+G@59EWI_GG5C[IA^JYO.E[NZ[I9]\L;]YIAYT=/]/GB>+GL2 F=@:_0F
MF%);J3ZMU#>D CM#9VW(#5!\ SK&.FRN]R)CY+;OWK@FC-N2[T6&YZA;W\MH
M,6P2_;86I'Q</]<[-<VF39NSAWB0)UF>P#3/&40I1Q#37'VEDCC"/(T3BJV2
MQ\]*FMK4M%&TV2RTFUG.PVDV"3@!R3-?[^,SV]2@=Y_[V N&4V(\+VU4#NLU
M^I!N^F\8Q@R*LHKRDSQ(D7IN_MU%PJ4A(1)E&$92M[L) @0)BT-(11+0.,>9
M8%9NL9G8J7%&K;5V5=O8D@%U) SQ-N,1]RAZ)I4M@#N59TV2Y#/XM?V_E^A"
M.Z2<,HZAZ%'IQPZ.0RZRO'OX6791W;<QB3IM1 D22YV].4^#@-)ZD<Z%8J.8
M))!RDD*)"<*ZGG*46;7WO"!K:A344;4^$-Y3%OR@G$D!PMCR:.@2UN9GP@X0
M'.%X^"QX;@^(>\!P?E9\3M[HQ\8]AI\Z0>Z[96!JV",MQ3\?U9/?/NE0&QW0
M/"=9FHD<4YBJ[XIF#@ESEN4PPQ'C&4>2,;M$L!-"ID89.QU!K23XM5;3LG;#
M23C-R.%:D'SO3-GB8Y^_=0$ M]E:IP2-FYMUP=2C3*Q+UPY[Z3^(LA1B/XRV
MD]"3!CKD%<50!$1 1*(4DA"E$(=II%Y_'E!I%0]W6=S4B. @PMLR_KT'6C,J
M< >89U)H%-49_?N8><I^,L/%*5?TB!R5-<S,/^0/P[L&%X/:-([ZI*.O]+;M
M6MR)95D\B2:<19]\?A35)ZE;N"4$RR2))4S"6%>($@DD08:A3!%)XRS$(K.B
M%DOY4^.:;MNV)GJ-=0T BTLEZ9T,B!DA>839,T-U$:Y5!WNZ;\/?M/I_TGGI
ME=YX<=LD;QAXKLM26>DP=JVJ(0"=*& UZ#$#XNMN;F_7XE9)>K^LUH42P.K
MWDW]XVZO71:P/$=A#EDJ(XB8CLX-<:1H+T]Y&$1Q'ABU0+>4.S6FV]8&WZOY
ML[4'; UJXM$M L$LQN(RV7E$V#?)G8.Q4Y/=NI>T+;@6879^0!XISLX5V':!
M=O:078RTLWC<>*%V]C;NQ=H-N'UH'].W]V)]JQ[TE_7JM^I.3S1D^3Q7M*[(
M/DUA*D0*44YCQ?(TA0+K#O=AAH+$R+GMD3,U:F^;<FYT!8VRH-76MH7I:6@O
M,[=#P#PS]4"L!G0OO8C$E<U+3S][Y-ZE%PT\;EUZ^7)W^VC;=/1-??:FJ)MZ
MZ"?YKB@96?RG(.MY$N1$I@&%*2>!<@N#0+F%0029Y'%(E*M(,WGM'IN9*E.C
M$YVO>?V>F^$P#-^/<P_NR^S5=2I8S-I0XL^DX#.PM4<OB!N+@#;)[W:>':S>
MM_H,U7GQ;4 [V$RV""V?.(Q #]KQM>&!"54KY !+&%*]9(Z1@#F/ L6-H?J<
M!SEEN0TWGI0R-=H[;$MI1X&G@31CMZOA\4Q<1PT[W4=77H3 *<F<EC0J?UPT
M]I :+E\\,.: W0G^N!"?Y%$WFSH"O);4%LO52[BFOFY9/MXWG]5'H+LS-9'&
M$N="PB030BV[@@SF5'%&C @/LYCIG"2K: 6GZDV-9S;6U;/ZMGV+_NU\9>\Z
M+-\R$,+M&)LQV<N-G&<*[ [:A<+J#3UNRZMO300=&]NX#3\!I'X&P&WPAUL5
MQPT;\0+O4<")'RD##YC5XIT7BT==N6=7:/.C>E?>K+0_.L\R'D=(9#"):*Q3
M<W*(!:)02H;2($YIP.UZ#O4(G!J?=_7MU)^= :TR^+51VK8#41_HAJ?&#J'T
M?8)R'8KV9\*&T+@]!.X3.NZIKR$$1\>\IO?9;^Y_$+=DT6P7WGPORGF8A@2'
MA$$LPP2B! 608HXA%5B7&T=I*(W.;D\\>VHT4JL'VNWI7[6&AIQQ"K?^W?HK
MT/"^368.A-6V_!F3!V_%'SYOM.WW,X9TM]S/76+_2KY>/8GUMO]=QJ3NU1S#
ME# ,$5+SO/J50O6BBCA.0YIDR/2%W'ORU%['6CGK#H+'@/6_B8-A\/P>&B-@
M]1*>M';P*[C_M-%>P)-&=%^_TQ<,B7.JOMV)IM+])RF%[@-R<[L6=2V*=H\Q
M9)1DB6 0!214_\08XCCC,$HXUX73 QX9==HSE#>U%_7FV\]@JZ)-8$T_LI??
M70]X^?:Q*Z"T;=ME@(V^._3Z]W4'P6@3E^04SK'BD7I@=16 9(S-Y<"C_L>,
M&'!D;--^H)'Y;0,+D:C;/LE.W9_:JXYEP!(9"!@P%K35!7+&()68!2)%H61V
M14A.29D:O[Y>+93.*WTPJ5;FW1Z3.C6U^WL3W5W=D278O\EF-7-Y!,RV/:[&
MU;MGY1M2^^HFER!S6]GDI*1QJYI<,O:HHLG%BSV$+?VRY$59ERP0_.UWIBZ]
MN=>_S4/!PB C"*)$TP\2,<RC.(64TICR6$J4B/FR#L#DWQP%+IU3QNAMPLW;
M=*22WQ";/X-&Q1*LQ4-3 $5/QX4R0?UFZ")>-U)F-.4/^.G$,W7- (T=[?",
M%,74A^-X 4QG-9E.[%(?6%9A2[T/&UA\7_SV/S63/+\IGHI2.?9U+E'MXK?K
MC9P1)@6G,!-!"E$D"*28"!BQ/ F$) &6J8V;UBMQ:BZ;[NW::&Q9>K\76C-B
M<PJ89Q+;804VVK;YA\W!O?M0)V-TW%;G[Y4Z;I5^4Q".JO4;WSB,7IHT1?7(
MFZ8'3WN@$B&48.5F02YY A&G*<R5.P:)6A-F 5'>EUTII]-BID8D;6ZN4A-L
M]1RTFCN#JAF=7(^59PX9 I,U;5Q&P2E7G!$U*D%<-O>0%7JN'K#QWFD9M,E?
M:UIOS_,LB#.,&0SSC*IE&(TA3C&"0N19EA!"HSR:-W7#OU9D71GLNI\59O,E
M/Q3I[_N^T7&VGTO\2MP6RZ5>!^C2DTWQZQ^*9=LIS+#66P_X/,RC*,<!S+,H
M@BB-=;<41& D,$89)FF0X1;\MTL^+O0;@:,#_U;W;/,&N<$IB!,0O6^Z[7JN
M@1V0C9YNOIOFYQQ. !OI>&,8<'9G&[UX7#S2.'_W>"<9O1;L'6#T7SW,>]VD
M"GU;U9U-UN+S>L4?ZZZ+-VJI7I5S0C$2<9Y"$NF=1)8AB.-$0JGHD\?JNZ ^
MMW%D>R5.S:>M>\#H26K;</M#49**_+%LFGG<"^5!Z(X?NB)^O0FO^/2U6%IV
M]>@?"3/GURF^GBEVHZO.8FRU!3MU0:.O.X_8&!JGSG&_U%']9&,0#EUF\QL'
M4M%:/)""M[WT;I9-2:#FT:\?UVLE>TYCA',=V4E1RB!*E#]-.-(''$&>I5F$
M@] HFLQ"YM3HJ%6YZ;O;%"!K% 7D\NLR&'1#WG$+I6_F:5%LU:W1;,Y.&XUG
MH-79(?N8 ^26?PSDCLM YD <<9#%K4."Y_2#.BW>/HKJ[ZOU/]3D_YH\%!51
M;X%(>2#B )(D56MYSB6D<:#^8:&(29Y&22XMCE3-I$[T[%17WONM412P1E/=
MPY<M'GGS47EGLZ#L!]]@8>D&RY&BZ[2NW0Z/33'#5E_0*NP409O(.I=(CA58
M=QVBEN%UI@!=CJ[K?<J(P76F%NW'UAG?-<PO?%<LR9(59/%^65;KQVUH5YAD
M823K<):00)3FBH4SDL,XB/*0!03)S"J-\(R<J?E_6S7!3L]!1RSG<#5S]QR@
MY9E>AP!E[=3UP.#4D3LG:U3GK<?@0X>M[_*AY?S:K-8X09@D*($LCY4[%N4I
MS%-"(8X#E/%0QC&WK-\WS93A37*;56[P$5J7W^QK,/#\*IN:/Z#H7F_RKDV5
MO3&3<L^9<%Q'[ZHDVTZIYO6CX)M@K4)LMP="EM.$1AE,,\XARO, YGDN8,35
M-!S%:G 3JTB'LY*F]E*VBH+%3E/KRN]G,(VC,$@H3F&<1 I305)(:)[#%,<H
MXHSG* [GE>ZZ.B:F6WG^,*T[R0+B#UDS[\8)7KZ7CRU('24][%KU(N&ZZ/T9
M:6.7M[]L](E"]CTW#&3=@[75Z]6R+'@=/;M:?EN392F%DL/?JBNJY_=MQ/K[
MLE3*W"RY_J'N9Z461CC(60H#E$K-T3',@SR!-,$YT<LH04(KCG:CU]08_?V2
MK>N4#<5!4E?:VA[YZ?.\/Y9 /BX6SZ!MYU[6!]RKIH2.)3\Y&E=#-AM_M,;?
M.MLS"G2LFH'&+K Q##26U7O^&]L<$J9;L-W2JR/=QB5CMX >4;?CQP\D^B=2
M+/1SWJW67\FB4R;GC:#5SZ1J?_NR6JBGW.I"KM]^6WV[6Z\>;^_>Z2/8^]6Z
M*OY+\->KLJH;V<YY%H89DS%D',4093* ),VI6B&+ *<\U2VOYT]B35?&M.]>
M2QM2Z>KJCUO^LA:DVB11KI8"/%\JH3S::!I2_<N.D&?:US;LU?K:F@OE:@U+
M9? ,M$8^J[\N:KINJ?ZKLG<AMG\&;]1?9J % A"IQ_R3&NX6#*#1J,MG:SD;
M5("&Q>%DX6^XW$X<'O0<=Q+Q!_31A.)1U+75>\_KUO2]#5*6T%"M#K!$D2Y8
MP&$>"P9ECL,@27F Q<#"O#V2I[82Z)9O/2:9#@<-;#IL/")FM.\%9\]D[@[B
M*XK>&L+EJ9YMG_07*E5K",KY*K2F#QA&9V_O'Q:K9R$Z56W;;%/*2"9(FD&2
M!?HX*(P4D>$0<I3&D:0D0]0J5OFLI,G15;>,M!T5G4?3C'J<8.2;:DX5X-X5
MZ)BUR'G(W>U%QRFSG)<V*I/T&GW('/TW# P=(<6Z+I;_ZGG[XU\+M;9?L[OG
M#^))H: C'B3)9*)<',@CJML1J-4RD5&JELP1Y4F2!T):G6"9B9T:AW1:"VR5
MK1=.'V_^-BS Q Q],YIQCZEGSKD&3OLP%"MTW$:EF(D>-TC%"HZCF!6[NP<Z
M,?5VXK;J:Q@CS,,X@4$J=6(#"B&)6 )Y)E(JL<B"V*AN]>G'3XUJV@UYVV*Y
M9[ S]%,&(^*9*,S!L/<^3MKLUN78%S&NGW'2O"/GXO15]I%G;]H@YO_U2-;J
M+5D\?Q$/JW4U9T$2\RQFD.9(0H12HMY=2M2O+"<I5X;ED6D0VAD94WN!-VJ"
MK9Z@4=0\,NT<FI??9D<8^=ZGMH;'*G*M!X#!06SGGCM:/%N/8=W0MKY+A\W*
MN\IDJ[*L$W_E:EWWTFIVXTB42![R'$J6J6F:ASDDN1"0)3*D+-&E)JPJA?7(
MF]IKWRG<I_0%>PH/VPCM ]QL;G<(HV=FN I!Z_G?$!>G#D&?S%$]!$, #ET&
MT]N&D4RGED.[TR:9R$@N<XAB78"0Q!C2.(XA8RE)98YPG!&[D_HC&=,[9^^6
M";$CC6, S6CB*E \$\->T13W^Y!G37?Z[A]+&?5M/VODX?M]_L)!A;\Z=;8[
MN\I?BMN[JM0YRG11W-;A1.JWY2-9?"B83E_^F>@2PSH_1KP30I\#OU-?IWD6
M$)+)-(29)!RB#%&(69)"G*<!3D.=ZBN,VW,X5FYJ#DFC,E@T.H/[G=) ZDK#
M.G0'2"7.JEZ3V_&\S$TO/4K>:>U,Y?H9:(QK*B_LS)N!=DQ;"T''1*!LK"-R
MP+N7'5*KPETO-K2CE?L:?XAMBX5Y&8.>$F-N98Y9F,P+6@?ES/S(N'+5WU0%
MU4[_'.<QIBC*(<.!5'YY&L.<Q"%,L<0Q0AG!46Z3@75"AM5D.D+NU6YMNE#:
M#5S'=R"T7+L/ V:T]7I;L_<'K>#YLB;#E^C'YOM9EG?DO,Q2_-C0L\OO$Y=>
M&P'Y>;U23Z^>/ZMAKA31Z-.!!TT]S7Y3&*4\2]3+CG@60B24&TY27>0GY0R)
M6,8LH<,"("\+GIICO=%V!FI]ZRE\J_&U,8\]8V#&&SZ0]4PFUX%Z192C&4*>
M@AQ[A+]0C*,9).=#' WOO_888J]!RB:'F8L\880JV$DD(*(D@40P 94'*F06
M\#3!5F&.E\5-C9HZ;HI6MYLD#O[O?\FC,/K734G$H6<1)U$G1,8T0#%D,B:Z
MXJ2 .:(1#!"B"19IQ.+4;I/6'>[C[-A>0'[F!7+;TY]K81SO\.>H[Y7SQ'TS
M5#P=_9P4^4(G/Y?,/W_P<_$N?VDX'XJE>%^)^W(N<H1($'$8,2+U-G"HZ 8'
MRB<-),6QB%E@1?)6TJ?&^0:)?^!7K3VHU?>0C;,;&%OWU#'<GCG*&=)>DG*.
M$!L],6>GP>22<X[ &9*@<_P0-PGM^GNUDW+#V./]XT+GYOYEK9;WORS7@BQT
MSJ->[+\2ZJNFF_/,,<MY'L8YC!%A$!&!U$I<1E!21@1-% =*.J"#J1/EC%[:
M\:ORUBJ#G<YUH(EU_20GHV?&E.,-QF085'VV,PN<'+$9H+5MNDF8OWSSJ[#V
MFF$^3+,7S2F_"LR^+/+K'CXT4.GT*<V;HF2+5?FH9(COU2N%R3_F 8EP0-3"
MF*8AA2A%'-(\S6"$<<9EE&>QL$I@L) ]-6=U<ZQY<[L6M<Z6Y&L#>X(BFN68
MP##&&"*9J0'(D@CJJ0=)E(5$AK:18UZ 'V>'XHLHA4[3 1TK5LMZH_5H5/P-
MBMF\YPEHS[/;V=-^L-,;_*HU![7J3F/8K %S'-UF+G_DN#=K8(XCXNP?,6Q2
M^:9F*O6\YSKZK@W$:]KA(9E'&0XCF'"NS]ZH@#F3%!(6TH2'29PGS&8*.2MI
M:A/&1M&VHN /5LT8^W$UHR,G:'DFGRU0M9*ZYI]6TUUK06,LG/+*>6FCLDBO
MT8><T7_#X([:^LG*Y6W^_[Z)U+U;+=0SRB:=3Q=/>M?$Y,\I99($"89YIHN;
M$D9@'L42,N4<I31-PQS;MMJVD3\U-MFH#W[8&/ GW9&P:\,?-R4Q?]5V@-80
M^Q;=5L-D1D,>P?=,3AYP']+S>PAZKIN!6^DP=I?P(0"=:!\^Z#'#DX[?*4>,
M+)J 1_98SM6R#\L$*:J+6011&.D$ <%@D.(P#2-*8F84J'1!QM2(;9M5V^BY
M"1-6FMIG'1_">9F<'('D>^/1'I]!:<=G$+@Z[?CPN:.G'9\Q[%3:\;E+!^0/
M;?HYUZT,=^NM<EO?(@@2PG 6Z9+M B(9"4BBC,!42"($3S-&<^.$H#YI4WOI
M=_W#_RYT<+C@X.9)K,FMT!6_:Y5U*L$WL;YO"GJKSXIE6;"F]HY%DDCO.%SF
M".?H>F:+C:IMV]..LM9U6<S@LTB:<0GC2%DPY^%TE,1BBLG%K)3>AXR79F)J
MSU[>B/%-0UM0GPGJW'Z)LQ"),(\Y3$-"U5HSU0VH!8*"L32)*$MY%-LUH.Z1
M.#4^[HEA'EC1J1]XL]6C4S@]$_#52 [H0&V(CN/^TWU21^X^;0C"<>]ITQL'
M1LQP7C>@((O/I.#OEVWWU+;"04ZC+,,$P8B37*WW>* ['<8P"G$J4DD2@:P2
M4RY*FQKI[)0%6EM8+.VZ(YM!;$8QSH#S3"_G,?-07L((%+?Q(A<ECAL'8F+\
M47R'T4T#XS9(>:<(2O]/D]036>@@A)NJKF13+&_KE=$\RG%,HCR#$B5,1VR$
M$&=(*G]&)S2D2$3,JB>8D=2I,8O6MIYY=;=Z('9Z6T8'&"%N1C#.<?1,-%L(
MZQ\Z*L\ J<!&ZY[EN'TP@ U*;L, C"2/&P!@ \;1T;_5S<,8Z8UX6 M6-$O_
MC'(49#10RR>D_DEY" E3_W":*NY)(L;LJO1W'SXU?NGJ9D<I>Y"9,<=0('SO
M2YM@8$T IXQU^I[O"1CU=3YEVN%;>_*:@0N/7;B/+KWQ43DENT_J#GAJ<:,K
M<;1^,D.Z%S%",%:> T1,K4=(1#!,&:%2I D6.+-:BMC)G]HK?CXB3D^*W=^;
MK<&ZK]S^379]W8>.F^'ZQM]H^'9$1A@(^Y71,#C=KI4L=1AW]30,H*/UU,#'
M##BP^_BHG_!)?I*R8*+\9:GNVT\<+>=ACB4+<@P#'F80!2R%E%() TGBA">"
MQY%Y$3\#@5,CQ49EW=IKU2@-'K768+6?0FZXS#*&W>"(SC&8GCFMQ?&3!*V^
MH%88'*22N\;1XJS.,9XC'===C:O=X9T%2!?/[TR>,]X1GH55>Z=X-O?Y**#R
M57V[ZGGADWQ7Z%IR!5E\7C7MG]]^K\2R+.A"W556\XRS+ YE#&-".40QYA"+
M6/$X)9Q').49LMHD<Z78U/C>I#3(#%"RJ(L\EG="5.J:I0"%,MAES1"+L37S
MAU]BQ#Q/*@9U2&9@:YF>Q+>V@8UQX->=>>#M4G%VDVOEI7J]&^1'K'5BH=R$
MJJ+80VI7/V7 \P?2OU[?J27 UMML"@F^_?Z@4P#G(F(HS B!N: 4(D0%Q#*4
M$(42HXB&,HFL$HTNBYL<5=>+7]$H-P-+85NSZ3*XAJSJ##+?7%FCU=5T6PFT
M5=9E,5 C5-SRV&61X[*3D?E'G&-VUX"%_F<%M%#,Q>O@_B:WZ8THB]NE3KR?
M(R23.$<81D3G7B/)(!&(PP1G.<MX)#'FQFO\R[*FQB%;;9N4Q1EH4A8!WVIL
ML2#M@=E@3>\./,]L,B9N%FMX=_B-M'R_ D>[A;L9,A?7[#V/&&^Y;F;+WDK=
M\!8[;BW7U?QG\KVX?[QO3R8091D.LP3R.$[4*CL,E&O&,&1$_<A3+%.$39CT
MZ,E3X\U6.;.7_!BGRU1XE?6>B:_5RV'HV5EK+[E'ZJ:.:Z1^.W2+CI\ZROMY
MUIC-VWC^@H$!&=O8^4_R]>I>NTHU97\1=5&AUZNR*NO7G:IU'/],GIN#E4TT
M=ARF(J1I"),TC"$B$D&*4UT:ETK=I(CFW"KE^CIUIO:6UYK"6E70ZKIW_#@T
M2O[*03-;F8TW%)XIQ\$HV >E. '/;1C+=2J-&_CB!+ZC4!DW3QU&M!]V&^'S
MG-($2Q+#C'.U8(QC#DD82QAB%G/=+#H,N4U/F<ZSK2APA%XRW[2,[BF '=-U
M43.CK8%8>.:@#P8 6)/,"5.=,D;W^:.^_B<,.WR73UUR=35NQM:/@G<>7?=P
MV-5SBS%! 5;+DY3JKL]!$D&B>[2*"&>(Q"A+0Z,&[_:B)^?9M)KK,Z%6=V#R
M';]V!,PXP ^NOMV4RY"V;6& EXIZ]H#YJK?=)_ZEBFT;PG*ATK;I$P;&[NKR
M,M_4O3??BW).,QZDC,:0XSR ""4A)$B$BK)2G+,P8[E=SX"]IT^-BVKE@-9.
MN?)*/]OHV3WDS AF,!Z>.<0<"OOXU5,FNXU.W9,P;NSI*>..(DM/7C30Z=#+
MC%=ZF=%=B'1C5U\][ZYIER*U I\>ZNC5O]3E#]XO/XMUL>*;DBAM192WW\6:
M%:7XO"Z8F',IJ>XJ#VD@(HC2F$*:Y A2(;*$H33$R"I,?T3=IT8UK0$S4)N@
M)N@?BB7@.G)\78('L6Z.'RP+=H[Y73#TGZ8YPB/N$W7M[FX6E8 ^@Y,;2MKZ
M&=C_@I2Z[E^#P8FR11L<0 V$0V=N_-%SZPV.J/^X[N3X W/DC[Z "L-FR(^B
MTIFHG]>KIX(+_NKY%Z70^V4;+[:\O6%5\=3T0-CL:Q.1DBQ%,<0TXCJ1/='M
M6C%4DUT8!PG#26K5>L!>A:G-5W4FMERL?BN!_CH"N5$=D*WN?[:;K0:,B]FD
MXQ=MSW.'4KY)>]^HK^>)'[0%:@KX$]@: 796>#EW& ZB4PH?H,:H3#P<ID-"
MO>))GE8./03^Z;$J*[+D=7Q<6R*QJ4H1)YPS3!.8$4D@PC2$.$T1#!AG,@S"
M,,Z0TW7"4$VGQK);IZ^C\0S<W-ZNZVY?PTI1^A]O1VN!,49Q IZ_J>._]QTP
M'7GW/OZUHS*N1S]8VVGY[]>";NVM7RWP9>:@OXE2+QJ67,=F,]T/<:4_:I</
M>EO\XB8&5F\QXBG788$"(L%SF$<(P9QG&:,IS0D/['I=O:Q!-DPX5H/OELT:
MP\;9YO+[I1EGMAOOB_ [FA+;+U%=U[2%!52K^N,9Z$ SI3VR4<9Y4I/LE2;]
MKF9B-\/G>KIVI-7+S.E*YZ+)_-WN#LY#+'&*$(,IE6JB#L,$TCC*8$)#M;)D
M$2,A&="UV8.J1LP[?@_G+876*K<3\:"N<#Z&=YPI=>AH_?[FR8ZENX.CZ<QY
M%P9B4A/9*3U_5[/3!:!=3SF71 V,<Q9E*<29_/^?2:4;5S\?1/4QP1!'*8,X
MTSVC@YQ DB("N90IQ1%B&;6*JQR@P]3V%+O1@.\>*]U,]^=B6:=.U>9L2&13
MKZCY<&BGZ2&#9L;^GH?",[LWVL\.JT'M%4K9&.$U0/,*&-V&A _08]S0\>%
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MJ<Q PM(20)*5@,8B VF:Y+@4&/$DMC$@3">>IFTQU^)&SYV8=E1C#+D9X80
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MB_HD5H^FZ4C7871TH;J \PIN5"5FU,@9TI=ZC$58?^INMM?UJ1XK?=6O>O*
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M4;.]XF:< C.Z/436-#L(@5<R/#_3J)0UJ.PQL0Q_V#6D49GL'^IZ(_C;C8Y
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MFW<:;=9.@3!NLW;F43\A2X?7WO=/R]6Z^B_M@*S7OY%:O10\0Y(360 *\P3
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MN0$<7M_]H?E&)00#Q8]9PN01>R/Z;7?\T;&6,ZC.VI P#(C,E0%-$PD0%C%
MB @*<ZGM:U,#NC_PU$AA*UNDA3,WF0^PNFXNNR(0^.4V4][*0#ZGJ;-Q?##8
M:(;Q.17Z1O'9?[>OE/5EM>0;MJ[O%[R[0:F[,DV0\I3G3  ):0$@@1)0P@N
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M.QO-4(%YP9("(*&#64I,%7?D&#"*"$.RD!12[]<HW>138Y-#[^]"[=>ZHU<
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MP G,,U@4)/.0DG=FZJD9/B<I>7(KL^^4O'/K8,8\8= -3$-74O)VPH^9DC>
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M#S3U>)M\6.P.3(# 4]UXM]46:.HN<?CGQ5<=H+#JRESWKF/*-).%2!* 4Y$
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M#C*'@X/Q\W-3#&SQJ!WY;\AJ]2*7*UTHL_Y-J)_$/U?56KQ5]K^.$4U*R@N
M>*[[AA;Z)\74.<]8*@I&N"3&;D3C::=&NDT'J*WP;1,NUA?_+GI6MNI*^_/_
MU#I$7"EAX7HR7P\#9V 0E /SYT[FYFHI>G,(;BMWU @>O0T%K87O+@C$(WGH
M?$%MYX2S1FS0U68^VG@.-6L-#]QF]D\[5JO?IR]\$>H;I;YNC^HO/O^Y4#3Z
MO7J^EXI/FVV*-!VI9Y"P&*,2 HI+W70^+0'!>0QHGDG$RKS,S>H5NPHPM:V@
M2>I9[I)Z]CKHO]QI$1&M1M33P[(PO>TRF5G?(<$/O$-XQ]V^@KPC>'ZKQ-L*
M,6XE>$>(3JJ]NX[C8 O_D^@([G5]U#;DW4\U<56W=8>^+N?S]RT?SW F:<(2
M#HC404)%*0'FA0 4IGF1)WG*&3:VB"TGGQH9;L6_BTY:[6Q5L"XD9KL>!A9Q
M0)0#L]Y6\FOX1G]H^:-. 4,WD!/<%E9R0-A'LI5]PV]G,SOB-V@YVXXYGOWL
MJ.V!%>TZAGO'\HVBV6]+N5;#B:,FZ5T\(\\@IAG*U$XN2P ):;8*!EB6(Y%@
ME@FS+%NK6:>V46R%CK92ZYHQ6[G;E _[QN37L3>^9_.+:/@+MVM@!JD3;(&2
M]Q[EUV<>O5NY,1CG^I:;/VS'35Q4L[?=YOAE>X'^EJS%#$F<EDF:@1S* D D
MI+)@:0)RDO*2E3Q&G)OPT,49IL8Y6R&[5F*1$C/2<IH1S64@ATG%"SR!"<0:
M&6.RN*K]&6*H!?N/Q^6/_Z&>;3CAWU#_"-H?&R*X/.HH+_U5I;8O^/4/.F:P
M'!7$M>S@>NGQ"7TC3THI!VG">@T(OQD0ER8;-^'ABLHG^0W7/F^_';U;K*OU
MRQOU3JST-287/_^/>)EEI.1"EYS)U!\ 4LD!$5*" A%U:.&"QKG1Q>+%&::V
M';5"1IV442-FI.0TWX[. WE].[H9GL OOS4R5MO1H/;.V]'Y44?;C@:5ZF]'
MPQ]TO$/2?MFOXEFM_W>B3]7+QQ5Y.NRSO"^"];#\3>P_S'4[^!Q+=1XN4MWB
M.,DXH#G/ 4LSI#M9)!1;G8=ODF9J)-$H$^T%C#IU[DY;E_>*QJV7$16]IRZW
MS0VPGH8W3V.M4NAKJ, +9'\KY0-8OU=4-TDT[GV5#_!.+J^\#.IX4E!TSZOY
M1E<FVG<F>O>3S3?*S'JO &B=#XW?_+-\1U8ZR:!6AY5&KH_50GQ8BZ=ZAF@2
MYT*99S'.$ITG$P-,TA@(3)*2DTR6R*B5HV_!ID;8?;WZ?;JVFD7Z2Q?U=-,$
ML=6NJ?;9MHSY0VL8-2I:!O%Z6W+#P^0K+&3HP^>8:VA_:/4,N-]#KB_AQCT4
M>X;TY!#M>WRWS>!2@0(=8G;_@U1SG8[Y?KG2T19[,>_Y_]W4:^W"^KUKCSE+
M4Y*D-,Y 62("8*D.[-I4!US$O$@DQKE9$+!OP::V&?Q]L1)DWEA\38RP8HJG
MILMHD_3LVOC2VS*:$?QK+$Y@@O_\YL/=<2?-NVBG#)#+%=#JW$5_(]4B^D6K
M^NM=%TNVUZRM]TE^^N-VWUA[Y79OPHW*[;XA/>9V[^,[^F#T1O&;/C%H690@
M;6_W?3'2WU[V'_E"7O1?W>N8A\_/35W27B9@/[J'Y652E(4 6:F#VW@A 84\
M!VF>0IS @DMH%^T;1,RI\7[K%.A$WJ; 6OI@PJRGH7/FU5<IM-=&2P^H%C_J
MJ]@O!ZT+'?0_U^D9-8K>[5>WIZSWL*]Q%L2OMR>,J..Z@8+"?>(?"CN;H^/H
MXM:E[:9/9-W]]E7HW$.N/5GOJYJ1N:YBO2OD.F-)CFDL((BI^JI KLNI,E$
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M$[.CF?]R/<S.(Q>BA=F%F=P.*>T]RC?U'C6B?-3?,C5_5UZ.%B4F5-M<J,P
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M;R\/GW(L+L'8<K-8UU_(BSY%J.$[;V//DW N&J!$4"0HC@&"NOETR7) "T%
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M5#YFF*N?=TRRT-%]]^S?FZJNM"W[1ATF*]Z0V7+QH(Z?M12KE8YY0!GF$#.
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M%ANA(\AU11]ME/VS6G]_LZG7ZGBU^K*<5^SE0?Q<_Z84_M<LAE(2GE"00Y0
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M,8%[']^.WMF<UK,O:IG%:B5XY]U38_)N-OT/0@'5]GV#*!$%Q3%@B$)]C8P
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M\<'H0*(=&2#5^CU;8%C3S51F.O-$D9C5H%A.$!DJ<"E&@=8G8=71D+C^QMU
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MJN5@E'U==]@E7A>KH3.YMF[A(I6B1:'(P]:L;J\E!*4#>*FLY5EQQ]J<^N]
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M5Q5!,2N!=D(#UJ/Q3B6E19LZX\$FP#Q%B\)1$7N0KCJXA+R'G4M6!,\L<<4
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M\#!=1P^=N 3XNW+]^>>5Z"_FR]6UT?&7#9.N4EJ4%E[5JEY;>X:D;&K.;H'
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M"]<F]1UQX?+0XX:Y.]F9X(&N0;;.,[P:=A8P%2\0I'5DG4*AG3E$#:5D+J5
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MYF$]_7WY[FRU7(5-<TZF74S($@3#,RA9)/BB!63NC>/2HTMMJAH?HFI<PS.
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M$_)FZB\G3DLC:I&%J#-HE?8>'.TLM5.'J\/EHE*-;I*;\#/R96)/D!UX.0V
MGW^N5;1I:3Y1BMP_J0M@8(I<P4S:J>?LRG-E&&->RC:WGX.S\G.OG2'PV6[)
M' "6@U?+UTTHL0J+51=K9CTH:_EFM@EQ)I(C<J8X!)X+^01DQ&+6#$0V3J*J
M)\5MIA0/R\?(B0;_?*OE")CTL+$\%-!?#PI??<=%FI(()I@30QT%V&")0Y6)
M0^9<K8C@7ON"K-&0U?UI'?GFLT.PMU5W/W50Q\J>A%UP6BL^KI:V4,)PX3.$
M4D]0A:6 ,+  5G&%B3/N7)M;_0;,C'OLW>/*&!DPQRZ=+E8-Q7_3Q?K?7!-"
M(,?1R$*L^T1"B :\T@C9NXS1)5)*F^%:#9@9]SC_GW#5' N8?YX-YV[0)636
M(1D-S(C:"L]*\(+$(HT34F81K>SSI/>P"+U9L>\_X;(Y#BQ'1NBO9GUL-EM.
M'>_*1O/@16U\CSYA/7YD4+-,ZQ&&\M*[_Z^];VMN*\G1?)]?L3'OF,[[)6)C
M(]QV>;8Z7+;7=FU'/S&0-YL[,EE-4G697[](BI(E6I0.R7-XDNR*J)(I4>+)
M!#X@ 20N-C=Z G7=X7G[]"U'CP?!6 MN_S!TV7B-->UD0Q=F=.*>^"9-345"
MTE NK;MH1.0A\A++,*E@I]KA>8<8SE#VCL/8!<C>/>6S-9?Q-FCS?C&-N=HJ
M96.K*'06DR4A"8EL%51DJ_@H0.KDB0@>C6OS!-Q_K^<=V&A9'@?&W;^.9$Y2
M1B$B=\ -+Z"\,1 ,^0]DJ9L8DC=,#M/Z\T0;O)@;V4%P/HY8[@6Z\[G#7>YU
M._<D@6H[!1:*!AY49:++Q,1D@ D?&2E8LN.'J>@]X2;/VU-L33)' M\YG)3/
MD>9V]]VH([#>00I26SD2=>H0<U0\0;+2DH>-CN-(-V^][O.\?<ESD\[A('@)
M OK(?>;3"LS[Q$2)M>MYJF-E!9"]D2#P:#1C5BG1J(CNN=/S=C#/34B'A.$E
MB.DC%ZA/TL>SXGQ."2+G'I20"-[D L49G5+DI,>&Z>-_ZIU>S%7]68CID# \
M!S'MR4?7SFLID$-)NM[B"@>^D)&1'4.FK$<<:'QF2X&A<T@$:$(H1P#=OTSJ
MP-,4XPJ+90Y8,:2]HK%$L>2!O'1OA&/<B;.ZU.Q3>IL]4EN^6CDA'B_@-'W^
M8OA):BD=)2NDCB,:<A&L$^!B0A#H;?'.%[_=5:1MZ>VX[_,^>\]0>H? 8X_3
M0,:3WQ<IK;M&XM6KZ3)>S9?5N[_CI"ZIL!0#9)TC*3,IB*=)0Y*FJ,2-0C[0
MY((AM]5)^NR?TC<FFEHY&L/SQ A[V_PWPU;IYR_GLS5IKO'J4UY\%1,M4K%8
M$D@5;SNN*A.!:>\49\8)/TR;R1$V>]Z9"3U"_3$A;!AW%R":>]OXNRC')\BL
M0\44!(ED,2CGR&+(=3J92X74K?1LP-X-3=#@O!,9VA7DD5 Z=A?*![O_K=L.
M)XC<J>R),2DC*(UU0F0JP)"K9 IM7^!#,=S1GO*0IY]WKD#_ G :-K9R#O43
M%OZ1"#&=+:=QW4%V(HT-6C RV[E6H()QX'74(+4LS-#_PC5?</AP2^=]5S_P
M*3$ZABY F)X_+N^:@&\1REC'LF(%,K,!E"?!<%Y;2(H%*6/V8JQLTZ&V?-[7
M!^T*XVDP>+G">B].NXM0SFG'D_2@L)H(BJP#3PXK<&<3DTX4CFW&) _>\GG?
M%IR=L/:,P7,6ULU8Z!DQZWJ=>O1N]24O/GW!62?F1JL\DUF",W$SK]U)KR!%
MBTQS%HQI3%2/V_"X@9 6^B:?$# 7+5=OY[-?U]KI?I>33"SE,G.PA3E0CB,X
ML@U %E&<($V9U+F)TV/[/--[@5-"_V3B>C0.QPXFWAO-<SM'84V*Y206E)9E
M T1J3F>XS41P%ND,ES)9%W3T6T[?KD&0NQYQJ4 ^'A3SWCDT>I7L>B^W&U@7
M&^8TL<8S+JV$XJ*MUBT1109./EZ0!I/5:3M_8@?&MC[X3&]<3HRL8[@QMMZZ
M7?NWWJ\R",9MH7W;7.I UP0!0X$8A,U>(!K735]]]]%G>GTQ$IH.X\CXS1$?
M;.(ESF*^HCUX59+2FJR^6*=#,:,!?=$@%7GA3%IM1+>!D]N??*;A_I% =1 _
M1FU3NR43OTP7M3]UL8*GI,&IPLCG5*EV7K,@C8H<D?[)?$\=M?[@,PU7CZ:A
M]N=&(_IIMS$H1'9*&T5;J.$,+F@SM0FZB$QZL@J]]^$$YGI[8=9FS/5].#1R
M[=+-@,[ULF](@[.4-T'@U;S^:*(M6B52 5U(9!3G @(K'JR1HF@AZ>UNION3
MC[E40[[_6$?/+&O%OK^Y@Y@D*\6Z-E$8@:2J$P<LQD"V(8EB&8;M=(]G#LZ;
MS[U4RWX@>!W!E%;P]%PQ[*W^+QX%.< *F(ODNSA!-++!@#92(Q9M7>B6+[?G
M@R_5+1@8D4.P=73(/K&GVWW?GZ3N0G3H/((H)E1SUD-0VH*P5J>BI8[1=H/L
M?@\>)XP[//OG)^)%(Z'9#CN\#10RY9.N97_D)I$A48NI4),YBSGJ0 9&$?CL
M-.E]'SJ.)=@>R@[AP3EHLF]APU*"C88IR-%7,[7V>(B!@\L:R=*(66;5&[I&
M#O*VAZ_#^' ."+N+(084(<120'I3ZCT'!^_$.JDP<6F2,[IC%&Z/IXYCV+6'
MKX.X< [PNHTJ,F6ET\D#8R'5[J@(CFL&*B7KI6<^FH[W4-T?.D[\MSUP'<*#
M<\#6?=,R^&0TLQ(,#_76GPM 3/2M]%%Y)Z.R:30SO_?P;WL8.Y07+81TN^QO
M1];O)&((O!!1C5%$U"I.3I+]Z34KIF0=RO8HW2-PMV,1EWK/-51TY$3L/@<5
M>B]K?<*MXRG4DZ$(6ZLH-1FU%HF@/AB&LF Q?7L8]<&7>H,V(GP/9>OHD+T]
M32HI'Z,:'6 RB\Q U(M"Y7B&$)R 8#7CJ<3HM]O(/Q. WO6D,^WV,W;$N1?&
MC8[";F7GO]WL>7[/\K&V),U)N.PZP"E=!,^% LDRBT9B(#/[$!7:?0D-A)W[
MP< 3*F\@AIP)[!Z:*'AKHJQN#!3%I4&;%$07:GC*9?#&:A#)J< 41R-$GPA\
M<C4-1*=' V-_;#H37&ZD;Y-G,4DB,)8XV<<VU=Y0)9'9(6I<RRE,G#/,; !5
MN'E\ W'KL=7@(8P8&VH[*F<?"S)8E,%)<L)L-AE4-EB'=VNP+C$MBS#.=;,$
MNS^S@6!U_Z :B.2-(VE7,IB*.JHH-&"H]H((!GS@ 4R*PCDK7#3=$EP.>WX#
M$>N3(ZP/5IP%VB9)1AO0.V"R7DZ'2#J9Y0Q%%ITM0RU"MP2!3H]K(#(]$I;V
M(G1OT/F??_F.T&_H!^NWUN_4O_J0R_^H__[\X<<'GQ_Q"M-B>KW\CSC_>O/Y
MZV3I+_,KXM/RQJW_0+M;3*N(K-\CD=GZR<^SZ6KY*J]P>K5\N+_E].LO5\^"
MZ]A'_N7;9K?)L'GR=Q@;>N/Y]U4FU9+^_;B:_:TN"<FZ*',*D#*=?XH5 =XF
M@AJSIB@RXH,<IJ;^X3J.[D00O^1T?97?E</'!WU:!QDU8RKS(L&P.EO/*PL^
M*2*-4=QZSV)V W4@[FL+XY9='X&O[\KZ1V%J WTU;E9.O_SB]^ER(H(J1O@(
M.GI6CYA$BY<(V:/7+"HR.7 01#Y8QLC%_.- 8=X77QH U>&$^[;M67I_A;.W
M^#6_FE>7?>*-SL5$!Z4H#JIX"XADJ62A5>#:,5/R,-IR@-V,"_$CP-7;!+V>
M.-T VK?,JI_RUY 7$Q4"-W5P;O!.TB9JWE!6]0X<!9%;>@+;('!]=#F-]T<9
M'"7SOEG6'N[6YOR'CS]O-F,5%J$,(Q^1MJ"<98#6:#!6H)7):&V'.<J?7%;C
M19@CX_ (%HZ(Q^5B-?E0*;@^33A*I7@Q("59/@J-JI.( V0E%-9LN< [X8X^
M]1[FZ+MMO#UX[,BX&M5D/)S^+8!F@_4HA.8A(9149R5$+< 5DR$[ZY %F87H
M-)VN.VS&/!B/8-DVTP^@W\AL_VDZFWZ]_KI9N'"R.*TEV%BSJJW/X#0R\-PY
MD2W]IU5OC'_PZ)%9?PCCYGU0<6SVX^_W%NYEEED;04:69'5:"@?/6 3CE22E
M9^B(ZS28O1O[[S]ZG".C-_8?3,4&+->#,_7>3&?YQU7^2CK3F\!CT,"UB$!G
M)@,GZ$N.Q:O,M-.\C!,->';M(W>*:"*\=6($M(#Y:N#_N%Q>Y_3J>C&=?7Y_
M4W*];K.RY0>L=_J?B_ER.;&R>A#2$&FU)\6.&D)11'.1G0N,.RL'FMI[T'H;
MCS/TC*IM4 _/XG:!O+Y2WKU)SF1*D2-$4QO,<B/)JPVYWF4;RX4,?OL:?U@<
M/[W<QL,4H\"X1P:W@.+!B@767166/\YNJ+:5?KA^\Q6N\FN<+FX&7$0NA2^2
M@]$U04P5#\@U:0/KR(2WW(GM9K-C6S)]D^!,6V?U)&VM<&$O()ZS!*^_U(3R
M.]7&)\*:*$PLD ,Z4,()P!#)G\K!*EF$)F>Z+2%\9!=GVO!K9#DZ%@[MYL(]
M2I''?UKK+&;+?$P:W.%/ZRD#KJ?M]I3\M@./M\E*AO'@(J\-@UD!50J]$L%#
M25Q*:\GV/ZW":2XYK@2C@DP*K%!YTS)(D1QJE&@R"I1ZF/O+"TF.ZQ%_PR7+
M[</D!DR.'V>D;?)'8N)Z<V_J']3]UDL<5:^!19&@7:"SRV@)CL@(-;E&%7*'
MG F#X/6)15U*(MU>,)D/P[-VX;?)0^"(@@BE29B3!*5%!N\=0LI%FNALB'88
M/_+)98T+P=Z8WPU4!W"B 5A]()[0 KZ\F*57^==\-?^E[FEC(FTNF#)7CI'=
M"\R$.BO#(P3A-! )HQ#)DV .H]TZ+*Y)B!T"A>^3@WKE2P-0^\\\RPN\HAV]
M2%^GLVDU1E;37_/#3:%A.KHJBE8)(IK2M5^0!Q>1A6"S4G$8L'5:WKBQX>'@
MUC]O&@!<#T&)*(W/J:P;LS%0T61 Y=?3/))/&$N,G1)46KUI/H.LN&/LOQ,C
MH ',O[A:_TY.3\8^)DF+HHRRX)*KNT(!*.L@+$,R[$-D6HE!<-UM?4UZSX.A
M9KOZIW\6GEF8\N'KY>KM?/6/O/J0X_SS;/K?.?4>J>SZP"&#E0=M^C3Q2E[3
MW&-B(.L=+T&-@0\L @NQCB PELEA;+)SB5=J.HE8# ZRJ<V)LC: 29*)E%E"
M*PRW^<]XY>'QRGWP-V!Q[QY,;L$2>%#G9QUR3"6 *)J< X,(J&,$XT(,-KHB
M@AWFP+_(XMY]H/!D<>\^?&D 5,,4416=<YTZK@014N7 2;RU \8\9NX=2W*8
M:LE++^[="UPG*>[=@],-H/T'LBCG?^2\3G>[2:S91$**),GWOA:*<C*YB[80
MT$J(*:,-2">2'<9_VKFD)@_P$Z)E/@3K&L#@TU6B(C&K8A#@=*QC*8A8(18-
M*9/+F2P1:KM][I^%OB?'8G\L; ^/MY5,WME "P(C34W>0@E(=CH('TKBW+/,
M6FMX,%Y.Z<CX.X!E#>"NAZ"<1ZZ=5P92C1^K(GR]R A0E+#"*RZ+&\G._)<)
MYA_C.)T8 0U@_LZ(R8M?IS$_3H"[L?/KO2X_S5=X]5PL<9(59QB"!^F\)NHG
M"RZ6"%')(+*H@Q_EL/9KWUMJW/[M&9N[K-U1@7+)$G.3'/YZOMC\J/X>G_@H
M?.'H03-.1[.M/*MS0()*R!*Y%L$.$U4[[3X;M^?/5+:.A]297>O=51O-;^R(
M;Y,>MB<T+5?3K_4&]+N_V$PM[OT"L/^E#7E5.# A>[I4_-;&^EVYO_H/^:HN
MJ8K$<KV8<$]POW6\MIE'%P."]P)!::< &2-WA2?K(U?>Q&%26H];=T.7DD&6
MI'.$7'C-\L]$P,0*,)2&%8U"\(%N;2_C4O*$^!WPTG(/$#1@OSV\OV QIU"P
M0';UV):UZ;V,'DH,BAQ%&WGXLR/Q,%!X\M)R'[XT *I! G*%#+*4C027<S4I
M,4%(18 TF9F@@RIVF,C[I5]:[@6N4UQ:[L/I!M"^^^8KD)^3L8ZS)B\"E"=X
M^>PCB(":L8+9FF$@^Z]T:;D76CI?6N[#N@8PV(/+;I1C(?((26@%BL=:=9 ,
ML"*]DD;XO#V6\<]@?4,&PXD1T KFP_,[#ML[WG1LN?'A;SNVW#GL-2+D17;2
M <M"@@K.@[>&@68F6BN=5@/=K0ZUH\:U?L_(?$PPQH9)*^)R"!L.;' 4>,E&
M) :)U^HXR0V@+QQ<*G6DN_2)#31OZ;0;/?M8_='"U2BHF@W6WU25?L+?\S&3
M\![YE'Y"X,\MKZ=H]=UCOH7][D)Y+#L;+"-=FB490BX3AXVUH".3*CFRZ >J
M GUB4<?JWW>_Y%KB._O\9KY<OL3%XH\R7]Q<7JV-/VXUP\ 9^&))#(T/M44I
MAQ!(_F2)AEST0?;\S,):*/@_'B7;BJM/;C1PN-^1Z<7UZLM\40?UK?/1E2G"
ME@0E!:(02X$HE#1(%D+M59]T'"8 \?AZQH52KRQ_M$7)4?1O$D6;&$M2FKNL
M$#0Z(DWR";Q&"9;S9)A D<,P?;%WK:@1I70$MY\%T &D;P!"M.K:W#&^G%_/
M5HL_-M&T%'C4F7F(-0%1!18 E3!@5$#MBTC2#(.?1Y?3&G@.X?2\;[(W@)W7
M\P4Y +.'>V#:,Y/H?-<\6K+X;0*TN8!QBK;GE$MBF,3)QU;30C>:GI%S--$;
M ,ZZ0<^+67I#OWGUM^O%=)FF\5XPOQ[>SH?JTC)19V?0R<Z4!^.U1*V%C6Z@
M:O&G%S9NV<0@<.J3%0T@ZWL:U9NGF]->*L8YJ=08D60D%D-4,@42CR%)QY(1
MP_24W;VF<=73:>WK@_C0+*(VDJ=BM$5K#;K4H>K1>$!#XA>S9"E)8=5 &61/
MK:HU<^DPSG<"U %L: !2;_-O?ZL?]L>KZ:_3)?'E7:&-X3VMR[.(WL8 @J\U
MNC$0DB\@HTE9)A-T&B9M_MFEM0BN0U P'Y(E#6#L)5Y-29W/IOAZ@3,BZ[*2
M[:]S4N^W9;56*?1D)&K/)9%+U3SZ3(A@*<;:#='+83#V[-):L]I[PEB_+&D
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MO7-..S5,8]0]%SJNJ]@#-+9':@S(IP9@N$N@[^WL[]/5E_?U$/DTW_7;MPV
M$C=,,0^^!%G;WUM 24:IYMSG(IV/VVET?15S][B+D8=L# FW[5+PL7@_=A"D
M+OW&?P^2E^HQ!5<S&*3 FWD0WAHG>)0Y=QM>UBW(<?O8D>=>MW&8'\Z(%M"S
M ;UWD;E2K_I0^&I+D]?$L@:FLHZ)6RY2IVN'[O@9/=9Q&,NVF7X _49F^T_3
MV?3K]==;=SG7GN&T>>MC3;U*BO1>U"!U3M5=YB9U:KO<B?$/'CTRZP]AW+P/
M*H[-?OS]WL+)A2Y1,3IK12"%%Z2#8+F%J*.)RHF26'_GQH-'CQBKZH/]!U.Q
M85-YC^/RS5W:)F8AF&8$?5$[&@IZY;R3D)- S6/(T@[37++/78Q;%=6((3,Z
M/,8.Q]Y,*OYQN;S.Z><9\7P[(6?BA8ZQ=MM'&S.9"HHH&L@WX(;,!*UB"7DK
MW677[<]SCQK7>1L/ O/!^#$VNG;1]$,=^E()^RY<33_?5">^F,VN\6JSW9]P
M.EOE=3>IUSE/5.;!H$6(7A=0B=-A$XD$LN3:FS9ZN6VJ[VK#TL^"QHWHMH'4
M,7A[(7C^N,)%+=1XL?I'QL7'_&N>3:)AEFA-MICU=:8E\0&=EU!$U-PYBR3R
MIX3X(VL<-_1Q4:@_%@'G) @;O^'%9SK"Z$?YI^E57J[FLWP[SOU]7KQ?S--U
M7$VB=IP%'H&S.IBLWG0B*P)*83PH0[K"=*OE'FB!XQK-YR<"0_'^G/#_8?X'
M7JVF>?FV=@3YB$2!2?*IA%K$DF*P=.@%\E5"81 XAH#.%57Z-V@>6<BXG0S.
M#\_'\O*<</OQFE[7LZO6/V?:*'J.,1@+>IT:4L<>U3V"]-*A33'QF'H'[?8J
MQNV/<'Z(/8J+YP37)ZRM:F.]GE_7"]<D'"<W(S!=1Y%( T&7 "Q;>NU]=OJD
M1O;MPL;MLG!^H.Z;UV/C_";J\[_S5?KK'Y^^3!=I?6U/)PMY!,$(T%G76[H@
M2523A&0-0VZ,=4%V@NOCGS]N?X0V4-<#Y<<&3X^"\^FW.?W^)\)2GI3@I52N
M@,PB5[/&@V<1P1*Z=#:.R.!.K2OOK:\3>/UE@[<!SE\(^%\46L_KZ6*YJC;]
MA&3=&:DRH,BNGAT(7C$-Q C!=7(RRFYW'H,LK]L]"?L3^\,R_IR@__)+?;=>
MMLY6M(8:=\\%2ZCY&R[5K=J4ZS0B"RZ4G)F-0F]/V>P!X]^OHQN8+_S6[X2L
M;+9IQ6V7EWNTF).4INT+T"-Z6>S[B'Y:7!RUL:8Z7VC/<_;(((=J&$2'Y%R1
M=K2HC8N,)Y3#E#%<:N<+'Y")M-85M6%X3<AT+H1J<W&.T0GK.F4B_MGYXN3X
M/D'GBWW0T4"*W>/E.S'%E!36R3"<U2I" R&K ,%*X9C/-HMA6L\=7HIW3KTP
M]L)(IU*\?1C6 .KVK;DQ3AI$IR$R3]L3CD.@[Z'P['/6J)+0@^#Q DKQ]H+&
MD:5X^_"IQ;8_,A4C@\F@<QVT6&<LHJ<OUC@LF46C=:?6?L.V_3FGJN-#5%TO
M[!F[9JES=X!<^W.AB\"*]: T20]:[6IFG=$VY&C%GVU_]N+\06U_]F'#V$&D
M_S.]NK[5N*AS'8L%<3T:5DL.GD@"+GGGZYP0Q;KE7GW[S'-HZ[,7M^;'DVYD
M;;+)MGJW^)@7OT[C1B9B804C.3XRDWZUBM&9'A44443.43(60F^*X[$57%Q5
M[:&'U='L:0->E5Z;'2QO6]?$VNE>&N!6DD$G,\E9Y@FT%)XQ+S1/IF^,?;^,
M\332\9S]'B9'DKD!]^WV4N9&CRJ;?.3UOL547:Q\ (P8(1$9>-;!$84&<<X>
M+&-TC!S+UGE?-![;\KVK5V?D>6+4"G00ECQ/G\%E$A;)DE,"K:>5]V?9[M7K
MX9Q*) \]E0YC1 OHV8 ^:>MUX;5U4*A#&*V%X&6"[&12.J+FHE-SFW/L]; 7
MRW;T>MB'?F,7^S_H4A!%"5XY#S&0B:^XQ:KM&'AC4_!"BI+ZZ[[<8*^'O1BW
ML]?#/E0<F_T/NA1P)B,KA7PR*0LHS(D<,^XA:)V(!,Q'VU]$I,%>#P>S_V J
M-F!3]IK3D1TCDZLP8)%L)I5K84>Q&:(,R0H6R?4?9D3+R7L]#%;FTX@A,SH\
MFA"-V?JJN[:&>WF]7,V_U@X#&*97T]4?$^Y+,,47T,[RFY1YCR6 (1T?-<?D
MNW7$.@#K3RSK@MI"[(66[V#;%^L:P.&'6O%\G>M8S5T$_N'W>'6=IK//#W[W
M>QI,I"F!O.  /C)?ZZ8UG7$^T1>R6J(E-UD,,X^GQTU<4$.)8S ^%BS&OH79
M[.5#KK$>VMO[O"CSQ=>:H_PM\_/_XF):#[^:WS1-FZ'N+[[66XU)MC$R0\89
M5X[5)AH%T).I7DQM[15%BKE;,N^Q*[F@'A&' /GTW&P$NH_ND7X8*_MKNO+;
M?)-ACT$EYPMY$"$259G+Y$:01Y*BS@E%T-EV*\'<\\$7U+GA6& .PJMSP>']
M>NC-WRPG6N<2.*L25FM%#9WU*+0!SAURU"S9[;'L1X+RL55<4"^&P1%Z-!>;
M+8.@G2WS/Z^KI?-K/FYTYZZ/ZJ>LH=-">RI?V'[67<8VX]*E: P$69OA&54C
M4]H!1^4)!3XQ.\R@CUTK.KK(X.'GWD0[; A>.Q(B)SV9LBEQ<"9;$,%&68J2
M7 ]3=_'8:D9.H>X#"=_E[A]+] 8\ZNT]T)^M;W^,2RG(S"%F;>N<( W>> 6N
M2,6]T$)ME[(.A)W-@IJ"SP&<?@8ZAY"]3?1L$@\$$<:DHL'9];CM(DC".!VJ
MH>CDM+9ANV7*</@9,X6G5X8_#Z(#J-\>C#;71Y8'E)@D2$L>A-*1K$&C(S!O
M1.;&&3?0-*Y'E],<? YA]=, .H#N[8'GFS>1BG5HN(>H%=GU"CEX[P1@T<:X
M+(JT)SG"]KM.&ZZT8N S[##"C^W_OU_,8\YI6>/!-7BQCF*\^V4=6)M]?C-?
M+O/R[=]^>/6"?O'S K].O Y<E!H?9J6 \KR0KM8%),MH1. RL6XATWV?W)0"
M.I#9\U-1?G@_??-&_1)PF?_7O_U_4$L#!!0    ( #6!J59Y3G+=0@<  #HE
M   :    8VQB<RUE>#,Q,5\R,#(S,#,S,7AQ,2YH=&WM6FUOVS80_KY?P;E8
MFP#R6QPWG9L%R&(7R]"F7>:AV*>!$D\6%TI42<J.^^MW1\HOB5W,P98M#9(/
M2B3>D0]U#Y\[,CK^=OC^;/S[AQ'+7*[8A]]^?'M^QAK-=OMC[ZS='HZ'[*?Q
MN[?LL-7ILK'AA95.ZH*K=GMTT6"-S+ERT&[/9K/6K-?29M(>7[:IJ\.VTMI"
M2SC1.#FF)W@%+DZ^.?ZVV61#G50Y%(XE!K@#P2HKBPG[*,!>L6:SMCK3Y=S(
M2>;80>>@QSYJ<R6G/+0[Z12<+/HY;H?[X[8?Y#C68GYR+.242?%#0\8\[G1Z
MG2/>[;\Z?,6[O-^'HT[R$OC+?C>)^W]T$60;S8./=7,%/S1R630SH/$'AP>M
MHW[I7L^D<-F@V^E\U_"F)\>I+AR.9] __!FZV>C,P;5K<B4GQ<!/J1%<%\V)
M5MH,GG7\SVMJ::8\EVH^>#&6.5AV 3-VJ7->O(@LAJ%IP<@T&%KY&1 3PO.W
MLP#Y"/M1LH#%%+H'!'ITG<E8.M;KMKHW$2]G<W^0#K=">OZL^[+S>@/,EA>7
M8*3!_$]O[FQT.3Y_<WYV.CY_?_$K^^UB.+IDOX[.Z);U.@>[3.#/RCJ9SN]]
M!O_T1?^_.,\C-N13*=C/+?:.?_ZL(_8A&T8L 4.HF,NX>_ZL_^HKF,K7\LJ[
MK8 T7,]9QJ? #$PES%"<728M^Z7B!E>?FK-+*+5Q3!?LC38YZW::OS"=LK?2
M<L?9. /#2ZB<3&S$SHL$N^Y__Q6\@Z\E5@<W8O4CMQ@AC$4^9U>%GBD0$XA"
MR$P(E- X>*$QV6+?7!:,%W-6%<Y4@-@Q_?I,C!'D+,<[([EB*4_PD6$ZQV3A
M=+#;,"@@ 6NYF9-)SJ\ QUWKT^(S@6!P2.73.(Y!!HDTF+;1K$!W1"+ L%DF
MDXS9BBXK_QD8J#NA">32*LSO5"K,I,MP@K:$Q .D?DN$I@5.<XIN@L7S]=?P
MQ,)_%6=O-Q8"2V6!<2;*K.(:(071')O-6KLL4M033@4F_IVH2F"?R)VU($;(
M.TD:5&+HB;7$9J56M*P986\-C<P7OG*-R*)2:(!<U$@8/YSU>!)N,Y8J/;,+
MHAJ82.NP['6,T\. &U%&:WRS"S ;:)\H]Z_B/+R5I'CNPXWAD[$""@L#Y%BL
MI,U((BA6.>H=:1[="VD3I6V%DD)*:+0*<2^-3D#@8\OV,,P"D#<AEJ/K)./%
M!-@IBLQEI="BV^/-;G\/]KUKMR_"7;B55)\6@6_4/R,E6J-AH 5AV7F@],9
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MGEK2:_Q-=?)B"<&G2B)BOURJ(O$'!/M/6ZO_=&MUJK *0U RE0GM<&FOG$A
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M ;F$C891&(,O:\W:O=VXW\BNP;N[%YMMY[YM2K-\?Z]V=_C)6O,GK50)C;)
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M4$L! A0#%     @ -8&I5K/1)LV'A $ :;,/ !$              ( !
M &-L8G,M,C R,S S,S$N:'1M4$L! A0#%     @ -8&I5AG'?]YS#P  6ZX
M !$              ( !MH0! &-L8G,M,C R,S S,S$N>'-D4$L! A0#%
M  @ -8&I5AE$F)+,%P  />$  !4              ( !6)0! &-L8G,M,C R
M,S S,S%?8V%L+GAM;%!+ 0(4 Q0    ( #6!J5;O7#[%234  %1" @ 5
M          "  5>L 0!C;&)S+3(P,C,P,S,Q7V1E9BYX;6Q02P$"% ,4
M"  U@:E6'X:T*OYU 0 2(@( %               @ '3X0$ 8VQB<RTR,#(S
M,#,S,5]G,2YJ<&=02P$"% ,4    "  U@:E6X@+KRQM) 0 >] $ %
M        @ $#6 , 8VQB<RTR,#(S,#,S,5]G,BYJ<&=02P$"% ,4    "  U
M@:E6IT?480'$   58 @ %0              @ %0H00 8VQB<RTR,#(S,#,S
M,5]L86(N>&UL4$L! A0#%     @ -8&I5EASS,(V<0  ;20% !4
M     ( !A&4% &-L8G,M,C R,S S,S%?<')E+GAM;%!+ 0(4 Q0    ( #6!
MJ59Y3G+=0@<  #HE   :              "  >W6!0!C;&)S+65X,S$Q7S(P
M,C,P,S,Q>'$Q+FAT;5!+ 0(4 Q0    ( #6!J59J6D5YEP4  ,4:   8
M          "  6?>!0!C;&)S+65X,S)?,C R,S S,S%Q,2YH=&U02P4&
/  H "@"< @  -.0%

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
